MXPA06001121A

MXPA06001121A - Benzimidazole, benzthiazole and benzoxazole derivatives and their use as lta4h modulators

Info

Publication number: MXPA06001121A
Application number: MXPA/A/2006/001121A
Authority: MX
Inventors: Jianmei Wei; Frank U Axe; Scott D Bembenek; Christopher R Butler; James P Edwards; Anne M Fourie; Cheryl A Grice; Brad M Savall; Kevin L Tays
Original assignee: Frank U Axe; Scott D Bembenek; Christopher R Butler; James P Edwards; Anne M Fourie; Cheryl A Grice; Janssen Pharmaceutica Nv; Brad M Savall; Kevin L Tays; Jianmei Wei
Priority date: 2003-07-28
Filing date: 2006-01-27
Publication date: 2006-12-13

Abstract

Leukotriene A4 hydrolase (LTA4H) inhibitors of Formula (I), compositions containing them, and their use for the inhibition of LTA4H enzyme activity and the treatment, prevention or inhibition of inflammation and/or conditions associated with inflammation. Wherein X is selected from the group consisting of NR5, O, and S, with R5 being on of H and CH3;Y is selected from the group consisting;W is selected from the group consisting Of CH2 and CHR1-CH2,with R1 being one H and OH, wherein R1-attached carbon member in said CHR1-CH2 is not directly attached;R4 is selected from the group consisting of H, OCH3, CI, F Br, OH, NH2, CN, CF3 and CH3;R6 is H or F;and R2 and R3 are each independently selected from various groups.

Description

DERIVATIVES OF BENZYMIDAZOL BENZOTIAZOLE AND BENZOXAZOLE AND THEIR USE AS MODULATORS OF LEUKOTRENE A4 HIDROLASE FIELD OF THE INVENTION The invention relates to inhibitors of leukotriene A4 hydrolase (LTA4H) for the treatment of inflammation. More particularly, this invention relates to certain benzoxazol-2-yl, benzothiazol-2-yl and 1H-benzimidazol-2-yl compounds useful as selective inhibitors of the LTA4H enzyme for the treatment of inflammatory conditions.

BACKGROUND OF THE INVENTION Inflammation is normally an acute response by the immune system to invasion by microbial pathogens, chemicals or physical injury. In some cases, however, the inflammatory response may progress to a chronic state, and may be the cause of inflammatory disease. The therapeutic control of this chronic inflammation in various diseases is an important medical necessity. Leukotrienes (LT) are biologically active metabolites of arachidonic acid (B. Samuelsson, Science 1983, 220 (4597): 568-575) which have been implicated in inflammatory diseases, including asthma (DA Munafo et al., J. Clin. Invest. 1994, 93 (3): 1042-1050), intestinal disease inflammatory (IBD) (P. Sharon and WF Stenson, Gastroenterology 1984, 86 (3): 453-460), chronic obstructive pulmonary disease (COPD) (PJ Barnes, Respiration 2001, 68 (5): 441-448), arthritis (RJ Griffiths et al., Proc. Nati, Acad. Sci. USA 1995, 92 (2): 517-521; F. Tsuji et al., Life Sci. 1998, 64 (3): L51-L56), psoriasis (K. Ikai, J. Dermatol, Sci. 1999, 21 (3): 135-146; Yl Zhu and MJ Stiller, Skin Pharmacol. Appl. Skin Physio. 2000, 13 (5): 235-245) and atherosclerosis ( Friedrich, EB et al., Arterioscler Thromb Vasc Biol 23, 1761-7 (2003), Subbarao, K. et al., Arterioscler Thromb Vasc Biol 24, 369-75 (2004), Helgadottir, A. et al., Nat Genet 36, 233-9 (2004); Jala, VR et al Trends in Immun., 25, 315-322 (2004)). Synthesis of leukotriene is initiated by the conversion of arachidonic acid to an unstable epoxide intermediate, leukotriene A4 (LTA4), by 5-lipoxygenase (5-LO) (AW Ford-Hutchinson et al., Annu Rev. Biochem. , 63: 383-347). This enzyme is predominantly expressed by cells of myeloid origin, particularly neutrophils, eosinophils, monocytes / macrophages and mast cells (G.K. Reid et al., J. Biol. Chem. 1990, 265 (32): 19818-19823). LTA4 can be either conjugated to glutathione by leukotriene C4 (LTC4) synthase to produce cysteinyl leukotriene, LTC4, or hydrolyzed to diol, leukotriene B4 (LTB4) (B. Samuelsson, Science 1983, 220 (4597): 568-575) . LTC4 and its metabolites, LTD4 and LTE4, induce smooth muscle contraction, bronchoconstriction and vascular permeability, while LTB4 is a potent chemoattractant and activator of neutrophils. The stereospecific hydrolysis of LTA4 to LTB4 is catalyzed by leukotriene A4 hydrolase (LTA4H), a cytosolic enzyme containing zinc. This enzyme is expressed ubiquitously, with high levels in epithelial cells of the small intestine, lung and aorta (B. Samuelsson and C.D. Funk, J. Biol. Chem. 1989, 264 (33): 19469-19472). Moderate expression of LTA4H is observed in leukocytes, particularly neutrophils (T. Yokomizo et al., J. Lipid Mediators Cell Signaling 1995, 12 (2.3): 321-332). Leukotriene B4 is a key proinflammatory mediator, capable of recruiting inflammatory cells, such as neutrophils and eosinophils, as well as active neutrophils (FA Fitzpatrick et al., Ann., NY Acad. Sci. 1994, 714: 64-74; SW Crooks et al. RA Stockiey, Int. J. Biochem, Cell Biol. 1998, 30 (2): 173-178, A. Klein et al., J. Immunol., 2000, 164: 4271-4276). LTB4 mediates its proinflammatory effects by binding to G protein-coupled receptors, the leukotriene receptor B4 1 (BLT1) and the leukotriene receptor B4 2 (BLT2) (T. Yokomizo et al., Arch. Biochem. Biophys., 2001, 385 (2): 231-241). The first identified receptor, BLT1, binds to LTB4 with high affinity, leading to intracellular signaling and chemotaxis. BLT1 is expressed mainly in peripheral leukocytes, particularly neutrophils, eosinophils, macrophages (Huang, W. W. et al., J Exp Med 188, 1063-74 (1998)) and monocytes (Yokomizo, T., Izumi, T. &; Shimizu, T. Life Sci 68, 2207-12 (2001)). The murine receptor is also expressed on effector T cells and was recently shown to mediate the LTB4-dependent migration of the CD8 + T cell effector (Goodarzi, K., Goodarzi, M., Tager, AM, Luster, AD & , UH Nat Immunol 4, 965-73 (2003) Ott, V. L, Cambier, J. C, Kappler, J., Marrack, P. & Swanson, B.J. Nat lmmunol4, 974-81 (2003)), CD4 + T-type early auxiliary effector type 1 (TH1) and chemotaxis and TH2 adhesion to endothelial cells, as well as recruitment of early CD4 + and CD8 + T cells effectors in animal model of asthma (Tager, AM et al., Nat Immunol 4, 982-90 (2003)). The LTB4 receptor BLT2 (S. Wang et al., J. Biol. Chem. 2000, 275 (52): 40686-40694; T. Yokomizo et al., J. Exp. Med. 2000, 192 (3): 421-431) shares 42% amino acid homology with BLT1, but is expressed more broadly, including in peripheral tissues such as the spleen, ovary and liver, as well as in leukocytes. BLT2 binds to LTB4 with lower affinity than BLT1, mediates chemotaxis at higher LTB4 presentations and differs from BLT1 in its affinity for certain antagonists. Although LTB4 receptor antagonists may differ in their affinity for BLT1 versus BLT2, blocking the production of LTB4 using LTA4H inhibitors would be expected to inhibit downstream events mediated through BLT1 and BLT2. Studies have shown that the introduction of exogenous LTB4 into normal tissues can induce inflammatory symptoms (RDR Camp et al., Br. J. Pharmacol. 1983, 80 (3): 497-502; R. Camp et al., J. Invest. Dermatol. 1984, 82 (2): 202-204). Elevated levels of LTB4 have been observed in a number of inflammatory diseases including IBD, COPD, psoriasis, rheumatoid arthritis (RA), cystic fibrosis and asthma (SW Crooks and RA Stockiey, Int.J. Biochem.Cell Biol. 1998, 30 ( 2): 173-178). Therefore, the reduction of LTB4 production by an inhibitor of LTA4H activity would be predicted to be had therapeutic potential in a wide range of diseases. This idea is supported by a study of mice deficient in LTA4H that, although otherwise healthy, show markedly decreased neutrophil inflow in inflammation of the ear induced by arachidonic acid and model of zymosan-induced peritonitis (RS Byrum et al., J. Immunol 1999, 163 (1): 6810-6819). It has been shown that LTA4H inhibitors are effective anti-inflammatory agents in preclinical studies. For example, oral administration of LTA4H inhibitor SC57461 caused inhibition of ionophore-induced LTB4 production in mouse blood ex vivo, and in rat peritoneum in vivo (JK Kachur et al., J. Pharm. Exp. Ther. , 300 (2), 583-587). Eight weeks of treatment with the same inhibitor compound significantly improves the symptoms of colitis in upper cotton tamarin (T.D. Penning, Curr.Pharm.Des. 2001, 7 (3): 163-179). The spontaneous colitis that develops in these animals is very similar to human IBD. The results therefore indicate that LTA4H inhibitors would have therapeutic utility in these and other human inflammatory diseases. Events that induce the inflammatory response include the formation of the proinflammatory mediator leukotriene B4. Hydrolase LTA4H catalyzes the formation of this mediator, and inhibitors of LTA4H block the production of the proinfiamatory mediator LTB4, thus providing the ability to prevent and / or treat conditions mediated by leukotriene, such as inflammation. The inflammatory response is characterized by pain, temperature increased, redness, swelling, or reduced function, or a combination of two or more of these symptoms. With respect to the onset and evolution of inflammation, inflammatory diseases or diseases or conditions mediated by inflammation include but are not limited to acute inflammation, allergic inflammation and chronic inflammation. Examples of textbooks on the subject of inflammation include J. I. Gallin and R. Snyderman, Inflammation: Basic Principles and Clinical Correlates, 3rd Edition, (Lippincott Williams &Wilkins, Philadelphia, 1999); V. Stvrtinova, J. Jakubovsky and I. Hulin, "Inflammation and Fever", Pathophysiology Principles of Diseases (Textbook for Medical Students, Academic Press, 1995); Cecil et al., Textbook Of Medicine, 18a. Edition (W. B. Saunders Company, 1988); and Steadmans Medical Dictionary. Background and review material on inflammation and conditions related to inflammation can be found in articles such as the following: C. Nathan, Points of control in inflammation, Nature 2002, 420: 846-852; K. J. Tracey, The inflammatory reflex, Nature 2002, 420: 853-859; L.M. Coussens and Z. Werb, Inflammation and Cancer, Nature 2002, 420: 860-867; P. Libby, Inflammation in atherosclerosis, Nature 2002, 420: 868-874; C. Benoist and D. Mathis, Mast cells in autoimmune disease, Nature 2002, 420: 875-878; H. L. Weiner and D. J. Seikoe, Inflammation and therapeutic vaccination in CNS diseases, Nature 2002, 420: 879-884; J. Cohen, The Immunopathogenesis of Sepsis, Nature 2002, 420: 885-891; D. Steinberg, Atherogenesis in perspective: Hypercholesterolemia and inflammation as partners in crime, Nature Medicine 2002, 8 (11): 1211-1217. References cited are incorporated herein by reference. Inflammation due to any of a plurality of conditions, such as asthma, chronic obstructive pulmonary disease (COPD), atherosclerosis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease (including Crohn's disease and ulcerative colitis) or psoriasis, which are characterized by excessive or prolonged inflammation at a certain stage of the disease. Applicants have discovered benzoxazol-2-yl, benzothiazol-2-yl and 1H-benzimidazol-2-yl compounds and derivatives thereof, their use as enzyme inhibitors, such as the LTA4H enzyme, in the formation of proinflammatory mediators. , such as the mediator of LTB4, also its use for the treatment of inflammatory conditions; and the preparation of pharmaceutical compositions for the treatment of inflammation.

BRIEF DESCRIPTION OF THE INVENTION LTA4H enzyme inhibitors, having the following general formula (I), are provided by the present invention: 0) wherein X is selected from the group consisting of NR5, O, and S, where R5 is one of H and CH3; And it is selected from the group consisting of CH2, and O; Z is selected from the group consisting of O and bond; W is selected from the group consisting of CH2 and CHR1-CH2) R1 being one of H and OH, wherein the carbon member attached to R1 at said CHR1-CH2 is not directly attached to the nitrogen member to which W is attached; R 4 is selected from the group consisting of H, OCH 3, Cl, F, Br, I, OH, NH 2, CN, CF 3 and CH 3; R6 is H or F; and R2 and R3 are each independently selected from the group consisting of A) H, C-? -7 alkyl, C3-7 alkenyl, wherein the carbon in said alkenyl which is attached to the nitrogen member has only individual bonds , C3- alkynyl, where the carbon in said alkynyl which is attached to the nitrogen member has only individual linkages, optionally benzofused C3-7 cycloalkyl, C5-7 cycloalkenyl, C3- cycloalkyl-C- [alpha] alkyl, -C- [beta] -cycloalkyl C3-7 and phenyl, wherein each of the substituents A) is independently substituted with 0, 1 or 2 RQ, and each of R1Q is a substituent on a carbon member which is at least one carbon member removed from the nitrogen member; B) a HetRa substituent; C) -alkyl of C -? - 7C (O) Rx, optionally substituted with CH2RAr or CH2RAr '; D) -alkyl of C2-5C (O) Rx, wherein two valence carbon members allowed in the C2-5 alkyl of said -C2-5C (O) Rx alkyl are part of a C3-6 carbocycle saturated; E) -C2-5OH alkyl wherein two valence carbon members allowed in the C2.5 alkyl of said -C2.5OH alkyl are part of a saturated C3-6 carbocycle; F) -Co-4 alkylphenyl, wherein the phenyl is said -Co-4 alkylphenyl is fused to two adjacent carbon members in said phenyl to Rf, or is benzofused; G) -alkyl of C0-Ar6, wherein Ar6 is a 6-membered heteroaryl having a carbon member attachment point and having one or two heteroatom members -N =, and benzofused; H) -alkyl of Co-4Ar5, where Ar5 is a heteroaryl of 5 members, having a heteroatom member selected from the group consisting of O, S, and > NRY, and having 0 or 1 additional heteroatom member -N =, optionally containing two carbonyl groups, and optionally benzofused; I) -alkyl of C? -4Ar5 ', wherein Ar5 is a 5-membered heteroaryl containing 3 or 4 nitrogen members, optionally substituted with R ?, and having a valence site allowed as a point of attachment; J) -alkyl of C0-Ar6"6, wherein Ar6" 6 is a phenyl bonded to C0-alkyl fused at sites of valence allowed to a 6-membered heteroaryl, wherein said 6-membered heteroaryl has one or two members of heteroatom -N =; K) -alkyl of C0-Ar6"5, wherein Ar6" 5 is a phenyl bonded to C0-4 alkyl fused at sites of valence allowed to a 5-membered heteroaryl, said 5-membered heteroaryl having a heteroatom member selected of the group consisting of O, S, and >; NRY, and said 5-membered heteroaryl having 0 or 1 additional heteroatom member which is -N =; and L) one of 2- (4-ethyl-phenoxy) -benzothiazole, 2- (4-ethyl-phenoxy) -benzoxazole, and 2- (4-ethyl-phenoxy) -1H-benzimidazole; M) SO 2 -C 1-4 alkyl; alternatively R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is the binding nitrogen, said heterocyclic ring being selected from the group consisting of i) a 4-7 membered heterocyclic ring HetRb, said 4-7 membered heterocyclic ring HetRb having a heteroatom member which is nitrogen of binding, and being substituted with 0, 1, or 2 substituents in the same or different substitution members, said substituent being selected from the group consisting of -R ?, -CN, -C (0) R ?, -alkyl of C0-4CO2R ?, -alkyl of C0-4C (O) CO2RY, -alkyl of C0-4ORY, -alkyl of C0- 4C (O) NR? Rz, -alkyl of C0- NRYC (O) RZ, -C (O) NRzOR ?, -alkyl of C0. 4NR? C (O) CH2OR? - -alkyl of C0-4NRYC (O) CH2C (O) RY - C0 alkyl. 4NR? CO2R? -alkyl of C0-4NRYC (O) NRYRZ, -alkyl of C0-4NRYC (S) NRYRZ - -NR? C (O) CO2R ?, -NRYRZ, -alkyl of C0-4NRWSO2RYI 1, 3-dihydro-indole-2 -one-1-yl, 1,3-dihydro-benzimidazol-2-one-1-yl, tetrazol-5-yl, 1-R? -1 H-tetrazoI-5-yl, R? -triazolyl, 2-R ? -2H-tetrazol-5-yl, pyrrolidin-2-thion-1-yl, piperidin-2-thion-1-yl, -C0-4C (O) N (RY) alkyl (SO2RY), -alkyl C0-4N (RY) (SO2) NRYRY, -alkyl of C0-4N (RY) (SO2) NRYCO2RY, halogen, N-CN N CN N-CN N'0H W H H * Y, -N H? S-RY, H, and ^ R? K H RV; ii) a 5-7 membered heterocyclic ring HetRc, said heterocyclic ring of 5-7 HetRc having an additional heteroatom member separated from the binding nitrogen by at least one carbon members, said additional heteroatom member being selected from the group consists of O, S (= O) or-2, and > NRM, said 5-7 membered heterocyclic ring HetRc having 0 or 1 carbonyl member, and being substituted with 0, 1, or 2 substituents on the same or on different carbon substitution means, said substituents being selected from the group consisting of -C (0) R ?, -CO2R? -C3-4CO2R alkyl? and Rz; iii) one of imidazolidin-1-yl, 2-imidazolin-1-yl, pyrazol-1-yl, imidazol-1-yl, 2H-tetrazol-2-yl, 1H-tetrazol-1-yl, pyrrol-1- ilo, 2-pyrrolin-1-yl, and 3-pyrrolin-1-yl, wherein each of said 2H-tetrazol-2-yl and 1H-tetrazol-1-yl is substituted on the carbon member with 0 or 1 of -C0-4Rz alkyl, -alkyl of C0-4SRY, -C0-4CO2RY alkyl, and HetRa substituent; and iv) one of 1, 2,3,4-tetrahydro-quinolin-1-yl, 1, 2,3,4-tetrahydro-isoquinolin-2-yl, ndol-1-yl, isoindol-2-yl, indolin-1-yl, benzimidazol-1-yl, 2,8-diaza-spiro [4.5-decan-1-one-8-yl, 4-. { [(2-tert-butoxycarbonylamino-cyclobutylenecarbonyl) -amino] -methyl} -piperidin-1-yl, 4-. { [(2-amino-cyclobutanecarbonyl) -amino] -methyl} -piperidin-1-yl, 3,9-diaza-spiro [5.5] undecan-3-carboxylic acid 9-yl-tert-butyl ester, 4-oxo-1-phenyl-1,3,8-triaza-spiro [4.5] dec-8-yl, and 4-oxo-1, 3,8-triaza-esprro [4.5] dec-8-yl; wherein the HetRa substituent is a 4-7 membered heterocyclic ring having a carbon member attachment point and containing a > NRM as a heteroatom member, and said heteroatom member being separated from the carbon member attachment point by at least one additional carbon member; R? is selected from the group consisting of H, -alkyl of C-, -alkyl of C0-4RAr, each optionally substituted with 1, 2, or 3 substituent RN RL is selected from the group consisting of -CO2Rs and -C (O ) NRsRs'; RM is selected from the group consisting of Rz, indol-7-yl, -SO2R ?, -alkyl of C3-4CO2R ?, -CO2R ?, -C (O) NRzOR ?, -C (O) R ?, -C (O) C1-4ORalkyl ?, -C0-4C (O) NRSRS 'alkyl, Co-4C (O) CO2RY alkyl, 1,3-dihydro-indol-2-one-1-yl, 1, 3-dihydro-benzimidazol-2-one-1-yl, tetrazol-5-yl, 1-R? -1H-tetrazol-5-yl, R? -triazolyl, 2-R? -2H-tetrazol-5-yl and -C0-4C (O) N (R?) alkyl (SO2R?), each optionally substituted with 1, 2 or 3 RN substituents; RN is selected from the group consisting of OCH3, Cl, F, Br, I, OH, NH2, CN, CF3, CH3, OC (O) CH3, and NO2; Rp is selected from the group consisting of R ?, -alkyl of C2. 4OR ?, RAr, -alkyl of C1-2CO2R ?, -alkyl of C? -2CONRsRs', indole-7-yl, and -SO2alkyl of C? -4; RQ is selected from the group consisting of fluoro, chloro, bromo, iodo, trifluoromethyl, trichloromethyl, -CN, -alkyl of C? -, -alkyl of Co-4RAr, -alkyl of C0-4RAr ', -alkyl of C0- 4ORY, - C0 alkyl. CO2RY, - C0 alkyl 4NRYRZ, -alkyl of C0-4NRYCORY, -alkyl of C0-4NR? CONR? Rz, -alkyl of C0-4NRYSO2RY, and -C0-4SRY alkyl; Rs and Rs are independently selected from the group that consists of H, -alkyl of C? -, and -alkylphenyl of C0-4; alternatively, Rs and Rs are taken together with the nitrogen member to which said Rs and Rs' are bonded to form a 4- to 7-membered heterocyclic ring having 0 or 1 additional heteroatom member selected from the group consisting of O, S , and > NRY, provided that said additional member and heteroatom is separated by at least two carbon members of said nitrogen member to which Rs and Rs' are attached, and provided that where R? is C0-4RAr alkyl, then RAr is not substituted with RL; Rw is selected from the group consisting of R ?, and -C3-7 cycloalkyl; Rx is selected from the group consisting of -OR ?, -NRYRZ, -C1-4 alkyl, and -C0-4RAr alkyl; R? is selected from the group consisting of H, -C? -alkyl, -C0-4RAr alkyl and -C0-4RAr alkyl, and optionally substituted with 1, 2, or 3 RN substituents; Rz is selected from the group consisting of R ?, -alkyl of C2. 4OR ?, -alkyl of C1-2C02R ?, -alkyl of C1-2C (0) NRsRs ', and -alkyl of C2- 4NRSRS'; when R? and Rz join a nitrogen member, R? and Rz are selected as defined above or R? and Rz are taken together with the nitrogen member attached to R? - and Rz- to form a 4-7 membered heterocyclic ring HetRd having 0 or 1 additional heteroatom member selected from the group consisting of O, S, and > NRM, said ring 4-7 membered heterocyclic HetRd having 0 or 1 carbonyl member, and said 4-7 membered heterocyclic ring HetRd having 0 or 1 allowed valence carbon member 0 or 1 substituted with at least one of RM, -C02H, and -alkyl of C0 -? OR ?; RAr is a portion with a carbon member attachment point and said portion is selected from the group consisting of phenyl, pyridyl, pyrimidyl, and pyrazinyl, wherein each valence carbon member allowed in each of said portions is independently substituted with at least one of 0, 1, 2 or 3 RN, and 0 or 1 RL; RAr "is a ring of 3 to 8 members, having 0, 1 or 2 heteroatom members selected from the group consisting of O, S, N, and> NRY, having 0, 1, or 2 unsaturated bonds, which has 0 or 1 carbonyl member, wherein each valence member allowed in each of the rings is independently substituted with 0, 1, or 2 R?; and Rf is a linear 3 to 5 member hydrocarbon portion having 0 or 1 unsaturated carbon-carbon bond having 0 or 1 carbonyl member, or an enantiomer, diastereomer, racemate, tautomer, hydrate, solvate or a pharmaceutically acceptable salt, ester or amide thereof Modalities of the present invention comprise novel compounds which are inhibitors of LTA4H enzyme and having the general formula (II): Or an enantiomer, diastereomer, racemate, tautomer, hydrate, solvate or a pharmaceutically acceptable salt, ester or amide thereof, wherein R 4, R 6, X, Y, Z, and W are defined as in the compound of the formula I), R2 'is defined as R2 in the compound of the formula (I), and R3 is defined as R3 in the compound of the formula (I), provided that (a) at least one of said R2' and R3 'is not ethyl when a selection in the group consisting of selections (s1), (s2), (s3), and (s4), is satisfied, and each of these selections is specified as (s1): R4 is H , Z is O, W is CH2, Y is CH2, and X is S; (s2): R4 is H, Z is O, W is CH2, Y is CH2 and X is NH; (s3): R4 is H, Z is O, W is CH2, Y is O, and X is S; (s4): R4 is 5-chloro, Z is O, W is CH2, Y is CH2, and X is S; (b) further provided that when Z is a bond, Y is CH2, W is CHR1-CH2, R1 is H, and one of R2 'and R3' is 1H-imidazol-2-yl, then the other of R2 and R3 is selected from A1), B) -L), wherein B) -L) is as defined above for the compound of the formula (I), and A1) consists of H, alkenyl of C3-, wherein the carbon in said C3-7 alkenyl which is attached to the nitrogen member has only single bonds, C3-7 alkynyl, wherein the carbon in said alkynyl which is attached to the nitrogen member has only individual linkages, optionally benzofused C3-7 cycloalkyl, Cs-7 cycloalkenyl, C3-7 cycloalkyl-C-7 alkyl, C3-7 cycloalkyl-C3-7 alkyl; and (c) further provided that when X is S, Y is O, Z is a bond and W is CH2, then one of R2 and R3 is not XCG when the other is alkyl of C1-6, then XCG is the group HC16 wherein HC16 is one of H, C1-6 alkyl, halogen-C-? -6 alkyl, allyl, and C1-6 alkoxymethyl, and GO is a group attached to a carbon member having a substituent = Or forming an amido group (> NC (0) -) with the nitrogen member to which said GO group is attached.

Other embodiments of the present invention comprise new compounds that are inhibitors of LTA4H enzyme and that have the general formula (III): ("i) or an enantiomer, diastereomer, racemate, tautomer, hydrate, solvate or a pharmaceutically acceptable salt, ester or amide thereof, wherein R4, R6, X, Y, Z, and W are defined as in the compound of the formula (I ), R2 'is defined as R2 in the compound of the formula (I), and R3"is defined as R3 in the compound of the formula (I), provided that (a) said R2 and R3 also satisfies one of the following (e1): at least one of R2"and R3 is not C? -5 alkyl, when Z is O and X is S; (e2): none of R2"and R3" is C? .4C (O) Rx alkyl, where Rx is an alkyl of CM, OH, -C1-4alkyl, -C0-4RArOalkyl, or -NRYRY , when Y is O, Z is a bond, and R2"is different from R3 ', and (e3): none of R2" and R3"is -alkyl of C? -6CN, when Y is O, Z is a link and R2"is different from R3"; and (b) further provided that when X is S, Y is O, Z is a bond, and W is CH2, then one of R2 and R3 is not XCG when the other is alkyl of C -? - 6, where XCG is the group HCl 6 wherein HC16 is one of H, C? -6 alkyl, halogen-alkyl of C -? - 6, allyl and alkoxymethyl of C -? - 6, and GO is a group linked by a carbon member having a substituent a = O which forms an amido group (> N-C (O) -) with the nitrogen member to which said GO group is attached. Isomeric forms of the compounds of the above formulas, and their pharmaceutically acceptable salts, amides and esters, are encompassed within the present invention, and the reference herein to one of said isomeric forms refers to at least one of said forms Isomeric One skilled in the art will recognize that the compounds according to the invention can exist, for example in an individual isomeric form while other compounds can exist in the form of a regioisomeric mixture. Whether it is explicitly stated or not in any part of the written description and claims, it is understood that each assignment of substituent and member in the context of this invention is made independently of any other assignment of member and substituent, to unless stated otherwise. As a first example on terminology of substituents, if the substituent S1ejTmpio is one of S-i and S2, and the substituent S2ejTmpio is one of S3 and S4, then these assignments refer to embodiments of this invention given in accordance with the choices whose example is o-i and example is 03, or example is 1 and example is 4; S eemem io is S2 and S2ejem io is S3; S1Exempio is S2 and S2ejemio is S4; and equivalents of each of said elections. The shorter terminology "S1empty is one of Si and S2, and S2empty is one of S3 and S4" is therefore used here for brevity, but not by way of limitation. The first example above on substituent terminology, which is indicated in generic terms, is understood to illustrate the various assignments of substituent R described herein. The previous convention given here for substituents extends, when applicable, to members such as X, Y, Z and W, and the index n. In addition, when more than one assignment is given to any member or substituent, the embodiments of this invention comprise the various groupings that can be made from the listed, independently taken and equivalent assignments thereof. In the manner of a second example or substituent terminology, if it is here described that the STmempio substituent is one of Si, S2 and S3, this list refers to embodiments of this invention for which SejemPio is Si; S mpio is S2; Sejempio is S3; S mpio is one of Si and S2; Seje pio is one of S and S3; Sejempio is one of S2 and S3; Sejempio is one of Si, S2 and S3; and Sejempio is any equivalent of each of these elections. The shorter terminology "Sejempio is one of Si, S2, and S3" is therefore used here for brevity purposes, but not by way of limitation. The second previous example about Substituent terminology, which is indicated in generic terms, means to polish the various assignments of substituent R described herein. The above convention given here for substituents extends, when applicable, to members such as X, Y, Z, and W, and to the index n. The nomenclature "C¡.j" with j > i, when applied herein to a class of substituents, is meant to refer to embodiments of this invention for which each and every carbon number and member, from i to j including i and j, is independently carried out. By way of example, the term C? -3 refers independently to embodiments having a carbon member (C), embodiments having two carbon members (C2), and embodiments having three carbon members (C3). The term alkyl Cn-m refers to an aliphatic chain, either straight or branched, with a total number N of carbon members in the chain satisfying n < N < m, with m > n. When any variable referring to a substituent, member of the compound or index, occurs more than once, it is understood that the full range of assignments applies to each occurrence, regardless of the specific assignment (s) to any another occurrence of said variable. In accordance with previous interpretative considerations on assignments and nomenclature, that the explicit reference here to a set implies, where it is chemically significant and unless it is indicated otherwise, the independent reference to modalities of said set, and references to each and all the possible modalities of subsets of the set referred to for purposes of clarity. The present invention also relates to methods for inhibiting LTA4H enzyme activity with said compounds, and pharmaceutical compositions containing said compounds and methods for using said compositions in the treatment or prevention of conditions that are mediated by LTA4H enzyme activity. The pharmaceutical compositions according to the present invention include at least one of the compounds of the present invention. If more than one of those compounds is included in a composition, the therapeutically effective amount may be a jointly effective amount. As said inhibitors of the LTA4H enzyme, the compounds and compositions according to the present invention are useful in the prevention, inhibition or treatment of inflammation. The invention also relates to a pharmaceutical composition for treating or preventing a condition mediated by LTA4H in a subject, comprising a therapeutically effective amount of at least one LTA4H modulator selected from compounds of formulas (I), (II), and (II), enantiomers, distereomers, racemates thereof, pharmaceutically acceptable salts, amides and esters thereof. In addition, the invention relates to a pharmaceutical composition for inhibiting inflammatory response in a subject, comprising a therapeutically effective amount of minus one LTA4H inhibitor selected from compounds of formulas (I), (II), and (III), enantiomers, diastereomers, racemates thereof, pharmaceutically acceptable salts, amides, and esters thereof. The invention further relates to an anti-inflammatory composition comprising a therapeutically effective amount of at least one antiinflammatory compound selected from compounds of formulas (I), (II), and (III), enantiomers, diastereomers, racemates of the same, pharmaceutically acceptable salts, amides and esters thereof. The invention relates to methods of treating or preventing inflammation in a subject, which comprises administering to the subject in connection with an inflammatory response a pharmaceutical composition comprising a therapeutically effective amount of at least one anti-inflammatory compound selected from compounds of the formulas (I ), (II), and (lll), enantiomers, diastereomers, racemates thereof, pharmaceutically acceptable salts, amides and esters thereof. The invention also relates to methods for treating or preventing a condition mediated by LTA4H in a subject, which comprises administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of at least one LTA4H modulator selected from compounds of the formulas (I ), (II), and (III), enantiomers, diastereomers, racemates thereof, pharmaceutically acceptable salts, amides, and esters thereof. Furthermore, the invention relates to methods for inhibiting inflammation in a subject, which comprises administering to the subject a pharmaceutical composition which comprises a therapeutically effective amount of at least one LTA4H inhibitor selected from compounds of formulas (I), (II), and (III), enantiomers, diastereomers, racemates thereof, pharmaceutically acceptable salts, amides, and esters of the same. This invention relates to methods for the treatment, prevention and / or inhibition of conditions that are associated and / or cause inflammation, such as any of a plurality of the following conditions: asthma, chronic obstructive pulmonary disease (COPD), atherosclerosis, arthritis rheumatoid, multiple sclerosis, inflammatory bowel diseases (including Crohn's disease and ulcerative colitis), or psoriasis, each characterized by prolonged excessive inflammation at some stage of the disease. Additional features and advantages of the invention will be apparent from the following detailed description, including examples and the appended claims.

DETAILED DESCRIPTION OF THE INVENTION The present invention is directed to compounds of formulas (I), (II), or (III) as defined herein, enantiomers, diastereomers, racemates thereof, pharmaceutically acceptable salts, amides and esters thereof, pharmaceutical compositions which contain at least one of said compounds, methods of use, including and / or prevention of conditions such as those that are mediated by LTA4H, and methods for making such pharmaceutical compositions. The following terms are defined below, and for their use throughout the description. "Alkyl" includes straight and branched chain hydrocarbons with at least one hydrogen removed to form a radical group. Alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, 1-methylpropyl, pentyl, stpentyl, sec-pentyl, hexyl, heptyl, octyl, etc. Alkyl does not include cycloalkyl. "Alkenyl" includes straight and branched chain hydrocarbon radicals as above with at least one carbon-carbon double bond (sp2). Unless indicated otherwise, by the prefix indicating the number of carbon members, alkenyls include ethenyl (or vinyl), prop-1 -enyl, prop-2-enyl (or allyl), iso-propenyl (or -methyl vinyl), but-1-enyl, but-2-enyl, butadienyl, pentenyl, hexa-2,4-dienyl, etc. "Alkynyl" includes straight and branched chain hydrocarbon radicals as above with at least one carbon-carbon triple bond (sp). Unless indicated otherwise, by the prefix indicating the number of carbon members, the alkynyl include ethynyl, propynyl, butynyl and pentynyl. The hydrocarbon radicals having a mixture of double bonds and triple bonds, such as 2-penten-4-ynyl, are grouped as alkynyl here. "Alkoxy" includes a straight or branched chain group with a terminal oxygen linking the alkyl group with the rest of the molecule. Alkoxy includes methoxy, ethoxy, propoxy, isopropoxy, butoxy, t-butoxy, pentoxy, etc. "aminoalkyl", "thioalkyl", and "sulfonylalkyl" are analogous to alkoxy, replacing the terminal oxygen atom of alkoxy with, respectively, NH (or NR), S, and SO2. Unless indicated otherwise, by the prefix indicating the number of carbon members, "cycloalkyl" includes cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclooctyl, etc. Unless indicated otherwise by the prefix indicating the number of members in the cyclic structure, "heterocyclyl", "heterocyclic" or "heterocycle" is a single or fused aromatic, saturated or partially saturated 3-ring system 8 members comprising carbon atoms wherein the carbon atoms are selected from N, O, and S. Examples of heterocyclyls include thiazolyl, furyl, pyranyl, isobenzofuranyl, pyrrolyl, imidazolyl, pyrazolyl, isothiazolyl, isoxazolyl, pyridyl, pyrazinyl, pyrimidinyl , pyridazinyl, indolizinyl, isoindolyl, indolyl, indazolyl, purinyl, quinolyl, furazanyl, pyrrolidinyl, pyrrolinyl, imidazolidinyl, imidazolinyl, pyrazolidinyl, pyrazolinyl, piperidyl, piperazinyl, indolinyl, and morpholinyl. For example, heterocyclyls or preferred heterocyclic radicals include morpholinyl, piperazinyl, pyrrolidinyl, pyridyl, cyclohexylimino, cycloheptylimino and most preferably piperidyl. The substitution positions are referred to in conventional terms. For example, group substitution positions Piperidine and piperazine are numbered as follows: "Carbocycle" is a partially saturated cycloalkyl or cycloalkyl that is not benzo "Aryl" includes phenyl, naphthyl, biphenylyl, tetrahydronaphthyl, etc., any of which may be optionally substituted. Aryl also includes arylalkyl groups such as benzyl, phenethyl and phenylpropyl. Aryl includes a ring system containing an optionally substituted 6-membered carbocyclic aromatic ring, said system can be bicyclic, bridged and / or fused. The system may include rings that are aromatic, or partially or cotely saturated. Exas of ring systems include indenyl, pentalenyl, 1-4-dihydronaphthyl, indanyl, benzimidazolyl, benzothiophenyl, indolyl, benzofuranyl, isoquinolinyl, etc. Exas illustrating heteroaryl are thienyl, furanyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, benzothienyl, benzofuranyl, benzimidazolyl, benzoxazolyl, benzothiazolyl. "Halogen" includes fluorine, chlorine, bromine and iodine and is preferably fluorine or chlorine. The term "carbonyl" refers to a portion > C = O, in such a way when this term is characterized as being part of a chain or cyclic structure, the carbon member in the carbonyl group is taken to be one of the carbon members of said chain or cyclic structure. As in the standard chemical nomenclature, the phenyl group is referred to herein as "phenyl" or as "Ph". It is understood that the substitutions and combinations of substitutions mentioned herein, whether explicitly indicated or not, refer to substitutions that are consistent with the valence of the member being replaced. Terms such as "allowed valence site", "valence member allowed" and morphological variations thereof are used here in this sense. For exa, "allowed valence" when applied to the carbon member refers to the tetravalence of C; refers to the trivalency of N when applied to a nitrogen member; and refers to the four bonds of a nitrogen member that is normally characterized by a positive electric charge: The allowed valence options are part of the scope of the technique. "Patient" or "subject" includes mammals such as humans and animals (e.g., dogs, cats, horses, rats, rabbits, mice, non-human primates) in need of observation, experimentation, treatment or prevention in connection with the relevant disease or condition. Preferably, the patient is a human being. "Composition" includes a product that comprises the specified ingredients in the specified amounts, including in the effective quantities, as well as any product resulting directly or indirectly from combinations of the specified ingredients in the specified quantities. "Therapeutically effective amount" or "effective amount" and grammatically related terms means that amount of active compound or pharmaceutical agent that induces the biological or medicinal response in a tissue, animal or human system that is being sought by a researcher, veterinarian, physician or another clinician, which includes relief of the symptoms of disease or disorder that is being treated.

PICTURE OF ACRONYMS The compounds of formulas (I), (II), or (III) comprise compounds that satisfy any of the combinations of definitions given herein and equivalents thereof. It is understood that some compounds referred to herein are chiral and / or have geometric isomeric centers, for exa E and Z isomers. The present invention encompasses all such optical isomers, including diastereoisomers and racemic mixtures, and geometric isomers possessing the activity that characterizes the compounds of this invention. In addition, certain compounds referred to herein may exist in solvated as well as unsolvated forms. It is understood that this invention encompasses all those solvated and unsolvated forms that possess the activity that characterizes the compounds of this invention. The compounds according to the present invention that have been modified to be detectable by some analytical technique, they are also within the scope of this invention. An example of such compounds is an isotopically labeled compound such as, an isotopically-labeled 18F compound that can be used as a probe in the detection and / or imaging techniques. Such as positron emission tomography (PET) and single photon emission computed tomography (SPECT). Other examples of such compounds is an isotopically-labeled compound, such as a compound labeled with deuterium and / or tritium that can be used in reaction kinetics studies. It is understood that the substitutions and combinations of substitutions mentioned herein, whether explicitly indicated or not, refer to substitutions that are consistent with the valency of the member being replaced. For example, a substitution applied to a carbon member refers to the tetravalency of C; refers to the trivalency of N when applied to a nitrogen member; and refers to the four bonds of a nitrogen member conventionally characterized by a positive electric charge. The valence options allowed are part of the scope of the technique. The "pharmaceutically acceptable salts, amides and / or esters thereof" refer to those salts, amides and ester forms of the compounds of the present invention that would be apparent to the pharmaceutical chemist, ie, those which are non-toxic and which would favorably affect the pharmacological properties of said compounds of the present invention. Those compounds that have favorable pharmacological properties would be evident to the pharmaceutical chemist, ie, those who are non-toxic and who possess such pharmacological properties to provide sufficient palatability, absorption, distribution, metabolism and excretion. Other factors, of a more practical nature, which are also important in the selection are costs of the starting materials, ease of crystallization, yield, stability, hygroscopic character and flowability of the resulting bulk drug. Representative acids and bases that can be used in the preparation of pharmaceutically acceptable salts include the following: Acids include acetic acid, 2,2-dichloroacetic acid, adiated amino acids, adipic acid, alginic acid, ascorbic acid, L-aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, (+) - camphoric acid, camphorsulfonic acid, (+) - (1S) -alphafor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, cinnamic acid, citric acid , cyclamic acid, dodecyl sulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxy-ethanesulfonic acid, formic acid, acid fumaric acid, galactactic acid, gentisic acid, glucoheptonic acid, D-gluconic acid, D-glucuronic acid, L-glutamic acid, a-oxo-glutaric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, (+) - acid L-lactic acid (±) -DL-lactic acid, lactobionic acid, maleic acid, (-) - L-malic acid, malonic acid, (±) -DL-mandelic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1,5-disulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, oleic acid, oratic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, L-pyroglutamic acid, salicylic acid, 4-amino-salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, (+) - L-tartaric acid, thiocyanic acid, p-toluenesulfonic acid and undecylenic acid; and bases include ammonia, L-arginine, benetamine, benzathine, calcium hydroxide, choline, deanol, diethanolamine, diethylamine, 2- (diethylamino) -ethanol, ethanolamine, ethylenediamine, N-methyl-glucamine, hydrabamine, 1 H-imidazole , L-lysine, magnesium hydroxide, 4- (2-hydroxyethyl) -morpholine, piperazine, potassium hydroxide, 1- (2-hydroxyethyl) -pyrrolidine, secondary amine, sodium hydroxide, triethanolamine, tromethamine and zinc hydroxide. See, for example, S.M. Berge, et al., "Pharmaceutical Salts", J. Pharm. Sci. 1977, 66: 1-19, which is incorporated herein by reference. Examples of suitable esters include C? -7 alkyl, C5-cycloalkyl, phenyl, substituted phenyl and phenyl-C? -6 alkyl esters. Preferred esters include methyl esters. The present invention includes prodrugs within its scope of the compounds of this invention. In general, said prodrugs will be functional derivatives of the compounds that are readily convertible in vivo to the required compound. Therefore, in the methods of treatment of the present invention, the term "administer" will encompass the treatment of the various disorders described with the specifically described compound or with a compound that may not be specifically described, but is converted to the specified compound in vivo after administration to the patient. Conventional procedures for the selection and preparation of suitable prodrug derivatives are described, for example, in "Design of Prodrugs", ed. H. Bundgaard, Elservier, 1985. Modalities of this invention, wherein X is O, are made in accordance with the synthesis methods delineated in the AD and FL schemes, have demonstrated LTA4H inhibitory activity and are selected from the group consisting of : Example Compound 11 2- [4- (2-piperidin-1-yl-ethoxy) -phenoxy] -benzoxazole; 13 (1 - { 2- [4- (benzooxanzol-2-yloxy) -phenoxy] ethyl} -piperidin-4-yl) -methanol; 14 1 -. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-ol; 16 { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -dibuti-amina; 21 (1- { 2- [4- (benzoxazol-2-yloxy) -phenoxy] -ethyl} -piperidin-2-yl) -methanol; 27 1-. { 3- [4- (benzoxazol-2-yloxy) -phenoxy] -propyl} -4-phenyl-piperidin-4-ol; 28 1-3- [4- (benzoxazol-2-yloxy) -phenoxy] -propyl} -4-benzyl-piperidin-4-ol; 29 2- [4- (2-piperidin-1-yl-ethyl) -phenoxy] -benzoxazole; 35 { 3- [4- (benzoxazol-2-yloxy) -phenyl] -propyl} -cyclohexy-ethyl-amine; 36 1 -3- [4- (Benzoxazol-2-yloxy) -phenyl] -propyl} -piperidin-4-ol; 40 1-. { 3- [4- (benzoxazol-2-yloxy) -phenoxy] -2-hydroxy-propyl} -4-phenyl-piperidin-4-ol; 41 1- [2- (4-Benzoxazol-2-ylmethyl-phenoxy) -ethyl] -piperidine-4-carboxylic acid ethyl ester; 44 2- [4- (2-pyrrolidin-1-y-ethoxy) -phenoxy] -benzoxazole; Four. Five . { 3- [4- (benzoxazol-2-yloxy) -phenoxy] -propyl} dimethyl amine; 46 { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} dimethyl amine; 47 2- [4- (2-azepan-1-yl-ethoxy) -phenoxy] -benzoxazole; 53 1-. { 2- [4- (benzoxazol-2-yloxy) -phenoxyl-ethyl} -4-phenyl-piperidin-4-ol; 54 { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -cyclohexyl-ethyl-amine; 55 { 2- [4- [2-ethyl-piperidin-1-yl] -ethoxy] -phenoxy} -benzoxazole; 56 1 -. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4-phenyl-piperidin-4-carbonitrile; 57 1 - (1 - { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4-pheni) -piperidin-4-yl) -ethanone; 58 2-. { 4- [2- (4-Methyl-piperidin-1-yl) -ethoxy] -phenoxy} -benzoxazoI; 59 1 -. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4- (4-chloro-phenyl) -piperidin-4-ol; 60 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4- (4-bromo-phenyl) -piperidin-4-ol; 61 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4- (4-chloro-3-trifluoromethyl-phenyl) -piperidin-4-ol; 62 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4-benzyl-piperidin-4-ol; 63 { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -cyclohexyl-methyl-amine; 64 { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -cyclopropylammethyl propyl amine; 65 { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -butyl-ethyl-amine; 2- (.. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -benzyl-amino} -ethanol; 67 2-. { 4- [2- (4-Benzyl-piperidin-1-yl) -ethoxy] -phenoxy} -benzoxazole; 68 (1- { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -piperidin-3-yl) -methanol; 69 2- (. {2- 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -propyl-amino) -ethanol; 77 2- [4- (2-Azetidin-1-yl-ethoxy) -phenoxy] -benzoxazole; 78? - (1- { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -2-phenyl-acetamide; 79 ethyl ester of 1- acid. { 2- [4- (BenzoxazoI-2-yloxy) -phenoxy] -ethyl} -piperidine-3-carboxylic acid; 86 2-. { 4- [3- (4-Phenyl-piperidin-1-yl) -propoxy] -phenoxy} -benzoxazole; 88 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -4-phenyl-piperidin-4-ol; 89 { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -cyclohexyl-ethyl-amine; 90 2- [4- (2-Pyrrolidin-1-yl-ethyl) -phenoxy] -benzoxazole; 91 2- [4- (2-Azepan-1-yl-etiI) -phenoxy] -benzoxazole; 92 { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl propyl amine; 93 { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -dibutylamine; 94 1 -. { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-ol; 96 methyl ester of 1- acid. { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; 116 1-. { 3- [4- (Benzoxazol-2-yloxy) -phenyl] -propyl} -4-phenyl-piperidin-4-ol; 120 2- [4- (3-Piperidin-1-yl-propyl) -phenoxy] -benzoxazole; 121. { 3- [4- (Benzoxazol-2-yloxy) -phenyl] -propyl} -dibutyl-amine; 122 { 3- [4- (Benzoxazol-2-yloxy) -phenyl] -propyl} -cyclopropylmethyl propyl amine; 135 1 - [4- (Benzoxazol-2-yloxy) -phenoxy] -3-pyrrolidin-1-yl-propan-2-ol; 136 1- [2- (4-Benzoxazol-2-ylmethyl-phenoxy) -ethyl] -4-phenyl-p-perindo-4-ol; 137- [2- (4-Benzoxazol-2-ylmethyl-phenoxy) -ethyl] -piperidine-4-carboxylic acid amide; 271 2- (4-Piperidin-1-ylmethyl-phenoxy) -benzoxazole; 481 2- [4- (2-Morpholin-4-yl-ethoxy) -phenoxy] -benzoxazole; and 484. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -diethyl-amine. Other embodiments of this invention, wherein X is S, are made in accordance with the synthetic methods delineated in schemes A-G, and L-L, have demonstrated the inhibitory activity of LTA4H, and are selected from the group consisting of: Example Compound 12. { 2- [4- (6-chloro-benzothiazol-2-yloxy) -phenoxy] -phenoxy] -ethyl} -diethyl-amine; 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-ol; 17 ethyl ester of 1- acid. { 2- [4- (benzothiazoi-2-yloxy) -phenoxy] -ethyl} - piperidine-4-carboxylic; 18 acid 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carboxylic acid; 19 (1- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -pyrrolidin-1-yl-methanone; Ethyl 3 - [(1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carbonyl) -amino] -propionic acid ethyl ester; 22 acid amide 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carboxylic acid; 1- (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -pyrrolidin-2-one; 24 1 '-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - [1, 4 '] bipiperidinyl-2-one; 8-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -2,8-diaza-spiro [4.5] decan-1-one; 26 2- [4- (3-pyrrolidin-1-yl-propoxy) -phenoxy] -benzothiazole; 30 { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclohexyl-ethylamine; 31 acid amide 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-3-carboxylic acid; 32 1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -3-methyl-1,3-dihydro-benzimidazole-2 -one; 33 methyl ester of acid 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; 34 (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.}. -piperidin-4-yl) - (4-methyl- piperazin-1-yl) -methanone; Methyl 1- [2- (4-benzothiazol-2-ylmethyl-phenoxy) -ethyl] -piperidine-4-carboxylic acid methyl ester; 43 3- (- {. 2- [4- (Benzothiazol-2-yloxy) -phenoxy-ethyl} -. Cyclopropyl-amyne) -propionic acid; 48 { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} dimethyl amine; 49 2- [4- (2-pyrrolidin-1-yl-ethoxy) -phenoxy] -benzothiazole; fifty . { 3- [4- (benzothiazol-2-yloxy) -phenoxy] -propyl} dimethyl amine; 51 2- [4- (2-azepan-1-yl-ethoxy) -phenoxy] -benzothiazole; 52 2- [4- (2-azepan-1-yl-ethoxy) -phenoxy] -6-methoxy-benzothiazole; 70 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -4-phenyl-piperidin-4-ol; 71 { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -cyclohexyl-ethyl-amine; 72 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -4- (4-chloro-phenyl) -piperidin-4-ol; 73 { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -dibutyl-amine; 74 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -4- (4-bromo-phenyl) -piperidin-4-ol; 75 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -4- (4-chloro-3-trifluoromethyl-phenyl) -piperidin-4-ol; 76 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -4-benzyl-piperidin-4-ol; 80 1 '-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - [1, 4 '] bipiperidine; 81 (1- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -etyl] -piperidin-4-yl) -methanol; 82? / - (1- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -2-phenyl- acetamide; 83 1 '-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - [1, 4 '] bipiperidinyl-2-one; 84 2- (4- { 2- [4- (2-morpholin-4-yl-ethyl) -piperazin-1-yl] -ethoxy.} - phenoxy) -benzothiazole; 85 2- (4- { 2- [4- (2-morpholin-4-yl-ethyl) -piperazin-1-yl-ethyl} - phenoxy) -benzothiazole; 87 1-. { 3- [4- (benzothiazol-2-yloxy) -phenoxy] -propyl} -4-phenyl-piperidin-4-ol; 95 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -4-phenyl-piperidin-4-ol; 97 2- [4- (2-pyrrolidin-1-yl-ethyl) -phenoxy] -benzothiazole; 98 2- [4- (2-azepan-1-yl-ethyl) -phenoxy] -benzothiazole; 99 { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl-propyl-amine; 100 { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -dibutyl-amine; 101 2- [4- (2-piperidin-1-yl-ethyl) -phenoxy] -benzothiazole; 102 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperdin-4-ol; 103 methyl ester of 1- acid. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; 104 acid amide 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-carboxylic acid; 105 ethyl ester of 1- acid. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-3-carboxylic acid; 106 ethyl ester of 1- acid. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -4-phenyl-piperidine-4-carboxylic acid; 107 (1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -ethyl ester. piperidin-4-yl) -acetic; 108 1- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -etyl] -piperidin-4-yl) -1,3-dihydro-indole-2- ona; 109 1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperdin-4-yl) -pyrrolidin-2-one; 110? - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.}. -piperidin-4-yl) -2-phenyl-acetamide; 111 8-. { 2- [4- (benzothiazol-2-yloxy) -pheni]] - eti)} -2,8-diaza-spiro [4.5] decan-1-one; 112 1-. { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl) -p -peridin-3-ol; 113 1- ethyl ester. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; 114 1 '-. { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - [1, 4 '] bipiperidine; 115 2-. { 4- [2- (4-methyl-piperazin-1 -li) -ethyl] -phenoxy} -benzothiazole; 143 2- (4- { 2- [4- (1-Benzyl-1 H -tetrazol-5-yl) -piperidin-1-yl] -ethoxy.} - phenoxy) -benzothiazole; 144 4- (1. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carbonyl) -piperazine-1-carboxylic acid tert-butyl ester; 146 2- (4- { 2- [4- (2-morpholin-4-yl-ethyl) -piperazin-1-yl] -ethyl} -phenoxy) -benzothiazole; 147 1- [2- (4-Benzothiazol-2-ylmethyl-phenoxy) -ethyl] -piperidine-4-carboxylic acid amide; 148 1 -. { 1 - [2- (4-benzothiazol-2-ylmethyl-phenoxy) -ethyl] -piperidin-4-yl} - pyrrolidin-2-one; 149 1- [4- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carbonyl) -piperazin-1-yl] -ethanone; 150 acid 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; 151 1- (1- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -pyrrolidin-2-thione; 152 2- (4- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperazin-1-yl) -ethanol; 153 2- (4- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} - piperazin-1-yl) -1-pyrrolidin-1-yl-ethanone; 2- (4- { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - piperazin-1-yl) -1-morpholin-4-yl-ethanone; 155 acid 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-3-carboxylic acid; 156 acid 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-2-carboxylic acid; 157 (1- {2- {4- (benzothiazol-2-yloxy) -phenyl] -etyl} -piperidin-3-yl) -acetic acid; 158 (1- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -acetic acid ethyl ester; 159 (1- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -carbamic acid tert-butyl ester; 160 (1- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -acetic acid; 161 (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-3-yl) -methanol; 162 (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclohexyl-amino) -acetic acid methyl ester; 163 (4- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperazin-1-yl) -acetic acid; 164 1- (1. {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -5-oxo-pyrrolidine-2-carboxylic acid ethyl ester; 166 1- (1- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -etyl} -piperidin-4-yl) -5-oxo-pyrrolidine-2-carboxylic acid; 167. 4- (4- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl.} - piperazin-1-yl) -phenol; 168? / - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenoxy-3-ethyl} -piperidin-4-yl) -4-chloro-β-cyclopropyl-benzenesulfonamide; 170 3- (- {. 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - cyclopropylmethyl-amino) -propionic acid; 171 3- (- {. 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl) -isopropyl-amino) -propionic acid; 172 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -etl} -piperidin-4-ilamine; 173 3- [acid. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - (1-methyl-piperidin-4-yl) -amino] -propionic; 174 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -benzyl-amino) -propionic acid; 175 3 - ((1-acetyl-piperidin-4-yl) -. {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -amino) -propionic acid; 176 4- (1-. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -1-H-tetrazol-5-yl) -piperidine-1-tert-butyl ester carboxylic; 177 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etyl} -cyclopropyl-amino) -propionic acid; 178 3 - ((1-acetyl-piperidin-4-yl) -. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -amino) -propionic acid; 179 3- [acid. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - (1-methyl-piperidin-4-yl) -amino] -propionic; 180 3- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -propionic acid; 181 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -fenii] -ethyl} -isopropyl-amino) -propionic acid; 182 2- (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) -1-pyrrolidin-1-yl-ethanone; 183 (R) -1- acid. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-3-carboxylic acid; 184 1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -1,3-dihydro-benzimidazol-2-one; 185 2- (4- { 2- [4- (6-Methyl-pyridin-2-yl) -piperazin-1-yl] -ethyl} -phenoxy) -benzothiazole; 186 2-4- [2- (4-ethanesulfonyl-piperazin-1-yl) -ethyl] -phenoxy} -benzothiazole; 187 2- (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -1-morpholin-4-yl-ethanone; 188 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -methyl-amino) -propionic acid; 189 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopentyl-amino) -propionic acid; 190 3- (- {. 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclobutyl-amino) -propionic acid; 192 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -benzyl-amino) -propionic acid; 193 (1 - { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) - (4-hydroxymethyl-piperidin-1-yl) -metanone; 194 { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amine; 195 (1- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl] -piperidin-4-yl) - [4- (2-hydroxy-ethyl) -piperazine-1 -yl] -metanone; 196 (1 - { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) - [4- (2-hydroxy-ethyl) -piperidin-1- il] -metanone; 197 2- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.} - cyclopropyl-amino) -ethanol; 198 3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propan-1-ol; 199 4- ( { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -butyric acid; 200 3 - [(1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-carbonyl) -aminoj-propionic acid; 201 4- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl.} - cyclopropyl-amino) - butyronitrile; 202 3- (1 -. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -propionic acid; 203 [(1 -. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carbonyl) -methyl-amino] -acetic acid; 204 3- (4- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperazin-1-yl) -phenol; 205 2- (4- { 2- [4- (4-methoxy-phenyl) -piperazin-1-yl] -ethoxy.} - phenoxy) -benzothiazole; 206 2-. { 4- [2- (5-piperidin-4-yl-tetrazol-1-yl) -ethoxy] -phenoxy} -benzothiazole; 207 (S) -1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -4-hydroxy-pyrrolidin-2 -one; 208 { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl-amine; 209 2 - [(. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -.-cyclopropyl-amino) -methyl] -cyclopropanecarboxylic acid ethyl ester; Ethyl 4- (4- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperazin-1-carbonyl) -benzoic acid ethyl ester; 211 2 - [(. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -methyl-cyclopropanecarboxylic acid; 212 1 - ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propan-2-ol; 213 3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino) -1,11-trifluoro-propan-2-ol; 214 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl.} - cyclopropyl-amino) - propionamide; 215 3- ({2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propane-1,2-diol; 216 2-. { 4- [2- (5-phenyl-tetrazol-2-yl) -ethoxy] -phenoxy} -benzotiazo, 217 2-. { 4- [2- (5-phenyl-tetrazol-1-yl) -ethoxy] -phenoxy} -benzothiazole; 218? / -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -N-cyclopropyl-2- (2H-tetrazol-5-yl) -acetamide; 219 (S) -3- ( { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino) -2-methyl-propan-1-ol; 220 (f?) - 3- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -2-methyl-propan-1-ol; 221 2-. { 4- [2- (5-methylsulfanyl-tetrazol-2-yl) -ethoxy] -phenoxy} -benzothiazole; 222 2-. { 4- [2- (5-Methylsulfanyl-tetrazol-1-yl) -ethoxy] -phenoxy} -benzothiazole; 223 2- [4- (2-tetrazol-2-yl-ethoxy) -phenoxy] -benzothiazole; 224 2- [4- (2-tetrazol-1-yl-ethoxy) -phenoxy] -benzothiazole; 225 acid (1 2R) -2-. { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethylamino} -cyclohexanecarboxylic; 226 acid (1 S, 2R) -2-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino} -cyclohexanecarboxylic; 227 (1 f?, 2f?) - 2-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino} -cyclohexanol; 228 (1S, 2f?) - 2-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino} -cyclohexanol; 229 4- (1 -. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-ii) -butyric acid; 250- [4- (Benzothiazol-2-yloxy) -benzyl] -piperidine-4-carboxylic acid; 251 1 -. { 1 - [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -pyrrolidin-2-one; 252 2- (2-fIuoro-4-piperidin-1-ylmethyl-phenoxy) -benzothiazole; 253 N-. { 1- [4- (benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -2-hydroxy-acetamide; 254 1- (2-. {[[4- (benzothiazol-2-yloxy) -benzyl] -cyclopropyl-amino} -eti) -4-hydroxy-pyrrolidin-2-one; 255 N-. { 1- [4- (benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -N-methyl-methanesulfonamide; 256 2-. { 4- [4- (1 H-Tetrazol-5-yl) -piperidin-1-ylmethyl] -phenoxy} -benzothiazole; 257 1 -. { 4- [4- (benzothiazol-2-yloxy) -benzyl] -piperazin-1-yl} -2-hydroxy-ethanone; 258 N-. { 1- [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-ylmethyl} -metanesulfonamide; 259 3-. { 1- [4- (benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -oxazolidin-2-one; 260 4-. { 1- [4- (benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -morpholin-3-one; 261 (R) 1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -4-hydroxy-pyrrolidin-2-one; 262 2- (4- { 2- [4- (1 H-Tetrazol-5-yl) -piperidin-1-yl] -ethyl} -phenoxy) -benzothiazole; 263 (1- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-2-yl) -methanol; 264 (1 -. {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl] ethyl ester. -1 H- tetrazol-5-yl) -acetic; 265 (1 -. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -1H-tetrazol-5-yl) -acetic acid ethyl ester; 266 hydrochloride. { 4- [2- (5-piperidin-4-yl-tetrazol-2-yl) -ethoxy] -phenoxy} -benzothiazole; 267 7-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -4-spiro- [3-phthalis] -piperidine; 268 ethyl ester of 1- acid. { 3- [4- (benzothiazol-2-yloxy) -phenyl] -propyl} -piperidine-4-carboxylic acid; 269 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamine hydrochloride; 270 2- (4- { 2- [4- (1 H -tetrazol-5-yl) -piperidin-1-yl] -ethoxy.} -phenoxy) -benzothiazole; 271 2- (4-piperidin-1-ylmethyl-phenoxy) -benzoxazole; 272 [4- (benzothiazol-2-yloxy) -benzyl] -cyclohexyl-ethyl-amine; 273 [4- (benzothiazol-2-yloxy) -benzyl] -cyclopropylmethyl-propyl-amine; 274 1- [4- (Benzothiazol-2-yloxy) -benzyl] -p -peridine-4-carboxylic acid amide; 275 1 '- [4- (benzothiazol-2-yloxy) -benzyl] - [1,4'] bipiperidinyl-2-one; 276 { 4- [4- (benzothiazol-2-yloxy) -benzyl] -piperazin-1-yl} -pyridin-3-yl-methanone; 277 tert-butyl acid ester. { 1- [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-ylmethyl} -carbamic; 278 methyl acid ester. { 1- [4- (benzothiazol-2-yloxy) -benzyl] -piperidine- 4-ylmethyl} -carbamic; 279 n-butyl tert-butyl ester. { C - [[4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl] -methylamino-sulfonyl} -carbamic, 280 N-hydrochloride. { 1- [4- (benzothiazol-2-yloxy) -benzyl] -piperidin-4-ylmethyl-sulfonamide, 281 N-. { 1- [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-ylmethyl} -acetamide; 282 acid. { 1 - [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -acetic; 283 ( { 1 - [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-ylmethyl} -carbamoyl) -methyl acetic acid ester; 284 [2- (. {1- [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-ylmethyl] -carbamoyl) -cyclobutyl] -carbamic acid tert-butyl ester; 285 dihydrochloride. { 1- [4- (Benzothiazol-2-yloxy) -benzyl] -piper-dine-4-ylmethyl-2-amino-cyclobutanecarboxylic acid amide; 286 2- (4-pyrrolidin-1-ylmethyl-phenoxy) -benzothiazole; 287 2 - ([4- (benzothiazol-2-yloxy) -benzyl] -ethyl-amino} -ethanol; 288 2- { 1- [4- (benzothiazol-2-yloxy) -benzyl] -piperidine -2-yl.) -ethanol; 289 1 - { 4- [4- (benzothiazol-2-yloxy) -benzyl] -piperazin-1-yl} -ethanone; 290 8- [4- ( benzothiazol-2-yloxy) -benzyl] -2,8-diaza-spiro [4.5] decan-1-one; 291 Spiro [isobenzofuran-1 (3H), 4'-piperidin] -3-one, 1 '- [4- (benzothiazol-2-yloxy) -benzyl] 292 (R) -1 - [4- (benzothiazole-2 -iloxy) -benzyl] -pirroüdin-3-ol; 293 2- [4- (2-methyl-piperidin-1-ylmethyl) -phenoxy] -benzothiazole; 294 [4- (benzothiazol-2-yloxy) -benzyl] -d-ethyl-amine; 295 [4- (benzothiazol-2-yloxy) -benzyl] -butyl-methyl-amine; 296 2-. { 1- [4- (benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -ethanol; 297 1 - [4- (benzothiazol-2-yloxy) -benzyl] -piperidin-4-ol; 298. { 1- [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-2-yl} -methanol; 299 (ft) -. { 1 - [4- (Benzothiazol-2-yloxy) -benzyl] -pyrrolidin-2-yl} -methanol; 300 2- (4-azetidin-1-ylmethyl-phenoxy) -benzothiazole; 301 1 - [4- (benzothiazol-2-yloxy) -benzyl] - [1,4] diazepan-5-one; 302 { 1- [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-2-yl} -methanol; 303 1- [4- (Benzothiazol-2-yloxy) -benzyl] -piperidine-3-carboxylic acid amide; 304 9- [4- (Benzothiazol-2-yloxy) -benzyl] -3,9-diaza-spiro [5.5] undecane-3-carboxylic acid tert-butyl ester; 305 2-. { 1- [4- (benzothiazol-2-yloxy) -benzyl] -piperidin-3-yl} -ethanol; 306 cis-4- trifluoromethanesulfonate salt. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino} -cyclohexanecarboxylic; 307 (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-ii) - (tetrahydro-furan-2-yl) -methanone; 308 (1-. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl] -piperidine-4-carbonyl) -ampaned propan-2-sulfonic acid; 309 (4- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) -oxo-acetic acid methyl ester; 310 N- (1- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -ethyl} -piperidine-4-carbonyl) -benzenesulfonamide trifluoromethanesulfonate salt; 311 trifluoromethanesulfonate salt of N- (1-. {2- [4- (benzothiazol-2-yloxy) -phenyl] -etii.} - piperidine-4-carbonyl) -methanesulfonamide; 312 (4- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) -oxo-acetic acid trifluoromethanesulfonate salt; 313 (4-. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -morpholin-4-yl-methanone; 314 1 - (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -2-thiophen-2-yl-ethanone; 315 (4-. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -pyridin-3-yl-methanone; 316 (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -cyclopropyl-methanone; 317 1 - (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -etii.} - piperazin-1-yl) -2-methoxy-ethanone; 318 1- (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -2,2,2-trifluoro-ethanone; 319 4- (4- { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -. - piperazin-1 -carbonyl) -benzoic acid; 320 (4-. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -pyridin-4-yl-methanone; 321 (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -etyl] -piperazin-1-yl) - (5-methyl-pyrazin-2-yl) -methanone; 322 (/?) - (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.}. -p.perazin-1-yl) - (tetrahydro-furan-2-yl) -methanone; 323 (S) - (4- { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl] -piperazin-1-yl) - (tertrahydro-furan-2-yl) -methanone; 324 (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl] -piperazin-1-yl) - (tetrahydro-furan-3-yl) -methanone; 325 1- (4- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -2-hydroxy-ethanone; 326 2- [2- (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -2-oxo-ethyl] -cyclopentanone; 327 3- (4. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) -propionic acid trifluoromethanesulfonate salt; 328 3- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -oxazolidn-2-one; 329 4- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -morpholin-3-one; 330 4- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperdin-4-yl) -morpholin-3-one; 331 3- (1- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -oxazolidin-2-one; 332 benzyloxy-1-acid amide. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; 333 (1 -. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etyl] -piperidin-4-yl) -acetic acid; 334 (ft) -1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.}. -piperidin-4-yl) -4-hydroxy-pyrrolidin-2- ona; 335 hydroxyamide of acid 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; 336 (S) -1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -4-hydroxy-pyrrolidine -2-ona; 337 (1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -carbamic acid tert-butyl ester; 338 2-. { 4- [2- (4-fluoro-piperidin-1-yl) -ethyl] -phenoxy} -benzothiazole; 339 2-. { 4- [2- (4,4-difluoro-piperidin-1-yl) -ethyl] -phenoxy} -benzothiazole; 340 (R) -1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -pyrrolidin-3-ol; 341 N-1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -formamide; 342 (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -urea; 343 1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -3-cyano-2-phenyl-isourea; 344 1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -3-cyano-2-methyl-isothiourea; 345 N- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -methanesulfonamide; 346 1- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -3-cyano-2-methyl-guanidine; 347 8-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -1-phenyl-1, 3,8-triaza-spiro [4.5] decan-4-one; 348 8-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -1, 3,8-triaza-spiro [4.5] decane-2,4-dione; 349 (1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -methyl-carbamic acid tert-butyl ester; 350 N- (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -etyl] -piperidin-4-yl) -N-methyl-acetamide; 351 N- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -N-methyl-methanesulfonamide; 352 [(1 - { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl] -piperidin-4-yl) -methyl-carbamoyl-methyl ester of acetic acid; 353 N- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -N-acetamide; 354 (1 -. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl-ethyl-ethyl} -piperidin-4-ylcarbamoyl) -methyl acetic acid ester; 355 2- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -methyl-amino) -3- (1 H -imidazol-2-yl) -propionic acid; 356 2- (4-. {2- [4- (3-nitro-pyridin-2-yl) - [1,4] diazepan-1-yl-ethyl} - phenoxy) -benzothiazole; 357 2- (4-piperdin-1-ylmethyl-phenoxy) -benzothiazole; 358 1 - [4- (benzothiazol-2-yloxy) -benzyl] -4-phenyl-piperidin-4-ol; 359 1 - [4- (benzothiazol-2-yloxy) -benzyl] -piperidin-4-ol; 360 { 1- [4- (benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -methanol; 361 N-. { 1- [4- (benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} - methanesulfonamide; 362 N-. { 1- [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-ylmethyl} -2-hydroxy-acetamide; 363 methyl ester of acid. { 1- [4- (benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -carbámico; 364 { 1- [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-ylmethyl} -urea; 365 N-. { 1- [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-ylmethyl} -2,2,2-trifluoroacetamide; 366 acid. { 4- [4- (benzothiazol-2-yloxy) -benzyl] -piperazin-1-yl} -acetic; 367 2- [4- (4-methanesulfonyl-piperazin-1-ylmethyl) -phenoxy] -benzothiazole; 368 1 -. { 4- [4- (benzothiazol-2-yloxy) -benzyl] -piperazin-1-yl} -2,2,2-trifluoro-ethanone; 369 2- (4-morpholin-4-ylmethyl-phenoxy) -benzothiazole; 370 phenyl ester of acid. { 1- [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -carbamic; 371 N-1 - [4- (benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -benzenesulfonamide; 372 3- [4- (Benzothiazol-2-yloxy) -benzyllane] -propionic acid ethyl ester; 373 3- [4- (Benzothiazol-2-yloxy) -benzylamino] -propionic acid; 374 [(1- {2- [4- (Benzothiazol-2-yloxy) -phenox] -ethyl} -piperidine-4-carbonyl) -methyl-amino] -acetic acid ethyl ester; 376 ethyl ester of 1'- acid. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - [1, 4 '] bipiperidinyl-4-carboxylic; 377 1 'acid. { 2- [4- (benzothiazol-2-yloxy) - [phenoxy] -ethyl} - [1, 4 '] bipiperidinyl-4-carboxylic acid; 378 { 2- [4- (benzothiazol-2-yloxy) -phenyl-etl} -cyclopropyl-ethylamine; 379 trifluoromethanesulfonic acid salt of 3- (. {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -2-methyl-propionic acid; 380 2- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl-amino) -ethanol; 381 2- [2- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -ethoxy] -ethanol; 382 3- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -etyl} -. Cyclopropylmethyl-amino) -propan-1-ol; 383. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl- (3-tetrazol-2-yl-propyl) -amine; 384. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl- (3-pyrrol-1-yl-propyl) -amine; 385 4- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -butyronitrile; 386 (2-cyano-ethyl) -amide of 1- acid. { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; 387. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl- [3- (2H-tetrazol-5-yl) -propyl] -amine; 388 3- [5- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -etyl}. -piperidin-4-yl) -tetrazole- 1-yl] -propionitrile; 389 { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl- [3- (2H-tetrazol-5-yl) -propyl] -amine; 390 (2-hydroxy-1, 1-dimethyl-ethyl) -amide of 1-acid. { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; 391 { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl- [3- (1 H- [1, 2,4] triazol-3-yl) -propyl] -amine; 392 { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl- [3- (5-methyl-1 H- [1, 2,4] triazol-3-yl) -propyl] -amine; 393. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl- [3- (5-phenyl-1 H- [1, 2,4] triazol-3-yl) -propyl] -amina; 394 2- (4- { 2- [4- (1-methyl-1 H-tetrazol-5-yl) -piperidin-1-yl] -ethyl} -phenoxy) -benzothiazole; 395 2- (4- { 2- [4- (2-methyl-2H-tertrazol-5-yl) -piperidin-1-yl] -ethyl} -phenoxy) -benzothiazole; 396 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carbonyltryl; 397 2- (4- { 2- [4- (1 H- [1, 2,3] triazol-4-yl) -piperidin-1-yl] -ethyl} -phenoxy) -benzothiazole; 398 ethyl ester of 4- acid. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino} -butyric; 399 4- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etyl} -cyclopropylmethyl-amino) -butyric acid ethyl ester; 400 2- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.} - cyclopropylmethyl-amino) - propyl] -isoindole-1,3-dione; 401 4- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -butyric acid; 402 1- (3- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethylamino} -propyl) -pyrrolidin-2-one; 403 N-1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -N1-cyclopropylmethyl-propane-1,3-diamine; 404 5- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -pentanoic acid methyl ester; 405 N- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -propyl-acetamide; 406 [morpholine-4-carboxylic acid [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl-amino) -propyl] -amide; 407 N- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -propyl-methanesulfonamide; 408 5- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -pentanoic acid; 409 1- [3- ( { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - isopropyl-amino) -propyl] -pyrrolidin-2-one; 410 1 - [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -propyl] -pyrrolidin-2-one; 411 1 - [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl] -pyrrolidin-2-one; 412 1 - [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - propyl-amino) -propyl] -pyrrolidin-2-one; 413 4 - ((1-Acetyl-piperidin-4-yl) -. {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -amino) -butyric acid ethyl ester; 414 ethyl ester of 4 - ((1-acetyl-piperidin-4-yl) -. {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -amino) -butyric acid ester; 415 4- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -metanesulfonyl-amino) -butyric acid; 416 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etyl-cydopropyl-amino) -acetic acid; 417 6- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -hexanoic acid ethyl ester; 418 7- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -.-cyclopropyl-amino) -heptanoic acid ethyl ester; 419 6- (. {2- 2- [4- (Benzothiazoi-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amine) -hexanoic acid; 420 7- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etiyl} -cyclopropyl-amino) -heptanoic acid; 421 N-1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -N1-cyclopropyl-propane-1,3-diamine; 422 N- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyraz-acetamide; 423 N- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.}. -cidopropyl-amino) - propyl] -isobutyramide; 424 N- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl-benzamide; 425 N- [3- ( { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl] -4-chloro-benzamide; 426 N- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phene!] -ethyl.} - cyclopropyl-amino) -propyl-methanesulfonamide; 427 [3- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl-phenyl] -cyclopropyl-amino) -propyl] -amide trifluoromethanesulfonic acid of propan-2-sulfonic acid; 428 8- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -octanoic acid ethyl ester; 429 1- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl] -3-phenyl-urea; 430 8- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino-octanoic acid; 431 [3- (. {2- [4- (benzothiazole 2-yloxy) -phenyl] -ethyl.} - cyclopropyl-amino) -propyl] -amide of tetrahydro-furan-2-carboxylic acid; 432 N- [3- (. {2- 2- 4- (benzothiazol-2-yloxy) -pheno] -ethyl.}. -cyclopropyl-amino) -propyl] -2-hydroxy-acetamide; 433 4- (. {2- [4- (benzothiazol-2-yloxy)] -phenyl] -ethyl.} - cyclopropylamine) -butyric acid: 434 1- {3- [4- (benzothiazol-2-yloxy) -benzylamino] -propyl} - pyrrolidin-2-one; 435 1- (3-. {[[4- (benzothiazol-2-yloxy) -benzyl] -methyl-amino} -propyl) -pyrrolidin- 2-one; 436 1- (3-. {[[4- (benzothiazol-2-yloxy) -benzyl] -isopropylamino} -propyl) -pyrrolidin-2-one; 437 1- (3 - ([4- (benzothiazol-2-yloxy) -benzyl] -etl-amino) -propyl) -pyrrolidin-2-one; 438 [4- (benzothiazol-2-yloxy) -benzyl] -cyclopropyl-amine; 439 N-1 - [4- (benzothiazol-2-yloxy) -benzyl] -N1-cyclopropyl-propane-1,3-diamine; 440 N- (3- {[[4- (benzothiazol-2-yloxy) -benzyl] -cyclopropyl-amino} -propyl) -isobutyramide; 441 1- (3-. {[[4- (benzothiazol-2-yloxy) -benzyl] -cyclopropyl-amino} -propyl) -3-isopropyl-urea; 442 1 -. { 1 - [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -3-isopropyl-urea; 443 N- acid methyl ester. { 1- [4- (benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -oxamic; 444 N-. { 1- [4- (benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -isobutyramide; 445 { 1- [4- (benzothiazol-2-yloxy) -benzyl] -p -perdin-4-yl} Tetrahydrofuran-2-carboxylic acid amide; 446 1 -. { 1 - [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -4-hydroxy-pyrrolidin-2-one; 447 1-. { 1- [4- (benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -4-hydroxy-pyrrolidin-2-one; 448 { 1 - [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -urea; 449 N- acid. { 1 - [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -oxamic; 450 N-. { 1- [4- (benzothiazoI-2-yloxy) -benzyl] -piperidin-4-yl} -2-hydroxy-acetamide; 451 N-. { 1 - [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -2,2,2-trifluoroacetamide; 452 2- [4- (1, 1-Dioxo-116-thiomorpholin-4-ylmethyl) -phenoxy] -benzothiazole; 453 N-butyl tert-butyl ester. { 1- [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-amino sulfonyl} -carbamic; 454 N-. { 1 - [4- (benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -acetamida; 455 N-. { 1 - [4- (Benzothiazol-2-loxi) -benzyl] -piperidin-4-yl} -N, N-dimethylsulfamide; 456 1 -. { 1 - [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -3-ethyl-urea; 457 1 -. { 1 - [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -3-ethyl-thiourea; 458 { 1- [4- (benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} propan-1-sulfonic acid amide; 459 { 1- [4- (benzothiazoi-2-yloxy) -benzyl] -piperidin-4-yl} propan-2-sulfonic acid amide; 460 N-. { 1- [4- (benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -sulfamide; 461 N-. { 1 - [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -formamide; 462 ethyl ester of acid. { 1- [4- (benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -carbamic; 463 N-. { 1- [4- (benzothiazol-2-yloxy) -benzyl] -p -peridin-4-yl} -propionamide; 464 N-. { l- [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl-butyramide; 465 1 -. { 1 - [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -3-propyl-urea; 466 propyl ester of acid. { 1- [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl) -carbamic acid; 467 1 -. { 1 - [4- (benzothiazol-2-yloxy) -benzyl] -p -peridin-4-yl} -3-methyl-urea; 469 1 -. { 1 - [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -1, 3-dimethyl-urea; 470 1 -. { 1 - [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -1-methyl-urea; 471 N-. { 1- [4- (benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -N-rnetyl-acetamide; 472 methyl ester of acid. { 1- [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -methylcarbamic; 473 methyl ester of N- acid. { 1- [4- (benzothiazol-2-yloxy) -benzyl] -p.peridin-4-yl} -N-methyl-oxalamic; 474 N- acid. { 1 - [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -N-methyl-oxalámico; 475 N-. { 1- [4- (benzothiazole-2-yloxy) -benzyl] -p -peridin-4-yl} -N? Droxi-guanidine; 476 isopropyl ester of acid. { 1- [4- (benzothiazoI-2-yloxy) -benzyl] -piperidin-4-yl} -carbamic; 477 3-. { 1- [4- (benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -1, 1-dimethyl-urea; 478 ester. { 1 - [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-ylcarbamoyl} - acetic acid methyl ester; 479 { 1- [4- (benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -tiourea; 482 2- [4- (2-morpholin-4-yl-ethoxy) -phenoxy] -benzothiazole; and 483. { 2- [4- (2-piperidin-1-yl-ethoxy) -phenoxy] -benzothiazole. Additional embodiments of this invention, wherein X is NR5 with R5 being one of H and CH3, are made in accordance with the synthetic methods delineated in the AC, F, G and JL schemes, have demonstrated the inhibitory activity of LTA4H, and select from the group consisting of: Example Compound 37 1 -. { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -4-phenyl-piperidin-4-ol; 38 { 2- [4- (1-Benzimidazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl-propyl-amine; 39 cyclohexyl-ethyl-. { 2- [4- (1-methyl-1 - / - benzimidazol-2-yloxy) -phenyl] -ethyl} -amine; 117 1 -. { 2- [4- (1-Benzimidazol-2-yloxy) -phenoxy] -ethyl} -4- (4-bromo-phenyl) -piperidin-4-ol; 118 1-. { 2- [4- (1H-benzimidazol-2-yloxy) -phenoxy] -etl} -4- (4-chloro-phenyl) -piperidin-4-ol; 119 1 -. { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -4-benzyl-piperidin-4-ol; 123 { 2- [4- (1 H-benzimidazol-2-yloxy) -phenyl] -ethyl} -cyclohexyl-ethyl-amine; 124 2- [4- (2-pyrrolidin-1-yl-ethyl) -phenoxy] -1H-benzimidazole; 125 2- [4- (2-azepan-1-ethyl-ethyl) -phenoxy] -1 H -benzimidazole; 126 { 2- [4- (1-V-benzimidazol-2-yloxy) -phenoxy] -ethyl} -dibutyl-amine; 127 1-. { 2- [4- (1H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-ol; 128 methyl ester of acid 1-. { 2- [4- (1H-benzimidazol-2-yloxy) -phenoxy] -etl} -piperidine-4-carboxylic acid; 129 { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -cyclohexyl-ethyl-amine; 130 2-. { 4- [2- (4-methyl-piperidin-1-yl) -ethoxy] -phenoxy} -1 H-benzimidazole; 131 2-. { 4- [2- (2-ethyl-piperidin-1-yl) -ethoxy] -phenoxy} -1 H-benzimidazole; 132 2- [4- (2-piperidin-1-yl-ethoxy) -phenoxy] -1 H-benzimidazole; 133 (1 -. {2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -etyl] -piperidin-4-yl) -methanol; 134 1 -. { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -etl} -periment-4-ol; 138 2- [4- (2-azepan-1-yl-ethoxy) -phenoxy] -1 H-benzimidazole-amide; 139 { 3- [4- (1H-benzimidazol-2-yloxy) -phenoxy] -propyl} dimethyl amine; 140 2- [4- (2-pyrrolidin-1-yl-ethoxy) -phenoxy] -1 H -benzimidazole; 141. { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -diethyl-amine; 142 2- [4- (2-morpholin-4-yl-ethoxy) -phenoxy] -1 H-benzimidazole; 230 2- [4- (2-piperidin-1-yl-ethyl) -phenoxy] -1 H-benzimidazole; 231 1 - (1 - { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -pyrrolidin-2-one; 480 (1- { 2- [4- (1H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -methanol; and 485 ethyl ester of 1- acid. { 2- [4- (1H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carboxylic acid. The compounds of the present invention can be prepared according to the reaction schemes described below.

The schemes represent two basic approaches to the synthesis of the target compound, both in a linear manner, starting from either end of the molecule. Those skilled in the art will recognize that certain compounds are more advantageous produced by one scheme over another. To obtain the various compounds herein, starting materials carrying the generally desired substituents can be used through the reaction scheme with or without protection, as appropriate. The starting materials can be obtained from commercial sources or can be synthesized by methods known to one skilled in the art. Alternatively, it may be necessary to use, in place of the ultimately desired substituent, a suitable group, which can be carried through the reaction scheme and replaced as appropriate with the desired substituent. Any product containing a chiral center can be separated into its enantiomers by conventional techniques. The method embodiments illustrated herein include, when they have the chemical meaning, one or more steps such as hydrolysis, halogenation, protection and deprotection. These steps can be implemented in light of the teachings provided here and the scope of the technique. During any of the methods for preparing the compounds of the present invention, it may be necessary and / or desirable to protect sensitive or reactive groups on any of the molecules in question. In addition, the compounds of the invention can be modified using protective groups; said groups, precursors or prodrugs are also within the scope of the invention. This can be achieved by means of conventional protecting groups, such as those described in "Protective Groups in Organic Chemistry", ed. J.F.W. McOmie, Plenum Press, 1973; and T.W. Greene & P.G.M. Wuts, "Protective Groups in Organic Synthesis", 3a. Ed., John Wiley & Sons, 1999. Protective groups can be removed in a convenient subsequent step using methods known in the art.

SCHEME A HO. VV or- MMN 3 A4 A6 Referring to scheme A, n is 1 or 2 4-benzyloxyphenol commercially available, A1, is alkylated with alkyl halides, A2; Various amino alkyl chlorides are commercially available. The The reactions can be carried out under a wide range of temperatures, including ambient temperature and higher temperatures, in the presence of a known inorganic base to facilitate O-alkylation, such as but not limited to K2C03, Cs2CO3 and mixtures thereof ( J. Med. Chem, 1997, 40, 1407-1416). Suitable solvents include but are not limited to DMF. Removal of the benzyl group on A3 can be achieved using catalytic hydrogenation conditions well known to those skilled in the art (Greene, TW; Wuts, PGM Protective Groups in Organic Synthesis, 3rd Ed .; John Wiley &Sons: New York , 1999). Suitable catalysts include but are not limited to Pd on carbon (Pd / C), in solvents such as ethyl acetate, alcohols and mixtures thereof. Examples of alcohols include but are not limited to CH3OH, ethanol, / -PrOH. These reactions are typically carried out at room temperature. Removal of the benzyl group in A3 can be achieved in some embodiments using metal reductions by dissolution or hydrogenation conditions by transfer at suitable temperatures. For example, metal reductions by dissolution are typically performed at temperatures below room temperature (-33 ° C). The reaction of A4 with aromatic bicyclic ring system, A5, suitably protected if appropriate, can be achieved within a wide range of temperatures including room temperature and higher temperatures in the presence of a suitable base including but not limited to amine or base inorganic as defined above. Suitable amine bases include but are not limited to triethylamine (TEA),? /,? / - diisopropylethylamine, 1, 8- diazabicyclo [5.4.0] undec-7-ene (DBU), resin-bound amine bases and mixtures thereof. When X is oxygen or sulfur, the protective groups are not applicable. Suitable solvents include but are not limited to DMF, CH3CN, acetone and mixtures thereof. When X is NR5, and R5 is a suitable silicon-based protecting group, such as SEM (trimethylsilylethoxymethyl), the removal of the silicon-based protecting group on NR5 can be achieved using conditions well known to those skilled in the art (Greene et al., as cited above). Typical reaction conditions include but are not limited to the use of tetrabutylammonium fluoride (TBAF), in suitable solvents such as THF at elevated temperature.

SCHEME B A4"A6 Referring to scheme B, commercially available 4-benzyloxyphenol, A1, is alkylated with dihalogenoalkanes, preferably dibromoalkanes such as 1,2-dibromoethane and 1,3-dibromopropane, B1, both of which are commercially available, under a wide range of temperatures with preferred elevated temperatures (Zhou, Z. -L et al., J. Med. Chem. 1999, 42: 2993-3000). The reactions are conducted in the presence of a known inorganic base to facilitate O-alkylation such as, but not limited to, K2CO3, Cs2C3 and mixtures thereof. Suitable solvents include but are not limited to CH3CN and DMF. The compounds of structure B2 are treated with amines, B3, either in the presence or absence of a suitable amine base as described above under a wide range of temperatures with preferred elevated temperatures. Suitable solvents include CH 3 CN, CH 2 Cl 2 and DMF. The additional conversion of the resulting products, from structure A3, to compounds of structure A6, is as detailed above for scheme A.

SCHEME C A4 A6 Referring to scheme C, the benzyl group of the compounds of structure B2 can be removed using catalytic hydrogenation conditions well known to those skilled in the art (Greene et al., as mentioned before). Suitable catalysts include but are not limited to Pd / C, in solvents such as THF and mixtures of THF / ethanol. These reactions are typically carried out at room temperature. Removal of the benzyl group on B2 can be achieved in some embodiments using hydrogenation conditions by transfer using suitable solvents and temperatures. The compounds of the general structure C1 are treated with amines of structure B3 either in the presence or absence of a suitable amine base as described above under a wide range of temperatures with preferred elevated temperatures. Suitable solvents include but are not limited to CH 3 CN, CH 2 Cl 2 and DMF. The additional conversion of the resulting products, A4, to A6 compounds, is as detailed above for Scheme A.

SCHEME D A5 C1 Referring to scheme D, the compounds of structure A6 can also be prepared by treating compounds of structure C1 with aromatic bicyclic compounds, A5, wherein X = S and O, in the presence of a suitable inorganic base, as defined above, under a wide range of temperatures with preferred elevated temperatures. Suitable solvents include but are not limited to DMF, CH3CN and mixtures thereof. The conversion of compounds of structure D1 to compounds of structure A6 can be achieved by treatment with compounds of structure B3. These reactions can be performed either in the presence or absence of a suitable amine base as defined above or an inorganic base such as, but not limited to, K2C03, Cs2C03 and mixtures thereof as described above, under a wide range of temperatures with preferred elevated temperatures. Suitable solvents include but are not limited to CH3CN and DMF. It is contemplated that when X is NR5 and R5 is a suitable silicon-based protecting group that the synthesis would follow that described. The Removal of the silicon-based protecting group at the end of the synthetic sequence is further contemplated to occur using conditions as described in texts such as Greene et. to the. (as cited before).

SCHEME E Referring to scheme E, the treatment of compounds of structure E1 with aromatic bicyclic compounds, A5, wherein X is S, because not also O, in the presence of a suitable inorganic base, as defined above, under a wide range of Temperatures with elevated temperatures are preferred. Suitable solvents include but are not limited to DMF, CH3CN and mixtures thereof. Compounds of structure E2 can be converted to compounds of structure E3 using typical bromination conditions including but not limited to the use of PBr3 at elevated temperatures. Suitable solvents include but are not limited to benzene. E2 structure compounds can also be converted to compounds of structure E4 using standard conditions for sulfonylation well known to those skilled in the art. These include but are not limited to the use of TsCI to prepare tosylates, as denoted by the scheme, in the presence of an amine base at room temperature in CH2Cl2. The conversion of compounds of structure E3 to compounds of structure E5 can be achieved by treatment with compounds of structure E3. These reactions can be carried out either in the presence or absence of a suitable amine base as described above or an inorganic base such as, but not limited to K2CO3, Cs2CO and mixtures of them under a wide range of temperatures with temperatures preferred elevations. Suitable solvents include but are not limited to CH3CN and DMF. The compounds of structure E4 can be converted to the compounds of structure E5 by treatment with compounds of structure B3. These reactions can be carried out in the presence or absence of a suitable amine base as described above under a wide range of temperatures. Suitable solvents include but are not limit to CH3CN and DMF.

It is contemplated that when X is NR5, and R5 is a suitable silicon-based protecting group that the synthesis would follow that described above. The removal of the silicon-based protective group at the end of the synthetic sequence is further contemplated as occurring under as described in texts such as Greene et. to the. (as cited previously).

SCHEME F Referring to scheme F, 4- (2-hydroxy-ethyl) -phenol and commercially available 4- (2-hydroxy-propyl-phenol are converted to the corresponding alkyl halides F1, wherein HAL is chloride or bromide, using These conditions include, but are not limited to, treatment with 48% HBr solutions at elevated temperatures.The resulting bromophenols of structure F1 can be treated with amines of the B3 structure either in the presence or absence of a Suitable amine base as described above under a wide range of temperatures Suitable solvents include but are not limited to CH3CN and DMF The reaction of F2 with the aromatic bicyclic ring system, A5, suitably protected if appropriate, can be achieved within a wide range of temperatures including ambient temperature and higher temperatures, in the presence of an amine or suitable inorganic base as defined above. Suitable solvents include but are not limited to DMF, CH 3 CN, acetone and mixtures thereof. When X is O or S, the protective groups are not applicable. When X is NR5, and R5 is a suitable silicon-based protecting group, such as SEM (trimethylsilylethoxymethyl), the removal of the silicon-based protecting group or NR5 can be achieved using conditions well known to those skilled in the art (Greene et al., as cited above). Typical reaction conditions include but are not limited to the use of TBAF, in suitable solvents such as THF at elevated temperatures.

SCHEME G F3 Referring to scheme G, G1, where n is 0 or 2 and HAL is bromide or chloride, are commercially available materials or can be obtained from **, and G1, where n is 1, is contemplated to be available using conditions standard alkylation starting from 4- (2-hydroxy-ethyl) -phenol and benzyl bromide. The benzyl group in G1 It serves as a protective group. Other compatible protecting groups known to one skilled in the art can be used in this sequence. Compounds with the general structure G2 can be obtained by treatment with amines of the general structure B3, either in the presence or absence of a suitable amine base as described above under a wide range of temperatures. Suitable solvents include but are not limited to CH3CN and DMF. The removal of benzyl can be achieved using catalytic hydrogenation conditions well known to those skilled in the art (Greene et al., As cited above). Suitable catalysts include but are not limited to Pd / C, in solvents such as ethyl acetate, alcohols and mixtures thereof. Examples of alcohols include but are not limited to CH3OH, ethanol, / -PrOH. These reactions are typically carried at room temperature. Removal of the benzyl group in G2 can be achieved in some embodiments using hydrogenation conditions by transfer at suitable temperatures. The additional conversion of the resulting products, F2, to the objective compounds F3 is as detailed above for scheme F.

SCHEME H H4 HS Referring to the H, 4-benzyloxyphenol, commercially available scheme, A1, is treated with epichlorohydrin, H1, both of which are commercially available. The reaction can be carried out under a wide range of temperatures, with preferred elevated temperatures, in the presence of an inorganic base such as, but not limited to K2CO3, Cs2CO3 and mixtures thereof. Suitable solvents include but are not limited to DMF. The conversion of compounds of structure H2 to compounds of structure H3 can be achieved by treatment with amines of general structure B3 either in the presence or absence of a suitable amine base as described above or an inorganic base such as, but not limited to K2CO3, CS2CO3 and mixtures thereof under a broad range of temperatures with high temperatures being preferred. Suitable solvents include but are not limited to CH3CN and DMF. Removal of the benzyl group in H3 can be achieved using catalytic hydrogenation conditions well known to those skilled in the art (Greene et al., As cited above). Suitable catalysts include but are not limited to Pd / C, in solvents such as ethyl acetate, alcohols and mixtures thereof. Examples of alcohols include but are not limited to ethanol, CH3OH, / -PrOH. These reactions are typically carried out at room temperature. Removal of the benzyl group in B2 can be achieved in some embodiments using hydrogenation conditions by transfer using suitable solvents and temperatures. The conversion of compounds of structure H4 to final target compounds H5 can be achieved by treatment with the aromatic bicyclic ring system, A5, wherein X is O, in the presence of a suitable inorganic base, as defined above, under a broad range of temperatures with lower temperatures being preferred. Suitable solvents include but are not limited to acetone. It is contemplated that when X is NR5, and R5 is a suitable silicon-based protecting group that the synthesis would follow that described above. Removal of the silicon-based protecting group at the end of the synthetic sequence is further contemplated to occur using conditions as described in texts such as Greene et. to the. (as cited before).

SCHEME I Referring to scheme I, compounds of type 15 are prepared by heating commercially available 4-hydroxyphenyl acetic acid with, in the case that X is S, 2-aminothiophenol. In the case that X is O, 2-aminophenol is used. The two starting materials are heated in the absence of solvent, and the resulting phenols, 13, are treated with dihalogenoalkanes, preferably dibromoalkanes such as 1,2-dibromoethane and 1,3-dibromopropane, B1, both of which are commercially available, under a wide range of temperatures with high temperatures being preferred (Zhou, Z. -L et al., as cited above). The reactions are conducted in the presence of a known inorganic base to facilitate O-alkylation such as, but not limited to K2CO3, Cs2CO3 and mixtures thereof. Suitable solvents include but are not limited to CH3CN and DMF. The compounds of structure 14 are treated with amines, kB3, either in the presence or absence of a suitable amine base as described above under a wide range of temperatures, with preferred the elevated temperatures. Suitable solvents include CH 3 CN, CH 2 Cl 2 and DMF.

SCHEME J Referring to scheme J, the compounds of structure J1 can be further elaborated within the limits of the claims to give more highly functionalized target compounds. For example, hydrolysis using methods well known to those skilled in the art such as but not limited to the use of aqueous solutions of LiOH, KOH or NaOH, or aqueous solutions of HCl or CH3C02H, or the use of (CH3) 3SiOK. In addition, those skilled in the art will recognize that certain compounds are more advantageously produced by one method compared to another and that salts of the desired compounds can be produced initially. The compounds of structure J2 can be further modified to give amides using methods well known to those skilled in the art including but not limited to the use of (COCI2) 2 to convert to the intermediate acid chloride followed by exposure to amines of structure B3. Alternatively, standard amide bond formation conditions may be used, including but not limited to the use of 1, (3-dimethylaminopropyl) -3-ethylcarbodumide (EDCI), with or without additives such as HOBT, and amines of structure B3 . The compounds of structure J4 can be further modified by reductive amination using standard conditions well known to those skilled in the art, including but not limited to the use of an amine of structure B3 and NaBH (Oac) 3 in an appropriate solvent such as CH2Cl2, CICH2CH2CI or CF3CH2OH.

SCHEME K Referring to scheme K, commercially available 3-fluoro-4-hydroxy-benzoic acid, K11, is converted to K2 amides, with amines of structure B3, using peptide coupling conditions standards well known to those skilled in the art such as, but not limited to 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI), 1,3-dicyclohexylcarbodiimide hydrochloride (DCC), 0- (7-azabenzotriazole hexafluorophosphate -1-il) -? /,? /,? T, / V-tetramethyluronium (HATU), O-benzotriazole-1 -? /,? /,? / 'Hexafluorophosphate, / V-tetramethyluronium (HBTU) and mixtures thereof. Suitable solvents include, but are not limited to, CH2Cl2 and THF. The resulting amides of structure K2 are reduced to amines of the formula K3 under reducing conditions well known to those skilled in the art, including but not limited to lithium aluminum hydride in an appropriate solvent such as, but not limited to THF. The conversion of benzyl amines K3 to the final objective compounds, K4, can be achieved by treatment with the aromatic bicyclic ring system, A5, wherein X is S or O, in the presence of a suitable inorganic base under a wide range of temperatures , the elevated temperatures being preferred. Suitable inorganic bases include, but are not limited to K2CO3, Cs2CO3 and mixtures thereof. Suitable solvents include, but are not limited to, acetone and CH3CN. It is contemplated that when X is NR5, and R5 is a suitable silicon-based protecting group that the synthesis would follow that described above. Removal of the silicon-based protecting group at the end of the synthetic sequence is further contemplated to occur using conditions as described in texts such as Greene et. to the. (as cited before).

SCHEME L Referring to scheme L, an alternative embodiment towards the preparation of compounds of formula (I) wherein n is 0 is described. The starting material L1, 4-hydroxybenzaldehyde, is converted to ethers of formula L2 by treatment with an aromatic bicyclic ring system, A5, wherein X is S or O, in the presence of a base under a wide range of temperatures, high temperatures being preferred. Suitable inorganic bases include but are not limited to K2CO3, Cs2CO3 and mixtures thereof. Suitable solvents include, but are not limited to, acetone and CH3CN. It is contemplated that when X is NR5, and R5 is a suitable silicon-based protecting group, that the synthesis would follow that described above. Removal of the silicon-based protecting group at the end of the synthetic sequence is further contemplated to occur using conditions as described in texts such as Greene et. to the. (as cited before). The aldehydes of the formula L2 are converted to amines of the formula L3 under reductive amination conditions with amines of the formula B3. Suitable reducing agents include Na (Oac) 3BH and NaCNBH3, with or without the addition of activating agents such as acetic acid or ZnCl2. Suitable solvents include THF and methanol, and the reaction temperatures may vary from 0 ° C to 70 ° C. The preferred reaction conditions are Na (Oac) 3BH in THF at room temperature. Pharmaceutically acceptable salts, esters and amides of compounds according to the present invention refer to those forms of salts, esters and amides of the compounds of the present invention which would be apparent to the pharmaceutical chemist, ie, those which are non-toxic and which would favorably affect the pharmacokinetic properties of said compounds of the present invention. Those compounds which have favorable pharmacokinetic properties would be evident to the pharmaceutical chemist, ie, those who are non-toxic and who possess such pharmacokinetic properties to provide sufficient palatability, absorption, distribution, metabolism and excretion. Other factors, of a more practical nature, which are also important in the selection, are costs of the starting materials, ease of crystallization, yield, stability, hygroscopicity and flowability of the resulting bulk drug. In addition, acceptable salts of carboxylates include sodium, potassium, calcium and magnesium. Examples of suitable cationic salts include hydrobromic, hydrochloric, perchloric, sulfuric, maleic, fumaric, malic, tartaric, citric, benzoic, mandelic, methanesulfonic, hydroethanesulfonic, benzenesulfonic, oxalic, palmitic, 2-naphthalenesulfonic, p-toluenesulfonic, cyclohexansulfamic and saccharic. More extensive sets of examples of acids and bases that can be used in the preparation of pharmaceutically acceptable salts include the following: Acids such as acetic acid, 2,2-dichlorolactic acid, acylated amino acids, adipic acid, alginic acid, ascorbic acid, acid L-aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, (+) - camphoric acid, camphor sulfonic acid, (+) - (1S) -alphafor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, acid cinnamic, citric acid, cyclamic acid, dodecylsulfuric acid, ethane-1,2-disulfonic acid, ethanesulfonic acid, 2-hydroxy-ethanesulfonic acid, formic acid, fumaric acid, galactactic acid, gentisic acid, glucoheptonic acid, D-gluconic acid, D-glucuronic acid, L-glutamic acid, a-oxo-glutaric acid, glycolic acid, hippuric acid, hydrobromic acid, hydrochloric acid, (+) - L-lactic acid, acid (±) -DL-lactic acid, lactobionic acid, maleic acid, (-) - L-malic acid, malonic acid, (±) -DL-mandelic acid, methanesulfonic acid, naphthalene-2-sulfonic acid, naphthalene-1 acid, 5-disulfonic, 1-hydroxy-2-naphthoic acid, nicotinic acid, nitric acid, oleic acid, oratic acid, oxalic acid, palmitic acid, pamoic acid, phosphoric acid, L-pyroglutamic acid, salicylic acid, 4-amino acid salicylic acid, sebacic acid, stearic acid, succinic acid, sulfuric acid, tannic acid, (+) - L-tartaric acid, thiocyanic acid, p-toluenesulfonic acid and undecylenic acid; and bases such as ammonia, L-arginine, benetamine, benzathine, calcium hydroxide, choline, deanol, diethanolamine, diethylamine, 2- (diethylamino) -ethanol, ethanolamine, ethylenediamine, N-metii-glucamine, hydrabamine, 1 H-imidazole, L-lysine, magnesium hydroxide, 4- (2-hydroxyethyl) -morpholine, piperazine, potassium hydroxide, 1- (2-hydroxyethyl) -pyrrolidine, secondary amines , sodium hydroxide, triethanolamine, tromethamine and zinc hydroxide. See, for example, S.M. Berge, et al., "Pharmaceutical Salts", J. Pharm. Sci. 1977, 66: 1-19, which is incorporated herein by reference. Examples of suitable esters include such esters wherein one or more carboxylic substituents are replaced by p-methoxybenzyloxycarbonyl, 2,4,6-trimethylbenzyloxycarbonyl, 9-anthryloxycarbonyl, CH3SCH2COO-, tetrahydrofur-2-yloxycarbonyl, tetrahydropyran-2-yloxycarbonyl, fur- 2-Iloxycarbonyl, benzoylmethoxycarbonyl, p-nitrobenzyloxycarbonyl, 4-pyridylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2,2,2-tribromoethoxycarbonyl, t-butyloxycarbonyl, t-amyloxycarbonyl, diphenylmethoxycarbonyl, triphenylmethoxycarbonyl, adamantyloxycarbonyl, 2-benzyloxyphenyloxycarbonyl, 4- methylthiophenyloxycarbonyl or tetrahydropyran-2-yloxycarbonyl. The compounds of the present invention can be used in pharmaceutical compositions for treating patients (humans and other animals) with disorders involving the action of the LTA4H enzyme. In particular, the compounds of the present invention can be used in pharmaceutical compositions to treat inflammation. Very particularly the compounds of the present invention can be used in pharmaceutical compositions to treat inflammatory conditions such as inflammatory bowel disease (IBD) (such as Crohn's disease and colitis). ulcerative), chronic obstructive pulmonary disease (COPD), arthritis, psoriasis, asthma, cystic fibrosis, atherosclerosis, rheumatoid arthritis and multiple sclerosis. The present invention relates to pharmaceutical compositions containing said compounds and methods of using said compositions in the treatment or prevention of conditions that are mediated by LTA4H enzyme activity. Accordingly, the present invention also contemplates a pharmaceutical composition comprising at least one compound according to this invention, preferably dispersed in a pharmaceutically acceptable carrier. At least one compound according to this invention is present in said composition in an amount sufficient to inhibit the activity of LTA4H enzyme. Most particularly, at least minus one compound according to this invention is present in said composition in an anti-inflammatory amount. Accordingly, a pharmaceutical composition comprising an anti-inflammatory amount of at least one compound according to the present invention in a pharmaceutically acceptable carrier is also contemplated herein. The composition comprises a unit dose of at least one compound according to this invention. In preferred practice, at least one compound according to the present invention which is comprised in the pharmaceutical composition is capable of inhibiting the activity of LTA4H enzyme in the amount at which the compound is present in the pharmaceutical composition, when that composition Pharmaceutical is introduced as a unit dose in a patient or appropriate subject. The terms "unit doses" and their equivalent grammatical forms are used herein to refer to physically discrete units suitable as unit doses for human and other animal patients, each unit containing a predetermined effective pharmacological amount in the active ingredient calculated to produce the desired pharmacological effect . The specifications for the novel unit dose forms for this invention are determined by, and directly depend on, the characteristics of the active ingredient, and the limitations inherent in the technique of combining said active ingredient for therapeutic use in humans and other animals. The pharmaceutical compositions can be prepared using conventional pharmaceutical excipients and combination techniques. Examples of suitable unit dosage forms are tablets, capsules, pills, powder packets, granules, wafers and the like, segregated multiples of any dosage unit form, as well as liquid solutions and suspensions. Oral dosage forms may be elixirs, syrups, capsules, tablets and the like. Examples of solid carriers include those materials generally used in the manufacture of pills or tablets, such as lactose, starch, glucose, methylcellulose, magnesium stearate, dicalcium phosphate, mannitol and the like, thickeners such as tragacanth and methylcellulose USP, finely divided SiO2, polyvinylpyrrolidone, stearate magnesium and the like. Typical liquid oral excipients include ethanol, glycerol, water and the like. All excipients may be mixed as necessary with inert diluents (eg, sodium and calcium carbonate, sodium and calcium phosphates and lactose), disintegrants (eg, corn starch and alginic acid), diluents, granulating agents, lubricants (for example, magnesium stearate, stearic acid and talc), binders (starch and gelatin), thickeners (for example, paraffin, waxes and petrolatum), flavoring agents, coloring agents, preservatives and the like by conventional techniques known to those skilled in the art. the technique in preparation of dosage forms. Coatings may be present and include, for example, glyceryl monostearate and / or glyceryl distearate. Capsules for oral use include hard gelatin capsules in which the active ingredient is mixed with a solid diluent and soft gelatin capsules in which the active ingredient is mixed with water or oil, such as peanut oil, liquid paraffin or oil of olive tree Parenteral dosage forms can be prepared using water or another sterile vehicle. For intramuscular, intraperitoneal, subcutaneous and intravenous use, the compounds of the invention will generally be provided in sterile aqueous solutions or suspensions, regulated in their pH at an appropriate pH and appropriate isotonicity. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Aqueous suspensions may include suspending agents such as cellulose derivatives, sodium alginate, polyvinylpyrrolidone, and gum tragacanth, and a wetting agent, such as lecithin. Suitable preservatives for aqueous suspensions include ethyl p-hydroxybenzoate and n-propyl. Physiologically acceptable carriers are well known in the art. Examples of liquid carriers are solutions in which the compounds according to the present invention form solutions, emulsions and dispersions. Compatible antioxidants, such as methylparaben and propylparaben, may be present in solid and liquid compositions, such as sweeteners. The pharmaceutical compositions according to the present invention may include suitable emulsifiers typically used in emulsion compositions. Such emulsifiers are described in standard publications such as Fiedler, 1989, Lexikon der Hilfsstoffe für Pharmazie, Kosmetic und agrenzende Gebiete, Cantor ed., Aulendorf, Germany, and in Handbook of Pharmaceutical Excipients, 1986, American Pharmaceutical Association, Washington, DC, and The Pharmaceutical Society of Great Britain, London, UK, which is incorporated herein by reference. The gelling agents can also be added to compositions according to this invention. Polyacrylic acid derivatives, such as carbomers, are examples of gelling agents, and most particularly, various types of carbopol, which are typically used in amounts of about 0.2% to about 2%. The suspensions can be prepared as a cream, an ointment, including a water-free ointment, an emulsion of water in oil, an oil in water emulsion, an emulsion gel, or a gel. It is envisioned that the compounds of the invention may be administered orally or parenterally, including intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical administration, and inhalation. For oral administration, the compounds of the invention will generally be provided in the form of tablets, capsules or as a solution or suspension. "Therapeutically effective amount" or "effective amount" and grammatically related terms means that amount of active compound or pharmaceutical agent that induces the biological or medicinal response in a subject that is being sought by a researcher, veterinarian, physician or other clinician., which includes relief of the symptoms of disease or disorder that is being treated. "Subject" or "patient" includes mammals such as humans and animals (e.g., dogs, cats, horses, rats, rabbits, mice, non-human primates) in need of observation, experimentation, treatment or prevention in connection with the relevant disease or condition. Preferably, the patient or subject is a human being. Effective doses of the compounds of the present invention can be achieved by conventional methods. The specific dose level required for any particular patient will depend on a number of factors, including the severity of the condition, the route of administration and the patient's weight. In general, it is expected that the daily dose (either administered as a single dose or as a divided dose) will be in the range of from about 0.01 mg to about 1000 mg per day, very generally from about 1 mg to about 500 mg per day, and very generally from about 10 mg to about 200 mg per day . Expressed as dose per unit body weight, a typical dose will be expected to be between about 0.0001 mg / kg and about 15 mg / kg, especially between about 0.01 mg / kg and about 7 mg / kg, and very specifically between about 0.15 mg / kg. kg and 2.5 mg / kg. The predicted oral dose ranges include from about 0.01 to 500 mg / kg, daily, most preferably from about 0.05 to about 100 mg / kg, taken in 1-4 separate doses. Some compounds of the invention can be applied as oral doses in the range of about 0.05 to about 50 mg / kg daily, while others can be dosed at 0.05 to about 20 mg / kg daily. The infusion doses may vary from about 1.0 to about 1.0 x 104 μg / (kg.min) of inhibitor, mixed with a pharmaceutical carrier for a period ranging from a few minutes to several days. For topical administration, the compounds of the present invention can be mixed with a pharmaceutical carrier at a concentration of about 0.1 to about 10% drug to the vehicle. A method to treat inflammation in a patient presenting or which is susceptible to an inflammatory condition is also contemplated. A method to treat a condition mediated by LTA4H is also contemplated. The methods comprise administering to the patient an effective amount of a pharmaceutical composition that includes a unit dose of an active ingredient that is at least one of the compounds according to this invention dispersed in a pharmaceutically acceptable carrier. To provide a more concise description, some of the quantitative expressions given here do not qualify with the term "approximately." It is understood that, whether the term "approximately" is used explicitly or not, each quantity given here refers to a given actual value, and also refers to the approximation to said given value that would reasonably be inferred based on the experience in the art, including approximations due to the experimental and / or measurement conditions for said given value. Whenever a yield is given as a percentage, said yield refers to a mass of the entity for which the yield is given with respect to the maximum amount of the same entity that could be had under the particular stoichiometric conditions. The concentrations given as percentages refer to mass ratios, unless indicated differently.

EXAMPLES In order to illustrate the invention, the following examples are included.

These examples do not limit the invention. It only means that they suggest a method for putting the invention into practice. Those skilled in the art can find other methods for practicing the invention that are obvious to them. However, those methods are considered within the scope of this invention.

General experimental procedures The NMR spectra were obtained either as a Bruker spectrometer model DPX400 (400 MHz) or DPX500 (500 MHz). The format of the 1H NMR data given below is: chemical shift in ppm field below the tetramethylsilane reference (multiplicity, coupling constant J in Hz, integration). The mass spectra were obtained in an Agilent 1100 MSD series using electroaspersion ionization (ESI) either in positive or negative mode as indicated. The "calculated mass" for a molecular formula is the monoisotopic mass of the compound. Reverse phase CLAP retention times are reported in minutes, using the methods and conditions reported below. Instrument: Gilson 215 Solvent: CH3CN (0.05% trifluoroacetic acid, TFA) / H2O (0.05% TFA) Flow rate: 25 ml / min Gradient: 0 min at 10% CH3CN; linear ramp of 20 minutes at 99% CH3CN; Column: YMC-Pack ODS-A AA 12505-1530WT SH-362-5 (S-5 um, 12 nM, 150x30 mm) Temperature: 25 ° C Wavelength: Double detection at 220 and 254 nM Instant column chromatography was achieved using ISCO Foxy 200 or ISCO OPTIX 10X systems using one of the following commercially available pre-packed columns: Biotage 40S (SiO2 40 g), Biotage 40M (SiO2 90 g), Biotage 40L (SiO2 120 g), Biotage 65M (SiO2) 300 g) or ISCO Redisep (SiO2, 10 g, 12 g, 35 g, 40 g, or 120 g).

EXAMPLE 1 2- (4-Benzyloxy-phenoxy) -ethyl bromide To a stirred solution of 4-benzyloxyphenol (72 g, 359.6 mmol) in CH 3 CN (600 mL) was added dibromoethane (155 mL, 1.80 mol) and K2C03 (105 g, 759.9 mmol). This brown suspension was heated to reflux and allowed to stir for 96 hr. The resulting suspension was cooled to room temperature, diluted with acetone (250 ml), and filtered through diatomaceous earth, which was then rinsed with additional acetone. The filtrate was concentrated under reduced pressure. The resulting oil was dissolved in CH3OH (500 ml), and the solution was stirred for 2 hr. The title compound was obtained by filtration and dried with air to give 70 g (228 mmol, 63% yield) as a tan solid. 1 H NMR (400 MHz, CDCl 3): 7.60-7.30 (m, 5H), 6.88 (d, J = 8.4, 2H), 6.80 (d, J = 8.4, 2H), 4.70 (s, 2H), 3.79 (t , J = 5.8, 2H), 3.07 (t, J = 5.8, 2H).

EXAMPLE 2 Bromide of 1-f3- (4-benzyloxy-phenoxy) -propyl] To a stirring solution of 4-benzyloxyphenol (25 g, 124.9 mmol) in CH3CN (125 mL) was added dibromopropane (63 mL, 624 mmol) and K2CO3 (34.5 g, 250 mmol). This brown suspension was heated to reflux and allowed to stir for 66 hr. The suspension was then cooled to room temperature and filtered twice through diatomaceous earth pads.

The pads were rinsed with CH3CN, and the combined filtrates were * concentrated under reduced pressure. The resulting oil was purified on SÍO2 (300 g, 33% CH2Cl2 / hexanes) to give 35.4 g (110 mmol, 88% yield) of a brown solid. 1 H NMR (400 MHz, CDCl 3): 7.46-7.29 (m, 5H), 6.85 (q, J = 8.1, 2H), 6.82 (q, J = 7.2, 2H), 5.03 (s, 2H), 4.06 (t , J = 5.8, 2H), 3.61 (t, J = 6.5, 2H), 2.39 (m, J = 6.2, 2H).

EXAMPLE 3 4- (2-Bromo-ethoxy) -phenol 2- (4-benzyloxy-phenoxy) -ethyl ester (Example 1; 70 g, 227 mmol) was dissolved in THF (500 mL). To this solution was added Pd on carbon (10% by weight, 7 g) as a suspension in ethanol (50 ml). The resulting suspension was placed in a Parr hydrogenator at 2812 kg / cm2 of H2 and stirred overnight. The reaction mixture was filtered through a pad of diatomaceous earth, and the filtrate was concentrated under reduced pressure to give 48.5 g (224 mm, 99% yield) of a tan solid. 1 H NMR (400 MHz, CDCl 3): 6.83 (d, J = 9.1, 2 H), 6.77 (d, J = 9.1, 2 H), 4.51 (s, 1 H), 4.24 (t, J = 6.3, 2 H), 3.62 (t, J = 6.3, 2H).

EXAMPLE 4 4- (3-Bromo-propoxy) -phenol [3- (4-benzyloxy-phenoxy) -propyl bromide (10 g, 31.1 mmol) was dissolved in THF (100 mL). To this solution was added 10% palladium on carbon (1 g) as a suspension in THF (20 ml). The resulting suspension was placed in a Parr hydrogenator at 2812 kg / cm2 of H2, and stirred for the night. The reaction mixture was filtered through a pad of diatomaceous earth, and the filtrate was concentrated under reduced pressure to give 7 g (30.5 mmol, 98% yield) of a tan solid. 1 H NMR: (400 MHz, CDCl 3) 6.76 (d, J = 9.1, 2H), 6.69 (d, 9.1, 2H), 4.00 t, J = 5.9, 2H), 3.60 (t, J = 6.6, 2H ), 2. 23 (m, J = 6.1, 2H).

EXAMPLE 5 4- (2-Bromo-ethyl) -phenol 4- (2-Hydroxy-ethyl) -phenol (50 g, 362 mmol) was dissolved in 48% by weight of HBr (250 mL). This light yellow solution was heated to 80 ° C and stirred for 16 hr. The reaction mixture was allowed to cool to room temperature and then extracted with CH2Cl2 (3 x 50 ml). The combined extracts were dried, filtered and concentrated under reduced pressure to give 72 g (100% crude yield) of a tan solid. 1 H NMR (400 MHz, CDDI 3): 9.25 (s, 1 H), 7.04 (d, J = 8.4, 2H), 6. 67 (d, J = 8.4, 2H), 3.62 (t, J = 7.4, 2H), 2.97 (t, J = 7.4, 2H).

EXAMPLE 6 4- (3-bromo-propyl) -phenol A mixture of 4- (3-hydroxy-propyl) -phenol (52.7 g, 346.3 mmol) in 48% by weight of HBr (265 ml) was stirred at 80 ° C for 20 hr and then cooled to room temperature. Water (400 ml) was added, and the product was extracted with CH2Cl2 (500 ml). The extract was dried (MgSO4) and concentrated under reduced pressure to give the desired product as a beige solid (69 g, 92% yield). CCD (SiO2, CH2Cl2): Rf = 0.37. 1 H NMR (400 MHz, DMSO-d 6): 9.18 (s, 1 H), 6.99 (d, J = 8.3.2H), 6.67 (d, J = 8.4, 2H), 3.47 (t, J = 6.6, 2H ), 2.58 (t, J = 7.2, 2H), 2.05-1.95 (m, 2H).

EXAMPLE 7 2-Chloro-1 - (2-trimethylsilane-ethoxymethyl-1 H-benzimidazole) To a suspension of sodium hydride (6.2 g, 245 mmol) in DMF (275 ml) at 5 ° C was added 2-chlorobenzimidazole (37 g, 243 mmol) through a solid addition funnel for 30 min while keeping the internal temperature of the mixture below 10 ° C. They were added ml of additional DMF, and the ice bath was removed. After 2 hr, 2- (trimethylsilyl) ethoxymethyl chloride (SEM-CI) was added dropwise over 5 min. A white precipitate formed. The reaction mixture was stirred at room temperature for 18 hr. To the mixture was added H2O (500 ml) and ethyl acetate (750 ml). The organic layer was washed with additional H 2 O (500 ml), dried (MgSO 4), and concentrated under reduced pressure, giving 65.8 g (96% yield) of the desired product as a light golden oil, which solidified during the rest to give a solid beige. CCD (SiO2, 5% acetone / CH2Cl2): Rf = 0.64. MS (ESI): mass calculated for C13H? GCIN2OS, 282.10; m / z found, 283.1. 1 H NMR (400 MHz, CDCl 3): 7.70 (d, J = 7.3, 1 H), 7.46 (d, J = 7.6, 1 H), 7.40-7.25 (m, 2H), 3.58 (t, J = 7.9, 2H), 0.92 (t, J = 8.3, 2H), 0.04 (s, 9H).

EXAMPLE 8 2-Chloro-1-methyl-1 H-benzimidazole Dimethyl sulfate (11.0 mL, 116 mmol) was added to a solution of 2-chlorobenzimidazole (10.6 g, 70 mmol) in 2.5 M NaOH (70 mL, 175 mmoles), and the mixture was stirred at 23 ° C for 2 hr. The reaction mixture was filtered, and the solid product was washed with H20 (6 x 50 ml) and dried under vacuum to give a light brown solid (9.4 g, 81% yield).

MS (ESI): mass calculated for C8H7CIN2, 166.03; m / z found, 167.0 [M + H] +. 1 H NMR (400 MHz, CDCl 3): 7.75-7.70 (m, 1 H), 7.35-7.29 (m, 3 H), 3.82 (s, 3 H).

EXAMPLE 9 2-í4- (2-Bromo-ethoxy) -phenoxy-1-benzothiazole A solution of 4- (2-bromo-ethoxy) -phenol (example 3; 8.7 g, 40.1 mmol) and 2-chlorobenzothiazole (12 ml, 92 mmol) in CH3CN it was treated with Cs2CO3 in fine powder (26 g, 80 mmol), and the resulting mixture was stirred at 23 ° C for 30 hr. The reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The crude solid was purified on SiO2 (100 g, 0-40% ethyl acetate / hexanes) to give 6.7 g (47% yield) of a white solid. MS (ESI): mass calculated for C? 5H? 2BrN02S, 348.98; m / z found, 350.0 [M + H] +. 1 H NMR (400 MHz, CDCl 3): 7.78, (dd, J = 8.0, 0.4, 1 H), 7.70 (dd, J = 8.0, 0.7, 1 H), 7.42 (dt, J = 7.5, 1.3, 1 H ), 7.34 (dd, J = 9.1, 2H), 7.01 (dd, J = 9.1, 2H), 4.34 (t, J = 6.2, 2H), 3.70 (t, J = 6.2, 2H).

EXAMPLE 10 2- [4- (2-Bromo-ethyl) -phenoxy] -benzothiazole A. 2-r 4 - (Benzothiazol-2-yloxy) -phenyl] -ethanol. An alcohol solution 4-hydroxyphenethyl (867 mg, 6.3 mmol) and 2-chlorobenzothiazole 0.82 ml, 6.3 mmol) in CH 3 CN was treated with Cs 2 CO 3 in fine powder (4.1 g, 12.5 mmol), and the resulting suspension was stirred for 40 h at 70 ° C. . The reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated to a crude oil, which was purified on SiO2 (40 g, 0-50% ethyl acetate / hexanes) to give 940 mg (55% yield) ) of a clear oil. MS (ESI): mass calculated for C15H13NO2S, 271.07; m / z found, 272.2 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.78 (dd, J = 7.9, 0.4, 1 H), 7.75 (dd, J = 7.9, 0.7, 1 H), 7.46 (dt, J = 7.4, 1.3, 1 H), 7.38-7.29 (m, 3H), 3.93 (q, J = 6.4, 2H), 2.94, (t, J = 6.5, 2H), 1.50 (m, 1H). B. 2-r 4 - (2-Bromo-ethyl) -phenoxy-1-benzothiazole. A solution of 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethanol (174 mg, 0.64 mmol) in benzene (3 ml) was treated with PBr3 (0.060 ml, 0.64 mmol), and the resulting suspension was heated at 70 ° C for 90 min. The reaction mixture was cooled and diluted with ethyl acetate (30 ml). This solution was washed with H2O (10 ml), then brine (10 ml), dried, and concentrated under reduced pressure. The crude product was purified on S¡O2 (12 g; 0-50% ethyl acetate / hexanes) to give 120 mg of a light yellow oil. MS (ESI): mass calculated for C? 5H? 2BrNOS, 332.98; m / z found, 335.2 [M + H] +. 1 H NMR (400 MHz, CDCl 3): 7.79 (dd, J = 8.0, 0.3, 1 H), 7.76 (dd, J = 8.0, 0.6.1 H), 7.42 (dt, J = 7.4, 1.2, 1 H) , 7.38-7.29 (m, 3H), 3.62 (t, J = 7.5, 2H), 3.25 (t, J = 7.5, 2H).

EXAMPLE 11 2-r4- (2-Piperidin-1-yl-ethoxy-O-phenox-benzoxazole A. 1-r2- (4-benzyloxy-phenoxy) -etip-piperidine. To a mixture of 4- (benzyloxy) phenol (24.6 g, 123 mmoles) and 1- (2-chloroethyl) piperidine hydrochloride (20.6 g, 112 mmol) in DMF (175 ml) was added K2CO3 (25 g, 181 mmol) and Cs2CO3 (40 g, 123 mmol). The reaction was stirred for 3 days at room temperature, H 2 O (300 ml) and CH 2 Cl 2 were added to the mixture.The organic layer was washed with 10% NaOH then brine, dried (MgSO 4), filtered, and concentrated under pressure. reduced to give 33 g of a clear dark purple liquid.The liquid was purified on SiO2 (300 g, 0-50% ethyl acetate / hexanes) to give 23.4 g (67% yield) of a light yellow solid. SiO2, 50% hexanes / ethyl acetate): Rf = 0.11 MS (ESI): mass calculated for C20H25NO2, 311.19; m / z found, 312.2 [M + H] +. 1 H NMR (400 MHz, CDCl 3): 7.50-7.26 (m, 5H), 6.91 (d, J = 9.2, 2H,), 6.85 (d, J = 9.2, 2H), 5.02 (s, 2H), 4.06 ( t, J = 6.1, 2H), 2.76 (t, J = 6.1, 2H), 2.51 (br s, 4H), 1.65-1.55 (m, 4H), 1.45 (br s, 2H). B. 4- (2-Piperidin-1-yl-ethoxy) -phenol. To a solution of 1- [2- (4-benzyloxy-phenoxy) -ethyl] -piperidine (15.0 g, 48.2 mmol) in 1: 1 ethanol / ethyl acetate (400 mL) was added Pd charcoal (10% by weight, 1.5 g). The mixture was placed in a Parr hydrogenator at 2812 kg / cm2 of H2 for 20 hr. The reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure to give 9.4 g (88% yield) of the desired product as a light gray solid. CCD (SiO2, 50% acetone / CH2Cl2): Rf = 0.16. MS (ESI): mass calculated for C? 3H? GNO2, 221.14; m / z found, 222.1 [M + H] +. 1 H NMR (400 MHz, DMSO-d 6): 8.88 (s, 1 H), 6.73 (d, J = 6.6, 2 H), 6. 65 (d, J = 6.6, 2H), 3.93 (t, J = 6.0, 2H), 2.58 (t, J = 6.0, 2H), 2.40 (s, 4H), 1.51-1.45 (m, 4H), 1.35 (br s, 2H). C. 2- [4- (2-Piperidin-1-yl-ethoxy) -phenoxy] benzoxazole. To a stirred solution of 4- (2-piperidin-1-yl-ethoxy) -phenol (1.5 g, 6.8 mmol) in acetone (20 ml) at 5 ° C was added K2CO3 (1.0 g, 7.2 mmol). To the mixture was added 2-chloro-benzoxazole (0.5 ml, 4.4 mmol) at 5 ° C. The resulting mixture was heated to room temperature overnight. After 20 hr, the mixture was filtered, and the filtrate was concentrated under reduced pressure to a brown solid, which was purified on SiO2 (35 g, 50% acetone / CH2Cl2). The desired fractions were combined and concentrated under reduced pressure to give 1.2 g (80% yield) of the desired product as a white solid. CCD (SiO2, 50% acetone / CH2Cl2): Rf = 0.18. MS (ESI): mass calculated for C20H22N2O3, 338.16; m / z found, 339.1 [M + H] + 1 H NMR (400 MHz, CDCl 3): 7.52 (d, J = 7.2, 1 H), 7.41 (d, J = 7.2, 1 H), 7.35-7.20 (m , 4H), 6.97 (d, J = 9.1, 2H), 4.12 (t, J = 6.1, 2H), 2.79 (t, J = 6.0, 2H), 2.52 (s, 4H), 1.67-1.55 (m, 4H), 1.50-1.40 (m, 2H).

EXAMPLE 12 . { 2-F4- (6-Chloro-benzothiazol-2-yloxy) -phenoxy-ethyl) -diethyl-amine A. [2- (4-Benzyl-phenoxy) -ethyl-1-diethylamine. To a mixture of 4- (benzyloxy) phenol (51 g, 255 mmol) and (2-chloro-ethyl) -diethyl-amine hydrochloride (41.6 g, 242 mmol) in DMF (400 mL) was added K2CO3 (37 g , 268 mmoles) and Cs2C03 (87 g, 267 mmoies). The reaction mixture was stirred at room temperature for 17 days. H20 (600 ml) and CH2Cl2 were added to the mixture. The organic layer was washed with H2O, dried (MgSO4), filtered and concentrated under reduced pressure to give 33 g of a clear dark purple liquid, which was purified on SiO2 (300 g, ethyl acetate) to give an oil light yellow (34.5 g, 48% yield).

CCD (SiO2, 50% hexanes / ethyl acetate): Rf = 0.10. MS (ESI): mass calculated for C? 9H25NO2, 299.19; m / z found, 300.2 [M + H] +. 1 H NMR (400 MHz, CDCl 3): 7.50-7.28 (m, 5H), 6.89 (d, J = 9.2, 2H), 6.85 (d, J = 9.2, 2H), 5.02 (s, 2H), 4.00 (t , J = 6.4, 2H), 2.86 (t, J = 6.4, 2H), 2.63 (q, J = 7.2, 4H), 1.08 (t, J = 7.1, 6H). B. 4- (2-Diethylamino-ethoxy) -phenol. To a solution of [2- (4-benzyloxy-phenoxy) -ethyl] -diethyl-amine (21 g, 70 mmol) in 1: 1 ethanol / ethyl acetate (500 mL) was added Pd on carbon (10%). in weight, 1.5 g). The mixture was placed in a Parr hydrogenator at 2812 kg / cm2 of H2 for 20 hr. The reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure to give 13.1 g (89% yield) of the desired product as a light brown oil. MS (ESI): mass calculated for C? 2H? 9NO2, 209.14; m / z found, 210.2 [M + H] +. 1 H NMR (400 MHz, CDCl 3): 6.68 (S, 4 H,), 3.99 (t, J = 6.2, 2 H), 2.88 (t, J = 6.2, 2 H), 2.69 (q, J = 7.2, 4 H), 1.09 (t, J = 7.1, 6H).

C. (2- [4- (6-Chloro-benzothiazol-2-yloxp-phenoxy] -ethyl) -diethyl-amine To a solution of 4- (2-diethylamino-ethoxy) -phenol (500 mg, 2.39 mmol. ) in acetone (7 ml) containing Cs 2 CO 3 (876 mg, 2.69 mmol) was added 2,6-dichlorobenzthiazole (365 mg, 1.79 mmol) The mixture was refluxed for 3 days.The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give a brown oil, which was purified over S02 (35 g, acetone) to give 624 mg (76% yield) of the desired product. CCD (SiO2, acetone): Rf = 0.23. MS (ESI): mass found for C19H2? CIN2O2S, 376.10; m / z found, 377.1 [M + H] +. 1 H NMR (400 MHz, CDCl 3): 7.64 (d, J = 8. 5, 2 H), 7.34 (d, J = 8.8, 1 H), 7.25 (d, J = 6.8, 2 H), 6.96 (d, J = 9.1, 2H).

EXAMPLE 13 (1- {2-r4- (Benzoxazol-2-yloxy) -phenoxyethyl) -piperidin-4-y-methanol A. 4-f2- (4-Hydroxymethyl-piperidin-1-yO-ethoxy- phenol A solution of 4- (2-bromo-ethoxy) -phenol (example 3; 7 g, 32.2 mmol), piperidinemethanol (5.2 g, 45.3 mmol), and N, N-diisopropylethylamine (7.9 ml, 45.3 mmol) ) in CH3CN (100 ml) was stirred at 65 ° C. for 18 hr.The reaction mixture was cooled to room temperature and stirred for a further 48 h.The solvent was removed under reduced pressure to give a black semi-solid. The material was dissolved in CH 2 Cl (200 ml), and the solution was washed with H 2 O (2 x 50 ml) The aqueous phase was extracted again with 10% CH 3 OH / CH 2 Cl 2 (100 ml) .The organic layers were combined, dried (Na2SO), filtered, and concentrated under reduced pressure to a black oil, which was purified on Si02 (120 g, 0-100% acetone / CH2Cl2) to give the desired product as a brown oil.

He added diethyl ether to the oil to precipitate the product. Filtration gave the title compound as a tan solid (1.9 g, 23% yield). CCD (S¡O2, 5% 2M NH 3 in CH 3 OH / CH 2 Cl 2): Rf = 0.09. EM (ESI): mass calculated for C? H2? N03, 251.15; m / z found, 252.3 [M + H]. 1 H NMR (400MHz, CDCt 3): 6.69 (s, 4H), 4.03 (t, J = 5.9, 2H), 3. 51 (d, J = 6.5, 2H), 3.09 (d, J = 11.6, 2H), 2.79 (t, J = 5.9, 2H), 2.18-2.11 (m, 2H), 1.79 (d, J = 16.2, 2H), 1.49-1.62 (m, 1 H), 1.36 (dq, J = 3.6.12.3, 2H), 1.23 (br s, 2H). B. (1- {2-Ib-Benzoxazol-2-yloxy) -phenoxylethyl) -p.peridin-4-yl) -methanol.

A mixture of 4- [2- (4-hydroxymethyl-piperidin-1-yl) -ethoxy] -phenol (0.5 g, 1.98 mmol), 2-chloro-benzoxazole (205 μl, 1.8 mmol) and Cs2CO3 (1.35 g) , 4.15 mmole) in acetone (8.0 ml) was stirred at room temperature for 48 h.

The resulting mixture was filtered through diatomaceous earth, and the pad was washed with CH2Cl2. The combined filtrates were concentrated under reduced pressure to a yellow oil. The oil was purified on SiO 2 (40 g, 0-100% acetone / CH 2 Cl 2) to give a solid, which was dissolved in CH 2 Cl 2 (100 mL). This solution was washed with 1 N NaOH (3 x 5 ml), then H2O (5 ml), dried (Na2SO), filtered and concentrated under reduced pressure to give the title compound as a white solid (424 mg, 64% yield). CCD (SiO2, 5% 2M NH3 in CH3OH / CH2Cl2): Rf = 0.17. MS (ESI): mass calculated for C2iH24N2O4, 368.17; m / z found, 369.3 [M + H] +. 1 H NMR (400 MHz, CDCl 3): 7.53-7.50 (m, 1 H), 7.44-7.42 (m, 1 H), 7.34-7.21 (m, 4H), 7.00-6.96 (m, 2H), 4.13 (t , J = 6.0, 2H,), 3.55-3.48 (m, 2H), 3.02-3.09 (m, 2H), 2.82 (t, J = 6. 0.2H), 2.13 (dt, J = 2.4, 11. 8, 2H), 1.78-1.75 (m, 2H), 1.59-1.48 (m, 2H), 1.33 (dq, J = 3.7, 12.4, 2H).

EXAMPLE 14? Pyy "1- { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl.}. -piperidin-4-ol A. 1 -F2-4-Hydroxy-phenoxy) -ethyl ] -piperidin-4-ol To a stirred solution of 4- (2-bromo-ethoxy) -phenol (example 3; 9 g, 42 mmol) in CH 3 CN (150 ml) was added 4-hydroxypiperidine (5.3 g, 52.5 mmoles), followed by N, N-diisopropylethylamine (6.7 g, 52.5 mmol) The resulting solution was stirred overnight at room temperature, giving a suspension, the suspension was filtered, and the filtrate was concentrated under reduced pressure. Diethyl ether was added to the resulting oil, and the mixture was heated at 45 ° C for 2 min, forming a white precipitate.This suspension was stirred at room temperature for 2 hr, then filtered, giving 7.9 g (33 mmol, 79% yield). yield) of a white solid MS (ESI): calculated mass for C? 3H? 9NO3, 237.14; m / z found, 238.2 [M + H] +1. 1 H NMR (400 MHz, CD3OD): 7.10 and 7.02 ( q, J = 32.3, 9.0, 2H), 4.35 (t, J = 5.7, 2H), 3.59 (m, 1 H), 3.2 6-3.19 (m, 2H), 3.07 (t, J = 5.7, 2H), 2.60 (t, J = 9.9, 2H), 2.20-2.12 (m, 2H), 1.94-1.82 (m, 2H). B. 1-y2-r4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl) -pyridin-4-ol. To a stirred solution of 1- [2- (4-hydroxy-phenoxy) -ethyl] -piperidin-4-ol (500 mg, 2.1 mmol) in acetone (10 ml) was added Cs2CO3 (1.4 g, 4.41 mmol) . This suspension was cooled to 0 ° C, and 2-chloro-benzoxazole (388 mg, 2.5 mmol, 0.29 ml) was added dropwise. The reaction mixture was allowed to warm to room temperature overnight, and then filtered, and concentrated under reduced pressure. The resulting oil was purified on SiO2 (40 g, 0-100% acetone / CH2Cl2) to give 400 mg (1.1 mmol, 54% yield) of a white solid. MS (ESI): mass calculated for C20H22N2O, 354.16; m / z found, 355.2 [M + H] +1. 1 H NMR: (400 MHz, CDCl 3) 7.55 (dd, J = 7.2, 1.8, 1 H), 7.46 (dd, J = 7.3, 2.0, 1 H), 7.36 (d, J = 9.1, 2H), 7.32- 7.25 (m, 2H), 7.01 (d, J = 9.1, 2H), 4.18 (t, J = 5.4, 2H), 3.80 (m, 1 H), 3.01-2.86 (m, 4H), 2.40 (br s , 1 H), 1.99 (m, 2H), 1.74-1.65 (m, 2H), 1.48 (d, J = 4.1, 1 H). EXAMPLE 15 1- (2-f4- (Benzothiazol-2-yloxy) -phenoxy-1-ethyl) -piperidin-4-ol to a stirred solution of 1- [2- (4-hydroxy-phenoxy) -ethyl] -piperidin-4 -ol (example 14, step A, 500 mg, 1.25 mmol) in DMF (10 ml), Cs2CO3 (1.4 g, 4.41 mmol) and 2-chlorobenzothiazole (0.33 ml, 2.5) were added. mmoles). The suspension was heated to 80 ° C and stirred overnight. The reaction mixture was allowed to cool to room temperature and then filtered through diatomaceous earth. The filtrate was concentrated under reduced pressure, and the residue was purified on SiO2 (40 g, 0-100% acetone / CH2Cl2), giving 321 mg (0.86 mmol, 69% yield) of a tan solid. MS (ESI): mass calculated for C20H22N2O3S, 370.14; m / z found, 371.2 [M + H] +. 1 H NMR (400 MHz, CDCl 3): 7.64 (d, J = 8.0, 1 H), 7.56 (d, J = 7.8, 1 H), 7.30 (t, J = 7.2, 1 H), 7.21-7.14 (m , 3H), 6.87 (d, J = 9.1, 2H), 4.05 (t, J = 5.8, 2H), 3.67 (br, 1 H), 2.82 (m, 2H), 2.76 (t, J = 5.8, 2H), 2.27 (t, J = 9.5, 2H), 2.01 (br 2, 1 H), 1.90-1.82 (m, 2H), 1.64-1.52 (m, 2H).

EXAMPLE 16 . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl) -dibutyl-amine A. 4- (2-Dibutylamino-ethoxy) -phenol. To a stirred solution of 4- (2-bromo-ethoxy) -phenol (example 3, 8.2 g, 37 mmol) in CH 3 CN (150 ml), dibutylamine (5.98 g, 46.3 mmol) and N, N were added. -diisopropyethylamine (5.98 g, 46. 3 mmoles). The mixture was stirred overnight at 75 ° C. The resulting suspension was filtered, and the filtrate was concentrated under reduced pressure. Oil The resulting product was purified on SiO2 (110 g, 0-100% acetone / CH2Cl2) to give 7.7 g (29 mmol, 78% yield) of a brown solid. MS (ESI): mass calculated for C? 6H27NO2, 265.2; m / z found, 266.2 [M + H] +. 1 H NMR (400MHz, CDCl 3): 6.81 (d, J = 7.0, 2H), 6.63 (d, J = 6.0, 2H), 4.22 (br s, 2H), 3.25 (br s, 2H), 2.93 (br s, 4H), 2.16 (br s, 2H), 1.88 (br s, 1 H), 1.68 (br s, 4H ), 1.33 (d, J = 5.7, 4H), 0.94 (br s, 6H). B. { 2- (4-Benzoxazol-2-yloxy) -phenoxy-ethyl} -dibutylamine To a stirred solution of 4- (2-dibutylamino-ethoxy) -phenol (500 mg, 1.9 mmol) in acetone (9.4 ml) was added Cs2CO3 (1.3 g, 3.9 mmol) .This suspension was cooled to 0 ° C, and 2-chloro-benzoxazole (346 mg, 2.2 mmol, 0.26 ml) was added dropwise. The reaction was allowed to warm to room temperature overnight, then filtered The filtrate was concentrated under reduced pressure The resulting oil was dissolved in CH 2 Cl 2 and purified on SiO 2 (40 g, 0-100% acetone / CH 2 Cl 2) to give 180 mg (0.47 mmol, 25% yield) of a white solid: MS (ESI): mass calculated for C23H3oN2O3, 382.23, m / z found, 383.3 [M + H] +. 1 H NMR (400 MHz, CDCl 3): 7.50 (d, J = 7.2, 2H), 7.41 (d, J = 7.3, 2H), 7.31 (d, J = 9.1, 2H), 7.28-7.19 (m, 2H), 6.96 (d, J = 9.1, 2H) ), 4.13 (m, 2H), 2.88 (m, 2H), 2.54 (m, 4H), 1.47 (m, 4H), 1.32 (m, 4H), 0.92 (t, J = 7.3, 6H).

EXAMPLE 17 Ethyl ester of 1-f2- | 4- (benzothiazol-2-yloxy-phenoxy-ethyl.}. -piperidine-4-carboxylic acid A. 1- [2- (4-Hydroxy-phenoxy) -ethyl ethyl ester ethyl) -piperidine-4-carboxylic acid to a stirring solution of 4- (2-bromo-ethoxy) -phenol (example 3; g, 23.1 mmoles) in CH3CN (200 ml) was added ethyl isonipecotate (5.3 ml, 34.7 mmoles). The reaction mixture was heated to 84 ° C and stirred for 16 hr, then cooled to room temperature and concentrated under reduced pressure. The resulting oil was dissolved in CH2Cl2 and purified on SiO2 (300 g, 0-25% acetone / CH 2 Cl 2) to give a white solid (6.3 g, 93% yield). MS (ESI): mass calculated for C? 6H23NO4, 293.16; m / z found, 294.3 [M + H] +. 1 H NMR (400 MHz, CDCl 3): 6.63 (m, 4 H), 4.07 (q, J = 7.2, 2 H), 3. 96 (t, J = 5.7, 2H), 2.96 (m, 2H), 2.74 (t, J = 5.6, 2H), 2.26-2.23 (m, 3H), 1. 88-1.77 (m, 5H), 1.17 (t, J = 7.2, 3H). B. Ethyl ester of acid 1-. { 2- | 4- (Benzothiazol-2-yloxy) -phenoxy-ethyl} -piperidine-4-carboxylic acid. To a stirring solution of 1- [2- (4-hydroxy-phenoxy) -ethyl] -piperdin-4-carboxylic acid ethyl ester (2.5 g, 6.8 mmol) in CH3CN (34 ml) was added Cs2CO3 (5 g, 14.3 mmol) and 2-chlorobenzothiazole (1.26 ml, . 2 mmol). The reaction mixture was heated at 75 ° C for 3 hr, then cooled to room temperature and filtered. The filtrate was concentrated under reduced pressure. The residue was dissolved in CH 2 Cl 2 and purified on SiO 2 (40 g, 0-25% acetone / CH 2 Cl 2) to give a white solid (2.94 g, 100% yield). MS (ESI): mass calculated for C23H26N2O4S, 426.16; m / z found, 427.1 [M + H] +. 1 H NMR (400 MHz, CDCl 3): 7.76 (d, J = 8.0, 1 H), 7.64 (t, J = 8. 1, 1 H), 7.41 (t, J = 8.4, 1H), 7.30 (d, J = 9.0, 3H), 7.05 (d, J = 6.8, 2H), 4.19 (t, J = 5.5, 2H), 4.12 (q, J = 7.1, 2H), 3.02 (m, 2H), 2.83 (t , J = 5.5, 2H), 2.37 (m, 1 H), 2.25 (t, J = 11.6, 2H), 1.93 (m, 2H), 1.79 (m, 2H), 1.24 (t, J = 7.2) , 3H).

EXAMPLE 18 Potassium salt of 1- (2-y4- (benzothiazol-2-yloxy-V-phenoxy) -ethyl) -piperidine-4-carboxylic acid To a stirring solution of ethyl ester of 1- {2- {4- (benzothiazole -2-yloxy) -phenoxy] -ethyl.}. -piperidine-4-carboxylic acid (example 17; 235 mg, 0. 5 mmol) in THF (2.5 ml) was added potassium trimethylsilanoate (282 mg, 2. 2 mmol). The reaction mixture was stirred at room temperature during 2 hr, then concentrated under reduced pressure. The resulting oil is dissolved in H2O, and the solution was treated at pH 9 with 1 M HCl. The resulting solution was extracted with 1: 3 isopropyl alcohol / chloroform (3 x 25 ml). The combined extracts were concentrated under reduced pressure to give a tan solid which was triturated with diethyl ether. Filtration of the suspension gave a tan solid (140 mg, 64% yield). MS (ESI): mass calculated for C2? H22N2? 4S. (free acid), 398.13; m / z found, 399.1 [M + H]. 1 H NMR (400 MHz, DMSO-d 6): 8.01 (d, J = 7.3, 1 H), 7.76 (d, J = 7.5, 1 H), 7.51 (t, J = 8.4, 1 H), 7.45 (d , J = 9.0, 2H), 7.40 (t, J = 7.2, 1 H), 7.14 (d, J = 9.0, 2H), 4.18 (t, J = 5.5, 2H), 2.95 (m, 2H), 2.74 (t, J = 5.8, 2H), 2.10 (t, J = 10.5, 2H), 1.81 (m, 2H), 1.59 (m, 2H).

EXAMPLE 19 (1- (2-r4- (Benzothiazol-2-yloxy) -phenoxy-etl) -pperidin-4-yl) -pyrrolidin-1-yl-methanone To a suspension of acid 1- [ 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl-piperidine-4-carboxylic acid (example 18, 100 mg, 0.25 mmol) in CHCl3 (2 ml) was added oxalyl chloride (1321 μl, 1.5 mmoles). The reaction mixture was stirred at room temperature for 2 hr, and then concentrated under reduced pressure. The resulting solid was re-suspended in CHCl3 (2 ml), and added pyrrolidine (100 μl, 1.2 mmol). The solution that formed was stirred for 1 hr and then diluted with CH2Cl2 (10 mL) and washed with saturated aqueous NaHCO3 (10 mL). The organic layer was dried (Na2SO), filtered and concentrated under reduced pressure to a yellow oil. The crude oil was purified SiO2 (10 9; 0-100% acetone / CH2CI2) to give the desired product as a colorless oil (71 mg, 63% yield). MS (ESI): mass calculated for C25H29N303S, 451.19; m / z found, 452.1 [M + H] +. 1 H NMR (400 MHz, CDCl 3): 7.74 (d, J = 7.6, 1 H), 7.66 (dd, J = 8.0, 0.8, 1 H), 7.41-7.37 (m, 1 H), 7.29-7.24 (m , 3H), 6.99-6.96 (m, 2H), 4.13 (t, J = 6.0, 2H), 3.50-3.45 (m, 4H), 3.10-3.04 (m, 2H), 2.83 (t, J = 6.0, 2H), 2.38-2.31 (m, 1 H), 2.21-2.14 (m, 2H), 1.98-1.84 (m, 6H), 1.74-1.71 (m, 2H).

EXAMPLE 20 Ethyl 3-r (1- (2- [4- (benzothiazol-2-yloxp-phenoxy] -ethyl) -piperidine-4-carbonyl) -amino] -propionic acid ester 1-Hydroxybenzotriazole Hydrate (HOBT; 1.0 ml, 0.5 M in DMF, 0. 5 mmoles), 3-amino-propionic acid ethyl ester (120 mg, 0.785 mmol) and 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride hydrochloride (EDCI, 150 m, 0.785 mmol) were added in succession to Intervals of 5 minutes to a stirred suspension of acid 1-. { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carboxylic acid (example 18, 210 mg, 0.53 mmol) in CH 2 Cl 2 (3 ml). The resulting mixture was stirred overnight at room temperature. The reaction mixture was diluted with CH2Cl2 (10 mL) and washed with saturated aqueous NaHC3 (10 mL), then H2O (10 mL). The organic layer was dried (Na2SO), filtered, and concentrated under reduced pressure to give an off-white semisolid. The crude residue was purified over S02 (35 g, 0-5% 2 M NH3 in CH3OH / CH2Cl2) to give the desired product as a white solid (186 mg, 48% yield). MS (ESI): mass calculated for C26H3iN3? 5S, 497.20; m / z found, 498.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.74 (dd, J = 8.1, 0.6, 1 H), 7.66 (dd, J = 8.1, 0.8, 1 H), 7.39 (dt, J = 7.4, 1.3, 1 H) , 7.29-7.24 (m, 3H), 7.01-6.94 (m, 2H), 6.18-6.15 (m, 1 H), 4.19-4.11 (m, 4H), 3.53 (q, J = 6.0, 2H), 3.06 -3.04 (m, 2H), 2.81 (t, J = 5.9, 2H), 2.53 (t, J = 6.0, 2H), 2.18-2.06 (m, 3H), 1.88-1.72 (m, 4H), 1.28 ( t, J = 7.2, 3H).

EXAMPLE 21 (1- {2-r4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl-piperidin-2-yl) -methanol A.. { 1 - [2- (4-Benzyloxy-phenoxy) -etl] -piperidin-2-yl) -methanol. To a stirred solution of 2- (4-benzyloxy-phenoxy) -ethyl bromide (Example 1; 7.0 g mg, 22.8 mmol) and piperidin-2-yl-methanol (3.3 g, 28.7 mmol) in CH3CN (100 mL) was added K2CO3 (7.1 g, 51.4 mmol). The mixture was refluxed for 20 hr and then filtered. The filtrate was concentrated under reduced pressure to a light golden oil, which was purified on Si02 (120 g, 0-100% acetone / CH2Cl2) to give 6.0 g (77% yield) of a white solid. CCD (SiO2, acetone): Rf = 0.15. MS (ESI): mass calculated for C21H27NO3, 341.20; m / z found, 342.3 [M + H]. 1 H NMR (400 MHz, DMSO-d 6): 7.48-7.25 (m, 5H), 6.92 (d, J = 9. 1, 2H), 6.85 (d, J = 9.1, 2H), 5.02 (s, 2H), 4.38 (t, J = 5.3, 2H), 3.96 (t, J = 6.2, 2H), 3.55-3. 48 (m, 1 H), 3.43-3. 32 (m, 1 H), 3.15-3.00 (m, 1 H), 2.88-2.85 (m, 1 H), 2.75-2.62 (m, 1 H), 2.30-2.22 (m, 2H), 1.61 (d) , J = 9.4, 2H, 1.52-1.44 (m, 1 H), 1.44-1.31 (m, 1 H), 1.30-1.17 (m, 2H) B. 4- [2- (2-Hydroxymethyl-piperidin- 1 -D-ethoxyl-phenol To a solution of. {1- [2- (4-benzyloxy-phenoxy) -ethyl] -piperidin-2-yl} -methanol (6.0 g, 17.6 mmol) in 1: 1 ethanol / ethyl acetate (75 ml) was added Pd on carbon (10% by weight, 614 mg) The mixture was placed in a Parr hydrogenator at 2812 kg / cm2 of H2 for 20 h. The reaction was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure to give 4.5 g (100% yield) of the desired product as a clear and colorless oil CCD (SiO2, acetone): Rf = 0.29. ESI): mass calculated for C14H21NO3, 251.15; m / z found, 252.3 [M + Hf. 1 H NMR (400 MHz, CD 3 OD): 6.77 (d, J = 6.6, 2H), 6.68 (d, J = 6.6, 2H), 4.06-4.01 (m, 2H), 3.70-3.55 (m, 2H), 3.22. -3.10 (m, 1 H), 3.05-2.96 (m, 1 H), 2.88-2.79 (M, 1 H), 2.47-2.36 (m, 2H), 1.76-1.70 (m, 2H), 1.63-1 .32 (m, 4H). C? (1- {2-y4- (Benzoxazol-2-yloxO-phenoxy] -ethyl.}. -piperidin-2-yO-methanol A mixture of 4- [2- (2-hydroxymethyl-piperidin-1- il) -ethoxy] -phenol (197 mg, 0.78 mmol), 2-chloro-benzoxazole (1 16 μl, 1.02 mmol) and Cs CO3 (700 mg, 2.15 mmol) in acetone (10 ml) was stirred at room temperature for The resulting mixture was filtered through diatomaceous earth.The pad was washed with acetone, and the combined filtrates were concentrated under reduced pressure to a golden oil.The oil was purified over SiO2 (10 g, 0-100 g. % acetone / CH2Cl2) to give the desired product as a clear, colorless oil (202 mg, 70%) CCD (SiO2, acetone): Rf = 0.17 MS (ESI): mass calculated for C21H24N2O3S, 384.15; m / z found, 369.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.61 (d, J = 7.0, 2H), 7.50 (d, J = 7. 0, 2H), 7.41 (d, J = 9.1, 4H), 7.35-7.30 (m, 4H), 7.03 (d, J = 9.1, 4H), 4.41 (t, J = 5.3, 2H), 4.07 (t , J = 6.2, 4H), 3.60- 3.52 (m, 2H), 3.44-3.35 (m, 2H), 3.18- 3.08 (m, 2H), 2.90-2.85 (m, 2H), 2.78- 2.72 ( m, 2H), 2.35-2.28 (m, 4H), 1.62 (d, J = 9.2, 4H), 1.53-1.47 (m, 2H), 1.47-1.34 (m, 2H), 1.32-1.18 (m, 4H).

EXAMPLE 22 Amide of acid 1-. { 2-r4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl) -piperidin-4-carboxylic acid A suspension of 2- [4- (2-bromo-ethoxy) -phenoxy] -benzothiazole (example 9; 200 mg, 0.57 mmol), isonipecotamide (73 mg, 0.57 mmol) and Silicy® dimethylamine resin (800 mg, 1.14 mmol) in CH 3 CN were heated at 70 ° C for 18 h. The reaction mixture was filtered, and the collected resin was rinsed with CH3CN. The combined filtrates were concentrated under reduced pressure to give a crude solid, which was purified on SiO2 (10 g, 0-100% [10% 2N NH3 in CH3OH] in CH2Cl2 / CH2Cl2) to give 142 mg (63% yield). yield) of a white solid. MS (ESI): mass calculated for C2? H23N303S, 397.15; m / z found, 398.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.85 (dd, J = 8.0, 3.0, 1 H), 7.75 (dd, J = 8.0, 0.6, 1H), 7.42 (dd, J = 7.4, 1.1, 1H), 7.32-7.22 (m, 3H), 7.02-6.91 (m, 2H), 5.67 (br d, J = 47, 2H), 4.15 (t, J = 5.8, 2H), 3.09 (br d, J = 8.8, 2H), 2.85 (t, J = 5.7, 2H), 2.28-2.12 (m, 3H), 2.00-1.88 (m, 2H), 1.87-1.72 (m, 2H).

EXAMPLE 23 1- (1-f2-y4- (Benzot-azo-2-yloxO-phenoxy-ethyl) -piperidin-4-yO-pyrrolidin-2-one A suspension of 2- [4- (2-bromo-ethoxy) - phenoxy] -benzothiazole (example 9, 200 mg, 0.57 mmol), 1-piperidin-4-yl-pyrrolidin-2-one hydrochloride (117 mg, 0.57 mmol), and Silicycle® dimethylamine resin (800 mg, 1.14 mmol) ) in CH3CN was heated at 70 ° C for 18 hr The reaction mixture was filtered, and the collected resin was rinsed with CH3CN.The combined filtrates were concentrated under reduced pressure to give a crude solid, which was purified on SiO2 (10 g; 0-100% [2% NH3 in CH3OH] at 10% in CH2CI2 / CH2CI2) to give an off-white sticky solid (142 mg, 63% yield) MS (ESI): mass calculated for C24H27N3O3S, 337.18; m / z found, 348.5 [M + Hf. 1 H NMR (400 MHZ, CDCl 3): 7.85 (dd, J = 8.0, 0.5, 1H), 7.75 (dd, J = 8.0, 0.8, 1H), 7.41 (dt, J = 7.3, 1.5, 1H), 7.34-7.22 (m, 3H), 7.02-6.92 (m, 2H), 4.15 (br d, J = 48.8, 2H ), 3.80-3.65 (m, 1 H), 3.40 (t, J = 7. 0, 1 H), 3.30-3.10 (brs, 1 H), 3.15, (q, J = 7.2, 1 H), 2.96 (br s, 1 H), 2.42, (t, J = 7. 9.2 Hz), 2.10-1.99 (m, 1 H), 1.81-1.70 (m, 1 H) 1.68-1.52 (m, 4H), 1.50 (d, J = 6. 5,3H).

EXAMPLE 24 1 '- (2- [4- (Benzothiazol-2-yloxO-phenoxyp-ethylH1.4'] bipiperidinyl-2-one To a stirred solution of 2- [4- (2-bromo-ethoxy) -phenoxy] -benzothiazole (Example 9: 542 mg, 1.55 mmol) and [1,4 '] bipiperidinyl-2-one hydrochloride (371 mg, 1.69 mmol) in CH3CN (20 ml) was added K2CO3 (517 mg, 3.74 mmol). it was refluxed for 20 h and then filtered, the filtrate was concentrated under reduced pressure to a light golden oil, which was purified on SiO (10 g, 0-100% acetone / CH2CI2) to give 294 mg (42%). yield) of a white solid CCD (SiO2, acetone): Rf = 0.15 MS (ESI): mass calculated for C25H2gN3O3S, 451.19, m / z found, 452.4 [M + H]. 1H NMR (400 MHz, DMSO -d6): 7.92 (d, J = 1.1, 2H), 7.90 (d, J = 1. 1, 2H), 7.42 (t, J = 7.3, 2H), 7.37 (d, J = 9.0, 2H), 7.31 (t, J = 7.3 2H), 7.06 (d, J = 9.0, 2H), 4.32-4.21 (m, 1H), 4.10 (t, J = 5.7, 2H), 3.15 (t, J = 5.3, 2H), 3.00 (d, J = 11.5, 2H), 2.71 (t, J = 5.7, 2H), 2.21 (t, J = 6.5, 2H), 2.10 (t, J = 11.4, 2H), 1.75-1.58 (m, 6H) ), 1.43 (d, J = 10.0, 2H).

EXAMPLE 25 8-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy-1-ethyl) -2,8-diaza-spiro [4.51-decan-1-one) A suspension of 2- [4- (2-bromo-ethoxy) -phenoxy) ] -benzothiazoI (Example 9; 257 mg, 0.73 mmol), 2,8-diaza-spiro [4.5] decan-1-one hydrochloride (153 mg, 0.80 mmol) and Silicy® dimethylamine resin (1.7 g, 2.4 mmol) ) in CH3CN was heated at 80 ° C for 18 hr. The reaction mixture was filtered, and the collected resin was rinsed with CH3CN. The combined filtrates were concentrated under reduced pressure to a crude solid, which was purified on SiO2 (10 g, 0-100% [2% NH3 in CH3OH] in CH2Cl2 / CH2CI2) to give an off-white solid (152 mg, 49%). % of performance). MS (ESI): mass calculated for C23H25N3O3S, 423.16; m / z found, 424.2 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.78 (dd, J = 8.1, 0.6, 1 H), 7.69 (dd, J = 8.0, 0.8, 1 H), 7.41 (dt, J = 7.5, 1.3, 1 H), 7.32-7.27 (m, 3H), 7.00 (m, 2H), 6.36 (br s, 1 H), 4.15 (t, J = 5.9, 2H), 3.36 (t, J = 7.0, 2H), 3.00, (dt, J = 11.9, 3. 9, 2H), 2.87 (t, J = 5. 8.2H), 2.32 (dt, J = 11, 5.2, 4.2H), 2.10-1.98 (m, 2H), 2.07 (t, J = 7.0, 2H), 1.50 (br d, J = 13.3, 2H).

EXAMPLE 26 r 2- [4- (3-Pyrrolidin-1-yl-propoxy) -phenoxy] - Obenzothiazole A. 1 - [3-r 4 - (Benzyloxy-phenoxy) -prop-11-pyrrolidine. To a mixture of 1- [3- (4-benzyloxy-phenoxy) -propyl bromide (example 2, 1.50 g, 4.7 mmol) was added pyrrolidine (2.0 mL, 24.0 mmol) in CH3CN. The mixture was stirred for 20 hr then concentrated under reduced pressure to give a yellow oil, which was purified on SiO2 (35 g, acetone) to give 1.2 g (80% yield) of the desired product as a white solid. CCD (S¡O2, acetone): Rf = 0.05. MS (ESI): mass calculated for C20H25NO2, 311.19; m / z found, 312.2 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.50-7.30 (m, 5H), 6.90 (d, J = 9.1, 2H), 6.82 (d, J = 9.1, 2H), 5.02 (s, 2H), 4.00 (t , J = 6.1, 2H), 3.0-2.75 (m, 6H), 2.15 (d, J = 6.2, 2H), 1.94 (br s, 4H). B. 4- (3-Pyrrolidin-1-yl-propoxy) -phenol. To a solution of 1- [3- (4-benzyloxy-phenoxy) -propyl] -pyrrolidine (1.2 g, 3.9 mmol) in 1: 1 ethanol / ethyl acetate (65 mL) was added Pd on charcoal (10% strength). weight, 206 mg). The mixture was placed in a Parr hydrogenator at 2812 kg / cm2 of H2 for 20 hr. The resulting mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure to give 875 mg (100% yield) of the desired product as a brown solid.

MS (ESI): mass calculated for C? 3H? 9NO2, 221.14; m / z found, 222.2 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 8.90 (s, 1 H), 6.74 (d, J = 9.0, 2H), 6.65 (d, J = 9.0, 2H), 3.90 (t, J = 6.3, 2H ), 2.72 (br s, 6H), 1.90 (quintuplete, J 7.4, 2H), 1.76 (s, 4H). C. 2- [4- (3-Pyrrolidin-1-l-propoxO-phenoxy] -benzothiazole. To a stirred solution of 4- (3-pyrrolidin-1-yl-propoxy) -phenol (100 mg, 0.45 mmol. ) in acetone (5 ml) containing Cs2CO3 (213 mg, 0.65 mmol) was added 2-chlorobenzthiazole (65 μl, 0.50 mmol): The mixture was refluxed for 24 hr and then filtered.The filtrate was concentrated under pressure reduced to give a light golden oil, which was purified over S02 (10 g, acetone) to give 97 mg (61% yield) of the desired product CCD (SiO2, acetone): Rf = 0.02 .MS (ESI) : mass calculated for C2oH22N2O2S, 354.14, m / z found, 355.1 [M + Hf. H NMR (400 MHz, DMSO-d6): 7.73 (d, 1 H), 6.95 (d; 1 H), 7.39 (m, 1 H), 7.26 (m, 3H), 6.96 (d, J = 9.1, 2H), 4.06 (t, J = 6.4, 2H), 2.65 (t, J = 7.3, 2H), 2.55 (br s, 4H ), 2.04 (quintuplet, J = 6.5, 2H), 1.82 (brs, 4H).

EXAMPLE 27 1-. { 3- [4- (Benzoxazol-2-yloxy) -phenoxy-1-propyl} 4-phenyl-piperidin-4-ol A. 1- [3-4-hydroxy-phenoxy) -propylene-4-phenyl-piperidin-4-ol acid bromide. 4- (3-Bromo-propoxy) -phenol (example 4; 3 g, 13 mmol) was dissolved in CH 3 CN (65 ml). To this solution was added 4-hydroxy-4-phenylpiperidine (6.8 g, 39 mmol), and the mixture was stirred at room temperature overnight, yielding a white procedure. The suspension was filtered to give the title compound as a white solid (5 g, 11.9 mmol, 91% yield). MS (ESI): mass calculated for C2oH2sNO3 (free base), 327.18; m / z found, 328.2 [M + Hf. 1 H NMR (400 MHz, CD 3 OD): 7.49 (d, J = 7.5, 2H), 7.32 (t, J = 7.5, 2H), 7.21 (t, J = 7 .2, 1H), 6.73 (q, J = 12.3, 4H), 3.96 (t, J = 6.1, 2H), 2.85 (d, J = 11.3, 2H), 2.64-2.54 (m, 4H), 2.13 (dt, J = 9. 0.3, 9, 2H), 2.00 (m, 2H), 1.75 (d, J = 12.2, 2H). B. 1-f3- [4- (Benzoxazol-2-yloxO-phenoxyl-propyl) -4-phenyl-piperidin-4-oh To a stirred solution of acid bromide of 1- [3- (4-hydroxy-phenoxy) !) -propyl] -4-phenyl-piperidin-4-ol (500 mg, 1.5 mmol) in acetone (7 ml) was added CS2CO3 (1.03 g, 3.15 mmol). This suspension was cooled to 0 ° C, and 2-chloro-benzoxazole (276 mg, 1.8 mmol, 0.2 ml) was added dropwise. The reaction mixture was allowed to warm to room temperature overnight, then filtered and concentrated under reduced pressure. The resulting oil was dissolved in CH 2 Cl 2 and purified on SiO 2 (40 g, 0-100% acetone / CH 2 Cl 2) to give 450 mg (1.05 mmol, 70% yield) of a white solid.

MS (ESI): mass calculated for C 26 H 26 N 2 O 4, 444.20; m / z found, 445.20 [M + Hf. 1 H NMR (400 MHz, CD 3 OD): 7.47-7.43 (m, 3 H), 7.36-7.11 (m, 8 H), 6.90 (d, J = 9.1, 2 H), 3.99 (t, J = 5.8, 2 H), 2.80 (d, J = 9.5, 2H), 2.56 (t, J = 6.8 Hz, 2H), 2.44 (t, J = 10.9, 2H), 2.13 (t, J = 11.0, 2H), 1.98 (m, J = 6.8, 2H), 1.71 (d, J = 6.9, 2H).

EXAMPLE 28 1-. { 3- [4- (Benzoxazol-2-oxo-phenoxy] -propyl.} -4-benzyl-piperidin-4-ol A. 4-Benzyl-1 - [3- (4-hydroxy-phenoxy) -propyl ] -piperidin-4-ol.4-Benzyl-4-hydroxy-piperidine (750 mg, 3.9 mmol) was added to a solution of 4- (3-bromo-propoxy) -phenol (example 4, 300 mg, 1.31 mmol) ) in CH3CN (6 ml) The reaction mixture was stirred at room temperature overnight giving a white precipitate The suspension was filtered and the filtrate was concentrated under reduced pressure The resulting oil was purified over SiO2 (10 g) 0-100% acetone / CH2CI2) to give 110 mg (0.32 mmol, 25% yield) of a white solid MS (ESI): mass calculated for C2? H22NO3, 341.20; m / z found, 342.2 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.36-7.24 (m, 3 H), 7.22 (d, J = 6.9, 2 H), 6.7 (m, 4 H), 4. 07 (t, J = 6.5, 2 H) , 3.41 (d, J = 11.7, 2H), 3.19 (t, J = 7.8, 2H), 3.11 (t, J = 11.8, 4H), 2.84 (br s, 2H), 2.34 (br s, 4H), 2.18 (br s, 1 H), 1.72 (d, 14.5, 2H). B. 1- (3- [4- (Benzoxazol-2-yloxy) -phenoxy-1-propyl) -4-benzyl-piperidin-4-oL To a stirring solution of 4-benzyl-1- [3- (4- hydroxy-phenoxy) -propyl] -piperidin-4-ol (2.5 g, 7.3 mmol) in acetone (37 ml) was added Cs2CO3 (4.99 g, 15.3 mmol). This suspension was cooled to 0 ° C, and 2-chloro-benzoxazole (1.1 ml, 9.5 mmol) was added dropwise. The reaction mixture was allowed to warm to room temperature overnight, filtered and then concentrated under reduced pressure. The resulting oil was dissolved in CH2Cl2 and purified on SiO2 (110 g, 0-100% acetone / CH2Cl2) to give 310 mg (0.67 mol, 9% yield) of a white solid. MS (ESI): mass calculated for C28H3oN2O, 458.2; m / z found, 459.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.49 (d, J = 7.2, 1 H), 7.41 (d, J = 7.2, 1 H), 7.35-7.18 (m, 9H), 6.94 (d, J = 9.1, 2H), 4.04 (t, J = 6. 5,2H), 2.93-2.45 (m, 7H), 2.16 (s, 4H), 1.60 (d, J = 13.0, 2H), 1.29 (brs, 1 H) .

EXAMPLE 29 2-r4- (2-P-peridin-1-yl-ethyl) -phenox-benzoxazole A. 4- (2-P-peridin-1-yl-et-P-phenol.) A solution of 4- (2- bromo-ethyl) -phenol (example 5; 4.5 g, 22.4 mmol), piperidine (3.3 ml, 33.5 mmol), and N, N-diisopropylethylamine (5.8 ml, 33.5 mmol) in CH3CN (100 ml) was stirred at 60 ° C for 18 h. The resulting solution was cooled to room temperature and concentrated under reduced pressure to give a pale orange solid. Diethyl ether (100 ml) was added, and the title compound was collected by filtration as an off-white solid (4.6 g, 100% crude yield). CCD (SiO2, 5% NH3 2 M in CH3OH / CH2Cl2): Rf = 0.19. MS (ESI): mass calculated for Ci3H? 9NO, 205.15; m / z found, 206.1 [M + Hf. 1 H NMR (400 MHz, CD3OD): 7.07-7.04 (m 2H), 6.74-6.71 (m, 2H), 3.32-3.30 (m, 2H), 3.14-3.11 (m, 3H), 2.87-2.80 (m, 1H), 1.82-1.67 (m, 6H), 1.65-1.55 (m, 2H). B. 2-r4- (2-Piperidin-1-ethyl-ethyl) -phenox-benzoxazole. A mixture of 4- (2-piperidin-1-yl-ethyl) -phenol (0.5 g, 2.43 mmol), 2-chloro-benzoxazole (304 μL, 2.67 mmol) and CS2CO3 (1.8 g, 5.62 mmol) in acetone ( 10 ml) was stirred at room temperature for 48 h. The reaction mixture was filtered through diatomaceous earth, and the pad was washed with CH2Cl2. The combined filtrates were concentrated under reduced pressure to an orange oil, which was purified over S02 (40 g, 0-100% acetone / CH2Cl2) to give the desired product as a white solid (325 mg, 42% yield) . CCD (SiO2, 5% NH3 2 M in CH3OH / CH2Cl2): Rf = 0.36. MS (ESI): mass calculated for C2oH22N2O2, 322.17; m / z found, 323.1 [M + H]. 1 H NMR (400 MHz, CDCl 3): 7.53-7.51 (m, 1 H), 7.44-7.42 (m, 1H), 7. 34-7.20 (m, 6H), 2.87-2.83 (m, 2H), 2.60-2.56 (m, 2H), 2.48 (br s, 2H), 1.66-1.59 (m, 6H), 1.50-1.43 (m, 2H).EXAMPLE 30 . { 2-r 4 - (Benzothiazol-2-yloxy) -phenyl-ethyl) -cyclohexyl-ethyl-amine A. 4- [2- (Cyclohexyl-ethyl-amino) -ethyl] -phenol. To a stirring solution of 4- (2-bromo-ethyl) -phenol (Example 5, 4.48 g, 22.3 mmol) in CH 3 CN (100 mL) was added cyclohexyl-ethyl-amine (5.0 mL, 33.4 mmol), followed by N, N-diisopropylethylamine (7.76 ml, 44.6 mmol). The resulting solution was stirred at 60 ° C for 16 hr, giving a suspension. The suspension was allowed to cool to room temperature and filtered. The filtered solid was washed with ethyl acetate (2 x 20 ml) and dried to give a white solid (4.8 g, 87% yield). MS (ESI): mass calculated for C? 6H25NO, 247.19; m / z found, 248.2 [M + Hf 1 H NMR: (400 MHz, CDCl 3): 7.01 (d, J = 8.6, 2H), 6.87 (d, J = 8.6, 2H), 3.32-3.17 (m, 2H) , 3.15-2.98 (m, 4H), 2.30-2.21 (m, 2H), 1.77-1.59 (m, 2H), 1.57-1.46 (m, 5H), 1.40-1.10 (m, 3H). B. { 2-f4- (Benzothiazol-2-yloxy) -phenyl] -etyl) -cyclohexyl-ethyl-amine. To a stirred solution of 1- [2- (4-hydroxy-phenoxy) -ethyl] -piperidin-4-ol (495 mg, 2.0 mmol) in DMF (10 mL) was added Cs2CO3 (1.3 g, 4.0 mmoles) and 2- chlorobenzothiazole (0.33 ml, 2.5 mmol). The suspension was stirred at 80 ° C overnight. The reaction mixture was allowed to cool to room temperature and then filtered through diatomaceous earth. The filtrate was concentrated under reduced pressure, and the residue was purified on SiO2 (40 g, 0-100% acetone / CH2Cl2) to give 548 mg (72% yield) of a tan solid. MS (ESI): mass calculated for C23H28N2OS, 380.19; m / z found, 381.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 8.0, 1 H), 7.63 (d, J = 8.0, 1 H), 7.30 (t, J = 8.0, 1H), 7.29-7.20 (m, 5H), 2.78-2.68 (m, 4H), 2.62 (dd, J = 6.8, 7.4, 2H), 2.56-2.46 (m 1 H), 1.83-1.74 (m, 4H), 1.66-1.57 (m, 1 H, 1.21 (dd, J = 9.0, 8.6, 4H), 1.15-1.11 (m, 1 H), 1.06 (t, J = 7.2, 3H).

EXAMPLE 31 1- (2- [4- (Benzothiazol-2-yloxy) -phenyl-1-ethyl) -piperidine-3-carboxylic acid amide A suspension of 2- [4- (2-bromo-ethyl) -phenoxy] -benzothiazole (example 10, 250 mg, 0.75 mmol), nipecotamide (96 mg, 0.75 mmol) and Silicy® dimethylamine resin (1.1 g, 1.50 mmol) in CH3CN was heated to 70 ° C for 18 hr. The reaction mixture was filtered, and the collected resin was washed with CH 3 CN. The combined filtrates were concentrated under pressure reduced to a crude solid, which was purified on SiO2 (10 g, 0-100% [2 M NH 3 in CH 3 OH] in CH 2 Cl 2 / CH 2 Cl 2) to give 135 mg (47% yield) of a white solid. MS (ESI): mass calculated for C2? H23N3O2S, 381.15; m / z found, 382.4 [M + Hf 1 H NMR (400 MHz, CDCl 3): 8.10 (d, J = 8.1, 1 H), 7.75 (dd, J = 8. 0, 0.8, 1 H), 7.42 (dt, J = 7.4, 1.3, 1H), 7.21 (br s, 1 H) 6.42 (br s, 1 H), 3.05 (br d, J = 10.3, 1 H) , 2.95-2.80 (m, 3H), 2.80-2.62 (m, 2H), 2.47-2.40 (m, 1 H), 2.36 (d, J = 11.5, 1 H), 2.08 (t, J = 10.5, 1 H), 1.98 (d, J = 11.0, 1 H), 1.76-1.63 (m, 1 H), 1.63-1.50 (m , 2H).

EXAMPLE 32 1- (1- (2-r4- (Benzothiazol-2-yloxy) -phenin-ethyl) -piperidin-4-yl) -3-methyl-1,3-dihydro-benzimidazol-2-one A. Ester 2- [4- (Benzothiazol-2-yloxy) -phenylene-ethyl of toluene-4-sulfonic acid. To a stirred solution of 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethanol (Example 10, 12.25 g, 45.2 mmol) in CH 2 Cl 2 (225 mL) was added p-toluenesulfonyl chloride (17.23 g, 90 mmol) and TEA (31 ml, 225 mmol). The mixture was stirred at room temperature for 72 hr. The reaction mixture was concentrated under reduced pressure, and the residue was dissolved in ethyl acetate (400 ml). The solution was washed with saturated aqueous NaHCO3 (3 x 200 ml), dried (Na2SO4), and concentrated under reduced pressure. The resulting oil was dissolved in CH 2 Cl 2 and purified on SiO 2 (300 g, CH 2 Cl 2) to give a tan solid (8.8 g, 45% yield). MS (ESI): mass calculated for C22H? 9N2O4S2, 425.08; m / z found, 426.0 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.70 (q, J = 9.7, 4H), 7.39 (t, J = 7.8, 1 H), 7.32-7.17 (m, 8H), 4.23 (t, J = 6.9, 2H ), 2.99 (d, J = 6.9, 2H), 2.43 (s, 3H). B. 1 - (1 - (2- [4- (Benzothiazol-2-yloxy) -fenip-etl) -piperidin-4-yn-3-methyl-1,3-dihydro-benzimidazol-2-one To a stirring solution of 2- [4- (benzothiazoI-2-yloxy) -phenyl] -ethyl ester of toluene-4-sulfonic acid (400 mg, 0.94 mmol) in CH3CN (5 mL), 1- was added. methyl-3-piperidin-4-yl-1,3-dihydro-benzimidazol-2-one (653 mg, 2.82 mmol) The reaction mixture was stirred at room temperature overnight, then concentrated under reduced pressure and purified on SiO2 (12 g; 50% acetone / CH2Cl2) to give a clear oil (16 mg, 3.3% yield). MS (ESI): mass calculated for C28H28N4O2S, 484.19; m / z found, 485.5 [M + Hf. 1 H NMR (400 MHz, CD 3 OD): 7.75 (d, J = 7.9, 1 H), 7.65 (d, J = 8.1, 1 H), 7.41-7.29 (m, 7 H), 7.13 (m, 3 H), 4.37 (m, 1H), 3.40 (s, 3H), 3.25 (d, J = 11.8, 2H), 2.94 (m, 2H), 2.75 (m, 2h), 2.57 (qd, J = 12.6, 3.7, 2H) , 2.33 (t, J = 11.3, 2H), 1.81 (d, J = 12.2, 2H).

EXAMPLE 33 Methyl ester of acid 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenp-ethyl) -piperidine-4-carboxylic acid. 1-Methyl 2- (4-hydroxy-phenyl) -etip-piperidin-4-methyl ester -carboxylic To a stirring solution of 4- (2-bromo-ethyl) -phenol (example 5, 5.05 g, 25 mmol) in CH3CN (100 ml) was added piperidine-4-carboxylic acid methyl ester (5.07 ml, 37.5 mmol). ), followed by N, N-diisopropylethylamine (8.7 ml, 50 mmol). The reaction mixture was stirred at 60 ° C for 16 hr, and then allowed to cool to room temperature. CH 2 Cl 2 (250 mL) was added, and the resulting solution was washed with H 2 O (2 x 30 mL), dried, filtered and then concentrated under reduced pressure to give 5.2 g (79%) of a tan solid. MS (ESI): mass calculated for C15H21NO3, 263.15; m / z found, 264.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 6.97 (d, J = 8.2, 2 H), 6.70 (d, J = 8.6, 2 H), 3.67 (s, 3 H), 2.99 (d, J = 11.5, 2 H), 2.76 -2. 68 (m, 2H), 2.60-2.54 (m, 2H), 2.40-2.30 (m, 1H), 2.18 (t, J = 10. 8, 2H), 1.99-1.90 (m, 2H), 1.90-1.78 (m, 2H). B. 1- (2- [4- (Benzothiazol-2-yloxy) -phenyl) -piperidine-4-carboxylic acid methyl ester. To a stirring solution of 1- [2- (4-hydroxy-phenyl) -ethyl] -piperidine-4-carboxylic acid methyl ester (790 mg, 3.0 mmol) in DMF (15 ml), Cs2CO3 (1.95 g, 6.0 mmol) and 2-chlorobenzothiazole (0.47 ml, 3.9 mmol) were added. The suspension was heated to 100 ° C and stirred overnight. The reaction mixture was allowed to cool to room temperature and then filtered through diatomaceous earth. The filtrate was concentrated under reduced pressure, and the residue was purified over SiO2 (40 g, 0-100% acetone / CH2Cl2) to give 1.04 g (87% yield) of a tan solid. MS (ESI): mass calculated for C22H24N2O3S, 396.15; m / z found, 397.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 7.8, 1 H), 7.65 (d, J = 7.8, 1 H), 7.38 (t, J = 7.6, 1 H), 7.28-7.25 (m , 5H), 3.69 (s, 3H), 3.00-2.93 (m, 2H), 2.83 (dd, J = 7.6, 3.0, 2H), 2.61 (dd, J = 7.6, 3.0, 2H), 2.38-2.28 ( m 1 H), 2.11 (t, J = 10.4.2H), 1.98-1.89 (m, 2H), 1.87-1.74 (m, 2H).

EXAMPLE 34 (1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] ethyl} - piperidin-4-yl) - (4-methyl-piperazin-1-yl) -methanone A. Salt of trifluoroacetic acid acid 1- (2-γ4- (benzothiazol-2-yloxyHenir | -etiD-piperidine-4-carboxylic acid) To a solution of methyl ester of acid 1-. {2- [4- ( benzothiazol-2-yloxy) -phenyl] -ethyl.}. -piperidine-4-carboxylic acid (example 33; 4.6 g, 11.7 mmol) in THF / CH 3 OH 3: 1 (100 ml), lithium (1.1 g, 46.6 mmol) in H20 (25 mL). This dark yellow solution was stirred at room temperature for 16 hr and then concentrated under reduced pressure. The residue was dissolved in CH3OH and purified by reverse phase CLAP to give the title compound as a yellow solid (3.9 g, 68% yield). MS (ESI): mass calculated for C2? H22N2O3S, 382.14; m / z found, 383.4 [M + Hf. B. (1- (2-r4 (Benzothiazol-2-yloxy) -phenin-ethyl-VPIperidin-4-in- (4-methyl-piperazin-1-yl) -methanone.) To a mixture of TFA salt of acid 1- {. 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid (300 mg, 0.6 mmol) in CH2Cl2 (15 mL) and one drop of DMF, Oxalyl chloride (0.11 ml, 1.2 mmol) was added The mixture was stirred at room temperature for 1 hr The resulting mixture was concentrated under reduced pressure The residue was dissolved in CH2Cl2 (15 ml), and N-methylpiperizine was added ( 0.2 ml, 1.8 mmol) This reaction mixture was stirred at room temperature for 1 hr, diluted with CH2Cl2 (100 ml), washed with H2O, saturated aqueous NaHCO3 then brine, dried (Na2SO4) and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified over S¡02 (40 g, 0-10% 2M NH 3 in CH 3 OH / CH 2 Cl 2) to give the title compound (240 mg, 86%). MS (ESI): mass calculated for C26H32N2? 3S, 464.22; m / z found, 465.5 [M + Hf. 1H NMR (400 MH z, DMSO-d6): 7.72 (d, J = 7.6, 1 H), 7.65 (d, J = 7.6, 1 H), 7.37 (t, J = 7.6, 1 H), 7.29-7.22 (m, 5H ), 3.64 (br s, 2H), 3.51 (br s, 2H), 3.06 (d, J = 11.4, 2H), 2.83 (dd, J = 7.3, 3.5, 2H), 2.60 (dd, J = 7.3, 3.5, 2H), 2.5; 1-2.43 (m 1 H), 2.42-2.33 (m, 4H), 2.30 (s, 3H), 2.06 (t, J = 12.1, 2H), 1.99-1. 84 (m, 2H), 1.72 (d, J = 13.1, 2H).

EXAMPLE 35 (3-y4- (Benzoxazol-2-yloxy) -phenyl] -propyl.} - cyclohexyl-ethyl-amine A. f3- (4-Benzyloxy-phenyl-propy-p-cyclohexyl-ethyl-amine. To a solution of 3- (4-benzyloxy-phenyl) -propyl 1-bromide (504 mg, 1.65 mmol) and N-ethylcyclohexylamine (497 μl, 3.30 mmol) in CH 3 CN (15 ml) was added K 2 CO 3 (510 mg, 3.69 mmol) The reaction mixture was refluxed for 20 h The mixture was filtered and then concentrated under reduced pressure to a golden oil, which was purified on SiO2 (10 g, 50% acetone / CH2CI2) to give 484 mg (83% yield) of the desired product as a clear, colorless oil CCD (SiO2, acetone): Rf = 0.13 MS (ESI): mass calculated for 24H33NO, 351.26, m / z found, 352.4 [ M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.50-7.28 (m, 5H), 7.12 (d, J = 8. 6.2H), 6.90 (d, J = 8.6.2H), 5.06 (s, 2H), 2.60-2. 45 (m, 7H), 1.78 (br s, 6H), 1.20 (br s, 4H), 1.05 (t, J = 7.1, 4H).

B. 4-F3- (Cyclohexyl-ethylamino) -prop.p-phenol. To a solution of [3- (4-benzyloxy-phenyl) -propyl] -cyclohexyl-ethyl-amine (420 mg, 1.19 mmol) in 1: 1 ethanol / ethyl acetate (16 mL) was added Pd on carbon ( 10% by weight, 46 mg). The mixture was placed in a Parr hydrogenator at 2812 kg / cm2 of H2 for 20 hr. The resulting mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure to give 308 mg (99% yield) of the desired product as a golden oil. CCD (SiO2, acetone): Rf = 0.18. MS (ESI): mass calculated for C-17H27NO, 261.21; m / z found, 262.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.00 (d, J = 8.5, 2H), 6.75 (d, J = 8.5, 2H), 2.65 (br s, 5H), 2.54 (t, J = 7.6, 2H), 1.82 (br s, 6H), 1.30-1.05 (m, 8H). C. { 3- [4- (Benzoxazol-2-yloxy) -phenyl] -propyl) -cyclohexyl-ethyl-amine. To a mixture of 4- [3- (cyclohexyl-ethyl-amino) -propl] -phenol (283 mg, 1.08 mmol) and Cs2CO3 (885 mg, 2.72 mmol) in acetone (15 ml) at 5 ° C were added. added 2-chloro-benzoxazole (155 μL, 1.36 mmol). The reaction mixture was allowed to warm slowly to room temperature overnight, then filtered. The filtrate was concentrated under reduced pressure to give a golden oil, which was purified on SiO2 (10 g, acetone) to give 333 mg (81% yield) of the desired product as a golden oil. CCD (S¡O2, acetone): Rf = 0.12. MS (ESI): mass calculated for C 24 H 3 o N 2 O 2, 378.23; m / z found, 379.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.61 (d, J = 7.3, 1 H), 7.49 (d, J = 7.8, 1 H), 7.39 (d, J = 8.6, 2H), 7.38-7.25 (m, 4H), 2.62 (t, J = 7.5, 2H), 2.65-2.35 (m, 8H), 1.67 (br s, 5H), 1.19-1.10 (m, 4H), 0.95 (t, J = 7.1, 3H) .

EXAMPLE 36 1-. { 3- [4- (Benzoxazol-2-yloxy) -phenyl-1-propyl} -piperidin-4-ol. A. 1-y3- (4-Hydroxy-phenyl-propyl-piperidin-4-ol) A solution of 4- (3-bromo-propyl) -phenol (example 6, 1.42 g, 6.6 mmol), hydrochloride of 4 Hydroxypiperidine (908 mg, 6.6 mmol), and N, N-diisopropylethylamine (2.2 ml, 12.3 mmol) in CH 3 CN (20 ml) was stirred at 60 ° C. for 18 hr.The reaction mixture was cooled to room temperature, and the solvent was removed under reduced pressure to give an off-white solid.This material was dissolved in CH2Cl2 (200 ml), and the solution was washed with H2O (2 x 50 ml), dried (Na2SO), filtered and concentrated under reduced pressure to give a white solid Diethyl ether was added, and the title compound was collected by filtration (1.4 g, 90% yield) CCD (SiO2, 5% NH3 2M in CH3OH / CH2Cl2): Rf = 0.05. MS (ESI): mass calculated for C? 4H21NO2, 235.16; m / z found, 236.2 [M + Hf. 1 H NMR (400 MHz, CD3OD): 6.96-6.94 (m, 2H), 6.64-6.61 (m, 2H ), 3.89-3.82 (m, 1 H), 3.29- 3.20 (m, * 4H), 3.02-2.95 (m, 4H), 2.52 (t, J = 7.4, 2H), 1.95-1.87 (m, 4H), 1.68-1.60 (m, 2H). B. 1- (3-r4- (Benzoxazol-2-yloxy) -phenin-propyl) -piperidin-4-ol. A mixture of 1- [3- (4-hydroxy-phenyl) -propyl] -p-perdin-4-ol (0.4 g, 1.69 mmol), 2-chloro-benzoxazole (176 μl, 1.54 mmol) and Cs2CO3 (1.45 g, 4.45 mmol) in acetone (8.0 ml) was stirred at room temperature for 48 hr. The resulting mixture was filtered through diatomaceous earth, which was then washed with CH2Cl2. The combined filtrates were concentrated under reduced pressure to a yellow oil. The oil was purified on SiO2 (40 g; 0-100% acetone / CH2Cl2) to give a white solid, which was dissolved in CH2Cl2. The solution was washed with 1M NaOH (3 x 5 ml), then H2O (5 ml), dried (Na2SO), filtered, and concentrated under reduced pressure to give the title compound as a white solid (98 mg, 16.4% yield). CCD (SiO2, 5% 2M NH3 in CH3OH / CH2Cl2): Rf = 0.14. MS (ESI): mass calculated for C2? H24N203, 352.18; m / z found, 363.1 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.66-7.51 (m, 1 H), 7.44-7.42 (m, 1 H), 7.34-7.21 (m, 6 H), 3.72-3.69 (m, 1 H), 2.79-2.76 (m, 2H), 2.67 (t, J = 7.8, 2H), 2.38 (t, J = 7.6, 2H), 2.15-2.11 (m, 2H), 1.98-1.80 (m, 3H), 1.65-1.55 ( m, 3H), 1.42 (m, 1 H).

EXAMPLE 37 1-. { 2-4- (1H-Benzimidazol-2-yloxy) -phenoxy-1-ethyl} -4-phenyl-piperidin-4-ol A. 1 -r2- (4-Hydroxy-phenoxy) -etip-4-phenyl-piperidin-4-ol. To a solution of 4- (2-bromo-ethoxy) -phenol (example 3; 8.0 g, 36.8 mmol) and 4-hydroxy-4-phenylpiperidine (8.2 g, 46.3 mmol) in CH3CN (150 mL) was added DIEA ( 7.0 ml, 40.2 mmol). The mixture was stirred for 20 hr at room temperature and an additional 4 hr at 65 ° C, then concentrated under reduced pressure to give a brown solid. The solid was dissolved in ethyl acetate (250 ml), and the solution was washed with H2O (250 ml, 100 ml), dried (MgSO4), and concentrated under reduced pressure to give a brown solid. The solid was purified on SiO2 (120 g, 0-100% acetone / CH2Cl2), to give 8.9 g (77% yield) of the desired product as a tan solid. CCD (SiO2, acetone): Rf = 0.42. MS (ESI): mass calculated for C? 9H23NO3, 313.17; m / z found 314.2 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.52 (d, J = 8.6, 2H), 7.37 (t, J = 7.3, 2H), 7.27 (m, 1 H), 6.75 (s, 4H), 4.08 (t, J = 5.8, 2H), 3.05-2.90 (m, 2H), 2.88 (t, J = 5.8, 2H), 2.80-2.62 (m, 2H), 2.31-2.18 (m, 2H), 1.81 (d, J = 11.8, 2H). B. 4-Phenyl-1 - (2- (4-f1 - (2-trimethylsilanyl-ethoxymethiO-1 H-benzimidazol-2-yloxp-phenoxy.) -ethyl) -piperidin-4-ol. To a mixture of 2-Chloro-1- (2-trimethylalanyl-ethoxymethyl) -1H-benzimidazole (Example 7; 630 mg, 2.2 mmol) and 1- [2- (4-hydroxy) phenoxy) -ethyl] -4-phenyl-piperidin-4-ol (690 mg, 2.2 mmol) in DMF (10 ml) was added Cs2CO3 (1.5 g, 4.6 mmol). The reaction mixture was stirred at 100 ° C for 18 hr, and then divided into 1: 1 ethyl acetate / H 2 O (50 ml). The organic layer was collected, dried (MgSO4), and concentrated under reduced pressure to give a light brown oil, which was purified on SiO2 (35 g, acetone) to give 867 mg (70% yield) of the desired product as a light golden oil. CCD (SiO2, acetone): Rf = 0.38. MS (ESI): mass calculated for C32H4iN3O4Si, 559.29; m / z found, 560.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.55 (m, 3 H), 7.38 (m, 3 H), 7.30-7.20 (m, 5 H), 6.99 (d, J = 9.0, 2 H), 5.55 (s, 2 H), 4.17 (t, J = 5.9, 2H), 6.37 (m, 2H), 2.92 (m, 5H), 2.65 (t, J = 12.4, 2H), 2.21 (t, J = 15.9, 2H), 1.81 (d , J = 12.1, 2H), 0.96 (t, J = 8.1, 2H). C. 1 -. { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -4-phenyl-piperidin-4-ol. To a solution of 4-phenyl-1- (2- {4- [1- (2-trimethylsilanyl-ethoxymethyl) -1 H -benzimidazol-2-yloxy] -phenoxy} -ethyl) -piperidine -4-ol (816 mg, 1.46 mmol) in THF (5 ml) containing N, N, N, N-tetramethylethylenediamine (TMEDA, 2.2 ml, 14.6 mmol), a 1 M solution in THF of tetrabutylammonium fluoride was added. (TBAF, 15 ml, 15 mmol). The mixture was stirred at 55 ° C for 5 hr, then concentrated under reduced pressure. The resulting oil was dissolved in diethyl ether (100 ml), and the solution was washed with H2O (3 x 75 ml), dried (MgSO4), filtered, and concentrated under reduced pressure to give a white solid. HE added diethyl ether, and filtration gave the desired product as a white solid (155 mg, 25% yield). CCD (SiO2, acetone): Rf = 0.16. MS (ESI): mass calculated for C 26 H 27 N 3 3 3, 429.21; m / z found, 430.2 [M + Hf 1 H NMR (400 MHz, DMSO-d 6): 12.23 (br s, 1 H), 7.48 (d, J = 7.3, 2H), 7.35-7.25 (m, 6H), 7.20 (t, J = 7. 4, 1 H), 7.10-7.04 (m, 2H), 7.00 (d, J = 9.0, 2H), 4.80 (s, 1 H), 4.13 (t, J = 5.8, 2H), 2.76 (t, J = 5.8, 2H), 2.58-2.48 (m, 2H), 1.94 (dt, J = 12.7, 4.0, 2H), 1.58 (d, J = 12.1, 2H).

EXAMPLE 38 . { 2- [4- (1H-Benzimidazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl-propyl-amine A. 4- [2- (Cyclopropylmethyl-propyl-amino) -etyr] -phenol. To a solution of 4- (2-bromo-ethyl) -phenol (Example 5, 5.0 g, 25.0 mmol) in CH 3 CN (100 mL) was added cyclopropylmethyl-propyl-amine (5.4 mL, 37.5 mmol), followed by N, N-düsopropylethylamine (8.70 ml, 50.0 mmol). The resulting solution was stirred at 60 ° C for 16 hr, giving a suspension, which was cooled to room temperature and filtered. The filtered solid was washed with ethyl acetate (2 x 20 ml) and dried to give a white solid (5.7 g, 98% yield).

MS (ESI): mass calculated for C15H23NO, 233.18; m / z found, 234.1 [M + Hf 1 H NMR (400 MHz, DMSO-d 6): 7.01 (d, J = 8.6, 2H), 6.87 (d, J = 8.6, 2H), 3.34-3.30 (m, 2H ), 3.19-3.04 (m, 2H), 2.94-2.75 (m, 4H), 1.75-1.56 (m, 2H), 1.16-0.99 (m, 1H), 0.95-0.87 (m, 3H), 0.68-0.53 (m, 2H), 0.44-0.32 (m, 2H). E. { 2-r 4 - (1 H-Benzimidazol-2-yloxy) -phenyl-1-ethyl) -cyclopropylmethyl-propyl-amine. A mixture of 2-chloro-1H-benzimidazole (Example 7, 707 mg, 2.5 mmol), 4- [2- (cyclopropylmethyl-propyl-amino) -ethyl] -phenol (467 mg, 2.0 mmol), and Cs2CO3 (1.3 g, 4.0 mmol) in DMF (10 mL) was stirred at 100 ° C for 18 hr. The reaction mixture was cooled to room temperature, and then divided into 1: 1 ethyl acetate / H 2 O (200 ml). The organic layer was collected, dried (MgSO4), and concentrated under reduced pressure to give a light brown oil, which was purified on SiO2 (40 g, 0-100% acetone / CH2Cl2), giving 729 mg (76% of yield) of a light golden oil. MS (ESI): mass calculated for C28H4? N3? 2Si, 479.30; m / z found, 480.5 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.63-7.58 (m, 1 H), 7.49-7.39 (m, 1 H), 7.31 (s, 4 H), 7.26-7.22 (m, 2 H), 5.58 (s, 2 H) ), 3.69 (t, J = 8.2, 2H), 2.89-2.79 (m, 4H), 22.63-2.58 (m, 2H), 2.48 (d, J = 6.5, 2H), 1.61-1.50 (m, 2H) , 1.01-0.91 (m, 6H), 0.59-0.53 (m, 2H), 0.20-0.15 (m, 2H), 0.1 (s, 9H).

C. (2-r4- (1H-Benzimidazol-2-yloxy) -phenyl-1-ethyl-cyclopropylmethyl-propyl-amine) To a solution of cyclopropylmethyl-propyl- (2- {4- [1- (2-trimethylsilanyl) -ethoxymethyl) -1 H-benzimidazol-2-yloxy] -phenyl.}. -ethyl) -amine (411 mg, 0.87 mmol) in THF (5 mL), TBAF (1 M in THF, 2.57 mL, 2.57 mmol) was added by syringe, and the mixture was stirred under reflux for 16 hr.The reaction mixture was cooled to room temperature and concentrated under reduced pressure.The resulting oil was purified over S¡O2 (40 g; CH3OH / CH2CI2), giving 284 mg (95% yield) of a clear oil MS (ESI): mass calculated for C22H27N3O, 349.22, m / z found, 350.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3) : 7.34 (br s, 2H), 7.18-7.05 (m, 6H), 2.82-2.70 (m, 4H), 2.69-2.62 (m, 2H), 2.52 (d, J = 6. 8, 2H), 1.61 -1.50 (m, 2H), 0.91 (t, J = 6.8, 4H), 0.57-0.51 (m, 2H), 0.16 (dd, J = 5.3, 5.1, 2H).

EXAMPLE 39 Cyclohexyl-ethyl- (2- [4- (1-methyl-1 H-benzimidazol-2-yloxy) -phenyl] -ethyl) -amine. A mixture of 4- [2- (cyclohexyl-ethyl-amino) -ethyl] -phenol (247 mg, 1.0 mmol), N-methylbenzimidazole (Example 8, 200 mg, 1.2 mmol), and Cs2CO3 (652 mg, 2.0 mmol) in DMF (3 mL) was stirred at 100 ° C for 16 hr. The reaction mixture was cooled and filtered through diatomaceous earth, which it was then washed with ethyl acetate (30 ml). The combined filtrates were washed with H2O (3 x 10 mL) then brine (10 mL), dried (Na2SO4), filtered, and concentrated under reduced pressure. The crude material was purified on Si02 (10 g, 0-100% of [2 M NH 3 in CH 3 OH] in CH 2 Cl 2 / CH 2 Cl 2) to give 105 mg (28% yield) of a brown oil. MS (ESI): mass calculated for C24H3? N3O, 377.53; m / z found, 378.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.52 (d, J = 7.2, 1 H), 7.63-7.58 (m, 1 H), 7.33-7.18 (m, 7 H), 3.75 (s, 3 H), 2.81 -2.70, m, 4H), 2.68 (q, J = 7.1, 2H), 2.60-2.50 (m, 1H), 1.90-1.80 (m, 4H), 1.67 (d, J = 12.3, 1H), 1.35- 1.18 (m, 4H), 1.15-1.05 (m, 1 H), 1.12 (t, J = 7.1, 3H). EXAMPLE 40 1-. { 3- [4- (Benzoxazol-2-yloxy) -phenoxy-2-hydroxy-propyl) -4-phenyl-piperidin-4-yl A. 2- (4-Benzyloxy-phenoxymethyl-oxirane. (benzyloxy) phenol (15.0 g, 74.9 mmol) and epichlorohydrin (30 ml, 384 mmol) in DMF (200 ml) was added Cs2CO3 (51.2 g, 157 mmol) The mixture was heated at 75 ° C for 3 days. The reaction mixture was cooled to room temperature, and then partitioned in 1: 1 ethyl acetate / H20 (600 ml) The organic layer was collected, washed with H20 (3 x 250 ml), dried (MgSO4) , HE filtered, and concentrated under reduced pressure to give 38 g of a clear dark brown liquid. The liquid was purified on SiO2 (300 g, 50-100% CH2CI2 / hexanes) to give the desired product as a white solid (13 g., 68% yield). CCD (SiO2, CH2Cl2): Rf = 0.64. [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.55-7.28 (/ m 5 H), 6.91 (d, J = 9.3, 2 H), 6.86 (d, J = 9.3, 2 H), 5.03 (s, 2 H), 4.17 ( dd, J = 11.0, 3.2, 1 H), 3.95-3. 88 (m, 1 H), 3.36-3.33 (m, 1 H), 2.91 (t, J = 4.8, 1 H), 2.75 (dd, J = 4.9, 2.6, 1 H). B. 1-r 3 - (4-Benzyloxy-phenoxy) -2-hydroxy-propyl] -4-phenyl-piperidin-4-ol. To a solution of 2- (4-benzyloxy-phenoxymethyl) -oxirane (1.50 g, 5.85 mmol) and 4-hydroxy-4-phenylpiperidine (1.30 g, 7.33 mmol) in CH3CN (50 mL) was added K2C03 (1.0 g, 7.23 mmoles). The mixture was refluxed for 20 hr. The reaction mixture was filtered, and the filtrate was concentrated under reduced pressure to give a white solid, which was purified on SiO2 (40 g; acetone) to give 1.4 g (56% yield) of the desired product as a white solid. CCD (SiO2, acetone): Rf = 0.36. MS (ESI): mass calculated for C27H31NO4, 433.23; m / z found, 434.3 [M + Hf 1 H NMR (400 MHz, DMSO-d 6): 7.56-7.23 (m, 10 H), 6.93 (d, J = 9.2, 2 H), 6.88 (d, J = 9.2, 2H), 5.03 (s, 2H), 4.77 (s, 2H), 3.93 (br d, J = 10.8, 2H), 3.81 (t, J = 7. 2, 1 H), 2.80-2.60 (m, 2H) ), 2.50-2. 35 (m, 4H), 1.97-1.90 (m, 2H), 1.60-1.50 (d, J = 13.4, 2H).

C. 1-r2-Hydroxy-3- (4-hydroxy-phenoxy) -propyl-4-phenyl-piperidin-4-ol. To a solution of 1- [3- (4-benzyloxy-phenoxy) -2-hydroxy-propyl] -4-phenyl-piperidin-4-ol (1.3 g, 3.0 mmol) in 1: 1 ethanol / ethyl acetate (50 ml) was added Pd on carbon (10% by weight, 165 mg). The mixture was placed in a Parr hydrogenator at 2812 kg / cm2 of H2 for 20 hr. The reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure to give 1.0 g (100% yield) of desired product as a white solid. CCD (SiO2, acetone): Rf = 0.27. MS (ESI): mass calculated for C2oH25NO4) 343.18; m / z found, 344.3 [M + Hf. 1 H NMR (400 MHz, CD 3 OD): 7.61 (d, J = 8.1, 2 H), 7.42 (t, J = 7.4, 2 H), 7.30 (t, J = 7.3, 1 H), 6.90 (d, J = 9.0 , 2H), 6.81 (d, J = 9.0, 2H), 4.25 (br s, 1H), 4.05-3.95 (m, 2H), 3.10-2.92 (m, 2H), 2.80-2.60 (m, 4H), 2.30-2.20 (m, 2H), 1.81 (d, J = 11.8, 2H). D. 1-. { 3- [4- (Benzoxazol-2-yloxy) -phenoxy] -2-hydroxy-propyl) -4-phenylpiperidin-4-ol. To a mixture of 1- [2-hydroxy-3- (4-hydroxy-phenoxy) -propyl] -4-phenyl-piperidin-4-ol (251 mg, 0.73 mmole) and Cs2CO3 (667 mg, 2. 05 mmole ) in acetone (10 ml) at 5 ° C, 2-chloro-benzoxazole (108) μl, 0.95 mmol) was added. The reaction mixture, left on ice, was warmed to room temperature overnight and then filtered. The filtrate was concentrated under reduced pressure to give a golden oil, which was purified on SiO (10 g, acetone) to give 127 mg (38% yield) of the desired product as a solid.

White. CCD (SiO2, acetone): Rf = 0.27. MS (ESI): mass calculated for C2 H28N2O5, 460.20; m / z found, 461.3 [M + Hf 1 H NMR (400 MHz, DMSO-d 6): 7.60 (d, J = 6.6, 1 H), 7.55-7.35 (m, 5H), 7.32-7.25 (m, 4H), 7.20 (t, J = 7.3, 1 H), 7.06 (d, J = 9.1, 2H), 4.78 (s, 1 H), 4.10-3.85 ( m, 3H), 2.80-2.65 (m, 2H), 2.55-2.35 (m, 4H), 1.95 (t, J = 13. 1, 2H), 1.59 (d, J = 13.2, 2H).

EXAMPLE 41 Ethyl 1- [2- (4-benzoxazol-2-ylmethyl-phenoxy) -eti-piperidine-4-carboxylic acid ester. 4-Benzoxazol-2-ylmethyl-phenol. A mixture of 4-hydroxyphenylacetic acid (35 g, 230 mmol) and 2-aminophenol (43 g, 400 mmol) was heated at 180 ° C for 3 hr and then cooled to room temperature. The resulting solid was ground and dissolved in THF (200 ml), and carbonyldiimidazole (27 g, 170 mmol) was added. The solution was stirred at 60 ° C overnight. The reaction mixture was concentrated under reduced pressure, and partitioned between ethyl acetate (400 ml) and H2O (300 ml). The organic layer was concentrated under reduced pressure. The resulting oil was dissolved in CH2Cl2 and purified on SiO 2 (200 g, 0-50% acetone / CH 2 Cl 2) to give a brown solid (31 g, 40% yield). MS (ESI): mass calculated for C14HnN02, 225.08; m / z found, 226.1 [M + Hf. 1 H NMR (400 MHz, CD 3 OD): 7.62 (m, 1 H), 7.53 (m, 1 H), 7.32 (m, 2H), 7.17 (d, J = 8. 5.2H), 6.75 (d, J = 8.5, 2H), 4.18 (s, 2H). B. 2- [4- (2-Bromo-ethoxy) -benzyl] -benzoxazole. To a stirring solution of 4-benzoxazol-2-ylmethyl-phenol (5 g, 22.2 mmol) in CH3CN (100 mL) was added Na2CO3 (6.4 g, 46.6 mmol) and dibromoethane (7.9 mL, 88.8 mmol). The resulting suspension was heated at 70 ° C for 72 hr and filtered while hot. The filtrate was concentrated under reduced pressure. The resulting solid was suspended in diethyl ether and filtered, and the filtrate was concentrated under reduced pressure. The resulting oil was dissolved in CH2Cl2 and purified over SiO2 (110 g, CH2Cl2) to give an off-white solid (1 g, 13.7% yield). MS (ESI): mass calculated for C 6 H 4BrNO 2, 331.02; m / z found, 332.0 [M + Hf. 1 H NMR (400 MHz, CD 3 OD): 7.62 (m, 1 H), 7.53 (m, 1 H), 7.34 (m, 2 H), 7.29 (d, J = 8.6, 2 H), 6.92 (d, J = 8.7 , 2H), 4.28 (t, J = 5.9, 2H), 4.23 (s, 2H), 3.67 (t, J = 5.9, 2H). C. 1-f2- (4-Benzoxazoi-2-ylmethyl-phenoxy) -ethyl] -piperidine-4-carboxylic acid ethyl ester. To a stirred solution of 2- [4- (2-bromo-ethoxy) -benzyl] -benzoxazole (0.5 g, 1.5 mmol) in CH3CN (7.5 mL) was added ethyl isonepicotate (0.7 ml, 4.5 mmol). The mixture was stirred at room temperature for 48 hr, then concentrated under reduced pressure. The resulting oil was dissolved in CH2Cl2 and purified on SiO2 (40 g; 0-25% acetone / CH2Cl2) to give an off-white solid (275 mg, 45% yield). MS (ESI): mass calculated for C24H28N2? 4, 408.20; m / z found, 409.2 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.67 (m, 1 H), 7.45 (m, 1 H), 7.28 (d, J = 9.0, 4H), 6.88 (d, J = 8. 7.2H), 4.20 (s, 2H), 4.12 (q, J = 7.1, 2H), 4.08 (t, J = 5.9, 2H), 2.95 (d, J = 11.5, 2H), 2.77 (t, J = 5.9, 2H), 2.24 (m, 1 H), 2.16 (m, 2H), 1.84 (m, 2H), 1.76 (m, 2H), 1.24 (t, J = 7.2, 3H).

EXAMPLE 42 Methyl ester of 1- [2- (4-benzothiazol-2-ylmethyl-phenoxy-ethyl-4-carboxylic acid 4-benzothiazol-2-ylmethyl-phenol A mixture of 4-hydroxyphenylacetic acid (15.2 g, 100 mmol) and 2-amino-benzenethiol (10.7 ml, 100 mmol) was heated at 150 ° C for 16 hr and then cooled to room temperature The resulting solid was ground and dissolved in CH 2 Cl 2 (400 ml). was washed with 1 N HCl (2 x 50 ml) then saturated aqueous NaHCO3 (2 x 50 ml), dried, filtered and concentrated under reduced pressure. The residue was purified on SiO2 (0-50% ethyl acetate / hexanes) to give a white solid (10.5 g, 44% yield). MS (ESI): mass calculated for C14HnNOS, 241.06; m / z found, 342.1 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.89 (dd, J = 8.6, 4.8, 2H), 7.47 (t, J = 7.8, 1 H), 7.31 (t, J = 7.8, 1 H), 7.18 (d, J = 8.3, 2H), 6.77 (d, J = 8.6, 2H), 4.89 (s, 1 H), 4.33 (s, 2H). B. 2-r4- (2-Bromo-ethoxy-benzyl) -benzothiazole To a stirring solution of 4-benzothiazol-2-ylmethyl-phenol (10.5 g, 43.5 mmol) in CH3CN (100 mL) was added Cs2CO3 (28.3 g, 87 mmol) and dibromoethane (18.7 mL, 21.8 mmol). The resulting suspension was heated at 70 ° C for 16 hr, cooled to room temperature, and then dissolved in CH 2 Cl 2 (400 mL). The solution was washed with H2O (2 x 50 ml), dried and concentrated. The resulting oil was dissolved in CH2Cl2 and purified on SiO2 (0-50% ethyl acetate / hexanes) to give a white solid (7.5 g, 49.5% yield). MS (ESI): mass calculated for C? 6H? 4BrNOS, 347.00; m / z found, 348.1 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.99 (d, J = 8.1, 1 H), 7.79 (d, J = 8.1, 1 H), 7.45 (t, J = 7.6, 1 H), 7.36-7.25 (m , 3H), 6.89 (d, J = 8. 8.2H), 4.38 (s, 2H), 4.28 (t, J = 6.3, 2H), 3.63 (t, J = 6.3, 2H). C. 1- [2-4-Benzothiazol-2-ylpentyl-phenoxyl-ethyl-piperidine-4-carboxylic acid methyl ester. To a stirring solution of 2- [4- (2-bromo-ethoxy) - benzyl] -benzothiazole (1.0 g, 2.9 mmol) in CH3CN (20 mL) was added methyl isone-picotate (0.7 mL, 55.7 mmol) and N, N-diisopropylethylamine (1.5 mL, 8.6 mmol). The mixture was heated at 60 ° C for 16 hr, cooled to room temperature, and then dissolved in CH 2 Cl 2 (100 mL). The solution was washed with H2O (2 x 20 ml), dried and concentrated. The resulting oil was dissolved in CH2Cl2 and purified over SiO2 (0-15% CH3OH / CH2Cl2) to give a white solid (1.1 g, 92% yield). MS (ESI): mass calculated for C23H26N2O3S, 410.17; m / z found, 411.1 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.98 (d, J = 8. 3.1 H), 7.76 (d, J = 8. 3, 1 H), 7.42 (t, J = 7.8, 1 H), 7.33-7.24 (m, 3H), 6.88 (d, J = 8.8, 2H), 4.36 (s, 2H), 4.07 (t, J = 6.1, 2H), 3.66 (s, 3H), 2.97-2.90 (m, 2H), 2.76 (t, J = 6.1, 2H), 2.33- 2.24 (m 1 H), 2.15 (t, J = 11.4, 2H), 1.93-1.86 (m, 2H), 1.83-1.72 (m, 2H).

EXAMPLE 43 Trifluoroacetic acid salt of 3 - ((2- [4- (benzothiazol-2-yloxyMenoxH-ethyl-V-cyclopropyl-amino-V-propionic acid) 3-r2- (4-hydroxy-phenoxy-ethylamino-1-propionic acid ethyl ester. a stirring solution of 4- (2-bromo-ethoxy) -phenol (example 3; 2.4 g, 11 mmol) in CH3CN (50 mL) was added ethyl ester hydrochloride. 3-amino-propionic acid (3.4 g, 22 mmol) followed by N, N-diisopropylethylamine (7.7 mL, 44 mmol). The mixture was stirred at 60 ° C for 16 hr, allowed to cool to room temperature, and then dissolved in CH 2 Cl 2 (100 mL). The resulting solution was washed with H2O (2 x 15 ml), dried, filtered and then concentrated under reduced pressure to give a brown oil, which was used in the next step. B. Ethyl ester of 3- acid. { 2- [4- (Benzothiazol-2-yloxy) -phenop-ethylamino} -propionic To a stirring solution of 3- [2- (4-hydroxy-phenoxy) -ethylamino] -propionic acid ethyl ester (11 mmol) in DMF (30 mL) was added Cs2CO3 (10.8 g, 33 mmol) and 2 g. -chlorobenzothiazole (2.72 ml, 22 mmol). The suspension was stirred at 100 ° C overnight. The reaction mixture was allowed to cool to room temperature and then filtered through diatomaceous earth. The filtrate was concentrated under reduced pressure, and purified over SiO2 (100 g; 0-100% CH 3 OH / CH 2 Cl 2), giving 1.9 g (45% yield) of a light brown oil. MS (ESI): mass calculated for C22H22N204S, 386.13; m / z found, 387.1 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.66 (d, J = 8. 1, 1 H), 7.58 (d, J = 8. 3 H), 7.30 (d, J = 7.8, 1 H), 7.22. -7.15 (m, 3H), 6.86 (d, J = 9.1, 2H), 4.09 (dd, J = 7.1, 7.1, 2H), 4.01 (t, J = 5.3, 2H), 2.98 (t, J = 5.3 , 2H), 2.92 (t, J = 6.6, 2H), 2.49 (t, J = 6.6, 2H), 2.20 (br s, 1 H), 1.20 (t, J = 7.1, 3H). C. 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - cyclopropyl-amino) -propionic acid ethyl ester. To a solution of ethyl ester of 3- acid. { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethylamine} -propionic (500 mg, 1.29 mmol) in CH3OH (15 mL) was added acetic acid (0.73 mL, 12.9 mmol), 3 A and [(1-ethoxy-cyclopropyl) oxy] trimethylsilane (1.55 mL, 7.7 mmol) mollecular sieves. . Sodium cyanoborohydride (365 mg, 5.8 mmol) was added, and the mixture was heated to reflux overnight. The mixture was cooled, filtered and concentrated. The residue was dissolved in CH2Cl2, and the resulting solution was washed with saturated aqueous NaHCO3 then brine, dried and concentrated. This residue was purified on SiO2 (40 g, 10-50% ethyl acetate / hexanes), giving 374 mg (68% yield) of a colorless oil. MS (ESI): mass calculated for C23H26N2O4S, 426.16; m / z found, 427.1 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 8.3, 1 H), 7.64 (d, J = 8.1, 1 H), 7.38 (d, J = 7.8, 1 H), 7.29-7.22 (m , 3H), 6.94 (d, J = 9.1, 2H), 4.14 (dd, J = 7.1, 7.1, 2H), 4.10 (t, J = 6.1, 2H), 3.07 (t, J = 7. 1, 2H ), 3.05 (t, J = 6.1, 2H), 2.58 (t, J = 7.3, 2H), 1.92-1.86 (m, 1 H), 1.26 (t, J = 7.1, 3H), 0.54-0.43 (m , 4H). D. 3- (. {2- [4- (Benzothiazol-2-yloxy) -phenoxy-ethyl] -cyclopropyl-amino) -propionic acid trifluoroacetic acid salt. To a solution of 3- (. {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -cyclopropyl-amino) -propionic acid ethyl ester. (355 mg, 11.7 mmol) in THF (15 ml) and CH30H (5 ml), lithium hydroxide (80 mg, 3.3 mmol) in H2O (10 ml) was added. The mixture was stirred at room temperature for 16 hr, and then concentrated under reduced pressure. The residue was dissolved in CH3OH and purified by reverse phase CLAP to give the title compound (391 mg, 92% yield).

MS (ESI): mass calculated for C2? H22N2O4S, 398.13; m / z found, 399.1 [M + Hf. 1 H NMR (400 MHz, CD 3 OD): 7.73 (d, J = 8.3, 1 H), 7.64 (d, J = 8.1, 1 H), 7.48 (d, J = 7.8, 1 H), 7.35-7.25 (m , 3H), 7.11 (d, J = 9.1, 2H), 5.17 (br s, 1 H), 4.48 (t, J = 4.6, 2H), 3.81 (t, J = 4. 6, 2H), 3.76 ( t, J = 7.1, 2H), 3.04-2.93 (m, 3H), 1.17-1.10 (m, 2H), 1.05-0.97 (m, 2H).

EXAMPLE 44 2- [4- (2-Pyrrolidin-1-yl-ethoxy) -phenoxy] -benzoxazole The title compound was prepared according to the procedure of example 11 using 1- (2-chloro-ethyl) -pyrrolidine. MS (ESI): mass calculated for C? 9H2ON203, 324.15; m / z found, 325.1 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.75 (d, J = 8.1, 1 H), 7.66 (d, J = 8.0, 1 H), 7.40 (dt, J = 7.4, 1.3, 1 H), 7.31-7.23 (m, 3H), 6. 98 (d, J = 6.8, 2H), 4.08 (t, J = 6.3, 2H), 2.91 (t, J = 6.3, 2H), 2.67 (q, J = 7 .2 , 4H), 1.10 (t, J = 7.2, 6H).

EXAMPLE 45 . { 3- [4- (Benzoxazol-2-yloxy) -phenoxy] -propyl} dimethyl amine The title compound was prepared according to the procedure of example 11 using (2-chloro-propyl) -dimethyl-amine hydrochloride. MS (ESI): mass calculated for C? 8H2ON2O3, 312.15; m / z found, 313.1 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.48-7.45 (m, 1 H), 7.40-7.38 (m, 1 H), 7. 30 (d, J = 7.9, 2H), 7.23-7.18 (m, 2H), 6.91 (d, J = 8.3, 2H), 4.09 (br s, 2H), 3. 23 (br s, 2H), 2.85 (br s, 6H), 2.42 (br s, 2H).

EXAMPLE 46 (2-r4- (Benzothiazol-2-yloxy) -phenoxy] -etyl] -d-methyl-amine The title compound was prepared according to the procedure of example 11 using hydrochloride (2-) chloroethyl) -dimethylamine MS (ESI): mass calculated for C? 7H? 8N2? 3, 298.13; m / z found, 299.1 [M + Hf. 1 H NMR (400 MHz, CDCI3): 7.49- 7.47 (m, 1 H), 7.41 -7.38 (m, 1 H), 7. 32-7.27 (m, 2H), 7.26-7.18 (m, 2H), 6.98-6.95 (m, 2H), 4.05 (t, J = 5.7, 2H), 2.72 (t, J = 5.7, 2H), 2.32 (s, 6H).

EXAMPLE 47 2- [4- (2-Azepan-1-yl-ethoxy) -phenoxp-benzoxazole The title compound was prepared according to the procedure of Example 11 using 1- (2-chloro-ethyl) -azepan hydrochloride. MS (ESI): mass calculated for C 21 H 24 N 2 O 3, 352.18; m / z found, 353.2 [M + Hf 1 H NMR (400 MHz, CDCl 3): 7.49-7.47 (m, 1H), 7.41-7.38 (m, 1 H), 7.31-7.27 (m, 2H), 7.26-7.18. (m, 2H), 6.97-6.93 (m, 2H), 4.06 (t, J = 6.2, 2H), 2.94 (t, J = 6.2, 2H), 2.77-2.75 (m, 4H), 1.65-1.58 ( m, 8H).

EXAMPLE 48 . { 2-r 4 - (Benzothiazol-2-yloxy) -phenoxy] -ethyl} dimethyl-amine The title compound was prepared according to the procedure of Example 12 using (2-chloro-ethyl) -dimethyl-amine hydrochloride and 2-chlorobenzothiazole. MS (ESI): mass calculated for C? 7H18N2O2S, 314.11; m / z found, 315.1 [M + Hf. 1 H NMR (400 MHz, CD 3 OD): 7.79-7.77 (m, 1 H), 7.65-7.63 (m, 1 H), 7.45-7.29 (m, 4H), 7.18-7.14 (m, 2H) ,. 4.41 (t, J = 4.9, 2H), 3.63 (t, J = 4. 9, 2H), 3.04 (s, 6H).

EXAMPLE 49 2- [4- (2-Pyrrolidin-1-yl-ethoxy) -phenoxy] -benzothiazole The title compound was prepared according to the procedure of Example 12 using 1- (2-chloro-ethyl) -pyrrolidine and 2-chlorobenzothiazole. MS (ESI): mass calculated for C 9H20N2O2S, 340.12; m / z found, 341.1 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.77 (d, J = 7.6, 1 H), 7.66 (d, J = 8.6, 1 H), 7.41 (t, J = 7.4, 1 H), 7.32-7.25 (m, 3H), 7.00 (d, J = 9.0, 2H), 4.16 (t, J = 6. 0, 2H), 2.96 (t, J = 6.0, 2H), 2.67 (t, J = 6.6, 4H), 1.86 (quintuplet, J = 3.5, 4H).

EXAMPLE 50 . { 3- [4- (Benzothiazol-2-yloxy) -phenoxy-1-propyl) -dimethyl-amine The title compound was prepared according to the procedure of Example 12 using (2-chloro-propyl) -dimethyl-amine hydrochloride and 2-chlorobenzothiazole.

MS (ESI): mass calculated for C18H2oN202S, 328.12; m / z found, 329.1 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.72 (d, J = 8.1, 1 H), 7.64 (d, J = 7.9, 1 H), 7.37 (t, J = 7.5, 1 H), 7.31-7.20 (m , 3H), 6.92 (d, J = 7.9, 2H), 4.11 (s, 2H), 3.25 (s, 2H), 2.85 (s, 6H), 2.43 (s, 2H).

EXAMPLE 51 2- [4- (2-Azepan-1-yl-ethoxy) -phenoxy] -benzothiazole The title compound was prepared according to the procedure of Example 12 using 1- (2-chloro-ethyl) -azepan hydrochloride Y 2-chlorobenzothiazole. MS (ESI): mass calculated for C21H24N202S, 368.16; m / z found, 369.2 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.70 (d, J = 7.5, 1H), 7.65 (d, J = 7.9, 1 H), 7.38-7.34 (m, 1 H), 7.29-7.23 (m, 3H), 6.97 (br d, 2H), 4.59 (br s, 2H), 3.64 (br s, 2H), 3.46 (br s, 2H), 3.13 (br s, 3H), 2.19 (br s, 2H), 1.87 (br s, 2H), 1.72- 1.58 (m, 2H).

EXAMPLE 52 2- [4- (2-Azepan-1-yl-ethoxy) -phenoxy-6-methoxy-benzothiazole The title compound was prepared according to the procedure of Example 12 using 1- (2-chloro-ethyl) hydrochloride -azepan and 2-chloro-6-methoxy-benzothiazole. MS (ESI): mass calculated for C22H26N2O3S, 398.17; m / z found, 399.2 [M + Hf. H NMR (400 MHz, CDCl 3): 7.75 (d, J = 8.9, 1H), 7.37-7.35 (m, 2H), 7.26 (br d, 2H), 7.09-7.05 (m, 3H), 4.19 (t, J = 6.1, 2H), 3.95 (s, 3H), 3.08 (t, J = 6.1, 2H), 2.91 -2.88 (m, 4H), 1.76 (br d, 8H).

EXAMPLE 53 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -etl} -4-phenyl-p-peridin-4-ol The title compound was prepared according to the procedure of Example 13 using 4-phenyl-piperidin-4-ol. MS (ESI): mass calculated for C26H26N2? 4, 430.19; m / z found, 431.2 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.60-7.45 (m, 3H), 7.40-7.18 (m, 8H), 7. 00 (d, J = 9.1, 2H), 4.18 (t, J = 5.9, 2H), 2.92 (t, J = 5.9, 2H), 2.66 (dt, J = 12.1, 2.4, 2H), 2.22 (dt, J = 13.4, 4.5, 2H), 1.80 (dd, J = 14.1, 2.4, 2H).

EXAMPLE 54 2-f4- (Benzoxazol-2-yloxy) -phenoxy-1-ethyl} -cyclohexyl-ethyl-amine The title compound was prepared according to the procedure of example 13 using cyclohexyl-ethyl-amine. MS (ESI): mass calculated for C23H28N2O3, 380.21; m / z found, 381.2 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.51 (d, J = 8.4, 1 H), 7.42 (d, J = 7.5, 1 H), 7.35-7.18 (m, 4H), 6.97 (d, J = 9.1, 2H), 3.98 (t, J = 6.9, 2H), 2.88 (t, J = 6.9, 2H), 2.67 (q, J = 7.1, 2H), 2.55-2.50 (m, 1 H), 1.82 (t, J = 7.4, 4H), 1.64 (d, J = 12.4, 1 H), 1.21 (t, J = 7.9, 4H), 1.08 (t, J = 7.1, 4H).

EXAMPLE 55 2- (4- [2- (2-Ethyl-piperidin-1-p-ethoxy-1-phenoxy) -benzoxazole The title compound was prepared according to the procedure of Example 13 using 2-ethyl-piperidine. ): mass calculated for C22H26N2O3, 366.19, m / z found, 367.2 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.51 (d, J = 7.4, 1H), 7.42 (d, J = 7.4, 1 H), 7.31 (d, J = 9.1, 2H), 7.30-7.20 (m, 2H), 6.97 (d, J = 9.1, 2H), 4.09 (t, J = 6. 4, 2H), 3.15-3.05 (m, 1H), 3.00-2.92 (m, 1H), 2.88-2.80 (m, 1H), 2.48-2.37 (m, 1 H), 2.30-2.25 (m, 1 H), 1.75-1.65 (m, 4H), 1.60-1.54 (m, 2H), 1.52-1.42 (m, 1 H), 1.38-1.24 (m , 2H), 0.92 (t, J = 7.4, 3H).

EXAMPLE 56 1- (2-r4- (Benzoxazol-2-yloxy) -phenoxy-1-ethyl) -4-phenyl-piperidn-4-carbonitriyl The title compound was prepared according to the procedure of the example 13 using 4-phenyl-p-peridin-4-carbontril. MS (ESL): mass calculated for C27H25N3O5, 439.19; m / z found, 440.2 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.61-7.49 (m, 3H), 7.43-7.38 (m, 3H), 7.36-7.29 (m, 3H), 7.28-7.20 (m, 3H), 7.03-6.96 (m , 2H), 4.15 (t, J = 5.6, 2H), 3. 18 (br d, 2H), 2.93 (t, J = 5.6, 2H), 2.71-2.61 (m, 2H), 2.22-2.10 (m, 8H).

EXAMPLE 57 1- (1- (2- [4- (Benzoxazol-2-yloxy) -phenoxy-ethyl) -4-phenyl-piperidin-4-yl) -ethanone The title compound was prepared according to the procedure of the example 13 using 1- (4-phenyl-piperidin-4-yl) -ethanone. MS (ESI): mass calculated for C2sH28N2? 4, 456.20; m / z found, 457.2 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.52-7.49 (m, 1H), 7.43-7.40 (m, 1 H), 7.37-7.1.6 (m, 9H), 6.99-6.92 (m, 2H), 4.10 ( t, J = 5.8, 2H), 2.87-2.82 (m, 2H), 2.78 (t, J = 5.8, 2H), 2.51-2.47 (m, 2H), 2.39 (br t, 2H), 2.17-2.05 ( m, 2H), 1.92 (s, 3H).

EXAMPLE 58 2- (4- [2- (4-Methyl-piperidin-1-yl) -ethoxy] -phenoxy-g-benzoxazole The title compound was prepared in accordance with procedure of example 13 using 4-methyl-piperidine. MS (ESI): mass calculated for C2? H24N2O3, 352.18; m / z found, 353.2 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.50 (d, J = 6.8, 1 H), 7.42 (d, J = 6.8, 1 H), 7.31 (d, J = 9.0, 2H), 7.30-7.20 (m, 2H), 6.97 (d, J = 9.0, 2H), 4.13 (t, J = 6. 0, 2H), 2.97 (d, J = 11.7, 2H), 2.80 (t, J = 6.0, 2H), 2.11 (dt, J = 11.7, J = 2.2, 2H), 1.67 (s, 2H), 1.34 (br s, 1 H), 1.28 (dt, J = 12.2, J = 3.4, 2H), 0.94 (d, J = 6. 2, 3H).

EXAMPLE 59 1- (2- [4- (Benzoxazol-2-yloxO-phenoxy-1-ethyl) -4- (4-chloro-phenyl) -piperidin-4-ol The title compound was prepared according to the procedure of example 13 using 4- (4-chloro-phenyl) -piperidin-4-ol MS (ESI): mass calculated for C26H25CIN2 → 4, 464.15; m / z found, 465.1 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.54-7.42 (m, 4H), 7.37-7.31 (m, 4H), 7. 29-7.21 (m, 2H), 7.03-6.98 (m, 2H), 4.16 (t, J = 5.8, 2H), 2.93-2.89 (m, 4H), 2.62 (dt, J = 12.2, 2.4, 2H) , 2.21-2.14 (m, 2H), 1.78-1.74 (m, 2H), 1.56 (br s, 1 H).

EXAMPLE 60 1- (2-f4- (Benzoxazol-2-oxo-0-phenoxy-1-ethyl) -4- (4-bromo-phenyD-piperidin-4-ol) The title compound was prepared according to the procedure of example 13 using 4 - (4-bromo-phenyl) -piperidin-4-ol MS (ESI): mass calculated for C 26 H 25 BrN 2 4, 508.10, m / z found, 509.1 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.55 -7.47 (m, 3H), 7.44-7.39 (m, 3H), 7.37-7.31 (m, 2H), 7.30-7.19 (m, 2H), 7.02-6.98 (m, 2H), 4.17 (t, J = 5.7, 2H), 2.94-2.89 (m, 4H), 2.62 (dt, J = 12.2, 2.4, 2H), 2.21-2.13 (m, 2H), 1.78-1.74 (m, 2H), 1.56 (brs, 1 H).

EXAMPLE 61 1- (2-r4- (Benzoxazol-2-yloxy) -phenoxy-1-ethyl) -4- (4-chloro-3-trifluoromethyl-phenyl) -piperidin-4-ol The title compound was prepared in accordance with The procedure of Example 13 using 4- (4-chloro-3-trifluoromethyl-phenyl) -piper-dinate 4-ol. MS (ESI): mass calculated for C27H24CIF3N2? 4, 532.14; m / z found, 533.1 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.89 (d, J = 2.1, 1 H), 7.62 (dd, J = 8.4, 2.1, 1 H), 7.51-7.41 (m, 3H), 7.33-7.21 (m, 4H), 6.99-6.95 (m, 2H), 4.14 (t, J = 5.7, 2H), 2.94-2.89 (m, 4H), 2.65-2.59 (m, 2H), 2.21-2.13 (m, 4H), 1.74 (brs, 1 H).

EXAMPLE 62 coX I 1- (2-f4- (Benzoxazol-2-yloxy) -phenoxy-ethyl) -4-benzyl-piperdin-4-ol The title compound was prepared according to the procedure of Example 13 using 4-benzyl- piperidin-4-ol. MS (ESI): mass calculated for C27H28N2O, 444.20; m / z found, 445.1 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.53-7.50 (m, 1 H), 7.43-7.40 (m, 1H), 7.53-7.21 (m, 10H), 7.01-6.95 (m, 2H), 4.12 (t, J = 5.9, 2H), 2.84 (t, J = 5.8, 2H), 2.78-2.76 (m, 4H), 2.47 (dt, J = 11.6, 2.4, 2H), 1.83-1.75 (m, 2H), 1.59 -1.53 (m, 2H).

EXAMPLE 63 . { 2- [4- (Benzoxazol-2-yloxyHenoxy-1-ethyl.} - cyclohexyl-methyl-amine The title compound was prepared according to the procedure of Example 13 using cyclohexyl-methyl-amine, MS (ESI): mass calculated for C 22 H 26 N 2 O 3, 366.19; m / z found, 367.3 [M + Hf 1 H NMR (400 MHz, DMSO-d 6): 7.62 (dd, J = 6.2, J = 2.0, 1 H), 7. 50 (dd, J = 6.1, 2.1, 1H), 7.42 (d, J = 9.1, 2H), 7.35-7.25 (m, 2H), 7.03 (d, J = 9.1, 2H), 4.04 (t, J = 6.1, 2H), 2.79 (t, J = 6.1, 2H), 2.45-2.32 (m, 1H), 1.73 (d, J = 7.9, 4H), 1.57 (d, J = = 12.2, 2H), 1.30- 1.12 (m, 4H), 1.10-1.00 (m, 1 H).

EXAMPLE 64 r x j? k . { 2- [4- (Benzoxazol-2-yloxO-phenoxy-1-ethyl.} - cyclopropylmethyl-propyl-amine The title compound was prepared according to the procedure of Example 13 using cyclopropylmethyl-propyl-amine, MS (ESI): mass calculated for C22H26N2O3, 366.19; m / z found, 367.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.52-7.50 (m, 1 H), 7.44-7.41 (m, 1 H), 7.33-7.21 (m, 4 H), 6.99-6.95 (m, 2 H), 4.09 (t , J = 6.2, 2H), 3.01 (t, J = 6.2, 2H), 2.64-2.59 (m, 2H), 2.49 (d, J = 6.3, 2H), 1.60-1.50 (m, 2H), 0.92 ( t, J = 7.3, 4H), 0.55-0.52 (m, 2H), 0.16-0.13 (m, 2H).

EXAMPLE 65 . { 2- [4- (Benzoxazol-2-y! Oxo-phenoxy-ethyl) -butyl-ethyl-amine The title compound was prepared according to the procedure of Example 13 using butyl-ethyl-amine. MS (ESI): mass calculated for C2? H26N2O3, 354.19; m / z found, 355.2 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.41 (d, J = 7.2, 1 H), 7.32 (dd, J = 7. 3, 1.6, 1 H), 7.22 (d, J = 9.1, 1 H), 7.18- 7.10 (m, 2H), 6.87 (d, J = 9.1, 2H), 4.02 (br s, 2H), 2.85 (br s, 2H), 2.61 (br s, 2H), 2.49 (br s, 2H), 1.42 (br s, 2H), 1.31-1.19 (m, 2H), 1.05 (br s, 3H), 0.83 (t, J = 7.3, 3H).

EXAMPLE 66 2- ( { 2- [4- (Benzoxazol-2-yloxO-phenoxy] -ethyl) -benzyl-amino) -ethanol The title compound was prepared according to the procedure of Example 13 using benzylamino-ethanol . MS (ESI): mass calculated for C 24 H 24 N 2 O, 404.17; m / z found, 405.2 [M + Hf. 1 H NMR (400 MHz, CD3OD): 7.46-7.37 (m, 3H), 7.33 (d, J = 16.9, 2H), 7.29-7.00 (m, 6H), 6.95 (d, J = 6.9, 2H), 4.06 (t, J = 5.8, 2H), 3.76 (s, 2H), 3.64 (t, J = 6.2, 2H ), 2.95 (d, J = 5.8, 2H), 2.76 (t, J = 6.1, 2H).

EXAMPLE 67 2- (4-f2- (4-Benzyl-piperdin-1-i0-ethoxy-phenoxy) -benzoxazole The title compound was prepared according to the procedure of Example 13 using 4-benzyl-piperidine. ): mass calculated for C27H2sN203, 428.21, m / z found, 429.1 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.53-7.50 (m, 1 H), 7.44-7.41 (m, 1 H), 7. 33-7.15 (m, 9H), 6.98-6.95 (m, 2H), 4.11 (t, J = 6.0, 2H), 3.01-2.96 (m, 2H), 2.79 (t, J = 6.0, 2H), 2.55 (d, J = 7.0, 2H), 2.09-2.02 (m, 2H), 1.67-1.64 (m, 2H), 1.59-1.51 (m, 1 H) 1.40-1.29 (m, 2H).

EXAMPLE 68 (1- { 2- [4- (Benzoxazol-2-yloxy) -phenoxy-ethyl) -piperidin-3-yl) -methanol The title compound was prepared according to the procedure of Example 13 using piperidine- 3-yl-methanol. MS (ESI): mass calculated for C2? H2 N2O4, 368.17; m / z found, 369.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.55-7.52 (m, 1 H), 7.48-7.44 (m, 1 H), 7.38-7.23 (m, 4H), 7.05-6.99 (m, 2H), 4.23 (t , J = 5.6, 2H), 3.71 (dd, J = 10.7, . 1, 1 H), 3.59 (dd, J = 10.6, 6.4, 1 H), 3.09 (brd, J = 9.7, 1 H), 2.94 (t, J = 5.6, 2H), 2.42 (t, J = 9.1, 1 H), 2.29 (t, J = 9.3, 1 H), 2.24-1.98 (m, 2H), 2.00-1.90 (m, 1 H), 1.90-1.80 (m, 1 H), 1.80-1.71 (m, 2H), 1.20-1.10 (m, 1 H).

EXAMPLE 69 2 - ((2-4- (Benzoxazol-2-yloxO-phenoxp-ethyl) -propyl-a? Tino) -ethanol The title compound was prepared according to the procedure of Example 13 using 2-propylamine Ethanol (ESI): mass calculated for C2oH24N2O4, 356.17, m / z found, 357.3 [M + Hf 1 H NMR (400 MHz, DMSO-d 6): 7.62 (dd, J = 6.2, 2.0, 1 H), 7.50 (dd, J = 6.1, 2.1, 1H), 7.42 (d, J = 9.1, 2H), 7.35-7.25 (m, 2H), 7.03 (d, J = 9.1, 2H), 4.31 (t, J = 5.4, 1H), 4.04 (t, J = 6.0, 2H), 3.46 (q, J = 6.4, 2H), 2.85 (t, J = 6. 0.2H), 2.59 (t, J = 6.5, 2H), 2.51-2.48 (m, 2H), 1.41 (q, J = 7.4, 2H), 0.84 (t, J = 7.3, 3H).

EXAMPLE 70 1-. { 2-r4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl) -4-phenyl-piperidin-4-ol The title compound was prepared according to the procedure of example 17 using 4-phenyl-piperidin- 4-ol. MS (ESI): mass calculated for C2eH26N2O3S, 446.17; m / z found, 447.2 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.74 (d, J = 8.1, 1 H), 7.66 (d, J = 7.4, 1H), 7.54 (d, J = 7.6, 2H), 7.42-7.35 (m, 3H ), 7.33-7.22 (m, 4H), 6.99 (d, J = 9.0, 2H), 4.19 (t, J = 5.8, 2H), 2.98-2.86 (m, 4H), 2.65 (dt, J = 13.8, 2.1, 2H), 2. 24 (dt, J = 13.4, 4.5, 2H), 1.80 (dd, J = 14.1, 2.2, 2H).

EXAMPLE 71 . { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -cyclohexyl-ethyl-amine The title compound was prepared according to the procedure of example 17 using cyclohexyl-ethyl-amine. MS (ESI): mass calculated for C23H28N2O2S, 396.19; m / z found, 397.2 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.74 (d, J = 8.1, 1 H), 7.65 (d, J = 7.9, 1 H), 7.39 (t, J = 7.9, 4H), 7.30-7.20 (m, 4H), 6.96 (d, J = 8.9, 2H), 3.98 (t, J = 6.8, 2H), 2.89 (t, J = 6.8, 2H), 2.66 (q, J = 7.1, 2H), 2.55-2.50 (m, 1 H), 1.82 (t, J = 7.7, 4H), 1.65 (d, J = 11.9, 1 H), 1.30-1.18 (m, 4H), 1.09 (t, J = 7.2, 4H).

EXAMPLE 72 1- (2-r4- (Benzothiazol-2-yloxy) -phenoxp-ethyl-V4- (4-chloro-pheep-piperidin-4-ol) The title compound was prepared in accordance with Method of example 17 using 4- (4-chloro-phenyl) -piperidin-4-ol. MS (ESI): mass calculated for C26H25CIN3? 3S, 480.13; m / z found, 481.1 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.74 (d, J = 7.6, 1 H), 7.66 (dd, J = 7.9, 0.8, 1H), 7.49-7.45 (m, 2H), 7.41-7.22 (m, 6H ), 7.01-6.97 (m, 2H), 4.18 (t, J = 5.8, 2H), 2.96-2.89 (m, 4H), 2.63 (dt, J = 12.1, 2.4, 2H), 2.21-2.14 (m, 2H), 1.79-1.74 (m, 2H), 1.56 (br s, 1 H).

EXAMPLE 73 . { 2-r4- (Benzothiazol-2-yloxy) -phenoxy-ethyl) -dibutylamine The title compound was prepared according to the procedure of example 17 using dibutylamine. MS (ESI): mass calculated for C23H30N2O2S, 398.20; m / z found, 399.2 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.63 (d, J = 8.1, 1 H), 7.55 (d, J = 7.9, 1 H), 7.28 (tt, J = 7.7, 1.3, 1 H), 7.20-7.13 (m, 3H), 6.85 (d, J = 12.8, 2H), 3.96 (t, J = 5.6, 2H), 2.80 (m, 2H), 2.43 (m, 4H), 1.38 (m, 4H) , 1.22 (m, 4H), 0.83 (t, J = 7.3 Hz, 6H).

EXAMPLE 74 1-l2-r4- (Benzothiazol-2-yloxy) -phenoxy-1-ethyl) -4- (4-bromo-phenyl) -piperidin-4-ol The title compound was prepared according to the procedure of Example 17 using 4- (4-bromo-phenyl) -piperidin-4-ol. MS (ESI): mass calculated for C26H25BrN2O3S, 524.08; m / z found, 525.1 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.74 (dd, J = 8.0, 0.6, 1 H), 7.67 (dd, J = 8.0, 0.8, 1 H), 7.53-7.47 (m, 2H), 7.43-7.37 ( m, 3H), 7.30-7.22 (m, 3H), 7.01-6.98 (m, 2H), 4.17 (t, J = 5.8, 2H), 2.94-2.89 (m, 4H), 2.63 (dt, J = 12.1, 2.5, 2H), 2.21-2.14 (m, 2H), 1.76 (dd, J = 14.22.6, 2H), 1.56 (brs, 1 H).

EXAMPLE 75 1-f2- [4- (Benzot-azo-2-yloxy) -phenoxy] -ethyl-V4- (4-chloro-3-trifluoromethyl-phenyl-piperidin-4-ol The title compound was prepared according to the procedure of Example 17 using 4- (4-chloro-3-trifluoromethyl-phenyl) -piperidin- 4-ol. MS (ESI): mass calculated for C27H24CIF3N2O3S, 548.11; m / z found, 549.1 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.89 (d, J = 2.1, 1 H), 7.62-7.48 (m, 4 H), 7.41-7.37 (m, 1 H), 7.30-7.24 (m, 3 H), 7.01 -6.97 (m, 2H), 4.17 (t, J = 5.8, 2H), 2.94-2.91 (m, 6H), 2.66-2.59 (m, 2H), 2.22-2.15 (m, 2H), 1.83 (brs, 1 HOUR).

EXAMPLE 76 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl) -4-benzyl-piperidin-4-ol The title compound was prepared according to the procedure of example 17 using 4-benzyl-piperidin-4 -ol. MS (ESI): mass calculated for C27H28N2O3S, 460.18; m / z found, 461.2 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.74 (d, J = 8.0, 1 H), 7.66 (d, J = 7.7, 1H), 7.41-7.23 (m, 9H), 6.99-6.94 (m, 2H), 4.13 (t, J = 5.9, 2H), 4.84 (t, J = 5.9, 2H), 2.78 (m, 4H), 2.50-2.45 (m, 2H), 1.83-1.76 (m, 2H), 1.59-1.52 (m, 2H), 1.23 (br s, 1 H).

EXAMPLE 77 2- [4- (2-Azetidin-1-yl-ethoxy) -phenoxy-1-benzoxazole The title compound was prepared according to the procedure of Example 21 using azetidine. MS (ESI): mass calculated for C 8H? 8N2O3, 310.13; m / z found, 311.2 [M + Hf 1 H NMR (400 MHz, DMSO-d 6): 7.61 (d, J = 7.0, 2H), 7.48 (d, J = 7.0, 2H), 7.41 (d, J = 9.1 , 2H), 7.32-7.24 (m, 2H), 7.00 (d, J = 6.9, 2H), 3.93 (t, J = 5.6, 2H), 3.18 (t, J = 6.9, 4H), 2.70 ( t, J = 5.6, 2H), 1.97 (t, J = 6.9, 2H).

EXAMPLE 78 ? / - (1- {2-y4- (Benzoxazol-2-yloxy) -phenoxy-1-ethyl-VPIperidin-4-yl-2-phenyl-acetamide The title compound was prepared according to the procedure of Example 22 using 2-phenyl-N-piperidin-4-yl-acetamide and 2-chloro-benzoxazole MS (ESI): mass calculated for C28H29N3O, 471.22, m / z found, 472.5 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.55-7.51 (m, 1 H), 7.47-7.43 (m, 1 H), 7. 41-7.23 (m, 9H), 7.00-6.95 (m, 2H), 5.28 (br, J = 7.8, 1 H), 4.10 (t, J = 5.7, 2H), 3.90-3.80 (m, 1 H), 3.60 (s, 2H), 2.89 (br d, J = 11.5, 2H), 2.81 (t, J = 5.8, 2H), 2.28 (dt, J = 11.6, 2.2, 2H), 1.92 (br dd, J = 12.6, 2.3, 2H), 1.46-1.37 (m, 2H).

EXAMPLE 79 Ethyl ester of l- acid. { 2-l4- (benzoxazol-2-yloxy) -phenoxy-ethyl) -piperidine-3-carboxylic acid The title compound was prepared according to the procedure of example 22 using piperidine-3-carboxylic acid ethyl ester and 2-chloro -benzoxazole MS (ESI): mass calculated for C23H26N2O5, 410.18; m / z found, 411.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.56-7.52 (m, 1 H), 7.47-7.43 (m, 1 H), 7. 37-7.32 (m, 2H), 7.32-7.23 (m, 2H), 7.02-6.98 (m, 2H), 4.18 (q, J = 7. 1, 2H), 4. 15 (t, J = 5.9, 2H), 3.14 (brd, J = 8.2, 1 H), 2.96-2.82 (m, 3H), 2.65 (t, J = 10.6, 3.7, 1 H), 2.37 (t, J = 10.7, 1 H), 2.20 (dt, J = 10.9, 2.7, 1 H), 2.03-1.97 (m, 1 H), 1. 82-1.75 (m, 1 H), 1.73-1.60 (m, 1 H), 1.54-1.45 (m, 1 H) 1.30 (t, J = 7.2, 3H).

EXAMPLE 80 1'-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy-ethyl-V [1,4'-bipiperidine] The title compound was prepared according to the procedure of Example 22 using 4-piperidinyl-piperidine. MS (ESI): mass calculated for C25H3iN302S, 437.21; m / z found, 438.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.77 (d, J = 8.0, 1 H), 7.69 (d, J = 7.0, 1 H), 7.42 (dt, J = 7.1, 1.1, 1 H), 7.35-7.26 (m, 3H), 7.04-6.97 (m, 2H), 4.15 (t, J = 5.9, 2H), 3.11 (brd) , J = 11.7, 2H), 2.84 (t, J = 6.0, 2H), 2.57 (br s, 2H), 2.40-2.30 (m, 1H), 2.16 (dt, J = 11.7, 1.6, 1 H), 1.85 (brd, J = 12.1, 2H), 1.75-1.59 (m, 8H), 1.52-1.40 (m, 2H).

EXAMPLE 81 (1- {2-y4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl.}. -piperidin-4-yl) -methanol The title compound was prepared according to the procedure of Example 17 using piperidin-4-yl-methanol. MS (ESI): mass calculated for C2? H24N2O3S, 384.15; m / z found 385.1 [M + Hf. 1 H NMR (500 MHz, CDCl 3): 7.75-7.73 (m, 1 H), 7.67-7.65 (m, 1 H), 7.41-7.37 (m, 1 H), 7.31-7.36 (m, 3 H), 6.98-6.95 (m, 2H), 4.13 (t, J = 5.9, 2H), 3.52 (t, J = 5.4, 2H), 3.10-3.03 (m, 2H), 2.83 (t, J = 5.9, 2H), 2.14 ( dt, J = 11.8, 2.4, 2H), 1.78-1.75 (m, 2H), 1.58-1.52 (m, 2H), 1.37-1.30 (m, 2H).

EXAMPLE 82 ? / - (1- (2-r4- (Benzothiazol-2-yloxy) -phenoxy-1-ethyl) -piperidin-4-yl) -2-phenyl-acetamide The title compound was prepared according to the procedure of Example 22 using 2-phenyl-N-piperidin-4-yl-acetamide. MS (ESI): mass calculated for C28H29N3O3S, 487.19; m / z found, 488.2 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.78 (dd, J = 8.0, 0.6, 1 H), 7.69 (dd, J = 7.9, 0.7, 1 H), 7.45-7.24 (m, 9H), 7.00-6.88 (m, 2H), 5.33 (d, J = 7.9, 1H), 4.10 (t, J = 5.8, 2H), 3.90-3.79 (m, 1 H), 3.60 (s, 2H), 2.88 (d, J = 11.7, 2H), 2.80 (t, J = 5.7, 2H), 2.27 (dt, J = 11.6, 2.2, 2H) ), 1.92 (dd, J = 12.7, 3.6, 2H), 1.39 (dq, J = 11.1, 3. 8.2H).

EXAMPLE 83 1 '-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxyl-ethylH1, 4 '] bipiperidinyl-2-one The title compound was prepared according to the procedure of Example 22 using [1,4'] bipperidinyl- 2-one. MS (ESI): mass calculated for C25H29N3O3S, 451.59; m / z found, 452.4 [M + Hf 1 H NMR (400 MHz, DMSO-d 6): 7.91 (d, J = 7.4, 1 H), 7.67 (d, J = 7. 4, 1 H), 7.45-7.32 (m, 4H), 7.06 (d, J = 9.0, 2H), 4.35- 4.15 (m, 1 H), 4.10 (t, J = 5.7, 2H), 3.15 (t , J = 5.3, 2H), 3.00 (d, J = 11.5, 2H), 2.71 (t, J = 5.7, 2H), 2.21 (t, J = 6.5, 2H), 2.10 (t, J = 11.5, 2H ), 1.75-1.60 (m, 6H), 1.43 (d, J = 10.0, 2H).

EXAMPLE 84 2- (4- (2- [4- (2-Morpholin-4-yl-ethyl) -piperazin-1-yl-ethoxyMenoxy) -benzothiazole The title compound was prepared according to the procedure of Example 22 using 4- (2-piperazin-1-yl-ethyl) -morpholine.

MS (ESI): mass calculated for C25H32N4O3S, 468.22; m / z found, 469.2 [M + Hf 1 H NMR (400 MHz, DMSO-d 6): 7.91 (d, J = 7.9, 1 H), 7.67 (d, J = 7.9, 1 H), 7.45-7.32 (m, 4H), 7.06 (d, J = 9.1, 2H), 4.09 (t, J = 5.8, 2H), 3.54 (t, J = 4.6, 2H), 2.68 (t, J = 5.7, 2H), 2.50- 2.20 (brs, 16H).

EXAMPLE 85 2- (4- (2- [4- (2-Morpholin-4-yl-ethyl) -piperazin-1-in-ethyl-V-phenoxy-benzothiazole The title compound was prepared according to the procedure of Example 32 using 4- ( 2-piperazin-1-yl-ethyl) -morfoIine MS (ESI): mass calculated for C25H32N402S, 452.22, m / z found, 453.2 [M + Hf 1 H NMR (400 MHz, DMSO-d 6): 7.92 (d, J = 8.0, 1 H), 7.68 (d, J = 8.0, 1H), 7.45-7.30 (m, 6H), 3.54 (t, J = 4.5, 4H), 2.75 (t, J = 8.3, 4H), 2.50-2.20 (br s, 16H).

EXAMPLE 86 2- (4-β3- (4-Phenyl-piperidin-1-yO-propoxfl-phenoxy) -benzoxazole The title compound was prepared according to the procedure of Example 27 using 4-phenyl-piperidine, MS (ESI): mass calculated for C27H28N2O3, 428.21; m / z found, 429.2 [M + Hf. 1 H NMR (400 MHz, CD3OD): 7.40-7.38 (m, 1H), 7.34-7.32 (m, 1 H), 7.24 (d, J = 9.1 , 2H), 7.22-7.12 (m, 4H), 7.07 (t, J = 7.0, 1 H), 6.94 (d, J = 9.1, 2H), 3.99 (t, J = 6.1, 2H), 3.06 (d , J = 11.7, 2H), 2.57 (t, J = 7.6, 2H), 2.49 (m, 1 H), 2.13 (t, J = 11, 6.2H), 1.97 (m, 2H), 1.73 (m, 4H).

EXAMPLE 87 1- (3- [4- (Benzothiazol-2-yloxy) -phenoxy-1-propyl) -4-phenyl-piperidin-4-ol The title compound was prepared according to the procedure of example 27 using 2-chlorobenzothiazole. MS (ESI): mass calculated for Q27H28N2O3S, 460.18; m / z found, 461.2 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 8.1, 1 H), 7.65 (d, J = 7.8, 1 H), 7.53 (d, J = 8.2, 2H), 7.39-7.35 (m, 3H), 7.29-7.23 (m, 5H), 6.96 (d, J = 9.1, 2H), 4.08 (t, J = 6.2, 2H), 2.92 (m, 2H), 2.72-2.49 (m, 4H) ), 2.34-2.02 (m, 4H), 1.81 (d, J = 12.3, 2H).

EXAMPLE 88 1-f2- [4- (Benzoxazol-2-yloxy) -fenin-ethyl-V4-phenyl-piperidin-4-ol The title compound was prepared according to the procedure of Example 29 using 4-phenyl-piperidin-4-ol . MS (ESI): mass calculated for C 26 H 26 N 2 O 3, 414.51; m / z found, 415.1 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.56-7.51 (m, 3H), 7.45-7.32 (m, 6H), 7.30-7.22 (m, 4H), 2.96-2.89 (m, 2H), 2.74-2.69 (m , 2H), 2.61-2.54 (m, 2H), 2.26-2.18 (m, 2H), 1.84-1.79 (m, 2H), 1.62 (brs, 1H).

EXAMPLE 89 . { 2-r4- (Benzoxazol-2-yloxO-phene-ethyl) -cyclohexyl-ethyl-amine The title compound was prepared according to the procedure of Example 29 using cyclohexyl-ethyl-amine. MS (ESI): mass calculated for C23H28N2O2, 364.22; m / z found, 365.1 [M + Hf. H NMR (400 MHz, CDCl 3): 7.51 (d, J = 7.8, 1 H), 7.41 (d, J = 7.6, 1 H), 7.33-7.18 (m, 6H), 2.80-2.68 (m, 4H) , 2.64 (dd, J = 6.8, 7.04, 2H), 2.58-2.50 (m 1 H), 1.80 (t, J = 8.8, 4H), 1.63 (d, J = 12.3, 1 H), 1.22 (dd, J = 9.8, 8.4, 4H), 1.08 (t, J = 7.0, 4H).

EXAMPLE 90 2-f4- (2-Pyrrolidin-1-yl-ethyl) -phenoxy-1-benzoxazole The title compound was prepared according to the procedure of Example 29 using pyrrolidine. MS (ESI): mass calculated for Cs? 9H20N2O2, 308.15; m / z found, 309.1 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.51 (d, J = 7.6, 1 H), 7.42 (d, J = 7.2, 1 H), 7.35-7.20 (m, 6H), 2.90-2.84 (m, 2H), 2.75-2.68 (m 2H), 2.62-2.55 (m, 4H), 1.85-1.79 (m, 4H).

EXAMPLE 91 2- [4- (2-Azepan-1-yl-ethyl) -phenoxy] -benzoxazole The title compound was prepared according to the procedure of Example 29 using azepam. MS (ESI): mass calculated for C21H24N2O2, 336.18; m / z found, 337.1 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.50 (d, J = 7.6, 1 H), 7.39 (d, J = 7.8, 1 H), 7.33-7.17 (m, 6H), 2.84-2.73 (m, 4H), 2.71 (t, J = 5.3, 4H), 1.71-1.57 (m, 8H).

EXAMPLE 92 . { 2- [4- (Benzoxazol-2-yloxy) -Henyl-1-ethyl.} - cyclopropylmethyl-propyl-amine The title compound was prepared according to the procedure of Example 29 using cyclopropylmethyl-propyl-amine, MS (ESI). : mass calculated for C22H26N202, 350.20, m / z found, 351.1 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.50 (d, J = 7.6, 1 H), 7.39 (d, J = 7. 8, 1 H), 7.33-7.17 (m, 6H), 2.85-2.74 (m, 4H), 2.56 (t, J = 7.6, 2H), 2.43 (d, J = 6.5, 2H), 1.56-1.44 (m, 2H), 0.90 (t, J = 7.2, 4H), 0.51 (dd, J = 7.8, 5.5, 2H), 0.13 (dd, J = 7.8, 5.5, 2H).

EXAMPLE 93 2- [4-Benzoxazol-2-yloxy) -phenyl-1-ethyl} -Dibutyl-amine The title compound was prepared according to the procedure of Example 29 using dibutyl-amine. MS (ESI): mass calculated for C23H30N2O2, 366.23; m / z found, 367.2 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.51 (d, J = 7.4, 1 H), 7.39 (d, J = 7.6, 1 H), 7.33-7.17 (m, 6H), 2.80-2.66 (m, 4H) , 2.49 (t, J = 7.3, 4H), 1.50-1.40 (m, 4H), 1.37-1. 26 (m, 4H), 0.93 (t, J = 7.2, 6H).

EXAMPLE 94 1-. { 2- [4-Benzoxazol-2-yloxy) -phenill-ethyl} -ethyl} -piperidin-4-ol The title compound was prepared in accordance with procedure of example 29 using 4-hydroxypiperidine. MS (ESI): mass calculated for C2oH22N2O3, 338.16; m / z found, 339.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.50 (d, J = 7.6, 1 H), 7.39 (d, J = 7.6, 1H), 7.34-7.16 (m, 6H), 3.72-3.63 (m, 1 H), 3.29 (br s, 1H), 2.91-2.78 (m, 4H), 2.63-2.56 (m, 2H), 2.21 (t, J = 10.0, 2H), 1.96-1.86 (m, 2H), 1.70 -1.57 (m, 2H).

EXAMPLE 95 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl-1-ethyl) -4-phenyl-piperidin-4-ol The title compound was prepared according to the procedure of Example 30 using 4-phenyl-piperidin-4 -ol. MS (ESI): mass calculated for C26H26N2O3S, 430.57; m / z found, 431.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.76-7.74 (m, 1 H), 7.67 (dd, J = 8.0, 0.7, 1 H), 7.56-7.53 (m, 2H), 7.42-7.36 (m, 3H) , 7.33-7.26 (m, 6H), 2.96-2.86 (m, 4H), 2.75-7.71 (m, 2H), 2.64-2.56 (m, 2H) 2.27-2.18 (m, 2H), 1.86-1.80 (m , 2H), 1.67-1.66 (br m, 2H).

EXAMPLE 96 1- (2-f4- (Benzoxazol-2-yloxy) -phenyl-1-ethyl) -piperidine-4-carboxylic acid methyl ester The title compound was prepared according to the procedure of Example 29 using piperidine-methyl-methyl ester. 4-carboxylic acid. MS (ESI): mass calculated for C22H24N2O4, 380.17; m / z found, 381.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.50 (d, J = 8.1, 1 H), 7.39 (d, J = 8.1, 1 H), 7.34-7.16 (m, 6H), 3.67 (s, 3H), 2.97 -2.90 (m, 2H), 2.84-2.78 (m, 2H), 2.60-2.55 (m, 2H), 2.35-2.25 (m, 1 H), 2.10 (t, J = 11.4, 2H), 1.96-1.88 (m, 2H), 1.84-1.73 (m, 2H).

EXAMPLE 97 2-r4- (2-Pyrrolidin-1-yl-ethyl) -phenoxp-benzothiazole The title compound was prepared according to the procedure of example 30 using pyrrolidine. MS (ESI): mass calculated for C19H2ON2OS, 324.13; m / z found, 325.3 [M + Hf. H NMR (400 MHz, CDCl 3): 7.73 (d, J = 8.0, 1H), 7.65 (d, J = 8.0, 1 H), 7.38 (t, J = 7.2, 1 H), 7.31-7.22 (m, 5H), 2.91-2. 83 (m, 2H), 2.77-2.69 (m 2H), 2.64-2.55 (m, 4H), 1.87-1.77 (m, 4H).

EXAMPLE 98 2-í4- (2-Azepan-1-yl-ethyl) -phenoxy-1-benzothiazole The title compound was prepared according to the procedure of Example 30 using azepam. MS (ESI): mass calculated for C21H24N2OS. 352.16; m / z found, 353.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 8.0, 1 H), 7.65 (d, J = 8.0, 1 H), 7.37 (t, J = 7.4, 1H), 7.30-7.22 (m, 5H), 2.87-2.70 (m, 8H), 1.73-1.57 (m, 8H).

EXAMPLE 99 . { 2-f4-Benzothiazol-2-yloxO-phenyl] -ethyl} Cyclopropylmethyl propyl amine The title compound was prepared according to the procedure of Example 30 using cyclopropylmethyl propyl amine.

MS (ESI): mass calculated for C22H26N2OS, 366.18; m / z found, 367.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 8.6, 1 H), 7.65 (d, J = 8.2, 1 H), 7.38 (t, J = 8.6, 1 H), 7.30-7.22 (m , 5H), 2.87-2.76 (m, 4H), 2.57 (t, J = 7.6, 2H), 2.44 (d, J = 6.5, 2H), 1.56-1.45 (m, 2H), 0.90 (t, J = 7.4, 4H), 0.52 (dd, J = 7.8, 5.5, 2H), 0.14 (dd, J = 5.7, 5.1, 2H).

EXAMPLE 100 . { 2-r4-Benzothiazol-2-yloxy) -phenyl] -etl) -d-butyl-amine The title compound was prepared according to the procedure of Example 30 using dibutyl-amine. MS (ESI): mass calculated for C23H30N2OS, 382.21; m / z found, 383.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 8.2, 1 H), 7.65 (d, J = 8.2, 1 H), 7.38 (t, J = 8.2, 1 H), 7.30-7.22 (m , 5H), 2.82-2.67 (m, 4H), 2.51 (t, J = 7.2, 4H), 1.50-1.40 (m, 4H), 1.37-1.25 (m, 4H), 0.93 (t, J = 7.2, 6H).

EXAMPLE 101 2-r4- (2-Piperidin-1-yl-ethyl) -phenoxy-1-benzothiazole The title compound was prepared according to the procedure of Example 30 using piperidine. MS (ESI): mass calculated for C20H22N2OS, 338.48; m / z found, 339.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.76-7.73 (m, 1 H), 7.64-7.61 (m, 1 H), 7.42-7.25 (m, 6H), 2.88-2.83 (m, 2H), 2.60-2.52 (m, 6H), 1.66-1.61 (m, 4H), 1.53-1.45 (m, 2H).

EXAMPLE 102 1-. { 2-r4- (Benzothiazol-2-yloxy) -pheno-ethyl) -piperidin-4-ol The title compound was prepared according to the procedure of example 30 using 4-hydroxypiperidine. MS (ESI): mass calculated for C20H22N2O2S, 354.14; m / z found, 355.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 8.2, 1 H), 7.64 (d, J = 8.0, 1 H), 7.37 (t, J = 8.2, 1 H), 7.29-7.20 (m , 5H), 3.75-3.65 (m, 1 H), 2.92-2.79 (m, 4H), 2.76 (brs, 1 H), 2.65-2.55 (m, 2H), 2.21 (t, J = 10.0, 2H) , 1.98-1.87 (m, 2H), 1.70-1.57 (m, 2H).

EXAMPLE 103 Methyl ester of acid 1-. { 2-f4- (benzothiazol-2-yloxy) -phenyl] -ethyl] -piperidine-4-carboxylic acid The title compound was prepared according to the procedure of Example 30 using piperidine-4-carboxylic acid methyl ester acid methyl ester . MS (ESI): mass calculated for C22H24N2O3S, 396.15; m / z found, 397.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 8.3, 1 H), 7.66 (d, J = 8.3, 1 H), 7.38 (t, J = 8.3, 1 H), 7.29-7.23 (m , 5H), 3.69 (s, 3H), 3.00-2.93 (m, 2H), 2.87-2.80 (m, 2H), 2.63-2.56 (m, 2H), 2.38-2.28 (m, 1 H), 2.11 ( t, J = 11.1, 2H), 1.98-1.91 (m, 2H), 1.86-1.74 (m, 2H). EXAMPLE 104 Amide of acid 1-. { 2-r4- (Benzothiazol-2-yloxy) -phenyl-ethyl-Vipipridin-4-carboxylic acid The title compound was prepared according to the procedure of Example 31 using piperidine-4-carboxylic acid amide.

MS (ESI): mass calculated for C2? H23N3O2S, 381.15; m / z found, 382.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.78 (dd, J = 8.1, 0.4, 1 H), 7.71 (dd, J = 7.9, 0.7, 1 H), 7.43 (dt, J = 7.5, 2.3, 1 H), 7.35-7.25 (m, 5H), 5.51 (br d, J = 26.0, 1 H), 3.09 (br d, J = 11.7, 2H), 2.87, (dd, J = 8.3, 7.6, 2H), 2.65 ( dd, J = 8.5, 5.4, 2H), 2.29-2.18 (m, 1 H), 2.13 (t, J = 11.4, 2H), 1.98 (br d, J = 11.2, 2H), 1.87-1.77 (m, 2H).

EXAMPLE 105 1- (2-R4- (Benzothiazol-2-yloxy) -phene-ethyl) -piperidine-3-carboxylic acid ethyl ester The title compound was prepared according to the procedure of Example 31 using ethyl ester of acid piperidin-3-carboxylic acid. MS (ESI): mass calculated for C 3 H 26 N 2 O 3 S, 410.17; m / z found, 411.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.77 (d, J = 8.0, 1 H), 7.70 (dd, J = 7.9, 0. 5, 1 H), 7.42 (dt, J = 7.5, 1.3, 1 H), 7.34-7.27 (m, 5H), 4.18 (q, J = 7.1, 2H), 3. 13 (brd, J = 8.8, 1 H) 2.92-2.85 (m, 2H), 2.70-2.59 (m, 2H), 2.30 (t, J = 10.7, 1 H), 2.13 (dt, J = 10.9, 2.7, 1 H), 2.04-1.97 (m, 1-H), 1.84-1.76 (m, 1 H), - 1.71- 1. 59 (m, 1 H), 1.57-1.45 (m, 1 H) 1.30 (t, J = 7.2, 3H).

EXAMPLE 106 Ethyl 1- (2-r4- (benzothiazol-2-yloxy) -phenyl-ethyl-4-phenyl-piperidine-4-carboxylic acid ester The title compound was prepared according to the process of Example 31 using 4-phenyl-piperidin-4-carboxylic acid ethyl ester. MS (ESI): mass calculated for C29H30N2O3S, 486.20; m / z found, 487.5 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.78 (dd, J = 8.1, 0.5, 1 H), 7.70 (dd, J = 7.9, 0.7, 1 H), 7.46-7.24 (m, 11 H), 4.19 (q, J = 7.1, 2H), 3.06 (brd, J = 10.1, 2H), 2.96-2.90 (m, 2H), 2.75-2.64 (m, 4H), 2.35 (t, J = 11.0, 2H), 2.14, (t, J = 11. 3. 2H), 1.24, (t, J = 7.3, 3H).

EXAMPLE 107 Ethyl (1- {. 2- [4- (Benzothiazol-2-yloxO-phene-ethyl-V-piperidin-4-y-acetic acid ethyl ester) The title compound was prepared according to the procedure of Example 31 using ethyl acetate of piperidin-4-yl-acetic acid MS (ESI): mass calculated for C 24 H 28 N 2 O 3 S, 424.18, m / z found, 425.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.76 (d, J = 7.8, 1 H), 7.70 (dd, J = 7. 9, 0.6, 1 H), 7.41 (dt, J = 7.2, 1.2, 1 H), 7.36-7.27 (m, 5H), 4.18 (q, J = 5.3, 2H), 3.21 (d, J = 11.3, 2H), 3.03-2.99, (m, 2H), 2.83-2.78 (m, 2H), 2.33-2.25 (m, 4H), 2.00-1.87 (m, 1 H), 1.86 (d, J = 14.3, 2H), 1.67-1.55 (m, 2H), 1.29 (t, J) = 7.1, 3H).

EXAMPLE 108 1- (1-. {2- [4-Benzothiazol-2-yloxy) -phenyl] -ethyl) -piperidi-4-yl) -1,3-dihydro-indol-2-one The title compound is prepared according to the procedure of Example 31 using 1-piperidin-4-yl-1,3-dihydro-indol-2-one. MS (ESI): mass calculated for C28H27N3O2S, 469.18; m / z found, 470.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.75 (dd, J = 8.1, 0.4, 1 H), 7.68 (dd, J = 7.9, 0.6, 1 H), 7.40 (dt, J = 7.5, 1.2, 1 H), 7.36-7.23 (m, 8H), 7.04 (dt, J = 7.3, 1. 7, 1H), 4.57-4.45 (m, 1 H), 3.54 (s, 2H), 3.36 (br d, J = 10.9, 2H), 3.00 (dd, J = 11.4, 6.3, 1 H), 2.88 (dd, J = 8.8, 4.5, 2H), 2.75-2.62 (m, 2H), 2.45 (t, J = 11.5, 2H), 1.80 (dd, J = 12.3, 2.1, 2H).

EXAMPLE 109 1- (1- { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -pyrrolidin-2-one The title compound is prepared according to the procedure of Example 31 using 1-piperidin-4-yl-pyrrolidin-2-one. MS (ESI): mass calculated for C 24 H 27 N 3 O 2 S, 421.18; m / z found, 422.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.76 (d, J = 8.0, 1 H), 7.69 (dd, J = 8. 0, 0.9, 1 H), 7.41 (dt, J = 7.5, 1.2, 1 H), 7.32-7.27 (m, 5H), 4.05 (dt, J = 11.9, 4. 5, 1 H), 3.40 (t, J = 7.0, 2H), 3.10 (br d, J = 11.7, 2H), 2.86 (dd, J = 11.0, 7.7, 2H), 2.66 (dd, J = 8.8, 5.3, 2H), 2.43 (t, J = 8.1, 2H), 2.19 (dt, J = 11.6, 2.8, 2H), 2.09-2.00 (m, 2H), 1.85-1.69 (m, 4H).

EXAMPLE 110 V- (1- (2-r4-Benzothiazol-2-yloxy) -fenin-ethyl-piperidin-4-yl) -2-phenyl-acetamide The title compound was prepared according to the procedure of Example 31 using 2- phenyI-N-piperidin-4-yl-acetamide. MS (ESI): mass calculated for C28H2S3N3O2S, 471.20; m / z found, 472.5 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.77 (dd J = 8.1, 0.5, 1 H), 7.70 (dd, J = 7.8, 0.7, 1 H), 7.45-7.37 (m, 3H), 7.36-7.26 (m, 8H), 5.39 (brd, J = 7.9, 1 H), 3. 93-3.82 (m, 1 H), 3.60 (s, 2H), 2.93 (br d, J = 11.1, 2H), 2.86 (dd, J = 10.9, 7. 6, 2H), 2.65 (dd, J = 8.5, 5.2, 2H), 2.25 (t, J = 11.2, 2H), 1.95 (dd, J = 12.8, 3.3, 2H), 1.47 (m, 2H).

EXAMPLE 111 8-. { 2- [4- (Benzothiazol-2-yloxy) -phenin-ethyl) -2,8-diaza-spiro [4.5] decan-1-one The title compound was prepared in accordance with procedure of Example 31 using 2,8-diaza-spiro [4.5] decan-1-one. MS (ESI): mass calculated for C23H25N3O2S, 407.17; m / z found, 408.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.78 (d, J = 8.1, 1 H), 7.70 (dd, J = 7.8, 0.6, 1 H), 7.42 (dt, J = 7.6, 1.3, 1 H), 7.35- 7.25 (m, 5H), 6.40 (br s, 1H), 3. 40 (t, J = 6.9, 2H), 3.00 (dt, J = 11.6, 3.6, 2H), 2.88 (dd, J = 10.3, 7.4, 2H), 2. 67 (dd, J = 8.5, 5.7, 2H), 2.23 (t, J = 10.7, 2H), 2.10-2.00 (m, 4H), 1.52 (br d, J = 13.1, 2H).

EXAMPLE 112 1-. { 2- (4-Benzothiazol-2-yloxy) -phenyl-1-ethyl.} - piperidin-3-ol The title compound was prepared according to the procedure of Example 31 using 3-hydroxypiperidine. MS (ESI): dough calculated for C20H22N2O2S, 354.14, m / z found, 355.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.77 (d, J = 7.6, 1 H), 7.70 (dd, J = 8.0, 0.8, 1 H ), 7.42 (dt, J = 7.5, 1.2, 1 H), 7.35-7.28 (m, 5H), 3.89 (m, 1 H), 2.89 (dd, J = 10.1, 7.3, 2H), 2.71-2.65 ( m, 2H), 2.64-2.54 (m, 2H), 2.53-2.36 (m, 3H), 1.92-1.80 (m, 1 H), 1.74-1.55 (m, 3H).

EXAMPLE 113 Ethyl ester of acid 1-. { 2- [4- (benzothiazol-2-yloxy) -phenn-ethyl} -piperidine-4-carboxylic acid The title compound was prepared according to the procedure of Example 31 using piperidine-3-carboxylic acid ethyl ester. MS (ESI): mass calculated for C23H26N2O3S, 410.17; m / z found, 411.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.77 (d, J = 8.0, 1 H), 7.69 (dd, J = 7. 9, 0.7, 1 H), 7.41 (dt, J = 7.5, 1.2, 1 H), 7.32-7.27 (m, 5H), 4.18 (q, J = 7.1, 2H), 3.00 (br d, J = 11.5, 2H), 2.88 (dd, J = 10.9, 7.7, 2H), 2.64 (dd, J = 8.5, 5.3, 2H), 2.35 (tt, J = 10.9, 4.3 , 1 H), 2.14, (t, J = 10.9, 2H), 2.02-1.94 (m, 2H), 1. 90-1.78 (m, 2H), 1.30 (t, J = 7.3, 3H).

EXAMPLE 114 1 '- (2-r4- (Benzothiazol-2-yloxy) -phenp-ethylH1.4 * 1 bipiperidine The title compound was prepared in accordance with procedure of Example 31 using 4-plperidinyl-piperidine. MS (ESI): mass calculated for C25H3? N3OS, 421.22; m / z found, 422.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.75 (d, J = 7.8, 1 H), 7.69 (dd, J = 7.8, 0.6, 1 H), 7.41 (dt, J = 7.6, 1.2, 1 H), 7.33- 7.25 (m, 5H), 3.15 (br d, J = 11.6, 2H), 2.90-2.70 (m, 7H) 2.65 (dd, J = 8.5, 5.3, 2H), 2.18-2.06 (m, 4H), 1.99 -1.87 (m, 4H), 1.85-1.75 (m, 2H), 1.64-1.56 (m, 2H). EXAMPLE 115 2-α-r 2 - (4-Methyl-piperazin-1-yl) -ethyl-1-phenoxy) -benzothiazole The title compound was prepared according to the procedure of Example 32 using 1-methyl-piperazine. MS (ESI): mass calculated for C2oH23N3OS, 353.16; m / z found, 354.1 [M + Hf. 1 H NMR (400 MHz, CD 3 OD): 7.77 (d, J = 8.01, 1 H), 7.64 (d, J = 9.1, 1 H), 7.41 (t, J = 8.2, 1 H), 7.37 (d, J = 8.6, 2H), 7.32-7.28 (m, 3H), 2.81-2.35 (m, 8H), 2.87 (m, 2H), 2.65 (m, 2H), 2.30 (s, 3H).

EXAMPLE 116 1- (3- [4- (Benzoxazol-2-yloxy) -fenip-propyl) -4-pheny1-piperidin-4-ol The title compound was prepared according to the procedure of Example 35 using 4-phenyl -piperidin-4-ol. MS (ESI): mass calculated for C2 H28N2? 3, 428.21; m / z found, 429.3 [M + Hf 1 H NMR (400 MHz, DMSO-d 6): 7.48 (d, J = 8.4, 1 H), 7.45 (m, 11 H), 7.19 (t, J = 8.3, 1 H), 4.76 (s, 1 H), 2.66 (t, J = 7.6.4H), 2.45 (m, 4H), 1.92 (t, J = 7.1, 2H), 1.78 (t, J = 7.1, 2H) , 1.58 (d, J = 12.3, 2H).

EXAMPLE 117 1- (2- [4- (1H-Benzimidazol-2-yloxy) -phenoxy] -ethyl) -4- (4-bromo-phenyp-piperidin-4-ol) The title compound was prepared in accordance with Method of Example 37 using 4- (4-bromo-phenyl) -piperidin-4-ol MS (ESI): mass calculated for C 26 H 26 BrN 3 O 3, 507.12, m / z found, 508.2 [M + Hf. 1 H NMR (400 MHz, CDCI3): 7.43-7.07 (m, 10H), 6.94-6.89 (m, 2H), 4.11 (t, J = 5.8, 2H), 2.87-2.83 (m, 4H), 2.65-2.58 (m, 2H), 2.13-2.05 (m, 2H), 1.75-1.68 (m, 2H).

EXAMPLE 118 1-. { 2- [4- (1 H-Benzimidazol-2-yloxy) -phenoxy-ethyl} -4- (4-Chloro-phenyl) -piperidin-4-ol The title compound was prepared according to the procedure of Example 37 using 4- (4-chloro-phenyl) -piperidin-4-ol. MS (ESI): mass calculated for C26H26CIN3? 3, 463.17; m / z found, 464.2 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.38-7.22 (m, 6H), 7.17-7.12 (m, 2H), 7.09-7.04 (m, 2H), 6.91-6.81 (m, 2H), 4.08 (t, J = 5.6, 2H), 2.84-2.80 (m, 4H), 2.62 (t, J = 11.8, 2H), 2.09-2.02 (m, 2H), 1.70-1.65 (m, 2H).

EXAMPLE 19 1-l2-r4- (1H-Benzimidazol-2-yloxp-phenoxy-ethyl) -4-benzyl-piperidin-4-0! The title compound was prepared according to the procedure of Example 37 using 4-benzyl-piperidin-4-ol. MS (ESI): mass calculated for C27H29N3O3, 443.22; m / z found, 444.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.53 (br s, 1 H), 7.34-7.24 (m, 4 H), 7.26-7.16 (m, 7 H), 6.91-6.85 (m, 2 H), 4.08 (t, J = 5.8, 2H), 2.85-2.77 (m, 6H), 2.48 (dt, J = 2.5, 11.7, 2H), 1.84-1.76 (m, 2H), 1.56 (m, 2H). EXAMPLE 120 2- [4- (3-Piperidin-1-yl-propyl) -phenoxy] -benzoxazole The title compound was prepared according to the procedure of Example 35 using piperidine. MS (ESI): mass calculated for C2? H24N2O2, 336.18; m / z found, 337.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.62 (dd, J = 5.7, 2.1, 1 H), 7.50 (dd, J = 6.1, 2.1, 1 H), 7.45-7.35 (m, 2H), 7.35- 7.25 (m, 4H), 2.62 (t, J = 7.6, 2H), 2.30 (s, 4H), 2.25 (t, J = 7.4, 2H), 1.80-1.70 (m, 2H), 1.55-1.45 (m , 4H), 1.42-1.35 (m, 2H).

EXAMPLE 121 (3-f4- (Benzoxazol-2-yloxy) -phenyl-1-propii) -dibutylamine The title compound was prepared in accordance with procedure of example 35 using dibutyl-amine. MS (ESI): mass calculated for C24H32N2? 2, 380.25; m / z found, 381.3 [M + Hf. 1 H NMR (400 MHz, DMSO-c 6): 7.63 (dd, J = 6.1, 2.1, 1 H), 7.50 (d, J = 6.1, 2.1, 1 H), 7.40 (d, J = 8.6, 2H) , 2.63 (t, J = 7.7, 2H), 2.50-2.30 (m, 6H), 1.70 (quintuplet, J = 7.2, 2H), 1.40-1.20 (m, 8H), 0.88 (t, J = 7.1, 6H ).

EXAMPLE 122 . { 3- [4- (Benzoxazol-2-yloxy) -fenin-propyl) -cyclopropylmethyl-propyl-amine The title compound was prepared according to the procedure of Example 35 using cyclopropylmethyl-propyl-amine. MS (ESI): mass calculated for C23H28N2O2, 364.22; m / z found, 365.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.63 (d, J = 8.6, 1 H), 7.40 (d, J = 8. 6, 1 H), 7.32 (d, J = 8.5, 2H), 7.30-7.25 (m, 4H), 2.63 (t, J = 7.6, 2H), 2.41 (t, J = 7.2, 2H), 2.28 ( d, J = 6.3, 2H), 1.71 (quintuplet, J = 7.2, 2H), 1.38 (q, J = 7. 2, 2H), 0.85 (t, J = 7.3, 2H), 0.88-0.77 (m, 2H), 0.42 (d, J = 4.2, 2H), 0.05 (d, J = 4.8, 2H).

EXAMPLE 123 . { 2- [4- (1H-Benzimidazol-2-yloxy) -phenyl] -ethyl) -cyclohexyl-ethyl-amine The title compound was prepared according to the procedure of Example 38 using cyclohexyl-ethylamine. MS (ESI): mass calculated for C23H29N3O, 363.23; m / z found, 364.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 11.44 (br s, 1H), 7.43-7.33 (m, 2H), 7. 13-7.05 (m, 6H), 3.17 (t, J = 11.7, 1 H), 3.10 (dd, J = 7.0, 7.0, 2H), 2.99-2.83 (m, 4H), 2.06 (d, J = 9.8 , 2H), 1.89 (d, J = 12.5, 2H), 1.69 (d, J = 12.5, 1H), 1.49-1.22 (m, 7H), 1.19-1.05 (m, 1H).

EXAMPLE 124 2- [4- (2-Pyrrolidin-1-ethyl-V-phenoxy-1 H-benzimidazole) The title compound was prepared according to the procedure of Example 38 using pyrrolidine, MS (ESI): mass calculated for C? 9H2? N3O, 307.17; m / z found, 308.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.35-7.22 (m, 2H), 7.14-7.04 (m, 6H), 2.79-2.72 (m, 2H), 2.67-2.57 (m, 6H), 1.87-1.77 (m , 4H).

EXAMPLE 125 2-f4- (2-Azepan-1-ethyl-ethyl) -phenoxy] -1H-benzimidazole The title compound was prepared according to the procedure of Example 38 using azepam. MS (ESI): mass calculated for C2? H25N3O, 335.20; m / z found, 336.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.38 (dd, J = 3.1, 2.7, 2H), 7.11 (dd, J = 3.1, 2.9, 2H), 7.10-7.00 (m, 4H), 3.25-3.15 (m, 4H), 3.06 (dd, J = 6.3, 5.3, 2H), 2.93 (dd, J = 6.1, 4.3, 2H), 2.00-1.91 (m, 4H), 1.75-1.67 (m, 4H).

EXAMPLE 126 . { 2- [4- (1H-Benzimidazol-2-yloxy) -phenyl] -ethyl) -dibutylamine The title compound was prepared according to the procedure of Example 38 using dibutylamine.

MS (ESI): mass calculated for C23H3? N3O, 365.25; m / z found, 366.5 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.40-7.29 (m, 2H), 7.17-7.06 (m, 6H), 2.83-2.60 (m, 8H), 1.59-1.47 (m, 4H), 1.38-1.26 (m , 4H), 0.93 (t, J = 7.2, 6H).

EXAMPLE 127 1 - . 1 -. { 2-F4- (1 H-Benzimidazol-2-yloxy) -phenyl-etl} -piperidin-4-ol The title compound was prepared according to the procedure of Example 38 using 4-hydroxypiperidine. MS (ESI): mass calculated for C2oH23N3O2, 337.18; m / z found, 338.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 11.70 (br s, 1 H), 7.50-7.44 (m, 1 H), 7. 33-7.27 (m, 1 H), 7.24 (br s, 4 H), 7.14-7.07 (m, 2 H), 3.93 (br s, 1 H), 3.68-3.58 (m, 1 H), 2.97-2.75 (m , 4H), 2.63-2.52 (m, 2H), 2.19 (t, J = 9.8, 2H), 1.94-1.84 (m, 2H), 1.65-1.54 (m, 2H).

EXAMPLE 128 1- (2-F4- (1H-Benzimidazol-2-yloxB-phenyl-ethyl) -piperidine-4-carboxylic acid methyl ester The title compound was prepared according to the procedure of Example 38 using piperidine methyl ester -4-carboxylic acid MS (ESI): mass calculated for C22H25N3Δ3,379.19, m / z found, 380.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 11.76 (br s, 1 H), 7.50- 7.44 (m, 1 H), 7. 24-7.06 (m, 7H), 3.68 (s, 3H), 3.00-2.92 (m, 2H), 2.77-2.70 (m, 2H), 2.53- 2.46 (m, 2H), 2.38-2.28 (m, 1 H), 2.10 (t, J = 11.1, 2H), 1.98-1.90 (m, 2H), 1.86-1.74 (m, 2H).

EXAMPLE 129 . { 2- [4- (1H-Benzimidazol-2-yloxyVfenoxp-ethyl.}. -cyclohexyl-ethyl-amine The title compound was prepared according to the procedure of Example 37 using cyclohexyl-ethyl-amine.

MS (ESI): mass calculated for C23H2gN3O2, 379.23; m / z found, 380.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 12.23 (s, 1 H), 7.34-7.25 (m, 4 H), 7.07 (d, J = 3.5, 2 H), 6.98 (d, J = 9.0, 2 H), 3.94 (t, J = 6.4, 2H), 2.80 (t, J = 6.4, 2H), 2.57 (d, J = 7.1, 2H), 2.50 (s, 2H), 1.72 (d, J = 7.8, 2H) , 1.55 (s, 1 H), 1.20 (t, J = 9.0, 4H), 0.99 (t J = 7.1, 3H).

EXAMPLE 130 2-. { 4-F2- (4-Methyl-piperidin-1-yl) -ethoxy-phenoxy) -1H-benzimidazole The title compound was prepared according to the procedure of Example 35 using 4-methyl-piperidine. MS (ESI): mass calculated for C2? H25N302, 351.19; m / z found, 352.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 12.30 (s, 1 H), 7.34-7.25 (m, 4H), 7.08 (d, J = 3.8, 2H), 6.99 (d, J = 9.0, 2H), 4.08 (t, J = 5.8, 2H), 2.89 (d, J = 11.4, 2H), 2.67 (t, J = 5.8, 2H), 2.00 (t, J = 11.4, 2H), 1.56 (d, J = 11.5, 2H), 1.36-1.25 (m, 1 H), 1.21-1.08 (m, 2H), 0.88 (d, J = 6.4, 3H).

EXAMPLE 131 2-. { 4-f2- (2-Ethyl-piperidin-1-yl) -ethoxyl-phenoxy-1H-benzimidazole The title compound was prepared according to the procedure of Example 37 using 2-ethyl-piperidine. MS (ESI): mass calculated for: C22H27N3O2, 365.21; m / z found, 366.3 [M + Hf 1 H NMR (400 MHz, DMSO-d 6): 12.28 (s, 1 H), 7.32-7.25 (m, 4H), 7. 08 (d, J = 3.8, 2H), 6.99 (d, J = 8.4, 2H), 4.05 (t, J = 6.1, 2H), 3.00-2.92 (m, 1 H), 2.91-2.85 (m, 1H ), 2.72-2.64 (m, 1 H), 2.38-2.20 (m, 2H), 1.67-1.36 (m, 6H), 1.35-1.19 (m, 2H), 0.84 (t, J = 7.5, 3H).

EXAMPLE 132 2-í4- (2-Piperidin-1-yl-ethoxy) -phenoxy-1 H-benzimidazole The title compound was prepared according to the procedure of Example 37 using piperidine. MS (ESI): mass calculated for C2oH23N3Δ2, 337.18; m / z found, 338.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 12.25 (br s, 1 H), 7.35-7.25 (m, 4 H), 7.10-7.00 (m, 2 H), 6.99 (d, J = 9.0, 2 H), 4.07 (t, J = 5.9, 2H), 2.79 (t, J = 5.9, 2H), 2.43 (s, 4H), 1.55-1.45 (m, 4H), 1.38 (s, 2H).

EXAMPLE 133 (1- (2-F4- (1H-Benzimidazol-2-yloxy) -phenoxy-ethyl) -piperidin-4-yl) -methanol The title compound was prepared according to the procedure of Example 35 using piperidin-4- il-methanol. MS (ESI): mass calculated for C2iH25N3? 3l 367.19; m / z found, 368.4 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 12.24 (s, 1 H), 7.35-7.25 (m, 4H), 7. 01 (s, 2H), 6.99 (d, J = 7.1, 2H), 4.40 (s, 1 H), 4.10 (t, J = 5.7, 2H), 3.25 (t, J = 5.4, 2H), 2.93 ( d, J = 11.1, 2H), 2.67 (t, J = 5.6, 2H), 1.98 (t, J = 11.6, 2H), 1.63 (d, J = 11.6, 2H), 1.28 (s, 1 H), 1.12 (d, J = 9.1, 2H).

EXAMPLE 134 1-l2-r4- (1H-Benzimidazol-2-yloxy) -phenoxy-ethyl) -piperidin-4-ol The title compound was prepared according to the procedure of Example 37 using 4-hydroxypiperidine. MS (ESI): mass calculated for C2oH23N3O3, 353.17; m / z found, 354.4 [M + Hf 1 H NMR (400 MHz, DMSO-d 6): 12.24 (s, 1 H), 7.35-7.25 (m, 4 H), 7.07 (d, J = 9.0, 2 H), 6.99 (d, J = 9.0, 2H), 4.40 (s, 1 H), 4.08 (t, J = 5.8, 2H), 2.53 (s, 1 H), 2.78 (d, J = 11.2, 2H), 2.66 ( t, J = 5.8, 2H), 2.12 (t, J = 10.3, 2H), 1.70 (d, J = 9.1, 2H), 1.38 (d, J = 9.9.2H).

EXAMPLE 135 1-4- (Benzoxazol-2-yloxy) -phenoxy] -3-pyrrolidin-1-yl-propan-2-ol The title compound was prepared according to the procedure of Example 40 using pyrrolidine. MS (ESI): mass calculated for C20H22N2O4, 354.16; m / z found, 355.2 [M + Hf 1 H NMR (400 MHz, DMSO-d 6): 7.62 (dd, J = 6.2, 2.0, 1 H), 7.50. (dd, J = 6.1, 2.1, 1H), 7.42 (d, J = 9.1, 2H), 7.35-7.25 (m, 2H), 7.03 (d, J = 9.1, 2H), 4.91 (d, J = 4.5 , 1 H), 4.05-4.00 (m, 1 H), 4.00-3.85 (m, 2H), 2.70 (m, 1 H), 2.50-2.40 (m, 5H), 1.68 (s, 4H).

EXAMPLE 136 1-F2- (4-Benzoxazol-2-y! Methyl-phenoX-o-ethyl-4-phenyl-piperidin-4-ol) The title compound was prepared according to the procedure of example 41 using 4-phenyl-piperidin-4 -ol MS (ESI): mass calculated for C27H28N2O3, 428.21, m / z found, 429.2 [M + Hf. 1 H NMR (400 MHz, CD3OD): 7.62-7.58 (m, 1 H), 7.54-7.45 (m , 3H), 7.33-7.25 (m, 6H), 7.20-7.15 (m, 1 H), 6.91 (d, J = 8.6, 2H), 4.20 (s, 2H), 4.13 (t, J = 5.5, 2H) , 2.87 (m, 4H), 2.66 (t, J = 11.4, 2H), 2.13 (dt, J = 12.8, 3.6, 2H), 1.72 (d, J = 12, 6.2H).

EXAMPLE 137 Amide of 1-F2- (4-benzoxazol-2-ylmethyl-phenoxy) -ethyl-1-piperidine-4-carboxylic acid The title compound was prepared according to the procedure of Example 41 using piperidin-4-amide carboxylic MS (ESI): mass calculated for C22H25N3O3, 379.19; m / z found, 380.4 [M + Hf.

H NMR (400 MHz, CD3OD): 7.64-7.60 (m, 1 H), 7.56-7.52 (m, 1 H), 7.36-7.31 (m, 2H), 7. 28 (d, J = 8.7, 2H) , 6.92 (d, J = 8. 7.2H), 4.22 (s, 2H), 4.11 (t, J = 5.6, 2H), 3.07 (d, J = 12.0, 2H), 2.79 (t, J = 5.6, 2H), 2.18-2.15 (m, 3H), 1.80-1.70 (m, 4H).

EXAMPLE 138 Amide of 2- [4- (2-azepan-1-yl-ethoxy) -phenoxy] -1 H -benzimidazole The title compound was prepared according to the procedure of example 11, steps A and B, and example 37 , steps B and C, using 1- (2-chloro-ethyl) -azepan hydrochloride. MS (ESI): mass calculated for C2? H2sN3? 2, 351.19; m / z found, 352.3 [M + Hf 1 H NMR (400 MHz, DMSO-d 6): 12.28 (s, 1 H), 7.35-7.25 (m, 4H), 7. 07 (d, J = 9.1, 2H), 7.00 (d, J = 9.1, 2H), 4.05 (t, J = 6.0, 2H), 2.86 (t, J = 6.0, 2H), 2.70 (t, J = 5.1, 4H), 1.65-1.50 (m, 8H).

EXAMPLE 139 'H rj (3-y4- (1 H -benz? Azazo? -? Oxi) -tenoxy? -propyl) -dimethyl-amine The title compound was prepared in accordance with procedure of example 11, steps A and B, and example 37, steps B and C, using (2-chloro-propyl) -dimethylamine hydrochloride. MS (ESI): mass calculated for C? 8H2? N3O2, 311.16; m / z found, 312.2 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.32-7.23 (m, 2H), 7.21-7.14 (m, 4H), 6.89-6.83 (m, 2H), 3.99-3.91 (m, 2H), 2.51 (t, J = 7.2, 2H), 2.31 (s, 6H) 2.02-1.95 (m, 2H).

EXAMPLE 140 2- [4- (2-Pyrrolidin-1-yl-ethoxy-phenoxy] -1 H -benzimidazole The title compound was prepared according to the procedure of Example 21, Steps A and B, and Example 35, Steps B and C, using pyrrolidine, MS (ESI): mass calculated for C? 9H2? N3O2, 323.16; m / z found, 324.2 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.27 (br s, 2H), 7.15 (d, J = 9.1, 4H), 6.81 (d, J = 6.8, 2H), 4.16 (t, J = 5.5, 2H), 3.05 (t, J = 5.5, 2H), 2.86 (br s, 4H) , 1.92 (br s, 4H).

EXAMPLE 141 H 4- (1H-Be dncimidazoX C. {2-r l-2-yloxy) -phenoxy-1-ethyl) -diethyl-amine The title compound was prepared according to the procedure of Example 21, Steps A and B, and example 35, steps B and C, using diethylamine. MS (ESI): mass calculated for C? 9H23N3O2, 325.18; m / z found, 326.3 [M + Hf. H NMR (400 MHz, CDCl 3): 7.29 (br s, 2H), 7.18 (d, J = 9.0, 2H), 7. 10-7.05 (m, 2H), 6.98 (d, J = 9. 0.2H), 4.03 (t, J = 6.2.2H), 2.78 (t, J = 6.1, 2H), 2. 55 (q , J = 7.1, 4H), 0.98 (t, J = 7.1, 6H).

EXAMPLE 142 2- [4- (2-Morpholin-4-yl-ethoxy) -phenoxy] -1 H -benzimidazole The title compound was prepared according to the procedure of Example 21, Steps A and B, and Example 37, Steps B and C, using morpholine. MS (ESI): mass calculated for C? 9H2iN3O3, 339.16; m / z found, 340.2 [M + Hf 1 H NMR (400 MHz, DMSO-d 6): 7.40-7.25 (m, 4H), 7.12-7.08 (m, 2H), 7.00 (d, J = 9.0, 2H), 4.10 (t, J = 5.7, 2H) , 3. 58 (t, J = 4.5, 4H), 2.70 (t, J = 5.7, 2H), 2.52-2.46 (m, 4H).

EXAMPLES 143-202 and 204-229 The compounds of this invention which are referred to herein for which explicit preparation description is not provided can be prepared according to procedures analogous to those described herein in the light of the knowledge of one skilled in the art and the teachings provided herein. For example, benzothiazole derivatives listed here with reference numerals 143-202 and 204-229 can be prepared according to procedures analogous to those described herein for related compounds.

EXAMPLE 203 [(1- (2-f4- (Benzothiazol-2-yloxy) -phenoxy-ethyl) -piperidine-4-carboniD-methyl-aminol-acetic acid The title compound was prepared according to the procedures for example 20 and example 18 using ester hydrochloride Ethyl sarcosine MS (ESI): mass calculated for C24H27N3OSS, 469.56; m / z found, 470.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.71 (d, J = 8.02, 1 H), 7.65 (d, J = 8.02, 1 H), 7.34-7.40 (m, 1 H), 7.23-7.30 (m, 3H ), 6.92-6.98 (m, 2H), 4.34-4.44 (m, 2H), 3.92 (br s, 2H), 3.45-3.54 (m, 3H), 3.35 (brs, 1 H), 3.25 (brs, 1 H), 3.12 (s, 2H), 2.96 (s, 1 H), 2.76 (br s, 2H), 1.92-2.08 (m, 4H).

EXAMPLES 230-231 and 485 As indicated in the context of this written description, the compounds of this invention which are referred to herein for which explicit preparation description is not provided can be prepared in accordance with procedures analogous to those described herein in the light of an expert's knowledge. in the art and teachings provided herein For example, benzimidazole derivatives listed herein with reference numerals 230-231 and 485 can be prepared according to procedures analogous to those described herein for related compounds.

EXAMPLE 250 1-r4- (Benzothiazol-2-yloxy) -benzyl-1-piperidine-4-carboxylic acid A. 1- (4-benzyloxy-benzyl-piperidine-4-carboxylic acid) ethyl ester A mixture of 4-benzyloxybenzyl chloride (15.2 g, 65.3 mmol), isonipecotic acid ethyl ester (15 mL, 97 mmol), and K2CO3 (13.5 g, 97.6 mmol) in CH3CN (300 mL) was stirred at reflux for 20 h. The reaction mixture was cooled The solvent was removed under reduced pressure to give a light golden oil.This material was diluted with / PrOH (100 ml), and the mixture was filtered.The solid was dried with air to give a white solid. (19.7 g, 85% yield) CCD (SIO2, 15% acetone / CH2Cl2): Rf = 0.32 MS (ESI): mass calculated for C22H27NO3, 353.2, m / z found, 354.3 [M + Hf 1H NMR ( 400 MHz, DMSO-d6): 7.44 (d, J = 7.1, 2H), 7.39 (t, J = 7. 1, 2H), 7.33 (d, J = 7.2, 1 H), 7.18 (d, J = 8. 2, 2H), 6.94 (2H, J = 8.6, 2H), 5.08 (s, 2H), 4.04 ( q, J = 7.09, 2H), 2.72 (d, J = 11.5, 2H), 2.32-2.18 (m, 1 H), 1. 94 (t, J = 11.6, 2H), 1.76 (d, J = 10.2, 2H), 1.59-1.48 (m, 2H), 1.17 (t, J = 7.1, 3H). B. 1- (4-Hydroxy-benzyl) -peridine-4-carboxylic acid ethyl ester. Ethyl 1- (4-benzyloxy-benzyl) -piperidine-4-carboxylic acid ester (10.0 g, 28.3 nmol) was dissolved in 1: 1 ethanoi / ethyl acetate (150 ml). To this solution was added Pd on carbon (10% by weight, 503 mg) as a suspension in ethanol (5.0 ml). The resulting suspension was placed in a Parr hydrogenator at 2812 kg / cm2 of H2 and stirred overnight. The reaction mixture it was filtered through a pad of diatomaceous earth, and the filtrate was concentrated under reduced pressure to give a light golden oil. The oil was purified on SiO2 (90 g, 50% acetone / CH2Cl2) to give a white solid (2.0 g, 27% yield). CCD (SiO2, 50% acetone / CH2Cl2): Rf = 0.32. MS (ESI): mass calculated for C? 5H2? N03, 263.2; m / z found, 264.2 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 9.25 (s, 1 H), 7.05 (d, J = 8.4, 2H), 6.68 (d, J = 8.4, 2H), 4.04 (q, J = 7.1, 2H ), 3.34 (s, 2H), 2.71 (d, J = 11.5, 2H), 2.32-2.18 (m, 1 H), 1.92 (t, J = 11.6, 2H), 1.76 (d, J = 10.2, 2H) ), 1.59-1.48 (m, 2H), 1.17 (t, J = 7.1, 3H). C. Ethyl ester of 1-r4 acid (Benzothiazol-2-yloxO-benzyl-piperidin-4-carboxylic acid) To a stirred solution of ethyl ester of 1- (4-hydroxy-benzyl) -piperidine 4-carboxylic acid (508 mg, 1.93 mmol) in CH3CN (15 ml), K2CO3 (564 mg, 4.1 mmol) and 2-chlorobenzothiazole (0.50 ml, 4.0 mmol) were added.The suspension was heated to 80 ° C and the The mixture was allowed to cool to room temperature and then filtered through diatomaceous earth.The filtrate was concentrated under reduced pressure, and the residue was purified on SiO2 (12 g, 0-15% acetone / CH2Cl2) to give a clear and colorless sticky oil (717 mg, 94% yield) CCD (SiO2, 15% acetone / CH2Cl2): Rf = 0.5 MS (ESI): mass calculated for C22H24N2O3S, 396.2; / z found, 397.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d6): 7.92 (d, J = 8.0, 1H), 7.68 (d, J = 8. 0, 1 H), 7. 48-7.33 (m, 5H), 7.33 (t, J = 7.1, 1 H), 4.06 (q, J = 7.1, 2H), 3.49 (s, 2H), 2.76 (d , J = 11.5, 2H), 2.34-2.22 (m, 1 H), 2.02 (t, J = 11.6, 2H), 1.80 (d, J = 10.2, 2H), 1.64-1.54 (m, 2H), 1.18 (t, J = 7.1, 3H). D. 1 - [4- (Benzothiazol-2-yloxy) -bencip-piperldine-4-carboxylic acid. To a stirring solution of 1 - [4- (benzothiazol-2-yloxy) -benzyl] -piperidine-4-carboxylic acid ethyl ester (663 mg, 1.7 mmole) in 25% of / PrOH / H 2 O (20 ml) was added potassium hydroxide (206 mg, 3.1 mmol). The reaction mixture was stirred at room temperature for 20 hr, and the solution was treated at pH 5.5 with 1 M HCl. The resulting solution was extracted with 10% / 'PrOH / CHCl3 (3 x 50 ml). The combined extracts were dried (MgSO 4), filtered and concentrated under reduced pressure to give a white solid (561 mg, 91% yield). MS (ESI): mass calculated for C2oH2oN2? 3S, 368.1; m / z found, 369.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.92 (d, J = 7.6, 1 H), 7.69 (d, J = 7. 6, 1 H), 7.48-7.34 (m, 5H), 7.33 (t, J = 7.1, 1H), 3.49 (s, 2H), 2.76 (d, J = 11.4, 2H), 2.22-2.11 (m, 1 H), 2.02 (t, J = 11.2, 2H), 1.80 (d, J = 13.2, 2H), 1.62-1.48 (m, 2H), 1.18 (t, J = 7.1, 3H).

EXAMPLE 251 1- (1- [4- (Benzothiazol-2-yloxp-benzyl-Piperidin-4-yl) -pyrrolidin-2-one A. 4- (Benzothiazol-2-yloxy) -benzaldehyde. To a mixture of 4 -hydroxybenzaldehyde (1 g, 8.2 mmol) and 2-chlorobenzothiazole (2.03 ml, 16.4 mmol) in CH3CN (100 ml) was added Cs2CO3 (5.5 g, 17.2 mmol) .The reaction mixture was stirred at 60 ° C for 24 hr. The resulting mixture was cooled to room temperature, filtered through diatomaceous earth and concentrated under reduced pressure to give the crude product as an orange oil.The oil was triturated with hexanes / CH2Cl2 (100 ml) and the solvent layer it was decanted and concentrated under reduced pressure to give an orange oil which was then purified on SiO2 (120 g, 0-50% ethyl acetate / hexanes) to give a white solid (853 mg, 41% yield). NMR (400 MHz, CDCl 3): 10.1 (s, 1 H), 7.97-7.78 (m, 2H), 7.78-7.70 (m, 2H), 7.60-7.50 (m, 2H), 7.48-7.38 (m, 1 H), 7.36-7.30 (m, 1 H) B. 1 - (1 - [4-Benzothiazol-2-yloxy) -benzin-p-peri din-4-yl) -pyrrolidin-2-one. A mixture of 4- (benzothiazol-2-yloxy) -benzaldehyde (500 mg, 1.9 mmol), 1-piperidin-4-yl-pyrrolidin-2-one hydrochloride (440 mg, 2.2 mmol), Et3N (300 μl, 2.2 mmol) and molecular sieves (500 mg, triturated, 4Á) in CICH2CH2CI (/ 10 ml) was stirred at room temperature for 1 hr. To the resulting mixture was added NaBH (OAc) 3 (830 mg, 3.92 mmol). The mixture was stirred at room temperature for 24 hr, filtered through diatomaceous earth, rinsed with CH2Cl2 (50 ml) and concentrated under reduced pressure to give the crude product as a yellow oil. The crude product was purified on SiO2 (40 g, 0-100% acetone / CH2Cl2) to give a clear oil that crystallized during rest (287 mg, 36% yield). MS (ESI): mass calculated for C23H25N3O2S, 407.5; m / z found, 408.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.76 (d, J = 8.0, 1H), 7.69 (d, J = 8.0, 1 H), 7.41-7.30 (m, 3H), 7.35-7.27 (m, 3H), 4.46-3.98 (m, 1 H), 3.71 (s, 2H), 3.36 (t, J = 6.9, 2H), 2.97 (d, J = 11.7, 2H), 2.40 (t, J = 8.1, 2H), 2.17-1.97 (m, 4H), 1.81-1.62 (m, 4H).

EXAMPLE 252 2- (2-Fluoro-4-piperidin-1-ylmethyl-phenoxy) -benzothiazole A. (3-Fluoro-4-hydroxy-phen-p-piperidin-1-yl-methanone. Fluoro-4-hydroxybenzoic acid (5.0 g, 32 mmol), piperidine (5 ml, 51 mmol), and EDCI (9.3 g, 49 mmol) in CH2Cl2 (100 ml) was stirred at room temperature for 20 h. reaction was added to CH 2 Cl 2 (200 mL) and washed with 1 M HCl (2 x 100 mL). The organic layers were combined, dried (MgSO 4) and concentrated under reduced pressure to give a light golden oil. The oil was purified on SiO2 (120 g, 0-10% acetone / CH2Cl2) to give a white solid (2.4 g, 34% yield).

CCD (SI02, 15% acetone / CH2Cl2): Rf = 0.35. MS (ESI): mass calculated for C? 2H? 4FNO2, 223.1; m / z found, 224.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 10.26 (s, 1 H), 7.18 (d, J = 11.6, 1 H), 7.00 (d, J = 8.3, 1 H), 6.98 (t, J = 8.5, 1 H), 3.42 (br s, 4 H), 1.65-1.45 (m, 6H). B. 2-Fluoro-4-piperidin-1-ylmethyl-phenol. A solution of lithium aluminum hydride (1.9 g, 50 mmol) in THF (40 ml) was stirred at 5 ° C. To the mixture was added (3-fluoro-4-hydroxy-phenyl) -piperidin-1-yl-methanone (2.3 g, 10.4 mmol) in THF (10 ml) for 15 min and then the mixture was heated to 60 ° C. .

After 20 hr, the mixture was cooled to 5 ° C and saturated NH CI (200 ml) was added followed by CH2Cl2 (200 ml). The organic layer was separated, dried (MgSO) and concentrated under reduced pressure to give a white solid (812 mg, 37% yield). CCD (SiO2, acetone): Rf = 0.22. MS (ESI): mass calculated for C? 2H? 6FNO, 209.1; m / z found, 210.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 6.58 (d, J = 13.4, 1 H), 6.48 (d, J = 8. 2, 1 H), 6.40 (t, J = 9.9, 1 H), 3.14 (s, 2H), 2.24 (br s, 4H), 1.54-1.30 (m, 6H). C. 2- (2-Fluoro-4-piperidin-1-ylmethyl-phenoxy) -benzothiazole. To a stirring solution of 2-fluoro-4-piperidin-1-ylmethyl-phenol (152 mg, 0.73 mmol) in CH3CN (10 mL) was added K2CO3 (201 mg, 1.5 mmol) and 2-chlorobenzothiazole (0.14 mL). , 1.1 mmol). The suspension was heated to 80 ° C and stirred overnight. The reaction mixture was allowed to cool to room temperature and then filtered through diatomaceous earth. The filtrate was concentrated under reduced pressure, and the residue was purified over SiO2 (12 g; 0- 50% acetone / CH2Cl2) to give a light golden oil (142 mg, 57% yield). CCD (SiO2, 50% acetone / CH2Cl2): Rf = 0.44. MS (ESI): mass calculated for C19H19FN2OS, 342.1; m / z found, 343.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.95 (d, J = 7.9, 1 H), 7.69 (d, J = 7.5, 1 H), 7.56 (t, J = 8.2, 1 H), 7.47-7.32. (m, 3H), 7.44 (d, J = 15.4, 1 H), 3.48 (s, 2H), 2.36 (s, 4H), 1.63-1.37 (m, 6H).

EXAMPLE 253 N- (1-f4- (Benzothiazol-2-yloxy) -benzyl-piperidin-4-yl.} -2-hydroxy-acetamide A. Tert-butyl acid ester {1-f4- ( benzothiazol-2-yloxy) -benzyl] -piperdin-4-yl} -carbamic acid: A mixture of 4- (benzothiazol-2-yloxy) -benzaldehyde (example 251, step A, 500 mg, 1.9 mmol), ester Tert-butyl of piperidin-4-yl-carbamic acid (785 mg, 3.9 mmol) and molecular sieves (500 mg, crushed, 4A) in CICH2CH2CI2 (10 mL) was stirred at room temperature for 40 min. NaBH (OAc) 3 was added in portions over 1.5 hr (4 x 207 mg, 3.9 mmol) The resulting mixture was stirred at room temperature for 24 hr, filtered through diatomaceous earth and rinsed with CH 2 Cl 2 (50 ml The filtrate was washed with NaHCO3 saturated aqueous (1 x 25 ml), dried (Na2SO) and concentrated under reduced pressure to give the crude product as a light yellow oil. The crude product was purified on SiO2 (40 g, 0-5% 2M NH3 in CH3OH / CH2Cl2) to give a white foam (504 mg, 59% yield). MS (ESI): mass calculated for C 24 H 29 N 3 O 3 S, 439.6; m / z found, 440.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.74 (d, J = 8.0, 1 H), 7.67 (d, J = 8.0, 1 H), 7.42-7.36 (m, 3H), 7.32-7.24 (m, 3H) , 4.44 (brs, 1 H), 3.50 (s, 2H), 2.82-2.76 (m, 2H), 2.16-2.06 (m, 2H), 1.96-1.88 (m, 2H), 1.45 (s, 9H), 1.48-1.38 (m, 2H). B. 1 - [4- (Benzothiazol-2-yloxy) -benzyl-piperidin-4-ylamine. To a solution of tert-butyl acid ester. { 1- [4- (benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} Carbamic acid (200 mg, 0.45 mmol) in CH 2 Cl 2 (2 ml) at 0 ° C was added 4 N HCl in dioxane (1.8 ml, 7.2 mmol) dropwise. The resulting reaction mixture was stirred at room temperature for 2 hr. The desired product was isolated by filtration and rinsed with Et2O (50 ml) to give a white powder (187 mg, 100% yield). MS (ESI): mass calculated for C? 9H2? N3OS, 339.5; m / z found, 340.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.68-7.64 (m, 1 H), 7.58-7.52 (m, 2H), 7. 48-7.44 (m, 1 H), 7.40-7.35 (m, 2H), 7.30-7.24 (m, 1 H), 7.20-7.14 (m, 1 H), 4.25 (s, 2H), 3.52-3.46 ( m, 2H), 3.36-3.28 (m, 1 H), 3.08-2.99 (m, 2H), 2.16-2.08 (m, 2H), 1.92-1.80 (m, 2H).

C. Esther. { 1-f4- (benzothiazol-2-yloxy) -benzyl-1-piperdin-4-ylcarbamoyl} - acetic acid methyl. To a solution of dihydrochloride of. { 1- [4- (Benzothiazol-2-yloxy) -benzyl] -piperdin-4-ylamine (413 mg, 1.0 mmol) in CH2Cl2 (20 mL) at room temperature was added TEA (0.70 mL, 5.0 mmol), followed by acetoxyacetyl chloride (0.16 ml, 1.5 mmol). The resulting mixture was stirred at room temperature overnight. The reaction mixture was dissolved in CH 2 Cl 2 (100 ml), washed with saturated aqueous NaHCO 3 (1 x 25 ml), dried (Na 2 SO 4) and concentrated under reduced pressure to give the crude product as an off-white solid. The crude product was purified on SiO2 (40 g, 0-10% CH3OH / CH2Cl2) to give a white solid (410 mg, 93% yield). MS (ESI): mass calculated for C23H25N3? 4S, 439.2; m / z found, 440.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.72 (d, J = 7.8, 1 H), 7.65 (d, J = 8.1, 1 H), 7.40-7.35 (m, 3H), 7.32-7.23 (m, 3H) , 6.11 (d, J = 8.3, 1 H), 4.53, (s, 2H), 3.93-3.82 (m, 1 H), 3.50 (s, 2H), 2.83 (d, J = 11.9, 2H), 2.15 (s, 3H), 2.14 (t, J = 11.9, 2H), 1.93 (d, J = 12.1, 2H), 1.56-1.45 (m, 2H). D. N-. { 1- [4- (Benzothiazol-2-yloxy) -benzyl] -piperdin-4-yl) -2-hydroxy-acetamide. To an ester solution. { 1- [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-ylcarbamoyl} Acetic acid methyl ester (368 mg, 0.84 mmol) in THF (30 ml), CH 3 OH (10 ml) and H 2 O (10 ml) was added lithium hydroxide (80.2 mg, 3.34 mmol). The resulting mixture was stirred at room temperature overnight. The mixture was extracted with CH2Cl2 (30 ml x 3). The organic phases combined were concentrated under reduced pressure to give the crude product as an off-white solid. The crude product was purified over SiO2 (40 g, 0-10% CH3OH / CH2Cl2) to give a white solid (297 mg, 82% yield). MS (ESI): mass calculated for C2iH23N3? 3S, 397.2; m / z found, 398.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.72 (d, J = 7.8, 1 H), 7.65 (d, J = 8.1, 1 H), 7.40-7.35 (m, 3H), 7.31-7.23 (m, 3H) , 6.83 (d, J = 8.1, 1H), 5.33 (br s, 1 H), 3.99 (s, 2H), 3.87-3.75 (m, 1 H), 3.50 (s, 2H), 2.85 (d, J = 11.4, 2H), 2.14 (t, J = 10.9, 2H), 1.92 (d, J = 12.6, 2H), 1.56-1.43 (m, 2H).

EXAMPLE 254 1- (2-fí4- (Benzothiazol-2-yloxy) -bendp-cyclopropyl-amine.} -et0-4-hydroxy-pyrrolidin-2-one A. [4- (Benzothiazole-2- iloxy) -benzyl] -cyclopropyl-amine A mixture of 4- (benzothiazol-2-yloxy) -benzaldehyde (5.0 g, 19.6 mmol), cyclopropylamine (3.35 g, 58.7 mmol) in CICH2CH2CI (80 mL) was stirred at room temperature environment for 40 min To the resulting reaction mixture was added NaBH (OAc) 3 in portions over 1.5 hr (4 x 2.1 g, 39.2 mmol) The resulting mixture was stirred at room temperature for 24 hr, filtered through diatomaceous earth and rinsed with CH2Cl2 (500 ml) .The filtrate was washed with Saturated aqueous NaHC03 (1 x 250 ml), dried (Na2SO4) and concentrated under reduced pressure to give the crude product as a pale yellow oil. The crude product was purified over S¡02 (330 g, 0-5% CH 3 OH / CH 2 Cl 2) to give a white solid (3.95 g, 68% yield). MS (ESI): mass calculated for C? 7H? 6N2OS, 296.1; m / z found, 297.3 [M + Hf. H NMR (400 MHz, CDCl 3): 7.72 (d, J = 8.1, 1 H), 7.63 (d, J = 8.1, 1 H), 7.40-7.33 (m, 3H), 7.32-7.27 (m, 2H). , 7.24 (t, J = 8.1, 1 H), 3.85 (s, 2H), 2.19-2.12 (m, 1 H), 1.86 (br s, 1 H), 0.48-0.35 (m, 4H). B. (2- {[4- (Benzthiazol-2-yloxy) -benzyl-cyclopropyl-amino-Di-carbamic acid) -butyl ester To a solution of [4- (benzothiazol-2-yloxy) -benzyl] -cyclopropylamine (2.96 g, 10 mmol) in CH3CN (40 ml) at room temperature was added N, N-diisopropylethylamine (3.48 ml, 20 mmol), followed by tert-butyl ester of (2-bromo-ethyl) -carbamic acid. (3.36 g, 15 mmol) The resulting mixture was heated overnight at 60 ° C. The mixture was cooled and dissolved in CH 2 Cl 2 (200 mL), washed with saturated aqueous NaHCO 3 (1 x 25 mL) and H 2 O ( 2 x 25 ml), dried (Na 2 S 4) and concentrated under reduced pressure to give the crude product as a pale yellow solid.The crude product was purified on SiO 2 (120 g, 0-50% ethyl acetate). hexanes) to give a white solid (3.44 g, 78% yield) MS (ESI): mass calculated for C 24 H 29 N 3 O 3 S, 439.2, m / z found, 440.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 8.1, 1 H), 7.64 (d, J = 8.1, 1 H), 7.39-7.22 (m, 6H), 4.75 (br s, 1 H), 3.74 (s, 2H), 3.25 (dd, J = 5.8, 6.1, 2H), 2.65 (t, J = 6.3, 2H), 1.82-1.75 (m, 1 H), 1.43 (s, 9H), 0.54-0.48 (m, 2H), 0.43-0.37 (m, 2H). C. N 1 -R 4 - (Benzothiazol-2-yloxy) -benzyl-N 1 -cyclopropyl-ethane-1,2-diamine. To a solution of (2- {[4- (benzothiazol-2-yloxy) -benzyl] -cyclopropyl-amino} -ethyl) -carbamic acid tert-butyl ester in CH 2 Cl 2 (16 ml) at 0 ° C. ° C was added trifluoroacetic acid in dioxane (4 ml) dropwise. The resulting reaction mixture was stirred at room temperature for 2 hr and concentrated under reduced pressure to give the crude product as a pale yellow oil. The oil was dissolved in CH 2 Cl 2 (100 mL), washed with saturated aqueous NaHCO 3 (1 x 25 mL), dried (Na 2 SO 4) and concentrated under reduced pressure to give the product as a clear oil. MS (ESI): mass calculated for C19H21N3OS, 339.1; m / z found, 340.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.71 (d, J = 8.1, 1 H), 7.61 (d, J = 8.1, 1 H), 7.37-7.18 (m, 6H), 3.75 (s, 2H), 2.76 (t, J = 6.3, 2H), 2.60 (t, J = 6.3, 2H), 1.98 (s, 2H), 1.79 -1.73 (m, 1 H), 0.51-0.45 (m, 2H), 0.42 ^ 0.37 (m, 2H). D. { 1- [2-. { 4 - (Benzothiazol-2-yloxy) -benzyl-cyclopropyl-amino} -ethyl) -hydroxy-pyrrolidin-2-one. To a solution of N 1 - [4- (benzothiazol-2-yloxy) -benzyl} N-Cyclopropyl-ethane-1,2-diamine (1.5 g, 4.4 mmol) in CH3CN (18 ml) at room temperature was added A,? -diisopropylethylamine (1.15 ml, 6.63 mmol), followed by 4- (R) -bromo-3-hydroxy-butyric acid ethyl ester (1.11 g, 5.3 mmol). The resulting mixture was heated to 60 ° C during the night. The mixture was cooled and dissolved in CH2Cl2 (100 mL), washed with saturated aqueous NaHCO3 (1 x 10 mL) and H2O (2 x 10 mL), dried (Na2SO4) and concentrated under reduced pressure to give the product raw as a light brown oil. The crude product was purified on reverse phase CLAP (0-99%, 0.05% TFA in H2O / CH3CN) to give a clear oil (435 mg, 18.3% yield). MS (ESI): mass calculated for C23H25N3O3S, 423.2; m / z found, 424.3 [M + Hf. 1 H NMR (400 MHz, CD 3 OD): 7.64 (d, J = 8.1, 1 H), 7.58-7.54 (m, 2 H), 7.49 (d, J = 8.1, 1 H), 7.37-7.33 (m, 2 H) , 7.26 (t, J = 7.6, 1 H), 7.16 (t, J = 7. 6, 1 H), 4.48 (dd, J = 8.8, 12.9, 2H), 4.32 (t, J = 5.8, 1 H), 3.84-3.75 (m, 1 H), 3. 64-3.56 (m, 2H), 3.38 (t, J = 6.3, 2H), 3.24 (t, J = 10.9, 1 H), 2.73-2.66 (m, 1 H), 2. 59 (dd, J = 6. 3.11.1, 1 H), 2.15 (d, J = 17.2, 1 H), 0.79 (d, J = 6.6H).

EXAMPLE 255 N- (1- [4- (Benzothiazol-2-yloxp-benzylpperidin-4-yl) -N-methyl-methanesulfonamide A. Ter-butyl ester of (1- [4- ( benzothiazol-2-yloxy) -benzyl-piperidin-4-yl) -methyl-carbamic acid, a mixture of 4- (benzothiazol-2-yloxy) -benzaldehyde (4.4 g, 17.2 mmol), tert-butyl methyl-methyl ester piperidin-4-yl-carbamic acid (4.06 g, 18.9 mmol) in CICH2CH2CI (172 mL) was stirred at room temperature for 40 min. To the resulting reaction mixture was added NaBH (OAc) 3 in portions over 1.5 hr (4 x 1.82 g, 34.4 mmol). The resulting mixture was stirred at room temperature for 24 hr, filtered through diatomaceous earth and rinsed with CH2Cl2 (300 mL). The filtrate was washed with saturated aqueous NaHCO3 (1 x 50 ml), dried (Na2SO4) and concentrated under reduced pressure to give the crude product as a pale yellow oil. The crude product was purified on SiO2 (330 g, 0-100% ethyl acetate / hexanes) to give a light yellow foam (3.75 g, 48% yield). MS (ESI): mass calculated for C25H31N3O3S, 453.2; m / z found, 454.5 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 8.1, 1 H), 7.66 (d, J = 8.1, 1 H), 7.41-7.35 (m, 3 H), 7.33-7.23 (m, 3 H) , 4.13-3.94 (m, 1 H), 3.53 (s, 2H), 2.93 (d, J = 11.6, 2H), 2.74 (s, 3H), 2.08 (t, J = 11.6, 2H), 1.81-1.69 (m, 2H), 1.65-1.57 (m, 2H), 1.46 (s, 9H). B. (1- [4- (Benzothiazol-2-yloxy) -benzyl-piperidin-4-yl) -methyl-amine. To a solution of tert-butyl acid ester. { 1- [4- (benzothiazol-2-yloxy) -benzyl] -piperidin-4-ii} methyl-carbamic acid (3.7 g, 8.2 mmol) in CH 2 Cl 2 (41 ml) at 0 ° C was added 4 N HCl in dioxane (8.2 ml, 32.6 mmol) dropwise. The resulting mixture was stirred at room temperature for 2 hr. The desired product was isolated by filtration and washed with Et2O (150 ml) to give a white powder (3.38 g, 97% yield). MS (ESI): mass calculated for C20H23N3OS, 353.2; m / z found, 354.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 8.92 (br s, 1 H), 7.72 (d, J = 8.1, 1 H), 7.63 (d, J = 8.1, 1 H), 7.39-7.33 (m, 3 H), 7.30-7.21 (m, 3H), 3.49 (s, 2H), 2.98-2.86 (m, 3H), 2.63 (s, 3H), 2.08-1.98 (m, 4H), 1.84-1.71 (m, 2H). C. N-. { 1-r4-Benzothiazol-2-oxo-benzyl-piperidin-4-yl) -N-methyl-methanesulfonamide. To a solution of 1- [4- (Benzothiazol-2-yloxy) -benzyl] piperdin-4-yl dihydrochloride} -methyl-amine (354 mg, 1.0 mmol) in CH2Cl (20 mL) at room temperature was added TEA (0.70 mL, 5.0 mmol), followed by methanesulfonyl chloride (0.12 mL, 1.5 mmol). The resulting mixture was stirred at room temperature overnight. The mixture was dissolved in CH2Cl2 (100 mL), washed with saturated aqueous NaHCO3 (1 x 25 mL), dried (Na2SO4) and concentrated under reduced pressure to give the crude product as a pale yellow solid. The crude product was purified over S¡02 (40 g, 0-10% CH 3 OH / CH 2 Cl 2) to give a white solid (378 mg, 88% yield). MS (ESI): mass calculated for C2iH25N3? 3S2, 431.1; m / z found, 432.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 8.1, 1 H), 7.66 (d, J = 8.1, 1 H), 7.41-7.35 (m, 3 H), 7.33-7.23 (m, 3 H) , 3.80-3.70 (m, 1 H), 3.50 (s, 2H), 2.96 (d, J = 11.6, 2H), 2.82 (s, 3H), 2.80 (s, 3H), 2.08 (t, J = 11.6 , 2H), 1.89-1.77 (m, 2H), 1.70-1.60 (m, 2H).

EXAMPLE 256 2-f4- [4- (1 H-Tetrazol-5-ip-p -peridin-1-ylmethyl-1-phenoxy) -benzothiazole A solution of 4- (benzothiazol-2-yloxy) -benzaldehyde (example 251 step A, 620 mg, 2.4 mmol), 4- (1H-tetrazol-5-yl) -piperidine hydrochloride (565 mg, 3.0 mmol), and Et3N (0.43 mL, 3.1 mmol) in 30% THF / CH2Cl2 (35 mL ) was stirred at room temperature for 30 min. To the stirring mixture was added Na (AcO) 3BH (787 mg, 3.7 mmol). After 20 hr, the reaction mixture was added to 10% of / PrOH / H 2 O (50 ml) and the organic layer was separated and dried (MgSO 4). The solvent was removed under reduced pressure to give a light yellow sticky oil. This material was diluted with ethanol (10 ml), heated to 80 ° C, and filtered while hot. To the filtrate was added Et20 (10 ml) and the flask was cooled on ice. A solid formed and was filtered to give a white solid (48 mg, 5% yield). MS (ESI): mass calculated for C2oH2oN6? S, 392.1; m / z found, 393.4 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.95 (d, J = 7.9, 1 H), 7.70 (d, J = 7.9, 1 H), 7.53-7.35 (m, 5H), 7.33 (t, J = 7.9, 1 H), 3.59 (s, 2H), 3.09-3.00 (m, 1H), 2.91 (d, J = 10.8, 2H), 2.22 (t, J = 9.8, 2H), 1.85-1.72 (m, 2H).

EXAMPLE 257 1- (4- [4- (Benzothiazol-2-yloxy) -benzyl-1-piperazin-1-yl) -2-hydroxy-ethanone A. 4- [4- (Benzothiazol-2-yloxy) tert-butyl ester -benzyl-piperazin-1-carboxylic acid. A mixture of 4- (benzothiazol-2-yloxy) -benzaldehyde (2.5 g, 9.8 mmol), piperazine-1-carboxylic acid-2-one tert-butyl ester (3.7 g, 19.6 mmol) and molecular sieves (2.5 g) , triturated, 4A) in CICH2CH2CI (25 ml) was stirred at room temperature for 40 min. To the resulting reaction mixture was added NaBH (OAc) 3 in portions over 1.5 hr (4 x 504 mg, 19.6 mmol). The resulting mixture was stirred at room temperature for 24 hr, filtered through diatomaceous earth and rinsed with CH2Cl2 (200 ml). The filtrate was washed with saturated aqueous NaHCO3 (1 x 50 ml), dried (Na2SO) and concentrated under reduced pressure to give the crude product as a yellow semi-solid. The crude product was purified on SiO2 (120 g, 0-100% acetone / CH2Cl2) to give an off-white solid (1.72 g, 42% yield). MS (ESI): mass calculated for C23H27N303S, 425.5; m / z found, 426.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.74 (d, J = 8.2, 1 H), 7.67 (d, J = 8.2, 1 H), 7.42-7.37 (m, 3H), 7.4-7.25 (m, 3H) , 3.53 (s, 2H), 3.45 (br t, J = 4.9, 4H), 2. 41 (br t, J = 4.5, 4H), 1.46 (s, 9H). . B. 2- (4-Piperazin-1-ylmethyl-phenoxy) -benzothiazole. To a solution of 4- [4- (benzothiazol-2-yloxy) -benzyl] -piperazine-1-carboxylic acid tert -butyl ester (1.7 g, 4.0 mmol) in CH 2 Cl 2 (20 mL) at 0 ° C was added 4 N HCl in dioxane (5 mL, 20 mmol) dropwise. The resulting mixture was stirred at room temperature for 2 hr and concentrated under reduced pressure to give the crude product as a white solid. The crude product was triturated with Et2O (50 ml) and isolated by filtration to give the desired product as a white powder (1.37 g, 87% yield). MS (ESI): mass calculated for C? 8H19N3OS, 325.4; m / z found, 326.3 [M + Hf. 1 H NMR (400 MHz, CD 3 OD): 7.81 (d, J = 8.0, 1 H), 7.77-7.72 (m, 2 H), 7.62 (d, J = 8.2, 1 H), 7.57-7.53 (m, 2 H), 7.45-7.40 (m, 1H), 7.35-7.31 (m, 1 H), 4.45 (s, 2H), 3.62 (br s, 8H). C. 1 -. { 4- [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-1-yl) -2-hydroxy-ethanone. To a mixture of glycolic acid (47 mg, 0.62 mmol) and HOBT (1.25 ml, 0.62 mmol, 0.5 M in DMF) in CH2Cl2 (25 ml) was added 2- (4-piperazin-1-ylmethyl-phenoxy) -benzothiazole (150 mg, 0.42 mmol) followed by EDCI (150 mg, 0.79 mmol). The resulting mixture was stirred at room temperature for 24 hr, diluted with CH 2 Cl (50 ml) and washed with saturated aqueous NaHCO 3 (1 x 20 ml). The organic layer was dried (Na2SO4) and concentrated under reduced pressure to give the crude product as a pale yellow oil. The crude product was purified on SiO2 (40 g, 0-3% 2M NH3 in CH 3 OH / CH 2 Cl 2) to give a white foam (93 mg, 59% yield). MS (ESI): mass calculated for C20H2? N3O3S, 383.5; m / z found, 384.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.74 (d, J = 8.0, 1 H), 7.68 (d, J = 8.0, 1 H), 7.45-7.25 (m, 6H), 4.16 (d, J = 4.1, 2H), 3.71-3.68 (m, 2H), 3.64-3.61 (m, 1 H), 3.55 (s, 2H), 3.32-3.25 (m, 2H), 2.53-2.44 (m, 4H).

EXAMPLE 258 'N-. { 1- [4- (Benzothiazol-2-yloxy) -bencip-piperidin-4-ylmethi-methanesulfonamide A. (1-r4- (Benzothiazol-2-yloxy) -bencip-piperidin-4-tert-butyl ester ilmetil) -carbamic. A mixture of 4- (benzothiazol-2-yloxy) -benzaldehyde (1.0 g, 3.9 mmol), piperidin-4-ylmethyl-carbamic acid tert-butyl ester (1.3 g, 5.9 mmol) and molecular sieves (1.0 g, crushed) , 4A) in CICH2CH2CI (15 ml) was stirred at room temperature for 40 min. To the resulting mixture was added NaBH (OAc) 3 in portions over 1.5 hr (4 x 412 mg, 7.8 mmol). The mixture was stirred at room temperature for 24 hr, filtered through diatomaceous earth and rinsed with CH CI2 (100 mL). The filtrate was washed with saturated aqueous NaHC03 (1 x 50 ml), dried (Na2SO4) and concentrated under reduced pressure to give the crude product as a semi- solid yellow. The crude product was purified over SiO2 (40 g, 0-100% acetone / CH2Cl2) to give a white foam (890 mg, 50% yield). MS (ESI): mass calculated for C25H3iN3? 3S, 453.6; m / z found, 454.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.74 (d, J = 8.0, 1 H), 7.67 (d, J = 8.0, 1 H), 7.41-7.36 (m, 3H), 7.32-7.24 (m, 3H), 4.59 (br s, 1H), 3.50 (s, 2H) ,. 3.06-3.00 (m, 2H), 2.94-2.88 (m, 2H), 1.97 (t, J = 11.4, 2H), 1.68 (d, J = 11.4, 2H), 1.44 (s, 9H), 1.22-1.33 (m, 2H). B. C- (1-r 4 - (Benzothiazol-2-yloxy) -bencip-piperidin-4-yl) -methylamine. To a solution of tert-butyl acid ester. { 1- [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-ylmethyl} Carboxyme (866 mg, 1.9 mmol) in CH 2 Cl 2 (5 mL) at 0 ° C was added 4N HCl in dioxane (2.4 mL, 9.5 mmol) dropwise. The resulting mixture was stirred at room temperature for 24 hr and concentrated under reduced pressure to give the crude product as a white solid. The crude product was triturated with Et2O (50 ml) and isolated by filtration to give the desired product as a white powder (813 mg, 100% yield). MS (ESI): mass calculated for C20H23N3OS, 353.5; m / z found, 354.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.80 (d, J = 8.0, 1 H), 7.69 (d, J = 8.6, 2H), 7.60 (d, J = 8.0, 1 H), 7.51 (d, J = 8.6, 1 H), 7.42-7.38 (m, 1 H), 7.33-7.28 (m, 1 H), 4.37 (s, 2H), 3.78 (brd, J = 12.7, 1 H), 2H), 3.13- 3.04 (m, 2H), 2.89 (d, J = 6.6, 2H), 2.08-1.92 (m, 3H), 1.68-1.56 (m, 2H). C, N-. { 1- [4- (Benzothiazol-2-yloxy) -benzyl-piperidin-4-ylmethyl) - methanesulfonamide. To a mixture of C-. { 1- [4- (benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -methanamine (150 mg, 0.39 mmol) in CH 2 Cl 2 (5 mL) was added Et 3 N (400 μL, 2.86 mmol). The resulting mixture was cooled to 0 ° C and CH3SO2CI was added via syringe (41 μL, 0.52 mmol). The mixture was stirred at room temperature for 24 hr, diluted with CH 2 Cl 2 (10 ml) and washed with saturated aqueous NaHCO 3 (1 x 5 ml). The organic layer was dried (Na 2 SO 4) and concentrated under reduced pressure to give the crude product as a white solid. The crude product was purified on SiO2 (10 g, 0-3% 2M NH3 in CH3OH / CH2Cl2) to give a white solid (112 mg, 67% yield). MS (ESI): mass calculated for C21H25N3O3S2, 431.6; m / z found, 432.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.74 (d, J = 8.0, 1 H), 7.67 (d, J = 8.0, 1 H), 7.42-7.36 (m, 3 H), 7.33-7.25 (m, 3 H) , 4.25 (br t, J = 6.6, 1 H), 3.51 (s, 2H), 3.04 (d, J = 6.6, 2H), 2.96 (s, 3H), 2.91-2.84 (m, 2H), 1.98 ( t, J = 11.7, 2H), 1.74 (brd, J = 12.7, 2H), 1.60-1.48 (m, 2H), 1.36-1.24 (m, 2H).

EXAMPLE 259 raNA0 3-. { 1- [4- (Benzothiazol-2-yloxy) -benzyl-1-piperidin-4-yl) -oxazolidin-2-one A. A salt of 3-piperidin-4-yl-oxazolidin-2-one hydrochloride. To a solution of 1-benzyl-4-piperidinone (10.3 g, 54 mmol) and ethanolamine (13.2 ml, 218 mmol) in CH3OH (20 ml) was added sodium cyanoborohydride (10.2 g, 163 mmol) and trifluoromethanesulfonic acid (5 ml) and the reaction was stirred at 23 ° C for 3 days. The mixture was cooled to 0 ° C and 12 N HCl was slowly added until evolution of gas ceased and the resulting mixture was stirred for 3 hr. additional The mixture was filtered and the filtrate was concentrated under reduced pressure. The crude oil was redissolved in H2O (50 ml), the solution was made basic by the addition of 10N NaOH. The mixture was extracted with CH2Cl2 (8 x 70 mL). The combined CH2Cl2 extracts were dried and concentrated under reduced pressure to give the crude product (12.0 g, 95%). A solution of 2- (1-benzyl-piperidin-4-ylamino) -ethanol (3.6 g, 15.3 mmol) in CICH2CH2CI (5 mL) was treated with carbonyldiimidazole (CD1) (2.6 g, 16 mmol) and the mixture was stirred at 23 ° C for 30 min. The mixture was diluted with CH2Cl2 (100 mL), washed with H2O (1 x 50 mL) and saturated aqueous NaHCO3 (1 x 50 mL), dried, and concentrated under reduced pressure to give 2.85 g (65%) of 3- (1-benzyl-piperidin-4-yl) -oxazolidin-2-one. To a solution of 3- (1-benzyl-p-peridin-4-yl) -oxazolidin-2-one (2.3 g, 8.8 mmol) in CICH2CH2Cl (40 mL) was added a-chloroethylacetyl chloride (1.5 g, 10.6 g. mmoles) and the mixture was heated at 100 ° C for 90 min. The mixture was cooled to 23 ° C and concentrated under reduced pressure. The crude residue was dissolved in CH 3 OH and heated to reflux for 1 hr. The mixture was cooled to 0 ° C and concentrated under reduced pressure to give the title compound (1.89 g, 99%). EM (ESI): exact mass calculated for C8Hi4N2O2, 170.1; m / z found, 171.2 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 8.97 (br s, 2 H), 4.27 (dd, J = 9.1, 7.8, 2 H), 3.80 (tt, J = 11.8, 4.2, 1 H), 3.49 (dd, J = 8.0, 6.6, 1 H), 3.30 (brd, J = 12.7, 2H), 2.97 (dt, J = 12.6, 2.3, 2H), 1.90 (ddd, J = 16.6, 13.0, 4.1 2H), 1.86- 1.75 (m, 2H). B. [4- (Benzothiazol-2-yloxy) -phenyl-1-methanol. To a mixture of 4-hydroxybenzyl alcohol (12 g, 97 mmol) in CH3CN (200 ml) containing K2CO3 (22 g, 159 mmol) was added 2-chlorobenzothiazole (22 g, 130 mmol) and the mixture was heated to reflux for 72 hr. The mixture was cooled to room temperature, filtered, and concentrated under reduced pressure to give the crude product as a golden oil. The crude oil was purified SiO2 (300 g, 5% acetone / CH2CI2) to give a colorless and clear oil. (15 g, 60% yield). MS (ESI): exact mass calculated for C? 4 HnNO2S, 257.1; m / z found, 258.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.92 (d, J = 7.4, 1 H), 7.69 (d, J = 8.0, 1 H), 7.50-7.31 (m, 5H), 7.32 (t, J = 7.5 , 1 H), 5.32 (t, J = 5.7, 1 H), 4.55 (d, J = 5.7, 2H). C. 2- (4-Chloromethyl-phenoxy) -benzothiazole. To a mixture of [4- (benzothiazol-2-yloxy) -phenyl] -methanol (11 g, 43 mmol) in CH 2 Cl 2 (100 mL) containing triethylamine (9 mL, 65 mmol) at 5 ° C was added dropwise to drop for 15 minutes thionyl chloride (4 ml g, 55 mmol). The ice bath was stirred and the mixture was warmed to room temperature and stirred for 24 hr. The The mixture was washed once with saturated K2CO3 (100 ml), dried (MgSO4), and concentrated under reduced pressure to give a black oil. The crude oil was purified SiO2 (300 g, 100% CH2CI2) to give a light orange oil. (10 g, 84% yield). MS (ESI): exact mass calculated for C14H10CINOS, 275.0; m / z found, 276.2 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.95 (d, J = 7.3, 1 H), 7.70 (d, J = 7.6, 1 H), 7.59 (d, J = 8.6, 2H), 7.47 (d, J = 8.6, 2H), 7.37 (t, J = 7.4, 1 H), 7.33 (t, J = 7.5, 1 H), 4.84 (s, 2H). D. 3-. { 1-f4- (Benzothiazol-2-yloxy) -bencip-piperidin-4-yl) -oxazolidin-2-one. To a mixture of 2- (4-chloromethyl-phenoxy) -benzothiazole (670 mg, 2.4 mmol) in CH3CN (15 ml) containing K2CO3 (544 mg, 3.9 mmol) was added 3-piperidin-4 hydrochloride salt. il-oxazolidin-2-one (355 mg, 1.7 mmol) and the mixture was heated at 60 ° C for 24 hr. The mixture was cooled to room temperature, filtered, and concentrated under reduced pressure to give the crude product as a golden oil. The crude oil was purified Si02 (12 g, acetone) to give a white solid (591 mg, 84% yield). MS (ESI): mass calculated for C22H23N3O3S, 409.2; m / z found, 410.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.94 (d, J = 8.7, 1 H), 7.70 (d, J = 7. 5, 1 H), 7.48-7.37 (m, 5H), 7.33 (d, J = 8.0, 1 H), 4.25 (T, J = 7.7, 2H), 3.60-3.42 (m, 5H), 2.85 (d , J = 11.5, 2H), 2.04 (t, J = 11.4, 2H), 1.78-1.58 (m, 4H).

EXAMPLE 260 4-. { 1-r 4 - (Benzothiazol-2-yloxy) -benzyl-piperdin-4-yl> -morpholin-3-one A. 4-Piperidin-4-yl-morpholin-3-one. To a solution of 1-benzyl-4-piperidinone (10.3 g, 54 mmole) and ethanolamine (13.2 ml, 218 mmole) in CH 3 OH (20 ml) was added sodium cyanoborohydride (10.2 g, 163 mmol) and trifluoromethanesulfonic acid (5 ml) and the reaction mixture was stirred at 23 ° C for 3 days. The mixture was cooled to 0 ° C and 12 N HCl was slowly added until evolution of gas ceased and the resulting mixture was stirred for an additional 3 hr. The mixture was filtered and the filtrate was concentrated. The crude oil was redissolved in H 2 O (50 ml), and the solution made basic by the addition of 10 N NaOH. The mixture was extracted with CH 2 Cl 2 (8 x 70 ml). The combined CH2Cl2 extracts were dried and concentrated under reduced pressure to give 12.0 g (95% yield) of crude product. A solution at 0 ° C of 2- (1-benzyl-piperidin-4-ylamino) -ethanol (2.13 g, 9.1 mmol) in ethanol (11 ml) and H2O (5 ml) was treated simultaneously with chloroacetyl chloride (1.8 ml, 22.7 mmol) and 35% aqueous NaOH solution and the mixture was stirred below 20 ° C for 3 hr. The reaction was diluted with H O (20 mL) and extracted with ethyl acetate (2 x 50 mL). The combined organic layers were washed with brine, dried, and concentrated to give 1.83 g (66% yield) of 4- (1-benzyl-piperidin-4-yl) -morpholin-3-one. To a solution of 4- (1-benzyl-piperidin-4-yl) -morpholin-3-one (1.1 g, 3.9 mmol) in CICH2CH2CI (20 mL) was added a-chloroethylacetyl chloride (660 mg, 4.6 mmol) and the reaction mixture was added. heated at 100 ° C for 16 hr. The mixture was cooled to 23 ° C and concentrated under reduced pressure. The resulting crude material was purified on Si02 (12 g, 0-10% 2M ammonia in CH3OH / CH2Cl2) to give 282 mg (53% yield) of 4-piperidin-4-yl-morpholin-3-one. MS (ESI): exact mass calculated for C8Hi4N2? 2, 184.1; m / z found, 185.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 3.72 (s, 2H), 2.94 (t, J = 6.6, 2H), 2.55 (t, J = 3.6, 2H), 2.46 (tt, J = 10.3, 3.7, 1 H ), 1.92 (dd, J = 12.3, 2.3, 2H), 1.82-1.70 (m, 2H), 1.70-1.60 (m, 1 H), 1.40-1.02 (m, 4H). B. 4- (1-r 4 - (Benzothiazol-2-yloxy) -benzyl-Piperid-4-yl) -morpholin-3-one. The title compound was prepared according to example 259, step D. MS (ESI): exact mass calculated for C 24 H 27 N 3 O 3 S ?, 423.16; m / z found, 424.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.77 (dd, J = 8.1, 0.6, 1 H), 7.70 (dd, J = 7.9, 0.7, 1H), 7.45-7.40 (m, 2H), 7.36-7.28 (m, 4H), 4.57 (tt, J = 12.1, 4.2, 1 H), 4.22 (s, 2H), 3.90 (t, J = 4.9, 2H), 3.56 (s, 2H), 3.34 (t, J = 5.1, 2H), 3.01 (br d, J = 11.6, 2H ), 2.18 (ddd, J = 11.7, 11.7, 2.2, 2H), 1.79 (dddd, J = 12.1, 12. 1, 12.0, 3.8, 2H), 1.72-1.65 (m, 2H).

EXAMPLE 261 H (R) 1 -d - (2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl) -piperidin-4-yl) -4-hydroxy-pyrrolidin-2-one A. Acetic acid salt (R) -4-hydroxy-1-piperidin-4-yl-pyrrolidin-2-one. A solution of 4-amino-1-benzylpiperidine (1.0 g, 5.2 mmol) and N, N-diisopropylethylamine (2.3 ml, 13.1 mmol) in CH3CN (12 ml) was treated with (R) -4-bromo-3-hydroxybutyrate (1.4 g, 6.8 mmol) and the mixture was heated at 65 ° C for 48 hr. The mixture was cooled and diluted with ethyl acetate (70 ml) and washed with H2O (20 ml). The organic layer was dried and concentrated under reduced pressure and the crude residue was purified on SiO2 (12 g, 0-5% 2M ammonia in CH3OH / CH2Cl2). The product was dissolved in ethanol (20 ml) and heated at 80 ° C for 48 hr. The mixture was concentrated under reduced pressure and the crude residue was purified over SiO2 (12 g, 0-5% 2M ammonia in CH3OH / CH2Cl2) to give 346 mg (25% yield) of 1- (1-benzyl-piperidine) -4-yl) -4-hydroxy-pyrrolidin-2-one. A solution of 1- (1-benzyl-piperidin-4-yl) -4-hydroxy-pyrrolidin-2-one (346 mg, 1.3 mmol) in ethanol (7 ml) was treated with Pd (OH) 2 (60 mL). mg) and the mixture was charged with gaseous hydrogen in a Parr apparatus at 3515 kg / cm 2 and stirred for 5 days. The mixture was filtered through diatomaceous earth and concentrated to give 280 mg (91% yield) of the title compound, which it was used without purification in subsequent reactions. MS (ESI): exact mass calculated for C9H? 6N202, 184.1; m / z found, 185.2 [M + Hf. B. (R) 1- (1- (2-r4- (Benzothiazol-2-yloxy) -phenoxy-pyridin-4-yl) -4-hydroxy-pyrrolidin-2-one The title compound was prepared according to Example 24 using acetic acid salt 4-hydroxy-1-piperidin-4-yl-pyrrolidin-2-one MS (ESI): exact mass calculated for C2 H27N3O4S ?, 453.2; m / z found , 454.5 [M + Hf. H NMR (400 MHz, CDCl 3): 7.77 (dd, J = 8.1, 0.5, 1 H), 7.69 (dd, J = 8.0, 0.7, 1 H), 7.42 (dt, J = 8.5, 1.3, 1 H), 7.34-7.27 (m, 5H), 7.02-6.97 (m, 2H), 4.58-4.53 (m, 1 H ), 4.18-4.04 (m, 3H), 3.62 (dd, J = 10.7, 5.6, 1 H), 3.34 (dd, J = 10.7, 2.2, 1 H), 3.15-3.08 (m, 1 H), 2.87 (t, J = 5.7, 2H), 2.75 (dd, J = 17.2, 6.6, 1 H), 2.44 (dd, J = 17.2, 2.6, 1 H), 2.34-2.24 (m, 2H), 1.90-1.68 (m, 3H).

EXAMPLE 262 2- (4- {2-f4- (1 H-Tetrazol-5-iO-p-peridin-1-ip-ethylHenoxy) -benzothiazole A. [4- (Benzothiazol-2-yloxy) -phenyl-1- acetaldehyde, a solution of methyl ester of (4-hydroxy-phenyl) -acetic acid (11.2 g, 62 mmol) and 2-chlorobenzothiazole (9.5 g ml, 56 mmol) in CH3CN was treated with fine powdered Cs2CO3 (27 g, 84 mmol) ), and the resulting mixture was stirred at 40 ° C for 17 hr and 60 ° C for 2 hr. The reaction mixture was filtered through diatomaceous earth, and the filtrate was concentrated under reduced pressure. The crude solid was purified by dissolving in ethyl acetate (350 ml) and washed with 10% NaOH (3 x 30 ml), 0.5 M citric acid (1 x 30 ml), saturated aqueous NaHCO3 (1 x 30 ml). ), brine (1 x 30 ml), then dried over NaSO4, filtered and concentrated under reduced pressure to give 16 g (95% yield) of [4- (benzothiazol-2-yloxy] methyl ester. ) -phenyl] -acetic acid as a white solid. A solution of [4- (benzothiazol-2-yloxy) -phenyl] -acetic acid methyl ester (5.4 g, 18 mmol) in 80 ml of toluene at -90 ° C was treated by the dropwise addition of a solution of 1.0 M diisobutylaluminum hydride in hexanes (27 ml, 27 mmol). The reaction was slowly warmed to -68 ° C for 30 min and then quenched by the addition of methanol (2.0 mL). The reaction mixture was warmed to -20 ° C and diluted with diethyl ether (100 ml) and 2.0 M HCl (60 ml) and stirred vigorously for 30 min. The organic layer was separated, washed with saturated aqueous NaHC 3, dried over Na 2 SO 4, filtered and concentrated to give the title compound (4.84 g, 99% yield). 2- (4- (2-y4- (1 H-Tetrazol-5-y-piperidin-1-yl] -ethyl) -phenoxy) -benzothiazole A solution of [4- (benzothiazol-2-yloxy) ) -phenyl] -acetaldehyde (628 mg, 2.3 mmol) and 4- (1 H-tetrazol-5-yl) -piperidine (443 mg, 2.34 mmol) in CH2Cl2 (10 ml) containing triethylamine (360 μL, 2.6 mmol) was treated with sodium triacetoxyborohydride (599 mg, 2.7 mmol) and the mixture was stirred at room temperature for 24 hr. The mixture was washed with saturated aqueous NaHCO3 (15 ml), dried (MgSO4), and concentrated under reduced pressure to give a white solid. The solid was washed with diethyl ether and dried with air to give the product as a white solid (214 mg, 23% yield). MS (ESI): mass calculated for C2? H22N6OS, 406.2; m / z found, 407.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.93 (d, J = 7.9, 1 H), 7.69 (d, J = 7.7, 1 H), 7.48-7.30 (m, 6H), 3.10 (d, J = 11.6, 2H), 3.08-2.97 (m, 1H), 2.87 (t, J = 6.7, 2H), 2.72 (t, J = 8.6, 2H), 2.34 (t, J = 11.0, 2H), 2.01 (d , J = 11.2, 2H), 1.79 (q, J = 9.9, 2H).

EXAMPLE 263 (1- {2-f4- (Benzothiazol-2-yloxy) -phenoxy-ethyl) -piperidin-2-yl) -methanol The title compound was prepared according to the procedure of Example 24 using piperidin-2- il-methanol. MS (ESI): mass calculated for C 21 H 24 N 2 O 3 S, 384.2; m / z found, 385.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.91 (d, J = 7.9, 1 H), 7.68 (d, = 8.0, 1H), 7.42 (t, J = 7.3, 1H), 7.37 (d, J = 9.0, 2H), 7.31 (t, J = 8.1, 1H), 7.05 (d, J = 9.1, 2H), 4.43 (t, J = 5.3, 1H), 4.08 (t, J = 6.2, 2H), 3.60-3.51 (m, 1H), 3.48-3.39 (m, 1H), 3.17-3.09 (m, 1H), 2.94 -2.84 (m, 1H), 2.80-2.70 (m, 1H), 2.33 (t, J = 10.4, 2H), 1.62 (d, J = 9.3, 2H), 1.58-1.47 (m, 1H), 1.47- 1.35 (m, 1H), 1.35-1.20 (m, 2H).

EXAMPLE 264 Ethyl (1- {2-f4- (benzothiazol-2-yloxy) -phenoxy-ethyl} -1H-tetrazol-5-yl) -acetic acid ethyl ester The title compound was prepared according to the procedure of Example 24 using (1 H-tetrazol-5-yl) -acetic acid ethyl ester. MS (ESI): mass calculated for C2oH? 9N50S, 425.1; m / z found, 426.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.91 (d, J = 8.0, 1H), 7.67 (d, J = 7.6, 1H), 7.46-7.36 (m, 3H), 7.32 (t, J = 8.4, 1H), 7.03 (d, J = 9.1, 2H), 4.88 (t, J = 5.0, 2H), 4.43 (t, J = 5.0, 2H), 4.35 (s, 2H), 4.14 (q, J = 7.1 , 2H), 1.20 (t, J = 7.1, 3H).

EXAMPLE 265 (1- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-3-yl) -methanol The title compound was prepared according to the procedure of Example 24 using piperidin-3-yl-methanol. MS (ESI): exact mass calculated for C21H2 N2O3S1, 384.2; m / z found, 385.1 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.77 (d, J = 8.1, 1 H), 7.68 (d, J = 7.9, 1 H), 7.42 (dt, J = 8.4, 1.2, 1 H), 7.34-7.26. (m, 3H), 7.02-6.97 (m, 2H), 4.15 (t, J = 5.9, 2H), 3.68 (dd, J = 10.6, 5.2, 1 H), 3.56 (dd, J = 10.4, 6.3, 1 H), 3.00 (d, J = 5.3, 1 H), 2.84 (t, J = 5.9, 2H), 2.83-2.79 (m, 1 H), 2.75-2.60 (m, 1 H), 2.30 (t , J = 9.5, 1 H), 2.16 (t, J = 9.5, 1 H), 1.92-1.78 (m, 2H), 1.77-1.68 (m, 1 H), 1.68-1.60 (m, 1 H), 1.24-1.12 (m, 1 H).

EXAMPLE 266 2- Hydrochloride. { 4-r2- (5-Piperidin-4-yl-tetrazol-2-yl) -ethoxy] -phenoxyl-benzothiazole A. 4- (2-. {2- 2- (4- (benzothiazole-) tert-butyl ester 2-Iloxo-phenoxy-1-ethyl-2H-tetrazol-5-yl) -piperidin-1-carboxylic acid. 2- [4- (2-bromo-ethoxy) -phenoxy] -benzothiazole (example 9; 500 mg, 1.4 mmol) and 4- (2H-tetrazol-5-yl) -piperidine-1-tert-butyl ester carboxylic acid (404 mg, 1.6 mmol) in CH3CN (10 ml) was added Cs2CO3 (537 mg, 1.7 mmol). The mixture was heated at 60 ° C for 20 hr and then filtered. The filtrate was concentrated under reduced pressure to a light golden oil, which was purified on SiO2 (40 g, 0-15% acetone / CH2Cl2) to give a white solid (483 mg, 65% yield). CCD (SiO2, 15% acetone / CH2Cl2): Rf = 0.84. MS (ESI): mass calculated for C 26 H 3 o N 6 O 4 S, 522.2; m / z found, 523.2 [M + Hf. H NMR (400 MHz, DMSO-d6): 7.90 (d, J = 7.7, 1 H), 7.67 (d, J = 7. 9, 1 H), 7.42 (t, J = 7.1, 1 H), 7.36 (d, J = 6.8, 2H), 7.31 (t, J = 8.1, 1 H), 7.01 (d, J = 6.9, 2H ), 5.05 (t, J = 4.7, 2H), 4.57 (t, J = 4.8, 2H), 3.92 (d, J = 12.4, 2H), 3.20-3.12 (m, 1H), 2.96 (br. 2H), 1.97 (dd, J = 13.3, 3, 2H), 1.65-1.52 (m, 2H), 1.40 (s, 9H). B. 2- (4-r2- (5-Piperidin-4-yl-tertrazole-2-yO-ethoxyl-phenoxyl-benzothiazole hydrochloride To a stirred solution of 4- (2-. 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl.} -2H-tetrazol-5-yl) -piperidin-1-carboxylic acid (440 mg0.84 mmole) in 88% formic acid (7.5 ml) was added concentrated HCl (75 μl, 0.009 mmol). The mixture was stirred at room temperature for 20 hr and concentrated under reduced pressure to give a clear, colorless oil. The oil was dried under high vacuum for 2 hr and a white solid was obtained (337 mg, 99% yield). EM (ESI): mass calculated for C2? H22N6O2S, 422.2; m / z found, 423.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.92 (d, J = 7.9, 1 H), 7.67 (d, J = 8.0, 1 H), 7.42 (t, J = 7.8, 1 H), 7.39 (d, J = 9.4, 2H), 7.32 (t, J = 7.4, 1 H), 5.08 (t, J = 4.7, 2H), 4.58 (t, J = 4.8, 2H), 3.40-3.22 (m, 4H), 3.03 (q, J = 15.1, 2H), 2.16 (d, J = 14.1, 2H), 1.92 (q, J = 14.3, 2H).

EXAMPLE 267 7- (2-r4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl) -4-spiro- [3-phthalide] -piperidine The title compound was prepared according to the procedure of example 24 using 4-spiro - [3-phthalide] -piperidine. MS (ESI): mass calculated for C27H24N2O4S, 472.2; m / z found, 473.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.92 (d, J = 7.9, 1 H), 7.83 (d, J = 7. 7, 1 H), 7.82-7.75 (m, 2H), 7.70 (d, J = 10.2, 1 H), 7.61 (t, J = 11.6, 1 H), 7.48- 7.38 (m, 3H), 7.32 ( t, J = 8.2, 1 H), 7.10 (d, J = 9.1, 2H), 4.19 (t, J = 5.7, 2H), 3.05 (d, J = 13.0, 2H), 2.86 (t, J = 5.6 , 2H), 2.50-2.44 (m, 2H), 2.28 (t, J = 13.5, 2H), 1. 65 (d, J = 12.5, 2H).

EXAMPLE 268 Ethyl ester of acid 1-. { 3- [4- (Benzothiazol-2-yloxyHenyl] -propyl.}. -piperidine-4-carboxylic acid The title compound was prepared according to the procedure of Example 35 using piperidine-4-carboxylic acid ethyl ester for the step A and 2-chlorobenzothiazole for step C. MS (ESI): mass calculated for C 24 H 28 N 2 O 3 S, 424.2, m / z found, 425.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.92 (d, J = 7.9, 1 H), 7.68 (d, J = 8.0, 1H), 7.43 (t, J = 8.1, 1 H), 7.38-7.28 (m, 5H), 4.05 (q, J = 7.1, 2H), 2.78 (d, J = 11.3, 2H), 2.63 (t, J = 7.5, 2H), 2.25 (t, J = 7.0, 3H), 1.93 (t, J = 13.2, 2H), 1.84-1.68 (m, 4H) ), 1.54 (q, J = 14.9, 2H), 1.18 (t, J = 7.1, 3H).

EXAMPLE 269 2-f4- (Benzothiazol-2-yloxy) -phenyl] -ethylamine hydrochloride A. [2- (4-Hydroxy-phenyl) -etip-carbamic acid tert-butyl ester. To a stirring solution of di-tert-butyl dicarbonate (34.2 g, 157 mmol) in THF (200 ml), tyramine (21.3 g, 155 mmol) in THF (100 ml) was added over 1 hr. The mixture was stirred for 2.5 hr and concentrated under reduced pressure to give a light golden oil which was purified on SiO2 (300 g, 0-25% acetone / CH2Cl2). The desired fractions were combined and concentrated under reduced pressure to give the product as a clear pink oil (37 g, 100% yield). CCD (S¡O2, 5% acetone / CH2Cl2): Rf = 0.31. MS (ESI): mass calculated for C? 3H? 9NO3, 237.1; m / z found, 260.2 [M + Naf. 1 H NMR (400 MHz, DMSO-d 6): 9.16 (s, 1 H), 6.96 (d, J = 8.4, 2H), 6. 82 (s, 1 H), 6.66 (d, J = 8.4, 2H), 3.05 (q, J = 8.3, 2H), 2.56 (t, J = 8.1, 2H), 1. 37 (s, 9H). B. Ter-butyl acid ester. { 2-f4- (benzothiazol-2-yloxy) -phenyl-1-ethyl} -carbámico The title compound was prepared following the procedure of Example 30, Step B using [2- (4-hydroxy-phenyl) -ethyl] -carbamic acid tert-butyl ester to give a white solid (9 g, 56% yield) ). CCD (SiO2, CH2Cl2): Rf = 0.19. MS (ESI): mass calculated for C20H22N2O3S, 370.1; m / z found, 371.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.92 (d, J = 7.9, 1 H), 7.68 (d, J = 8. 0, 1 H), 7.48-7.30 (m, 6H), 7.34 (t, J = 7.8, 1 H), 3.09 (d, J = 7.1, 2H), 2.75 (t, J = 7.4, 2H), 1.38 (s, 9H).

C. r2-f4- (Benzothiazol-2-yloxy) -ethylamine hydrochloride. The title compound was prepared according to the procedure of example 266, step B to give a white solid (6.4 g, 100% yield). MS (ESI): mass calculated for C? 5H14N2OS, 270.1; m / z found, 271.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 8.05 (br s, 2H), 7.94 (d, J = 7.8, 1 H), 7.68 (d, J = 7.8, 1 H), 7.53-7.39 (m, 5H ), 7.34 (t, J = 7.9, 1H), 3.09 (t, J = 6.9, 2H), 2.95 (t, J = 8.6.2H).

EXAMPLE 270 2- (4-f2- [4- (1 H-Tetrazol-5-yl) -piperidin-1-yl-ethoxy-phenoxy) -benzothiazole A. methyl ester of acid r4- (benzothiazol-2-yloxy-phenoxy] -acetic To a stirring mixture of sodium hydride (7.5 g, 187.5 mmol) in DMSO (100 mL) was added hydroquinone (10.0 g, 91.2 mmol) for 30 min.The mixture was then heated at 80 ° C for 2 minutes. hr and cooled to room temperature To the stirring mixture was added 2-chlorobenzothiazole (11.3 ml, 91.3 mmoles) for 30 minutes and the mixture was stirred at room temperature for 24 hr. To the mixture was added methyl 2-bromoacetate. (8.6 ml, 90.8 mmol) for 30 minutes and the mixture was stirred for 24 h.

H20 (1 L) was added to the mixture and the product was extracted with Et20 (2 x 500 ml), dried (MgSO), and concentrated under reduced pressure to give a beige solid. The solid was stirred in CH2Cl2 (200 ml) and filtered to give the product as a white solid (24.2 g, 84% yield). MS (ESI): mass calculated for Ci6H? 3NO4S, 315.1; m / z found, 316.2 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.92 (d, J = 8.0, 1 H), 7.66 (d, J = 8.1, 1 H), 7.47-7.40 (m, 3H), 7.32 (t, J = 7.5, 1 H), 7.07 (d, J = 8.6, 2H), 4.87 (s, 2H), 3.73 (s, 3H). B. [4- (Benzothiazol-2-yloxO-phenoxy-1-acetaldehyde) To a stirring solution of [4- (benzothiazol-2-yloxy) -phenoxy] -acetic acid methyl ester (1.0 g, 3.17 mmol) in THF (15 ml) at -78 ° C DIBAL-H (5 ml, 5 mmol) was added while maintaining the temperature below -75 ° C. The mixture was stirred at -72 ° C for 4 hr and quenched with H20 (10 mL), extracted with CH2Cl2 (2 x 10 mL), dried (MgSO4), and concentrated under reduced pressure to give a light golden oil (708 mg, 78% yield) .MS (ESI) ): mass calculated for C15HnNO3S 285.1; m / z found, 286.3 [M + Hf. O 2- (4- (2-f4- (1 H-Tetrazol-5-yl) -piperidin-1-y-ethoxyMenoxH-benzothiazole The title compound was prepared according to the procedure of Example 262, step B using 4- (1 H-tetrazol-5-yl) -piperidine MS (ESI): mass calculated for C2? H22N6O2S, 422.2; m / z found, 422.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.93 (d, J = 7.8, 1 H), 7.68 (d, J = 7.9, 1H), 7.49-7.40 (m, 3H), 7.33 (t, J = 7.3 , 1H), 7.14 (d, J = 9.0, 2H), 4.43 (t, J = 4.3, 2H), 3.62-3.43 (m, 4H), 3.25-3.10 (m, 3H), 2.25 (d, J = 12.0, 2H), 2.18-2.02 (m, 2H).

EXAMPLE 271 2- (4-Piperidin-1-ylmethyl-phenoxy) -benzoxazole A. 4-Piperidin-1-methylmethyl phenol. A mixture of 4-hydroxybenzaldehyde (10 g, 82 mmol), piperidine (16 mL, 164 mmol), and molecular sieves (10 g, triturated, 4 A) in CICH2CH2CI (150 mL) was stirred at room temperature for 40 min. To the resulting mixture was added NaBH (OAc) 3 in portions over 1.5 hr (7 x 5 g, 164 mmol). The mixture was stirred at room temperature for 24 hr. The resulting mixture was diluted with CH 2 Cl 2, (300 mL) filtered through diatomaceous earth and rinsed with additional CH 2 Cl 2 (100 mL). The filtrate was washed with saturated aqueous NaHCO3 (3 x 150 ml), and extracted with 25% isopropanol / CHCl3, dried (Na2S4) and concentrated under reduced pressure to give the crude product as an orange semi-solid. The crude product was purified on SiO2 (120 g, 0-100% acetone / CH2Cl2) to give a yellow solid (3.08 g, 48% yield). MS (ESI): mass calculated for C? 2H1 NO, 191.1; m / z found, 192.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.18 (d, J = 8.4, 2H), 6.75 (d, J = 8.4, 2H), 3.83 (s, 2H), 2.81 (br s, 4H), 1.77 (quintuplet, J = 5.7, 4H), 1.54 (br s, 2H). B. 2- (4-Piperidin-1-methylmethyl-phenoxy) -benzoxazoi. The title compound was prepared according to the procedure of example 13, step B using 4-piperidin-1-methylmethyl phenol. MS (ESI): mass calculated for C? 9H2oN2? 2S, 308.2; m / z found, 309.4 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.64 (d, J = 3.1 Hz, 1 H), 7.52 (d, J = 8.9 Hz, 1 H), 7.3 (q, J = 8.3 Hz, 4H), 7.34-7.26 (m, 2H), 3.45 (s, 2H), 2.33 (br. S, 4H), 1.57-1.46 ( m, 4H), 1.44-1.32 (m, 2H).

EXAMPLE 272 f4- (Benzothiazol-2-yloxy) -bencip-cyclohexyl-ethyl-amine The title compound was prepared according to the procedure of example 259, step D using cyclohexyl-ethyl-amine. MS (ESI): mass calculated for C22H26N2OS, 366.2; m / z found, 367.4 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.93 (d, J = 8.5, 1 H), 7.70 (d, J = 8. 0, 1 H), 7.45 (t, J = 8.5, 3H), 7.37 (d, J = 8.6, 2H), 7.33 (t, J = 8.3, 1 H), 3.63 (s, 2H), 2.58-2.41 (m, 3H), 1.76 (t, J = 11.9, 4H), 1.58 (d, J = 12.1, 1 H), 1.32-1.01 (m, 5H), 0.95 (t, J = 7.1, 3H).

EXAMPLE 273 [4- (Benzothiazol-2-yloxy) -bencip-cyclopropylmethyl-propyl-amine The title compound was prepared according to the procedure of Example 259, step D using (2-cyclopropyl-methylene) -eti-amine. MS (ESI): mass calculated for C2? H24N2OS, 352.2; m / z found, 353.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.94 (d, J = 8.0, 1 H), 7.70 (d, J = 8.1, 1 H), 7.45 (t, J = 8.5, 3H), 7.39 (d, J = 8.6, 2H), 7.33 (t, J = 8.0, 1 H), 3.66 (s, 2H), 2.53-2.44 (m, 3H), 2.32 (d, J = 6.5, 2H), 1.54-1.42 ( m, 2H), 1.32-1.01 (m, 5H), 0.85 (d, J = 7.3, 4H), 0.45 (d, J = 9.7, 2H), 0.06 (t, J = 6.2, 2H).

EXAMPLE 274 Amide of 1- [4- (benzothiazol-2-yloxy) -benzyl-piperidin-4- acid carboxylic The title compound was prepared according to the procedure of Example 259, step D using piperidine-4-carboxylic acid amide. MS (ESI): mass calculated for C2oH2? N3O2S, 367.1; m / z found, 368.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.94 (d, J = 7.4, 1 H), 7.70 (d, J = 7.9, 1 H), 7.48-7.38 (m, 5H), 7.33 (d, J = 7.1, 1 H), 7.22 (s, 1 H), 6.73 (s, 1 H), 3.49 (s, 2H), 2.83 (d, J = 11.4, 2H), 2.14-2.02 (m, 1 H), 2.00-1.93 (m, 2H), 1.73-1.62 (m, 2H), 1.58 (t, J = 15.4, 2H).

EXAMPLE 275 1 '-4- (Benzothiazol-2-yloxO-bencip-H. 4'] bipiperidinyl-2-one The title compound was prepared according to the procedure of Example 259, step D using [1,4 '] bipiperidinium- 2-one MS (ESI): mass calculated for C24H2 N3? 2S, 421.2, m / z found, 422.5 [M + Hf. 1 H NMR (400 MHz, DMSO-d6): 7.94 (d, J = 8.8, 1 H), 7.70 (d, J = 8.6.1 H), 7.48-7.38 (m, 5H), 7.33 (d, J = 9.0, 1 H), 4.37-4.25 (m, 1H), 3.52 (s, 2H) ), 3.16 (t, J = 5.2, 2H), 2.89 (d, J = 11.2, 2H), 2.22 (t, J = 6.6, 2H), 2.03 (t, J = 11. 1. 2H), 1.78-1.58 (m, 6H), 1.45 (d, J = 10.8, 2H).

EXAMPLE 276 . { 4- [4- (Benzothiazol-2-yloxy) -benzyl] -piperazin-1-yl) -pyridin-3-yl-methanone The title compound was prepared according to the procedure of Example 259, step D using piperazin-1-yl-pyridin-3-yl-methanone. MS (ESI): mass calculated for C 24 H 22 N 4 O 2 S, 430.2; m / z found, 431.4 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 8.65 (d, J = 4.8, 1 H), 8.61 (d, J = 1.9, 1 H), 7.94 (d, J = 7.9, 1 H), 7.84 (d , J = 7.8, 1 H), 7.69 (d, J = 8.0, 1 H), 7.60- 7.40 (m, 6H), 7.33 (d, J = 8.3, 1 H), 3.64 (br s, 2H), 3.58 (s, 2H), 3.37 (br s, 2H), 2. 41 (br s, 4H).

EXAMPLE 277 Ter-butyl acid ester. { 1- [4- (Benzothiazol-2-yloxy) -benzyl] - piperidin-4-methyl} -carbamic The title compound was prepared according to the procedure of example 259, step D using piperidin-4-ylmethylcarbamic acid tert-butyl ester. MS (ESI): mass calculated for C25H31N3O3S, 453.2; m / z found, 454.4 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.94 (d, J = 7.3, 1 H), 7.70 (d, J = 7.9, 1 H), 7.48-7.37 (m, 5H), 7.33 (d, J = 8.2, 1 H), 6.85 (t, J = 5.9, 1 H), 3.48 (s, 2H), 2.86-2.76 (m, 4H), 1.90 (t, J = 11.1, 2H), 1.56 (d, J = 11.8, 2H), 1.37 (s, 10H), 1.11 (t, J = 9.9, 2H).

EXAMPLE 278 Methyl ester of acid. { 1- [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-ylmethyl} -carbamic The title compound was prepared according to the procedure of Example 258, step C using methyl chloroformate. MS (ESI): mass calculated for C22H25N3O3S, 411.2; m / z found, 412.4 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.94 (d, J = 7.9, 1 H), 7.70 (d, J = 8.0, 1 H), 7.48-7.36 (m, 5H), 7.33 (d, J = 8.0, 1 H), 7.17 (t, J = 5.6, 1 H), 3.51 (s, 3H), 3.48 (s, 2H), 2.87 (t, J = 6.2, 2H), 2.80 (d, J = 11.1, 2H), 1.90 (t, J = 10.5, 2H), 1.60 (t, J = 12.8 , 2H), 1.38 (brs, 1 H), 1.20-1.06 (m, 2H).

EXAMPLE 279 Ter-butyl ester of N- acid. { C-f [4- (benzothiazol-2-yloxy) -benzyl-piperidin-4-ip-methylaminosulfonyl-Vcarbamic acid To a stirring solution of C-. { 1- [4- (benzothiazol-2-yloxy) -benzyl] -p.perdin-4-yl} methylamine (example 258, step B, 657 mg, 1.5 mmol) in CH2Cl2 (15 ml) containing triethylamine (1 ml, 7.2 mmol) was added carbamic acid, N- (sulfonyl chloride) tert-butyl ester (440) mg, 2.1 mmol). The mixture was stirred for 48 hr and taken to CH 2 Cl 2 (50 mL) and washed once with H 2 O (75 mL), dried (MgSO) and concentrated under reduced pressure to give a colorless and clear oil. The oil was purified over SiO2 (12 g, 0-50% acetone / CH2Cl2) and the desired fractions were combined and concentrated under reduced pressure to give a white solid (112 mg, 14% yield). CCD (SiO2, 50% acetone / CH2Cl2): Rf = 0.40. MS (ESI): mass calculated for C25H32N4O5S2, 532.2; m / z found, 533.4 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 10.74 (brs, 1H), 7.90 (d, J = 7.9, 1 H), 7.66 (d, J = 8.0, 1 H), 7.54 (br s, 1 H) , 7.44-7.34 (m, 5H), 7.30 (d, J = 8.3, 1 H), 3.48 (s, 2H), 2.84-2.70 (m, 4H), 1.90 (t, J = 10.4, 2H), 1.64 (d, J = 11.4, 2H), 1.38 (s, 10H), 1.16 -1.02 (m, 2H).

EXAMPLE 280 N- hydrochloride. { 1-f4- (Benzothiazol-2-yloxy) -benzifl-piperidin-4-ylmethyl} -sulfamide The title compound was prepared from example 279 following the procedure of example 266, step B. MS (ESI): mass calculated for C2oH24N4? 3S2, 432.1; m / z found, 433.4 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 10.08 (br s, 1 H), 7.80 (d, J = 8.2, 1 H), 7.76-7.68 (m, 3H), 7.58 (d, J = 8.6, 2H ), 7.45 (t, J = 8.4, 2H), 7.36 (t, J = 8. 8, 2H), 6.70-6.50 (br s, 2H), 4.33 (d, J = 5.4, 2H), 3.00-2.86 (br s, 1 H), 2.77 (t, J = 6.2, 2H), 1.91 (d, J = 13.4, 2H), 1.71 (brs, 1 H), 1.50-1.36 (m, 2H), 1.34-1.26 (m, 1 H).

EXAMPLE 281 N-. { 1-f4- (Benzothiazol-2-yloxy) -benzyl-1-piperidin-4-ylmethyl-acetamide The title compound was prepared according to the procedure of Example 258, step C using acetyl chloride. MS (ESI): mass calculated for C22H25N3O2S, 395.2; m / z found, 396.4 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.94 (d, J = 7.8, 1 H), 7.83 (t, J = 5.5, 1 H), 7.70 (d, J = 8.0, 1 H), 7.48-7.36 ( m, 5H), 7.33 (d, J = 8.2, 1H), 3.48 (s, 2H), 2.93 (t, J = 6.2, 2H), 2.81 (d, J = 11.4, 2H), 1.91 (t, J = 11.3, 2H), 1.80 (s, 3H), 1.61 (d, J = 11.0, 2H), 1.38 (br s, 1H), 1.20-1.06 (m, 2H).

EXAMPLE 282 Acid { 1-r 4 - (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-ylmethyl} -acetic The title compound was prepared according to the procedure of Example 259, step D using piperidin-4-yl-acetic acid ethyl ester and example 250, step D. MS (ESI): mass calculated for C2? H22N2O3S, 382.1; m / z found, 383.4 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 10.1 (brs, 1 H), 7.97 (d, J = 7.9, 1 H), 7.70 (br, J = 7.6, 3H), 7.58 (brs, 2H), 7.45 (t, J = 7.2, 1 H), 7.36 (t, J = 7.3, 1 H), 4.31 (br s, 1 H), 2.98 (br s, 3 H), 2.20 (d, J = 5.6, 3 H ), 1.87 (brs, 4H), 1.51 (br s, 2H).

EXAMPLE 283 Ester ((1- [4- (Benzothiazol-2-ylox-benzyl-1-piperidin-4-ylmethyl) -carbamoyl-D-methyl-acetic acid) The title compound was prepared according to the procedure of example 258, step D using ester [ (piperidi-4-ylmethyl-carbamoyl] -methyl acetic acid and example 253, step D. MS (ESI): mass calculated for C 24 H 27 N 3 O S, 453.2, m / z found, 454.4 [M + Hf. 1 H NMR (400 MHz , DMSO-d6): 8.01 (t, J = 5.8, 1 H), 7.94 (d, J = 7.5, 1 H), 7.70 (d, J = 8.0, 1 H), 7.80-7.36 (m, 5H) , 7.33 (t, J = 7.2, 1H), 4.43 (s, 2H), 3.48 (s, 2H), 2.98 (t, J = 6.3, 2H), 2.81 (d, J = 11.4, 2H), 2.08 ( s, 3H), 1.91 (t, J = 11.2, 2H), 1.60 (d, J = 11.2, 2H), 1.42 (br s, 1 H), 1.20-1.08 (m, 2H).

EXAMPLE 284 Ter-butyl acid ester r2- ( { 1-r4- (Benzothiazol-2-yloxy) -benzyl- piperidin-4-ylmethyl} carbamoyl) -cyclobutyl] -carbamic acid The title compound was prepared from example 258, step B following example 257, step C using 2-tert-butoxycarbonylamino-cyclobutanecarboxylic acid. MS (ESI): mass calculated for C30H38N O4S, 550.3; m / z found, 551.5 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.94 (d, J = 7.9, 1 H), 7.70 (d, J = 8.0, 1H), 7.47-7.35 (m, 7H), 7.33 (t, J = 7.3 , 1H), 3.47 (s, 2H), 2.95 (t, J = 6.1, 2H), 2.78 (t, J = 9.6, 2H), 2.45-2.35 (m, 2H), 2.13 (s, 1 H), 2.05-1.95 (m, 2H), 1.93-1.70 (m, 4H), 1.59 (d, J = 10.9, 2H), 1.38 (s, 9H), 1.20-1.05 (m, 2H).

EXAMPLE 285 2-Amino-cyclobutanecarboxylic acid (1 - [4- (benzothiazol-2-yloxy) -benzyl] -piperidin-4-ylmethyl} -amide hydrochloride The title compound was prepared according to the procedure of Example 266 , step B. MS (ESI): mass calculated for C25H3oN4? 2S, 450.2, m / z found, 451.4 [M + Hf. 1 H NMR (400 MHz, DMSO-d6): 8.78-8.55 (m, 4H), 7.97 (d, J = 8.1, 1 H), 7.78 (d, J = 8.6, 3H), 7.71 (d, J = 7.8, 1 H), 7.45 (t, J = 8.5, 1H), 7.36 (t, J = 7.1, 1 H), 4.32 (s, 2H), 3.20-3.05 (m, 2H), 3.00-2.85 (m, 2H), 2.472 (d, J = 4.7, 2H), 2.62-2.50 (m, 2H), 2.65-2.42 (m, 2H), 2.38-2.05 (m, 1 H), 2.02-1.70 (m, 6H), 1.68-1.50 (s, 2H).

EXAMPLE 286 2- (4-Pyrrolidin-1-ylmethyl-phenoxy) -benzothiazole The title compound was prepared according to the procedure of Example 259, step D using pyrrolidine. MS (ESI): mass calculated for C? 8H16N2OS, 310.1; m / z found, 311.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.94 (d, J = 9.0, 1 H), 7.70 (d, J = 8.0, 1 H), 7.48-7.37 (m, 5H), 7.33 (t, J = 7.7, 1 H), 3.62 (s, 2H), 2.49-2.40 (m, 4H), 1.78-1.65 (m, 4H).

EXAMPLE 287 2-fr4- (Benzothiazol-2-yloxy) -bencip-ethyl-amino} Ethanol The title compound was prepared according to the procedure of Example 259, step D using 2-ethylamino-ethanol. MS (ESI): mass calculated for C? 8H20N2O2S, 328.1; m / z found, 329.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.94 (d, J = 8.0, 1H), 7.70 (d, J = 7.7, 1 H), 7.50-7.36 (m, 5H), 7.33 (t, J = 7.7 , 1 H), 4.39 (t, J = 5.4, 1 H), 3.63 (s, 2H), 3.49 (q, J = 6.4, 2H), 2.57-2.45 (m, 4H), 1.00 (t, J = 7.1, 3H).

EXAMPLE 288 2-11-f4- (Benzothiazol-2-yloxy) -bencip-p-peridin-2-yl-ethanol The title compound was prepared according to the procedure of example 259, step D using 2-piperidin-2- i-Ethanol. MS (ESI): mass calculated for C 21 H 24 N 2 O 2 S, 368.2; m / z found, 369.4 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.93 (d, J = 8.0, 1 H), 7.70 (d, J = 7. 7, 1 H), 7.48-7.36 (m, 5H), 7.33 (t, J = 6.9, 1H), 4.42 (s, 1 H), 3.92 (d, J = 14.0, 1 H), 3.50 (br s , 2H), 3.31 (d, J = 6.4, 1 H), 2.70-2.60 (m, 1 H), 2.14-2.03 (m, 1 H), 1.87-1.75 (m, 1 H), 1.70-1.55 ( m, 3H), 1.53-1.27 (m, 5H).

EXAMPLE 289 1- (4-r4 - (, Benzothiazol-2-yloxy) -benzin-piperazin-1-yl) -ethanone The title compound was prepared according to the procedure of example 259, step D using 1-piperazin-1- il-ethanone. MS (ESI): mass calculated for C2oH2iN3O2S, 367.1; m / z found, 368.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.94 (d, J = 8.0, 1 H), 7.70 (d, J = 7.5, 1 H), 7.48-7.39 (m, 5H), 7.33 (t, J = 7.7, 1 H), 3.55 (s, 2H), 3.50-3.40 (m, 4H), 2.40 (t, J = 4.9, 2H), 2.33 (t, J = 5.0, 2H), 1.99 (s, 3H) .

EXAMPLE 290 8-f4- (Benzothiazol-2-yloxy) -benzyl] -2,8-diaza-espyror4.5] decan-1-one The title compound was prepared according to the procedure of Example 259, step D using 2,8-diaza-epiro [4.5] decan-1-one. MS (ESI): mass calculated for C22H23N3O2S, 393.2; m / z found, 394.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.94 (d, J = 7.4, 1 H), 7.70 (d, J = 8.0, 1 H), 7.54 (s, 1 H), 7.48-7.36 (m, 5H ), 7.33 (t, J = 8.2, 1 H), 3.51 (s, 2H), 3.15 (t, J = 6.8, 2H), 2.75 (d, J = 11.6, 2H), 2.05 (t, J = 10.0) , 2H), 1.91 (t, J = 6. 8, 2H), 1.70 (t, J = 12.6.2H), 1.33 (d, J = 12.8, 2H).

EXAMPLE 291 1 '- [4- (Benzothiazol-2-yloxy) -benzyl] spiro [isobenzofuran-1 (3H), 4'-piperidin-3-one The title compound was prepared according to the procedure of Example 259, Step D using spiro [isobenzofuran-1 (3H), 4'-piperidin] -3-one. MS (ESI): mass calculated for C26H22N2O3S, 442.1; m / z found, 443.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.95 (d, J = 7.9, 1 H), 7.83 (d, J = 7. 6, 1 H), 7.82-7.76 (m, 2H), 7.70 (d, J = 8.0, 1 H), 7.61 (t, J = 7.8, 1H), 7.56-7.48 (m, 2H), 7.47-7.40 (m, 3H), 7.33 (t, J = 7.4, 1 H), 3.66 (s, 2H), 2.90 (d, J = 11. 1, 2H), 2.41 (t, J = 11.0, 2H), 2.28 (t, J = 13.3, 2H), 1.66 (d, J = 12.6, 2H).

EXAMPLE 292 CT "OH (fi) -1-r4- (Benzothiazol-2-yloxO-benzyl-1-pyrrolidin-3-ol The title compound was prepared according to the procedure of example 259, step D using (R) -pyrrolidin-3-ol. MS (ESI): mass calculated for C? 8H? 8N2O2S, 326.1; m / z found, 327.2 [M + Hf. 1 H NMR (400 MHz, DMSO-d6): 7.94 (d, J = 8.0, 1 H), 7.70 (d, J = 8.1, 1 H), 7.48-7.36 (m, 5H), 7.33 (t, J = 7.2, 1 H), 4.72 (d, J = 4.5, 1H), 4.27-4.16 (m, 1H), 3.60 (q, J = 13.2, 2H), 2.73-2.65 (m, 1 H), 2.60 (q, J = 8.1, 1 H), 2.47-2.38 (m, 1 H), 2.36-2.30 ( m, 1 H), 2.07-1.95 (m, 1 H), 1.62-1.50 (m, 1 H).

EXAMPLE 293 2- [4- (2-Methyl-p-peridin-1-ylmethyl) -phenoxy-1-benzothiazole The title compound was prepared according to the procedure of Example 259, step D using 2- methyl-piperidine. MS (ESI): mass calculated for C2oH22N2OS, 338.2; m / z found, 339.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.94 (d, J = 8.0, 1 H), 7.70 (d, J = 8. 1, 1 H), 7.30-7.33 (m, 5H), 7.33 (t, J = 7.9, 1 H), 3.96 (d, J = 13.9, 1 H), 3.19 (d, J = 13.9, 1 H) , 2.70-2.60 (m, 1 H), 2.40-2.30 (m, 1 H), 1.98 (t, J = 13.0, 1 H), 1.68-1.56 (m, 2H), 1.54-1.34 (m, 2H) , 1.32-1.24 (m, 2H), 1.11 (d, J = 6.2, 3H).

EXAMPLE 294 r4- (Benzothiazol-2-yloxy) -benzp-diethyl-amine The title compound was prepared according to the procedure of example 259, step D using diethylamine. MS (ESI): mass calculated for C? 8H20N2OS, 312.1; m / z found, 313.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.94 (d, J = 7.9, 1 H), 7.70 (d, J = 8. 0, 1 H), 7.48-7.36 (m, 5H), 7.33 (t, J = 7.2, 1 H), 3.57 (s, 2H), 2.48 (q, J = 7.1, 4H), 1.00 (t, J) = 7.1, 6H).

EXAMPLE 295 [4- (Benzothiazol-2-yloxy) -benzyl-11-butyl-methyl-amine The title compound was prepared according to the procedure of Example 259, step D using butyl methyl amine. MS (ESI): mass calculated for C? 9H22N2OS, 326.2; m / z found, 327.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.94 (d, J = 7.9, 1 H), 7.70 (d, J = 7. 5, 1 H), 7.48-7.36 (m, 5H), 7.33 (t, J = 8.0, 1 H), 3.49 (s, 2H), 2.34 (t, J = 7.1, 2H), 2.13 (s, 3H) ), 1.50-1.40 (m, 2H), 1.38-1.24 (m, 2H), 0.88 (t, J = 7.3, 3H).

EXAMPLE 296 2-. { 1- [4- (Benzothiazol-2-yloxy) -benzyl-Piperidin-4-yl-ethanol The title compound was prepared according to the procedure of example 259, step D using 2-piperidin-4-yl-ethanol. MS (ESI): mass calculated for C 21 H 24 N 2 O 2 S, 368.2; m / z found, 369.4 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.74 (d, J = 7.9, 1H), 7.49 (d, J = 8.0, 1 H), 7.30-7.16 (m, 5H), 7.13 (t, J = 7.9 , 1 H), 4.13 (t, J = 5.1, 1H), 3.27 (s, 2H), 3.23 (q, J = 6.2, 2H), 2.59 (d, J = 11.1, 2H), 1.72 (t, J = 10.3, 2H), 1.42 (d, J = 12.1, 2H), 1.16 (t, J = 3.8, 3H), 1.00-0.85 (m, 2H).

EXAMPLE 297 1- [4- (Benzothiazol-2-yloxy) -benzyl-piperidin-4-ol The title compound was prepared in accordance with procedure of example 259, step D using piperidin-4-ol. MS (ESI): mass calculated for C? 9H2oN2? 2S, 340.1; m / z found, 341.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.94 (d, J = 7.9, 1 H), 7.68 (d, J = 8.0, 1 H), 7.46-7.36 (m, 5 H), 7.32 (t, J = 8.1 , 1 H), 4.60 (d, J = 4.9, 1 H), 3.58-3.40 (m, 3H), 2.80 (d, J = 9.9, 1 H), 2.65 (d, J = 10.7, 1 H), 1.87 (t, J = 9.2, 1 H), 1.80 (d, J = 8.6, 1 H), 1.71 (t, J = 9.8, 1 H), 1.62 (d, J = 13.3, 1 H), 1.48-1.38 (m, 1 H), 1. 12-1.00 (m, 1 H).

EXAMPLE 298 (1-f4- (Benzothiazol-2-yloxy) -benzyl-piperidin-2-yl) -methanol The title compound was prepared according to the procedure of Example 259, step D using piperidin-2-yl-methanol . MS (ESI): mass calculated for C2oH22N2O2S, 354.1; m / z found, 355.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.98 (d, J = 7.2, 1H), 7.74 (d, J = 8.0, 1 H), 7.53-7.42 (m, 5H), 7.37 (t, J = 8.3 , 1 H), 4.60 (t, J = 5.2, 1 H), 4.18 (d, J = 14.1, 1 H), 3.75-3.65 (m, 1 H), 3.56-3.46 (m, 1H), 3.37 (d, J = 3.8, 1 H), 2.72 (d, J = 11.9, 1 H), 2.36 (d, J = 4.8, 1 H), 2.07 (t, J = 9.7, 1 H), 1.72 (t, J = 13.2, 2H), 1.58-1.26 (m, 4H).

EXAMPLE 299 (ffl-C1- [4- (Benzothiazol-2-yloxy) -bencip-pyrrolidin-2-yl}. methanol The title compound was prepared according to the procedure of example 259, step D using (R) - pyrrolidin-2-yl-methanol MS (ESI): mass calculated for C? 9H2oN2O2S, 340.1; m / z found, 340.1 [M + Hf. 1 H NMR (400 MHz, DMSO-d6): 7.97 (d, J = 7.2, 1 H), 7.73 (d, J = 7. 8, 1 H), 7.50-7.38 (m, 5H), 7.36 (t, J = 7.9, 1 H), 4.90 (t, J = 5.4, 1 H), 4.14 (d, J = 13.4, 1H), 3.55-3.48 (m, 1 H), 3.42 (d, J = 13.4, 2H), 2.84 (t, J = 6.6, 1 H), 2.68-2.58 (m, 1 H), 2.20 (q, J = 8.6 , 1 H), 1.95-1.83 (m, 1 H), 1.72-1.55 (m, 3H).

EXAMPLE 300 2- (4-Azetidin-1-ylmethyl-phenoxy) -benzothiazole The title compound was prepared according to the procedure of Example 259, step D using azetidine. MS (ESI): mass calculated for C? 7H? 6N2OS, 296.1; m / z found, 297.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.80 (d, J = 8.5, 1 H), 7.56 (d, J = 8.0, 1 H), 7.35-7.24 (m, 5H), 7.19 (t, J = 7.3, 1 H), 3.43 (s, 2H), 3.02 (t, J = 7.0, 4H), 1.92-1.80 (m, 2H).

EXAMPLE 301 1 - . 1-f4- (Benzothiazol-2-yloxy) -bencip- [1, 41-diazepane-5-one The title compound was prepared according to the procedure of example 259, step D using [1, 4] diazepan-5-one . MS (ESI): mass calculated for C? 9H? 9N3O2S, 353.1; m / z found, 354.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.94 (d, J = 7.9, 1 H), 7.69 (d, J = 7.9, 1 H), 7.57 (t, J = 5.4, 1 H), 7.44-7.33 (m , 5H), 7.33 (t, J = 8.2, 1 H), 3.62 (s, 2H), 3.18-3.10 (m, 2H), 2.58-2.40 (m, 6H).

EXAMPLE 302 . { 1-r4- (Benzothiazol-2-yloxy) -benzipap-piperidin-3-yl) -methanol The title compound was prepared in accordance with procedure of example 259, step D using piperidin-3-yl-methanoI. MS (ESI): mass calculated for C20H22N2O2S, 354.1; m / z found, 355.3 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.98 (d, J = 7.2, 1H), 7.74 (d, J = 7.9, 1 H), 7.50-7.42 (m, 5H), 7.38 (t, J = 8.2 , 1 H), 4.46 (t, J = 5.3, 1H), 3.52 (d, J = 3.4, 2H), 3.36-3.29 (m, 1 H), 3.27-3.18 (m, 1 H), 2.92 (d, J = 8.1, 1H), 2.77 (d, J = 10.8, 1 H), 1.96 (d, J = 12.8, 1 H), 1.75-1.60 (m, 4H), 1.58-1.45 (m, 1 H), 1.00- 0.85 (m, 1 H).

EXAMPLE 303 Amide of 1-f4- (benzothiazol-2-yloxy) -benzyl] -piperidine-3-carboxylic acid The title compound was prepared according to the procedure of Example 259, step D using piperidine-3-carboxylic acid amide. MS (ESI): mass calculated for C20H21N3O2S, 367.1; m / z found, 368.4 [M + Hf .1 1 H NMR (400 MHz, DMSO-d 6): 7.70 (d, J = 7.8, 1 H), 7.46 (d, J = 8.0, 1 H), 7.25-7.00 (m, 7H), 6.53 (s, 1 H), 3.26 (d, J = 2.9, 2H), 2.57 (d, J = 10.3, 1 H), 2.49 (d, J = 11.3, 1 H), 2.15 -2.00 (m, 1 H), 1.78 (t, J = 10.7, 1 H), 1.69 (t, J = 9.4, 1 H), 1.51 (d, J = 10.0, 1 H), 1.40 (d, J = 12.9, 1 H), 1.22 (q, J = 12.6, 1H), 1.09 (q, J = 12.2, 1 H).

EXAMPLE 304 9- [4- (Benzothiazol-2-yloxy-benzyl-3,9-diaza-spiro [5.5] undecane-3-carboxylic acid tert-butyl ester The title compound was prepared according to the procedure from Example 259, step D using 3,9-diaza-spiro [5.5] undecane-3-carboxylic acid tert-butyl ester MS (ESI): mass calculated for C28H35N3O3S, 493.2; m / z found, 494.5 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 8.13 (d, J = 7.9, 1 H), 7.89 (d, J = 8.0, 1 H), 7.68-7.56 (m, 5H), 7.53 (t, J = 7.1, 1 H), 3.70 (s, 2H), 3.51-3.45 (m, 4H), 2.60-2.50 (m, 4H), 1.66 (t, J = 5.3, 4H), 1.58 (s, 9H) , 1.54 (t, J = 5.4, 4H).

EXAMPLE 305 2-. { 1- [4- (Benzothiazo! -2-yloxy) -benzyl] -piperidin-3-yl} Ethanol The title compound was prepared according to the procedure of Example 259, step D using 2-piperidin-3-yl-ethanol. MS (ESI): mass calculated for C 21 H 24 N 2 O 2 S, 368.2; m / z found, 369.4 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 7.71 (d, J = 8.4, 1 H), 7.47 (d, J = 7.9, 1H), 7.25-7.15 (m, 5H), 7.10 (t, J = 8.1 , 1H), 4.12 (t, J = 5.1, 1H), 3.33-3.15 (m, 4H), 2.58-2.42 (m, 2H), 1.67 (t, J = 9.6, 1 H), 1.53-1.33 (m , 4H), 1.30-1.00 (m, 3H), 0.70-0.58 (m, 1 H).

EXAMPLE 306 Salt of trifluoromethanesulfonate of cis-4- acid. { 2- [4- (Benzothiazol-2-yloxy) -phenyl-1-ethylamino} -cyclohexanecarboxylic The title compound was prepared according to the procedure of example 262, step B using cis-4-amino-cyclohexanecarboxylic acid. MS (ESI): exact mass calculated for C22H2 N2O3S, 396.2; m / z found, 397.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 9.15, (s, 1 H), 7.75 (d, J = 7.6, 1 H), 7.72 (dd, J = 8.0, 0.7, 1 H), 7.43 (dt, J = 7.2, 1.2, 1 H), 7.37-7.29 (m, 5H), 5.10 (br s, 1 H), 3.29 (br s, 2 H), 3.10 (t, J = 7.4, 3 H), 2.73 (br s, 1 H), 2.24 (br d, J 10.6, 2 H), 2.09 (brd , J = 9.3, 2H), 1.72-1.52 (m, 3H).

EXAMPLE 307 (4- { 2- [4- (Benzothiazol-2-yloxy) -phenp-ethyl) -piperazin-1-ip- (tetrahydro-furan-2-yl) -methanone A. Bis trifluoromethanesulfonate 2- [4- (2-piperazin-1-yl-ethyl) -phenoxy-benzothiazole. Ter-butyl ester of 4- acid. { 2-4- (benzothiazol-2-yloxy) -phenyl] -piperazine-1-carboxylic acid was prepared according to example 262, step B, using piperazin-1-carboxylic acid tert-butyl ester. A solution of 4- tertiary butyl ester. { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazine-1-carboxylic acid (3.9 g, 8.9 mmol) in CH 2 Cl 2 (5 mL) with a solution of 50% trifluoromethanesulfonic acid in CH 2 Cl 2 (35 mL) and stirring at 23 ° C for 4 hr. The reaction was concentrated and the residue was suspended in diethyl ether, filtered and dried to give the title compound as a white solid (5.4 g, 94% yield). EM (ESI): exact mass calculated for C? 9H2? N30? S ?, 339.1; m / z found, 340.4 [M + Hf. 1 H NMR (400 MHz, D 6 DMSO): 9.50-9.30 (br.s, 1 H), 7.94 (dd, J = 7.9, 0.6, 1 H), 7.68 (d, J = 7.6 Hz, 1 H), 7.48- 7.41 (m, 5H), 7.39-7.30 (m, 1 H), 4. 15-3.50 (br.s, 1 H), 3.45-3.32 (m, 8H), 3.32-3.20 (m, 2H), 3.01 (dd, J = 8.8, 5.2 Hz, 2H). B. (4-. {2- 2- (4- (Benzothiazol-2-yloxy) -phenn-ethyl> -piperazin-1-ip- (tetrahydro-furan-2-yO-methanone) The title compound was prepared according to the procedure of example 257 step C, using tetrahydro-furan-2-carboxylic acid and triethylamine, MS (ESI): exact mass calculated for C24H27N3? 3S, 437.2, m / z found, 438.5 [M + Hf 1 H NMR (400 MHz, CDCl 3): 7.77 (d, J = 7.3, 1 H), 7.71 (dd, J = 7.8, 0.8, 1 H), 7.42 (dt, J = 7.3, 1.2, 1 H), 7.33-7.26 (m, 5H), 4.65 (dd, J = 7.0, . 3, 1 H), 3.99 (ddd, J = 7.7, 7.1, 6.7, 1 H), 3.92-3.86 (m, 1 H), 3.82-3.72 (m, 2H), 3. 76 (s, 1H), 3.70-3.58 (m, 2H), 2.90 (dd, J = 10.3, 7.3, 2H), 2.70 (dd, J = 8.6, . 6, 2H), 2.64-2.54 (m, 3H), 2.38-2.28 (m, 1 H), 2.14-1.90 (m, 4H).

EXAMPLE 308 (1- (2-r4- (benzothiazol-2-yloxyHenoxp-ethyl) -piperidine-4-carbonylo-propan-2-sulfonic acid amide A solution of 1- (2- (4- (benzothiazole -2-yloxy) -phenoxy] -ethyl.}. -piperidine-4-carboxylic acid (example 22, 197 mg, 0.5 mmol) in THF (5 ml) was treated with NaH (14 mg, 0.6 mmol) and isopropylsulfonyl chloride (86) mg, 0.6 mmol) and the reaction was stirred at 60 ° C for 16 hr. The reaction was cooled and quenched by the addition of CH3OH (5 mL) followed by H2O (5 mL) and the pH was adjusted to pH 7. The solution was extracted with ethyl acetate (2 x 25 mL) and the Ethyl acetate was washed with 1 M NaOH (2 x 30 ml). The combined base washings were neutralized by the addition of 2 M HCl and extracted with chloroform (2 x 30 ml). The chloroform solutions were dried over Na2SO4, filtered and concentrated under reduced pressure. The crude product was purified on SiO2 (4 g, 0-10% 2M NH3 / CH3OH: CH2Cl2) to give the title compound as a solid (45 mg, 18% yield). MS (ESI): exact mass calculated for C 24 H 29 N 3 O 5 S 2, 503.2; m / z found, 504.5 [M + Hf. 1 H NMR (400 MHz, C6D6): 7.77 (d, J = 7.8, 1 H), 7.20 (dd, J = 8.0, 0.8, 1 H), 7.16-7.10 (m, 2H), 7.07 (dt, J = 8.3, 1.0, 1 H), 6.90 (dt, J = 8.0, 1.0, 1 H), 6.76 (d, J = 8.8, 1 H), 6.13 (s, 1 H), 3.98 (br s, 2 H), 3.51 (heptuplete, J = 6.8, 2H), 3.20 (br s, 2H), 2.82 (br s, 1 H), 2.37-2.00 (m, 4H), 1.96-1.84 (m, 2H), 1.33 (d, J = 6.6, 6H) 1.38-1.28 (m, 2H).

EXAMPLE 309 Methyl ester of (4-. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -piperazin-1-y-oxo-acetic acid A solution of bis-trifluoromethanesulfonate of 2- [4 - (2-piperazin-1-ethyl-ethyl) -phenoxy] -benzothiazole (296 mg, 0.52 mmol) in CH2Cl2 (3 ml) was treated with triethylamine (0.25 ml, 1.8 mmol), followed by the addition of methyl chlorooxoacetate (0.07 ml, 0.8 mmol) and the reaction was stirred at 23 ° C for 20 min. The reaction was diluted with CH2Cl2 (10 mL) and washed with saturated aqueous NaHCO3 (10 mL). The organic layer was dried over Na2SO, filtered and concentrated under reduced pressure to give the title compound (234 mg, 99% yield). MS (ESI): exact mass calculated for C22H23 3O4S, 425.1; m / z found, 426.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.76 (d, J = 7.6, 0.5, 1 H), 7.70 (d, J = 7.8, 1 H), 7.41 (dt, J = 7.3, 1.0, 1 H), 7.34- 7.26 (m, 5H), 3.91 (s, 3H), 3.72 (t, J = 4.8, 2H), 3.51 (t, J = 4.8, 2H), 2.86, (dd, J = 10, 6.8, 2H), 2.70, (dd, J = 8.6, 5.6, 2H), 2.62-2.57 (m, 4H).

EXAMPLE 310 N- (1-. {2-y4- (benzothiazol-2-ylox-phenyl-1-ethyl-piperidine-4-carbonyl) -benzenesulfonamide trifluoromethanesulfonate salt The title compound was prepared according to the procedure of example 34, step B using benzenesulfonamide, MS (ESI): exact mass calculated for C27H27N3? 4S2, 521.1; m / z found, 522.3 [M + Hf. 1 H NMR (400 MHz, CD3OD): 8.60-8.00 (m, 2H), 7.82 -7.76 (m, 1 H), 7.73-7.57 (m, 4H), 7.48-7.28 (m, 5H), 3.70 (brs, 1 H), 3.41-3.34 (m, 2H), 3.14-2.98 (m, 3H), 2.60 (brs, 1 H), 2.08 (br d, J = 13.6, 2H), 1.86 (br s, 2H) 1.30 (br s, 2H), 0.94-0.88 (m, 2H).

EXAMPLE 311 N- (1- (2-r4- (benzothiazol-2-ylox-phenyl-1-ethyl). -piperidine-4-carbonyl} -metanesulfonamide trifluoromethanesulfonate salt The title compound was prepared in accordance with the process of Example 34, step B using methanesulfonamide MS (ESI): exact mass calculated for C22H25N3 4 4S2, 459.1, m / z found, 460.3 [M + Hf. 1 H NMR (400 MHz, CD3OD): 7.81 (d, J = 7.8 , 1 H), 7.62 (d, J = 8.1, 1 H) 7.49-7.43 (m, 3H), 7.43-7.38 (m, 2H), 7.34 (t, J = 7.8, 1 H), 3.80 (brd, J = 10.4, 1 H), 3.48-3.40 (m, 2H), 3.33 (s, 3H), 3.28 (s, 2H), 3.20-3.04 (m, 3H), 2.70-2.60 (m, 1 H), 2.21 (br d, J = 12.4, 2H), 2.06-1.93 (m, 2H).

EXAMPLE 312 (4- (2-R4- (Benzothiazol-2-yloxO-phenyl-ethyl-piperazin-1-yl) -oxo-acetic acid trifluoromethanesulfonate salt The title compound was prepared according to the procedure of Example 253, step D. MS (ESI): exact mass calculated for C2? H2? N3O4S, 411.1; m / z found, 412.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.75 (t, J = 8.3, 2H), 7.70 (dt, J = 8.0, 0.8, 1H), 7.28-7.22 (m, 5H), 4.28-3.88 (br m, 4H), 3.58-3.20 (br m, 6H), 3.16-3.04 (br m, 2H ).

EXAMPLE 313 (4- (2-f4- (Benzothiazol-2-yloxy) -phenyl] -ethyl) -piperazin-1-yl) -morpholin-4-yl-methanone A solution of bis-trifluoromethanesulfonate of 2- [4 - (2-Piperazin-1-ethyl-ethyl) -phenoxy] -benzothiazole Example 307, Step A (268 mg, 0.47 mmol) in CH 2 Cl 2 (6 mL) was treated with PS-dimethylamine resin (1.3 g, 0.90 mmol) followed by 4-morpholinecarbonyl chloride (0.07 ml, 0.6 mmol) and the reaction was stirred 1 hr. The reaction was treated with PS-isocyanate resin to remove excess isocyanate and after 15 min, the reaction was filtered and concentrated to give the title compound (225 mg, 99% yield). MS (ESI): exact mass calculated for C24H28N4? 3S ?, 452.2; m / z found, 453.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.77 (dd, J = 8.0, 0.5, 1 H), 7.71 (dd, J = 7.8, 0.5, 1 H), 7.42 (dt, J = 7.3, 1.2, 1 H) , 7.34-7.28 (m, 5H), 3.78-3.70 (m, 4H), 3.39 (br t, J = 4.3, 4H), 3.31 (t, J = 4.8, 4H), 2.90 (dd, J = 10.4, 7.3, 2H), 2.70 (dd, J = 8.3, 7.3, 2H), 2.59 (brs, 4H).

EXAMPLE 314 1- (4- (2- [4- (Benzothiazol-2-yloxy) -phenylethyl) -piperazin-1-n-2-thiophen-2-ethanone The title compound was prepared in accordance with procedure of Example 313 using 2-thiopheneacetyl chloride. MS (ESI): exact mass calculated for C25H25N3O3S2, 463.1; m / z found, 464.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.77 (dd, J = 8.0, 0.5, 1 H), 7.71 (dd, J = 7.8, 0.8, 1 H), 7.43 (dt, J = 7.3, 1.2, 1 H) , 7.34-7.28 (m, 5H), 7.25 (dd, J = . 3, 1.2, 1 H), 7.00 (dd, J = 5.0, 3.2, 1H), 6.96-6.93 (m, 1H), 3.96 (d, J = 0.8, 2H), 3.74 (t, J = 4.8, 2H), 3.59 (t, J = 4.8, 2H), 2.86 (dd, J = 10.4, 7.6, 2H), 2.66 (dd, J = 8.3, 5.6, 2H), 2.55 (t, J = 5.3, 2H), 2.47 (t, J = 5.0, 2H).

EXAMPLE 315 (4- {2-f4- (Benzthiazol-2-yloxy-V-phenyl-1-ethyl.} - piperazin-1-ip-pyridin-3-yl-methanone The title compound was prepared according to the procedure of Example 313 using 2-nicotonyl chloride-hydrochloride MS (ESI): exact mass calculated for C25H24 4? 2S, 444.2, m / z found, 445.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 8.73-8.70 (m, 2H), 7.81 (dt, J = 7.9, 1. 9, 1 H), 7.77 (dd, J = 8.1, 0.5, 1 H), 7.71 (ddd, J = 7.9, 0.7, 0.4, 1 H), 7.45-7.39 (m, 2H), 7.34-7.28 (m, 5H), 3.90 (br s, 2H), 3.52 (br s, 2H), 2.92-2.85 (m, 2H), 2. 71 (dd, J = 8.9, 5.6, 2H), 2.74-2.60 (m, 2H), 2.54 (br s, 2H).

EXAMPLE 316 (4- {2- [4- (Benzot-azo-2-yloxyHenyl-1-yl} -piperazin-1-yl) -cyclopropyl-methanone The title compound was prepared according to the procedure of the example 313 using cyclopropanecarbonyl chloride, MS (ESI): exact mass calculated for C23H25N3O2S, 407.2, m / z found, 408.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.77 (dd, J = 8.1, 0.5, 1 H), 7.71 (dd, J = 7.9, 0.8, 1H), 7.43 (dt, J = 7.4, 1.3, 1 H), 7.34-7.28 (m, 5H), 3.74 (d, J = 16.0, 4H), 2.89 (dd, J = 9.4, 6.5, 2H), 2.70 (dd, J = 9.4, 6.5, 2H), 2.58 (br d, J = 20.8, 4H), 1.78 (tt, J = 8.0, 4.7, 1 H ), 1.06-1.01 (m, 2H), 0.83-0.78 (m, 2H).

EXAMPLE 317 1- (4- (2-f4- (Benzothiazol-2-yloxy) -phenin-ethyl.} - piperazin-1-yl) -2-methoxy-ethanone A solution of bis-trifluoromethanesulfonate of 2- [ 4- (2-piperazin-1-yl-etiI) -phenoxy] -benzothiazole exemplify 307, step A (200 mg, 0.35 mmol) in CHCl3 (14 ml) was treated with PS-dimethylamine resin (740 mg, 1.0 mmol) and the reaction was stirred for 1 hr. The resin was filtered, and the resulting free base solution was treated with methoxyacetic acid (0.04 ml, 0.5 mmol) and PS-carbonyldiimidazole resin (500 mg, 0.6 mmol) and the reaction was stirred for 1 hr. The reaction was filtered and concentrated and the crude product was purified on Si02 (12 g, 0-10% 2M NH 3 / MeOH: CH 2 Cl 2) to give the title compound (143 mg, 99% yield). MS (ESI): exact mass calculated for C22H25N3? 2S, 411.2; m / z found, 412.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.77 (dd, J = 8.1, 0.6, 1 H), 7.71 (dd, J = 7.9, 0.8, 1 H), 7.42 (dt, J = 7.5, 1.3, 1 H), 7.35-7.28 (m, 5H), 4.14 (s, 2H), 3.72 (t, J = 4.8, 2H) , 3.58 (t, J = 4.8, 2H), 3.47 (s, 3H), 2.89 (dd, J = 10.6, 7.3, 2H), 2.70 (dd, J = 8.5, 5.6, 2H), 2.58 (t, J = 5.1, 4H).

EXAMPLE 318 1- (4- {2-r4- (Benzothiazol-2-yloxyMenin-ethyl-piperazin-1-in-2.2.2-trifluoro-ethanone The title compound was prepared according to the procedure of the example 317 using trifluromethanesulfonic acid MS (ESI): exact mass calculated for C2iH2oF3N3O2S, 435.1; m / z found, 436.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.77 (dd, J = 8.2, 0.5, 1 H), 7.71 (dd, J = 7.9, 0.7, 1 H), 7.43 (dt, J = 8.5, 1.2, 1 H), 7.35-7.28 (m, 5H), 4.14 (s, 2H), 3.76 (t, J = 4.8, 2H), 3.68 (t, J = 4.7, 2H), 2.88 (dd, J = 10.0, 7.0, 2H) , 2.70 (dd, J = 8.7, 5.6, 2H), 2.62 (t, J = 4.6, 4H).

EXAMPLE 319 4- (4- (2-r4- (Benzothiazol-2-yloxy) -pheno-phenyl) -pyridin-1-carbonyl-benzoic acid The title compound was prepared according to the procedure of Example 262 , step A using terephthalic acid monomethyl ester and example 250, step D. MS (ESI): exact mass calculated for C27H25N3? 4S, 487.2, m / z found, 488.4 [M + Hf. 1 H NMR (400 MHz, DMSO- d6): 8.00 (d, J = 8.3, 2H), 7.93 (dd, J = 8.0, 0.8, 1 H), 7.69 (d, J = 8.0, 0.4, 1 H), 7.50 (d, J = 8.3, 2H), 7.43 (dt, J = 7.5, 1.3, 1 H), 7.40-7.29 (m, 5H), 3.66 (br s, 2H), 3.30 (br s, 2H), 2.88 (dd, J = 7.0, 7.0, 2H), 2.60 (dd, J = 8.3, 8.3, 2H), 2.55 (br s, 2H), 2.44 (br s, 2H).

EXAMPLE 320 (4- (2-f4- (Benzot-azo-2-yloxy) -phenyl-ethyl-piperazin-1-p-pyridin-4-yl-methanone The title compound was prepared according to the procedure of Example 317 using isonicotinic acid EM (ESI): exact mass calculated for C25H24N4? 2S, 444.2, m / z found, 445.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 8.74 (dd, J = 4.4, 1.6, 1 H), 7.77 (dd, J = 8.1, 0.5, 1H), 7.71 (dd, J = 7.9, 0.8, 1 H), 7.43 (dt, J = 7.4, 1.3, 1 H), 7.45- 7.39 (m, 2H), 7.35-7.28 ( m, 7H), 3.87 (br s, 2H), 3.44 (br t, J = 3.9, 2H), 2.88 (dd, J = 10.1, 6.9, 2H), 2.71 (dd, J = 8.8, 5.5, 2H), 2.70-2.64 (m, 2H), 2.54-2.49 (m, 2H).

EXAMPLE 321 (4- (2-r4- (Benzothiazol-2-yloxyKenyl1-ethyl-VPIperidin-1-ylH5-methyl-pyrazin-2-yl) -methanone The title compound was prepared in accordance with procedure of Example 317 using 5-methyl-pyrazine-2-carboxylic acid. MS (ESI): exact mass calculated for C25H25N502S, 444.2; m / z found, 445.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 8.89 (d, J = 1.4, 1H), 8.45 (d, J = 1.0, 1 H), 7.76 (dd, J = 8.1, 0.5, 1 H), 7.70 (dd, J = 8.0, 0.8, 1 H), 7.43 (dt, J = 7.4, 1.3, 1 H), 7.33-7.28 (m, 5H), 3.90 (br t, J = 4.7, 2H), 3.77 (br t, J = 4.8, 2H), 2.92 (dd, J = 10.5, 6.5, 2H), 2.80-2.72 (m, 2H), 2.69-2.64 (m, 2H), 2.66 (s, 3H).

EXAMPLE 322 (RH4- {2-r4- (Benzothiazol-2-yloxy) -phenyl-1-ethyl-piperazin-1-ylV (tetrahydro-furan-2-yl) -methanone The title compound was prepared in accordance with procedure of Example 317 using 5- () -tetrahydrofuran-2-carboxylic acid MS (ESI): exact mass calculated for C 24 H 27 N 3 O 3 S, 437.2, m / z found, 438.5 [M + Hf. 1 H NMR (400 MHz, CDCl 3 ): 7.77 (d, J = 7.3, 1 H), 7.71 (dd, J = 7. 8, 0.8, 1 H), 7.42 (dt, J = 7.3, 1.2, 1 H), 7.33-7.26 (m, 5H), 4.65 (dd, J = 7.0, . 3, 1 H) 3.99 (ddd, J = 7.1, 6.7, 6.7, 1 H), 3.92-3.86 (m, 1 H), 3.82-3.72 (m, 2H), 3. 76 (s, 1 H), 3.70-3.58 (m, 2H), 2.90 (dd, J = 10.3, 7.3, 2H), 2.70 (dd, J = 8.6, . 6, 2H), 2.64-2.54 (m, 3H), 2.38-2.28 (m, 1 H), 2.14-1.90 (m, 4H).

EXAMPLE 323 (SH4- (2- [4- (Benzothiazol-2-yloxy) -phenyl-ethyl) -piperazin-1-yn- (tetrahydro-furan-2-yl) -methanone The title compound was prepared in accordance with Example 317 procedure using 5- (S) -tetrahydrofuran-2-carboxylic acid MS (ESI): exact mass calculated for C 24 H 27 N 3 O 3 S, 437.2, m / z found, 438.5 [M + Hf. 1 H NMR (400 MHz, CDCI3): 7.77 (d, J = 7.3, 1 H), 7.71 (dd, J = 7.8, 0.8, 1 H), 7.42 (dt, J = 7.3, 1.2, 1 H), 7.33-7.26 (m, 5H ), 4.65 (dd, J = 7.0, 5.3, 1 H), 3.99 (ddd, J = 7.1, 6.7, 6.7, 1 H), 3.89 (ddd, J = 7.7, 7.5, 5.8, 1H), 3.82-3.72 (m, 2H), 3.76 (s, 1 H), 3.70-3.58 (m, 2H), 2.90 (dd, J = 10.3, 7.3, 2H), 2.70 (dd, J = 8.6, 5.6, 2H), 2.64 -2.54 (m, 3H), 2.38-2.28 (m, 1 H), 2.14-1.90 (m, 4H).

EXAMPLE 324 (4- {2-f4- (Benzothiazol-2-yloxy) -phenyl] -ethyl) -piperazin-1-yl) - (tetrahydro-furan-3-yl) -methanone The compound of the title was prepared according to the procedure of Example 317 using 5-tetrahydro-furan-3-carboxylic acid. MS (ESI): exact mass calculated for C24H27N303S, 437.2; m / z found, 438.5 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.77 (dd, J = 8.1, 0.5, 1 H), 7.71 (dd, J = 7.9, 0.8, 1 H), 7.42 (dt, J = 7.5, 1.3, 1 H), 7.33-7.26 (m, 5H), 4.06 (t, J = 8.2, 1 H), 3.97-3.87 (m, 3H), 3.77-3.67 (m, 2H), 3.59 (t, J = 5.1, 1 H), 3.35-3.24 (m, 1 H), 2.88 (dd, J = 10.2, 7.3, 2H), 2.79 (dd, J = 8.5, 5.7, 2H), 2.60-2.50 (m, 4H), 2.29 (dddd, J = 12.6, 7.6, 6.4 , 6.4, 1H), 2.17-2.08 (m, 1 H).

EXAMPLE 325 1- (4- {2-r4- (Benzothiazol-2-yloxy) -phenin-ethyl) -piperazin-1-yl) -2-hydroxy-ethanone The title compound was prepared in accordance with procedure of Example 317 using glycolic acid. MS (ESI): exact mass calculated for C2? H23N303S, 397.2; m / z found, 398.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.77 (dd, J = 8.1, 0.5, 1 H), 7.71 (dd, J = 8.0, 0.7, 1 H), 7.43 (dt, J = 7.5, 1.3, 1 H) , 7.35-7.28 (m, 5H), 4.21 (s, 2H), 3.75 (t, J = 5.0, 2H), 3.68 (br s, 1H), 3.35 (t, J = 5.0, 2H), 2.88 (dd) , J = 10.1, 7.0, 2H), 2.70 (dd, J = 8.6, 5.6, 2H), 2.58 (ddd, J = 8.4, 8.3, 5.2, 1 H).

EXAMPLE 326 2-r2- (4- {2-r4- (Benzothiazol-2-yloxy) -phenin-ethyl) -piperazin-1-yl) -2-oxo-ethyl] -cyclopentanone The title compound was prepared from according to the procedure of Example 317 using 5- (2-oxo-cyclopentyl) -acetic acid. MS (ESI): exact mass calculated for C26H29N3O3S, 463.2; m / z found, 464.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.77 (d, J = 7.7, 1 H), 7.71 (dd, J = 7.9, 0.7, 1 H), 7.42 (dt, J = 7.5, 1.2, 1 H), 7.33- 7.28 (m, 5H), 3.80-3.64 (m, 2H), 3. 54 (dd, J = 9.2, 3.9, 1 H), 2.92-2.84 (m, 3H), 2.88 (dd, J = 10.1, 7.0, 2H), 2.68 (dd, J = 8.5, 5.6, 2H), 2.60-2.25 (m, 2H), 2.15-2.06 (m, 1H), 1.93-1.80 (m, 1H), 1. 78-1.64 (m, 2H).

EXAMPLE 327 3- (4- (2-f4- (Benzothiazol-2-loxy) -phenyl] -etyl} -piperidin-1-p-propionic acid trifluoromethanesulfonate salt The title compound was prepared according to the procedure of example 262, step A using 3-piperazin-1-yl-propionic acid MS (ESI): exact mass calculated for C2? H 3N3O3S, 411.2; m / z found, 412.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 11.25 (br s, 1 H), 7.76 (dd, J = 8.0, 0.5, 1 H), 7.69 (dd, J = 7.8, 0.6, 1 H), 7.42 (dt, J = 7.4, 1.2, 1 H), 7.35-7.28 (m, 5H), 3.76 (s, 1 H), 3.04 (t, J = 6.4, 4H), 2.91 (dd, J = 10.3, 5.4, 4H), 2.86-2.79 (m, 2H), 2.63 (t, J = 6.4, 1 H), 2.08 (s, 4H).

EXAMPLE 328 3- (1- { 2- [4- (Benzothiazol-2-yloxy) -phene-ethyl) -p.peridin-4-yl) -oxazolidin-2-one The title compound was prepared in accordance with procedure of example 262, step A using 3-piperidin-4-yl-oxazolidin-2-one hydrochloride salt and example 259, step A. MS (ESI): exact mass calculated for C23H25N3? 3S- ?, 423.2; m / z found, 424.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.77 (dd, J = 8.1, 0.5, 1 H), 7.69 (dd, J = 7.9, 1.1, 1 H), 7.41 (dt, J = 8.5, 1.2.1 H) , 7.35-7.28 (m, 5H), 4.36, (t, J = 7.8, 2H), 3.72 (t, J = 4.8, 2H), 3.86-3.76 (m, 1 H), 3.57 (t, J = 8.1 , 2H), 3.11 (brd, J = 11.8, 2H), 2.86 (dd, J = 11.0, 7.6, 2H), 2.66 (dd, J = 8.6, 5.2, 2H), 2.18 (dt, J = 11.7, 2.7 , 2H), 1.89-1.72 (m, 4H).

EXAMPLE 329 4- (1- {2-f4- (Benzothiazol-2-yloxy) -phene-ethyl) -piperidin-4-ip-morpholin-3-one The title compound was prepared according to the procedure of the example 262, step A using piperidin-4-yl-morpholin-3-one, and example 260, step A. MS (ESI): exact mass calculated for C24H27N303S ?, 437.2; m / z found, 438.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.76 (d, J = 8.0, 1 H), 7.70 (dd, J = 7.9, 0.7, 1 H), 7.42 (dt, J = 7.4, 1.2, 1 H), 7.33. -7.28 (m, 5H), 4.57 (tt, J = 11.9, 4. 3, 1 H), 4.23 (s, 2H), 3.91, (t, J = 4.9, 2H), 3.34 (t, J = 5.1, 2H), 3.12 (brd, J = 11.6, 2H), 2.87 (dd) , J = 10.9, 7.6, 2H), 2.67 (dd, J = 8.7, 5.2, 2H), 2.23 (ddd, J = 11.7, 11.6, 2.5, 2H), 1.82 (ddd, J = 24.1, 12.1, 3.8, 2H), 1.76-1.70 (m, 2H).

EXAMPLE 330 4- (1- (2-f4- (Benzothiazol-2-yloxy) -phenoxyl-ethyl) -piperidin-4-i0-morpholin-3-one The title compound was prepared according to the procedure of example 17, step A using piperidin-4-yl-morpholin-3-one and example 260, step A. MS (ESI): exact mass calculated for 024 ^ 7 ^ 048 ^ 453.2; m / z found, 454.4 [M + Hf. 1 H NMR (400 MHz, CDCI3): 7.76 (dd, J = 8.1, 0.5, 1 H), 7.68 (dd, J = 7.9, 0.7, 1 H), 7.40 (dt, J = 7.4, 1.3, 1 H), 7.31 -7.28 (m, 3H), 7.02-6.96 (m, 2H), 4.57 (tt, J = 12.1, 4.2, 1 H), 4.22 (s, 2H), 4.14 (t, J = 5.6, 2H), 3.90 (t, J = 5.0, 2H), 3.33 (t, J = 5.1, 2H), 3.12 (br d, J = 11.7, 2H), 2.87 (t, J = 5.7, 2H), 2.32 (ddd, J = 11.8, 11.8, 2.4, 2H), 1.82 (dddd, J = 12.2, 12.1, 12.1, 3.8, 2H), 1.75-1.68 (m, 2H).

EXAMPLE 331 3- (1- { 2- [4- (Benzothiazol-2-yloxy) -phenoxy-ethyl) -piperidin-4-yl) -oxazolidin-2-one The title compound was prepared according to the process of Example 17, step A using 3-piperidin-4-yl-oxazolidin-2-one hydrochloride salt and example 259, step A. MS (ESI): exact mass calculated for C23H25N3O4S1, 439.2; m / z found, 440.5 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.76 (dd, J = 8.1, 0.7, 1 H), 7.69 (dd, J = 8.0, 0.7, 1 H), 7.42 (dt, J = 8.6, 1.3, 1 H), 7.35-7.26 (m, 3H), 7.02-6.97 (m, 2H), 4.36 (dd, J = 8.7, 7.3, 2H), 4.14 (t, J = 5.7, 2H), 3.80 (ddd, J = 16.4, 11.0, 5.6, 1 H), 3.60-3.53 (m, 2H ), 3.12 (brd, J = 12.0, 2H), 2.87 (d, J = 5.7, 2H), 2.28 (ddd, J = 11.7, 11.6, 3.8, 2H), 1.90-1.74 (m, 4H).

EXAMPLE 332 1- Benzyloxyamide. { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl > -piperidine-4-carboxylic acid A solution of 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} Example-34-piperidine-4-carboxylic acid, step A (383 mg, 1.0 mmol) in CH2Cl2 (10 ml) was treated with N-methylmorpholine (0.24 ml, 2.2 mmol) and cyanuric chloride (61 mg, 0.3 mmol) and the solution The resulting mixture was stirred for 1 hr, at which time the reaction was treated with O-benzylhydroxylamine and stirred for 16 h. The reaction was filtered through diatomaceous earth, concentrated and purified on SiO2 (12 g, 0-10% 2M NH3 / MeOH / CH2Cl2) to give the title compound (81 mg, 17% yield). MS (ESI): exact mass calculated for C28H29N3? 3S, 487.2; m / z found, 488.5 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 8.34 (br s, 1 H), 7.76 (dd, J = 8.1, 0.5, 1 H), 7.70 (dd, J = 7.9, 0.7, 1 H), 7.45-7.39 ( m, 6H), 7.34-7.28 (m, 4H), 4.96 (br s, 2H), 3.05 (br d, J = 11.6, 2H), 2.85 (dd, J = 10.6, 7.6, 2H), 2.63 (dd) , J = 8.5, 5.5, 2H), 2.04 (ddd, J = 11.0, 11.0, 2.8, 2H), 1.91-1.76 (m, 2H).

EXAMPLE 333 Acid (1- (2-r4- (benzothiazol-2-ylox-phenyl) -ethyl) -piperidin-4-yl} acetic acid The title compound was prepared according to the procedure of example 262, step A using ethyl ester of piperidin-4-ylacetic acid and example 250, step D. MS (ESI): exact mass calculated for C22H24N2O3S ?, 396.2; m / z found, 397.4 [M + Hf. H NMR (400 MHz, CD3OD ): 8.34 (brs, 1H), 7.82 (dd, J = 7.9, 0.6, 1 H), 7.67 (dd, J = 8.1, 0.5, 1H), 7.53-7.33 (m, 6H), 3.78-3.66 ( m, 2H), 3.46-3.38 (m, 2H), 3.22-3.14 (m, 2H), 3.14-3.07 (m, 2H), 2.39 (br d, J = 6.1, 1 H), 2.20-2.08 (br s, 1 H), 2.11 (br d, J = 13.5, 1 H), 1.72-1.54 (m, 2H).

EXAMPLE 334 (R) -1- (1- (2-r4- (Benzothiazol-2-yloxy) -phenyl] -ethyl) -piperidin-4-yn-4-hydroxy-pyrrolidin-2-one The title compound is prepared according to the procedure of example 262, step A using acetic acid salt of (R) -4-hydroxy-1-piperidin-4-yl-pyrrolidin-2-one and example 261, step A. MS (ESI) : exact mass calculated for C24H27N3O3S1, 437.2; m / z found, 438.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.77 (dd, J = 8.1, 0.5, 1 H), 7.66 (dd, J = 7.9, 0.7, 1 H), 7.40 (dt, J = 7.7, 1.3, 1 H) , 7.28-7.24 (m, 5H), 4.52 (ddd, J = 8.5, 5.9, 2.4, 1H), 4.11-4.00 (m, 1H), 3.60 (dd, J = 10.7, 5.6, 1 H), 3.31 ( dd, J = 10.7, 2.2, 1H), 3.12-3.04 (m, 2H), 2.83 (dd, J = 9.7, 6.5, 2H), 2.72 (dd, J = 17.2, 6.6, 1 H), 2.63 (dd , J = 9.8, 6.4, 2H), 2.72 (dd, J = 17.2, 2.6, 1 H), 2.21-2.12 (m, 2H), 1.85-1.67 (m, 4H).

EXAMPLE 335 Hydroxyamide of acid 1-. { 2-f4- (Benzothiazol-2-yloxy) -phenin-etiiV piperidine-4-carboxylic acid The title compound was prepared according to the procedure of Example 262, Step A using piperidine-4-carboxylic acid hydroxyamide. MS (ESI): exact mass calculated for C2? H23N3O3S ?, 397.2; m / z found, 398.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73-7.60 (m, 2H), 7.40-7.30 (m, 1H), 7. 30-7.16 (m, 5H), 3.48-3.36 (br s, 2H), 3.10-2.95 (m, 4H), 2.80-2.50 (br m, 3H), 2.23-1.96 (br m, 5H).

EXAMPLE 336 (SH1- (2- [4- (Benzothiazoi-2-yloxy) -fenin-etl) -piperidin-4-yl) -4-hydroxy-pyrrolidin-2-one The title compound was prepared in accordance with procedure of example 262, step A using acetic acid salt of (S) -4-hydroxy-1-piperidin-4-yl-pyrrolidin-2-one, example 261, step A using (S) -4-bromo-3 -hydroxybutyrate MS (ESI): exact mass calculated for C24H27N3O3S- ?, 437.2; m / z found, 438.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.77 (dd, J = 8.1, 0.5, 1 H), 7.66 (dd, J = 7.9, 0.7, 1 H), 7.40 (dt, J = 7.7, 1.3, 1 H) , 7.28-7.24 (m, 5H), 4.52 (ddd, J = 8.5, 5.9, 2.4, 1 H), 4.11-4.00 (m, 1 H), 3.60 (dd, J = 10.7, 5.6, 1H), 3.31 (dd, J = 10.7, 2.2, 1 H), 3.12-3.04 (m, 2H), 2.83 (dd, J = 9.7, 6.5, 2H), 2.72 (dd, J = 17.2, 6.6, 1 H), 2.63 (dd, J = 9.8, 6.4, 2H), 2.72 (dd, J = 17.2, 2.6, 1 H), 2.21-2.12 (m, 2H), 1.85-1.67 (m, 4H).

EXAMPLE 337 (1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl) -piperidin-4-yl) -carbamic acid tert-butyl ester The title compound was prepared in accordance with procedure of Example 262, step A using piperidin-4-yl-carbamic acid tert-butyl ester. MS (ESI): exact mass calculated for C25H3? N303S ?, 453.2; m / z found, 454.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (dd, J = 8.2, 0.6, 1 H), 7.65 (dd, J = 7.9, 0.7, 1 H), 7.39 (dt, J = 7.4, 1.3, 1 H), 7.29-7.23 (m, 5H), 4.47 (br d, J = 6. 6, 1 H), 3.55-3.45 (m, 1H), 2.93 (brd, J = 11.3, 2H), 2.82 (dd, J = 11.0, 7.7, 2H), 2.60 (dd, J = 8.6, 5.3, 2H ), 2.16 (t, J = 11.3, 2H), 1.97 (brd, J = 11.1, 2H), 1. 45 (s, 9H).

EXAMPLE 338 2- (4-r2- (4-Fluoro-piperidin-1-yl) -etip-phenoxy) -benzothiazole The title compound was prepared in accordance with procedure of example 262, step A using 4-fluoropiperidine. MS (ESI): exact mass calculated for C20H2? F? N3O? S ?, 356.1; m / z found, 357.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (dd, J = 8.1, 0.5, 1 H), 7.65 (dd, J = 8.0, 0.7, 1 H), 7.41-7.36 (m, 1 H), 7.28-7.24 (m, 5H), 4.70 (dm, J = 48.6, 1 H), 2.85 (dd, J = 10.9, 7.7, 2H), 2.71-2.63 (m, 2H), 2.62 (dd, J = 8.3, 5.4, 2H), 2.52-2.44 (m, 2H), 2.03-1.86 (m, 4H).

EXAMPLE 339 2-. { 4-f2- (4,4-Difluoro-piperidin-1-yl) -etip-phenoxy) -benzothiazole The title compound was prepared according to the procedure of example 262, step A using 4,4-difluoropiperidine. MS (ESI): exact mass calculated for C2oH20F2N3O? S ?, 374.1; m / z found, 375.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (dd, J = 8.1, 0.6, 1 H), 7.65 (dd, J = 8.0, 0.7, 1 H), 7.41-7.36 (m, 1 H), 7.28-7.24 ( m, 5H), 2.82 (dd, J = 10.2, 6.4, 2H), 2.71-2.60 (m, 6H), 2.09-1.97 (m, 4H).

EXAMPLE 340 (R) -1-. { 2-r4- (Benzothiazol-2-ylox-phenyn-ethyl) -pyrrolidin-3-ol The title compound was prepared according to the procedure of example 262, step A using (R) -3-hydroxypyrrolidine. MS (ESI): exact mass calculated for C? 9H2oN2O2S ?, 340.1; m / z found, 341.1 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (dd, J = 8.0, 0.4, 1 H), 7.66 (dd, J = 7.9, 0.8.1H), 7.39 (dt, J = 7.4, 1.2, 1 H), 7.31-7.24 (m, 5H), 4.36 (dddd, J = 7. 3, 4.8, 2.2, 2.2, 1H), 2.96 (ddd, J = 8.5, 8.5, 5.1, 1H), 2.90-2.83 (m, 2H), 2.79- 2.70 (m, 3H), 2.58 (dd, J = 10.0, 5.2, 2H), 2.36 (ddd, J = 8.8, 8.8, 6.5, 1 H), 2.21 (dddd, J = 13.7, 8.6, 7.2, 5.1, 1H), 1.82-1.73 (m, 1H).

EXAMPLE 341 N- (1- (2-r4- (Benzot-azozol-2-yloxy) -phenin-ethyl) -piperidin-4-ip-formamide The title compound was prepared from example 337 following the procedure of example 266, step B and example 317. MS (ESI): exact mass calculated for C2iH23N3O2S ?, 381.2; m / z found, 382.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 8.16 (s, 1 H) 7.72 (d, J = 8.6, 1 H), 7.65 (dd, J = 7.9, 0.7, 1 H), 7.42-7.36 (m, 1 H), 7.31-7.23 (m, 5H), 4.03-3.93 (m, 1 H), 3.13-3.03 (m, 2H), 2.90 (dd, J = 11.1, 7.2, 2H), 2.75-2.69 (m, 2H), 2.34 (t, J = 9.2, 2H), 2.08-2.00 (m, 2H), 1.72-1.60 (m, 2H).

EXAMPLE 342 (1- 2-f4- (Benzothiazol-2-yloxO-phene-ethyl) -pperidin-4-iO-urea 1 - {2- [4- (benzothiazol-2-yloxy) hydrochloride) phenyl] -ethyl.}. -piperidin-4-ylamine was prepared from (1- {2- {4- (benzothiazol-2-yloxy) -phenyl] -ethyl-tert-butyl ester. .}. -piperidin-4-yl) -carbamic example 337 following the procedure of example 266, step B. The resulting amine hydrochloride (227 mg, 0.58 mmole) in CH2Cl2 (5 ml) was treated with pyridine (0.14 ml, 1.7 mmole), trimethyl isocyanate (0.09 ml, 0.64 mmol), and triethylamine (0.08 ml, 0. 58 mmol) and the reaction was stirred for 16 h. The reaction was diluted with CH 2 Cl 2 (25 mL) and washed with NaHCO 3 (30 mL). The organic layer was dried over Na 2 SO 4, filtered and concentrated under reduced pressure. The crude material was purified on Si02 (12 g, 0-10% of [NH3 2M] CH3OH / CH2Cl2) to give the title compound (134 mg, 58% yield). MS (ESI): exact mass calculated for C2? H24N4? 2S ?, 396.2; m / z found, 397.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.72 (d, J = 8.7, 1 H), 7.65 (dd, J = 7.9, 0.7, 1 H), 7.42-7.36 (m, 1 H), 7.31-7.23 (m , 5H), 4.93 (d, J = 8.0, 1 H), 4.78 (s, 2H), 3.93 (br d, J = 11.7, 1H), 2.82 (dd, J = 10.7, 7.6, 2H), 2.60 ( dd, J = 8.5, 5.4, 2H), 2.16 (t, J = 11.3, 2H), 1.97 (dd, J = 12.7, 3.1, 2H), 1.47 (dddd, J = 12.8, 12.6, 12.6, 3.7, 2H ).

EXAMPLE 343 1- (1- {2-r4- (Benzothiazol-2-yloxy) -fenip-ethyl.}. -piperidin-4-yl) -3-cyano-2-phenyl-isourea The hydrochloride of 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-ylamine was prepared from (1- {2- {4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -carbamic acid tert-butyl ester. Example 337 by removal of the Boc group according to example 266, step B. The free base was prepared by suspending 1- hydrochloride. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-ylamine (1.3 g, 3.3 mmol) in CH2Cl2 (20 ml) and washing with a saturated NaHCO3 solution (20 ml). The organic layer was dried over Na2SO, filtered and concentrated under reduced pressure to give 1.0 g (83% yield) of free base of 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etif) -piperidin-4-ylamine. A solution of 1-. { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -peridin-4-yl amine (145 mg, 0.4 mmol) in ethanol (5 ml) was treated with cyanocarbodiimidate of diphenyl (319 mg, 1.34 mmol) and heated at 80 ° C for 16 hr. The reaction was concentrated under reduced pressure and purified over SiO2 (12 g, 0-10% of [NH3 2M CH3OH] / CH2Cl2) to give the title compound (173 mg, 85% yield). MS (ESI): exact mass calculated for C28H2 N5O2S ?, 496.2; m / z found, 498.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 8.7, 1 H), 7.66 (dd, J = 7. 9, 0.7, 1 H), 7.45-7.36 (m, 4H), 7.31-7.24 (m, 5H), 7.08 (d, J = 7.8, 2H), 6.36 (br d, J = 6.5, 1 H), 3.87-3.76 (m, 1H), 3.02 (br d, J = 11.2, 2H), 2.83 (dd, J = 8.4, 7.3, 2H), 2.64 (dd, J = 8.6, 5.4, 2H), 2.21 (t, J = 11.1, 2H), 2.07 (d, J = 11. 0, 2H), 1.76 (dd, J = 20.7, 10.4, 2H).

EXAMPLE 344 1- (1- (2-r4- (Benzothiazol-2-yloxy) -phenin-ethyl.}. -piperidin-4-yl) -3-cyano-2-methyl-isothiourea The hydrochloride of 1-. {2 - [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl.}. -piperidin-4-ylamine was prepared from (1- {2- {4- (benzothiazole-) -butyl butyl ester. 2-yloxy) -phenyl] -ethyl.}. -piperidin-4-yl) -carbamic acid, example 337, by removal of the Boc group in accordance with example 266, step B. The free base was prepared in accordance with example 343. A solution of 1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl amine (145 mg, 0.4 mmol) in ethanol (5 ml) was treated with dimethyl N-cyanodithioiminocarbonate (180 mg, 1.34 mmol) and heated at 80 ° C for 16 hr. The reaction was concentrated under reduced pressure and purified on SiO2 (12 g, 0-10% 2M NH3 / CH3OH / CH2Cl2) to give the title compound (143 mg, 69% yield). MS (ESI): exact mass calculated for C23H25N5O? S2, 451.2; m / z found, 452.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (dd, J = 8.1, 0.5, 1 H), 7.66 (dd, J = 7.9, 0.7, 1 H), 7.41-7.36 (m, 2H), 7.29-7.24 ( m, 5H), 6.13 (br d, J = 196, 2H), 2.97 (br d, J = 12.0, 2H), 2.82 (dd, J = 10.3, 7.3, 2H), 2.62 (dd, J = 8.5, . 5, 2H), 2.60-2.44 (br s, 3H), 2.18 (t, J = 11.5, 2H), 2.03 (d, J = 13.5, 2H), 1.7- 1.55 (m, 2H).

EXAMPLE 345 N- (1- (2-f4- (Benzothiazol-2-yloxy) -phenyl-ethyl) -p -peridin-4-yl) -methanesulfonamide The hydrochloride of 1-. { 2- [4- (benzothiazol-2-yloxy) -phenyl] -etl} -piperidin-4-ylamine was prepared from (1- {2- {4- (benzothiazol-2-yloxy) -phenyl-ethyl} -piperidin-4-yl) -carbamic acid tert-butyl ester. 337 by removing the group Boc according to example 266, step B. The free base was prepared according to example 343. The free base (240 mg, 0.68 mmol) in CH 2 Cl 2 (7 ml) was treated with triethylamine (142 μl, 1.0 mmol) followed by methanesulfonyl chloride (77 μl, 1.0 mmol) and the solution was stirred for 16 hr. The reaction was diluted with CH2Cl2 (20 ml) and washed with NaHCO3 solution (30 ml). The organic layer was dried and concentrated under reduced pressure then purified on SiO2 (12 g, 0-10% 2M NH3 / MeOH: CH2Cl2) to give 168 mg (57% yield) of the title compound. MS (ESI): exact mass calculated for C21H25N3O3S2, 431.1; m / z found, 432.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 8.0, 1H), 7.65 (dd, J = 7.9, 0.7, 1 H), 7.42-7.36 (m, 1 H), 7.29-7.24 (m, 5H), 4.45 (d, J = 7.6, 1 H), 3.42-3.31 (m, 1 H), 2.99 (s, 3H), 2.93 (brd, J = 12.0, 2H), 2.81 (dd, J = 10.6) , 7.5, 2H), 2.60 (dd, J = 8.5, 5.4, 2H), 2.18 (t, J = 11.0, 2H), 2.02 (d, J = 12.5, 2H), 1.47 (dddd, J = 11.2, 11.1 , 11.1, 3.7, 2H).

EXAMPLE 346 1- (1- {2-f4- (Benzothiazol-2-yloxy) -phenylethyl) -p -peridin-4-yl) -3-cyano-2-methyl-guanidine A solution of 1- ( 1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.}. -piperidin-4-yl) -3-cyano-2-phenyl-isourea, example 343, (76 mg, 0.15 mmoles) in ethanol (3 ml) was treated with a 40% solution of methylamine in water (0.2 ml) and the solution was stirred at 80 ° C for 1 hr. The reaction was cooled to 23 ° C and concentrated under reduced pressure to give a crude solid which was purified on SiO2 (4 g, 0-10% 2M NH3 / MeOH: CH2C! 2) to give 50 mg (76% strength). yield) of the title compound. MS (ESI): exact mass calculated for C23H26N6O? S ?, 434.2; m / z found, 435.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.72 (d, J = 8.1, 1 H), 7.67 (dd, J = 7. 9, 0.7, 1H), 7.42-7.36 (m, 2H), 7.29-7.24 (m, 5H), 5.67 (br s, 1t), 4.75 (br s, 1 H), 3.63 (br s, 1 H), 2.94 (br d, J = 11.9, 2H), 2.86 (d, J = 4.9, 2H), 2.82 (dd, J = 10.4, 7.4, 2H), 2.61 (dd, J = 8.5, 5.5, 2H), 2.18 (t, J = 11.4, 2H), 2.05-1.96 (m, 2H), 2.61 (dddd, J = 12.3, 12.3, 12.3, 3.6, 2H).

EXAMPLE 347 8- (2-f4- (Benzothiazol-2-yloxy) -phenin-ethyl.} -1-phenyl-1,3,8-triaza-spiro [4.51decan-4-one] The title compound was prepared in accordance with the procedure of example 262, step A using 1-phenyl-1,3,8-triaza-spiro [4.5] decan-4-one MS (ESI): exact mass calculated for C28H28N4? 2S ?, 484.2; m / z found, 485.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.74 (dd, J = 8.0, 0.5, 1 H), 7.66 (dd, J = 7.9, 0.7, 1 H), 7.52 (s, 1 H), 7.42-7.36 (m, 1 H), 7.34-7.24 (m, 6H), 6.91 (d, J = 8.0, 1H), 6.87 (t, J = 7.3, 1H), 4.75 (s, 2H) , 2.95-2.85 (m, 4H), 2.76-2.66 (m, 4H), 1.76 (d, J = 13.9, 2H).

EXAMPLE 348 8- (2-r4- (Benzothiazol-2-yloxy) -phenyl] -ethyl) -1.3.8-triaza-spiro [4.51 decane-2,4-dione] The title compound was prepared according to the procedure of the example 262, step A using 1, 3,8-triaza-spiro [4.5] decane-2,4-dione. MS (ESI): exact mass calculated for C22H22N4O3S1, 422.1; m / z found, 423.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (dd, J = 8.1, 0.5, 1 H), 7.67 (dd, J = 7.9, 1.1, 1H), 7.42-7.36 (m, 1 H), 7.34-7.24 ( m, 5H), 3.0 (ddd, J = 9.2, 4.3, 4.3, 2H), 2.86 (dd, J = 10.6, 6.9, 2H), 2.69 (dd, J = 9.0, 5.3, 2H), 2.72 (t, J = 10.2, 2H), 2.19-2.10 (m, 2H), 1.75 (d, J = 13.6, 2H).

EXAMPLE 349 (1- {2- [4- (Benzothiazol-2-yloxy) -phenp- ethyl} - pyridin-4-yl) -methylcarbamic acid tert-butyl ester The title was prepared according to the procedure of Example 262, Step A using tert-butyl methyl-piperidin-4-yl-carbamic acid ester. MS (ESI): exact mass calculated for C26H23N3O3S ?, 467.2; m / z found, 468.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (dd, J = 8.1, 0.5, 1 H), 7.66 (dd, J = 7.9, 0.7, 1 H), 7.41-7.36 (m, 1 H), 7.29-7.25 (m, 5H), 4.10-3.95 (br m, 1 H), 3. 07 (d, J = 11.6, 2H), 2.83 (dd, J = 11.1, 7.8, 2H), 2.75 (s, 3H), 2.61 (d, J = 8.6, 5.2, 2H), 2.11 (t, J = 10.9, 2H), 2.19-2.10 (m, 2H), 1.77 (dddd, J = 12.1, 12. 0, 12.0, 3.3, 2H), 1.70-1.64 (m, 2H), 1.47 (s, 9H).

EXAMPLE 350 N-1- (2- [4- (Benzothiazol-2-yloxy) -phenyl-1-ethyl) -piperidin-4-yl) -N-methyl-acetamide The title compound was prepared from Example 349 following example 266 , step B, example 343 and example 345 using acetyl chloride. MS (ESI): exact mass calculated for C23H27N3O2S ?, 409.2; m / z found, 410.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (dd, J = 8.1, 0.6, 1 H), 7.66 (d J = 8.0, 1.1, 1 H), 7.41-7.36 (m, 1 H), 7.31-7.25 (m , 5H), 4.53 (tt, J = 12.0, 4.2, 0.5H), 3.54 (tt, J = 11.7, 4.0, 0.5H), 3.15-3.04 (m, 2H), 2.90-2.78 (m, 5H), 2.70-2.58 (m, 2H), 2.24-2.06 (m, 5H), 2.00-1.96 (m, 1H), 1.82-1.60 (m, 3H).

EXAMPLE 351 N- (1-f2- [4- (Benzothiazol-2-yloxy) -fenin-etl) -piperidin-4-y-N-methylalmethanesulfonamide The title compound was prepared from the example 349 following example 266, step B, example 343 and example 345 using chloride of methanesulfonyl. MS (ESI): exact mass calculated for C25H29N3? 4S, 467.2; m / z found, 468.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 8.1, 1 H), 7.66 (dd, J = 7.9, 0.7, 1 H), 7.42-7.36 (m, 1 H), 7.29-7.24 (m , 5H), 3.78 (tt, J = 11.9, 4.2, 1 H), 3. 08 (dd, J = 9.6, 2.1, 1 H), 2.84 (s, 3H), 2.82 (s, 3H), 2.83-2.79 (m, 2H), 2.61 (dd, J = 8.5, 5.3, 2H), 2.18 (ddd, J = 11.8, 11.8, 2.2, 2H), 1.86 (dddd, J = 12.2, 12. 0, 12.0, 3.4, 2H), 1.76-1.69 (m, 2H).

EXAMPLE 352 Ester [(1- ({2-f4- (benzothiazol-2-yloxy) -phenyl-1-ethyl) -piperidin-4-yl) -methyl-carbamoy-methyl-acetic acid ester The title compound was prepared from the example 349 following example 266, step B, example 343 and example 345 using chlorocarbonylmethyl ether acetic acid ester. MS (ESI): exact mass calculated for C23H27N3O S, 467.2; m / z found, 468.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (dd, J = 8.1, 0.5, 1 H), 7.66 (d, J = 7.9, 1 H), 7.42-7.36 (m, 1 H), 7.29-7.24 (m , 5H), 4.76 (s, 0.6H), 4.71 (s, 1.4H), 4.48 (tt, J = 12.0, 4.3, 0.7 H), 3.36 (tt, J = 11.6, 4.4, 0.3 H), 3.16- 3.04 (m, 2H), 2. 90-2.78 (m, 5H), 2.68-2.58 (m, 2H), 2.19 (s, 3H), 2.19-2.05 (m, 2H), 2.01-1.84 (m, 1 H), 1.82-1.60 (m, 3H).

EXAMPLE 353 N-1-. { 2-r4- (Benzothiazol-2-yloxy) -phenin-ethyl) -piperidin-4-yl) -N-acetamide The title compound was prepared from example 337 following example 266, step B, example 343 and example 345 using acetyl chloride. MS (ESI): exact mass calculated for C25H29N3O4S, 395.2; m / z found, 396.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 8.0, 1 H), 7.66 (dd, J = 7. 9, 0.6, 1 H), 7.42-7.36 (m, 1 H), 7.29-7.24 (m, 5H), 5.48 (d, J = 7.8, 1 H), 3.87-3.77 (m 1 H), 2.95 ( dd, J = 11.6, 2H), 2.83 (dd, J = 10.8, 7.6, 2H), 2.62 (dd, J = 8.5, 5.3, 2H), 2.18 (d, J = 11.4, 2H), 2.00-1.94 ( m, 2H), 1.98 (m, 2H), 1.49 (dddd, J = 12.3, 12.2, 12.2, 3.6, 2H).

EXAMPLE 354 Ester (1- (2- [4- (benzothiazol-2-yloxy) -phenp-ethyl) -piperidin-4-ylcarbamoyl-methyl-acetic acid The title compound was prepared from Example 337 in accordance with example 266, step B, example 343 and example 354 using chlorocarbonylmethyl acetic acid ester EM (ESI): exact mass calculated for C 24 H 27 N 3 4 4 S, 453.2, m / z found, 454.3 [M + Hf. 1 H NMR (400 MHz , CDCI3): 7.73 (dd, J = 8.2, 0.6, 1 H), 7.67 (dd, J = 7.9, 0.7, 1 H), 7.42-7.36 (m, 1 H), 7.29-7.24 (m, 5H) , 6.05 (d, J = 8.0, 1 H), 4.54 (s, 2H), 3.96-3.85 (m 1 H), 3.00 (d, J = 8.2, 0.6, 2H), 2.85 (dd, J = 10.6, 7.4, 2H), 2.85 (dd, J = 10.6, 7.4, 2H), 2.66 (dd, J = 8.6, 5.3, 2H), 2.23 (t, J = 11.4, 2H), 2.18 (s, 3H), 1.98 (d, J = 9.7, 2H), 1.57 (dddd, J = 12.4, 12.4, 12.3, 3.6, 2H).

EXAMPLE 355 (S) -2 - ((2-r4- (Benzothiazol-2-yloxy) -phenyl) -ethyl) -methyl-amino) -3- (1 H-imidazol-2-yl) -propionic acid The title compound was prepared according to the procedure of Example 262, step A using (S) -3- (1 H-imidazol-2-yl) -2-methylamino-propionic acid.

MS (ESI): exact mass calculated for C22H22N O3S ?, 422.1; m / z found, 423.3 [M + Hf. 1 H NMR (400 MHz, CD 3 OD): 8.85, (s, 1 H), 7.81 (dd, J = 7.9, 0.6, 1 H), 7.72 (dd, J = 8.1, 0.5, 1 H), 7.58-7.42 (m , 4H), 7.39-7.34 (m, 3H), 4.34, (dd, J = 9.3, 4.9, 3H), 3.71-3.42, (m, 4H), 3.35-3.32 (m, 2H), 3.20 (d, J = 8.6, 2H), 3.08 (s, 3H).

EXAMPLE 356 2- (4- (2-r4- (3-Nitro-pyridin-2-yl) -ri, 41-diazepan-1-in-ethyl-hexoxy) -benzothiazole The title compound was prepared according to the procedure of Example 262, step A using 1- (3-n-thyridin-2-yl) - [1,4] diazepam EM (ESI): exact mass calculated for C25H25N5O3S ?, 475.2; m / z found, 476.1 [M + Hf 1 H NMR (400 MHz, CDCl 3): 8.36 (dd, J = 4.5, 1.7, 1 H), 8.14 (dd, J = 8.1, 1.7, 1 H), 7.77 (dd, J = 8.1, 0.5, 1 H ), 7.70 (dd, J = 8.0, 0.7, 1 H), 7.45- 7.40 (m, 1 H), 7.29-7.24 (m, 5H), 6.73 (dd, J = 8.0, 4.4, 1 H), 3.80 -3.75 (br s, 2H), 3.47-3.40 (br s, 2H), 3.07-3.01 (br s, 2H), 2.95-2.88 (m, 2H), 2.86-2.79 (m, 4H), 2.20-2.10 (br s, 2H).

EXAMPLE 357 2- (4-Piperidin-1-ylmethyl-phenox-benzothiazole) The title compound was prepared according to the procedure of Example 251, step B using piperidine, MS (ESI): mass calculated for C? 9H20N2OS, 324.4; m / z found, 325.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.75 (d, J = 8.2, 1 H), 7.73 (d, J = 8.2, 1 H), 7.36-7.42 ( m, 3H), 7.24-7.32 (m, 3H), 3.49 (s, 2H), 2.39 (br s, 3H), 1.56-1.64 (m, 5H), 1.40-1.48 (m, 2H).

EXAMPLE 358 1-r4- (Benzothiazol-2-yloxy) -bencip-4-phenyl-piperidin-4-ol The title compound was prepared according to the procedure of example 251, step B using 4-phenyl-piperidin-4-ol . MS (ESI): mass calculated for C25H24N2? 2S, 416.5; m / z found, 417.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.75 (d, J = 8.0, 1 H), 7.66 (d, J = 8.0, 1 H), 7.55-7.51 (m, 2H), 7.47-7.25 (m, 9H), 3.63 (s, 2H), 2.85-2.77 (m, 2H), 2. 50 (dt, J = 11.8, 2.5, 2H), 2.18 (dt, J = 13.0, 4.4, 2H), 1.80-1.74 (m, 2H), 1.55 (br s, 1 H).

EXAMPLE 359 1- [4- (Benzothiazol-2-yloxy) -bencip-piperidin-4-ol The title compound was prepared according to the procedure of example 251, step B using 4-piperidinol. MS (ESI): mass calculated for C? 9H or N2O2S, 340.4; m / z found, 341.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.74 (d, J = 8.0, 1 H), 7.67 (d, J = 8. 0, 1H), 7.42-7.36 (m, 3H), 7.32-7.24 (m, 3H ), 3.68-3.64 (m, 1 H), 3.46 (s, 2H), 2.81-2.25 (m, 2H), 2.20-2.15 (m, 2H), 1.95-1.90 (m, 2H), 1.67-1.58 ( m, 3H).

EXAMPLE 360 rß yCT0" . { 1- [4- (Benzothiazol-2-yloxy) -bencip-piperidin-4-yl} -methanol The title compound was prepared according to the procedure of Example 251, step B using piperidin-4-yl-methanol.

MS (ESI): mass calculated for C20H22N2O2S, 354.5; m / z found, 355.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.74 (d, J = 8.0, 1 H), 7.67 (d, J = 8.0, 1 H), 7.42-7.37 (m, 3 H), 7.32-7.25 (m, 3 H) , 3.54 (s, 2H), 3.51 (d, J = 6.5, 2H), 2.97-2.90 (m, 2H), 2.01 (dt, J = 11.6, 2.4, 3H), 1.73 (d, J = 12.1, 2H) ), 1.58-1.47 (m, 1H), 1.37-1.26. { m, 2H).

EXAMPLE 361 N-. { 1- [4- (Benzothiazol-2-yloxy) -bencip-piperidin-4-yD-methanesulfonamide The title compound was prepared according to the procedure of Example 253, steps A and B followed by example 258 step C. EM (ESI): mass calculated for C2oH23N3O3S2, 417.6; m / z found, 418.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.74 (d, J = 8.0, 1H), 7.68 (d, J = 8.0, 1H), 7.42-7.36 (m, 3H), 7.35-7.25 (m, 3H), 4.32. -4.5 (m, 1 H), 3.58 (s, 2H), 3.43-3.32 (m, 1 H), 2.99 (s, 3H), 2.87-2.80 (m, 2H), 2.18-2.10 (m, 2H) , 2.04-1.96 (m, 2H), 1.64-1.54 (m, 2H).

EXAMPLE 362 N-. { 1- [4- (Benzothiazol-2-yloxy) -benzin-p-peridin-4-ylmethyl) -2-hydroxy-acetamide The title compound was prepared according to the procedure of example 258, steps A and B followed by example 253 step C using glycolic acid. MS (ESI): mass calculated for C 2 H 25 N 3 O 3 S, 411.5; m / z found, 412.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.74 (d, J = 8.2, 1 H), 7.67 (d, J = 8.2, 1 H), 7.42-7.37 (m, 3 H), 7.32-7.25 (m, 3 H) , 4.11 (s, 2H), 3.51 (s, 2H), 3.24 (t, J = 6.3, 2H), 2.88-2.94 (m, 2H), 2.20 (d, J = 11.5, 1 H), 2.02-1.92 (m, 2H), 1.72-1.65 (m, 2H), 1.62-1.50 (m, 2H), 1.36-1.26 (m, 2H).

EXAMPLE 363 Acid methyl ester (1-f4- (benzothiazol-2-ylox-benzyl-piperidin-4-illcarbamic acid) The title compound was prepared in accordance with procedure of Example 253, steps A and B followed by example 258 step C using methyl isocyanate. MS (ESI): mass calculated for C2? H23N3O3S, 397.5; m / z found, 398.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.74 (d, J = 8.0, 1 H), 7.67 (d, J = 8.0, 1 H), 7.42-7.36 (m, 3H), 7.32-7.24 (m, 3H) , 4.57 (br s, 1 H), 3.66 (s, 3H), 3.51 (s, 2H), 2.85-2.79 (m, 2H), 2.18-2.09 (m, 2H), 1.98-1.90 (m, 2H) , 1.51-1.40 (m, 2H).

EXAMPLE 364 (1- [4- (Benzothiazol-2-yloxy) -benzin-piperidin-4-ylmethyl) -urea The title compound was prepared according to the procedure of Example 258, steps A, B and C using trimethylsilyl isocyanate. MS (ESI): mass calculated for C2? H24N4? 2S, 396.5; m / z found, 397.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.74 (d, J = 8.0, 1 H), 7.67 (d, J = 8.0, 1 H), 7.42-7.36 (m, 3H), 7.32-7.24 (m, 3H), 4.64 (br s, 1 H), 4.35 (s, 2H), 3.50 (s, 2H), 3.07 (br t, J = 6.3, 2H), 2.94-2.88 (m, 2H), 1.86-2.01 (m, 2H), 1.72-1.66 (m, 2H), 1.56-1.44 (s, 1 H), 1.24-1.23 (m, 2H).

EXAMPLE 365 N-. { 1-f4- (Benzothiazol-2-yloxy) -bencip-p-peridin-4-ylmethyl) -2.2.2-trifluoroacetamide The title compound was prepared according to the procedure of example 258, steps A and B and example 257, step C using trifluoroacetic acid. MS (ESI): mass calculated for C22H22F3N3O2S, 449.5; m / z found, 450.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.74 (d, J = 8.0, 1 H), 7.67 (d, J = 8.0, 1 H), 7.42-7.36 (m, 3H), 7.32-7.24 (m, 3H) , 6.41 (br s, 1H), 3.51 (s, 2H), 3.28 (t, J = 6.46, 2H), 2.92 (d, J = 11.5, 2H), 2.02-1.94 (m, 2H), 1.74-1.54 (m, 3H), 1.38-1.27 (m, 2H).

EXAMPLE 366 ? x OH Acid (4- [4- (benzothiazol-2-ylox-bencip-piperidin-1-iD-acetic acid The title compound was prepared in accordance with procedure of example 259, step C and D and example 250, step D using piperazin-1-yl-acetic acid. MS (ESI): mass calculated for C20H2? N3O3S, 383.5; m / z found, 384.4 [M + Hf. 1 H NMR (400 MHz, CD 3 OD): 7.77 (d, J = 8.0, 1 H), 7.62 (d, J = 8.0, 1 H), 7.50-7.46 (m, 2H), 7.42-7.26 (m, 4H) , 6.67 (s, 2H), 3.60 (s, 2H), 3.34 (br s, 4H), 2.77 (br s, 4H).

EXAMPLE 367 2- [4- (4-Methanesulfonyl-piperazin-1-ylmethyl) -phenoxy] -benzothiazole The title compound was prepared according to the procedure of example 257, steps A and B and example 258 step C. MS (ESI) : mass calculated for C? 9H2? N3O3S2, 403.53; m / z found, 404.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.74 (d, J = 8.0, 1 H), 7.68 (d, J = 8.0, 1 H), 7.42-7.36 (m, 3 H), 7.35-7.26 (m, 3 H) , 3.57 (s, 2H), 3.26 (br t, J = 4.7, 4H), 2.79 (s, 3H), 2.58 (br t, J = 4.7, 4H).

EXAMPLE 368 1- (4- [4- (Benzothiazol-2-yloxy) -benzyl-1-pyrrazin-1-ylV2.2,2-trifluoro-ethanone The title compound was prepared according to the procedure of example 257 , step A, B and C using trifluoroacetic acid MS (ESI): mass calculated for C20H? sF3N3O2S, 421.44, m / z found, 422.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.74 (d, J = 8.0, 1 H), 7.68 (d, J = 8.0, 1 H), 7.42-7.27 (m, 6H), 3.74-3.70 (m, 2H), 3.65-3.60 (m, 2H), 3.57 (s, 2H), 2.56-2.50 (m, 4H).

EXAMPLE 369 2- (4-Morpholin-4-ylmethyl-phenoxy) -benzothiazole The title compound was prepared according to the procedure of example 259, step C and D using morpholine. MS (ESI): mass calculated for C? 8H? 8N202S, 326.42; m / z found, 327.4 [M + Hf. 1 H NMR (500 MHz, CDCl 3): 7.74 (d, J = 7.7, 1 H), 7.67 (d, J = 7.7, 1 H), 7.42-7.37 (m, 3H), 7.33-7.25 (m, 3H), 3.72 (t, J = 3.7, 4H), 3.52 (s, 2H), 2.46 (br s, 4H).

EXAMPLE 370 Phenyl ester of acid. { 1- [4- (Benzothiazol-2-yloxy) -benzyl-1-piperidin-4-yl} -carbamic The title compound was prepared according to the procedure of example 253, steps A and B followed by example 258 step C using phenyl isocyanate. MS (ESI): mass calculated for C26H25N3O3S, 459.57; m / z found, 460.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.74 (d, J = 8.0, 1 H), 7.67 (d, J = 8.0, 1 H), 7.42-7.10 (m, 11H), 4.95 (brd, J = 7.8, 1 H), 3.67-3.58 (m, 1 H), 3.53 (s, 2H), 2.88-2.82 (m, 2H), 2.21-2.06 (m, 2H), 2.03-1.99 (m, 2H), 1.61-1.44 (m, 2H).

EXAMPLE 371 N- (1- [4- (Benzothiazol-2-yloxy) -benzin-piperidin-4-yl) -benzenesulfonamide The title compound was prepared according to the procedure of example 253, steps A and B followed by example 258, step C 5 using benzenesulfonyl chloride. MS (ESI): mass calculated for C25H25N3O3S2, 479.62; m / z found, 480.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.86-7.84 (m, 2 H), 7.75 (d, J = 8.0, 1 H), 7.67 (d, J = 8.0, 1 H), 7.60-7.48 (m, 3 H), 7.41-7.24 (m, 6H), 4.56 (br d, J = 0 7.8, 1 H), 3.48 (s, 2H), 3.26-3.16 (m, 1 H), 2.76-2.68 (m, 2H), 2.06 -1.97 (m, 2H), 1.78-1.70 (m, 1H), 1.52-1.42 (m, 2H).

EXAMPLE 372 3-R4- (Benzothiazol-2-yloxy) -benzylamino-1-propionic acid ethyl ester The title compound was prepared according to the procedure of Example 251, Steps A and B using 3-amino-propionic acid ethyl ester. MS (ESI): mass calculated for C? 9H20N2O3S, 356.45; m / z found, 357.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.74 (d, J = 8.0, 1 H), 7.67 (d, J = 8.0, 1 H), 7.44-7.25 (m, 6H), 4.21 (br s, 1 H), 4.15 (q, J = 7.2, 2H), 3.87 (s, 2H), 2.95 (t, J = 6.3, 2H) , 2.58 (t, J = 6.3, 2H), 1.26 (t, J = 7.2, 3H).

EXAMPLE 373 3- [4- (Benzothiazol-2-yloxy) -benzylamino-propionic acid The title compound was prepared according to the procedure of example 372, and example 250, step D. MS (ESI): mass calculated for C? 7H 6N2O3S, 328.39; m / z found, 329.3 [M + Hf. 1 H NMR (400 MHz, DMSO): 7.87 (d, J = 8.0, 1 H), 7.62 (d, J = 8.0, 1 H), 7.44-7.23 (m, 6H), 3.77 (s, 2H), 2.72. (t, J = 6.6, 2H), 2.29 (t, J = 6.6, 2H).

EXAMPLE 374 [(1- {2-f4- (benzothiazol-2-yloxy) -phenox-ethyl) -piperidine-4-carbonyl) -methyl-amino-1-acetic acid ethyl ester The title compound was prepared in accordance with procedure of example 18, step A and example 20 using 3-methylamino-propionic acid ethyl ester. MS (ESI): mass calculated for C26H31N3O5S, 497.62; m / z found, 498.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 8.0, 1 H), 7.65 (d, J = 8.0, 1 H), 7.41-7.35 (m, 1 H), 7.28-7.23 (m, 3H), 6.99-6.94 (m, 2H), 4.28-4.08 (m, 5H), 3.12 (s, 3H), 3.10- 3.04 (m, 1 H), 2.98-2.81 (m, 4H), 2.62-2.53 (m, 1 H), 2.24-2.12 (m, 2H), 1.97-1.83 (m, 2H), 1.81-1.64 (m , 2H), 1.32-1.24 (m, 3H).

EXAMPLE 376 Ethyl ester of 1 '- (2-f4- (benzothiazol-2-yloxyVfenoxp-et'D-ri, 4'1-bipiperidinyl-4-carboxylic acid The title compound was prepared according to the procedure of Example 9 and Example 24 using [1, 4 '] bipiperidinyl-4-carboxylic acid ethyl ester MS (ESI): mass calculated for C28H35N3O4S, 509.67; m / z found, 510.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 8.0, 1 H), 7.65 (d, J = 8.0, 1 H), 7.41-7.35 (m, 1 H), 7.29-7.23 (m, 3H), 6.99-6.92 (m, 2H) , 4.16-4.08 (m, 4H), 3.10-3.04 (m, 2H), 2.92-2.86 (m, 2H), 2.80 (t, J = 5.9, 1 H), 2.36-2.20 (m, 4H), 2.16-2.07 (m, 2H) , 1.95-1.87 (m, 2H), 1.82-1.57 (m, 7H), 1.24 (t, J = 7.0, 3H).

EXAMPLE 377 1 '-r2-r4- (Benzothiazol-2-yloxy) -phenox-ethyl) - [1,4'-bipiperidinyl-4-carboxylic acid The title compound was prepared according to the procedure of example 376 and example 250, step D. MS (ESI): mass calculated for C26H3? N304S, 481.62; m / z found, 482.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.76 (d, J = 8.0, 1 H), 7.64 (d, J = 8.0, 1 H), 7.44-7.38 (m, 1H), 7.32-7.27 (m, 3H), 7.08-7.03 (m, 2H), 4.17 (t, J = 5.4, 2H), 3.44-3.36 (m, 2H) , 3.24-3.19 (m, 2H), 3.05-2.84 (m, 5H), 2.40-2.20 (m, 3H), 2.14-2.04 (m, 4H), 1.86-1.72 (m, 4H).

EXAMPLE 378 . { 2- [4- (Benzothiazol-2-yloxyHenip-ethyl) -cyclopropyl-ethyl-amine A. (2- [4- (Benzothiazol-2-yloxy) -phenyl-1-ethyl) -cyclopropylamine. A mixture of [4- (benzothiazol-2-yloxy) -phenyl] -acetaldehyde (example 262 step A, 4.2 g, 15.6 mmol), cyclopropylamine (5.4 ml, 78.0 mmol) and acetic acid (4.5 ml, 78 mmol) in CH2Cl2 (156 ml) was stirred at room temperature for 1 hr. To the resulting mixture was added NaBH (OAc) 3 (6.61 g, 31.2 mmol). The mixture was stirred at room temperature for 24 hr, filtered through diatomaceous earth, rinsed with CH2CI2 (200 ml), washed with 1 N NaOH (3 x 50 ml), and concentrated under reduced pressure to give the raw product as a yellow oil. The crude product was purified on SiO2 (330 g; 0-10% CH3OH / CH2Cl2) to give a clear oil that crystallized on standing (3.4 g, 71% yield). MS (ESI): mass calculated for C? 8H? 8N2OS, 310.11; m / z found, 311.2 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.76 (d, J = 8.1, 1 H), 7.62 (d, J = 8.1, 1 H), 7.46-7.27 (m, 6H), 3.41 (t, J = 7.6, 2H), 3.08 (t, J = 7.6, 2H), 2.38-2.76 (m, 1 H), 0.95-0.89 (m , 4H). B. • f2-r4- (Benzothiazol-2-yloxy) -phenin-ethyl) -cyclopropyl-ethyl-amine. A mixture of acetaldehyde (180 μl, 3.2 mmol),. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} Cyclopropyl amine (500 mg, 1.6 mmol) in CH 2 Cl 2 (32 mL) was stirred at room temperature for 1 hr. To the resulting mixture was added NaBH (OAc) 3 (1.02 g, 4.8 mmol). The mixture was stirred at room temperature for 24 hr, filtered through diatomaceous earth, rinsed with CH 2 Cl 2 (100 ml), and concentrated under reduced pressure to give the crude product as a yellow oil. The crude product was purified on SiO2 (40 g, 0-10% CH3OH / CH2Cl2) to give a clear oil (465 mg, 86% yield). MS (ESI): mass calculated for C2oH22N2OS, 338.15; m / z found, 339.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.66 (d, J = 8.1, 1 H), 7.58 (d, J = 8.1, 1 H), 7.31 (t, J = 8.1, 1 H), 7.23-7.15 (m , 5H), 2.80 (s, 4H), 2.72 (dd, J = 7.3, 7.1, 2H), 1.78-1.70 (m, 1 H), 1.05 (t, J = 7.1, 3H), 0.50-0.36 (m , 4H).

EXAMPLE 379 Trifluoromethanesulfonic acid salt of 3 - ((2- [4- (benzothiazol-2-yloxy) -phenin-ethyl}. -cyclopropyl-amino) -2-methyl-propionic acid A. Acid methyl ester 3 - ((2-R4- (benzothiazol-2-yloxy) -phenyl-1-ethyl > -cyclopropyl-amino) -2-methyl-propionic. To a solution of. {2- (4- (benzothiazole-2- iloxy) -phenyl] -ethyl.}. -cyclopropyl-amine (500 mg, 1.6 mmol) in CH 3 CN (10 ml) at room temperature was added? /, / V-diisopropylethylamine (349 μl, 2 mmol), followed by ester 3-bromo-2-methyl-propionic acid methyl ester (362 mg, 2 mmol) The resulting mixture was heated overnight at 60 ° C. The mixture was cooled and dissolved in CH 2 Cl 2 (100 mL), washed with Saturated aqueous NaHCO3 (1 x 25 ml) and H2O (2 x 25 ml), dried (Na2SO4) and concentrated under reduced pressure to give the crude product as a whitish solid. The crude product was purified on SiO2 (40 g, 0-10% CH3OH / CH2Cl2) to give a pale whitish solid (158 mg, 39% yield). MS (ESI): mass calculated for C23H26N2O3S, 410.17; m / z found, 411.3 [M + Hf. 1 H NMR (400 MHz, CD 3 OD): 7.73 (d, J = 8.3, 1 H), 7.65 (d, J = 8. 3, 1 H), 7.38 (t, J = 8.1, 1 H), 7.28-7.23 (m, 5H), 3.66 (s, 3H), 3.01 (dd, J = 8. 8, 3.8, 1 H) 2.89-2.76 (m, 5H), 3.60 (dd, J = 6.6, 6.1, 1 H), 1.84-1.78 (m, 1 H), 1. 12 (d, J = 7.1, 3H), 0.51-0.30 (m, 4H). B. Trifluoromethanesulfonic acid salt of 3 - ((2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl] -ethyl) -cyclopropyl-amino) -2-methyl-propionic acid To a methyl ester solution 3- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino) -2-methyl-propionic acid (158 mg, 0.38 mmol) in 3: 1 :1 of THF / CH3OH (13 mL), a solution of lithium hydroxide (37 mg, 1.54 mmol) in H2O (3 mL) was added. The reaction solution was stirred at room temperature for 16 h and then concentrated under reduced pressure. The residue was dissolved in CH3OH and purified by reverse phase CLAP. The desired fractions were collected and concentrated under reduced pressure to give the title compound as a clear oil (179 mg, 92% yield). MS (ESI): mass calculated for C22H24N2O3S, 396.15; m / z found, 397.3 [M + Hf. 1 H NMR (400 MHz, CD 3 OD): 7.78 (d, J = 8.3, 1 H), 7.64 (d, J = 8. 1, 1H), 7.51-7.27 (m, 6H), 3.83 (t, J = 12.4, 1H), 3.55 (t, J = 8.1, 2H), 3.37 (d, J = 13.1, 1H), 3.25 (t , J = 8.8, 2H), 3.21-3.11 (m, 1H), 2.99-2.90 (m, 1H), 1.33 (d, J = 7.3, 3H), 1.17-0.97 (m, 4H).

EXAMPLE 380 2 - ((2-f4- (Benzot? Azol- -? Io? [) - ten? II-et? LH? Clopropylmethyl-amino) -ethanol The title compound was prepared according to the procedure of Example 378, step A using cyclopropyl-methylamine and example 379, step A using 2-bromoethanol MS (ESI): mass calculated for C 21 H 24 N 2 O 2 S, 368.16, m / z found, 369.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.70 ( d, J = 8.1, 1H), 7.62 (d, J = 8.1, 1H), 7.34 (t, J = 7.3, 1H), 7.27-7.18 (m, 5H), 3.56 (t, J = 5.3, 2H), 2.92-2.86 (m, 2H), 2.84-2.73 (m, 4H ), 2.49 (d, J = 6.6, 2H), 0.92-0.81 (m, 1H), 0.55-0.49 (m, 2H), 0.16-0.09 (m, 2H).

EXAMPLE 381 2-í2 - ((2- [4- (Benzothiazol-2-yloxyHenip-ethyl-V-cyclopropylmethyl-amino) -ethoxy-ethanol The title compound was prepared according to the procedure of Example 380. MS (ESI): mass calculated for C23H28N203S , 412.18; m / z found, 413.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.64 (d, J = 8.3, 2H), 7.41 (d, J = 8.3, 2H), 7.31 (t, J = 8.3, 1 H), 7.25-7.17 (m, 3H), 4.08 (brs, 1 H), 3.84-3.68 (m, 6H), 3.59-3.49 (m, 2H), 3.26-3.16 (m, 2H) , 1.11-0.99 (m, 1 H), 0.79-0.70 (m, 2H), 0.55-0.48 (m, 2H).

EXAMPLE 382 3- ( { 2- [4- (Benzothiazol-2-yloxy) -phenyl-1-ethyl.} - cyclopropylmethylamino) -propan-ol The title compound was prepared according to the procedure of Example 378, step A using cyclopropyl-methylamine and example 379, Step A using 3-bromo-propan-1-ol. MS (ESI): mass calculated for C22H26N2O2S, 382.17; m / z found, 383.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.70 (d, J = 8.1, 1 H), 7.62 (d, J = 8.1, 1 H), 7.34 (t, J = 8.1, 1 H), 7.27-7.18 (m, 5H), 3.77 (t, J = 5.3, 2H), 2.84-2.76 (m, 6H), 2.43 (d, J = 6.6, 2H), 1, 72-1.65 (m, 2H), 0.94-0.83 (m, 1 H), 0.57-0.49 (m, 2H), 0.18-0.11 (m, 2H).

EXAMPLE 383 Trifluoromethanesulfonic acid salt. { 2-r4- (benzothiazol-2-ylox Q -phenip-ethyl-V-cyclopropyl- (3-tetrazol-2-yl-propyl) -amine To a solution of 3- (. {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.}. -cyclopropylmethyl-amino) -propan-1-ol (example 382, 220 mg, 0.58 mmol) and 2H-tetrazole (61 mg, 0.87 mmol) in CH 2 Cl 2 (12 ml) was added supported triphenylphosphine in polymer (290 mg, 0.87 mmol) and di-tert-butyl azodicarboxylate (200 mg, 0.87 mmol) The reaction mixture was stirred at room temperature for 1 hr, filtered and the collected solids were washed with CH 2 Cl 2 (10 mg). ml) The filtrate was concentrated under reduced pressure to give the crude product as a light yellow oil The crude product was dissolved in CH 3 OH and purified by reverse phase CLAP The desired fractions were collected and concentrated under reduced pressure, giving the title compound as a clear oil (100 mg, 40% yield) MS (ESI): mass calculated for C23H26N6OS, 434.19; m / z found, 435.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 8.75 (s, 1 H), 7.75 (d, J = 8.1, 1H), 7.60 (d, J = 8.1, 1 H), 7.45-7.32 (m, 5H), 7.28 (t, J = 8.1, 1H), 3.54-3.40 (m, 4H), 3.29-3.25 (m, 2H), 3.19 (d, J = 7.3, 2H), 3.09 (t, J = 8.6, 2H), 2.56-2.47 (m, 2H), 1.16-1.05 (m, 1 H), 0.78-0.71 (m, 2H), 0.46-0.40 (m, 2H).

EXAMPLE 384 . { 2- [4- (Be- (3-pyrrol-1-yl-propyD-amine) The title compound was prepared according to the procedure of Example 379, Step A using 1- (3-bromo-propyl) -1 H -pyrrole ME (ESI): mass calculated for C25H27N3OS, 417.19; m / z found, 418.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.65 (d, J = 7.6, 1 H), 7.57 (d , J = 8.1, 1 H), 7.30 (t, J = 8.1, 1 H), 7.21-7.13 (m, 5H), 6.57 (t, J = 2.0, 2H), 6.07 (t, J = 2.0, 2H), 3.80 (t , J = 7.1, 2H), 2.80-2.69 (m, 4H), 2.57 (t, J = 7.1, 2H), 1.98-1.88 (m, 2H), 1.74-1.67 (m, 1 H), 0.47-0.40 (m, 2H), 0.37-0.31 (m, 2H).

EXAMPLE 385 OQT 1C 1"CN 4 - ((2- [4- (Benzothiazol-2-yloxy) -phenp-ethyl) -cyclopropylmethyl-amino) -butyronitrile The title compound was prepared according to the procedure of Example 378, Step A using cyclopropyl- methylamine and example 31 g, step A using 4-bromo-butyronitrile. MS (ESI): mass calculated for C23H25N3OS, 391.17; m / z found, 392.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.70 (d, J = 8.1, 1 H), 7.63 (d, J = 8.1, 1 H), 7.35 (t, J = 8.1, 1 H), 7.27-7.20 (m, 5H), 2.77-2.73 (m, 4H), 2.64 (t, J = 6.6, 2H), 2.39 (d, J = 6.3, 2H), 2.29 (t, J = 6.8, 2H), 1.74-1.66 (m , 2H), 0.89-0.78 (m, 1H), 0.55-0.48 (m, 2H), 0.13-0.08 (m, 2H).

EXAMPLE 386 (1-l2-f4- (benzothiazol-2-yloxy) -phenn-ethyl) -piperidine-4-carboxylic acid (2-cyano-ethyl) -amide 1-l2-f4- (a) -amide was prepared according to the procedure of the example 33, step B, using 3-amino-propionitrile. MS (ESI): mass calculated for C 24 H 26 N 4 O 2 S, 434.18; m / z found, 435.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.74 (d, J = 8.3, 1 H), 7.67 (d, J = 8.1, 1 H), 7.40 (t, J = 8.1, 1 H), 7.32-7.24 (m, 5H), 6.39 (t, J = 6.6, 1 H), 3.51 (dd, J = 6.3, 6.1, 2H), 3.11-3.00 (m, 2H), 2.89-2.82 (m, 2H), 2.69-2.58 (m, 4H), 2.23-2.13 (m, 1 H), 2.08 (t, J = 12.1, 2H), 1.94- 1.76 (m, 4H).

EXAMPLE 387 (2- [4- (Benzothiazol-2-yloxy) -phenyl-1-etyl-cyclopropylmethyl- [3- (2H-tetrazol-5-yl) -propyl-1-amine To a solution of 4- (. {2- [2- 4- (benzothiazoI-2-yloxy) -phenyl] -ethyl.} - cyclopropylmethyl-amino) -butyronitrile (example 385, 250 mg, 0.6 mmol) in toluene (32 ml) at room temperature was added trimethylaluminum (solution in toluene 2.0 M, 1.53 ml, 3.08 mmol), followed by azidotrimethylsilane (404 μl, 3.08 mmol) The resulting mixture was heated at 80 ° C. for 18 hr.The mixture was cooled to room temperature and diluted with CH 2 Cl 2 (200 ml) was washed with saturated aqueous NaHC 3 (1 x 25 ml) and H 2 O (2 x 25 ml), dried (Na 2 SO 4) and concentrated under reduced pressure to give the crude product as an off-white solid. on SiO2 (40 g, 0-20% CH3OH / CH2Cl2) to give an off-white solid (246 mg, 88% yield) MS (ESI): mass calculated for C23H26N6OS, 434.19, m / z found, 435.5 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 11.25 (br s, 1 H), 7.54 (dd, J = 7.8, 5.0, 2 H), 7.23 (dd, J = 8.1, 7.3, 1 H), 7.19-7.09 (m , 5H), 3.23-3.11 (m, 4H), 3.01-2.90 (m, 4H), 2.83 (d, J = 7.3, 2H), 2.18-2.07 (m, 2H), 1.01-0.91 (m, 1H) , 0.57-0.50 (m, 2H), 0.25-0.18 (m, 2H).

EXAMPLE 388 3-r 5 - (1- (2- [4- (Benzothiazol-2-yloxy) -phenylethyl) -piperidin-4-yl) -tetrazol-1-ip-propionitrile To a stirred suspension of (2- cyano-ethyl) -amide of 1- acid. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid (example 386, 500 mg, 1.15 mmol) and triphenylphosphine (755 mg, 2.88 mmol) in anhydrous CH3CN (10 ml) at 0 ° C were added diisopropyl azodicarboxylate (567 μl, 2.88 mmol) and 2 g. minutes later, azidotrimethylsilane (399 μl, 3.04 mmol) for 20 min. The reaction mixture was allowed to warm to room temperature for 30 min, then was stirred for an additional 14 hr. The reaction mixture was added to H20-ice (20 ml) and extracted with CH2Cl2 (2 x 25 ml). The combined organic layers were dried (Na2SO) and concentrated. The residue was purified on SiO2 (40 g, 0-15% CH3OH / CH2Cl2) to give an off-white solid (439 mg, 83% yield). MS (ESI): mass calculated for C24H25N7OS, 459.18; m / z found, 460.5 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.71 (d, J = 8.1, 1 H), 7.66 (d, J = 8.1, 1 H), 7.38 (t, J = 7.8, 1 H), 7.31-7.23 (m , 5H), 4.62 (t, J = 6.8, 2H), 3.20-3.10 (m, 4H), 3.04-2.04 (m, 1 H), 2.91-2.82 (m, 2H), 2.73-2.64 (m, 2H) ), 2.25 (t, J = 10.9, 2H), 2.18-2.05 (m, 2H), 2.04-1.95 (m, 2H).

EXAMPLE 389 (2-r4- (bc? I uua ^ .u? - ^ - ?? uxu-? T; ??? i | -fc; ???? - u? Ut n pÍl- [3- (2H-tetraz L-5-yl) -propyl] -amine The title compound was prepared according to the procedure of Example 387. MS (ESI): mass calculated for C2oH24N6OS, 420.17, m / z found, 421.5 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 13.02 (br s, 1 H), 7.50 (dd, J = 8.1, 3.5, 2H), 7.20 (t, J = 8.1, 1 H), 7.12-7.04 (m, 5H) ), 2.95-2.77 (m, 8H), 2.06-1.93 (m, 3H), 0.60-0.48 (m, 4H).

EXAMPLE 390 1- (1-Hydroxy-1,1-dimethyl-ethyl) -amide. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etl] -piperidine-4-carboxylic acid The title compound composed of the title was prepared according to the procedure of Example 33, steps B and C using 2-amino-2-methyl-propan-1-ol. MS (ESI): mass calculated for C25H3? N303S, 453.21; m / z found, 454.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.75 (d, J = 8.1, 1 H), 7.68 (d, J = 8.1, 1 H), 7.40 (t, J = 8.1, 1 H), 7.32-7.25 (m, 5H), 5.83 (s, 1 H), 5.06 (br s, 1 H), 3.50 (s, 2H), 3.14-3.06 (m, 2H), 2.01-2.84 (m, 2H), 2.70-2.63 (m , 2H), 2.20-2.10 (m, 3H), 1.95-1.74 (m, 4H), 1.32 (s, 6H).

EXAMPLE 391 Trifluoromethanesulfonic acid salt of (2- [4- (benzothiazol-2-yloxp-phenin-ethyl-cyclopropylmethyl-f3- (1 H-ri .2.41-triazole-3-ip-propylamine A. Ethyl ester hydrochloride salt of 4- (. {2-f4- (benzothiazol-2-yloxy) -pheno-ethyl) -cyclopropylmethyl-amino) -butyrimidic acid A solution of 4- (. {2- [4- (benzothiazole -2-yloxy) -phenyl] -ethyl.} - cyclopropiimethyl-amino) -butyronitrile (example 385, 932 mg, 2.38 mmol) in absolute ethanol (5 ml) and diethyl ether (10 ml) was treated with gaseous hydrogen chloride bubbly for 1 hr. The resulting suspension was filtered and washed with ether to give the title compound (1.12 g, 2% yield). Due to the instability, the raw material was used immediately without purification. B. Salt of (2-benzothiazol-2-yloxy ') -phenyl-1-ethyl acid > - cyclopropylmethyl- [3- (1 H-f 1, 2,4] triazol-3-yl) -popil] -amino trifluoromethanesulfonic acid. To a solution of 4- (. {2- [4- (benzothiazol-2-yloxy) -phenyl] -etyl] -cyclopropylmethyl-amino acid ethyl chloride hydrochloride salt butyrimide (511 mg, 1 mmol) in ethanol (4.5 ml) was added triethylamine (375 μl, 2.7 mmol), followed by a formic hydrazide solution (60 mg, 1 mmol) in ethanol (4.5 ml). The resulting mixture was stirred at room temperature for 2 hr and then refluxed for 1 hr. The mixture was cooled and diluted with CH2Cl2 (1500 mL), washed with saturated aqueous NaHCO3 (1 x 25 mL) and H2O (2 x 25 mL), dried (Na2SO4) and concentrated under reduced pressure to give the product Crude as a whitish solid. The crude product was purified on SiO (40 g, 0-15% CH 3 OH / CH 2 Cl 2) to give an off-white solid (317 mg, 73% yield). MS (ESI): mass calculated for C24H27N5OS, 433.19; m / z found, 434.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.91 (s, 1 H), 7.68 (d, J = 7.8, 1 H), 7.63 (d, J = 8.1, 1 H), 7.34 (t, J = 8.1, 1 H ), 7.25-7.19 (m, 5H), 2.90-2.76 (m, 6H), 2.72 (t, J = 6.3, 2H), 2.46 (d, J = 6.6, 2H), 2.00-1.90 (m, 2H) , 0.93-0.82 (m, 1H), 0.56-0.49 (m, 2H), 0.16-0.10 (m, 2H).

EXAMPLE 392 . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl) -cyclopropylmethyl- [3- (5-methyl-1 H-1, 2,41-triazol-3-yl) -propyl-amine The compound of The title was prepared according to the procedure of example 391, step B using acetic hydrazide. MS (ESI): mass calculated for C25H29N5OS, 447.21; m / z found, 448.4 [M + Hf. H NMR (400 MHz, CDCl 3): 7.65 (dd, J = 8.1, 8.1, 2H), 7.35 (t, J = 8.1, 1 H), 7.27-7.21 (m, 5H), 3.01-2.94 (m, 2H ), 2.93-2.84 (m, 4H), 2.81 (t, J = 6: 6, 2H), 2.61 (d, J = 6.8, 2H), 2.37 (s, 3H), 2.07-1.07 (m, 2H) , 1.01-0.80 (m, 1H), 0.62-0.53 (m, 2H), 0.25-0.17 (m, 2H).

EXAMPLE 393 (2-r 4 - (Benzothiozol-2-yloxy enin-etl) -cyclopropylmethyl- [3- (5-phenyl-1 H- [1,2,4] triazol-3-yO-propylamine The compound of title was prepared in accordance with the procedure of example 391, step B using benzoic acid hydrazide. MS (ESI): mass calculated for C30H31N5OS, 509.22; m / z found, 510.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 8.06 (dd, J = 16.8, 0.5, 2H), 7.70 (d, J = 8.1, 1H), 7.63 (d, J = 8.1, 1H), 7.42-7.30. , 4H), 7.28-7.20 (m, 5H), 2.99-2.87 (m, 6H), 2.85 (t, J = 6.6, 2H), 2.58 (d, J = 6.8, 2H), 2.09-2.00 (m, 2H), 1.00-0.89 (m, 1 H), 0.61-0.53 (m, 2H), 0.23-0.16 (m, 2H).

EXAMPLE 394 Trifluoroacetic acid salt of 2- (4- (2-f4- (1-methyl-1 H-tetrazol-5-yl) -piperidin-1-in-ethyl.} - phenoxy) -benzothiazole. 2- (4- { 2- [4- (1 H -tetrazol-5-yl) -piperidin-1-yl] -ethyl} -phenoxy) -benzothiazole solution (example 262, 80 mg, 1.97 mmoles) in DMF (20 ml) was added K2CO3 (256 mg, 1.85 mmol) and dimethyl carbonate (360 μl, 4.27 mmol) The reaction mixture was stirred at room temperature for 18 h, filtered and concentrated under pressure The crude product was dissolved in CH3OH and purified by reverse phase CLAP The desired fractions were collected and concentrated under reduced pressure to give the title compound as a colorless oil (289 mg, 27% yield). (ESI): mass calculated for C22H24N6OS, 420.17; m / z found, 421.3 [M + Hf. 1 H NMR (400 MHz, CD 3 OD): 7.72 (d, J = 7.8, 1 H), 7.58 (d, J = 7.8, 1 H), 7.44-7.28 (m, 5H), 7.25 (t, J = 8.1, 1 H), 4.06 (s, 3H), 3.80 (d, J = 12.1, 1 H), 3.66-3.35 (m, 4H), 3.28-3.17 (m, 2H), 3.16-3.08 (m, 2H), 2.33-2.23 (m, 2H), 2.22-2.07 (m, 2H).

EXAMPLE 395 2- (4- {2-r4- (2-Methyl-2H-tetrazol-5-yl) -piperidin-1-yl] -ethyl) -phenoxy) -benzothiazole The title compound was prepared in accordance with procedure of Example 394. MS (ESI): mass calculated for C22H24N6OS, 420.17; m / z found, 421.3 [M + Hf. H NMR (400 MHz, CD3OD): 7.75 (d, J = 7.8, 1 H), 7.60 (d, J = 7.8, 1 H), 7.46-7.33 (m, 5H), 7.28 (t, J = 7.8, 1 H), 4.31 (s, 3H), 3.79 (d, J = 13.4, 1 H), 3.62-3.06 (m, 8H), 2.48-2.30 (m, 2H), 2.15-2.02 (m, 2H).

EXAMPLE 396 1- (2-f4- (Benzothiazol-2-yloxy) -pheno-ethyl) -piperidin-4-carbonitrile The title compound was prepared according to the procedure of example 262, using piperidin-4-carbonitrile. MS (ESI): mass calculated for C2? H2? N3OS, 363.14; m / z found, 364.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.63 (d, J = 7.6, 1 H), 7.55 (d, J = 7.6, 1 H), 7.28 (t, J = 8.1, 1 H), 7.20-7.12 (m , 5H), 2.71 (dd, J = 7.1, 3.3, 2H), 2.68-2.55 (m, 3H), 2.52 (dd, J = 7.1, 3.3, 2H), 2.37-2.25 (m, 2H), 1.91- 1.73 (m, 2H).

EXAMPLE 397 2- (4- (2- (1 HM, 2,3,1Triazol-4-yl) -piperidin-1-yl-ethyl-phenoxy-benzothiazole To a solution of trimethylsilyldiazomethane (1.8 ml, 3.6 mmol) in diethyl ether ( 30 ml) at 0 ° C under nitrogen, n-butyllithium (2.5 M in hexane, 1.44 ml, 3.6 mmol) was added dropwise and the mixture was stirred at 0 ° C for 20 min. dropwise a solution of 1- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carbonitrile (Example 396, 1.09 g, 3.0 mmol) in THF (10 ml) at 0 ° C. The resulting mixture was stirred at 0 ° C. for 3 hr.The mixture was treated with saturated aqueous NH 4 Cl and extracted with CH 2 Cl 2 (2 x 100 ml) .The extracts were washed with H 2 O. 2 x 25 ml), dried (Na2SO4) and they were concentrated under reduced pressure to give the crude product as an off-white solid. The crude product was purified over SiO2 (40 g, 0-10% CH3OH / CH2Cl) to give an off white solid (768 mg, 54% yield). MS (ESI): mass calculated for C22H23N5OS, 405.16; m / z found, 406.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.63 (d, J = 8.1, 1 H), 7.56 (d, J = 8.1, 1 H), 7.42 (s, 1 H), 7.29 (t, J = 7.8, 1 H), 7.23-7.14 (m, 5H), 4.67 (br s, 1 H), 3.04 (d, J = 11.9, 2H), 2.84-2.70 (m, 3H), 2.63-2.56 (m, 2H), 2.16 (t, J = 11.1, 2H), 1.97 (d, J = 12.6, 2H), 1.82-1.70 (m, 2H).

EXAMPLE 398 Ethyl ester of 4- acid. { 2- [4- (Benzothiazol-2-yloxy) -phenyl-1-ethylamino} -butyric The title compound was prepared according to the procedure of Example 378, Step A using 4-amino-butyric acid ethyl ester. MS (ESI): mass calculated for C2iH24N2O3S, 384.15; m / z found, 385.3 [M + Hf. , 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 8.1, 1 H), 7.66 (d, J = 8.1, 1 H), 7.38 (t, J = 8.1, 1 H), 7.31-7.22 (m, 5H), 6.67 (br s, 1 H), 4.12 (dd, J = 7.3, 7.1, 2H), 2.95-2.80 (m, 2H), 2.69 (t, J = 6.8, 2H), 2.35 (t, J = 7.3, 2H), 2.29 (t, J = 7.3, 2H), 1.86-1.77 (m, 2H), 1.25 ( t, J = 7.1, 3H).

EXAMPLE 399 4 - ((2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl-amino-butyric acid ethyl ester The title compound was prepared according to the procedure of Example 378, Step A using cyclopropyl-methylamine and example 379, step A using 4-bromobutyric acid ethyl ester MS (ESI): mass calculated for C 25 H 3 O N 2 O 3 S, 438.20, m / z found, 430.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3 ): 7.71 (d, J = 8.1, 1H), 7.63 (d, J = 8.1, 1 H), 7.35 (t, J = 8.1, 1H), 7.27-7.20 (m, 5H), 6.67 (br s, 1 H), 4.10 (dd, J = 7.1, 7. 1, 2H), 2.83-2.71 (m, 4H), 2.60 (t, J = 7.1, 2H), 2.40 (t, J = 6.6, 2H), 2.31 (t, J = 7.3, 2H), 1.81-1.72 (m, 2H), 1.23 (t, J = 7.1, 3H), 0.88-0.79 (m, 1 H), 0.52-0.45 (m, 2H), 0.13-0.07 (m , 2H).

EXAMPLE 400 2-f3- ( {2-f4- (Benzot-azo-2-yloxy) -phenn-ethyl.} - cyclopropylmethyl-amino) -propyl-isoindol-1,3-dione The title compound was prepared according to the procedure of example 378, step A using cyclopropyl-methylamine and example 37g, step A using 2- (3-bromo-propyl) -isoindole-1,3-dione. MS (ESI): mass calculated for C3oH29N303S, 511.19; m / z found, 512.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.84-7.77 (m, 2 H), 7.72-7.63 (m, 3 H), 7.60 (d, J = 7.8, 1 H), 7.34 (t, J = 8.1, 1 H). , 7.27-7.18 (m, 5H), 3.71 (t, J = 7.1, 2H), 2.82-2.70 (m, 4H), 2.65 (t, J = 7.6, 2H), 2.39 (d, J = 6.6, 2H ), 1.88-1.79 (m, 2H), 0.87-0.76 (m, 1 H), 0.50-0.42 (m, 2H), 0.12-0.06 (m, 2H).

EXAMPLE 401 4- ( { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl-amino) -butyric acid The title compound was prepared from Example 399 followed by the procedure of example 378, step B. MS (ESI): mass calculated for C23H26N2O3S, 410.17; m / z found, 411.4 [M + Hf. 1 H NMR (400 MHz, CD 3 OD): 7.42 (d, J = 7.8, 1 H), 7.31 (d, J = 7.8, 1 H), 7.16-7.10 (m, 2H), 7.07 (t, J = 7.8, 1 H), 7.04-7.00 (m, 2H), 6.06 (t, J = 7.8, 1 H), 3.23-3.11 (m, 2H), 3.07 (t, J = 7.8, 2H), 2.01-2.77 (m, 4H), 2.19 (t, J = 7.1, 2H), 1.78-1.68 (m, 2H), 0.91-0.82 (m, 1 H), 0.49-0.41 (m, 2H), 0.20-0.13 (m, 2H).

EXAMPLE 402 1- (3- (2-f4- (Benzothiazol-2-yloxy) -phenoethylamino) -propyl) -pyrrolidin-2-one The title compound was prepared according to the procedure of Example 378, Step A using 1 - (3-aminium-propyl) -pyrrolidin-2-one. MS (ESI): mass calculated for C22H25N302S, 395.17; m / z found, 396.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.67 (d, J = 8.1, 1 H), 7.60 (d, J = 8.1, 1 H), 7.32 (t, J = 7.8, 1H), 7.28-7.15 (m, 5H), 5.61 (brs, 1 H), 3.34-3.25 (m, 4H), 2.94-2.81 (m, 4H), 2.65 (t, J = 7.3, 2H), 2.32 (t, J = 7.8, 2H) , 1.94 (t, J = 7.3, 2H), 1.79-1.69 (m, 2H).

EXAMPLE 403 N-1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl-ethyl-N1-cyclopropylmethyl-propane-1,3-diamine To a solution of 2- [3- (. {2- [4- (benzothiazole- 2-yloxy) -phenyl] -ethyl.} - cyclopropylmethyl-amino) -propyl] -isoindole-1,3-dione (Example 400, 3.0 g, 5.86 mmol) in EtOH (12 ml) was added hydrazine (220 μl , 7.03 mmol). The reaction mixture was stirred at room temperature for 24 hr. The mixture was dissolved in CH2Cl2 (200 mL), washed with saturated NaHCO3 (2 x 20 mL), H2O (1 x 20 mL), dried (Na2SO) and concentrated under reduced pressure to give the crude product as a solid. whitish The crude product was purified on SiO2 (330 g, 0-10% 2M NH3 in CH3OH / CH2Cl2) to give a clear oil (2.13 g, 96% yield). MS (ESI): mass calculated for C22H 7N3OS, 381.2; m / z found, 382.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.68 (d, J = 8.1, 1 H), 7.58 (d, J. = 8. 1, 1H), 7.31 (t, J = 8.1, 1 H), 7.24-7.16 (m, 5H), 2.79-2.71 (m, 4H), 2.67 (t, J = 6.8, 2H), 2.59 (t, J = 6.8, 2H), 2.37 (d, J = 6.6, 2H), 2.07 (s, 2H), 1.62-1.52 (m, 2H), 0.87-0.77 (m, 1 H), 0.50-0.44 (m, 2H), 0.12-0.06 (m, 2H).

EXAMPLE 404 - (. {2-f4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino) -pentanoic acid methyl ester The title compound was prepared according to the procedure of example 379, step A using 5-bromo-pentanoic acid methyl ester. MS (ESI): mass calculated for C 24 H 28 N 2 O 3 S, 424.18; m / z found, 425.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.72 (d, J = 8.1, 1 H), 7.63 (d, J = 8.1, 1 H), 7.36 (t, J = 8.1, 1 H), 7.27-7.20 (m , 5H), 3.65 (s, 3H), 2.85-2.80 (m, 4H), 2.66 (t, J = 7.6, 2H), 2.33 (t, J = 7.6, 2H), 1.81-1.75 (m, 1 H) ), 1.67-1.50 (m, 4H), 0.52-0.40 (m, 2H), 0.43-0.37 (m, 2H).

EXAMPLE 405 N- [3- ( { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -propyl-acetamide To a solution of N-1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -N1- cyclopropylmethyl-propane-1,3-diamine (example 403, 180 mg, 0.47 mmol) in CH 2 Cl 2 (10 ml) was added triethylamine (131 μl, 0.04 mmol), followed by acetic anhydride (76 μl, 0.71 mmol). The reaction mixture was stirred at room temperature for 24 hr. The mixture was dissolved in CH2Cl2 (100 mL), washed with saturated NaHCO3 (2 x 15 mL), HO (1 x 15 mL), dried (Na2SO) and concentrated under reduced pressure to give the crude product as a solid. whitish The crude product was purified over SiO2 (12 g, 0-10% CH3OH / CH2Cl2) to give a white solid (154 mg, 77% yield). MS (ESI): mass calculated for C24H29N3OS, 423.2; m / z found, 424.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 9.69 (br s, 1 H), 7.67 (d, J = 8.1, 1 H), 7.62 (d, J = 8.1, 1 H), 7.33 (t, J = 8.1, 1 H), 7.27-7.17 (m, 5H), 3.27 (dd, J = 6.6, 5.6, 2H), 2.96-2.89 (m, 2H), 2.87-2.81 (m, 2H), 2.78 (t, J = 6.8 , 2H), 2.53 (d, J = 6.8, 2H), 1.88 (s, 3H), 1.76-1.67 (m, 2H), 0.94-0.83 (m, 1 H), 0.60-0.53 (m, 2H), 0.21-0.15 (m, 2H).

EXAMPLE 406 f3- (. {2-r4- (Benzothiazol-2-yloxy) -phenyl] -ethyl) -cyclopropylmethyl-amino) -propyl-amide of morpholine-4-carboxylic acid The title compound was prepared according to the procedure of Example 405, using morpholin-4-carbonyl chloride. MS (ESI): mass calculated for C28H34N403S, 494.24; m / z found, 495.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.69 (t, J = 8.5, 2H), 7.41-7.23 (m, 6H), 6.85 (br s, 1 H), 3.68-3.60 (m, 4H), 3.51-3.40 (m, 6H), 3.39-3.27 (m, 4H), 3.26-3.17 (m, 2H), 3.09-3.01 (m, 2H), 2.19-2.06 (m, 2H), 1.25-1.14 (m, 1 H) ), 0.85-0.76 (m, 2H), 0.53-0.45 (m, 2H).

EXAMPLE 407 N- [3 - ((2-r4- (Benzothiazol-2-yloxy) -phenyl-1-ethyl) -cyclopropylmethyl-amino) -propip-methanesulfonamide The title compound was prepared according to the procedure of Example 405, using methanesulfonyl. MS (ESI): mass calculated for C23H29N3O3S2, 459.17; m / z found, 460.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.67 (t, J = 8.6, 2H), 7.39-7.17 (m, 6H), 7.06 (brs, 1 H), 3.43-3.09 (m, 8H), 3.07-2.98 ( m, 2H), 2.96 (s, 3H), 2.20- 2. 07 (m, 2H), 1.23-1.11 (m, 1 H), 0.79-0.67 (m, 2H), 0.49-0.41 (m, 2H).

EXAMPLE 408 - ((2- [4- (Benzothiazol-2-yloxy) -phenyl-1-ethyl) -cyclopropyl-amino) -pentanoic acid The title compound was prepared from example 379 and the procedure of example 404, step B. MS (ESI): mass calculated for C23H26N2O3S, 410.17; m / z found, 411.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 12.39 (br s, 1 H), 7.71 (d, J = 7.8, 1 H), 7.62 (d, J = 7.8, 1 H), 7.35 (t, J = 7.8, 1H), 7.31-7.20 (m, 5H), 3.04-2.90 (m, 4H), 2.82 (t, J = 7.8, 2H), 2.30 (t, J = 6.8, 2H), 1.98-1.91 (m, 1 H), 1.72-1.54 (m, 4H), 0.83-0.76 (m, 2H), 0.63-0.55 (m, 2H).

EXAMPLE 409 1- [3 - ((2-f4- (Benzothiazol-2-yloxy) -phenin-etl) -sopropyl-amino) -prop-p-pyrrolidin-2-one A mixture of 1- (3- { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino}. Propyl) -pyrrofidin-2-one (example 402, 500 mg, 1.26 mmol), acetone (185 μl, 2.52 mmol) in CH2Cl2 (25 mL) was stirred at room temperature for 1 hr. To the resulting mixture was added NaBH (OAc) 3 (536 mg, 2.52 mmol). The mixture was stirred at room temperature for 16 hr, filtered through diatomaceous earth, washed with CH2Cl2 (100 ml) and concentrated under reduced pressure to give the crude product as a yellow oil. The crude product was purified on SiO2 (40 g, 0-10% CH3OH / CH2Cl2). The desired fractions were combined and concentrated under reduced pressure to give a clear oil which crystallized on standing (290 mg, 53% yield). MS (ESI): mass calculated for C25H3? N3O2S, 437.21; m / z found, 438.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 8.3, 1 H), 7.66 (d, J = 8.3, 1 H), 7.38 (t, J = 8.3, 1 H), 7.28-7.23 (m, 5H), 3.35 (t, J = 6.8, 2H), 3.27 (t, J = 7.3, 2H), 3.05-2.95 (m, 1 H), 2.78-2.70 (m, 2H), 2.69-2.61 (m, 2H), 2.47 (t, J = 7.3, 2H), 2.37 (t, J = 8.1, 2H), 2.04-1.94 (m, 2H), 1.69-1.58 (m, 2H), 0.9g (d, J = 6.8, 6H).

EXAMPLE 410 1-r3- ( {2-r4- (Benzothiazol-2-yloxy) -phen-p-ethyl) -cyclopropylmethyl-amino) -propyn-pyrrolidin-2-one The title compound was prepared in accordance with the procedure of Example 409, using cyclopropancarbaldehyde. MS (ESI): mass calculated for C26H3? N3O2S, 449.21; m / z 10 found, 450.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.70 (d, J = 7.8, 1 H), 7.64 (d, J = 8.1, 1 H), 7.36 (t, J = 7.8, 1 H), 7.32-7.21 (m, 5H), 3.38 (t, J = 7.1, 2H), 3.31 (t, J = 7. 1, 2H), 3.09-3.02 (m, 2H), 2.95-2.83 (m, 4H), 2.72 (d, J = 7.1, 2H), 2.37 (t, J = 7.8, 2H), 2.05-1.95 (m, 2H), 1.92-1.82 (m, 2H), 1.02-0.91 (m, 1H), 0.66-0.59 (m, 2H), 0.20-0.23 (m, 2H).

EXAMPLE 411 1- [3- ( {2-r4- (Benzothiazol-2-yloxy) -pheno-ethyl) -cyclopropyl-amino) -propip-pyrrolidin-2-one To a solution of 1- (3. 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino.} - propyl] -pyrrolidin-2-one (example 402, 500 mg, 1.26 mmol) in EtOH (20 ml) was added acetic acid (716 μl, 1.26 mmol), molecular sieves (500 mg, 3A), (1-ethoxy), cyclopropoxy) -trimethyl-silane (1.51 ml, 7.58 mmole) and sodium cyanoborohydride (357 mg, 5.69 mmole). The reaction mixture was heated to reflux for 16 h, cooled and filtered through diatomaceous earth, washed with CH2Cl2 (100 mL) and concentrated under reduced pressure to give the crude product as a clear oil. The crude product was purified on SiO2 (40 g; 0-10% CH3OH / CH2Cl2). The desired fractions were combined and concentrated under reduced pressure to give a white solid (434 mg, 66% yield). MS (ESI): mass calculated for C25H29N302S, 435.2; m / z found, 436.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.72 (d, J = 7.8, 1 H), 7.64 (d, J = 7.8, 1 H), 7.36 (t, J = 7.8, 1H), 7.28-7.19 (m, 5H), 3.36 (t, J = 7.1, 2H), 3.28 (t, J = 7.1, 2H), 2.87-2.80 (m, 4H), 2.67 (t, J = 7.3, 2H), 2.37 (t, J = 7.8, 2H), 2.03-1.94 (m, 2H), 1.82-1.70 (m, 3H), 0.53-0.47 (m, 2H), 0.43-0.38 (m, 2H).

EXAMPLE 412 1-r 3 - ((2-f 4 - ('Benzothiazol-2-yloxy) -phenyl-ethyl.} - propyl-amino) -propip-pyrrolidin-2-one The title compound was prepared according to the process of Example 409, using propionaldehyde MS (ESI): mass calculated for C25H31N3O2S, 437.21, m / z found, 438.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.72 (d, J = 8.1, 1 H), 7.66 (d, J = 8.1, 1 H), 7.38 (t, J = 8.1, 1 H), 7.29-7.24 (m, 5H), 3.39 (t, J = 7.1, 2H), 3.30 (t, J = 7. 1, 2H), 2.86-2.80 (m, 4H), 2.64 (t, J = 7.6, 2H), 2.58 (t, J = 7.6, 2H), 2.42-2.35 (m, 2H), 2.07-1.97 (m , 2H), 1.80-1.71 (m, 2H), 1.59-1.47 (m, 2H), 0.92 (d, J = 7. 3, 3H).

EXAMPLE 413 Ethyl 4 - ((1-acetyl-piperidin-4-yl) -. {2-f4- (benzothiazol-2-yloxy) -phene-ethyl) -amino) -butyric acid ethyl ester The title compound was prepared from according to the procedure of Example 409, using 1-acetyl-piperidin-4-one. MS (ESI): mass calculated for C28H35N3O4S, 500.23; m / z found, 510.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.72 (d, J = 8.1, 1 H), 7.65 (d, J = 8.1, 1 H), 7.38 (t, J = 8.1, 1 H), 7.20-7.23 (m, 5H), 4.60 (d, J = 13.1, 1 H), 4.13 (dd, J = 7. 8, 6.8, 2H), 3.85 (d, J = 13.4, 1 H), 3.09-2.08 (m, 2H), 2.70-2.74 (m, 4H), 2.60 (t, J = 6.8, 2H), 2.52-2.44 (m, 3H), 2.04 (s, 3H), 1.85-1.73 (m, 4H), 1.48-1.35 (m, 2H), 1.26 (t, J = 7.1, 3H).

EXAMPLE 414 Ethyl 4 - ((1-acetyl-piperidin-4-ylH2-r4- (benzothiazol-2-yloxy) -phene-ethyl) -amino) -butyric acid ethyl ester The title compound was prepared according to the procedure of Example 400, using 1-methyl-piperidin-4-one. MS (ESI): mass calculated for C27H35N3O3S, 481.2; m / z found, 482.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.72 (d, J = 8.1, 1H), 7.65 (d, J = 8.1, 1H), 7.37 (t, J = 8.1, 1 H), 7.28-7.19 (m, 5H), 4.12 (dd, J = 7.3, 7.1, 2H), 3.11 (d, J = 12.1, 2H), 2.75- 2.69 (m, 4H), 2.58-2.50 (m, 3H), 2.38 (s, 3H), 2.20 (t, J = 7. 1, 2H), 2.24-2.15 (m, 2H), 2.03-1.97 (m, 2H), 1.73 (t, J = 6.3, 4H), 1.25 (t, J = 7. 1, 3H).

EXAMPLE 415 4 - ((2-l4- (Benzothiazol-2-yloxO-phenyl-1-ethyl-vaneset-n-sulfonyl-amino) -butyric acid The title compound was prepared from Example 398 following the procedure of Example 407 and Example 379, Step B. MS ( ESI): mass calculated for C20H22N2O5S2, 434.1, m / z found, 435.3 [M + Hf. 1 H NMR (400 MHz, CDCi3): 7.72 (d, J = 8.1, 1 H), 7.66 (d, J = 8.1, 1 H), 7.38 (t, J = 8.1, 1H), 7.33-7.24 (m, 5H), 3.48 (t, J = 7.6, 2H), 3.20 (t, J = 7.6, 2H), 2.96 (t, J = 7.3, 2H), 2.77 (s, 3H), 2.37 (t, J = 6.6, 2H), 1.91-1.81 (m, 2H).

EXAMPLE 416 Acid ((2-f4- (benzothiazol-2-yloxyHenip-ethyl) -cyclopropyl-amino) -acetic acid The title compound was prepared according to the procedure of Example 379, Steps A and B using acid methyl ester bromo-acetic MS (ESI): mass calculated for C20H20N2O3S, 368.12; m / z found, 369.3 [M + Hf. H NMR (400 MHz, CDCl 3): 7.70 (d, J = 8.1, 1H), 7.64 (d, J = 8.1, 1 H), 7.37 (t, J = 8.1, 1 H), 7.31-7.22 (m, 5H), 3.64 (s, 2H), 3.26 (dd, J = 7.6, 3.3, 2H), 2.98 (dd, J = 7.6, 3.3, 2H), 2.50-2.43 (m, 1 H), 0.84-0.79 ( m, 2H), 0.71-0.65 (m, 2H).

EXAMPLE 417 6 - ((2-f4- (Benzothiazoi-2-yloxy) -phenyl] -ethyl-cyclopropyl-amino-hexanoic acid ethyl ester The title compound was prepared according to the procedure of Example 370, Step A using ethyl ester of 6-bromo-hexanoic acid MS (ESI): mass calculated for C26H32N2O3S, 452.21, m / z found, 453.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.72 (d, J = 8.1, 1 H ), 7.64 (d, J = 8.1, 1 H), 7.36 (t, J = 8.1, 1H), 7.28-7.20 (m, 5H), 4.12 (dd, J = 7.3, 7.1, 2H), 2.87- 2.81 (m, 4H), 2.65 (t, J = 7.8, 2H), 2.30 (t, J = 7.6, 2H), 1.81-1.74 (m, 1 H), 1.69- 1.60 (m, 2H), 1.59-1.50 (m, 2H), 1.37-1.27 ( m, 2H), 1.24 (t, J = 7.1, 3H), 0.52- 0. 46 (m, 2H), 0.43-0.37 (m, 2H).

EXAMPLE 418 7 - ((2-f4- (Benzothiazol-2-yloxO-phenyl-ethyl) -cyclopropyl-amino) -hexanoic acid ethyl ester The title compound was prepared according to the procedure of Example 379, Step A using ester ethyl ester of 7-bromo-heptanoic acid MS (ESI): mass calculated for C27H34N2O3S, 466.23, m / z found, 467.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.71 (d, J = 8.1, 1 H), 7.60 (d, J = 8.1, 1H), 7.34 (t, J = 8.1, 1H), 7.27-7.18 (m, 5H), 4.10 (dd, J = 7.1, 7.1, 2H), 2.86- 2.70 (m, 4H), 2.63 (t, J = 7.6, 2H), 2.28 (t, J = 7.6, 2H), 1.80-1.74 (m, 1 H),1. 67-1.58 (m, 2H), 1.57-1.47 (m, 2H), 1.38-1.25 (m, 4H), 1.23 (t, J = 7.1, 3H), 0. 50-0.44 (m, 2H), 0.43-0.37 (m, 2H).

EXAMPLE 419 6- ( {2. -4- (Benzothiazol-2-ylox0-phenyl-1-ethyl) -cyclopropyl-amino-V-hexanoic acid The title compound was prepared from Example 417 following the procedure of Example 37g, step B. MS ( ESI): mass calculated for C 24 H 28 N 2 O 3 S, 424.18, m / z found, 425.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 11.17 (br s, 1 H), 7.69 (d, J = 8.1, 1 H) , 7.65 (d, J = 8.1, 1 H), 7.39-7.21 (m, 6H), 3.35-3.28 (m, 2H), 3.24-3.10 (m, 4H), 2.53-2.45 (m, 1 H), 2.31 (t, J = 7.1, 2H), 1.92-1.81 (m, 2H), 1.70-1.61 (m, 2H), 1.44-1.34 (m, 4H), 0.91-0.83 (m, 2H).

EXAMPLE 420 7- (. {2- [4- (Benzothiazol-2-yloxy) -phenn-ethyl.} - cyclopropyl-amino) -heptanoic acid The title compound was prepared from Example 418 following the procedure of example 379, step B. MS (ESI): mass calculated for C25H30N2O3S, 438.2; m / z found, 439.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 12.57 (brs, 1 H), 7.72 (d, J = 8.1, 1 H), 7.64 (d, J = 8.1, 1 H), 7.36 (t, J = 8.1, 1 H), 7.31-7.20 (m, 5H), 3.02-2.90 (m, 4H), 2. 78 (t, J = 7.8, 2H), 2.26 (t, J = 7.6, 2H), 1.97-1.90 (m, 1 H), 1.67-1.56 (m, 4H), 1.41-1.26 (m, 4H), 0.80-0.73 (m, 2H), 0.62-0.55 (m, 2H).

EXAMPLE 421 N-1- (2-r4- (Benzothiazol-2-yloxO-phenyl] -ethyl) -N1-cyclopropyl-propane-1,3-diamine The title compound was prepared according to the procedures for example 378, step A using cyclopropylamine, example 379, step A using 2- (3-bromo-propyl) isoindol-1,3-dione and example 403. MS (ESI): mass calculated for C2? H25N3OS, 367.17; m / z found, 468.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 7.6, 1H), 7.65 (d, J = 7.8, 1 H), 7.38 (t, J = 7.6, 1 H), 7.29-7.23 (m, 5H), 2.89-2.82 (m, 4H), 2.71 (t, J = 7.1, 4H), 1.83-1.77 (m, 1 H), 1.72-1.64 (m, 2H), 1.55 (br s, 2H), 0.54-0.48 (m, 2H), 0. 44-0.39 (m, 2H).

EXAMPLE 422 N- [3- ( { -2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl.} - cyclopropyl-amino) -propyl] -acetamide The title compound was prepared from from Example 421 following the procedure of Example 405. MS (ESI): mass calculated for C23H27N3O2S, 400.18; m / z found, 410.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.71 (d, J = 8.1, 1 H), 7.64 (d, J = 8.1, 1 H), 7.36 (t, J = 8.0118, 1 H), 7.28-7.21 (m , 5H), 6.77 (brs, 1 H), 3.26 (dd, J = 6.1, 5.8, 2H), 2.89-2.83 (m, 4H), 2.75 (t, J = 6.8, 2H), 1.89 (s, 3H) ), 1.84-1.78 (m, 1 H), 1.75-1.67 (m, 2H), 0.57-0.51 (m, 2H), 0.47-0.42 (m, 2H).

EXAMPLE 423 N- [3- ( { -2- [4- (Benzothiazol-2-yloxy) -phenp-ethyl) -cyclopropyl-amino) -propyl-isobutyramide The title compound was prepared in accordance with procedure of Example 421, using isobutyryl chloride. MS (ESI): mass calculated for C25H31N3O2S, 437.21; m / z found, 438.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.72 (d, J = 8.1, 1 H), 7.66 (d, J = 8.1, 1 H), 7.37 (t, J = 8.1, 1 H), 7.30-7.23 (m , 5H), 6.54 (brs, 1 H), 3.30 (dd, J = 6.1, . 8, 2H), 2.90-2.83 (m, 4H), 2.77 (t, J = 6.3, 2H), 2.31-2.19 (m, 1 H), 1.85-1.78 (m, 1 H), 1.75-1.67 (m , 2H), 1.12 (d, J = 6.8, 6H), 0.58-0.52 (m, 2H), 0.45-0.40 (m, 2H).

EXAMPLE 424 N- [3- ( { -2-r4- (Benzothiazol-2-yioxy) -phenyl-1-ethyl.} - cyclopropyl-amino) -propyl-benzamide The title compound was prepared according to the process of example 422, using benzoyl chloride. MS (ESI): mass calculated for C2SH29N3O2S, 471.20; m / z found, 472.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.78-7.67 (m, 4H), 7.61 (d, J = 7.8, 1 H), 7.44-7.39 (m, 1 H), 7.38-7.31 (m, 3H), 7.25-7.13 (m, 5H), 3.50 (dd, J = 6.1, 5.6, 2H), 2.89-2.77 (m , 6H), 1.85-1.75 (m, 3H), 0.56-0.49 (m, 2H), 0.45-0.38 (m, 2H).

EXAMPLE 425 N-3 - ((2-f4- (Benzothiazol-2-yloxO-pheypyl-ethyl) -cyclopropyl-amino) -propyl-4-chloro-benzamide The title compound was prepared according to the procedure of Example 422 , using 4-chloro-benzoyl chloride MS (ESI): calculated mass for C28H28CIN3? 2S, 505.16; m / z found, 506.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.80 (t, J = 5.0, 1 H), 7.68 (d, J = 7.6, 1 H), 7.65-7.50 (m, 3H), 7.37-7.29 (m, 3H), 7.25-7.15 (m, 5H), 3.47 (dd, J = 6.1, 5.31, 2H), 2.89-2.77 (m, 6H), 1.84-1.75 (m, 3H), 0.57-0.51 (m, 2H), 0.42-0.36 (m, 2H).

EXAMPLE 426 N-r3 - ((2-r4- (Benzot-azo-2-yloxy) -phenylethyl) -cyclopropyl-amino-propyl] -methanesulfonamide The title compound was prepared according to the procedure of Example 422, using chloride methanesulfonyl MS (ESI): mass calculated for C22H27N3O3S2, 445.15, m / z found, 446.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.72 (d, J = 7.8, 1 H), 7.64 (d , J = 7.8, 1 H), 7.36 (t, J = 7.8, 1H), 7.28-7.21 (m, 5H), 6.03 (br s, 1H), 3.15 (t, J = 6.1, 2H), 2.88 (s, 3H), 2.87-2.82 (m, 4H), 2.78 (t, J = 6.1, 2H), 1.82-1.71 (m, 3H), 0.58-0.52 (m, 2H), 0.49- 0.43 (m, 2H) ..

EXAMPLE 427 Salt of trifluoromethanesulfonic acid of f3- (. {2- [4- (benzothiazol-2-yloxy) -phenylethyl) -3-cyclopropyl-amino) -propyl] -amide of propan-2-sulfonic acid The compound of the title was prepared according to the procedure of example 422, using propan-2-sulfonyl chloride. MS (ESI): mass calculated for C24H3? N3O3S2, 473.18; m / z found, 474.4 [M + Hf. H NMR (400 MHz, CD3OD): 7.65 (d, J = 7.8, 1 H), 7.53 (d, J = 8.1, 1H), 7.39-7.16 (m, 6H), 3.44 (t, J = 8.3, 2H ), 3.37 (t, J = 8.3, 2H), 3.24-3.19 (m, 2H), 3.16-3.06 (m, 4H), 2.87-2.78 (m, 1 H), 2.07-1.94 (m, 2H), 1.67 (d, J = 4.04, 3H), 1.23 (d, J = 6.1, 3H), 1.07-1.00 (m, 2H), 0.98-0.91 (m, 2H).

EXAMPLE 428 Ethyl ester of 8- (. {-2- [4- (benzothiazol-2-yloxy) -phenp-ethyl) -cyclopropyl-amino-V-octanoic acid The title compound was prepared according to the procedure of Example 37g , step A, using 8-bromo-octanoic acid ethyl ester. MS (ESI): mass calculated for C28H36N203S, 480.24; m / z found, 481.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.72 (d, J = 8.1, 1H), 7.63 (d, J = 8.1, 1 H), 7.36 (t, J = 8.1, 1 H), 7.27-7.20 (m, 5H), 4.11 (dd, J = 7.3, 7.1, 2H), 2.87-2.81 (m, 4H), 2.64 (t , J = 7.3, 2H), 2.28 (t, J = 7.1, 2H), 1.82-1.75 (m, 1 H), 1.66- 1.58 (m, 2H), 1.56-1.47 (m, 2H), 1.36-1.27 (m, 6H), 1.24 (t, J = 7.1, 3H), 0.51- 0.45 (m, 2H), 0.43-0.38 (m, 2H).

EXAMPLE 429 1-f3- ( { -2-f4- (Benzothiazol-2-yloxy) -phenyl-ethyl) -cyclopropyl-amino) -propyl] -3-phenyl-urea The title compound was prepared according to the procedure of Example 422, using phenyl isocyanate. MS (ESI): mass calculated for C28H3oN4O2S, 486.21; m / z found, 487.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.61 (d, J = 8.1, 1 H), 7.57 (d, J = 8.1, 1 H), 7.28 (t, J = 8.1, 1H), 7.20-7.09 (m, 10H), 6.89 (t, J = 7.3, 1H), 5.64 (brs, 1 H), 3.16-3.09 (m, 2H), 2.70-2.64 (m, 4H), 2.57 (t, J = 7.1, 2H) , 1.67-1.60 (m, 1 H), 1.60-1.52 (m, 2H), 0.39-0.33 (m, 2H), 0.25-0.20 (m, 2H).

EXAMPLE 430 Acid 8- ( { -2-r4- (benzothiazol-2-ylox0-pheyp-ethyl) -cyclopropyl-amino) -octanoic acid The title compound was prepared from Example 428 following the procedure of Example 379, step B. MS (ESI): mass calculated for C26H32N2O3S, 452.21; m / z found, 453.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 12.76 (br s, 1 H), 7.72 (d, J = 7.6, 1 H), 7.63 (d, J = 7.8, 1 H), 7.36 (t, J = 7.6, 1 H ), 7.30-7.21 (m, 5H), 3.01-2.88 (m, 4H), 2.77 (t, J = 8.1, 2H), 2.27 (t, J = 7.8, 2H), 1.96-1.88 (m, 1 H) ), 1.66-1.54 (m, 4H), 1.38-1.23 (m, 6H), 0.77-0.70 (m, 2H), 0.61-0.54 (m, 2H).

EXAMPLE 431 [3- ( { 2- [4- (Benzothiazol-2-yloxy-Henyl-ethyl-Vodclopropyl-amino) -propyl] -amide of tetrahydro-furan-2-carboxylic acid To a solution of N-1-. 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etiI.}. -N1-cyclopropyl-propane-1,3-diamine (example 421, 330 mg, 0.9 mmol) in CH2Cl2 (18 mL) was added. 2-tetrahydrofuroic acid (129 μl, 1.35 mmol) and Si-carbodiimide (1.05 mmol / g, 1.71 g, 1.8 mmol) The reaction mixture was stirred at room temperature overnight, filtered and concentrated. purified over SiO2 (40 g, 0-10% CH3OH / CH2Cl2) to give a white solid (267 mg, 64% yield) MS (ESI): mass calculated for C26H3? N3O3S, 465.21; m / z found 466.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.72 (d, J = 8.1, 1 H), 7.64 (d, J = 8.1, 1 H), 7.36 (t, J = 8.1, 1H), 7.32 (br s, 1H), 7.29-7.21 (m, 5H), 4.32 (dd, J = 6.1, 2. 3, 1 H), 3.93-3.81 (m, 2H), 3.41-3.31 (m, 1H), 3.30-3.21 (m, 1 H), 2.90-2.80 (m, 4H), 2.75 (t, J = 6.8, 2H), 2.32-2.21 (m, 1H), 2.08-1.97 (m, 1H), 1.92-1.77 (m, 3H), 1.76-1.67 (m, 2H), 0.56-0.49 (m, 2H), 0.48-0.41 (m, 2H).

EXAMPLE 432 N-r3- ( {2-r4- (Benzothiazol-2-yloxy) -phenyl] -ethyl.} - cyclopropyl-amino) -propyl] -2-hydroxy-acetamide The title compound is prepared according to the procedure of Example 431 using glycolic acid. MS (ESI): mass calculated for C23H2 N303S, 425.18; m / z found, 426.3 [M + Hf. H NMR (400 MHz, CDCl 3): 7.73-7.63 (m, 2H), 7.44 (brs, 1 H), 7.40-7.33 (m, 1 H), 7.29-7.18 (m, 5H), 4.21 (s, 1 H), 3.91 (s, 2H), 3.37-3.28 (m, 2H), 2.90-2.82 (m, 4H), 2.75 (t, J = 6.1, 2H), 1.85-1.78 (m, 1 H), 1.77 -1.70 (m, 2H), 0.58-0.38 (m, 4H).

EXAMPLE 433 OATXA 4- ( { -2-f4- (Benzothiazol-2-yloxy) -phenoxy-1-ethyl) -cyclopropyl-amino-butyric acid A. (2-f4- (Benzothiazol-2-yloxy) -phenoxy-ethyl) -cyclopropyl-amine. To a stirring solution of 2- [4- (2-bromo-ethoxy) -phenoxy] -benzothiazole (example 9, 1. 1 g, 3.14 mmoles) in CH3CN (31 ml) was added cyclopropylamine (1.09 ml, 15.7 mmoles) and?,? -diisopropylethylamine (1.1 ml, 6.28 mmol). The mixture was heated at 60 ° C for 16 hr, cooled to room temperature, and then dissolved in CH 2 Cl 2 (100 mL). The solution was washed with H2O (2 x 20 ml), dried, and concentrated. The resulting oil was purified on SiO2 (40 g, 0-15% CH3OH / CH2Cl2) to give a clear oil (999 mg, 98% yield). MS (ESI): mass calculated for C? 8H? 8N2O2S, 326.11; m / z found, 327.2 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.71 (d, J = 8.1, 1 H), 7.59 (d, J = 8.1, 1 H), 7.33 (t, J = 8.1, 1H), 7.27-7.17 (m, 3H), 6.95-6.89 (m, 2H), 4.03 (t, J = 5.3, 2H), 3.06 (t, J = 5.3, 2H), 2.20-2 14 (m, 1 H), 2.02 (bs, 1 H), 0.47-0.41 (m, 2H), 0.39-0.34 (m, 2H). B. 4- (. {2-R4- (Benzothiazol-2-yloxy-phenoxy-1-ethyl) -cyclopropyl-amino) -butyric acid ethyl ester. To an agitated solution of. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -cyclopropyl-amine (050 mg, 2.91 mmol) in CH 3 CN (29 ml) was added 4-bromo-butyric acid ethyl ester (625 μl, 4.37 mmol) and N, N-diisopropylethylamine (1.0 ml, 5.82 mmol). The mixture was heated at 60 ° C for 16 hr, cooled to room temperature, and then dissolved in CH 2 Cl 2 (100 mL). The solution was washed with H2O (2 x 20 ml), dried and concentrated. The resulting oil was purified on SiO2 (40 g, 0-50% EtOAc / Hexanes) to give a colorless oil (1.0 g, 78% yield). MS (ESI): mass calculated for C24H28N2? 4S, 440.18; m / z found, 441.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.71 (d, J = 8.1, 1 H), 7.61 (d, J = 8.1, 1 H), 7.34 (t, J = 8.1, 1 H), 7.28-7.18 (m , 3H), 6.05-6.90 (m, 2H), 4.14-4.04 (m, 4H), 3.00 (t, J = 6.3, 2H); 2.71 (t, J = 7.1, 2H), 2.31 (t, J = 7.1, 2H), 1.90-1.80 (m, 3H), 1.23 (t, J = 7.1, 3H), 0.51-0.44 (m, 2H) , 0.43-0.38 (m, 2H). C. 4- ( { -2-R4- (Benzothiazol-2-yloxy) -phenoxy-1-ethyl) -cyclopropyl-amino) -butyric acid. To a solution of 4- (. {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl) -cyclopropyl-amino) -butyric acid ethyl ester (970 mg, 2.2 mmol) in 3: 1 of THF / CH3OH (80 ml), lithium hydroxide (211 mg, 8.8 mmol) was added in water (20 ml). This solution was stirred at room temperature for 16 hr and then the pH was adjusted to 7 using aqueous 1 N HCl. The mixture was extracted with CH2Cl2 (2 x 100 ml). The combined organic phase was concentrated under reduced pressure. The resulting oil was purified on SiO2 (40 g, 0-10% CH3OH / CH2Cl2) to give a white solid (877 mg, 07% yield). MS (ESI): mass calculated for C22H24N2? 4S, 412.15; m / z found, 413.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 11.44 (br s, 1 H), 7.68 (d, J = 8.1, 1 H), 7.62 (d, J = 8.1, 1 H), 7.35 (t, J = 8.1, 1 H), 7.27-7.20 (m, 3H), 7.01-6.95 (m, 2H), 4.44 (t, J = 5.0, 2H), 3.56 (t, J = 5.005, 2H), 3.32 (t, J = 8.1, 2H), 2.67-2.60 (m, 1 H), 2.46 (t, J = 6.8, 2H), 2.18-2.00 (m, 2H), 1.32-1.25 (m, 2H), 0.88-0.81 (m, 2H).

EXAMPLE 434 1-. { 3-r4- (Benzothiazol-2-yloxy) -benzyllamino-1-propyl) -pyrrolidin-2-one The title compound was prepared according to the procedure of example 251, step B using 1- (3-amino-propyl) ) -pyrrolidin-2-one. MS (ESI): mass calculated for C 21 H 23 N 3 O 2 S, 381.15; m / z found, 382.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.71 (d, J = 8.1, 1H), 7.64 (d, J = 8.1, 1 H), 7.45-7.41 (m, 2H), 7.36 (t, J = 8.1, 1 H), 7.32-7.28 (m, 2H), 7.24 (t, J = 8.1, 1 H), 3.81 (s, 2H), 3.38-3.27 (m, 5H), 3.63 (t, J = 6.8, 2H), 3.35 (t, J = 7.6, 2H), 2. 02-1.93 (m, 2H), 1.82-1.73 (m, 2H).

EXAMPLE 435 1- (3-fr4- (Benzothiazol-2-yloxy) -benzop-methyl-amino) -propyl) -pyrrolidin-2-one The title compound was prepared according to the procedure of Example 400 using formaldehyde.

MS (ESI): mass calculated for C22H25N3O2S, 3g5.17; m / z found, 3g6.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.71 (d, J = 8.1, 1 H), 7.64 (d, J = 8.1, 1 H), 7.43-7.27 (m, 5 H), 7.24 (t, J = 8.1, 1 H) , 3.54 (s, 2H), 3.32 (dd, J = 7.1, 7.1, 4H), 2.43 (t, J = 7.1, 2H), 2.34 (t, J = 7.1, 2H), 2.23 (s, 3H), 2.00-1.91 (m, 2H), 1.80-1.70 (m, 2H).

EXAMPLE 436 1- (3- (f4- (Benzothiazol-2-yloxO-benzip-isopropyl-amino) -propyO-pyrrolidin-2-one The title compound was prepared according to the procedure of Example 409 using acetone EM (ESI) : mass calculated for C 24 H 9 N 3 O 2 S, 423.20, m / z found, 424.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.72 (d, J = 8.1, 1 H), 7.65 (d, J = 8.1, 1 H), 7.45-7.40 (m, 2H), 7.37 (t, J = 7.8, 1H), 7.30-7.21 (m, 3H), 3.55 (s, 2H), 3.20-3.20 (m, 4H), 3.01-2.90 (m , 1H), 2.42 (t, J = 7.1, 2H), 2.32 (t, J = 7.8, 2H), 1.97-1.83 (m, 2H), 1.63-1.53 (m, 2H), 1.02 (d, J = 6.6, 6H).

EXAMPLE 437 1- (3- (r4- (Benzothiazol-2-yloxy) -benzyl-1-ethyl-amino-propyl) -pyrrolidin-2-one The title compound was prepared according to the procedure of Example 409 using acetaldehyde. ESI): mass calculated for C23H27N302S, 409.18, m / z found, 410.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.72 (d, J = 8.1, 1 H), 7.66 (d, J = 8.1, 1 H), 7.43-7.34 (m, 3H), 7.32-7.23 (m, 3H), 3.56 (s, 2H), 3.30 (dd, J = 7.1, 7.1, 4H), 2.53 (dd, J = 7.1, 7.1, 2H), 2.45 (t, J = 7.1, 2H), 2.34 (t, J = 7.8, 2H), 2.00-1.91 (m, 2H), 1.73-1.64 (m, 2H), 1.04 (t, J = 7.1, 3H).

EXAMPLE 438 xY X .NH [4- (Benzothiazol-2-yloxy) -benzyl] -cyclopropyl-amine The title compound was prepared according to the procedure of Example 251, Step B using cyclopropylamine. MS (ESI): mass calculated for C17H? 6N2OS, 296.10; m / z found, 297.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.72 (d, J = 8.1, 1 H), 7.63 (d, J = 8.1, 1 H), 7.40-7.33 (m, 3H), 7.32-7.27 (m, 2H), 7.24 (t, J = 8.1, 1H), 3.85 (s, 2H), 2.10-2.12 (m, 1 H), 1.86 (brs, 1 H), 0.48-0.35 (m, 4H).

EXAMPLE 439 N-1-f4- (Benzothiazol-2-yloxy) -benzyl] -N1-cyclopropyl-propane-1,3-diamine The title compound was prepared according to the procedure of Example 421 using the compound of Example 438. MS (ESI): mass calculated for C20H23N3OS, 353.16; m / z found, 354.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 8.1, 1 H), 7.65 (d, J = 8.1, 1 H), 7.41-7.32 (m, 3H), 7.30-7.23 (m, 3H) , 3.75 (s, 2H), 2.67 (t, J = 7.1, 2H), 2.58 (t, J = 7.1, 2H), 1.80-1.73 (m, 1 H), 1.72-1.64 (m, 2H), 1.19 (br s, 2H), 0.52-0.46 (m, 2H), 0.42-0.36 (m, 2H).

EXAMPLE 440 N- (3- (f4- (Benzothiazol-2-yloxy) -benzyl-cyclopropyl-amino) -prop-p-sobutyramide The title compound was prepared in accordance with procedure of example 422 using isobutyryl chloride. MS (ESI): mass calculated for C 24 H 29 N 3 O 2 S, 423.20; m / z found, 424.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.72 (d, J = 8.1, 1 H), 7.65 (d, J = 8.1, 1 H), 7.40-7.22 (m, 6H), 6.26 (br s, 1 H) , 3.73 (s, 2H), 3.23 (dd, J = 6.3, 5.8, 2H), 2.61 (t, J = 6.6, 2H), 2.29-2.18 (m, 1H), 1.79-1.68 (m, 3H), 1.09 (d, J = 6.8, 6H), 0.54-0.47 (m, 2H), 0.43-0.37 (m, 2H).

EXAMPLE 441 1- (3- { [4- (Benzothiazol-2-yloxy) -benzyl-1-cyclopropyl-amino.}. Propyl) -3-isopropyl-urea The title compound was prepared according to the procedure of example 422 using isopropyl isocyanate. MS (ESI): mass calculated for C 24 H 3 o N 4 O 2 S, 438.21; m / z found, 439.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.69 (d, J = 8.1, 1 H), 7.63 (d, J = 8.1, 1 H), 7.38-7.29 (m, 3H), 7.27-7.20 (m, 3H), 5.44 (br s, 1 H), 5.15 (d, J = 7.8, 1 H), 3.87-3.76 (m, 1 H), 3.70 (s, 2H), 3.12 (dd, J = 6.3, 6.1, 2H), 2.56 (t, J = 7. 1, 2H), 1.76-1.67 (m, 3H), 1.07 (d, J = 6.3, 6H), 0.49-0.42 (m, 2H), 0.40-0.34 (m, 2H).

EXAMPLE 442 OAX Y? 1- (1-r4- (Benzothiazol-2-yloxy) -benzyl-1-piperidin-4-yl) -3-isopropyl-urea The title compound was prepared according to the procedure of example 253, step C using Isopropyl isocyanate. MS (ESI): mass calculated for C23H28N4? 2S, 424.19; m / z found, 425.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 8.1, 1 H), 7.67 (d, J = 8.1, 1 H), 7.41-7.35 (m, 3 H), 7.32-7.24 (m, 3 H) , 4.77 (dd, J = 8.1, 7.8, 1 H), 3.88-3.78 (m, 1 H), 3.66-3.55 (m, 1 H), 3.51 (s, 2H), 2.82 (d, J = 11.6, 2H), 2.13 (t, J = . 0, 2H), 1.94 (d, J = 11.9, 2H), 1.69 (brs, 1H), 1.48-1.36 (m, 2H), 1.14 (d, J = 6. 6, 6H).

EXAMPLE 443 Methyl ester of N- acid. { 1-f4- (benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl) -oxamic acid The title compound was prepared according to the procedure of Example 253, step C using chloro-oxoacetic acid methyl ester .

MS (ESI): mass calculated for C22H23N3O4S, 425.14; m / z found, 426.2 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.78 (d, J = 8.1, 1 H), 7.64 (d, J = 8.1, 1 H), 7.55-7.50 (m, 2H), 7.44-7.36 (m, 3H) , 7.31 (t, J = 8.1, 1H), 3.84 (s, 2H), 3.81-3.72 (m, 1 H), 3.41 (s, 3H), 3.11 (d, J = 10.9, 2H), 2.59-2.47 (m, 2H), 2.00-1.91 (m, 2H), 1.79-1.66 (m, 2H).

EXAMPLE 444 N- (1-f4- (B OenzAot¡azoAl-2-yloxy) -benzyl-piperidin-4-yl) -isobutyramide The title compound was prepared according to the procedure of Example 253 using isobutyryl chloride. MS (ESI): mass calculated for C23H27N3O2S, 409.18; m / z found, 410.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.84 (d, J = 8.6, 2H), 7.69 (t, J = 7.8, 2H), 7.44 (d, J = 8.6, 2H), 7.41-7.33 (m, 2H) , 7.27 (t, J = 8.1, 1H), 4.33 (s, 2H), 4.16-4.00 (m, 1 H), 3.57-3.42 (m, 2H), 3.31-3.16 (m, 2H), 2.58-2.45 (m, 1 H), 2.31-2.07 (m, 4H), 1.10 (d, J = 6.8, 6H).

EXAMPLE 445 (1 - [4- (Benzothiazol-2-yloxy) -benzyl-piperidin-4-yl}. -amide of tetrahydro-furan-2-carboxylic acid The title compound was prepared from example 253, step D following The procedure of Example 431. MS (ESI): mass calculated for C 24 H 27 N 3 O 3 S, 437.18, m / z found, 438.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 11.03 (br s, 1 H), 7.73 (d , J = 7.8, 1 H), 7.67 (d, J = 7.8, 1 H), 7.46-7.42 (m, 2H), 7.41-7.32 (m, 3H), 7.27 (d, J = 7.8, 1 H) , 4.31 (t, J = 8.34, 1 H), 3.98-3.89 (m, 1 H), 3.84 (s, 2H), 3.19 (d, J = 11.6, 2H), 2.43 (t, J = 10.4, 2H ), 2.34-2.21 (m, 2H), 2.08-1.69 (m, 8H).

EXAMPLE 446, H 0A ° XAANV 1-. { 1- [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -4-hydroxy-pyrrolidin-2-one The title compound was prepared from Example 253, step D following the procedure of Example 254, step D. MS (ESI): mass calculated for C23H25N3? 3S, 423.16; m / z found, 424.3 [M + Hf. 1 H NMR (400 MHz, CD 3 OD): 7.80 (d, J = 8.1, 1 H), 7.68-7.62 (m, 3 H), 7.53-7.49 (m, 2 H), 7.42 (t, J = 8.1, 1 H) , 7.32 (t, J = 8.3, 1H), 4.44 (t, J = 6. 3, 1 H), 4.38 (s, 2H), 4.25-4.15 (m, 1 H), 3.68-3.57 (m, 3H), 3.33-3.13 (m, 3H), 2.71 (dd, J = 10.9, 6.3 , 1H), 2.28 (t, J = 17.7, 1H), 2.13-2.02 (m, 2H), 2.01-1.92 (m, 2H).

EXAMPLE 447 1-. { 1- [4- (Benzothiazol-2-yloxO-benzyl] -piperidin-4-yl) -4-hydroxy-pyrrolidin-2-one The title compound was prepared from example 253, step D following the procedure from Example 254, step D. MS (ESI): mass calculated for C23H25N3? 3S, 423.16; m / z found, 424.3 [M + Hf. 1 H NMR (400 MHz, CD 3 OD): 7.80 (d, J = 8.1, 1 H), 7.68-7.62 (m, 3H), 7.53-7.49 (m, 2H), 7.42 (t, J = 8.1, 1 H), 7.32 (t, J = 8.3, 1 H), 4.44 (t, J = 6.3, 1 H), 4.38 ( s, 2H), 4.25-4.15 (m, 1 H), 3.68-3.57 (m, 3H), 3.33-3.13 (m, 3H), 2.71 (dd, J = 10.9, 6.3, 1 H), 2.28 (t , J = 17.7, 1 H), 2.13-2.02 (m, 2H), 2.01-1.92 (m, 2H).

EXAMPLE 448 . { 1-r 4 - (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -urea The title compound was prepared according to the procedure of Example 253, step C using trimethylsilyl isocyanate. MS (ESI): mass calculated for C20H22N4O2S, 382.15; m / z found, 383.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.71 (d, J = 7.8, 1 H), 7.63 (d, J = 7.8, 1 H), 7.40-7.33 (m, 3H), 7.30-7.21 (m, 3H) , 5.82 (d, J = 7.8, 1 H), 5.10 (d, J = 4.6, 1 H), 3.84 (s, 1 H), 3.56 (brs, 1 H), 3.48 (s, 2H), 2.81 ( d, J = 11.6, 2H), 2.12 (t, J = 11.1, 2H), 1.90 (d, J = 11.9, 2H), 1.51-1.39 (m, 2H).

EXAMPLE 449 N-f1-r4- (benzothiazol-2-yloxy) -bencip-piperidin-4-yl acid} -oxamic The title compound was prepared from example 443 following the procedure of example 433, step C. MS (ESI): mass calculated for C2? H2iN3O S, 411.13; m / z found, 412.3 [M + Hf. 1 H NMR (400 MHz, CD 3 OD): 7.78 (d, J = 8.1, 1 H), 7.64 (d, J = 8.1, 1 H), 7.55-7.50 (m, 2H), 7.44-7.36 (m, 3H), 7.31 (t, J = 8.1, 1 H), 3.84 (s, 2H), 3.81-3.72 (m, 1 H) , 3.11 (d, J = 10.0, 2H), 2.59-2.47 (m, 2H), 2.00-1.91 (m, 2H), 1.79-1.66 (m, 2H).

EXAMPLE 450 OAOAYY N- (1-f4- (Benzothiazol-2-yloxy) -benzyl-1-piperidin-4-yl) -2-hydroxy-acetamide The title compound was prepared according to the procedure of Example 431 using glycolic acid. MS (ESI): mass calculated for C2? H23N3O3S, 387.15; m / z found, 398.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.71 (d, J = 7.8, 1 H), 7.65 (d, J = 8.1, 1 H), 7.40-7.35 (m, 3H), 7.31-7.23 (m, 3H) , 6.83 (d, J = 8.1, 1 H), 5.33, (br s, 1 H), 3.09 (s, 2H), 3.87-3.75 (m, 1 H), 3.50 (s, 2H), 2.85 (d , J = 11.4, 2H), 2.14 (t, J = 10.9, 2H), 1.92 (d, J = 12.6, 2H), 1.56-1.43 (m, 2H).

EXAMPLE 451 N-. { * 1-r4- (Benzothiazol-2-yloxy) -bencip-piperidin-4-yl 2,2,2-trifluoroacetamide The title compound was prepared according to the procedure of example 431 using trifluoroacetic acid.

MS (ESI): mass calculated for C2? H2oF3N3O2S, 435.12; m / z found, 436.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.71 (d, J = 8.3, 2H), 7.54 (d, J = 8.6, 2H), 7.47 (d, J = 8.8, 2H), 7.41 (t, J = 8.3, 1 H), 7.34-7.28 (m, 1H), 4.24 (s, 2H), 5 4.15-4.02 (m, 1 H), 3.50 (d, J = 12.1, 2H), 3.40, (brs, 1H), 2.87 (t, J = 11.9, 2H), 2.22-2.02 (m, 4H).

EXAMPLE 452 2- [4- (1,1-DÍQXO-1 l6-thiomorpholin-4-methylmethyl) -phenoxy-1-benzothiazole The title compound was prepared according to the procedure of Example 251 using 1,1-thiomorpholine dioxide. MS (ESI): mass calculated for C? 8H? 8N2O3S2, 374.08; m / z 5 found, 375.2 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.72 (d, J = 8.1, 1 H), 7.67 (d, J = 8.1, 1 H), 7.42-7.31 (m, 5 H), 7.27 (t, J = 7.8, 1 H) , 3.66 (s, 2H), 3.03 (d, J = 26.3, 8H). 0 EXAMPLE 453 N- (1-f4- (benzothiazol-2-yloxy-benzyl-piperidin-4-aminosulfonyl) -carbamic acid tert-butyl ester The title compound was prepared according to the process of Example 253 using N- (sulfonyl chloride) tert-butyl ester, carbamic acid, MS (ESI): mass calculated for C 24 H 30 N 4 O 5 S 2, 518.17, m / z found, 519.5 [M + Hf. 1 H NMR (400 MHz, CDCl 3) : 7.73 (d, J = 8.2, 1H), 7.67 (d, J = 8.2, 1 H), 7.42-7.35 (m, 3H), 7.34-7.24 (m, 3H), 5.18 (br s, 1 H) , 3.55 (s, 2H), 3.39-3.29 (m, 1 H), 2.83 (d, J = 11.7, 2H), 2.31-2.18 (m, 2H), 1.98 (d, J = 11.7, 2H), 1.72 -1.59 (m, 2H), 1.47 (s, 9H).

EXAMPLE 454 OA CACrV N-F1-r4- (Benzothiazol-2-yloxy) -benzyl-Piperidin-4-yl) -acetamide The title compound was prepared according to the procedure of Example 253, step C using acetyl chloride. MS (ESI): mass calculated for C2? H23N3O2S, 381.15; m / z found, 382.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 7.8, 1 H), 7.67 (d, J = 8.1, 1 H), 7.43-7.36 (m, 3H), 7.33-7.24 (m, 3H) , 5.65 (brs, 1 H), 3.87-3.76 (m, 1 H), 3.54 (s, 2H), 2.86 (d, J = 12.1, 2H), 2.17 (t, J = 11.4, 2H), 1.97 ( s, 3H), 1.93 (d, J = 11.9, 2H), 1.56-1.44 (m, 2H).

EXAMPLE 455 N-. { 1-r4- (Benzothiazol-2-yloxy) -benzyl-1-piperidin-4-yl) -N, N-dimethylsulfamide The title compound was prepared according to the procedure of example 253, step C using N, N chloride -dimethyl-sulphamoyl. MS (ESI): mass calculated for C2? H26N4? 3S2, 446.14; m / z found, 447.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 8.1, 1 H), 7.66 (d, J = 8.1, 1 H), 7.41-7.35 (m, 3 H), 7.32-7.23 (m, 3 H) , 4.37 (d, J = 7.8, 1 H), 3.49 (s, 2H), 3.28-3.17 (m, 1 H), 2.81 (d, J = 10.9, 2H), 2.78 (s, 6H), 2.11 ( t, J = 11.1, 2H), 1.98 (d, J = 10.9, 2H), 1.61-1.50 (m, 2H).

EXAMPLE 456 1-. { 1- [4- (Benzothiazol-2-yloxp-benzyl-1-pperidin-4-yl) -3-ethyl-urea The title compound was prepared according to the procedure of Example 253, step C using ethyl isocyanate.

MS (ESI): mass calculated for C22H26N4? 2S, 410.18; m / z found, 411.5 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.72 (d, J = 8.1, 1 H), 7.66 (d, J = 8.1, 1 H), 7.42-7.34 (m, 3 H), 7.32-7.23 (m, 3 H), 4.54 (br s, 1 H), 4.45 (d, J = 7.6, 1 H), 3.67-3.55 (m, 1 H), 3.50 (s, 2 H), 3.23-3.14 (m, 2 H), 2.80 (d , J = 11.9, 2H), 2.13 (t, J = 11.4, 2H), 1.93 (d, J = 12.6, 2H), 1.48-1.36 (m, 2H), 1.12 (t, J = 7.3, 3H).

EXAMPLE 457 1 - . 1 - (1-f4- (Benzothiazol-2-yloxy) -benzyl-1-Piperidin-4-yl) -3-ethyl-thiourea The title compound was prepared according to the procedure of Example 253, step C using isothiocyanate of ethyl. MS (ESI): mass calculated for C22H26N4OS2, 426.15; m / z found, 427.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.71 (d, J = 7.8, 1 H), 7.67 (d, J = 8.1, 1 H), 7.41-7.34 (m, 3 H), 7.32-7.24 (m, 3 H) , 6.03 (br s, 1 H), 5.74 (br s, 1 H), 4.20-4.00 (m, 1 H), 3.51 (s, 2H), 3.47-3.35 (m, 2H), 2.82 (d, J = 11.6, 2H), 2.05 (t, J = 11.1, 2H), 2.05 (d, J = 11.0, 2H), 1.57-1.45 (m, 2H), 1.21 (t, J = 7.3, 3H).

EXAMPLE 458 (1-f4- (Benzothiazol-2-yloxO-benzyl-1-pyridin-4-yl) -amide of propane-1-sulfonic acid The title compound was prepared according to the procedure of Example 253, step C using chloride of 1-propansulfoniium, MS (ESI): mass calculated for C22H27 3O3S2, 445.15, m / z found, 446.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 8.1, 1 H), 7.65 (d, J = 8.1, 1 H), 7.40-7.34 (m, 3H), 7.32-7.22 (m, 3H), 4.85 (d, J = 8.1, 1 H), 3.48 (s, 2H), 3.36-3.24 (m, 1 H) , 3.02-2.04 (m, 2H), 2.81 (d, J = 11.9, 2H), 2.11 (t, J = 10.6, 2H), 1.95 (d, J = 12.6, 2H), 1.89-1.78 (m, 2H) ), 1.65-1.54 (m, 2H), 1.04 (t, J = 7.3, 3H).

EXAMPLE 459 propan-2-sulfonic acid The title compound was prepared according to the procedure of Example 253, step C using 2-propanesulfonyl chloride. MS (ESI): mass calculated for C22H27N3O3S2, 445.15; m / z found, 446.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 8.1, 1 H), 7.66 (d, J = 8.1, 1 H), 7.41-7.35 (m, 3H), 7.32-7.24 (m, 3H) , 3.79 (d, J = 5.6, 1H), 3.51 (s, 2H), 3.38-3.27 (m, 1 H), 2.89-2.78 (m, 2H), 2.19-1.94 (m, 5H), 1.76 (d , J = 30.8, 6H), 1.69-1.55 (m, 2H).

EXAMPLE 460 N-. { 1-F4- (Benzothiazol-2-yloxy) -benzyl-piperidin-4-yl} -sulfamide The title compound was prepared from example 453 following the procedure of example 253, step B. MS (ESI): mass calculated for C? 9H22N4? 3S2, 418.11; m / z found, 419.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 10.68 (br s, 1 H), 7.60 (d, J = 8.3, 1 H), 7.56 (d, J = 8.3, 1 H), 7.48-7.38 (m, 2H), 7.32-7.24 (m, 3H), 7.18 (t, J = 7.8, 1 H), 6.24 (br s , 2H), 4.10 (s, 2H), 3.80-3.66 (m, 1 H), 3.57-3.10 (m, 2H), 3.04-2.61 (m, 2H), 2.41-1.61 (m, 4H).

EXAMPLE 461 N-f1-F4- (Benzothiazol-2-yloxy) -benzyl-1-piperidin-4-yl) -formamide The title compound was prepared according to the procedure of example 431, formic acid. MS (ESI): mass calculated for C2oH2? N3O2S, 367.14; m / z found, 368.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 12.28 (br s, 1 H), 7.73 (d, J = 7.8, 1 H), 7.68 (d, J = 7.8, 1H), 7.47-7.24 (m, 6H), 6.33 (d, J = 7.3, 1H), 4.05-3.94 (m, 1 H), 3.80 (s, 2H), 3.14 (d, J = 11.6, 2H), 2.41 (t, J = 11.9, 2H), 1.99 (d, J = 13.1, 2H), 1.83-1.70 (m, 2H).

EXAMPLE 462 Ethyl ester of acid. { 1-F4- (benzothiazol-2-yloxy) -benzyl) -p -peridin-4-yl) -carbamic acid The title compound was prepared according to the procedure of Example 253, step C using ethyl chloroformate. MS (ESI): mass calculated for C22H25N3O3S, 411.16; m / z found, 412.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 8.1, 1 H), 7.66 (d, J = 8.1, 1 H), 7.41-7.34 (m, 3 H), 7.32-7.22 (m, 3 H) , 4.62 (br s, 1 H), 4.10 (dd, J = 7.3, 6.8, 2H), 3.59-3.51 (m, 1 H), 3.49 (s, 2H), 2.80 (d, J = 11.6, 2H) , 2.12 (t, J = 11. 6, 2H), 1.93 (d, J = 12.1, 2H), 1.51-1.39 (m, 2H), 1.23 (t, J = 7.1, 3H).

EXAMPLE 463 N-. { 1-F4- (Benzothiazol-2-yloxy) -bencip-piperidin-4-yl} -propionamide The title compound was prepared according to the procedure of Example 253, step C using propionyl chloride. MS (ESI): mass calculated for C22H25N3O2S, 395.17; m / z found, 396.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.72 (d, J = 8.1, 1 H), 7.65 (d, J = 8.1, 1 H), 7.41-7.34 (m, 3H), 7.32-7.22 (m, 3H) , 5.61 (d, J = 8.1, 1 H), 3.87-3.76 (m, 1 H), 3.49 (s, 2H), 2.82 (d, J = 11.9, 2H), 2.22-2.07 (m, 4H), 1.90 (d, J = 13.1, 2H), 1.51-1.39 (m, 2H), 1.14 (t, J = 7.6, 3H).

EXAMPLE 464 N-. { 1-F4- (Benzothiazol-2-yloxy) -benzyl-piperidin-4-yl) -butyramide The title compound was prepared according to the procedure of Example 253, step C using butyryl chloride. MS (ESI): mass calculated for C23H27N3O2S, 400.18; m / z found, 410.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.72 (d, J = 8.1, 1 H), 7.65 (d, J = 8.1, 1 H), 7.40-7.35 (m, 3 H), 7.31-7.23 (m, 3 H), 5.64 (d, J = 8.1, 1 H), 3.87-3.77 (m, 1 H), 3.49 (s, 2H), 2.81 (d, J = 11.6, 2H), 2.16-2.07 (m, 4H), 1.91 (d, J = 12.9, 2H), 1.71-1.60 (m, 2H), 1.51-1.39 (m, 2H), 0.93 (t, J = 7.3, 3H).

EXAMPLE 465 1-. { 1-f4- (Benzothiazol-2-yloxy) -benzyl-1-piperidin-4-yl) -3-propyl-urea The title compound was prepared according to the procedure of example 253, step C using isocyanate propyl. MS (ESI): mass calculated for C23H28N4O2S, 424.19; m / z found, 425.5 [M + Hf. H NMR (400 MHz, CDCl 3): 7.70 (d, J = 8.1, 1 H), 7.63 (d, J = 8.1, 1H), 7.39-7.33 (m, 3H), 7.28-7.21 (m, 3H), 5.54 (br s, 1H), 5.37 (d, J = 8.1, 1 H), 3.66-3.56 (m, 1 H), 3.48 (s, 2H), 3.11 (dd, J = 7.1, 6.8, 2H), 2.80 (d, J = 11. 1, 2H), 2.11 (t, J = 11.1, 2H), 1.91 (d, J = 11.1, 2H), 1.54-1.38 (m, 4H), 0.91 (t, J = 7.3, 3H).

EXAMPLE 466 Propyl ester of acid. { 1-r4- (Benzothiazol-2-ylox-benzyl-1-piperidin-4-yl.} -carbamic acid The title compound was prepared according to the procedure of Example 253, step C using propyl chloroformate, MS (ESI): mass calculated for C23H27N3O3S, 425.18, m / z found, 426.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.72 (d, J = 8.1, 1 H), 7.63 (d, J = 8.1, 1 H), 7.39-7.33 (m, 3H), 7.31-7.21 (m, 3H), 4.83 (d, J = 7.6, 1 H), 4.00 (t, J = 6.6, 2H), 3.58-3.40 (m , 1 H), 3.47 (s, 2H), 2.70 (d, J = 11.6, 2H), 2.10 (t, J = 10.9, 2H), 1.91 (d, J = 11.1, 2H), 1.67-1.56 (m , 2H), 1.52-1.40 (m, 2H), 0.92 (t, J = 7.6, 3H).

EXAMPLE 467 1- (1-r4- (Benzothiazol-2-yloxp-bencip-piperidin-4-yl) -3-methyl-urea The title compound was prepared according to the procedure of Example 253, step C using methyl isocyanate. MS (ESI): mass calculated for C21H24N4O2S, 396.16; m / z found, 397.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.71 (d, J = 8.1, 1 H), 7.65 (d, J = 8.1, 1 H), 7.45-7.34 (m, 3 H), 7.33-7.22 (m, 3 H) , 5.71 (br s, 2H), 3.69-3.59 (m, 1 H), 3.56 (s, 2H), 2.87 (d, J = 11.9, 2H), 273 (d, J = 4.8, 3H), 2.21 ( t, J = 10.1, 2H), 1.03 (d, J = 10.4, 2H), 1.58-1.45 (m, 2H).

EXAMPLE 469 1 - . 1 - (1-4- (Benzothiazol-2-yloxO-bencip-piperidin-4-ip-1,3-dimethy urea) The title compound was prepared according to the procedure of example 255, step C using methyl isocyanate MS (ESI): mass calculated for C22H26N4O2S, 410.18; m / z found, 411.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.72 (d, J = 8.1, 1 H), 7.65 (d, J = 8.1, 1 H), 7.41-7.34 (m, 3H), 7.31-7.22 (m, 3H), 4.63 (dd, J = 4.6, 4.6, 1 H), 4.21-4.11 (m, 1 H), 3.49 (s, 2H), 2.93 (d, J = 11.9, 2H), 2.79 (d, J = 4.8, 3H), 2.71 (s, 3H), 2.08 (t, J = 11.0, 2H), 1.76-1.64 ( m, 2H), 1.63-1.54 (m, 2H).

EXAMPLE 470 1 - . 1-f 1 - [4- (Benzothiazol-2-yloxy) -benzyl-1-piperidin-4-yl) -1-methyl-urea The title compound was prepared according to the procedure of example 255, step C using trimethylsilyl isocyanate. MS (ESI): mass calculated for C 21 H 24 N 4 O 2 S, 396.16; m / z found, 397.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.72 (d, J = 8.1, 1 H), 7.65 (d, J = 8.1, 1 H), 7.42-7.34 (m, 3 H), 7.32-7.21 (m, 3 H) , 4.93 (s, 2H), 4.16-4.03 (m, 1 H), 3.50 (s, 2H), 2.94 (d, J = 11.4, 2H), 2.76 (s, 3H), 2.09 (t, J = 11.4 , 2H), 1.79-1.66 (m, 2H), 1.65-1.56 (m, 2H).

EXAMPLE 471 N-. { 1- [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -N-methylacetamide The title compound was prepared according to the procedure of Example 255, step C using acetyl chloride. MS (ESI): mass calculated for C22H25N3O2S, 395.17; m / z found, 396.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.72 (d, J = 8.1, 1 H), 7.65 (d, J = 8.1, 1 H), 7.41-7.34 (m, 3 H), 7.31-7.22 (m, 3 H) , 4.55-4.44 (m, 1H), 3.49 (s, 2H), 3. 01-2.80 (m, 2H), 2.84 (s, 3H), 2.15-2.09 (m, 2H), 2.07 (s, 3H), 1.77-1.65 (m, 2H), 1.64-1.53 (m, 2H).

EXAMPLE 472 (1- [4- (Benzothiazol-2-yloxy) -benzyl-piperidin-4-yl} -methylcarbamic acid methyl ester The title compound was prepared according to the procedure of Example 255, step C Methyl chloroformate, MS (ESI): mass calculated for C21H25N3O3S, 411.16, m / z found, 412.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 8.1, 1 H), 7.66 (d, J = 8.1, 1 H), 7.42-7.35 (m, 3H), 7.33-7.24 (m, 3H), 4.16-3.96 (m, 1 H), 3.69 (s, 3H), 3.51 (s, 2H), 2.95 (d, J = 11.4, 2H), 2.78 (s, 3H), 2.08 (t, J = 10.9, 2H), 1.82-1.69 (m, 2H), 1.65-1.57 (m, 2H).

EXAMPLE 473 Methyl ester of N- acid. { 1-r4- (benzothiazol-2-yloxy) -benzyl- pperidin-4-il} -N-methyl-oxalamic The title compound was prepared according to the procedure of Example 255, step C using chloro-oxoacetic acid methyl ester. MS (ESI): mass calculated for C23H25N3? 4S, 439.16; m / z found, 440.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.73 (d, J = 8.1, 1 H), 7.66 (d, J = 8.1, 1 H), 7.41-7.34 (m, 3 H), 7.33-7.23 (m, 3 H) , 4.41-4.32 (m, 1 H), 3.87 (s, 3H), 3.51 (s, 2H), 2.97 (d, J = 11.9, 2H), 2.88 (s, 3H), 2.13 (t, J = 11.9 , 2H), 1.95-1.83 (m, 2H), 1.72-1.62 (m, 2H).

EXAMPLE 474 N- (1-f4- (benzothiazol-2-yloxy) -benzyl-piperidin-4-yl-N-methyl-oxalamic acid The title compound was prepared from example 473 following the procedure of example 433 , step C. MS (ESI): mass calculated for C22H23N3O4S, 425.14, m / z found, 426.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.68 (d, J = 8.1, 1 H), 7.59 ( d, J = 8.1, 1 H), 7.37-7.28 (m, 3H), 7.27-7.16 (m, 3H), 4.27-4.16 (m, 1 H), 3.43 (s, 2H), 2. 93 (d, J = 11,897, 2H), 2.75 (s, 3H), 2.01 (t, J = 11.9, 2H), 1.82-1.65 (m, 2H), 1.58-1.47 (m, 2H).

EXAMPLE 475 N- (1-r4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl.} - N'-hydroxy-guanidine A. 1-f4- (Benzothiazol-2-yloxy) -benzyl-1-piperidine 4-yl-cyanamide To a suspension of 1- [4- (benzothiazol-2-yloxy) -benzyl] -piperidin-4-ylamine (339 mg, 1.0 mmol) in CH3OH (2.0 ml) was added sodium acetate (180 mg, 2.2 mmol) at room temperature The suspension became a clear solution The solution was cooled to 0 ° C. Cyanogen bromide (159 mg, 1.5 mmol) in CH3OH (0.7 ml) was added dropwise. The reaction mixture was stirred at 5 ° C for 2 hr and then at room temperature overnight.The mixture was filtered through a fritted funnel and the filtrate was absorbed on silica gel (40 g) and purified (0%). -10% CH3OH / CH2Cl2) to give an unstable oil (123 mg, 34% yield) MS (ESI): mass calculated for C2oH2oN4OS, 364.14, m / z found, 365.3 [M + Hf. B. N- (1- [4- (Benzothiazol-2-yloxy) -benzyl-piperidin-4-yl.} - N'-hydroxy-guanidine. To a solution of 1- [4- ( benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl- cyanamide (123 mg, 0.34 mmol) in DMF (2 ml) was added hydroxylamine hydrochloride (41.5 mg, 0.60 mmol), followed by sodium carbonate (119 mg, 1.12 mmol) in small portions. The reaction mixture was stirred at room temperature for 2 hr and partitioned between EtOAc (20 ml) and H2O (20 ml). The organic phase was washed with brine, dried and concentrated under reduced pressure to give the crude product as a pale solid. The crude product was purified on SiO2 (12 g, 0-10% CH3OH / CH2Cl2) to give a white solid (117 mg, 86% yield). MS (ESI): mass calculated for C2oH23N5O4S, 307.16; m / z found, 308.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.71 (d, J = 8.1, 1 H), 7.63 (d, J = 8.1, 1H), 7.38-7.32 (m, 3H), 7.28-7.21 (m, 3H), 4.69 (br s, 2H), 3.46 (s, 2H), 3.27-3.16 (m, 1 H), 2.78 (d, J = 10.9, 2H), 2.04 (t, J = 11.1, 2H), 1.02 (d , J = 11.1, 2H), 1.51-1.38 (m, 2H).

EXAMPLE 476 Isopropyl ester of acid. { 1-f4- (benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl} -carbamic The title compound was prepared according to the procedure of Example 253, step C using isopropyl isocyanate.

MS (ESI): mass calculated for C23H27N3O3S, 425.18; m / z found, 426.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.72 (d, J = 8.1, 1 H), 7.63 (d, J = 8.1, 1 H), 7.38-7.33 (m, 3 H), 7.31-7.21 (m, 3 H) , 4.05-4.85 (m, 1 H), 4.75 (d, J = 7.1, 1 H), 3.58-3.49 (m, 1H), 3.47 (s, 2H), 2.79 (d, J = 11.6, 2H), 2.09 (t, J = 11.4, 2H), 1.91 (d, J = 11.9, 2H), 1.50-1.39 (m, 2H), 1.21 (d, J = 6.5, 6H).

EXAMPLE 477 3- (1 - [4- (Benzothiazol-2-yloxy) -benzyl] -piperidin-4-yl) -1,1-dimethyl-urea The title compound was prepared according to the procedure of Example 253, step C using N, N-dimethylcarbamoyl chloride. MS (ESI): mass calculated for C22H26N O2S, 410.18; m / z found, 411.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.71 (d, J = 8.1, 1H), 7.64 (d, J = 8.1, 1 H), 7.39-7.33 (m, 3H), 7.30-7.21 (m, 3H), 4.41 (d, J = 7.8, 1 H), 3.73-3.62 (m, 1 H), 3.48 (s, 2H), 2.87 (s, 6H), 2.81 (d, J = 11.6, 2H), 2.11 (t , J = 11.9, 2H), 1.93 (d, J = 11.6, 2H), 1.50-1.38 (m, 2H).

EXAMPLE 478 Ester (1-r4- (benzothiazol-2-yloxy) -benzyl-1-piperidin-4-ylcarbamoyl) -methyl acetic acid The title compound was prepared according to the procedure of Example 253, step C using chlorocarbonylmethyl acid ester acetic. MS (ESI): mass calculated for C23H25N3O4S, 430.16; m / z found, 440.4 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.72 (d, J = 7.8, 1 H), 7.65 (d, J = 8.1, 1 H), 7.40-7.35 (m, 3H), 7.32-7.23 (m, 3H) , 6.11 (d, J = 8. 3, 1H), 4.53, (s, 2H), 3.93-3.82 (m, 1H), 3.50 (s, 2H), 2.83 (d, J = 11.9, 2H), 2.15 (s, 3H), 2.14 (t, J = 11.9, 2H), 1.93 (d, J = 12.1, 2H), 1.56-1.45 (m, 2H).

EXAMPLE 479 . { 1-f4- (Benzothiazol-2-yloxy) -benzyl-piperidin-4-ylthiourea A. 1 - (1 - [4- (Benzothiazol-2-yloxy) -benzyl-piperidin-4-yl}. -3-benzoyl thiourea The title compound was prepared in accordance with procedure of example 253, step C using benzoyl isocyanate. MS (ESI): mass calculated for C27H26N4O2S2, 502.15; m / z found, 503.3 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 10.80 (d, J = 8.1, 1 H), 9.06 (s, 1 H), 7.81 (d, J = 8.3, 2H ), 7.72 (d, J = 8.3, 1 H), 7.65 (d, J = 7.8, 1 H), 7.59 (t, J = 7.6, 1 H), 7.50-7.45 (m, 2H), 7.42-7.34 (m, 3H), 7.33-7.22 (m, 3H), 4.40-4.29 (m, 1 H), 3.53 (s, 2H), 2.80 (d, J = 11.1, 2H), 2.26 (t, J = 10.1, 2H), 2.12 (d, J = 11. 9, 2H), 176-1.64 (m, 2H). B. (1-f4 (Benzothiazol-2-yloxO-bencip-piperidin-4-yl) -thiourea A 1- {1- [4- (benzothiazol-2-yloxy) -benzyl] -piperidine- 4-yl.). 3-benzoyl-thiourea (300 mg, 0.60 mmol) was added 10% aqueous sodium hydroxide (10 ml) The reaction mixture was heated to reflux for 1 hr. cooled to room temperature and extracted with 10% CH3OH / CH2Cl2 (3 x 50 mL) The organic layer was dried (Na2SO4) and concentrated under reduced pressure to give the crude product as an off-white solid. on SiO2 (40 g, 0-10% CH3OH / CH2Cl2) to give the title compound as a white solid (219 mg, 92% yield) MS (ESI): mass calculated for C20H22N4OS2, 398.12; m / z found, 39g.3 [M + Hf. H NMR (400 MHz, CDCl 3): 772 (d, J = 8.1, 1 H), 7.68 (d, J = 8.1, 1 H), 7.42-7.36 (m, 3H), 7.34-7.26 (m, 3H), 6.00 (m, 1 H), 4.29-4.02 (m, 1 H), 3.57 (s, 2H), 2.88 (d , J = 11.1, 2H), 2.29 (s, 2H), 2.20 (t, J = 11.1, 2H), 2.04 (d, J = 10.1, 2H), 1.60-1.45 (m, 2H).

EXAMPLE 480 (1- {2-f4- (1 H-Benzimidazol-2-yloxy) -phenoxy-1-ethyl) -piperidin-4-p-methanol The title compound was prepared according to the procedure of example 37, using piperidin-4-yl-methanol. MS (ESI): mass calculated for C2? H25N3O3, 367.18; m / z found, 368.4 [M + Hf. 1 H NMR (400 MHz, DMSO-d 6): 12.24 (s, 1 H), 7.32 (s, 2 H), 7.27 (d, J = 8.9, 2 H), 7.08 (s, 2 H), 7.00 (d, J = 8.9, 2H), 4.41 (s, 1 H), 4.09 (s, 2H), 3.24 (s, 2H), 2.92 (d, J = 11.1, 2H), 2.68 (s, 2H), 198 (t, J = 11.6, 2H), 1.62 (d, J = 11.6, 2H), 1.24 (br s, 1 H), 1.11 (d, J = 9.2, 2H).

EXAMPLE 481 2-f4- (2-Morpholin-4-yl-ethoxy) -phenoxy-1-benzoxazole The title compound was prepared according to the procedure of example 11, using 4- (2-chloro-ethyl) -morphoin. MS (ESI): mass calculated for C? 9H2oN2? 4, 340.14; m / z found, 341.1 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.51 (d, J = 7.1, 1 H), 7.42 (d, J = 7.2, 1 H), 7.36-7.30 (m, 2H), 7.29-7.20 (m, 2H). , 7.03-6.05 (m, 2H), 4.14 (t, J = 57, 2H), 3.80-372 (m, 4H), 2.83 (t, J = 5.7, 2H), 2.60 (t, J = 4.6, 4H ).

EXAMPLE 482 AACATi 2-r4- (2-Morpholin-4-yl-ethoxy) -phenoxy-1-benzothiazole The title compound was prepared according to the procedure of Example 12, using 4- (2-chloro-ethyl) - morpholine and 2-chloro-benzothiazole. MS (ESI): mass calculated for C? 9H2oN2? 3S, 35; m / z found, 341.1 [M + Hf. 1H 6.12 NMR (400 MHz, CDCl 3): 774 (d, J = 7.6, 1 H), 7.66 (d, J = 7.3, 1 H), 7.39 (t, J = 7.3, 1 H), 7.31-7.20 ( m, 3H), 7.00-6.93 (m, 2H), 4.14 (t, J = 5.7, 2H), 3.80-372 (m, 4H), 2.83 (t, J = 5.7, 2H), 2.60 (t, J = 4.6, 4H).

EXAMPLE 483 2- [4- (2-Piperidin-1-yl-ethoxy-O-phenoxy-benzothiazo] The title compound was prepared according to the procedure of Example 12, using 4- (2-chloro-ethyl) -piperidine and 2- chloro-benzothiazole MS (ESI): mass calculated for C2oH22N2? 2S, 354.14, m / z found, 355.1 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.74 (d, J = 8.1, 1 H), 7.65 (d, J = 8.0, 1 H), 7.30 (t, J = 7.3, 1 H), 7.30-7.22 (m, 3H), 7.00-6.92 (m, 2H), 4.13 (t, J = 6.0, 2H), 2.81 (t, J = 6.0, 2H), 2.58-2.48 (br s, 4H), 1.68-1.58 (m, 4H), 1.52-1.42 (m, 2H).

EXAMPLE 484 HACAA . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl) -diethyl-amine The title compound was prepared according to the procedure of Example 11, using (2-chloro-ethyl) -diethyl-amine. MS (ESI): mass calculated for C? 9H22N203, 326.16; m / z found, 327.1 [M + Hf. 1 H NMR (400 MHz, CDCl 3): 7.51 (d, J = 7.6, 1H), 7.42 (d, J = 7.2, 1 H), 7.36-7.29 (m, 2H), 7.28-7.19 (m, 2H), 7.02-6.04 (m, 2H), 4.07 (t, J = 6.3, 2H), 2.90 (t, J = 6.3, 2H), 2.65 (q, J = 7.2, 4H), 1.09 (t, J = 7.1, 6H).

Test Methods The test results provided herein are illustrative results of the tests performed for compounds of this invention.

Test of LTA4 Recombinant Human Hydrolase for LTA4 Hydrolase Inhibitor Activity The compounds of the present invention were tested for LTA4 hydrolase inhibitor activity against recombinant human LTA4 hydrolase (rhLTA4H). Vectors were prepared and used to express rhLTA4H essentially in the following manner: DNA encoding LTA4 hydrolase was amplified by polymerase chain reaction (PCR) using a human placenta cDNA library as a template. The oligonucleotide primers for the PCR reaction were based on the 5 'end, and the 3' end complement, of the published nucleotide sequence for the coding region of the human LTA4 hydrolase gene (CD Funk et al., Proc. Nati, Acad. Sci. USA 1987, 84: 6677-6681). The 1.9 kb DNA fragment encoding LTA4 hydrolase was isolated and cloned into the pFastBad vector (Invitrogen). Recombinant baculovirus was generated as described by the manufacturer, and was used to infect Spodoptera frugiperda (Sf-9) cells. The recombinant LTA4 hydrolase enzyme was purified from the infected Sf-g cells essentially as described in J. K. Gierse et al. (Protein Expression and Purification 1993, 4: 358-366). The solution of purified enzyme was adjusted to contain 0.29 mg / ml of LTA4 hydrolase, 50 mM of Tris (pH 8.0), 150 mM of NaCl, 5 mM of dithiothreitol, 50% of gl / cerol, and complete mixture of EDTA-free protease inhibitor (Roche) The specific activity of the enzyme was about 3.8 μmol / min / mg. The LTA4 substrate was prepared from the methyl ester of LTA4 (Cayman Chemical) by treatment with 67 equivalents of NaOH under nitrogen at room temperature for 40 minutes. The LTA4 substrate in its free acid form was kept frozen at -80 ° C until needed. Each compound was diluted to different concentrations in test pH buffer (0.1 M potassium phosphate (pH 7.4), 5 mg / ml fatty acid free BSA) containing 10% DMSO. An aliquot of 25 μl of each compound dilution was incubated for 10 minutes at room temperature with an equal volume of test pH buffer containing 36 ng of recombinant human LTA4H. The solution was then adjusted to 200 μl with a test pH regulator. LTA4 (acid free) was thawed and diluted in a test pH regulator to a concentration of 357 ng / ml, and 25 μl (9 ng) of LTA4 substrate was added to the reaction mixture (total volume = 225 μl) at zero time. Each reaction was carried out at room temperature for 10 min. The reaction was stopped by diluting 10 μl of the reaction mixture with 200 μl of test pH buffer. LTB4 was quantified in the diluted sample by a commercially available enzyme-linked immunoassay (Cayman Chemical Co.), as recommended by the manufacturer. Positive controls, under essentially identical conditions but without the addition of an inhibitor compound, and negative controls, which contained all test components except enzyme, were routinely performed in each experiment. The IC 50 values were determined by adjusting the activity data at different concentrations of compound to a 4 parameter equation using the Grafit program (Erithacus software). It is expected that the Cl50 values presented in the following tables fall within the three times typical variability of tests of this type. The values presented here are, in general, an average of one to three determinations.

TABLE 1 TABLE 2 TABLE 3 Production of LTB4 by murine blood stimulated by calcium ionophore for LTA4H inhibitor activity. CD-1 mice were sacrificed, and blood was collected in syringes containing heparin by cardiac puncture. The blood was diluted 1: 15 with RPMI-1640 medium, and 200 μl aliquots of the diluted blood were added to wells of a 06-well microtiter plate. LTA4H inhibitor test compounds were prepared at different concentrations in RPMI-1640 medium containing 1% DMSO, and 20 μl of each test solution was added to a well containing diluted whole blood (final DMSO concentration of 0.1 %). After the contents of the microtitre plate were incubated for 15 minutes at 37 ° C in a humidified incubator, calcium ionophore A23187 (Sigma Chemical Co., St. Louis, Mo.) was added to each sample well ( final concentration = 20 ng / ml). Incubation was continued under the same conditions for 10 more minutes to allow the formation of LTB4. The reaction was terminated by centrifugation (833 x g, 10 min at 4 ° C), and the supernatants were analyzed for LTB4 by a commercially available enzyme-linked immunoassay (Cayman Chemical Co.) in accordance with the manufacturer's instructions. Positive controls, under essentially identical conditions but without the addition of an inhibitor compound, and unstimulated negative controls, which contained all test components except calcium ionophore, were routinely performed in each experiment. The IC 50 values were determined by adjusting the data of activity at different concentrations of compound to a 4-parameter equation using the Grafit program (Erithacus software). TABLE 4 TABLE 5 TABLE 6 Murine arachidonic acid-induced inflammation model LTA4H inhibitor compounds of the present invention were dissolved in 20% cyclodextran / H2O at a concentration of 3 mg / ml. The solutions were administered by oral forced feeding to female Balb / c mice weighing approximately 20 grams each (0.2 ml per mouse, 30 mg of LTA4H inhibitor compound per kg). Sixty minutes after administering an LTA4 inhibitor, each mouse received topical application 20 μl of arachidonic acid (100 mg / ml in acetone) to the left ear and 20 μl of acetone only to the right ear. After 3 hr, the mice were sacrificed, the blood was withdrawn in heparinized syringes, and 8 mm ear biopias were taken. The ear biopsies were weighted to determine edema and then frozen at -80 ° C until needed for determination of incoming neutrophil flow. Aliquots of one hundred microliters of heparinized blood were added to wells of a microtiter plate, together with equal volumes of RPMI-1640 medium, and calcium inonophore A23187 was added to each sample well (final concentration = 20 ng / μl). The contents of the microtiter plate were incubated for 10 minutes at 37 ° C in a humidified incubator. The reaction was terminated by centrifugation (833 x g, 10 minutes at 4 ° C). The supernatants were analyzed for LTB4 by a commercially available enzyme-linked immunoassay (Cayman Chemical Co.) in accordance with the manufacturer's instructions. The percent inhibition of Production of stimulated LTB4 ex vivo (% inhibitor of LTB4) was determined when compared with identical treated animals, except that the solution administered by oral forced feeding was devoid of inhibitor compound. The inflow of neutrophils was quantified by measuring the activity of myeloperoxidase (MPO), a neutrophil-specific enzyme. The ear biopsies were homogenized in 0.5 ml of extraction pH regulator (0.3 M sucrose, 0.22% (w / v) of hexadecyltrimethylammonium bromide (C ), and 2.5 mM of citrate prepared from a supply solution of 0.5 M citrate (pH 5.0) The residues were removed by centrifugation at 14,000 xg for 10 minutes, 10 μl aliquots of the resulting supernatant were added to wells of a microtitre plate, together with 90 μl aliquots of pH regulator. dilution (10 mM citrate, 0.22% C ), followed by the addition of 20 μl of TMB liquid substrate system (Sigma Chemical Co.) to each sample well The contents of the microtiter plate were maintained at room temperature for 1 hr. The reaction was stopped by the addition of 100 μl of 1 M H2SO4 to each well of the sample, and the myeloperoxidase activity in each sample was determined from the absorbance at 405 nm. right ear, tra only with acetone, it was subtracted from that for the left ear, treated with arachidonic acid in acetone, for each animal. The percent inhibition of incoming neutrophil flux (% Ide inhibition of MPO) by compounds of the invention was determined when compared with identically treated animals, except that the solution administered by oral forced feeding was devoid of inhibitor compound.

TABLE 7 TABLE 8 Having described the invention in specific detail and illustrated the manner in which it can be practiced, it will be apparent to those skilled in the art that innumerable variations, applications, modifications and extensions of the basic principles can be made. involved without departing from their spirit or scope. It should be understood that the foregoing is merely illustrative and the present invention should not be limited to the specific form or arrangements of parts described and shown herein.

Claims

NOVELTY OF THE INVENTION CLAIMS 1. - The use of at least one LTA4H modulator selected from compounds of the formula (I): (I) wherein X is selected from the group consisting of NR5, O, and S, where R5 is one of H and CH3; And it is selected from the group consisting of CH2, and O; Z is selected from the group consisting of O and bond; W is selected from the group consisting of CH2 and CHR1-CH2, R1 being one of H and OH, wherein the carbon member attached to R1 in said CHR1-CH2 is not directly attached to the nitrogen member to which W is attached; R4 is selected from the group which consists of H, OCH 3, Cl, F, Br, I, OH, NH 2, CN, CF 3 and CH 3; R6 is H or F; Y R2 and R3 are each independently selected from the group consisting of A) H, C? -7 alkyl, C3-7 alkenyl, wherein the carbon in said alkenyl which is attached to the nitrogen member has only bonds individual, C3-7 alkynyl, wherein the carbon in said alkynyl which is attached to the nitrogen member has only single bonds, optionally benzofused C3-7 cycloalkyl, C5.7 cycloalkenyl, C3-7 cycloalkyl C1-7 alkyl, C3-7 cycloalkyl C3- alkyl 7 and phenyl, wherein each of substituents A) is independently substituted with 0, 1 or 2 RQ, and each of R1Q is a substituent on a carbon member that is at least one carbon member removed from the member nitrogen; B) a HetRa substituent; C) -alkyl of C? .7C (O) Rx, optionally substituted with CH2RAr or CH2RAr; D) -alkyl of C -5C (O) Rx, wherein two valence carbon members allowed in the C2-5 alkyl of said -C2-5C (O) Rx alkyl are part of a C3-6 carbocycle saturated; E) -C2-5OH alkyl wherein two valence carbon members allowed in the C2-5 alkyl of said -C2-5OH alkyl are part of a saturated C3-β carbocycle; F) -Co-4 alkylphenyl, wherein the phenyl is said -Co-4 alkylphenyl is fused to two adjacent carbon members in said phenyl to Rf, or is benzofused; G) -alkyl of Co-4Ar6, wherein Ar6 is a 6-membered heteroaryl having a point of attachment of carbon member and having one or two heteroatom members -N =, and benzofused; H) -alkyl of Co ^ Ar5, where Ar5 is a 5-membered heteroaryl, having a heteroatom member selected from the group consisting of O, S, and > NRY, and having 0 or 1 additional heteroatom member -N =, optionally containing two carbonyl groups, and optionally benzofused; I) -alkyl of C -4Ar5 ', wherein Ar5 is a 5-membered heteroaryl containing 3 or 4 nitrogen members, optionally substituted with R ?, and having a valence site allowed as a point of attachment; J) -alkyl of Co ^ Ar6'6, wherein Ar6'6 is a phenyl bonded to C0-4 alkyl fused at sites of valence allowed to a 6-membered heteroaryl, wherein said 6-membered heteroaryl has one or two heteroatom members -N =; K) -alkyl of Co-4Ar6'5, wherein Ar6"5 is a phenyl bonded to C0-4 alkyl fused at sites of valence allowed to a 5-membered heteroaryl, said 5-membered heteroaryl having a heteroatom member selected of the group consisting of O, S, and> NRY, and said 5-membered heteroaryl having 0 or 1 additional heteroatom member which is -N =; and L) one of 2- (4-ethyl-phenoxy) -benzothiazole , 2- (4-ethyl-phenoxy) -benzoxazole, and 2- (4-ethyl-phenoxy) -1H-benzimidazole; M) S02-C1-4alkyl; alternatively R2 and R3 are taken together with the nitrogen at which are joined to form a heterocyclic ring containing at least one heteroatom member which is the binding nitrogen, said heterocyclic ring being selected from the group consisting of i) a 4-7 membered heterocyclic ring HetRb, said heterocyclic ring 4-7 members HetRb having a heteroatom member which is the binding nitrogen, and being replaced with 0, 1, or 2 substitutes in the same or in different substitution members, said substituent being selected from the group consisting of -R ?, -CN, -C (O) R ?, -Co-CO2 alkyl- C0-4C (O) alkyl CO2R ?, Co-ORY alkyl, -Co-C (O) NRYRZ alkyl, -C0-4NRYC (O) RZ alkyl, -C (O) NRzOR ?, -Calkyl- NRYC (O) CH2ORY , - -C0-4NR alkyl? C (O) CH2C (O) R ?, -C0-NRYCO2RY alkyl, -C0-alkyl 4NR? C (0) NR? Rz, -alkyl of C0.4NRYC (S) NRYRZ, - -NR? C (O) CO2R ?, -NRYRZ, -alkyl of C0-4NRWSO2RY, 1,3-dihydro-indole- 2-one-1-yl, 1,3-dihydro-benzimidazol-2-one-1-yl, tetrazol-5-yl, 1-R? -1 H-tetrazol-5-yl, R? -triazolyl, 2 -R? -2H-tetrazol-5-yl, pyrrolidin-2-thion-1-yl, piperidin-2-thion-1-yl, -OC-4C (O) N (R?) Alkyl (SO2R?) , -alkyl of C0-4N (RY) (SO2) NRYRY, -alkyl of C0. 4N (R?) (S? 2) NR? C02R ?, halogen, ii) a heterocyclic ring of 5-7 members HetRc, said heterocyclic ring of 5-7 HetRc having an additional heteroatom member separated from the binding nitrogen by at least one carbon members, said additional heteroatom member being selected from the group consists of O, S (= 0) or-2, and > NRM, said 5-7 membered heterocyclic ring HetRc having 0 or 1 carbonyl member, and being substituted with 0, 1, or 2 substituents on the same or on different carbon substitution means, said substituents being selected from the group consisting of -C (0) R ?, -CÜ2RY-C3 alkyl. C02R? and Rz; iii) one of imidazolidin-1-yl, 2-imidazolin-1-yl, pyrazol-1-yl, imidazol-1-yl, 2H-tetrazol-2-yl, 1H-tetrazol-1-yl, pyrrole-1- ilo, 2-pyrrolin-1-yl, and 3-pyrrolin-1-yl, wherein each of said 2H-tetrazol-2-yl and 1H-tetrazole-1-yl is substituted on the carbon member with 0 or 1-CC alkyl R2, -C0-4SRY alkyl-C0-4CO2RY alkyl and HetRa substituent; and iv) one of 1, 2,3,4-tetrahydro-quinoIin-1-yl, 1, 2,3,4-tetrahydro-isoquinolin-2-yl, indole-1-yl, isoindol-2-yl, indolin-1-yl, benzimidazol-1-yl, 2,8-diaza-spiro [4.5] decan-1-one-8-yl, 4-. { [(2-tert-butoxycarbonylamino-cyclobutylenecarbonyl) -amino] -methyl} -piperidin-1 -yl, 4-. { [(2-amino-cyclobutanecarbonyl) -amino] -methyl} -piperidin-1-yl, 3-g-diaza-spiro [5.5] undecan-3-carboxylic acid g-yl-tert-butyl ester, 4-oxo-1-phenyl-1,3,8-triaza -spiro [4.5] dec-8-yl, and 4-oxo-1, 3,8-triaza-spiro [4.5] dec-8-yl; wherein the HetRa substituent is a 4-7 membered heterocyclic ring having a carbon member attachment point and containing a > NRM as a heteroatom member, and said heteroatom member being separated from the carbon member attachment point by at least one additional carbon member; R? is selected from the group consisting of H, -C1-4alkyl, -Cal-4RRAalkyl > each optionally substituted with 1, 2, or 3 RN substituent; RL is selected from the group consisting of -CO2Rs and -C (O) NRsRs; RM is selected from the group consisting of Rz, indol-7-yl, -SO2R ?, -alkyl of C3-4CO2R ?, -CO2R ?, -C (O) NRzOR ?, -C (O) R ?, -C (O) C? -4OR? Alkyl, -C0-4C (O) NRsRs' alkyl, C0-4C (O) CO2RY, 1,3-dihydro-indol-2-one-1-yl alkyl, , 3-dihydro-benzimidazol-2-one-1-yl, tetrazol-5-yl, 1-R? -1H-tetrazol-5-yl, R? -triazolyl, 2-R? -2H-tetrazol-5 ilo and -alkyl of C0-4C (O) N (R?) (SO2R?), each optionally substituted with 1, 2 or 3 RN substituents; RN is selected from the group consisting of OCH3, Cl, F, Br, I, OH, NH2, CN, CF3, CH3, OC (O) CH3, and NO2; Rp is selected from the group consisting of R ?, -alkyl of C2-4? R ?, RAr, -alkyl of C1-2CO2R ?, -alkyl of C1.2CONRsRs', indole-7-iio, and -SO2alkyl of C ?-4; RQ is selected from the group consisting of fluoro, chloro, bromo, iodo, trifluoromethyl, trichloromethyl, -CN, -C? -4 alkyl, -C0-4Rαalkyl, -C0-4RAr alkyl. -C0-ORY alkyl, -C0-4CO2RY alkyl, -C0-4NRYRZ alkyl, -C0-4NRYCORY alkyl, -C0-4NRYCONRYRZ alkyl, -C0-4NR alkyl? SO2R ?, and -C0 alkyl .4SRY; Rs and Rs' are independently selected from the group consisting of H, -C 1-4 alkyl, and -C0-4 alkylphenyl, * alternatively, Rs and Rs are taken together with the nitrogen member to which said Rs and Rs are joined to form a 4 to 7 membered heterocyclic ring having 0 or 1 additional heteroatom member selected from the group consisting of O, S, and > NRY, provided that said additional member and heteroatom is separated by at least two carbon members of said nitrogen member to which Rs and Rs are attached, and provided that where R? is Co-4RAr alkyl, then RAr is not substituted with RL; Rw is selected from the group consisting of R ?, and -C3-7 cycloalkyl; Rx is selected from the group consisting of -OR ?, -NRYRZ, -alkyl of C? -, and -alkyl of C0-4RAr; R? is selected from the group consisting of H, -C1-4 alkyl, -C0-4RAr alkyl and -Co-4RAr alkyl. and optionally substituted with 1, 2, or 3 RN substituents; Rz is selected from the group consisting of R ?, -alkyl of C -4? R ?, -alkyl of C? -2CO R ?, -alkyl of C? .2C (O) NRsRs', and -alkyl of C2. NRSRS '; when R? and Rz join a nitrogen member, R? and Rz are selected as defined above or R? and Rz are taken together with the nitrogen member attached to R? - and Rz- to form a 4-7 membered heterocyclic ring HetRd having 0 or 1 additional heteroatom member selected from the group consisting of O, S, and > NRM, said 4-7 membered heterocyclic ring HetRd having 0 or 1 carbonyl member, and said 4-7 membered heterocyclic ring HetRd having 0 or 1 allowed valence carbon member substituted with at least one of RM, -CO2H, and -alkyl of C0-? OR ?; RAr is a portion with a carbon member attachment point and said portion is selected from the group consisting of phenyl, pyridyl, pyrimidyl, and pyrazinyl, wherein each valence carbon member allowed in each of said portions is independently substituted with at least one of 0, 1, 2 or 3 RN, and 0 or 1 RL; RAr 'is a ring of 3 to 8 members, having 0, 1 or 2 heteroatom members selected from the group consisting of O, S, N, and > NRY having 0, 1, or 2 unsaturated bonds, having 0 or 1 carbonyl member, wherein each valence member allowed in each of the rings is independently substituted with 0, 1, or 2 R ?; and Rf is a linear 3 to 5 membered hydrocarbon portion having 0 or 1 unsaturated carbon-carbon bond having 0 or 1 carbonyl member; or an enantiomer, diastereomer, racemate, tautomer, hydrate, solvate or a pharmaceutically acceptable salt, ester or amide thereof, for preparing a medicament for treating or preventing a condition mediated by LTA4H in a subject. 2. The use claimed in claim 1, wherein at least one LTA4H modulator is selected from compounds of the formula (II): (11) or an enantiomer, diastereomer, racemate, tautomer, hydrate, solvate or a pharmaceutically acceptable salt, ester or amide thereof, wherein R 4, R6, X, Y, Z, and W are defined as in the compound of the formula (I), R2 is defined as R2 in the compound of the formula (I), and R3 is defined as R3 in the compound of the formula (I), provided that (a) at least one of said R2 'and R3' is not ethyl when a selection in the group consisting of selections (s1), (s2), (s3), and (s4), is satisfied, and each of these selections is specifies how (s1): R4 is H, Z is O, W is CH, Y is CH2, and X is S; (s2): R4 is H, Z is O, W is CH2, Y is CH2 and X is NH; (s3): R4 is H, Z is O, W is CH2, Y is O, and X is S; (s4): R4 is 5-chloro, Z is O, W is CH2, Y is CH2, and X is S; (b) further provided that when Z is a bond, Y is CH2, W is CHR1-CH2, R1 is H, and one of R2 and R3 is 1H-imidazoI-2-yl, then the other of R2 and R3 'is select from A1), B) -L), where B) -L) are as defined above for the compound of the formula (I), and A1) consists of H, C3-7 alkenyl, in where the carbon in said C3-7 alkenyl which is attached to the nitrogen member has only individual bonds, C3-7 alkynyl, wherein the carbon in said alkynyl which is attached to the nitrogen member has only individual linkages, optionally benzofused C3-7 cycloalkyl, C5.7 cycloalkenyl, C3-7 cycloalkyl C-7 alkyl, C3-7 C-cycloalkyl; and (c) also provided that when X is S, Y is O, Z is a bond and W is CH2, then one of R2 and R3 is not XCG when the other is C6 -6 alkyl, then XCG is the group HC16 wherein HC16 is one of H, C? -6 alkyl, halo? -C6 alkyl, allyl, and C? _6 alkoxymethyl, and GO is a group attached to a carbon member having a substituent = Or forming an amido group with the nitrogen member to which said GO group is attached. 3. The use claimed in claim 1, wherein at least one LTA4H modulator is selected from compounds of the formula (III): (lll) or an enantiomer, diastereomer, racemate, tautomer, hydrate, solvate or a pharmaceutically acceptable salt, ester or amide thereof, wherein R4, R6, X, Y, Z, and W are defined as in the compound of the formula (I ), R2 is defined as R2 in the compound of the formula (I), and R3 is defined as R3 in the compound of the formula (I), provided that (a) said R2 and R3"also satisfies one of the following (e1): at least one of R2 and R3"is not alkyl of C? -5, when Z is O and X is S; (e2): none of R2"and R3" is Ci alkyl. 4C (O) Rx, where Rx is an alkyl of C? -4, OH, -O-C1-4alkyl, -Oalkyl of C0-4RAr, OR -NRYRY, when Y is O, Z is a bond, and R2"is different from R3, and (e3): none of R2" and R3"is -alkyl of C1-6CN, when Y is O , Z is a link and R2 'is different from R3"; and (b) further provided that when X is S, Y is O, Z is a bond, and W is CH2, then one of R2 and R3 is not XCG when the other is Cl-6 alkyl, where XCG is the group HCl 6 wherein HC16 is one of H, C? -6 alkyl, halogen-C? -6 alkyl, allyl and alkoxymethyl of d-6, and GO is a group bonded by a carbon member having a substituent a = O which forms an amido group with the nitrogen member to which said GO group is attached. 4. The use claimed in claim 1, wherein said R4 is H. 5. - The use claimed in claim 1, wherein said R2 and R3 are each independently selected from the group consisting of A), B), C), D), E) and I), as defined in claim 1. 6. The use claimed in claim 1, wherein said R2 and R3 are each independently selected from group A), as defined in claim 1. 7.- The use claimed in the claim 1, wherein said R2 and R3 are each independently selected from group B), as defined in claim 1. 8. The use claimed in claim 1, wherein said R2 and R3 are each independently selected from group C), as defined in claim 1. 9. The use claimed in claim 1, wherein said R2 and R3 are each independently selected from group D), as defined in claim 1. 10. The use claimed in claim 1, wherein said R2 and R3 are each independently selected from the group E), as defined in claim 1. 11. The use which is claimed in claim 1, wherein said R2 and R3 are each independently selected from group I), as defined in claim 1. 12. The use claimed in claim 1, wherein said R2 and R3 are taken together with the nitrogen to which they are bound to forming a heterocyclic ring containing at least one heteroatom member which is the binding nitrogen, said heterocyclic ring is selected from the group consisting of i) and ii), as defined in claim 1. 13.- The use that is claimed in claim 1, wherein said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is the binding nitrogen, said heterocyclic ring being selected from group i), as defined in claim 1. 14. The use claimed in claim 1, wherein said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring which contains minus one heteroatom member which is the binding nitrogen, said heterocyclic ring is selected from group ii), as defined in claim 1. 15. The use claimed in claim 1, wherein The condition mediated by LTA4H is inflammation due to at least one of asthma, chronic obstructive pulmonary disease, atherosclerosis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases and psoriasis. 16. The use claimed in claim 1, wherein at least one LTA4H modulator is one of: 2- [4- (2-piperidin-1-yl-ethoxy) -phenoxy] -benzoxazole; (1- {2- [4- (benzooxanzol-2-yloxy) -phenoxy] ethyl} -piperidin-4-yl) -methanol; 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-ol; . { 2- [4- (benzoxazol-2- iloxy) -phenoxy] -ethyl} -dibutyl-amine; (1- {2- [4- (benzoxazol-2-yloxy) -phenoxy] -ethyl} -piperidin-2-yl) -methanol; 1-. { 3- [4- (benzoxazol-2-yloxy) -phenoxy] -propyl} -4-phenyl-piperidin-4-ol; 1-. { 3- [4- (benzoxazol-2-yloxy) -phenoxy] -propyl} -4-benzyl-piperidin-4-ol; 2- [4- (2-piperidin-1-yl-ethyl) -phenoxy] -benzoxazole; . { 3- [4- (benzoxazol-2-yloxy) -phenyl] -propyl} -cyclohexyl-ethyl-amine; 1 -3- [4- (Benzoxazol-2-yloxy) -phenyl] -propyl} -piperidin-4-ol; 1-. { 3- [4- (benzoxazol-2-yloxy) -phenoxy] -2-hydroxy-propyl} -4-phenyl-piperidin-4-ol; 1- [2- (4-Benzoxazol-2-ylmethyl-phenoxy) -etl] -piperidine-4-carboxylic acid ethyl ester; 2- [4- (2-pyrrolidin-1-yl-ethoxy) -phenoxy] -benzoxazole; . { 3- [4- (benzoxazol-2-yloxy) -phenoxy] -propyl} dimethyl amine; . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} dimethyl amine; and 2- [4- (2-azepan-1-yl-ethoxy) -phenoxy] -benzoxazole. 17. The use claimed in claim 1, wherein at least one LTA4H modulator is one of: 1-. { 2- [4- (benzoxazol-2-yloxy) -phenoxyl-ethyl} -4-phenyl-piperidin-4-ol; . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -cyclohexyl-ethyl-amine; . { 2- [4- [2-ethyl-piperidin-1-yl] -ethoxy] -phenoxy} -benzoxazole; 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4-phenyl-piperidin-4-carbonitrile; 1 - (1 -. {2- [4- (Benzoxazo-2-yloxy) -phenoxy] -ethyl} -4-pheni) -piperidin-4-yl) -ethanone; 2-. { 4- [2- (4-Methyl-piperidin-1-yl) -ethoxy] -phenoxy} -benzoxazole; 1 -. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4- (4-chloro-phenyl) -piperidin-4-ol; 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4- (4-bromo-phenyl) -piperidin-4-ol; 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4- (4-chloro-3-trifluoromethyl-phenyl) -piperidin-4-ol; 1 -. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4-benzyl-piperidin-4-ol; . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -cyclohexyl-methyl-amine; Y . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -cyclopropylmethyl-propyl-amine. 18. - The use claimed in claim 1, wherein at least one LTA4H modulator is one of:. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -butyl-ethyl-amine; 2- (. {2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -benzyl-amino) -ethanol; 2-. { 4- [2- (4-Benzyl-piperidin-1-yl) -ethoxy] -phenoxy} -benzoxazole; (1 - { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} - piperidin-3-yl) -methane I; 2- ( { 2- [4- (Benzoxazoi-2-yloxy) -phenoxy] -ethyl} -propyl-amino) -ethanol; 2- [4- (2-Azetidin-1-yl-ethoxy) -phenoxy] -benzoxazole; ? - (1- {2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -2-phenyl-acetamide; 1- ethyl ester. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -piperidine-3-carboxylic acid; 2-. { 4- [3- (4-Phenyl-piperidin-1-yl) -propoxy] -phenoxy} -benzoxazole; 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -4-phenyl-piperidin-4-ol; . { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -cyclohexyl-ethyl-amine; 2- [4- (2-Pyrrolidin-1-yl-ethyl) -phenoxy] -benzoxazoI; and 2- [4- (2-Azepan-1-ethyl-ethyl) -phenoxy] -benzoxazole. 10. The use claimed in claim 1, wherein at least one LTA4H modulator is one of:. { 2- [4- (Benzoxazo-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl-propyl-amine; . { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -dibutyl-amine; 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-ol; methyl ester of 1 - acid. { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; 1 -. { 3- [4- (Benzoxazol-2-yloxy) -phenyl] -propyl} -4-phenyl-piperidin-4-ol; 2- [4- (3-Piperidin-1-yl-propyl) -phenoxy] -benzoxazole; . { 3- [4- (Benzoxazol-2-yloxy) -phenyl] -propyl} -dibutyl-amine; . { 3- [4- (Benzoxazol-2-yloxy) -phenyl] -propyl} -cyclopropylmethyl-propyl-amine; 1- [4- (Benzoxazol-2-yloxy) -phenoxy] -3-pyrrolidin-1-yl-propan-2-ol; 1 - [2- (4-Benzoxazol-2-ylmethyl-phenoxy) -etl] -4-phenyl-piperidin-4-ol; 1- [2- (4-Benzoxazol-2-ylmethyl-phenoxy) -ethyl] -piperidine-4-carboxylic acid amide; 2- [4- (2-Morpholin-4-yl-ethoxy) -phenoxy] - benzoxazole; Y . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -diethyl-amine. 20. The use claimed in claim 1, wherein at least one LTA4H modulator is one of:. { 2- [4- (6-chloro-benzothiazol-2-yloxy) -phenoxy] -phenoxy] -ethyl} -diethyl-amine; 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-ol; 1- ethyl ester. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carboxylic acid; acid 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carboxylic acid; (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -pyrrolidin-1-yl-methanone; 3 - [(1- {2- [4- (Benzothiazol-2-yloxy) -phenoxy-ethyl} -piperidine-4-carbonyl) -amino] -propionic acid ethyl ester; acid amide 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carboxylic acid; 1 - (1- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -pyrrolidin-2-one; 1 '-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - [1, 4 '] bipiperidinyl-2-one; 8-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -2,8-diaza-spiro [4.5] decan-1 -one; 2- [4- (3-pyrrolidin-1-yl-propoxy) -phenoxy] -benzothiazole; . { 2- [4- (benzothiazoI-2-yloxy) -phenyl] -ethyl} -cyclohexy-ethyl-amine; acid amide 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-3-carboxylic acid; 1- (1- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -3-methyl-1,3-dihydro-benzimidazole-2- ona; methyl ester of acid 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; (1- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) - (4-methyl-piperazin-1-yl) -methanone; 1- [2- (4-Benzothiazol-2-ylmethyl-phenoxy) -ethyl] -piperidine-4-carboxylic acid methyl ester; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - cyclopropyl-amino) -propionic acid; . { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} dimethyl amine; 2- [4- (2-pyrrolidin-1-yl-ethoxy) -phenoxy] -benzothiazole; . { 3- [4- (benzothiazol-2-yloxy) -phenoxy] -propyl} dimethyl amine; 2- [4- (2-azepan-1-yl-ethoxy) -phenoxy] -benzothiazole; 2- [4- (2-azepan-1-yl-ethoxy) -phenoxy] -6-methoxy-benzothiazole; 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -4-phenyl-piperldin-4-ol; . { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -cyclohexy-ethyl-amine; 1 -. { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -4- (4-chloro-phenyl) -piperidin-4-ol; . { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -dibutyl-amine; 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -4- (4-bromo-phenyl) -piperidin-4-ol; 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -4- (4-chloro-3-trifluoromethyl-phenyl) -piperidin-4-ol; 1-. { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -4-benzyl-piperidin-4-ol; 1'-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - [1, 4 '] bipiperidine; (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -methanol; ? - (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -2-phenyl-acetamide; 2- (4- { 2- [4- (2-morpholin-4-yl-ethyl) -piperazin-1-yl] -ethoxy.} - phenoxy) -benzothiazole; 2- (4- { 2- [4- (2-morfoyl-4-yl-ethyl) -piperazin-1-yl] -ethyl} -phenoxy) -benzothiazole; 1 -. { 3- [4- (benzothiazol-2-yloxy) -phenoxy] -propyl} -4-phenyl-piperidin-4-ol; 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -4-phenyl-piperidin-4-ol; 2- [4- (2-pyrrolidin-1-yl-ethyl) -phenoxy] -benzothiazole; 2- [4- (2-azepan-1-yl-ethyl) -phenoxy] -benzothiazole; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl-propyl-amine; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -dibutyl-amine; 2- [4- (2-piperidin-1-yl-ethyl) -phenoxy] -benzothiazole; 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperdin-4-ol; acid amide 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; 1- ethyl ester. { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-3-carboxylic acid; 1- ethyl ester. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -4-phenyl-piperidine-4-carboxylic acid; (1- {2- [4- (Benzothiazol-2-yloxy) -phenyl} -ethyl} -pyridin-4-yl) -acetic acid ethyl ester; 1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.}. -piperidin-4-yl) -1,3-dihydro- indole-2-one; 1- (1-. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperdn-4-yl) -pyrrolidin-2-one; A / - (1- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperidin-4-yl) -2-phenyl-acetamide; 8-. { 2- [4- (benzothiazol-2-yloxy) -pheni]] - eti)} -2,8-diaza-spiro [4.5] decan-1 -one; 1 -. { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl) -piperidin-3-ol; 1- ethyl ester. { 2- [4- (BenzothiazoI-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; 1 '-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - [1, 4 '] bipiperidine; 2-. { 4- [2- (4-methyl-piperazin-1-li) -ethyl] -phenoxy} -benzothiazole; 2- (4- { 2- [4- (1-Benzyl-1H-tetrazol-5-yl) -piperidin-1-yl] -ethoxy.} - phenoxy) -benzothiazole; 4- (1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carbonyl) -piperazin-1-carboxylic acid tert-butyl ester; 1- [2- (4-Benzothiazol-2-ylmethyl-phenoxy) -ethyl] -piperidine-4-carboxylic acid amide; 1 -. { 1 - [2- (4-benzothiazol-2-ylmethyl-phenoxy) -ethyl] -piperidin-4-yl} -pyrrolidin-2-one; 1 - [4- (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carbonyl) -piperazin-1-yl] -ethanone; acid 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; 1 - (1 -. {2- [4- (benzothiazoI-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -pyrrolidin-2-thione; 2- (4- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} - piperazin-1-yl) -ethanol; 2- (4-. {2- 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl] -piperazin-1-yl) -1-pyrrolidin-1-yl-ethanone; 2- (4-. {2- 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl] -piperazin-1-yl) -1-morpholin-4-yl-ethanone; acid 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-3-carboxylic acid; acid 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etl} -piperidine-2-carboxylic acid; (1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-3-yl) -acetic acid; (1- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -acetic acid ethyl ester; (1- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -carbamic acid tert-butyl ester; (1 - { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -acetic acid; (1- { 2- [4- (benzothiazol-2- iloxy) -phenyl] -ethyl} -piperidin-3-yl) -methanol; (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclohexyl-amino) -acetic acid methyl ester; (4- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - piperazin-1-yl) -acetic acid; 1- (1. {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -5-oxo-pyrrolidine-2-carboxylic acid ethyl ester; 1- (1- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -pyridin-4-yl) -5-oxo-pyrrolidine-2-carboxylic acid; 4- (4- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperazin-1-yl) -phenol; ? / - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -4-chloro-β-cyclopropyl-benzenesulfonamide; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - cyclopropylmethyl-amino) -propionic acid; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl) -isopropyl-amine) -propionic acid; 1 -. { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-ilamine; 3- [acid. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - (1-methyl-piperidin-4-yl) -amino] -proponic; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -benzyl-amino) -propionic acid; 3 - ((1-Acetyl-piperidin-4-yl) -. {2- 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -amino) -propionic acid; 4- (1- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -1-H-tetrazol-5-yl) -piperidine-1-carboxylic acid tert-butyl ester; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propionic acid; 3 - ((1-Acetyl-piperidin-4-yl) -. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -amino) -propionic acid; 3- [acid. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - (1-methyl-piperidin-4-yl) -amino] -propionic; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -propionic acid; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - isopropyl-amino) -proponic acid; 2- (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) -1-pyrrolidin-1-yl-ethanone; acid (R)? -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-3-carboxylic acid; 1- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.} - piperidin-4-yl) -1, 3-dihydro-benzimidazol-2-one; 2- (4- { 2- [4- (6-Methyl-pyridin-2-yl) -piperazin-1-yl] -ethyl} -phenoxy) -benzothiazole; 2-4- [2- (4-Ethanesulfonyl-piperazin-1-yl) -ethyl] -phenoxy} -benzothiazole; 2- (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -1-morpholin-4-yl-ethanone; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etyl] -methyl-amino) -propionic acid; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopentyl-amino) -propionic acid; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclobutyl-amino) -propionic acid; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -benzyl-amino) -propionic acid; (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) - (4-hydroxymethyl-piperidin-1-yl) -methanone; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amine; (1 - { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) - [4- (2-hydroxy-ethyl) -piperazin-1- il] -metanone; (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) - [4- (2-hydroxy-ethyl) -p -peridin-1} -yl] -metanone; 2- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.} - cyclopropyl-amino) -ethanol; 3- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propan-1-ol; 4- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -butyric acid; 3 - [(1 - { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carbonyl) -amino] -propionic acid; 4- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -butyronitrile; 3- (1 - { 2- [4- (BenzothiazoI-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -propionic acid; [(1 -. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carbonyl!) -methyl-amino] -acetic acid; 3- (4- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperazin-1-yl) -phenol; 2- (4- { 2- [4- (4-methoxy-phenyl) -piperazin-1-yl] -ethoxy.} - phenoxy) -benzothiazole; 2-. { 4- [2- (5-piperidin-4-yl-tetrazol-1-yl) -ethoxy] -phenoxy} -benzothiazole; (S) -1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -4-hydroxy-pyrrolidin-2-one; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl- amine; 2 - [(. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -.-cyclopropyl-amino) -methyl] -cyclopropanecarboxylic acid ethyl ester; 4- (4-. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperazin-1-carbonyl) -benzoic acid ethyl ester; 2 - [( { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -methyl] -cyclopropanecarboxylic acid; 1 - (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propan-2-ol; 3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.} - cyclopropyl-amino) -1,1,1-trifluoro-propan-2-ol; 3- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propionamide; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propane-1,2-diol; 2-. { 4- [2- (5-phenyl-tetrazol-2-yl) -ethoxy] -phenoxy} -benzothiazole; 2-. { 4- [2- (5-phenyl-tetrazol-1-yl) -ethoxy] -phenoxy-benzothiazole; ? / -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -N-cyclopropyl-2- (2H-tetrazol-5-yl) -acetamide; (S) -3- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -2-methyl-propan-1-ol; (f?) - 3- (. {2- 2- (4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -2-methyl-propan-1-ol; 2-. { 4- [2- (5-methylsulfanyl-tetrazol-2-yl) -ethoxy] -phenoxy} -benzothiazole; 2-. { 4- [2- (5-Methylsulfanyl-tetrazol-1-yl) -ethoxy] -phenoxy} -benzothiazole; 2- [4- (2-tetrazol-2-yl-ethoxy) -phenoxy] -benzothiazole; 2- [4- (2-tetrazol-1-yl-ethoxy) -phenoxy] -benzothiazole; acid (1 f?, 2;?) - 2-. { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethylamino-cyclohexanecarboxylic acid; acid (1S, 2R) -2-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino} -cyclohexanecarboxylic; (1R, 2R) -2-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino} -cyclohexanol; (IS ^ R ^^ - -benzothiazole ^ -yloxyHenyl] -ethylaminoj-cyclohexanol: 4- (1- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine- 4-yl) -butyric; (R) 1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl.}. -p.peridin-4-yl) -4- hydroxy-pyrrolidin-2-one; 2- (4-. {2- 2- [4- (1H-Tetrazol-5-yl) -piperidin-1-yl] -ethyl} -phenoxy) -benzothiazole; - { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl.}. -piperidin-2-yl) - methanol; (1- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -1H-tetrazol-5-yl) -acetic acid ethyl ester; (1- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethi}. -1H-tetrazol-5-yl) -acetic acid ethyl ester; 2- hydrochloride. { 4- [2- (5-piperidin-4-yl-tetrazol-2-yl) -ethoxy] -phenoxy} -benzothiazole; 7- { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -4-spiro- [3-phthalide] -piperidine; 1- ethyl ester. { 3- [4- (benzothiazol-2-yloxy) -phenyl] -propyl} -piperidine-4-carboxylic acid; 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamine hydrochloride; 2- (4- { 2- [4- (1H-tetrazol-5-yl) -piperidin-1-yl] -ethoxy.} - phenoxy) -benzothiazole; cis-4- trifluoromethanesulfonate salt. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino-cyclohexanecarboxylic acid; (4- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-ii) - (tetrahydro-furan-2-yl) -methanone; (1- ({2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carbonyl) -amide of propane-2-sulfonic acid; (4- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) -oxo-acetic acid methyl ester; N- (1- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -ethyl} -piperidine-4-carbonyl) -benzenesulfonamide trifluoromethanesulfonate salt; N- (1-. {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -3-piperidine-4-carbonyl) -methanesulfonamide trifluoromethanesulfonate salt; (4- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) -oxo-acetic acid trifluoromethanesulfonate salt; (4- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -morpholin-4-yl-methanone; 1 - (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -etii.}. -plperazin-1-yl) -2-thiophen-2-yl-ethanone; (4- { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - p-piperazin-1-yl) -pyridin-3-yl-methanone; (4-. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -cyclopropyl-methanone; 1 - (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -etyl] -piperazin-1-yl) -2-methoxy-ethanone; 1 - (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -2,2,2-trifluoro-ethanone; acid 4- (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazine-1-carbonyl) -benzoic acid; (4-. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -pyridin-4-yl-methanone; (4- { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl.} - piperazin-1-yl) - (5-methyl-pyrazin-2-yl) -methanone; (f?) - (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) - (tetrahydro-furan-2-yl) -methanone; (S) - (4- { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) - (tertrahydro-furan-2-yl) -methanone; (4- { 2- [4- (BenzothiazoI-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) - (tetrahydro-furan-3-yl) -methanone; 1- (4- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -2-hydroxy-ethanone; 2- [2- (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl] -piperazin-1-yl) -2-oxo-ethyl] -cyclopentanone; 3- (4. {2- [4- (BenzothiazoI-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) -propionic acid trifluoromethanesulfonate salt; 3- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperidin-4-yl) -oxazolidin-2-one; 4- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -morpholin-3-one; 4- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperdin-4-yl) -morpholin-3-one; 3- (1- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -etyl] -piperidin-4-yl) -oxazolidin-2-one; benzyloxy-1-acid amide. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; (1 - { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -acetic acid; (R) -1- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -4-hydroxy-pyrrolidin-2-one; hydroxyamide of acid 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; (S) -1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -fenii] -ethyl.}. -piperidin-4-yl) -4-hydroxy-pyrrolidin-2-one; (1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -carbamic acid tert-butyl ester; 2-. { 4- [2- (4-fluoro-piperidin-1-yl) -ethyl] -phenoxy} -benzothiazole; 2-. { 4- [2- (4,4-difluoro-piperdin-1-yl) -ethyl] -phenoxy} -benzothiazole; (R) -1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -pyrrolidin-3-ol; N-1 -. { 2- [4- (benzothiazole- 2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -formamide; (1- { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etyl] -piperidin-4-yl) -urea; 1 - (1 -. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -3-cyano-2-phenyl-isourea; 1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -3-cyano-2-methyl-isothiourea; N- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperidin-4-yl) -methanesulfonamide; 1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.} - p -peridin-4-yl) -3-cyano-2-methyl-guanidine; 8-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -1-phenyl-1, 3,8-triaza-spiro [4.5] decan-4-one; 8-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -1, 3,8-triaza-spiro [4.5] decane-2,4-dione; (1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -methyl-carbamic acid tert-butyl ester; N- (1-. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -N-methyl-acetamide; N- (1-. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -N-methyl-methanesulfonamide; [(1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -methyl-carbamoyl] -methyl acetic acid ester; N- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -N-acetamide; (1 -. {2- [4- (Benzothiazoi-2-yloxy) -phenyl-ethyl-ethyl} -piperidin-4-carbamoyl) -methalic acid ester; 2- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -methyl-amino) -3- (1 H-imidazol-2-yl) -proponic acid; 2- (4- { 2- [4- (3-nitro-pyridin-2-yl) - [1,4] diazepan-1-yl] -ethyl} -phenoxy) -benzothiazole; [(1- {2- [4- (Benzothiazol-2-yloxy) -phenox] -ethyl} -piperidine-4-carbonyl) -methyl-amino] -acetic acid ethyl ester; ethyl ester of 1'- acid. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - [1, 4 '] bipiperidinyl-4-carboxylic acid; 1'- acid. { 2- [4- (benzothiazol-2-yloxy) - [phenoxy] -ethyl} - [1, 4 '] bipperidinyl-4-carboxylic acid; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-ethyl-amine; trifluoromethanesulfonic acid salt of 3- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino) -2-methyl-propionic acid; 2- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.} - cyclopropylmethyl-amino) -ethanol; 2- [2- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -ethoxy] -ethanol; 3- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl-amino) -propan-1-ol; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etl} -cyclopropylmethyl- (3-tetrazol-2-yl-propyl) -amine; . { 2- [4- (benzothiazol-2-yloxy) -phenyl] -eti} -cyclopropyl- (3-pyrrol-1-yl-propyl) -amine; 4- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -butyronitrile; (2-cyano-ethyl) -amide of 1- acid. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl- [3- (2H-tetrazol-5-yl) -propyl] -amine; 3- [5- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl] -p.peridin-4-yl) -tetrazol-1-yl] -prop onitrile; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl- [3- (2H-tetrazol-5-yl) -propyl] -amine; 1- (hydroxy-1, 1-dimethyl-ethyl) -amide. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl- [3- (1 H- [1, 2,4] triazol-3-yl) -propyl] -amine; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl- [3- (5-methyl-1 H- [1, 2,4] triazol-3-ii) -propyl] -amine; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl- [3- (5-phenyl-1 H- [1, 2,4] triazol-3-yl) -propyl] -amine; 2- (4- { 2- [4- (1-methyl-1 H-tetrazol-5-yl) -piperidin-1-yl] -ethyl} -phenoxy) -benzothiazole; 2- (4- { 2- [4- (2-methyl-2H-tertrazol-5-yl) -piperidin-1-yl] -ethyl} -phenoxy) -benzothiazole; 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etl} -piperidine-4-carbonitrile; 2- (4- { 2- [4- (1 H- [1,2,3] triazol-4-yl) -piperidin-1-yl] -ethyl} -phenoxy) -benzothiazole; 4-ethyl ester. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino} -butyric; 4- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl-amino) -butyric acid ethyl ester; 2- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -propl] -isoindole-1,3-dione; 4- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) - butyric; 1- (3- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethylamino} -propyl) -pyrrolidin-2-one; N-1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -N1-cyclopropylmethyl-propane-1,3-diamine; 5- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -.-cyclopropyl-amino) -pentanoic acid methyl ester; N- [3- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -propyl] -acetamide; [3- ( { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - (cyclopropylmethyl-amino) -propyl] -amide of morpholin-4-carboxylic acid; N- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -propyl] -methanesulfonamide; 5- ( { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -pentanoic acid; 1- [3- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - isopropyl-amino) -propyl] -pyrrolidin-2-one; 1- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -cyticpropylmethyl-amino) -propyl] -pyrrolidin-2-one; 1- [3- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl] -pyrrolidin-2-one; 1 - [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - propyl-amino) -propyl] -pyrrolidin-2-one; 4 - ((1-Acetyl-piperidin-4-yl) -. {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -amino) -butyric acid ethyl ester; ethyl acyl ester 4 - ((1-acetyl-piperidin-4-yl) -. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -amino) -butyric acid; 4- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -metanesulfonyl-amino) -butyric acid; 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etill-cyclopropyl-amino) -acetic acid; 6- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino) -hexanoic acid ethyl ester; 7- (. {2- 2- [4- (BenzothiazoI-2-yloxy) -phenyl] -ethyl} -.-cyclopropyl-amino) -heptanoic acid ethyl ester; 6- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -hexanoic acid; 7- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -heptanoic acid; N-1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -N1-cyclopropyl-propane-1,3-diamine; N- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino) -propyl] -acetamide; N- [3- (. {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl] -isobutyramide; N- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl] -benzamide; N- [3- ( { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl] -4-chloro-benzamide; N- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl] -methanesulfonamide; [3- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl] -3-cyclopropyl-amino) -propyl] -amide trifluoromethanesulfonic acid of propan-2-sulfonic acid; 8- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino) -octanoic acid ethyl ester; 1- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl] -3-phenyl-urea; 8- ( { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino-octanoic acid; [3- (. {2- [4- (benzothiazole 2-yloxy) -phenyl] -ethyl.} - (cyclopropyl-amino) -propyl] -amide of tetrahydro-furan-2-carboxylic acid; N- [3- (. {2- [4- (benzothiazole- 2 -loxy) -phenyl] -ethyl.} - cyclopropyl-amino) -propyl] -2-hydroxy-acetamide, 4- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl} ] -ethyl.}.-cyclopropyl-amino) -butyric acid 2- [4- (2-morpholin-4-l-ethoxy) -phenoxy] -benzothiazole; and. {2- [4- (2-piperidine- 1-yl-ethoxy) -phenoxy] -benzothiazole 21. The use claimed in claim 1, wherein at least one LTA4H modulator is one of: 1- { 2- [4- (1H -benzimidazol-2-yloxy) -phenoxy] -ethyl.} -4-phenyl-piperidin-4-ol; {. 2- [4- (1 H-benzimidazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl-propyl-amine; cyclohexyl-ethyl- {2- [4- (1-methyl-1 H-benzimidazol-2-yloxy) -phenyl] -ethyl} -amine; 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl.} -4- (4-bromo-phenyl) -piperidin-4-ol; 1 -. {2- [4 - (1 H-benzimidaz ol-2-yloxy) -phenoxy] -ethyl} -4- (4-chloro-phenyl) -piperidin-4-ol; 1 -. { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -4- benzyl-piperidin-4-ol; . { 2- [4- (1H-benzimidazol-2-yloxy) -phenyl] -ethyl} -cyclohexyl-ethyl-amine; 2- [4- (2-pyrrolidin-1-yl-ethyl) -phenoxy] -1 H -benzimidazole; 2- [4- (2-azepan-1-ethyl-ethyl) -phenoxy] -1 H -benzimidazole; . { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -dibutyl-amine; 1 -. { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-ol; methyl ester of acid 1-. { 2- [4- (1H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carboxylic acid; . { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -cyclohexyl-ethyl-amine; 2-. { 4- [2- (4-methyl-piperidin-1-yl) -ethoxy] -phenoxy} -1 H-benzimidazole; 2-. { 4- [2- (2-ethyl-piperidin-1-yl) -ethoxy] -phenoxy} -1 H-benzimidazole; 2- [4- (2-piperidin-1-yl-ethoxy) -phenoxy] -1 H -benzimidazole; (1- {2- [4- (1H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -methanol; 1-. { 2- [4- (1H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -periodine-4-ol; 2- [4- (2-azepan-1-yl-ethoxy) -phenoxy] -1 H -benzimidazole-amide; . { 3- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -propyl} dimethyl amine; 2- [4- (2-pyrrolidin-1-yl-ethoxy) -phenoxy] -1 H -benzimidazole; . { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -diethylamine; 2- [4- (2-morpholin-4-yl-ethoxy) -phenoxy] -1 H -benzimidazole; 2- [4- (2-piperidin-1-yl-ethyl) -phenoxy] -1 H -benzimidazole; 1 - (1- { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} - piperidin-4-yl) -pyrrolidin-2-one; 1- ethyl ester. { 2- [4- (1H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carboxylic acid. 22. The use claimed in claim 2, wherein said R4 is H. 23. The use claimed in claim 2, wherein said R2 and R3 are each independently selected from the group consisting of A), B), C), D), E) and I), as defined in claim 2. 24.- The use claimed in the claim 2, where said R2 and R3 are each independently selected from group A), as defined in claim 2. 25.- The use claimed in claim 2, wherein said R2 and R3 are each independently selected from group B), as defined in claim 2. 26.- The use claimed in claim 2, wherein said R2 and R3 are each independently selected from group C), as defined in claim 2. 27.- The use which is claimed in claim 2, wherein said R2 and R3 are each independently selected from the group D), as defined in claim 2. 28.- The use claimed in claim 2, wherein said R2 and R3 are each independently selected from the group E), as defined in claim 2. 29.- The use claimed in claim 2, wherein said R2 and R3 are each independently selected from group I), as defined in claim 2. 30.- The use claimed in claim 2, wherein said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is the binding nitrogen, said heterocyclic ring being selected from the group consisting of i) and ii), as defined in claim 2. 31.- The use claimed in claim 2, wherein said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is the binding nitrogen, said heterocyclic ring being selected from group i), as defined in the claim 2. 32.- The use claimed in claim 2, wherein said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is the binding nitrogen, said heterocyclic ring being selected from group ii), as defined in the claim 2. The use claimed in claim 2, wherein the condition mediated by LTA4H is inflammation due to at least one of asthma, chronic obstructive pulmonary disease, atherosclerosis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases and psoriasis. 34. The use claimed in claim 3, wherein said R4 is H. 35. The use claimed in claim 3, wherein said R2 and R3 are each independently selected from the group consisting of A), B), C), D), E) and I) , as defined in claim 3. 36.- The use claimed in claim 3, wherein said R2 and R3 are each independently selected from group A), as defined in claim 3. 37. The use claimed in claim 3, wherein said R2 and R3 are each independently selected from group B), as defined in claim 3. 38. The use claimed in claim 3, wherein said R2 and R3 are each independently selected from group C), as defined in claim 3. 39.- The use claimed in claim 3, wherein said R2 and R3 are each independently selected from group D), as defined in claim 3. 40.- The use which is claimed in claim 3, wherein said R2 and R3 are each independently selected from the group E), as defined in claim 3. 41. The use claimed in claim 3, wherein said R2 and R3 are each independently selected from group I), as defined in claim 3. 42.- The use claimed in claim 3, wherein said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is the binding nitrogen, said heterocyclic ring being selected from the group consisting of i) and ii), as defined in claim 3. 43.- The use claimed in claim 3, wherein said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is the binding nitrogen, said heterocyclic ring being selected from the group i), as defined in claim 3. 44. The use claimed in claim 3, wherein said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least a heteroatom member which is the binding nitrogen, said heterocyclic ring is selected from group ii), as defined in claim 3. 45. The use claimed in claim 3, wherein the condition mediated by LTA4H is inflammation due to at least one of asthma, chronic obstructive pulmonary disease, atherosclerosis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases and psoriasis. 46.- The use of at least one LTA4H modulator selected from compounds of the formula (I): ) wherein X is selected from the group consisting of NR5, O, and S, where R5 is one of H and CH3; And it is selected from the group consisting of CH2, and O; Z is selected from the group consisting of O and bond; W is selected from the group consisting of CH2 and CHR1-CH2, R1 being one of H and OH, wherein the carbon member attached to R1 at said CHR1-CH2 is not directly attached to the nitrogen member to which W is attached; R 4 is selected from the group consisting of H, OCH 3, Cl, F, Br, I, OH, NH 2, CN, CF 3 and CH 3; R6 is H or F; and R2 and R3 are each independently selected from the group consisting of A) H, C? - alkyl, C3-7 alkenyl, wherein the carbon in said alkenyl which is attached to the nitrogen member has only individual bonds, alkynyl of C3-7, wherein the carbon in said alkynyl which is attached to the nitrogen member has only individual bonds, optionally benzofused C3-7 cycloalkyl, C5-7 cycloalkenyl, C3-7 cycloalkyl- C1-7alkyl , -C3-7-C-cycloalkyl alkyl and phenyl, wherein each of substituents A) is independently substituted with 0, 1 or 2 RQ, and each of RQ is a substituent on a carbon member that it is at least one carbon member removed from the nitrogen member; B) a HetRa substituent; C) -alkyl of C? -7C (O) Rx, optionally substituted with CH2RAr or CH2RAr '; D) -alkyl of C2-5C (0) Rx, wherein two valence carbon members allowed in the C2-5 alkyl of said -C2-5C (O) Rx alkyl are part of a C3-6 carbocycle saturated; E) -C2-5OH alkyl wherein two valence carbon members allowed in the C2-5 alkyl of said -C2-5 alkyl? H are part of a saturated C3-6 carbocycle; F) -C0-4 alkylphenyl, wherein the phenyl is said -Co-4 alkylphenyl is fused to two adjacent carbon members in said phenyl to Rf, or is benzofused; G) -alkyl of Co-4Ar6, wherein Ar6 is a 6-membered heteroaryl which has a cross-linking member carbon and having one or two heteroatom members -N =, and benzofused; H) -alkyl of Co ^ Ar5, where Ar5 is a 5-membered heteroaryl, having a heteroatom member selected from the group consisting of O, S, and > NRY, and having 0 or 1 additional heteroatom member -N =, optionally containing two carbonyl groups, and optionally benzofused; I) -alkyl wherein Ar5 is a 5-membered heteroaryl containing 3 or 4 nitrogen members, optionally substituted with R ?, and having a valence site allowed as a point of attachment; J) -alkyl of Co ^ Ar6"6, wherein Ar6" 6 is a phenyl linked to Co-4 alkyl fused at sites of valence allowed to a 6-membered heteroaryl, wherein said 6-membered heteroaryl has one or two heteroatom members -N =; K) -alkyl of Co-4Ar6"5, wherein Ar6" 5 is a phenyl bonded to Co-4 alkyl fused at sites of valence allowed to a 5-membered heteroaryl, said 5-membered heteroaryl having a heteroatom member selected of the group consisting of O, S, and > NRY, and said 5-membered heteroaryl having 0 or 1 additional heteroatom member which is -N =; and L) one of 2- (4-ethyl-phenoxy) -benzothiazole, 2- (4-ethyl-phenoxy) -benzoxazole, and 2- (4-ethyl-phenoxy) -1 H-benzimidazole; M) SO2-Ci ^ alkyl; alternatively R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is the linking nitrogen, said heterocyclic ring being selected from the group consisting of i) a heterocyclic ring of 4-7 members HetRb, said 4-7 membered heterocyclic ring having HetRb having a heteroatom member which is the binding nitrogen, and being substituted with 0, 1, or 2 substituents on the same or different substitution members, said substituent being selected from the group consisting of -R ?, -CN, -C (O) R ?, -alkyl C0-CO2RY, -alkyl C0-4C (O) CO2RY, -C0-4ORY alkyl, -C0- C (O) NRYRZ alkyl, -C0-4NRYC (O) RZ alkyl, -C (0) NRzOR ?, -C0- NRYC (O) CH2ORY alkyl- - C0-4NR alkyl? C (0) CH2C (0) R ?, -C0.4NRYCO2RY alkyl- C0-4NR alkyl? C (0) NR? Rz, -C0-4NRYC (S) NRYRZ alkyl, - -NR? C (O) CO2R ?, -NR? Rz, -C0-4NRwSO2R? Alkyl, 1,3-dihydro-indol-2-one-1-yl, 1,3-dihydro-benzimidazol-2-one -1-yl, tetrazol-5-yl, 1-R? -1H-tetrazol-5-yl, R? -triazolyl, 2-R? -2H-tetrazol-5-yl, pyrrolidin-2-thionyl-1- ilo, piperidin-2-tion-1-yl, -C0-4C (O) N (R?) (SO2R?) alkyl, -C0-4N (RY) alkyl (SO2) NRYRY, -C0-alkyl 4N (R?) (SO2) NR? CO2R ?, halogen, ii) a 5-7 membered heterocyclic ring HetRc, said heterocyclic ring of 5-7 HetRc having an additional heteroatom member separated from the binding nitrogen by at least one carbon members, said additional heteroatom member being selected from the group consists of O, S (= O) 0-2, and > NRM, said 5-7 membered heterocyclic ring HetRc having 0 or 1 carbonyl member, and being substituted with 0, 1, or 2 substituents on the same or on different carbon substitution media, said substituents being selected from the group consisting of -C (O) R ?, -CO2R? - C3-C02R alkyl? and Rz; iii) one of imidazolidin-1-yl, 2-imidazolin-1-yl, pyrazol-1-yl, imidazol-1-yl, 2H-tetrazol-2-yl, 1H-tetrazol-1-yl, pyrrole-1- ilo, 2-pyrrolin-1-yl, and 3-pyrrolin-1-yl, wherein each of said 2H-tetrazol-2-yl and 1H-tetrazol-1-yl is substituted on the carbon member with 0 or 1-C0-4RZ alkyl, -C0-4SRY alkyl, -C0-4CO2RY alkyl, and HetRa substituent; and iv) one of 1, 2,3,4-tetrahydro-quinolin-1-yl, 1, 2,3,4-tetrahydro-isoquinolin-2-yl, indole-1-yl, isoindol-2-yl, indolin -1-yl, benzimidazol-1-yl, 2,8-diaza-spiro [4.5] decan-1-one-8-yl, 4-. { [(2-tert-butoxycarbonylamino-cyclobutylenecarbonyl) -amino] -methyl} -piperidin-1-yl, 4-. { [(2-amino-cyclobutanecarbonyl) -amino] -methyl} -piperidin-1-yl, 3,9-diaza-spiro [5.5] undecan-3-carboxylic acid 9-yl-tert-butyl ester, 4-oxo-1-phenyl-1,3,8-triaza-spiro [4.5] dec-8-yl, and 4-oxo-1, 3,8-triaza-spiro [4.5] dec-8-yl; wherein the HetRa substituent is a 4-7 membered heterocyclic ring having a carbon member attachment point and containing a > NRM as a heteroatom member, and said heteroatom member being separated from the carbon member attachment point by at least one additional carbon member; R? is selected from the group consisting of H, -C 4 alkyl, -Co-4RAr alkyl, each optionally substituted with 1, 2, or 3 RN substituent; RL is selected from the group consisting of -CO2Rs and -C (O) NRsRs; RM is selected from the group consisting of Rz, indol-7-yl, -SO2R ?, -alkyl of C3.4CO2R ?, -CO2R ?, -C (O) NRzOR ?, -C (O) R ?, -C (O) C? -4OR? Alkyl, -C0-4C (O) NRSRS 'alkyl, C0-C (O) CO2RY alkyl, 1,3-dihydro-indol-2-one-1-yl, , 3-dihydro- benzimidazol-2-one-1-yl, tetrazol-5-yl, 1-R? -1H-tetrazol-5-yl, R? -triazolyl, 2-R? -2H-tetrazol-5-yl and -alkyl C0-4C (O) N (RY) (SO2RY), each optionally substituted with 1, 2 or 3 RN substituents; RN is selected from the group consisting of OCH3, Cl, F, Br, I, OH, NH2, CN, CF3, CH3, OC (O) CH3, and NO2; Rp is selected from the group consisting of R ?, -alkyl of C2-4? R ?, RAr, -alkyl of C? -2CO2R ?, -alkyl of C1-2CONRsRs', indole-7-yl, and -S02alkyl of C? -4; RQ is selected from the group consisting of fluoro, chloro, bromo, iodo, trifluoromethyl, trichloromethyl, -CN, -C1- alkyl, -C0-4RAr alkyl, -C0-4RAr alkyl, -CO- ORY alkyl , -C.sub.4 CO.sub.
2 R? alkyl, -C.sub.4-4NR.sub.RZ alkyl, -C.sub.-NRYCOR.alkyl, -C.sub.4-4NRYCONRYR.sub.2 alkyl, -C.sub.alkyl. 4 NR? SO2R ?, and -Co-SR alkyl ?; Rs and Rs' are independently selected from the group consisting of H, -C 4 alkyl, and C 0-4 alkylphenyl; alternatively, Rs and Rs are taken together with the nitrogen member to which said Rs and Rs are bonded to form a 4- to 7-membered heterocyclic ring having 0 or 1 additional heteroatom member selected from the group consisting of O, S, and > NRY, provided that said additional member and heteroatom is separated by at least two carbon members of said nitrogen member to which Rs and Rs are attached, and provided that where R? is Co-4RAr alkyl, then RAr is not substituted with RL; Rw is selected from the group consisting of R ?, and -C3-7 cycloalkyl; Rx is selected from the group consisting of -OR ?, -NRYRZ, -C1-4 alkyl, and -C0-4RAr alkyl; R? is selected from the group consisting of H, -C 4 alkyl, 4 C 4 alkyl, and C 4 4 R alkyl, and optionally substituted with 1, 2, or 3 RN substituents; Rz is selected from the group consisting of R ?, -alkyl of C2-4OR ?, -alkyl of C? -2CO2R ?, -alkyl of C? -2C (0) NRsRs ', and -alkyl of C2-4NRSRS'; when R? and Rz join a nitrogen member, R? and Rz are selected as defined above or R? and Rz are taken together with the nitrogen member attached to R? - and Rz- to form a 4-7 membered heterocyclic ring HetRd having 0 or 1 additional heteroatom member selected from the group consisting of O, S, and > NRM, said 4-7 membered heterocyclic ring HetRd having 0 or 1 carbonyl member, and said 4-7 membered heterocyclic ring HetRd having 0 or 1 allowed valence carbon member substituted with at least one of RM, -CO2H , and -alkyl of C0-? OR ?; RAr is a portion with a carbon member attachment point and said portion is selected from the group consisting of phenyl, pyridyl, pyrimidyl, and pyrazinyl, wherein each valence carbon member allowed in each of said portions is independently substituted with at least one of 0, 1, 2 or 3 RN, and 0 or 1 RL; RAr 'is a ring of 3 to 8 members, having 0, 1 or 2 heteroatom members selected from the group consisting of O, S, N, and > NRY, which has 0, 1, or 2 unsaturated bonds, having 0 or 1 carbonyl member, wherein each valence member allowed in each of the rings is independently substituted with 0, 1, or 2 R ?; and Rf is a linear 3 to 5 membered hydrocarbon portion having 0 or 1 unsaturated carbon-carbon bond having 0 or 1 carbonyl member; or an enantiomer, diastereomer, racemate, tautomer, hydrate, solvate or a salt, ester or pharmaceutically acceptable amide thereof, for preparing a medicament for treating, preventing or inhibiting inflammation in a subject. 47.- The use claimed in claim 46, wherein said R4 is H. 48.- The use claimed in claim 46, wherein said R2 and R3 are each independently selected from the group consisting of A ), B), C), D), E) and I), as defined in claim 46. 49. The use claimed in claim 46, wherein said R2 and R3 are each independently selected from the group A), as defined in claim 46. 50. The use claimed in claim 46, wherein said R2 and R3 are each independently selected from group B), as defined in claim 46. 51 The use claimed in claim 46, wherein said R2 and R3 are each independently selected from the group C), as defined in claim 46. 52. The use claimed in claim 46, in wherein said R2 and R3 are each independently selected from the group D), as defined in claim 46. 53.- The us or claimed in claim 46, wherein said R2 and R3 are each independently selected from the group E), as defined in claim 46. 54.- The use claimed in claim 46, wherein said R2 and R3 are each independently selected from group I), as defined in claim 46. 55. The use claimed in claim 46, wherein said R2 and R3 are taken together with the nitrogen to which they are attached. joined to form a heterocyclic ring containing at least one heteroatom member which is the binding nitrogen, said heterocyclic ring is selected from the group consisting of i) and ii), as defined in claim 46. 56.- The use claimed in claim 46, wherein said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is the binding nitrogen, said heterocyclic ring being selects from group i), as defined in claim 46. 57. The use claimed in claim 46, wherein said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring. lico containing at least one heteroatom member which is the binding nitrogen, said heterocyclic ring is selected from group ii), as defined in claim 46. 58.- The use claimed in claim 46, wherein the inflammation is associated with at least one of asthma, chronic obstructive pulmonary disease , atherosclerosis, rheumatoid arthritis, multiple sclerosis, intestinal inflammatory diseases and psoriasis. 59. The use claimed in claim 46, wherein at least one LTA4H modulator is one of: 2- [4- (2-piperidin-1-yl-ethoxy) - phenoxy-benzoxazole; (1- {2- [4- (benzooxanzol-2-yloxy) -phenoxy] ethyl} -piperidin-4-yl) -methanol; 1 -. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-ol; . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -dibutyl-amine; (1- {2- [4- (benzoxazol-2-yloxy) -phenoxy] -ethyl} - pyridin-2-yl) -methanol; 1-. { 3- [4- (benzoxazol-2-yloxy) -phenoxy] -propyl} -4-phenyl-piperidn-4-ol; 1 -. { 3- [4- (benzoxazol-2-yloxy) -phenoxy] -propyl} -4-benzyl-piperidin-4-ol; 2- [4- (2-piperidin-1-ethyl-ethyl) -phenoxy] -benzoxazole; . { 3- [4- (benzoxazol-2-yloxy) -phenyl] -propyl} -cyclohexyl-ethyl-amine; 1-3- [4- (benzoxazol-2-yloxy) -phenyl] -propyl} -piperidin-4-ol; 1-. { 3- [4- (benzoxazol-2-yloxy) -phenoxy] -2-hydroxy-propyl} -4-phenyl-piperidin-4-ol; 1- [2- (4-Benzoxazol-2-ylmethyl-phenoxy) -ethyl] -piperidine-4-carboxylic acid ethyl ester; 2- [4- (2-pyrrolidin-1-yl-ethoxy) -phenoxy] -benzoxazole; . { 3- [4- (benzoxazol-2-yloxy) -phenoxy] -propl} dimethyl amine; . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} dimethyl amine; and 2- [4- (2-azepan-1-yl-ethoxy) -phenoxy] -benzoxazole. 60.- The use claimed in claim 46, wherein at least one LTA4H modulator is one of: 1-. { 2- [4- (benzoxazol-2-yloxy) -phenoxyl-ethyl} -4-phenyl-piperidin-4-ol; . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -cyclohexyl-ethyl-amine; . { 2- [4- [2-ethyl-piperidin-1-yl] -ethoxy] -phenoxy} -benzoxazole; 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4-phenol-piperidin-4-carbonitrile; 1 - (1 -. {2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4-pheni) -piperidin-4-yl) -ethanone; 2-. { 4- [2- (4-Methyl-piperidin-1-yl) -ethoxy] -phenoxy} -benzoxazole; 1 -. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4- (4-chloro-phenyl) -piperidin-4-ol; 1 -. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4- (4-bromo-phenyl) -piperidin-4-oI; 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4- (4-chloro-3-trifluoromethyl-phenyl) -piperidin-4-ol; 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4-benzyl-piperidin-4-ol; . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -cyclohexyl- methyl amine; Y . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -cyclopropylmethyl-propyl-amine. 61.- The use claimed in claim 46, wherein at least one LTA4H modulator is one of:. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -butyl-ethyl-amine; 2- (. {2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -benzyl-amino) -ethanol; 2-. { 4- [2- (4-Benzyl-piperidin-1-yl) -ethoxy] -phenoxy} -benzoxazole; (1 - { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -piperidin-3-yl) -methanol; 2- (. {2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -propyl-amino) -ethanol; 2- [4- (2-Azetidin-1-yl-ethoxy) -phenoxy] -benzoxazole; ? / - (1- {2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -2-phenylisoamide; 1- ethyl ester. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -piperidine-3-carboxylic acid; 2-. { 4- [3- (4-Phenyl-piperidin-1-yl) -propoxy] -phenoxy-benzoxazole; 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -4-phenyl-piperidin-4-ol; . { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -cyclohexyl-ethyl-amine; 2- [4- (2-Pyrrolidin-1-yl-ethyl) -phenoxy] -benzoxazole; and 2- [4- (2-Azepan-1-ethyl-ethyl) -phenoxy] -benzoxazole. 62.- The use claimed in claim 46, wherein at least one LTA4H modulator is one of:. { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethi-propyl-amine; . { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -dibutyl-amine; 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-ol; methyl ester of acid 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; 1-. { 3- [4- (Benzoxazol-2-yloxy) -phenyl] -propyl} -4-phenyl-piperidin-4-ol; 2- [4- (3-Piperidin-1-yl-propyl) -phenoxy] -benzoxazoI; . { 3- [4- (Benzoxazol-2-yloxy) -phenyl] -propyl} -dibutyl-amine; . { 3- [4- (Benzoxazol-2-yloxy) -phenyl] -propyl} -cyclopropylmethyl propyl amine; 1 - [4- (Benzoxazol-2-yloxy) -phenoxy] -3-pyrrolidin-1-yl-propan-2-ol; 1 - [2- (4-Benzoxazole- 2-ylmethyl-phenoxy) -ethyl] -4-phenyl-piperidin-4-ol; 1- [2- (4-Benzoxazol-2-ylmethyl-phenoxy) -ethyl] -piperidine-4-carboxylic acid amide; 2- [4- (2-Morpholin-4-yl-ethoxy) -phenoxy] -benzoxazole; Y . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -diethyl-amine. 63.- The use claimed in claim 46, wherein at least one LTA4H modulator is one of:. { 2- [4- (6-chloro-benzothiazol-2-yloxy) -phenoxy] -phenoxy] -ethyl} -diethyl-amine; 1-. { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -etii} -piperidin-4-ol; 1- ethyl ester. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carboxylic acid; acid 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carboxylic acid; (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -pyrrolidin-1-yl-methanone; 3 - [(1- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carbonyl) -amino] -propionic acid ethyl ester; acid amide 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carboxylic acid; 1 - (1 -. {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-ii) -pyrrolidin-2-one; 1'-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - [1, 4 '] bipiperidinyl-2-one; 8-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -2,8-diaza-spiro [4.5] decan-1-one; 2- [4- (3-pyrrolidin-1-yl-propoxy) -phenoxy] -benzothiazole; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclohexyl-ethyl-amine; acid amide 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-3-carboxylic acid; 1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.} - p -peridin-4-yl) -3-methyl-1,3-dihydro-benzimidazole -2-ona; methyl ester of acid 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; (1- {2- [4- (benzothiazol-2-yloxy) -phenyl] -etiI} -piperidin-4-yl) - (4-methyl-piperazin-1-yl) -methanone; 1- [2- (4-Benzothiazol-2-ylmethyl-phenoxy) -ethyl] -piperidine-4-carboxylic acid methyl ester; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - cyclopropyl-amino) -propionic acid; . { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} dimethyl amine; 2- [4- (2-pyrrolidin-1-yl-ethoxy) -phenoxy-benzothiazole; . { 3- [4- (benzothiazol-2-yloxy) -phenoxy] -propyl} dimethyl amine; 2- [4- (2-azepan-1-yl-ethoxy) -phenoxy] -benzothiazole; 2- [4- (2-azepan-1-yl-ethoxy) -phenoxy] -6-methoxy-benzothiazole; 1-. { 2- [4- (benzothiazoi-2-yloxy) -phenoxy] -ethyl} -4-phenyl-piperidin-4-ol; . { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -cyclohexyl-ethyl-amine; 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -4- (4-chloro-phenyl) -piperidin-4-ol; . { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -dibutyl-amine; 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -4- (4-bromo-phenyl) -piperidin-4-ol; 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -4- (4-chloro-3-trifluoromethyl-phenyl) -piperidin-4-ol; 1 -. { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -4-benzyl-piperidin-4-ol; 1 '-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -etl} - [1, 4 '] bipiperidine; (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -methanol; / V- (1- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -2-phenyl-acetamide; 2- (4- { 2- [4- (2-morpholin-4-yl-ethyl) -piperazin-1-yl] -ethoxy.} - phenoxy) -benzothiazole; 2- (4- { 2- [4- (2-morpholin-4-yl-ethyl) -piperazin-1-yl] -ethyl} -phenoxy) -benzothiazole; 1-. { 3- [4- (benzothiazol-2-yloxy) -phenoxy] -propyl} -4-phenyl-piperidin-4-ol; 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -4-phenyl-piperidin-4-ol; 2- [4- (2-pyrrolidin-1-yl-ethyl) -phenoxy] -benzothiazole; 2- [4- (2-azepan-1-ethyl-ethyl) -phenoxy] -benzothiazole; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl-propyl-amine; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -dibutyl-amine; 2- [4- (2-piperidin-1-yl-ethyl) -phenoxy] -benzothiazole; 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperdin-4-ol; acid amide 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; 1- ethyl ester. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-3-carboxylic acid; 1- ethyl ester. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -4-phenyl-piperidine-4-carboxylic acid; (1 -. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -acetic acid ethyl ester; 1- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -1,3-dihydro-indoi-2-one; 1 - (1 -. {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperdin-4-yl) -pyrrolidin-2-one; ? / - (1- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -2-phenyl-acetamide; 8-. { 2- [4- (benzothiazoI-2-yloxy) -pheni]] - eti)} -2,8-diaza-spiro [4.5] decan-1-one; 1-. { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl) -piperidin-3-ol; 1- ethyl ester. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; 1'-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - [1, 4 '] bipiperidine; 2-. { 4- [2- (4-methyl-piperazin-1-li) -ethyl] -phenoxy} -benzothiazole; 2- (4- { 2- [4- (1-Benzyl-1 H-tetrazol-5-yl) -piperidin-1-yl] -ethoxy.} - phenoxy) -benzothiazole; 4- (1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carbonyl) -piperazin-1-carboxylic acid tert-butyl ester; 1- [2- (4-Benzothiazol-2-ylmethyl-phenoxy) -ethyl] -piperidin-4-carboxylic acid amide; 1 -. { 1 - [2- (4-Benzothiazol-2-ylmethyl-phenoxy) -ethyl] -piperidin-4-yl} pyrrolidin-2-one; 1 - [4- (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carbonyl) -piperazin-1-yl] -ethanone; acid 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; 1- (1-. {2- 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl] -piperidin-4-yl) -pyrrolidin-2-thione; 2- (4- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperazin-1-yl) -ethanol; 2- (4- { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - piperazin-1-yl) -1-pyrrolidin-1-yl-ethanone; 2- (4- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperazin-1-yl) -1-morfoin-4-yl-ethanone; acid 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-3-carboxylic acid; acid 1-. { 2- [4- (benzothiazoi-2-yloxy) -phenyl] -ethyl} -piperidine-2-carboxylic acid; (1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-3-yl) -acetic acid; (1 -. {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -etiyl] -piperidin-4-yl) -acetic acid ethyl ester; tert-butyl ester of (1- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -carbamic acid; (1 - { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -etiI.}. -piperidin-4-yl) -acetic acid; (1- { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etyl] -piperidin-3-yl) -methanol; (. {2- [4- (Benzothiazol-2-yloxyl) -phenyl] -ethyl} -.-cyclohexyl-amino) -acetic acid methyl ester; (4- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - piperazin-1-yl) -acetic acid; 1- (1. {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -5-oxo-pyrrolidine-2-carboxylic acid ethyl ester; 1 - (1-. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl] -piperidin-4-yl) -5-oxo-pyrrolidine-2-carboxylic acid; 4- (4- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperazin-1-yl) -phenol; ? - (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -4-chloro-N-cyclopropyl-benzenesulfonamide; 3- ( { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - cyclopropylmethyl-amino) -proponic acid; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl) -isopropyl-amino) -propionic acid; 1-. { 2- [4- (benzotlazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-ilamine; 3- [acid. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - (1-methyl-piperidin-4-yl) -amino] -propionic; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -benzyl-amino) -propionic acid; 3 - ((1-Acetyl-piperidin-4-yl) -. {2- 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -amino) -propionic acid; 4- (1- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -1H-tetrazol-5-yl) -piperidine-1-carboxylic acid tert-butyl ester; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propionic acid; 3 - ((1-Acetyl-piperidin-4-yl) -. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -amino) -propionic acid; 3- [acid. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - (1-methyl-piperidin-4-yl) -amino] -propionic; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -propionic acid; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - isopropyl-amino) -propionic acid; 2- (4-. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.} - piperazin-1-yl) -1-pyrrolidin-1-yl-ethanone; acid (R) -1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-3-carboxylic acid; 1- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperidin-4-yl) -1,3-dihydro-benzimidazol-2-one; 2- (4- { 2- [4- (6-Methyl-pyridin-2-yl) -piperazin-1-yl] -ethyl} -phenoxy) -benzothiazole; 2-4- [2- (4-Ethanesulfonyl-piperazin-1-yl) -ethyl] -phenoxy} -benzothiazole; 2- (4-. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -1-morpholin-4-yl-ethanone; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -methyl-amino) -propionic acid; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopentyl-amino) -propionic acid; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclobutyl-amino) -propionic acid; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -benzyl-amino) -propionic acid; (1 - { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) - (4-hydroxymethyl-piperidin-1-yl) -methanone; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amine; (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -eti}.} - piperidin-4-yl) - [4- (2-hydroxy-ethyl) - piperazin-1-yl] -methanone; (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) - [4- (2-hydroxy-ethyl) -piperidin-1-yl} ] -metanone; 2- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.} - cyclopropyl-amino) -ethanol; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl.} - -cyclopropyl-amino) -propan-1-ol; 4- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -butyric acid; 3 - [(1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-carbonyl) -amino] -propionic acid; 4- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amine) -butyronitrile; 3- (1 - { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -propionic acid; [(1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-carbonyl) -methyl-amino] -acetic acid; 3- (4- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperazin-1-yl) -phenol; 2- (4- { 2- [4- (4-methoxy-phenyl) -piperazin-1-yl] -ethoxy.} - phenoxy) -benzothiazole; 2-. { 4- [2- (5-piperidin-4-yl-tetrazol-1-yl) -ethoxy] -phenoxy} - benzothiazole; (S) -1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -4-hydroxy-pyrrolidin-2-one; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethylamine; 2 - [(. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -.-cyclopropyl-amino) -methyl] -cyclopropanecarboxylic acid ethyl ester; 4- (4- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperazine-1-carbonyl) -benzoic acid ethyl ester; 2 - [(. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -methyl] -cyclopropanecarboxylic acid; 1- (. {2- 2- (4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propan-2-ol; 3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -etiI.} - cyclopropyl-amino) -1,1,1-trifluoro-propan-2-ol; 3- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propionamide; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propane-1,2-diol; 2-. { 4- [2- (5-phenyl-tetrazol-2-yl) -ethoxy] -phenoxy} -benzothiazole; 2-. { 4- [2- (5-phenyl-tetrazol-1-yl) -ethoxy] -phenoxy-benzothiazole; ? / -. { 2- [4- (benzothiazoI-2-yloxy) -phenyl] -ethyl} -N-cyclopropyl-2- (2H-tetrazol-5-yl) -acetamide; (S) -3- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -2-methyl-propan-1-ol; (R) -3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -2-methyl-propan-1-ol; 2-. { 4- [2- (5-methylsulfanyl-tetrazol-2-yl) -ethoxy] -phenoxy} -benzothiazole; 2-. { 4- [2- (5-Methylsulfanyl-tetrazol-1-yl) -ethoxy] -phenoxy} -benzothiazole; 2- [4- (2-tetrazol-2-yl-ethoxy) -phenoxy] -benzothiazole; 2- [4- (2-tetrazol-1-yl-ethoxy) -phenoxy] -benzothiazole; acid (1 f?, 2R) -2-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino-cyclohexanecarboxylic acid; acid (1S, 2R) -2-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino} -cyclohexanecarboxylic; (1 R ^ R ^ - ^ - ^ - Ibbenzothiazol ^ -yloxy) -phenyl] -ethylamino} -cyclohexanol; (1S, 2f?) - 2-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino} -cidohexanol; 4- (1 - { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -butyric acid; (R) 1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -etiI.}. -piperidine- 4-yl) -4-hydroxy-pyrrolidin-2-one; 2- (4- { 2- [4- (1 H-Tetrazol-5-yl) -piperidin-1-yl] -ethyl} -phenoxy) -benzothiazole; (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-2-yl) -methanol; (1- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -1H-tetrazol-5-yl) -acetic acid ethyl ester; (1- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -1H-tetrazol-5-yl) -acetic acid ethyl ester; 2- hydrochloride. { 4- [2- (5-piperidin-4-yl-tetrazoI-2-yl) -ethoxy] -phenoxy} -benzothiazole; 7- { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -4-spiro- [3-phthalide] -piperidine; 1- ethyl ester. { 3- [4- (benzothiazol-2-yloxy) -phenyl] -propyl} -piperidine-4-carboxylic acid; 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamine hydrochloride; 2- (4- { 2- [4- (1 H-tetrazol-5-yl) -piperidin-1-yl] -ethoxy.} - phenoxy) -benzothiazole; cis-4- trifluoromethanesulfonate salt. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino-cyclohexanecarboxylic acid; (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1 -ii) - (tetrahydro-furan-2-yl) -methanone; (1 -. {-2- [4- (benzothiazol-2-yloxy) -phenoxy] -etyl} -piperidine-4-carbonyl) -amide of propan-2-sulfonic acid; (4- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) -oxo-acetic acid methyl ester; N- (1-. {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carbonyl) -benzenesulfonamide trifluoromethanesulfonate salt; N- (1- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carbonyl) -methanesulfonamide trifluoromethanesulfonate salt; (4- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) -oxo-acetic acid trifluoromethanesulfonate salt; (4-. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -etyl} -piperazin-1-yl) -morpholin-4-yl-methanone; 1 - (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -2-thiophen-2-yl-ethanone; (4-. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -etyl] -piperazin-1-yl) -pyridin-3-yl-methanone; (4-. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -cyclopropyl-methanone; 1 - (4- { 2- [4- (benzothiazole-2- iloxy) -phenyl] -ethyl} -piperazin-1-yl) -2-methoxy-ethanone; 1 - (4- { 2- [4- (benzothiazoI-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -2,2,2-trifluoro-ethanone; 4- (4- { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazine-1-carbonyl) -benzoic acid; (4-. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -pyridin-4-yl-methanone; (4- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) - (5-methyl-pyrazin-2-yl) -methanone; (f?) - (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) - (tetrahydro-furan-2-yl) -methanone; (S) - (4- { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) - (tertrahydro-furan-2-yl) -methanone; (4- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) - (tetrahydro-furan-3-yl) -methanone; 1- (4- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -2-hydroxy-ethanone; 2- [2- (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl] -piperazin-1-yl) -2-oxo-ethyl] -cyclopentanone; 3- (4. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) -propionic acid trifluoromethanesulfonate salt; 3- (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -oxazolidin-2-one; 4- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -morpholin-3-one; 4- (1 -. {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperdin-4-yl) -morpholin-3-one; 3- (1- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl] -piperidin-4-yl) -oxazolidin-2-one; benzyloxy-1-acid amide. { 2- [4- (benzothiazol-2-yloxy) -pheni] -etl} -piperidine-4-carboxylic acid; (1 - { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -acetic acid; (f?) - 1- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -4-hydroxy-pyrrolidin-2-one; hydroxyamide of acid 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic; (S) -1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -4-hydroxy-pyrrolidin-2- ona; (1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -carbamic acid tert-butyl ester; 2-. { 4- [2- (4-fluoro-piperidin-1-yl) -etl] - phenoxy } -benzothiazole; 2-. { 4- [2- (4,4-difluoro-piperidin-1-yl) -ethyl] -phenoxy} -benzothiazole; (R) -1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -pyrrolidin-3-ol; N-1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -formamide; (1- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -urea; 1- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -3-cyano-2-phenyl-isourea; 1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -3-cyano-2-methyl-isothiourea; N- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -methanesulfonamide; 1- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -3-cyano-2-methyl-guanidine; 8-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -1-phenyl-1, 3,8-triaza-spiro [4.5] decan-4-one; 8-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -1, 3,8-triaza-spiro [4.5] decane-2,4-dione; (1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -methylcarbamic acid tert-butyl ester; N- (1-. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl] -piperidin-4-yl) -N-methyl-acetamide; N- (1-. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl] -piperldin-4-yl) -N-methyl-methanesulfonamide; [(1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -methyl-carbamoyl] -methyl acetic acid ester; N- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -etiI.}. -piperidin-4-yl) -N-acetamide; Ester (1 -. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] ethyl] -piperidin-4-ylcarbamoyl) -methyl acetic acid; 2- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -methyl-amino) -3- (1 H -imidazol-2-yl) -propionic acid; 2- (4- { 2- [4- (3-nitro-pyridin-2-yl) - [1,4] diazepan-1-yl] -ethyl} -phenoxy) -benzothiazole; [(1- {2- [4- (Benzothiazol-2-yloxy) -phenox] -ethyl} -piperidine-4-carbonyl) -methyl-amino] -acetic acid ethyl ester; ethyl ester of 2- 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl ester} - [1, 4 '] bipiperidinyl-4-carboxylic acid; 1 'acid. { 2- [4- (benzothiazol-2-yloxy) - [phenoxy] -ethylH1, 4 '] bipryperidinyl-4-carboxylic acid; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-ethyl-amine; Get ouf of trifluoromethanesulfonic acid of 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -2-methyl-propionic acid; 2- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.}. -cyclopropylmethyl-amino) -ethanol; 2- [2- (. {2- [4- (Benzothiazol-2-yloxy) -yl] -ethyl} - cyclopropylmethyl-amino) -ethoxy] -ethanol; 3- (. {2- 2- [4- (benzothiazol-2-yloxy) -yl] -ethyl} - cyclopropylmethyl-amino) -propan-1-ol; . { 2- [4- (benzothiazol-2-yloxy) -yl] -ethyl} -cyclopropylmethyl- (3-tetrazol-2-yl-propyl) -amine; . { 2- [4- (Benzothiazol-2-yloxy) -yl] -ethyl} -cyclopropyl- (3-pyrrol-1-yl-propyl) -amine; 4- (. {2- 2- [4- (benzothiazol-2-yloxy) -yl] -etyl} -cyclopropylmethyl-amino) -butyronitrile; (2-cyano-ethyl) -amide of 1- acid. { 2- [4- (Benzothiazol-2-yloxy) -yl] -ethyl} -piperidin-4-carboxylic acid; . { 2- [4- (Benzothiazol-2-yloxy) -yl] -ethyl} -cyclopropylmethyl- [3- (2H-tetrazol-5-yl) -propyl] -amine; 3- [5- (1- { 2- [4- (Benzothiazol-2-yloxy) -yl] -ethyl} -piperidin-4-yl) -tetrazol-1-yl] -propionitrile; . { 2- [4- (benzothiazoI-2-yloxy) -yl] -ethyl} -cyclopropyl- [3- (2H-tetrazol-5-yl) -propyl] -amine; 1- (hydroxy-1, 1-dimethyl-ethyl) -amide. { 2- [4- (Benzothiazol-2-yloxy) -yl] -ethyl} -piperidine-4-carboxylic acid; . { 2- [4- (Benzothiazol-2-yloxy) -yl] -ethyl} -cyclopropylmethyl- [3- (1 H- [1, 2,4] triazol-3-yl) -propyl] -amine; . { 2- [4- (Benzothiazol-2-yloxy) -yl] -ethyl} -cyclopropylmethyl- [3- (5-methyl-1 H- [1, 2,4] triazol-3-yl) -propyl] -amine; . { 2- [4- (Benzothiazol-2-yloxy) -yl] -ethyl} -cyclopropylmethyl- [3- (5-yl-1 H- [1, 2,4] triazol-3-yl) -propyl] -amine; 2- (4- { 2- [4- (1-methyl-1 H-tetrazol-5-yl) -piperidin-1-yl] -ethyl} -oxy) -benzothiazole; 2- (4- { 2- [4- (2-methyl-2H-tertrazol-5-yl) -piperidin-1-yl] -ethyl} -oxy) -benzothiazole; 1-. { 2- [4- (benzothiazol-2-yloxy) -yl] -ethyl} -piperidine-4-carbonitrile; 2- (4- { 2- [4- (1 H- [1,2,3] triazol-4-yl) -piperidin-1-yl] -ethyl} -oxy) -benzothiazole; 4-ethyl ester. { 2- [4- (Benzothiazol-2-yloxy) -yl] -ethylamino} -butyric; 4- (. {2- 2- [4- (Benzothiazol-2-yloxy) -yl] -ethyl} -cyclopropylmethyl-amino) -butyric acid ethyl ester; 2- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -propyl] -isoindole-1,3-dione; 4- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cecidopropylmethyl-amino) -butyric acid; 1- (3- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethylamino} -propyl) -pyridinidin-2-one; N-1-. { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -N1-cyclopropylmethyl-propane-1,3-diamine; 5- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -.-cyclopropyl-amino) -pentanoic acid methyl ester; N- [3- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -propyl] -acetamide; [3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - (cyclopropylmethyl-amino) -propyl] -amide of morfoin-4-carboxylic acid; N- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -propyl] -methanesulfonamide; 5- ( { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -pentanoic acid; 1- [3- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -etyl] -isopropyl-amino) -propyl] -pyrrolidin-2-one; 1- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -etiI.} - cyclopropylmethyl-amino) -propyl] -pyrrolidin-2-one; 1- [3- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl] -pyrrolidin-2-one; 1- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -propyl-amino) -propyl] -pyrrolidin-2-one; 4 - ((1-Acetyl-piperidin-4-yl) -. {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -amino) -butyric acid ethyl ester; ethyl acyl ester 4 - ((1-acetyl-piperidin-4-yl) -. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -amino) -butyric acid; 4- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -metanesulfonyl-amino) -butyric acid; 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etill-cyclopropyl-amino) -acetic acid; 6- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino) -hexane-1-ethyl ester; 7- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino) -heptanoic acid ethyl ester; 6- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -hexanoic acid; 7- (. {2- 2- 4- (benzothiazol-2-yloxy) -pheni] -etiI} -cyclopropyl-amino) -heptanoic acid; N-1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -N1-cyclopropyl-propane-1,3-diamine; N- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl] -acetamide; N- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl] -isobutyramide; N- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl] -benzamide; N- [3- ( { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl] -4-chloro-benzamide; N- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl-methanesulfonamide; [3- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl] -3-cyclopropyl-amino) -propyl] -amide trifluoromethanesulfonic acid of propan-2-sulfonic acid; 8- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino) -octanoic acid ethyl ester; 1- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl] -3-phenyl-urea; 8- ( { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl-cyclopropyl-amino-octanoic acid; [3- (. {2- 2- [4- (benzothiazol-2-yloxy)] tetrahydrofuran-2-carboxylic acid-phenyl] -ethyl.} - cyclopropyl-amino) -propyl] -amide: N- [3- (. {2- [4- (benzothiazol-2-yloxy) - phenyl] -ethyl.} - cyclopropyl-amino) -propyl] -2-hydroxy-acetamide, 4- (. {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl}. -cyclopropyl-amino) -butyric acid 2- [4- (2-morpholin-4-yl-ethoxy) -phenoxy] -benzothiazole; and. {2- 2- [4- (2-piperldin-1-yl-ethoxy) -phenoxy] -benzothiazole 64. The use claimed in claim 46, wherein at least one LTA4H modulator is one of: 1- { 2- [4- (1H-benzimidazol-2-yloxy. ) -phenoxy] -ethyl.} -4-phenyl-p-peridin-4-ol;. {2- [4- (1H-benzimidazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl-propyl-amine cyclohexyl-ethyl- {2- [4- (1-methyl-1 H-benzimidazol-2-yloxy) -phenyl} -ethyl} -amine; 1 -. {2- 2- [4- ( 1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl.} -4- (4- bromo-phenyl) -piperidin-4-ol; 1 -. { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -4- (4-chloro-phenyl) -piperidin-4-ol; 1 -. { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -4-benzyl-piperidin-4-ol; . { 2- [4- (1H-benzimidazol-2-yloxy) -phenyl] -ethyl} -cyclohexyl-ethyl-amine; 2- [4- (2-pyrrolidin-1-yl-ethyl) -phenoxy] -1 H -benzimidazole; 2- [4- (2-azepan-1-yl-ethyl) -phenoxy] -1 H-benzimidazole; . { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -dibutyl-amine; 1 -. { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-ol; methyl ester of acid 1-. { 2- [4- (1H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carboxylic acid; . { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -cyclohexyl-ethyl-amine; 2-. { 4- [2- (4-methyl-piperidin-1-yl) -ethoxy] -phenoxy} -1 H-benzimidazole; 2-. { 4- [2- (2-ethyl-piperidin-1-yl) -ethoxy] -phenoxy} -1 H-benzimidazole; 2- [4- (2-piperidin-1-yl-ethoxy) -phenoxy] -1 H -benzimidazole; 1 -. { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-ol; 2- [4- (2-azepan-1-yl-ethoxy) -phenoxy] -1 H -benzimidazole-amide; . { 3- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -propyl} dimethyl amine; 2- [4- (2-pyrrolidin-1-yl-ethoxy) -phenoxy] -1 H -benzimidazole; . { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -diethyl-amine; 2- [4- (2-morpholin-4-yl-ethoxy) -phenoxy] -1 H -benzimidazole; 2- [4- (2-piperidin-1-ethyl-ethyl) -phenoxy] -1H-benzimidazole; 1 - (1 -. {2- [4- (1 H -benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -pyrrolidin-2-one; (1 -. {2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -methanol; and ethyl ester of acid 1-. { 2- [4- (1H-benzimidazoI-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carboxylic acid. 65.- The use claimed in claim 46, wherein at least one LTA4H modulator is selected from compounds of the formula (II): (II) or an enantiomer, diastereomer, racemate, tautomer, hydrate, solvate or a pharmaceutically acceptable salt, ester or amide thereof, wherein R4, R6, X, Y, Z, and W are defined as in the compound of the formula (I), R2 is defined as R2 in the compound of the formula (I), and R3 'is defined as R3 in the compound of the formula (I), provided that (a) at least one of said R2 ' and R3 'is not ethyl when a selection in the group consisting of selections (s1), (s2), (s3), and (s4), is satisfied, and each of said selections is specified as (s1): R4 is H, Z is O, W is CH2, Y is CH2, and X is S; (s2): R4 is H, Z is O, W is CH2, Y is CH2 and X is NH; (s3): R4 is H, Z is O, W is CH2, Y is O, and X is S; (s4): R4 is 5-chloro, Z is O, W is CH2, Y is CH2, and X is S; (b) in addition provided that when Z is a bond, Y is CH2, W is CHR1-CH, R1 is H, and one of R2 'and R3' is 1 H-imidazol-2-yl, then the other of R2 ' and R3 'is selected from A1), B) -L), wherein B) -L) is as defined above for the compound of the formula (I), and A1) consists of H, C3-7 alkenyl, wherein the carbon in said C3-7 alkenyl which is attached to the member of nitrogen has only individual bonds, alkynyl of Q3.7, where the carbon in said alkynyl which is attached to the nitrogen member has only individual linkages, optionally benzofused C3-7 cycloalkyl, Cs-7 cycloalkenyl, C3.7-cycloalkyl-C6-7 alkyl, -C3-cycloalkylC3-7 alkyl; and (c) also provided that when X is S, And it is O, Z is a link and W is CH2, then one of R2 and R3 is not XCG when the other is C? -6 alkyl, then XCG is the group HC16 wherein HC16 is one of H, C? -6 alkyl, halogen-C? -6 alkyl, allyl, and alkoxymethyl of C? -6, and GO is a group attached to a carbon member having a substituent = O that forms an amido group (> N-C (O) -) with the nitrogen member to which said GO group is attached. 66.- The use claimed in claim 64, wherein said R4 is H. 67.- The use claimed in claim 64, wherein said R2 and R3 are each independently selected from the group that consists of A), B), C), D), E) and I), as defined in claim 64. 68.- The use claimed in claim 64, wherein said R2 and R3 are selected each one independently of group A), as defined in claim 64. 69. - The use claimed in claim 64, wherein said R2 and R3 are each independently selected from group B), as defined in claim 64. 70. The use claimed in claim 64, wherein said R2 and R3 are each independently selected from the group C), as defined in claim 64. 71.- The use which is claimed in claim 64, wherein said R2 and R3 are each independently selected from the group D), as defined in claim 64. 72.- The use claimed in claim 64, wherein said R2 and R3 are each independently selected from the group E), as defined in claim 64. 73. The use claimed in claim 64, wherein said R2 and R3 are each independently selected from group I), as defined in claim 64. 74. The use claimed in claim 64, wherein said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member that is the binding nitrogen, said The heterocyclic ring is selected from the group consisting of i) and ii), as defined in claim 64. 75.- The use claimed in claim 64, wherein said R2 and R3 are taken together with the nitrogen to which are joined to form a heterocyclic ring containing at least one heteroatom member which is the binding nitrogen, said heterocyclic ring being selected from group i), as defined in claim 64. 76. - The use claimed in claim 64, wherein said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is the binding nitrogen, said ring heterocyclic is selected from group ii), as defined in claim.64. 77. The use claimed in claim 64, wherein the condition mediated by LTA4H is inflammation due to at least one of asthma, chronic obstructive pulmonary disease, atherosclerosis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases and psoriasis. 78. The use claimed in claim 46, wherein at least one LTA4H modulator is selected from compounds of the formula (III): (lll) or an enantiomer, diastereomer, racemate, tautomer, hydrate, solvate or a pharmaceutically acceptable salt, ester or amide thereof, wherein R4, R6, X, Y, Z, and W are defined as in the compound of the formula (I ), R se defined as R2 in the compound of the formula (I), and R3"is defined as R3 in the compound of the formula (I), provided that (a) said R2 and R3 also satisfy one of the following: (e1): at least one of R2 and R3"is not alkyl of C ^ s, when Z is O and X is S; (e2): none of R2"and R3" is alkyl of C? .4C (O) Rx, where Rx is an alkyl of C1.4, OH, -Oalkyl of C? -4, -Oalkyl of Co-4RAr, or -NRYRY, when Y is O, Z is a bond , and R2 is different from R3"; and (e3): none of R2" and R3 is-C1-6CN alkyl, when Y is O, Z is a bond and R2 'is different from R3", and (b) also whenever when X is S, Y is O, Z is a bond, and W is CH2, then one of R2"and R3 is not XCG when the other is Ci-β alkyl, where XCG is the group HCl 6 wherein HC16 is one of H, C1-6alkyl, halogen-C1-6alkyl, allyl and Ci-βalkoxymethyl, and GO is a group bonded by a carbon member having a substituent a = O which forms an amido group with the nitrogen member to which said GO group is attached. 70. - The use claimed in claim 78, wherein said R4 is H. 80. - The use claimed in claim 78, wherein said R2 and R3 are each independently selected from the group consisting of A), B), C), D), E) and I), as defined in claim 78. 81. - The use claimed in claim 78, wherein said R2 and R3 are each independently selected from group A), as defined in claim 78. 82. The use claimed in claim 78, wherein said R2 and R3 are each independently selected from group B), as defined in claim 78. 83. The use claimed in claim 78, wherein said R2 and R3 are each independently selected from group C) , as defined in claim 78. 84. The use claimed in claim 78, wherein said R2 and R3 are each independently selected from the group D), as defined in claim 78. 85.- The use claimed in claim 78, wherein said R2 and R3 are each independently selected from the group E), as defined in claim 78. 86.- The use claimed in claim 78, wherein said R2 and R3 are each selected independently of the group or I), as defined in claim 78. 87. The use claimed in claim 78, wherein said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring which confers at least minus one heteroatom member which is the binding nitrogen, said heterocyclic ring is selected from the group consisting of i) and ii), as defined in claim 78. 88. The use claimed in claim 78, wherein said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is nitrogen of Union, said heterocyclic ring is selected from group i), as defined in claim 78. 89.- The use claimed in claim 78, wherein said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is the binding nitrogen, said heterocyclic ring being selected from group ii), as defined in claim 78. 90.- The use claimed in claim 78, where inflammation is associated with at least one of asthma, chronic obstructive pulmonary disease, atherosclerosis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases and psoriasis. 91.- The use of at least one LTA4H modulator selected from compounds of the formula (I): 0) wherein X is selected from the group consisting of NR5, O, and S, where R5 is one of H and CH3; And it is selected from the group consisting of CH2, and O; Z is selected from the group consisting of O and bond; W is selected from the group consisting of CH2 and CHR1-CH2, R being one of H and OH, wherein the carbon member attached to R1 at said CHR1-CH2 is not directly attached to the nitrogen member to which W is attached; R 4 is selected from the group consisting of H, OCH 3, Cl, F, Br, I, OH, NH 2, CN, CF 3 and CH 3; R6 is H or F; and R2 and R3 are each independently selected from the group consisting of A) H, C? -7 alkyl, C3-7 alkenyl, wherein the carbon in said alkenyl which is attached to the nitrogen member has only individual bonds, C3-7 alkynyl, wherein the carbon in said alkynyl which is attached to the nitrogen member has only individual bonds, optionally benzofused C3-7 cycloalkyl, C5-7 cycloalkenyl, C3- cycloalkyl-C1.7 alkyl , - C3-C-cycloalkyl alkyl and phenyl, wherein each of substituents A) is independently substituted with 0, 1 or 2 RQ, and each of R1Q is a substituent on a carbon member which is minus one carbon member removed from the nitrogen member; B) a HetRa substituent; C) -alkyl of C? -7C (0) Rx, optionally substituted with CH2RAr or CH2RAr; D) -alkyl of C2-5C (O) Rx, wherein two valence carbon members allowed in the C2-5 alkyl of said -C2-5C (O) Rx alkyl are part of a C3-6 carbocycle saturated; E) -C2-5alkyl? H wherein two valence carbon members allowed in the C2-5 alkyl of said -C2-5OH alkyl are part of a carbocycle of C3-6 saturated; F) -C0-4 alkylphenyl, wherein the phenyl is said -Co-4 alkylphenyl is fused to two adjacent carbon members in said phenyl to Rf, or is benzofused; G) -alkyl of CcwAr6, wherein Ar6 is a 6-membered heteroaryl having a carbon member attachment point and having one or two heteroatom members -N =, and benzofused; H) - CC alkyl AG5, wherein Ar5 is a 5-membered heteroaryl, having a heteroatom member selected from the group consisting of O, S, and > NRY, and having 0 or 1 additional heteroatom member -N =, optionally containing two carbonyl groups, and optionally benzofused; I) -alkyl wherein Ar5 'is a 5-membered heteroaryl containing 3 or 4 nitrogen members, optionally substituted with R ?, and having a valence site allowed as a point of attachment; J) -alkyl of Co ^ Ar6"6, wherein Ar6" 6 is a phenyl linked to Co-4 alkyl fused at sites of valence allowed to a 6-membered heteroaryl, wherein said 6-membered heteroaryl has one or two heteroatom members -N =; K) -CG alkyl "AG6" 5, wherein Ar6"5 is a phenyl bonded to C0-4 alkyl fused at sites of valence allowed to a 5-membered heteroaryl, said 5-membered heteroaryl having a heteroatom member selected from the group consisting of O, S, and > NRY, and said 5-membered heteroaryl having 0 or 1 additional heteroatom member which is -N =; and L) one of 2- (4-ethyl-phenoxy) -benzothiazole, 2- (4-ethyl-phenoxy) -benzoxazole, and 2- (4-ethyl-phenoxy) -1H-benzimidazole; M) SO 2 -C 4 alkyl; alternatively R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is the linking nitrogen, said heterocyclic ring being selected from the group consisting of i) a 4-7 membered heterocyclic ring HetRb, said 4-7 heterocyclic ring HetRb members having a heteroatom member which is the binding nitrogen, and being substituted with 0, 1, or 2 substituents on the same or different substitution members, said substituent being selected from the group consisting of -R ?, -CN , -C (O) R ?, -alkyl of C0-4CO2RY, -alkyl of C0-4C (O) CO2R?, -C0-4ORY alkyl, -C0-C (O) NR? Rz alkyl, -C0-4NR alkyl? C (O) Rz, -C (O) NRzOR ?, -Co-4NRYC alkyl (0) CH2ORY, - -C0-4NR alkylC (O) CH2C (O) R ?, -Calkyl NRYCO2RY, -C0 alkyl. 4NR? C (O) NR? Rz, -alkyl of C0- NRYC (S) NRYRZ, - -NR? C (O) CO2R ?, -NRYRZ, -alkyl of C0-4NRWSO2RY, 1,3-dihydro-indole- 2-ona-1-yl, 1,3-dihydro-benzimidazol-2-one-1-yl, tetrazol-5-yl, 1-R? -1 H-tetrazol-5-yl, R? -triazolyl, 2 -R? -2H-tetrazol-5-yl, pyrrolidin-2-thion-1-yl, piperdin-2-thion-1-yl, -OC alkyl. 4C (O) N (R?) (SO2R?), -C0-4N (RY) alkyl (SO2) NRYRY, -C0-4N alkyl (R?) (SO2) NR? CO2R ?, halogen, -CN -CN -CN -OH "N- * Y-? S" RY -N? 0'RY "N? R-v H H, H, H, and R? H; ii) a 5-7 membered heterocyclic ring HetRc, said heterocyclic ring of 5-7 HetRc having an additional heteroatom member separated from the binding nitrogen by at least one carbon member, said member of additional heteroatom being selected from the group consisting of O, S (= O) 0-2, and > NRM, said 5-7 membered heterocyclic ring HetRc having 0 or 1 carbonyl member, and being substituted with 0, 1, or 2 substituents on the same or on different carbon substitution means, said substituents being selected from the group consisting of -C (O) R ?, -C? 2R? -alcyl of C3_4C? 2R? and RZ; iii) one of imidazolidin-1-yl, 2-imidazolin-1-yl, pyrazol-1-yl, imidazol-1-yl, 2H-tetrazol-2-yl, 1 H-tetrazol-1-yl, pyrrol- 1-yl, 2-pyrrolin-1-yl, and 3-pyrrolin-1-yl, wherein each of said 2H-tetrazol-2-yl and 1 H-tetrazol-1-yl is substituted on the carbon member with 0 or 1 of -Cal-4Rz alkyl, -C0-4SRY alkyl, -C0-4CO2RY alkyl, and HetRa substituent; and iv) one of 1, 2,3,4-tetrahydro-quinolin-1-yl, 1, 2,3,4-tetrahydro-isoquinolin-2-yl, indole-1-yl, isoindol-2-yl, indolin -1-yl, benzimidazol-1-yl, 2,8-diaza-spiro [4.5] decan-1-one-8-yl, 4-. { [(2-tert-butoxycarbonylamino-cyclobutylenecarbonyl) -amino] -methyl} -piperidin-1 -yl, 4-. { [(2-amino-cyclobutanecarbonyl) -amino] -methyl} -piperidin-1-yl, 3,9-diaza-spiro [5.5] undecan-3-carboxylic acid 9-yl-tert-butyl ester, 4-oxo-1-phenyl-1,3,8-triaza-spiro [4.5] dec-8-yl, and 4-oxo-1, 3,8-triaza-spiro [4.5] dec-8-yl; wherein the HetRa substituent is a 4-7 membered heterocyclic ring having a carbon member attachment point and containing a > NR as a heteroatom member, and said heteroatom member being separated from the carbon member attachment point by at least one additional carbon member; R? is selected from the group consisting of H, -C1_4alkyl, -C1-R4R alkyl, each optionally substituted with 1, 2, or 3 RN substituent; RL is selected from group consisting of -CO2Rs and -C (O) NRsRs; RM is selected from the group consisting of Rz, indol-7-yl, -SO2R ?, -alkyl of C3-4CO2R ?, -CO2R ?, -C (0) NRzOR ?, -C (O) R ?, -C (O) C? -4OR? Alkyl, -C0-4C (O) NRsRs' alkyl, C0-4C (O) CO2RY, 1,3-dihydro-indol-2-one-1-yl alkyl, , 3-dihydro-benzimidazoI-2-one-1-yl, tetrazol-5-yl, 1-R? -1H-tetrazol-5-yl, R? -triazolyl, 2-R? -2H-tetrazole-5- ilo and -alkyl of C0-4C (O) N (RY) (SO2RY), each optionally substituted with 1, 2 or 3 R substituents; R is selected from the group consisting of OCH 3, Cl, F, Br, I, OH, NH 2, CN, CF 3, CH 3, OC (O) CH 3, and NO 2; Rp is selected from the group consisting of R ?, -alkyl of C2-4? R ?, RAr, -alkyl of C? -2CO2R ?, -alkyl of C? -2CONRsRs', indole-7-yl, and -SO2alkyl of C? -4; RQ is selected from the group consisting of fluoro, chloro, bromo, iodo, trifluoromethyl, trichloromethyl, -CN, -alkyl of C1.4, -alkyl of C0-4RAr, -alkyl of C0-4RAr ', -alkyl of C0- ORY, -C0-4CO2RY alkyl- C0-4NRYRZ alkyl, -C0-NRYCORY alkyl, -C0-4NRYCONRYRZ alkyl, -C0-4NR alkyl, SO2R ?, and -C0-4SRY alkyl; Rs and Rs' are independently selected from the group consisting of H, -C1-4alkyl, and -C0-4 alkylphenyl; alternatively, Rs and Rs 'are taken together with the nitrogen member to which said Rs and Rs' are bonded to form a 4- to 7-membered heterocyclic ring having 0 or 1 additional heteroatom member selected from the group consisting of O, S, and > NRY, provided that said additional member and heteroatom is separated by at least two carbon members of said nitrogen member to which Rs and Rs are attached, and provided that where R? is Co-4RAr alkyl, so RAr is not replaced with RL; Rw is selected from the group consisting of R ?, and -C3-7 cycloalkyl; Rx is selected from the group consisting of -OR ?, -NRYRZ, -alkyl of C? -4, and -alkyl of Co-4RAr; RY is selected from the group consisting of H, -C4 alkyl, -C0-4RAr alkyl, and -C0-4RAr alkyl, and optionally substituted with 1, 2, or 3 RN substituents; Rz is selected from the group consisting of R ?, -alkyl of C2-4? R ?, -alkyl of C? -2C02RY, -alkyl of C? -2C (0) NRsRs ', and -alkyl of C2-4NRSRS'; when R? and Rz join a nitrogen member, R? and Rz are selected as defined above or R? and Rz are taken together with the nitrogen member attached to R? - and Rz- to form a 4-7 membered heterocyclic ring HetRd having 0 or 1 additional heteroatom member selected from the group consisting of O, S, and > NRM, said 4-7 membered heterocyclic ring HetRd having 0 or 1 carbonyl member, and said 4-7 membered heterocyclic ring HetRd having 0 or 1 allowed valence carbon member substituted with at least one of RM, -CO2H , and -coal of Co-? OR ?; RAr is a portion with a carbon member attachment point and said portion is selected from the group consisting of phenyl, pyridyl, pyrimidyl, and pyrazinyl, wherein each valence carbon member allowed in each of said portions is independently substituted with at least one of 0, 1, 2 or 3 RN, and 0 or 1 RL; RAr 'is a ring of 3 to 8 members, having 0, 1 or 2 heteroatom members selected from the group consisting of O, S, N, and > NRY, which has 0, 1, or 2 unsaturated bonds, which has 0 or 1 carbonyl member, where each valence member allowed in each of the rings is independently substituted with 0, 1, or 2 R ?; and Rf is a linear 3 to 5 membered hydrocarbon portion having 0 or 1 unsaturated carbon-carbon bond having 0 or 1 carbonyl member; or an enantiomer, diastereomer, racemate, tautomer, hydrate, solvate or a pharmaceutically acceptable salt, ester or amide thereof, for preparing a medicament for inhibiting the activity of LTA4H enzyme. 92.- The use claimed in claim 91, wherein said R4 is H. 93.- The use claimed in claim 91, wherein said R2 and R3 are each independently selected from the group consisting of A ), B), C), D), E) and I), as defined in claim 91. 94.- The use claimed in claim 91, wherein said R2 and R3 are each independently selected from the group A), as defined in claim 91. 95. The use claimed in claim 91, wherein said R2 and R3 are each independently selected from group B), as defined in claim 91. 96 The use claimed in claim 91, wherein said R2 and R3 are each independently selected from group C), as defined in claim 91. 97. The use claimed in claim 91, in wherein said R2 and R3 are each independently selected from group D), as defined in claim 91. 98. - The use claimed in claim 91, wherein said R2 and R3 are each independently selected from the group E), as defined in claim 91. 9.- The use claimed in claim 91, wherein said R2 and R3 are each independently selected from group I), as defined in claim 91. 100.- The use claimed in claim 91, wherein said R2 and R3 are taken together with the nitrogen to which they are attached. joined to form a heterocyclic ring containing at least one heteroatom member which is the binding nitrogen, said heterocyclic ring is selected from the group consisting of i) and ii), as defined in claim 91. 101.- The use claimed in claim 01, wherein said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is the binding nitrogen, said ring hete Rocyclic is selected from group i), as defined in claim 91. 102. The use claimed in claim 91, wherein said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring. which contains at least one heteroatom member which is the binding nitrogen, said heterocyclic ring is selected from the group i), as defined in claim 91. 103. The use claimed in claim 01, wherein the Condition mediated by LTA4H is inflammation due to at least one of asthma, chronic obstructive pulmonary disease, atherosclerosis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases and psoriasis. 104. The use claimed in claim 91, wherein at least one LTA4H modulator is one of: 2- [4- (2-piperidin-1-yl-ethoxy) -phenoxy] -benzoxazole; (1- {2- [4- (benzooxanzol-2-yloxy) -phenoxy] ethyl} -piperidin-4-yl) -methanol; 1 -. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-ol; . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -dibutyl-amine; (1- {2- [4- (benzoxazol-2-yloxy) -phenoxy] -ethyl} -piperidin-2-yl) -methanol; 1 -. { 3- [4- (benzoxazol-2-yloxy) -phenoxy] -propyl} -4-phenyl-piperidin-4-ol; 1-. { 3- [4- (benzoxazol-2-yloxy) -phenoxy] -propyl} -4-benzyl-piperidin-4-ol; 2- [4- (2-piperidin-1-ethyl-ethyl) -phenoxy] -benzoxazole; . { 3- [4- (benzoxazol-2-yloxy) -phenyl] -propyl} -cyclohexyl-ethyl-amine; 1-3- [4- (benzoxazol-2-yloxy) -phenyl] -propyl} -piperidin-4-ol; 1-. { 3- [4- (benzoxazol-2-yloxy) -phenoxy] -2-hydroxy-propyl} -4-phenyl-piperidin-4-ol; 1- [2- (4-Benzoxazol-2-ylmethyl-phenoxy) -ethyl] -piperidine-4-carboxylic acid ethyl ester; 2- [4- (2-pyrrolidin-1-yl-ethoxy) -phenoxy] -benzoxazole; . { 3- [4- (benzoxazol-2-yloxy) -phenoxy] -propyl} dimethyl amine; . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} dimethyl amine; and 2- [4- (2-azepan-1-yl-ethoxy) -phenoxy] -benzoxazole. 105. The use claimed in claim 91, wherein at least one LTA4H modulator is one of: 1 -. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4-phenyl-piperidin-4-ol; . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -cyclohexyl-ethyl-amine; 2-. { 4- [2- (2-ethyl-piperidin-1-yl) -ethoxy] -phenoxy} -benzoxazole; 1 -. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4-phenyl-piperidin-4-carbonitrile; 1 - (1 - { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4-pheny) -piperidin-4-yl) -ethanone; 2-. { 4- [2- (4-Methyl-piperidin-1-yl) -ethoxy] -phenoxy} -benzoxazole; 1 -. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4- (4-chloro-phenyl) -piperidin-4-ol; 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4- (4-bromo-phenyl) -piperidin-4-ol; 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4- (4-chloro-3-trifluoromethyl-phenyl) -piperidin-4-ol; 1 -. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4-benzyl-piperidin-4-ol; . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -cyclohexyl-methyl-amine; Y . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -cyclopropylmethyl-propyl-amine. 106. The use claimed in claim 91, wherein at least one LTA4H modulator is one of:. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -butyl-ethyl-amine; 2- (. {2- [4- (Benzoxazo-2-yloxy) -phenoxy] -ethyl} -benzyl-amino) -ethanol; 2-. { 4- [2- (4-Benzyl-piperidin-1-yl) -ethoxy] -phenoxy} -benzoxazole; (1 - { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -piperidin-3-yl) -methanol; 2- (. {2- 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -propyl-amino) -ethane I; 2- [4- (2-Azetidin-1-yl-ethoxy) -phenoxy] -benzoxazole; ? / - (1- {2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -2-phenyl-acetamide; 1- ethyl ester. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -piperidine-3-carboxylic acid; 2-. { 4- [3- (4-Phenyl-piperidin-1-yl) -propoxy] -phenoxy-benzoxazole; 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -etiI} -4-phenyl-piperidin-4-ol; . { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -cyclohexyl-ethyl-amine; 2- [4- (2-Pyrrolidin-1-yl-ethyl) -phenoxy] -benzoxazole; and 2- [4- (2-Azepan-1-yl-ethyl) -phenoxy] -benzoxazole. 107. The use claimed in claim 91, wherein at least one LTA4H modulator is one of:. { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl-propyl-amine; . { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} - dibutyl-amine; 1 -. { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-ol; methyl ester of acid 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; 1-. { 3- [4- (Benzoxazol-2-yloxy) -phenyl] -propyl} -4-phenyl-piperidin-4-ol; 2- [4- (3-Piperidin-1-yl-propyl) -phenoxy] -benzoxazole; . { 3- [4- (Benzoxazol-2-yloxy) -phenyl] -propyl} -dibutyl-amine; . { 3- [4- (Benzoxazol-2-yloxy) -fenif] -propyl} -cyclopropylammethyl propyl amine; 1- [4- (Benzoxazol-2-yloxy) -phenoxy] -3-pyrrolidin-1-yl-propan-2-ol; 1- [2- (4-Benzoxazol-2-ylmethyl-phenoxy) -ethyl] -4-phenyl-piperidin-4-ol; 1 - [2- (4-BenzoxazoI-2-ylmethyl-phenoxy) -ethyl] -piperidine-4-carboxylic acid amide; 2- [4- (2-Morpholin-4-yl-ethoxy) -phenoxy] -benzoxazole; Y . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -diethyl-amine. 108.- The use claimed in claim 01, wherein at least one LTA4H modulator is one of:. { 2- [4- (6-chloro-benzothiazol-2-yloxy) -phenoxy] -phenoxy] -ethyl} -diethylamine; 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-ol; 1- ethyl ester. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carboxylic acid; acid 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carboxylic acid; (1 - { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -pyridinium-1-yl-methanone; 3 - [(1- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carbonyl) -amino] -propionic acid ethyl ester; acid amide 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -etiI} -piperidine-4-carboxylic acid; 1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -etyl] -piperidin-4-yl) -pyrrolidin-2-one; 1'-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - [1, 4 '] bipiperidinyl-2-one; 8-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -2,8-diaza-spiro [4.5] decan-1-one; 2- [4- (3-pyrrolidin-1-yl-propoxy) -phenoxy] -benzothiazole; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclohexyl-ethyl-amine; acid amide 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-3- carboxylic; 1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperidin-4-yl) -3-methyl-1,3-dihydro-benzimidazole-2- ona; methyl ester of acid 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; (1- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) - (4-methyl-piperazin-1-yl) -methanone; 1- [2- (4-Benzothiazol-2-ylmethyl-phenoxy) -ethyl] -piperidine-4-carboxylic acid methyl ester; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - cyclopropyl-amino) -propionic acid; . { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} dimethyl amine; 2- [4- (2-pyrrolidin-1-yl-ethoxy) -phenoxy-benzothiazole; . { 3- [4- (benzothiazol-2-yloxy) -phenoxy] -propyl} dimethyl amine; 2- [4- (2-azepan-1-yl-ethoxy) -phenoxy] -benzothiazole; 2- [4- (2-azepan-1-yl-ethoxy) -phenoxy] -6-methoxy-benzothiazole; 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -4-phenyl-piperidin-4-ol; . { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -cyclohexyl-ethyl-amine; 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -4- (4-chloro-phenyl) -piperidin-4-ol; . { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -dibutyl-amine; 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -4- (4-bromo-phenyl) -piperidin-4-ol; 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -4- (4-chloro-3-trifluoromethyl-phenyl) -piperidin-4-ol; 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -4-benzyl-piperidin-4-ol; 1'-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - [1, 4 '] bipiperidine; (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -methanol; ? / - (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -2-phenyl-acetamide; 2- (4- { 2- [4- (2-morpholin-4-yl-ethyl) -piperazin-1-yl] -ethoxy.} - phenoxy) -benzothiazole; 2- (4- { 2- [4- (2-morpholin-4-yl-ethyl) -piperazin-1-yl] -ethyl} -phenoxy) -benzothiazole; 1 -. { 3- [4- (benzothiazol-2-yloxy) -phenoxy] -propyl} -4-phenyl-piperidin-4-ol; 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -4-phenyl-piperidin-4-ol; 2- [4- (2-pyrroidin-1-yl-ethyl) -phenoxy] -benzothiazole; 2- [4- (2-azepan-1-yl-etif) -phenoxy] -benzothiazole; . { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl-propyl-amine; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -dibutyl-amine; 2- [4- (2-piperidin-1-yl-etiI) -phenoxy] -benzothiazole; 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperdin-4-ol; acid amide 1-. { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; 1- ethyl ester. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etiI} -piperidine-3-carboxylic acid; 1- ethyl ester. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -4-phenyl-piperdin-4-carboxylic acid; (1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -acetic acid ethyl ester; 1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -1,3-dihydro-indol-2-one; 1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperdin-4-yl) -pyrrolidin-2-one; ? / - (1 -. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperidin-4-yl) -2-phenyl-acetamide; 8-. { 2- [4- (benzothiazol-2-yloxy) -pheni]] - eti)} -2,8-diaza-spiro [4.5] decan-1-one; 1 -. { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl) -piperidin-3-ol; 1- ethyl ester. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; 1 '-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - [1, 4 '] bipiperidine; 2-. { 4- [2- (4-methyl-piperazin-1-li) -ethyl] -phenoxy} -benzothiazole; 2- (4- { 2- [4- (1-benzyl-1H-tetrazol-5-yl) -piperidin-1-yl] -ethoxy.} - phenoxy) -benzothiazole; 4- (1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carbonyl) -piperazin-1-carboxylic acid tert-butyl ester; 1- [2- (4-Benzothiazol-2-ylmethyl-phenoxy) -ethyl] -piperidine-4-carboxylic acid amide; 1 -. { 1 - [2- (4-Benzothiazol-2-ylmethyl-phenoxy) -ethyl] -piperidin-4-yl} -pyrrolidin-2-one; 1 - [4- (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-carbonyl) -piperazin-1-yl] -ethanone; acid 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; 1- (1- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -pyrrolidin-2-thione; 2- (4- { 2- [4- (benzothiazoI-2-yloxy) -phenoxy] -ethyl} -piperazin-1-yl) -ethanol; 2- (4- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] - ethyl} -piperazin-1-yl) -1-pyrrolidin-1-yl-ethanone; 2- (4- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} - piperazin-1-yl) -1-morpholin-4-yl-ethanone; acid 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -peridin-3-carboxylic acid; acid 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-2-carboxylic acid; (1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-3-yl) -acetic acid; (1- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -acetic acid ethyl ester; (1- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -carbamic acid tert-butyl ester; (1 - { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -acetic acid; (1- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-3-yl) -methanol; (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclohexyl-amino) -acetic acid methyl ester; (4- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - piperazin-1-yl) -acetic acid; 1- (1. {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -5-oxo-pyrrolidine-2-carboxylic acid ethyl ester; 1- (1- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -5-oxo-pyrrolidine-2-carboxylic acid; 4- (4- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperazin-1-yl) -phenol; ? / - (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -4-chloro- / V-cyclopropyl-benzenesulfonamide; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - cyclopropylmethyl-amino) -propionic acid; 3- ( { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl) -isopropyl-amino) -propionic acid; 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piper¡din-4-ilam¡na; 3- [acid. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - (1-methyl-piperidin-4-yl) -amino] -propionic; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -benzyl-amino) -propionic acid; 3 - ((1-Acetyl-piperidin-4-yl) -. {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -amino) -propionic acid; 4- (1. {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -.l -1H-tetrazol-5-yl) -piperin-1-tert-butyl ester - carboxylic; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propionic acid; 3 - ((1-Acetyl-p-peridin-4-yl) -. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -amino) -propionic acid; 3- [acid. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - (1-methyl-piperidin-4-yl) -amino] -propionic; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -propionic acid; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - isopropyl-amino) -propionic acid; 2- (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) -1-pyrrolidin-1-yl-ethanone; acid (R) -1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-3-carboxylic acid; 1 - (1 -. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -1,3-dihydro-benzimidazol-2-one; 2- (4- { 2- [4- (6-Methyl-pyridin-2-yl) -piperazin-1-yl] -ethyl} -phenoxy) -benzothiazole; 2-4- [2- (4-Ethanesulfonyl-piperazin-1-yl) -ethyl] -phenoxy} -benzothiazole; 2- (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) -1-morpholin-4-yl-ethanone; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -methyl-amino) -propionic acid; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopentyl-amino) -propionic acid; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclobutyl-amino) -propionic acid; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -benzyl-amino) -propionic acid; (1- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) - (4-hydroxymethyl-piperidin-1-yl) -metanone; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amine; (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) - [4- (2-hydroxy-ethyl) -piperazin-1-yl} ] -metanone; (1 - { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl.} - piperidn-4-yl) - [4- (2-hydroxy-ethyl) -piperidine -1-yl] -metanone; 2- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.} - cyclopropyl-amino) -ethanol; 3- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propan-1-ol; 4- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -butyric acid; 3 - [(1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} - piperidin-4-carbonyl) -amino] -propionic; 4- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -butyronitrile; 3- (1 - { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -propionic acid; [(1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carbonyl) -methyl-amino] -acetic acid; 3- (4- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl] -piperazin-1-yl) -phenol; 2- (4- { 2- [4- (4-methoxy-phenyl) -piperazin-1-yl] -ethoxy.} - phenoxy) -benzothiazole; 2-. { 4- [2- (5-piperidin-4-yl-tetrazol-1-yl) -ethoxy] -phenoxy} -benzothiazole; (S) -1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -4-hydroxy-pyrrolidin-2 -one; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethylamine; 2 - [(. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -.-cyclopropyl-amino) -methyl] -cyclopropanecarboxylic acid ethyl ester; 4- (4-. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperazin-1-carbonyl) -benzoic acid ethyl ester; 2 - [( { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -methyl] -cyclopropanecarboxylic acid; 1- (. {2- 2- (4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propan-2-ol; 3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.} - cyclopropyl-amino) -1,1,1-trifluoro-propan-2-ol; 3- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propionamide; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propane-1,2-diol; 2-. { 4- [2- (5-phenyl-tetrazol-2-yl) -ethoxy] -phenoxy} -benzothiazole; 2-. { 4- [2- (5-phenyl-tetrazol-1-yl) -ethoxy] -phenoxy-benzothiazole; ? / -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -N-cyclopropyl-2- (2H-tetrazol-5-yl) -acetamide; (S) -3- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -etyl} -cyclopropyl-amino) -2-methyl-propan-1-yl; (R) -3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -2-methyl-propan-1-ol; 2-. { 4- [2- (5-methylsulfanyl-tetrazol-2-yl) -ethoxy] -phenoxy} -benzothiazole; 2-. { 4- [2- (5-Methylsulfanyl-tetrazol-1-yl) -ethoxy] -phenoxy} -benzothiazole; 2- [4- (2-tetrazol-2-yl-ethoxy) -phenoxy] -benzothiazole; 2- [4- (2-tetrazol-1-yl- ethoxy) -phenoxy] -benzothiazole; acid (1 2R) -2-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino-cyclohexanecarboxylic acid; acid (1S, 2R) -2-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino} -cyclohexanecarboxylic; (1R, 2R) -2-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino} -cyclohexanol; (1 S, 2R) -2-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino-cyclohexanol; 4- (1- { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -butyric acid; (R) 1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -4-hydroxy-pyrrolidin-2-one; 2- (4- { 2- [4- (1 H-Tetrazol-5-yl) -piperidin-1-yl] -ethyl} -phenoxy) -benzothiazole; (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -etyl} -piperidin-2-yl) -methanol; (1- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -1H-tetrazol-5-yl) -acetic acid ethyl ester; (1- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -1H-tetrazol-5-yl) -acetic acid ethyl ester; 2- hydrochloride. { 4- [2- (5-piperidin-4-yl-tetrazol-2-yl) -ethoxy] -phenoxy} -benzothiazole; 7- { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -4-spiro- [3-phthalide] -piperidine; 1- ethyl ester. { 3- [4- (benzothiazol-2-yloxy) -phenyl] -propyl} -piperidine-4-carboxylic acid; 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamine hydrochloride; 2- (4- { 2- [4- (1 H-tetrazol-5-yl) -piperidin-1-yl] -ethoxy.} - phenoxy) -benzothiazole; cis-4- trifluoromethanesulfonate salt. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino-cyclohexanecarboxylic acid; (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1 -ii) - (tetrahydro-furan-2-yl) -methanone; (1 -. {-2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carbonyl) -amide of propan-2-sulfonic acid; (4- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) -oxo-acetic acid methyl ester; N- (1- {2- [4- (benzothiazoi-2-yloxy) -phenyl] -ethyl} -ethyl} -piperidine-4-carbonyl) -benzenesulfonamide trifluoromethanesulfonate salt; N- (1 -. {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine trifluoromethanesulfonate salt 4-carbonyl) -methanesulfonamide; (4- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) -oxo-acéfic acid trifluoromethanesulfonate salt; (4- { 2- [4- (benzothiazl-2-yloxy) -phenyl] -ethyl.} - piperazin-1-yl) -morpholin-4-yl-methanone; 1 - (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -2-thiophen-2-yl-ethanone; (4-. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -etiI.} - piperazin-1-yl) -pyridin-3-yl-methanone; (4-. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -cyclopropyl-methanone; 1- (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) -2-methoxy-ethanone; 1 - (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -2,2,2-trifluoro-ethanone; 4- (4- { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-carbonyl) -benzoic acid; (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -etyl] -piperazin-1-yl) -pyridin-4-yl-methanone; (4- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) - (5-methyl-pyrazin-2-yl) -methanone; (R) - (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) - (tetrahydro-furan-2-yl) - methanone; (S) - (4- { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl.}. -p.perazin-1-yl) - (tertrahydro-furan-2-yl) - methanone; (4- { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) - (tetrahydro-furan-3-yl) -methanone; 1- (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -2-hydroxy-ethanone; 2- [2- (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -2-oxo-ethyl] -cyclopentanone; 3- (4. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -etyl} -piperazin-1-yl) -propionic acid trifluoromethanesulfonate salt; 3- (1-. {-2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -oxazolidin-2-one; 4- (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -morpholin-3-one; 4- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperdin-4-yl) -morpholin-3-one; 3- (1- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl] -piperidin-4-yl) -oxazolidin-2-one; benzyloxy-1-acid amide. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etl} -piperidin- 4-carboxylic; (1 - { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -acetic acid; (R) -1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -4-hydroxy-pyrrolidin-2-one; hydroxyamide of acid 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; (S) -1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -4-hydroxy-pyrrolidin-2-one; (1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -carbamic acid tert-butyl ester; 2-. { 4- [2- (4-fluoro-piperidin-1-yl) -etll] -phenoxy-benzothiazole; 2-. { 4- [2- (4,4-difluoro-piperidin-1-yl) -ethyl] -phenoxy} -benzothiazole; (R) -1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -pyrrolidin-3-ol; N-1 -. { 2- [4- (benzothiazol-2-yloxy) -fenii] -ethyl} -piperidin-4-yl) -formamide; (1- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -urea; 1- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperidin-4-yl) -3-cyano-2-phenyl-isourea; 1- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -etiI.}. -piperidin-4-yl) -3-cyano-2-methyl-isothiourea; N- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperidin-4-yl) -methanesulfonamide; 1 - (1 -. {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperidin-4-yl) -3-cyano-2-methyl-guanidine; 8-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -1-phenyl-1, 3,8-triaza-spiro [4.5] decan-4-one; 8-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -1, 3,8-triaza-spiro [4.5] decane-2,4-dione; (1- {2- [4- (Benzofiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -methylcarbamic acid tert-butyl ester; N- (1-. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -N-methyl-acetamide; N- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -N-methyl-methanesulfonamide; [(1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -methyl-carbamoyl] -methyl acetic acid ester; N- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -N-acetamide; ester (1 -. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl-ethyl-ethyl} -piperidin-4-ylcarbamoyl) -methylic acid; 2- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] - acid ethyl} -methyl-amino) -3- (1 H-imidazol-2-yl) -propionic acid; 2- (4- { 2- [4- (3-nitro-pyridin-2-yl) - [1,4] diazepan-1-yl] -ethyl} -phenoxy) -benzothiazole; [(1- {2- [4- (Benzothiazol-2-yloxy) -phenox] -ethyl} -piperidine-4-carbonyl) -methyl-amino] -acetic acid ethyl ester; ethyl ester of 1 '- acid. { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} - [1, 4 '] bipiperidinyl-4-carboxylic acid; 1 2- [4- (Benzothiazol-2-yloxy) - [phenoxy] -ethyl acid} - [1, 4 '] bipiperidinyl-4-carboxylic acid; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-ethyl-amine; trifluoromethanesulfonic acid salt of 3- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -etii.} - cyclopropyl-amino) -2-methyl-propionic acid; 2- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -ethanol; 2- [2- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -ethoxy] -ethanol; 3- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -propan-1-ol; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etiI} -cyclopropylmethyl- (3-tetrazol-2-yl-propyl) -amine; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl- (3-pyrrol-1-yl-propyl) -amine; 4- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -butyronitrile; (2-cyano-ethyl) -amide of 1- acid. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl- [3- (2H-tetrazol-5-yl) -propyl] -amine; 3- [5- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -tetrazol-1-yl ] -propitronitrile; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl- [3- (2H-tetrazol-5-yl) -propyl] -amine; 1- (hydroxy-1, 1-dimethyl-ethyl) -amide. { 2- [4- (Benzotlazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl- [3- (1 H- [1, 2,4] triazol-3-yl) -propyl] -amine; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl- [3- (5-methyl-1 H- [1, 2,4] triazol-3-yl) -propyl] -amine; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl- [3- (5-phenyl-1 H- [1, 2,4] triazol-3-yl) - propyl] -amine; 2- (4- { 2- [4- (1-methyl-1 H-tetrazol-5-yl) -piperidin-1-yl] -ethyl} -phenoxy) -benzothiazole; 2- (4- { 2- [4- (2-methyl-2H-tertrazol-5-yl) -piperidin-1-yl] -ethyl} -phenoxy) -benzothiazole; 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carbonitrile; 2- (4- { 2- [4- (1 H- [1,2,3] triazol-4-yl) -piperidin-1-yl] -ethyl} -phenoxy) -benzothiazole; 4-ethyl ester. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino} -butyric; 4- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl-amino) -butyric acid ethyl ester; 2- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.} - cyclopropylmethyl-amino) -propyl] -isoindole-1,3-dione; 4- (. {2- 2- [4- (Benzot-azo-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -butyric acid; 1- (3- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethylamino} -propyl) -pyrrolidin-2-one; N-1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -N1-cyclopropylmethyl-propane-1,3-diamine; 5- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -.-cyclopropyl-amino) -pentanoic acid methyl ester; N- [3- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -propyl] -acetamide; [3- ( { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - (cyclopropylmethyl-amino) -propyl] -amide of morpholin-4-carboxylic acid; N- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -propyl] -methanesulfonamide; 5- ( { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -pentanoic acid; 1- [3- ( { 2- [4- (benzothiazol-2-yloxy) -fenii] -ethyl.}. -isopropyl-amino) -propyl] -pyrrolidin-2-one; 1- [3- ( { 2- [4- (benzothiazoI-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -propyl] -pyrrolidin-2-one; 1- [3- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl] -pyrrolidin-2-one; 1 - [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - propyl-amino) -propyl] -pyrrolidin-2-one; 4 - ((1-Acetyl-piperidin-4-yl) -. {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -amino) -butyric acid ethyl ester; Acid ethyl ester 4 - ((1-acetyl-piperidin-4-yl) - { 2- [4- (benzothiazol-2-yloxy) -pheny] - ethyl} -amino) -butyric; 4- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -metanesulfonyl-amino) -butyric acid; 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etill-cyclopropyl-amino) -acetic acid; 6- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino) -hexanoic acid ethyl ester; 7- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino) -heptanoic acid ethyl ester; 6- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etyl} -cyclopropyl-amino) -hexanoic acid; 7- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amine) -heptanoic acid; N-1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -N1-cyclopropyl-propane-1,3-diamine; N- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl] -acetamide; N- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl] -isobutyramide; N- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl] -benzamide; N- [3- ( { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl] -4-chloro-benzamide; N- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl-methanesulfonamide; [3- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl] -3-cyclopropyl-amino) -propyl] -amide trifluoromethanesulfonic acid of propan-2-sulfonic acid; 8- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylamino) -octanoic acid ethyl ester; 1- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl] -3-phenyl-urea; 8- ( { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino-octanoic acid; [3- ( { 2- [4- (benzothiazole-2 tetrahydro-furan-2-carboxylic acid amide; N- [3- (. {2- [4- (benzothiazole-2-yl) -amino-phenyl] -ethyl.} -. cyclopropyl-amino) -propyl] -amide; iloxy) -phenyl] -ethyl.} - cyclopropyl-amino) -propyl] -2-hydroxy-acetamide, 4- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl]} -cyclopropyl-amino) -butyric acid 2- [4- (2-morpholin-4-yl-ethoxy) -phenoxy] -benzothiazole; and. {2- 2- [4- (2-piperidin-1-yl- ethoxy) -phenoxy] -benzothiazole. 100.- The use claimed in claim 91, wherein at least one LTA4H modulator is one of: 1-. { 2- [4- (1H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -4-phenol-piperidin-4-ol; . { 2- [4- (1H-benzimidazol-2-yloxy) -phenyl] -etiij-cyclopropylmethyl-propyl-amine; cyclohexyl-ethyl-. { 2- [4- (1-methyl-1 H-benzimidazol-2-yloxy) -phenyl] -ethyl} -amine; 1 -. { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -4- (4-bromo-phenyl) -piperidin-4-ol; 1 -. { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -4- (4-chloro-phenyl) -piperidin-4-ol; 1 -. { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -4-benzyl-piperidin-4-ol; . { 2- [4- (1H-benzimidazol-2-yloxy) -phenyl] -etiI} -cyclohexyl-ethyl-amine; 2- [4- (2-pyrrolidin-1-yl-ethyl) -phenoxy] -1 H -benzimidazole; 2- [4- (2-azepan-1-yl-ethyl) -phenoxy] -1 H -benzimidazole; . { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -dibutyl-amine; 1 -. { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-ol; methyl ester of acid 1-. { 2- [4- (1H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carboxylic acid; . { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -cyclohexyl-ethyl-amine; 2-. { 4- [2- (4-methyl-piperidin-1-yl) -ethoxy] -phenoxy} -1 H-benzimidazole; 2-. { 4- [2- (2-ethyl-piperidin-1-yl) -ethoxy] -phenoxy} -1 H-benzimidazole; 2- [4- (2-piperidin-1-yl-ethoxy) -phenoxy] -1 H -benzimidazole; 1 -. { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-ol; 2- [4- (2-azepan-1-yl-ethoxy) -phenoxy] -1 H -benzimidazole-amide; . { 3- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -propyl} dimethyl amine; 2- [4- (2-pyrrolidin-1-yl-ethoxy) -phenoxy] -1 H -benzimidazole; . { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -diethyl-amine; 2- [4- (2-morpholin-4-yl-ethoxy) -phenoxy] -1 H -benzimidazole; 2- [4- (2-piperidin-1-ethyl-ethyl) -phenoxy] -1H-benzimidazole; 1 - (1 ~ { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -pyrrolidin-2-one; (1- { 2- [4- (1H-benzimidazol-2-yloxy) - phenoxy] -ethyl} -piperidin-4-yl) -methanol; and ethyl ester of acid 1-. { 2- [4- (1H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carboxylic acid. 110. - The use claimed in claim 91, wherein at least one LTA4H modulator is selected from compounds of the Formula (II): (II) or an enantiomer, diastereomer, racemate, tautomer, hydrate, solvate or a pharmaceutically acceptable salt, ester or amide thereof, wherein R 4, R6, X, Y, Z, and W are defined as in the compound of the formula (I), R2 'is defined as R2 in the compound of the formula (I), and R3 is defined as R3 in the compound of the formula (I), provided that (a) at least one of said R2 'and R3 is not ethyl when a selection in the group consisting of selections (s1), (s2), (s3), and (s4), is satisfied, and each of these selections is specify as (s1): R4 is H, Z is O, W is CH2, Y is CH2 > and X is S; (s2): R4 is H, Z is O, W is CH2, Y is CH2 and X is NH; (s3): R4 is H, Z is O, W is CH2, Y is O, and X is S; (s4): R4 is 5-chloro, Z is O, W is CH2, Y is CH2, and X is S; (b) further provided that when Z is a bond, Y is CH2, W is CHR1-CH2, R1 is H, and one of R2 and R3 is 1H-imidazol-2-yl, then the other of R2 'and R3 is selected from A1), B) -L), wherein B) -L) is as defined above for the compound of the formula (I), and A1) consists of H, C3-7 alkenyl, wherein the carbon in said C3- alkenyl which is attached to the nitrogen member has only single bonds, C3.7 alkynyl, wherein the carbon in said alkynyl which is attached to the nitrogen member has only individual bonds, C3-7 cycloalkyl optionally benzofused, C5-7 cycloalkenyl. -C3.7-cycloalkyl-C1- alkyl-, C7-7-cycloalkyl-C3.7 alkyl; and (c) further provided that when X is S, Y is O, Z is a bond and W is CH2, then one of R2 and R3 is not XCG when the other is C6-alkyl, then XCG is the group HC16 wherein HC16 is one of H, C1-6 alkyl, halogen-Cl-6 alkyl, allyl, and C1.6 alkoxymethyl, and GO is a group attached to a carbon member having a substituent = O that forms an amido group (> NC (O) -) with the nitrogen member to which said GO group is attached. 111. The use claimed in claim 110, wherein said R4 is H. 112. The use claimed in claim 110, wherein said R2 and R3 are each independently selected from the group consisting of A ), B), C), D), E) and I), as defined in claim 110. 113. - The use claimed in claim 110, wherein said R2 and R3 are each independently selected from group A), as defined in claim 110. 114. The use claimed in claim 110, wherein said R2 and R3 are each independently selected from group B), as defined in claim 110. 115. The use claimed in claim 110, wherein said R2 and R3 are each independently selected from group C) , as defined in claim 110. 116.- The use claimed in claim 110, wherein said R2 and R3 are each independently selected from the group D), as defined in claim 110. 117.- The use claimed in claim 110, wherein said R2 and R3 are each independently selected from the group E), as defined in claim 110. 118. The use claimed in claim 110, wherein said R2 and R3 are each independently selected Figure imgb0003 of the group I), as defined in claim 110. 119. The use claimed in claim 110, wherein said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing At least one heteroatom member which is the binding nitrogen, said heterocyclic ring is selected from the group consisting of i) and ii), as defined in Claim 110. 120.- The use claimed in claim 110, wherein said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is nitrogen of binding, said heterocyclic ring is selected from group i), as defined in claim 110. 121. The use claimed in claim 110, wherein said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is the binding nitrogen, said heterocyclic ring being selected from group ii), as defined in claim 110. 122. The use claimed in claim 110, wherein the condition mediated by LTA4H is inflammation due to at least one of asthma, chronic obstructive pulmonary disease, atherosclerosis, rheumatoid arthritis, multiple sclerosis, Inflammatory bowel diseases and psoriasis. 123.- The use claimed in claim 91, wherein at least one LTA4H modulator is selected from compounds of the formula (III): (lll) or an enantiomer, diastereomer, racemate, tautomer, hydrate, solvate or a pharmaceutically acceptable salt, ester or amide thereof, wherein R4, R6, X, Y, Z, and W are defined as in the compound of the formula (I ), R2 is defined as R2 in the compound of the formula (I), and R3"is defined as R3 in the compound of the formula (I), provided that (a) said R2 and R3 also satisfies one of the following: (e1): at least one of R2 and R3 is not C1.5 alkyl, when Z is O and X is S; (e2): none of R2"and R3" is C? -4C (O) alkyl Rx, where Rx is one of C1-4 alkyl, OH, -Oalkyl of d-4, -Oalkyl of Co-4RAr, or -NRYRY, when Y is O, Z is a bond, and R2 'is different from R3"; and (e3): none of R2 'and R3"is -alkyl of C? -6CN, when Y is O, Z is a bond and R2" is different from R3", and (b) in addition whenever X is S , Y is O, Z is a bond, VW is CH2, then one of R2 'and R3"is not XCG when the other is C1.6 alkyl, where XCG is the group HCl 6 wherein HC16 is one of H, C? -6 alkyl, halo-Ci-b alkyl, allyl and C? -6 alkoxymethyl, and GO is a group bonded by a carbon member having a substituent a = O which forms an amido group with the nitrogen member to which said GO group is attached. 124. The use claimed in claim 123, wherein said R4 is H. 125. The use claimed in claim 123, wherein said R2 and R3 are each independently selected from the group consisting of A ), B), C), D), E) and I), as defined in claim 123. 126.- The use claimed in claim 123, wherein said R2 and R3 are each independently selected from the group A), as defined in claim 123. 127. The use claimed in claim 123, wherein said R2 and R3 are each independently selected from group B), as defined in claim 123. 128.- The use claimed in claim 123, wherein said R2 and R3 are each independently selected from group C), as defined in claim 123. 129.- The use claimed in claim 123, wherein said R2 and R3 are each independently selected from group D), as defined in the claim 123. 130. The use claimed in claim 123, wherein said R2 and R3 are each independently selected from group E), as defined in claim 123. 131. The use claimed in claim 123, wherein said R2 and R3 are each independently selected from group I) , as defined in claim 123. 132. The use claimed in claim 123, wherein said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one member of heteroatom which is the binding nitrogen, said heterocyclic ring is selected from the group consisting of i) and ii), as defined in claim 123. 133.- The use claimed in claim 123, wherein said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is the binding nitrogen, said heterocyclic ring being selected from group i), as defined in claim 123. 134. The use claimed in claim 123, wherein said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is the Binding nitrogen, said heterocyclic ring is selected from group ii), as defined in claim 123. 135. The use claimed in claim 123, wherein the condition mediated by LTA4H is inflammation due to at least one from asthma, chronic obstructive pulmonary disease, atherosclerosis, rheumatoid arthritis, multiple sclerosis, inflammatory bowel diseases and psoriasis. 136. - A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of the formula (I): (i) wherein X is selected from the group consisting of NR5, O, and S, where R5 is one of H and CH3; And it is selected from the group consisting of CH2, and O; Z is selected from the group consisting of O and bond; W is selected from the group consisting of CH2 and CHR1-CH2, R1 being one of H and OH, wherein the carbon member attached to R1 at said CHR1-CH2 is not directly attached to the nitrogen member to which W is attached; R4 is selected from the group which consists of H, OCH 3, Cl, F, Br, I, OH, NH 2, CN, CF 3 and CH 3; R6 is H or F; Y R2 and R3 are each independently selected from the group consisting of A) H, C? -7 alkyl, C3- alkenyl, wherein the carbon in said alkenyl which is attached to the nitrogen member has only bonds individual, C3-7 alkynyl, wherein the carbon in said alkynyl which is attached to the nitrogen member has only single bonds, optionally benzofused C3-7 cycloalkyl, Cs- cycloalkenyl. C3-7 cycloalkyl C7 alkyl, C7.7 cycloalkyl C3.7 alkyl and phenyl, wherein each of the substituents A is independently substituted with 0, 1 or 2 RQ, and each of R1Q is a substituent on a carbon member which is at least one carbon member removed from the nitrogen member; B) a HetRa substituent; C) -alkyl of C? -7C (O) Rx, optionally substituted with CH2RAr or CH2RAr '; D) -alkyl of C2-5C (O) Rx, wherein two valence carbon members allowed in the C5 alkyl of said -C2-5C (O) Rx alkyl are part of a C3-6 carbocycle saturated; E) -C2-5OH alkyl wherein two valence carbon members allowed in the C2-5 alkyl of said -C2-5 alkyl? H are part of a saturated C3-6 carbocycle; F) -C0-4 alkylphenyl, wherein the phenyl is said to be -C0-4 alkylphenyl is fused to two adjacent carbon members in said phenyl to Rf, or is benzofused; G) -C0-4Ar6 alkyl, wherein Ar6 is a 6-membered heteroaryl having a carbon member attachment point and having one or two heteroatom members -N =, and benzofused; H) -C0-4Ar5 alkyl, wherein Ar5 is a 5-membered heteroaryl, having a heteroatom member selected from the group consisting of O, S, and > NRY, and having 0 or 1 additional heteroatom member -N =, optionally containing two carbonyl groups, and optionally benzofused; I) -alkyl wherein Ar5 is a 5-membered heteroaryl containing 3 or 4 nitrogen members, optionally substituted with R ?, and having a valence site allowed as a point of attachment; J) -alkyl of C0-4Ar6"6, wherein Ar6" 6 is a phenyl bonded to C0-4 alkyl fused at sites of valency allowed to a 6-membered heteroaryl, wherein said 6-membered heteroaryl has one or two heteroatom members -N =; K) -C0-4Ar6 alkyl "5, wherein Ar6" 5 is a phenyl bonded to C0-4 alkyl fused at sites of valency allowed to a 5-membered heteroaryl, said 5-membered heteroaryl having a heteroatom member selected of the group consisting of O, S, and > NRY, and said 5-membered heteroaryl having 0 or 1 additional heteroatom member which is -N =; and L) one of 2- (4-ethyl-phenoxy) -benzothiazole, 2- (4-ethyl-phenoxy) -benzoxazole, and 2- (4-ethyl-phenoxy) -1 H-benzimidazole; M) S? 2-C? - alkyl; alternatively R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is the linking nitrogen, said heterocyclic ring being selected from the group consisting of i) a heterocyclic ring of 4-7 HetRb members, said 4-7 membered heterocyclic ring HetRb having a heteroatom member which is the linking nitrogen, and being substituted with 0, 1, or 2 substituents on the same or on different substitution members, said substituent being selected from the group consisting of -R ?, -CN, -C (0) R ?, -alkyl of C0-4CO2RY, -alkyl of Co- C (O) C02RY, -alkyl of C0- ORY, -alkyl of Co- C (O) NRYRZ, -alkyl of Co-4NRYC (O) RZ -C (O) NRzOR ?, -alkyl of Co. NR? C (O) CH2OR?, - -alkyl of CO-4NR? C (O) CH2C (O) R ?, -C0-4NRYCO2RY alkyl, -C0 alkyl- 4NR? C (O) NR? Rz, -alkyl of C0- NRYC (S) NRYRZ, - -NR? C (O) C02R ?, -NRYRZ, -alkyl of C0-4NRwSO2R ?, 1,3-dihydro-indole -2-one-1-yl, 1,3-dihydro-benzimidazol-2-one-1-yl, tetrazol-5-yl, 1-R? -1 H-tetrazol-5-yl, R? -triazolyl, 2 -R? -2H-tetrazol-5-yl, pyrrolidin-2-thion-1-yl, piperidin-2-thion-1-yl, -OC-4C (0) N (R?) Alkyl (S02R?) , -alkyl of C0-4N (RY) (SO2) NRYRY, -alkyl of C0-4N (R?) (SO2) NR? CO2R ?, halogen, ii) a 5-7 membered heterocyclic ring HetRc, said heterocyclic ring of 5-7 HetRc having an additional heteroatom member separated from the binding nitrogen by at least one carbon members, said additional heteroatom member being selected from the group consists of O, S (= O) 0-2, and > NRM, said 5-7 membered heterocyclic ring HetRc having 0 or 1 carbonyl member, and being substituted with 0, 1, or 2 substituents on the same or on different carbon substitution means, said substituents being selected from the group consisting of -C (O) R ?, -CO2R? - C3-CO2R alkyl? and Rz; iii) one of imidazolidin-1-yl, 2-imidazolin-1-yl, pyrazol-1-yl, imidazol-1-yl, 2H-tetrazol-2-yl, 1H-tetrazol-1-yl, pyrrole-1- ilo, 2-pyrrolin-1-yl, and 3-pyrrolin-1-yl, wherein each of said 2H-tetrazol-2-yl and 1 H-tetrazol-1-yl is substituted on the carbon member with 0 or 1-C0-4Rz alkyl, -C0-4SRY alkyl, -C0-4CO2RY alkyl, and HetRa substituent; and iv) one of 1, 2,3,4-tetrahydro-quinolin-1-yl, 1, 2,3,4-tetrahydro-isoquinolin-2-yl, ndol-1-yl, isoindol-2-yl, indolin-1-yl, benzimidazol-1-yl, 2,8-diaza-spiro [4.5] decan-1-one-8-yl, 4-. { [(2-tert-butoxycarbonylamino-cyclobutylenecarbonyl) -amino] -methyl} -piperidin-1-yl, 4-. { [(2-amino-cyclobutanecarbonyl) -amino] -methyl} -piperidin-1-yl, 3,9-diaza-spiro [5.5] undecan-3-carboxylic acid 9-yl-tert-butyl ester, 4-oxo-1-phenyl-1,3,8-triaza-spiro [4.5] dec-8-yl, and 4-oxo-1, 3,8-triaza-spiro [4.5] dec-8-yl; wherein the HetRa substituent is a 4-7 membered heterocyclic ring having a carbon member attachment point and containing a > NRM as a heteroatom member, and said heteroatom member being separated from the carbon member attachment point by at least one additional carbon member; R? is selected from the group consisting of H, -alkyl of d-4, -alkyl of Co-4RAr > each optionally substituted with 1, 2, or 3 RN substituent; RL is selected from the group consisting of -CO2Rs and -C (O) NRsRs; RM is selected from the group consisting of Rz, indol-7-yl, -SO2R ?, -alkyl of C3-C02R ?, -CO2R ?, -C (O) NRzOR ?, -C (O) R ?, -C (O) C? -4OR? Alkyl, -C0-4C (O) NRSRS 'alkyl, C0-4C (O) CO2RY, 1,3-dihydro-indol-2-one-1-yl alkyl, , 3-dihydro-benzimidazol-2-one-1-yl, tetrazol-5-yl, 1-R? -1 H-tetrazol-5-yl, R? -triazolyl, 2-R? -2H-tetrazole-5 -yl and -alkyl of C0-4C (O) N (RY) (SO2RY), each optionally substituted with 1, 2 or 3 RN substituents; RN is selected from the group consisting of OCH3, Cl, F, Br, I, OH, NH2, CN, CF3, CH3, OC (O) CH3, and O2; Rp is selected from the group consisting of R ?, -alkyl of C2-4OR ?, RAr, -alkyl of C1.2CO2R ?, -alkyl of C? -2CONRsRs', indole-7-yl, and -S02alkyl of C1- 4; RQ is selected from the group consisting of fluoro, chloro, bromo, iodo, trifluoromethyl, trichloromethyl, -CN, -C1-4alkyl, -Cal-4RaR alkyl, -C0-4Rr alkyl, -C0-4alkyl R ?, -C0-4CO2RY alkyl, -Calkyl - NR? Rz, -C0-4NRYCORY alkyl, -C0-4NRYCONRYRZ alkyl, -C0-4NR alkyl? SO2R ?, and -C0-SRY alkyl; Rs and Rs' are independently selected from the group consisting of H, -alkyl of C-, and -alkylphenyl of C0.4; alternatively, Rs and Rs are taken together with the nitrogen member to which said Rs and Rs are bonded to form a 4- to 7-membered heterocyclic ring having 0 or 1 additional heteroatom member selected from the group consisting of O, S, and > NRY, provided that said additional member and heteroatom is separated by at least two carbon members of said nitrogen member to which Rs and Rs are attached, and provided that where R? is Co-4RAr alkyl, then RAr is not substituted with RL; Rw is selected from the group consisting of R ?, and -3-cycloalicylate; Rx is selected from the group consisting of -OR ?, -NRYRZ, -alkyl of C1.4, and -alkyl of Co-4RAr; R? is selected from the group consisting of H, -C1.4 alkyl, -C04RAr alkyl and -C0-4RAr alkyl, and optionally substituted with 1, 2, or 3 RN substituents; Rz is selected from the group consisting of R ?, -alkyl of C2-4? R ?, -alkyl of C? 2CO2R ?, -alkyl of C? .2C (0) NRsRs', and -alkyl of C2-4NRSRS '; when R? and Rz join a nitrogen member, R? and Rz are selected as defined above or R? and Rz are taken together with the nitrogen member attached to R? - and Rz- to form a 4-7 membered heterocyclic ring HetRd having 0 or 1 additional heteroatom member selected from the group consisting of O, S, and > NRM, said 4-7 membered heterocyclic ring HetRd having 0 or 1 carbonyl member, and said 4-7 membered heterocyclic ring HetRd having 0 or 1 allowed valence carbon members subsituted with at least one of RM, -CO2H, and -alkyl of C0-? OR ?; RAr is a portion with a carbon member attachment point and said portion is selected from the group consisting of phenyl, pyridyl, pyrimidyl, and pyrazinyl, wherein each valence carbon member allowed in each of said portions is independently substituted with at least one of 0, 1, 2 or 3 RN, and 0 or 1 RL; RAr 'is a ring of 3 to 8 members, having 0, 1 or 2 heteroatom members selected from the group consisting of O, S, N, and > NRY, which has 0, 1, or 2 unsaturated bonds, having 0 or 1 carbonyl member, wherein each valence member allowed in each of the rings is independently substituted with 0, 1, or 2 R ?; and Rf is a linear 3 to 5 membered hydrocarbon portion having 0 or 1 unsaturated carbon-carbon bond having 0 or 1 carbonyl member; or an enantiomer, diastereomer, racemate, tautomer, hydrate, solvate or a pharmaceutically acceptable salt, ester or amide thereof. 137.- The pharmaceutical composition according to claim 136, further characterized in that at least one compound (i) is at least one compound of the formula (II): (10 or an enantiomer, diastereomer, racemate, tautomer, hydrate, solvate or a pharmaceutically acceptable salt, ester or amide thereof, wherein R 4, R6, X, Y, Z, and W are defined as in the compound of the formula (I), R2 'is defined as R2 in the compound of the formula (I), and R3 is defined as R3 in the compound of the formula (I), provided that (a) at least one of said R2 'and R3 is not ethyl when a in the group consisting of selections (s1), (s2), (s3), and (s4), it is satisfied, and each of these selections is specified as (s1): R4 is H, Z is O, W is CH2, Y is CH2, and X is S; (s2): R4 is H, Z is O, W is CH2, Y is CH2 and X is NH; (s3): R4 is H, Z is O, W is CH2, Y is O, and X is S; (s4): R4 is 5-chloro, Z is O, W is CH2, Y is CH2, and X is S; (b) further provided that when Z is a bond, Y is CH2, W is CHR1-CH2, R1 is H, and one of R2 and R3 is 1H-imidazol-2-yl, then the other of R2 'and R3' is selected from A1), B) -L), wherein B) -L) is as defined above for it composed of the formula (I), and A1) consists of H, C3-7 alkenyl, wherein the carbon in said C3.7 alkenyl which is attached to the member of nitrogen has only single bonds, C3-7 alkynyl, where the carbon in said alkynyl which is attached to the nitrogen member only individual linkages, optionally benzofused C 3 cycloalkyl, C 5-7 cycloalkenyl, C 3-7 cycloalkyl C 1-7 alkyl, C 3-7 cycloalkyl C 3-7 alkyl; and (c) further provided that when X is S, Y is O, Z is a bond and W is CH2, then one of R2 and R3 is not XCG when the other is C1-6 alkyl, then XCG is the group HC16 wherein HC16 is one of H, C? -6 alkyl, halo? -C6 alkyl, allyl, and C? -6 alkoxymethyl, and GO is a group attached to a carbon member having a substituent = O which forms an amido group with the nitrogen member to which said GO group is attached. 138.- The pharmaceutical composition according to claim 136, further characterized in that said R4 is H. 139. The pharmaceutical composition according to claim 136, further characterized in that said R2 and R3 are each independently selected from the group consisting of of A), B), C), D), E) and I), as defined in claim 136. The pharmaceutical composition according to claim 136, further characterized in that said R2 and R3 are selected each one independently of group A), as defined in claim 136. 141. - The pharmaceutical composition according to claim 136, further characterized in that said R2 and R3 are each independently selected from group B), as defined in claim 136. 142. The pharmaceutical composition according to claim 136, further characterized in that said R2 and R3 are each selected independently of group C), as defined in claim 136. 143. The pharmaceutical composition according to claim 136, further characterized in that said R2 and R3 are each independently selected from group D), as defined in claim 136. The pharmaceutical composition according to claim 136, further characterized in that said R2 and R3 are each independently selected from the group E), as defined in claim 136. 145. The pharmaceutical composition according to claim 136, further characterized in that said R2 and R3 are each independently selected from group I), as 146. The pharmaceutical composition according to claim 136, further characterized in that said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring. containing at least one heteroatom member which is the binding nitrogen, said heterocyclic ring is selected from the group consisting of i) and ii), as defined in claim 136. 147.- The pharmaceutical composition according to claim 136, further characterized in that said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is the binding nitrogen, said heterocyclic ring being selected from group i) , as defined in claim 136. 148.- The pharmaceutical composition according to claim 136, further characterized in that said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is the binding nitrogen, said heterocyclic ring is selected from group ii), as defined in claim 1 36. 149. The pharmaceutical composition according to claim 136, further characterized in that at least one compound of the formula (II) is one of: 2- [4- (2-pyridin-1-yl-ethoxy ) -phenoxy] -benzoxazole; (1- {2- [4- (benzooxanzol-2-yloxy) -phenoxy] ethyl} -piperidin-4-yl) -methanol; 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-ol; . { 2- [4- (benzoxazoI-2-yloxy) -phenoxy] -ethyl} -dibutyl-amine; (1- {2- [4- (benzoxazol-2-yloxy) -phenoxy] -ethyl} -piperidin-2-yl) -methanol; 1 -. { 3- [4- (benzoxazol-2-yloxy) -phenoxy] -propyl} -4-pheny1-p1peridin-4-ol; 1 -. { 3- [4- (benzoxazol-2-yloxy) -phenoxy] -propyl} -4-benzyl-piperidin-4-or, 2- [4- (2- piperidin-1-yl-ethyl) -phenoxy] -benzoxazole; . { 3- [4- (benzoxazol-2-yloxy) -phenyl] -propyl} -cyclohexyl-ethyl-amine; 1 -3- [4- (Benzoxazol-2-yloxy) -phenyl] -propyl} -piperidin-4-ol; 1 -. { 3- [4- (benzoxazol-2-yloxy) -phenoxy] -2-hydroxy-propyl} -4-phenyl-piperidin-4-ol; 1- [2- (4-Benzoxazol-2-methylmethyl-phenoxy) -ethyl] -piperidine-4-carboxylic acid ethyl ester; 2- [4- (2-pyrrolidin-1-yl-ethoxy) -phenoxy] -benzoxazole; . { 3- [4- (benzoxazol-2-yloxy) -phenoxy] -propyl} dimethyl amine; . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} dimethyl amine; and 2- [4- (2-azepan-1-yl-ethoxy) -phenoxy] -benzoxazole. 150.- The pharmaceutical composition according to claim 136, further characterized in that at least one compound of the formula (II) is one of: 1-. { 2- [4- (benzoxazol-2-yloxy) -phenoxyl-ethyl} -4-phenyl-piperidin-4-ol; . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -cyclohexyl-ethyl-amine; 2 { 4- [2- (2-ethyl-piperidin-1-yl) -ethoxy] -phenoxy} -benzoxazole; 1 -. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4-phenyl-piperidine-4-carbonyl ether; 1 - (1 -. {2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4-pheni) -piperidin-4-yl) -ethanone; 2-. { 4- [2- (4-Methyl-p -peridin-1-yl) -ethoxy] -phenoxy-benzoxazole; 1 -. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4- (4-chloro-phenyl) -piperidin-4-ol; 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4- (4-bromo-phenyl) -piperidin-4-ol; 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4- (4-chloro-3-trifluoromethyl-phenyl) -piperidn-4-ol; 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4-benzyi-piperidin-4-ol; . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -cyclohexyl-methyl-amine; Y . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -cyclopropylmethyl-propyl-amine. 151. The pharmaceutical composition according to claim 136, further characterized in that at least one compound of the formula (II) is one of:. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -efil} -butil-ethyl- amine; 2- (. {2- 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -benzyl-amino} -ethanol; 2-. { 4- [2- (4-Benzyl-piperidin-1-yl) -ethoxy] -phenoxy} -benzoxazole; (1 -. {2- 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -etyl} -piperidin-3-yl) -methanol; 2- (. {2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -propyl-amino) -ethanol; 2- [4- (2-Azetidin-1-yl-ethoxy) -phenoxy] -benzoxazole; ? / - (1 - { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -etyl] -piperidin-4-yl) -2-phenyl-acetamide; 1- ethyl ester. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -piperidine-3-carboxylic acid; 2-. { 4- [3- (4-Phenyl-piperidin-1-yl) -propoxy] -phenoxy} -benzoxazole; 1 -. { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -4-phenyl-piperidin-4-ol; . { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -cyclohexyl-ethyl-amine; 2- [4- (2-Pyrrolidin-1-yl-ethyl) -phenoxy] -benzoxazole; and 2- [4- (2-Azepan-1-ethyl-ethyl) -phenoxy] -benzoxazole. 152.- The pharmaceutical composition according to claim 136, further characterized in that at least one compound of the formula (II) is one of:. { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl-propyl-amine; . { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -dibutyl-amine; 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-ol; methyl ester of acid 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -etiI} -piperidin-4-carboxylic acid; 1-. { 3- [4- (Benzoxazol-2-yloxy) -phenyl] -propyl} -4-phenyl-piperidin-4-oi; 2- [4- (3-Piperidin-1-yl-propyl) -phenoxy] -benzoxazole; . { 3- [4- (Benzoxazol-2-yloxy) -phenyl] -propyl} -dibutyl-amine; . { 3- [4- (Benzoxazol-2-yloxy) -phenyl] -propyl} -cyclopropylmethyl-propyl-amine; 1 - [4- (Benzoxazol-2-yloxy) -phenoxy] -3-pyrrolidin-1-yl-propan-2-ol; 1 - [2- (4-Benzoxazol-2-ylmethyl-phenoxy) -ethyl] -4-phenyl-piperidin-4-ol; 1- [2- (4-Benzoxazol-2-ylmethyl-phenoxy) -ethyl] -piperidine-4-carboxylic acid amide; 2- [4- (2-Morpholin-4-yl-ethoxy) -phenoxy] -benzoxazole; Y . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -diethyl-amine. 153. - The pharmaceutical composition according to claim 136, further characterized in that at least one compound of the formula (II) is one of: { 2- [4- (6-chloro-benzothiazol-2-yloxy) -phenoxy] -phenoxy] -etl} -diethyl-amine; 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-ol; 1- ethyl ester. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carboxylic acid; acid 1-. { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carboxylic acid; (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -pyrrolidin-1-yl-methanone; 3 - [(1- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carbonyl) -amino] -propionic acid ethyl ester; acid amide 1 -. { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carboxylic acid; 1- (1- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -pyrrolidin-2-one; 1 '-. { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} - [1, 4 '] bipiperidinyl-2-one; 8-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -2,8-diaza-spiro [4.5] decan-1-one; 2- [4- (3-pyrrolidin-1-yl-propoxy) -phenoxy] -benzothiazole; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclohexyl-ethyl-amine; acid amide 1-. { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-3-carboxylic acid; 1 - (1 -. {2- [4- (benzothiazol-2-yloxy) -phenyl] -etyl] -piperidin-4-yl) -3-methyl-1,3-dihydric acid benzimidazol-2-one; methyl ester of acid 1-. { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidyl-4-carboxylic acid; (1- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) - (4-methyl-p-piperazin-1-yl) - methanone; 1- [2- (4-Benzothiazol-2-ylmethyl-phenoxy) -ethyl] -piperidine-4-carboxylic acid methyl ester; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - cyclopropyl-amino) -propionic acid; . { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} dimethyl amine; 2- [4- (2-pyrrolidin-1-yl-ethoxy) -phenoxy] -benzothiazole; . { 3- [4- (benzothiazol-2-yloxy) -phenoxy] -propyl} dimethyl amine; 2- [4- (2-azepan-1-yl-ethoxy) -phenoxy] - benzothiazole; 2- [4- (2-azepan-1-yl-ethoxy) -phenoxy] -6-methoxy-benzothiazole; 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -4-phenyl-piperdin-4-ol; . { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -cyclohexyl-ethyl-amine; 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -4- (4-chloro-phenyl) -piperidin-4-ol; . { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -dibutyl-amine; 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -4- (4-bromo-phenyl) -piperidin-4-ol; 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -4- (4-chloro-3-trifluoromethyl-phenyl) -piperidin-4-ol; 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -4-benzyl-piperidin-4-ol; 142- [4- (BenzothiazDl-2-yloxyHenoxy] -ethyl.} - [1,4 '] bipiperidine; (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -pperidin-4-yl) -methanol;? / - (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -2-phenyl-acetamido; 2- (4-. {2- 2- [4- (2-morpholin-4-yl-ethyl) -piperazin-1-yl] -ethoxy} -phenoxy) -benzothiazole 2- (4- { 2- [4- (2-morpholin-4-yl-ethyl) -piperazin-1-yl] -ethyl} -phenoxy) -benzothiazole; [4- (Benzothiazoi-2-yloxy) -phenoxy] -propyl.} -4-phenyl-piperidin-4-ol; 1-. {2- [4- (benzothiazol-2-yloxy) -phenyl] - ethyl.} -4-phenyl-piperidin-4-ol; 2- [4- (2-pyrrolidin-1-yl-ethyl) -phenoxy] -benzothiazole; 2- [4- (2-azepane-1-yl -ethyl) -phenoxy] -benzothiazole; {. 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.} - cyclopropylmethyl-propyl-amine; {. 2- [4- (benzothiazole -2-yloxy) -phenyl] -ethyl.} - dibutyl-amine; 2- [4- (2-piperidin-1-yl-etl) -phenoxy] -benzothiazole; - [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl.}. -piperdin-4-ol; 1- {2 - [4- (benzothiazol-2-yloxy) -phenyl] - amide. ethyl.}. -piper idin-4-carboxylic; 1- ethyl ester. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-3-carboxylic acid; 1- ethyl ester. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -4-phene-piperidine-4-carboxylic acid; (1 -. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -acetic acid ethyl ester; 1 - (1 -. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -1,3-dihydro-indol-2-one; 1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] - ethyl} -piperdin-4-yl) -pyrrolidin-2-one; ? - (1- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperidin-4-yl) -2-phenyl-acetamide; 8-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl]] - eti)} -2,8-diaza-spiro [4.5] decan-1-one; 1-. { 2- [4- (benzothiazol-2-yloxy) -phenyl] -etl] -piperidin-3-ol; 1- ethyl ester. { 2- [4- (benzothiazoi-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic; 1'-. { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - [1, 4 '] bipiperidine; 2-. { 4- [2- (4-methyl-piperazin-1-li) -ethyl] -phenoxy} -benzothiazole; 2- (4- { 2- [4- (1-Benzyl-1H-tetrazol-5-yl) -piperidin-1-yl] -ethoxy.} - phenoxy) -benzothiazole; 4- (1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carbonyl) -piperazin-1-carboxylic tert-butyl ester; 1- [2- (4-Benzothiazol-2-ylmethyl-phenoxy) -ethyl] -piperidine-4-carboxylic amide; 1-. { 1- [2- (4-benzothiazol-2-ylmethyl-phenoxy) -ethyl] -piperidin-4-yl} -rolidin-2-one; 1- [4- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carbonyl) -piperazin-1-yl] -etanone; 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic; 1- (1- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -pyrrolidin-2-thione; 2- (4- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperazin-1-yl) -ethanol; 2- (4-. {2- 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl] -piperazin-1-yl) -1-pyrrolidin-1-yl-ethanone; 2- (4- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -etyl] -piperazin-1-yl) -1-morpholin-4-yl-ethanone; 1 -. { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-3-carboxylic; 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-2-carboxylic; (1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-3-yl) -acetic; (1 -. {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -acetic ethyl ester; (1 -. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -carbamic tert-butyl ester; (1 - { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -acetic; (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-3-yl) -methanol; methyl ester (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etyl] -cyclohexyl-amino) -acetic; (4- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - piperazin-1-yl) -acetic acid; 1- (1. {2- [4- (Benzot-azazol-2-yloxy) -phenoxy] -etiI} -pyridin-4-yl) -5-oxo-pyrrolidine ethyl ester -2-carboxylic; 1 - (1 -. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -5-oxo-pyrrolidine-2-carboxylic acid; 4- (4- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperazin-1-yl) -phenol; ? / - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -4-chloro-β-cyclopropyl-benzenesulfonamide; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -cyclopropylmethyl-amino) -propionic acid; 3- ( { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl) -isopropyl-amino) -propionic acid; 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piper¡din-4-ilam¡na; 3- [acid. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - (1-methyl-piperidin-4-yl) -amino] -propionic; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -benzyl-amino) -proponic acid; 3 - ((1-Acetyl-piperidin-4-yl) -. {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -amino) -propionic acid; 4- (1 -. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -1-H-tetrazol-5-yl) -piperidine-1-carboxylic acid tert-butyl ester; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propionic acid; 3 - ((1-Acetyl-piperidin-4-yl) -. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -amino) -propionic acid; 3- [acid. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - (1-methyl-piperidin-4-yl) -amino] -propionic; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -propionic acid; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - isopropyl-amino) -propionic acid; 2- (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) -1-pyrrolidin-1-yl-ethanone; acid (f?) - 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-3-carboxylic acid; 1- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -1,3-dihydro-benzimidazol-2-one; 2- (4- { 2- [4- (6-methyl-pyridin-2-yl) - piperazin-1 -yl] -ethyl} -phenoxy) -benzothiazole; 2-4- [2- (4-Ethanesulfonyl-piperazin-1-yl) -ethyl] -phenoxy} -benzothiazole; 2- (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -1-morpholin-4-yl-ethanone; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -methyl-amino) -propionic acid; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopentyl-amino) -propionic acid; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etiI.} - cyclobutyl-amino) -propionic acid; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -benzyl-amino) -propionic acid; (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) - (4-hydroxymethyl-piperidin-1-yl) -methanone; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amine; (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) - [4- (2-hydroxy-ethyl) -piperazine-1-yl} ] -metanone; (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) - [4- (2-hydroxy-ethyl) -piperidin-1-} il] -metanone; 2- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.} - cyclopropyl-amino) -ethanol; 3- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propan-1-ol; 4- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -butyric acid; 3 - [(1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carbonyl) -amino] -propionic acid; 4- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -butyronitrile; 3- (1- { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -propionic acid; [(1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carbonyl) -methyl-amino] -acetic acid; 3- (4- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperazin-1-yl) -phenol; 2- (4- { 2- [4- (4-methoxy-phenyl) -piperazin-1-yl] -ethoxy.} - phenoxy) -benzothiazole; 2-. { 4- [2- (5-piperidin-4-yl-tetrazol-1-yl) -ethoxy] -phenoxy} -benzothiazole; (S) -1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -4-hydroxy-pyrrolidin-2-one; . { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethylamine; 2 - [(. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} ethyl ester. -cyclopropyl- amino) -methyl] -cyclopropanecarboxylic acid; 4- (4-. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperazin-1-carbonyl) -benzoic acid ethyl ester; 2 - [(. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amyno) -methyl] -cyclopropanecarboxylic acid; 1- (. {2- 2- (4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propan-2-ol; 3- ( { 2- [4- (benzothiazoI-2-yloxy) -phenyl] -ethyl.} - cyclopropyl-amino) -1,1,1-trifluoro-propan-2-yl; 3- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propionamide; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propane-1,2-diol; 2-. { 4- [2- (5-phenyl-tetrazol-2-yl) -ethoxy] -phenoxy} -benzothiazole; 2-. { 4- [2- (5-phenyl-tetrazol-1-yl) -ethoxy] -phenoxy-benzothiazole; / V-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -N-cyclopropyl-2- (2H-tetrazol-5-yl) -acetamide; (S) -3- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -eti}.] - cyclopropyl-amino) -2-methyl-propan-1-ol; (R) -3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -2-methyl-propan-1-ol; 2-. { 4- [2- (5-methylsulfanyl-tetrazol-2-yl) -ethoxy] -phenoxy} -benzothiazole; 2-. { 4- [2- (5-Methylsulfanyl-tetrazol-1-yl) -ethoxy] -phenoxy} -benzothiazole; 2- [4- (2-tetrazol-2-yl-ethoxy) -phenoxy] -benzothiazole; 2- [4- (2-tetrazol-1-yl-ethoxy) -phenoxy] -benzothiazole; acid (1R, 2R) -2-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino-cyclohexanecarboxylic acid; acid (1S, 2R) -2-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino} -cyclohexanecarboxylic; (1R, 2R) -2-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino} -cyclohexanol; (1S, 2R) -2-. { 2- [4- (Benzotlazol-2-yloxy) -phenyl] -ethylamino} -cyclohexanol; 4- (1- { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -butyric acid; (R) 1- (1- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -4-hydroxy-pyrrolidin-2-one; 2- (4- { 2- [4- (1 H-Tetrazol-5-yl) -piperidin-1-yl] -ethyl} -phenoxy) -benzothiazole; (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-2-yl) -methanol; (1- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -ethyl ester. tetrazol-5-yl) -acetic; (1- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -1H-tetrazol-5-yl) -acetic acid ethyl ester; 2- hydrochloride. { 4- [2- (5-piperidin-4-yl-tetrazol-2-yl) -ethoxy] -phenoxy} -benzothiazole; 7- { 2- [4- (benzothiazoI-2-yloxy) -phenoxy] -ethyl} -4-spiro- [3-phthalide] -piperidine; 1- ethyl ester. { 3- [4- (benzothiazol-2-yloxy) -phenyl] -propl} -piperidine-4-carboxylic acid; 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamine hydrochloride; 2- (4- { 2- [4- (1 H-tetrazol-5-yl) -piperidin-1-yl] -ethoxy.} - phenoxy) -benzothiazole; cis-4- trifluoromethanesulfonate salt. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino-cyclohexanecarboxylic acid; (4- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-ii) - (tetrahydro-furan-2-yl) -methanone; Propan-2-sulfonic acid (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carbonyl) -amide; (4- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) -oxo-acetic acid methyl ester; N- (1- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -ethyl} -piperidine-4-carbonyl) -benzenesulfonamide trifluoromethanesulfonate salt; N- (1 -. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carbonyl) -methanesulfonamide trifluoromethanesulfonate salt; (4- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) -oxo-acetic acid trifluoromethanesulfonate salt; (4- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -morpholin-4-yl-methanone; 1 - (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -2-thiophen-2-yl-ethanone; (4- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) -pyridin-3-yl-methanone; (4-. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -cyclopropyl-methanone; 1 - (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -2-methoxy-ethanone; 1 - (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -2,2,2-trifluoro-ethanone; 4- (4- { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazine-1-carbonyl) -benzoic acid; (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) -pyridin-4-yl-methanone; (4- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) - (5-methyl-pyrazin-2-yl) -methanone; (R) - (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) - (tetrahydro-furan-2-yl) ) -metanone; (S) - (4- { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) - (tertrahydro-furan-2-yl) -methanone; (4- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) - (tetrahydro-furan-3-yl) -methanone; 1- (4- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -2-hydroxy-ethanone; 2- [2- (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -etyl] -piperazin-1-yl) -2-oxo-ethyl] -cyclopentanone; 3- (4. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) -propionic acid trifluoromethanesulfonate salt; 3- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -etii.}. -piperidin-4-yl) -oxazolidin-2-one; 4- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -morpholin-3-one; 4- (1- { 2- [4- (benzofiazol-2-yloxy) -phenyl] -ethyl} - piperdin-4-yl) -morpholin-3-one; 3- (1- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl] -piperidin-4-yl) -oxazolidin-2-one; benzyloxy-1-acid amide. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; (1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -acetic acid; (R) -1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -4-hydroxy-pyrrolidin-2-one; hydroxyamide of acid 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etl} -piperidine-4-carboxylic acid; (S) -1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -4-hydroxy-pyrrolidin-2-one; (1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -carbamic acid tert-butyl ester; 2-. { 4- [2- (4-fluoro-piperidin-1-yl) -ethyl] -phenoxy-benzothiazole; 2-. { 4- [2- (4,4-difluoro-p.peridin-1-yl) -ethyl] -phenoxy} -benzotiazoI; (R) -1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -pyrrolidin-3-ol; N-1-. { 2- [4- (benzothiazol-2-yloxy) -phenyl] -etii} -piperidin-4-yl) -formamide; (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] - etl} -piperidin-4-yl) -urea; 1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -fenii] -ethyl.}. -piperidin-4-yl) -3-cyano-2-phenyl-isourea; 1- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -3-cyano-2-methyl-isothiourea; N- (1-. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperidin-4-yl) -methanesulfonamide; 1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -3-cyano-2-methyl-guanidine; 8-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -1-phenyl-1, 3,8-triaza-spiro [4.5] decan-4-one; 8-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -1, 3,8-triaza-spiro [4.5] decane-2,4-dione; (1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -methyl-carbamic acid tert-butyl ester; N- (1-. {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -N-methyl-acetamide; N- (1-. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -etyl] -piperidin-4-yl) -N-methyl-methanesulfonamide; [(1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl] -piperidin-4-yl) -methyl-carbamoyl] -methyl ester of acetic acid; N- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -N-acetamide; ester (1 -. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl-ethyl-ethyl} -piperidin-4-ylcarbamoyl) -methylic acid; 2- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -methyl-amino) -3- (1 H -imidazol-2-yl) -propionic acid; 2- (4- { 2- [4- (3-nitro-pyridin-2-yl) - [1,4] diazepan-1-yl] -ethyl} -phenoxy) -benzothiazole; [(1- {2- [4- (benzothiazol-2-yloxy) -phenox] -ethyl} -piperidine-4-carbonyl) -methyl-amino] -acetic acid ethyl ester; ethyl ester of 1 '- acid. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - [1, 4 '] bipiperidinyl-4-carboxylic acid; 1 'acid. { 2- [4- (benzothiazol-2-yloxy) - [phenoxy] -ethyl} - [1, 4 '] bipiperidinyl-4-carboxylic acid; . { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-ethyl-amine; trifluoromethanesulfonic acid salt of 3- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino) -2-methyl-propionic acid; 2- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -etyl} -. Cyclopropylmethyl-amino) -ethanol; 2- [2- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.} - cyclopropylmethyl-amino) -ethoxy] -ethanol; 3- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -propan-1-ol; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl- (3-tetrazol-2-yl-propyl) -amine; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl- (3-pyrrol-1-yl-propyl) -amine; 4- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -butyronitrile; (2-cyano-ethyl) -amide of 1- acid. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; . { 2- [4- (benzothiazol-2-loxi) -phenyl] -ethyl} -cyclopropylmethyl- [3- (2H-tetrazol-5-yl) -propyl] -amine; 3- [5- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -etyl] -piperidin-4-yl) -tetrazol-1-yl] -propionitrile; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl- [3- (2H-tetrazol-5-yl) -propyl] -amina; 1- (1-hydroxy-1, 1-dimethyl-ethyl) -amide. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl- [3- (1 H- [1, 2,4] triazol-3-yl) -propyl] -amine; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl- [3- (5-methyl-1 H- [1, 2,4] triazol-3-yl) -propyl] -amine; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl- [3- (5-phenyl-1 H- [1, 2,4] triazol-3-yl) -propyl] -amine; 2- (4- { 2- [4- (1-methyl-1 H-tetrazol-5-yl) -piperidin-1-yl] -ethyl} -phenoxy) -benzothiazole; 2- (4- { 2- [4- (2-methyl-2H-tertrazol-5-yl) -piperidin-1-yl] -ethyl} -phenoxy) -benzothiazole; 1 -. { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -peridin-4-carbonitrile; 2- (4- { 2- [4- (1 H- [1 ^ .SltriazoM-ilJ-piperidin-l-ylj-ethylHenox-benzothiazole, ethyl ester of 4-. {2- 2- 4- ( benzothiazol-2-yloxy) -phenyl] -ethylamino} -butyric acid 4- (. {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl ethyl ester -amino) -butyric; 2- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -propyl] -isoindole-1, 3- dione; 4- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -butyric acid; 1- (3- {2- 2- 4- (benzothiazol-2-yloxy) -phenyl] -ethylamino.} - propyl) -pyrrolidin-2-one; N-1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -N1-cyclopropylmethyl-propane-1,3-diamine; 5- (. {2- 2- [4- (Benzothiazol-2-yloxy) -fenii] -ethyl} -cyclopropyl-amino) -pentanoic acid methyl ester; N- [3- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -propyl] -acetamide; [3- ( { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - (cyclopropylmethyl-amino) -propyl] -amide of morpholin-4-carboxylic acid; N- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl-amino) -propyl] -methanesulfonamide; 5- ( { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -pentanoic acid; 1- [3- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - isopropyl-amino) -propyl] -pyrrolidin-2-one; 1- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -propyl] -pyrrolidin-2-one; 1- [3- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino) -propl] -pyrrolidin-2-one; 1- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -propyl-amino) -propyl] -pyrrolidin-2-one; 4 - ((1-Acetyl-piperidin-4-yl) -. {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -amino) -butyric acid ethyl ester; ethyl acyl ester 4 - ((1-acetyl-piperidin-4-yl) -. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -amino) -butyric acid; 4- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -metanesulfonyl-amino) -butyric acid; 2- [4- (benzothiazol-2-yloxy) -phenyl] -etill-cyclopropyl-amine) -acetic acid; 6- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino) -hexanoic acid ethyl ester; 7- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino) -heptanoic acid ethyl ester; 6- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -hexanoic acid; 7- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -heptanoic acid; N-1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -N 1 -cyclopropyl propane-1,3-diamine; N- [3- (. {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino) -propyl] -acetamide; N- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino) -propyl] -sobutyramide; N- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl] -benzamide; N- [3- ( { 2- [4- (benzothiazoi-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl] -4-chloro-benzamide; N- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl] -methanesulfonamide; [3- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl] -3-cyclopropyl-amino) -propyl] -amide trifluoromethanesulfonic acid of propan-2-sulfonic acid; 8- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -octanoic acid ethyl ester; 1- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl] -3-phenyl-urea; 8- ( { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino-octanoic acid; [3- ( { 2- [4- (benzothiazole-2 tetrahydro-furan-2-carboxylic acid amide; N- [3- (. {2- [4- (benzothiazole-2-yl) -3-cyclopropyl-amino) -propyl] -amide; iloxy) -phenyl] -ethyl.} - cyclopropyl-amino) -propyl] -2-hydroxy-acetamide, 4- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl]} -cyclopropyl-amino) -butyric acid 2- [4- (2-morpholin-4-yl-ethoxy) -phenoxy] -benzothiazole; and. {2- 2- [4- (2-piperidin-1-yl- ethoxy) -phenoxy] -benzothiazole 154. The pharmaceutical composition according to claim 136, further characterized in that at least one compound of the formula (II) is one of: 1-. {2- [4- ( 1H-benzimidazol-2-yloxy) -phenoxy] -ethyl.} -4-phenyl-piperidin-4-ol;. {2- [4- (1H-benzimidazol-2-yloxy) -phenyl] - ethyl.} - cyclopropylmethyl propyl amine; cyclohexyl-ethyl- {2- [4- (1-methyl-1 H-benzimidazol-2-yloxy) -phenyl] -ethyl} -amine; { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl.} -4- (4-bro mo-phenyl) -piperidin-4-ol; 1 -. { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -4- (4-chloro-phenyI) -piperidin-4-ol; 1 -. { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -4-benzyl-piperidin- 4-ol; . { 2- [4- (1 H-benzimidazol-2-yloxy) -phenyl] -ethyl} -cyclohexyl-ethyl-amine; 2- [4- (2-pyrrolidin-1-yl-ethyl) -phenoxy] -1 H -benzimidazole; 2- [4- (2-azepan-1-yl-etii) -phenoxy] -1 H -benzimidazole; . { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -dibutyl-amine; 1 -. { 2- [4- (1H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-ol; methyl ester of acid 1-. { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carboxylic acid; . { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -etiI} -cyclohexyl-ethyl-amine; 2-. { 4- [2- (4-methyl-piperidin-1-yl) -ethoxy] -phenoxy} -1 H-benzimidazole; 2-. { 4- [2- (2-ethyl-piperidin-1-yl) -ethoxy] -phenoxy} -1 H-benzimidazole; 2- [4- (2-piperidin-1-yl-ethoxy) -phenoxy] -1 H -benzimidazole; 1 -. { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-ol; 2- [4- (2-azepan-1-yl-ethoxy) -phenoxy] -1H-benzimidazole-amide; . { 3- [4- (1H-benzimidazol-2-yloxy) -phenoxy] -propyl} dimethyl amine; 2- [4- (2-pyrrolidin-1-yl-ethoxy) -phenoxy] -1 H-benzimidazole; . { 2- [4- (1H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -diethyl-amine; 2- [4- (2-morpholin-4-yl-ethoxy) -phenoxy] -1 H -benzimidazole; 2- [4- (2-piperidin-1-ethyl-ethyl) -phenoxy] -1H-benzimidazole; 1 - (1 - { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -pyrrolidin-2-one; (1- {2- [4- (1H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -methanol; and ethyl ester of acid 1-. { 2- [4- (1H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carboxylic acid. 155.- The pharmaceutical composition according to claim 136, further characterized in that at least one compound (i) is at least one compound of the formula (III): (lll) or an enantiomer, diastereomer, racemate, tautomer, hydrate, solvate or a pharmaceutically acceptable salt, ester or amide thereof, wherein R4, R6, X, Y, Z, and W are defined as in the compound of the formula (I ), R2"is defined as R2 in the compound of the formula (I), and R3 is defined as R3 in the compound of the formula (I), provided that (a) said R2 and R3 also satisfies one of the following ( e1): at least one of R2 and R3"is not alkyl of C? -5, when Z is O and X is S; (e2): none of R2"and R3" is C? 4C (O) Rx, where Rx is an alkyl of d-4, OH, -O-C1-4alkyl, -O-alkyl of Co-4RAr, or -NRYRY, when Y is O, Z is a bond, and R2 'is different from R3"; and (e3): none of R2" and R3"is -alkyl of C? -6CN, when Y is O, Z is a bond and R2 is different from R3 ', and (b) also provided that when X is S, Y is O, Z is a bond, and W is CH, then one of R2"and R3 'is not XCG when the other is Ci-β alkyl, where XCG is the group HCl 6 wherein HC16 is one of H, C1-6 alkyl, halogen-C6-6 alkyl, allyl and C6-6 alkoxymethyl, and GO is a group linked by a carbon member having a substituent a = O which forms an amido group with the nitrogen member to which said GO group is attached. 156. The pharmaceutical composition according to claim 155, further characterized in that said R4 is H. 157. The pharmaceutical composition according to claim 155, further characterized in that said R2 and R3 are each independently selected from the group consisting of A), B), C), D), E) and I), as defined in claim 155. 158. The pharmaceutical composition according to claim 155, further characterized in that said R2 and R3 are selected each one independently of group A), as defined in claim 155. 159. The pharmaceutical composition according to claim 155, further characterized in that said R2 and R3 are each independently selected from group B), as defined in Claim 155. 160. The pharmaceutical composition according to claim 155, further characterized in that said R2 and R3 are each independently selected from the group C), as defined in claim 155. 161. - The pharmaceutical composition according to claim 155, further characterized in that said R2 and R3 are each independently selected from group D), as defined in claim 155. The pharmaceutical composition according to claim 155, further characterized in that said R2 and R3 are each independently selected from the group E), as defined in claim 155. 163.- The pharmaceutical composition according to claim 155, further characterized in that said R2 and R3 are each independently selected from group I), as defined in claim 155. 164. The pharmaceutical composition according to claim 155, further characterized because said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is the binding nitrogen, said heterocyclic ring is selected from the group consisting of i) and ), as defined in claim 155. 165. The pharmaceutical composition according to claim 155, characterized in that Furthermore, said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is the binding nitrogen, said heterocyclic ring being selected from group i), as define in claim 155. The pharmaceutical composition according to claim 155, further characterized in that said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is the nitrogen of union, said heterocyclic ring is selected from group ii), as defined in Claim 155. 167.- A compound of the formula (II): (10) or an enantiomer, diastereomer, racemate, tautomer, hydrate, solvate or a pharmaceutically acceptable salt, ester or amide thereof, wherein X it is selected from the group consisting of NR5, O, and S, where R5 is one of H and CH3; And it is selected from the group consisting of CH2, and O; Z is selected from the group consisting of O and bond; W is selected from the group consisting of CH2 and CHR1-CH2, R1 being one of H and OH, wherein the carbon member attached to R1 in said CHR1-CH2 is not directly attached to the nitrogen member to which W is attached; R4 is selected from the group consisting of H, OCH3, Cl, F, Br, I, OH, NH2, CN, CF3 and CH3; R6 is H or F; and R2 'is defined as R2 and R3 is defined as R3, as follows: R2 and R3 are each independently selected from the group consisting of A) H, C7 alkyl, C3- alkenyl, wherein the carbon in said alkenyl which is attached to the nitrogen member has only single bonds, C3-7 alkynyl, wherein the carbon in said alkynyl which is attached to the nitrogen member has only individual bonds, optionally benzofused C3-7 cycloalkyl, C5-7 cycloalkenyl, cycloalkynyl C3-7-C7-alkyl, C3-7-C3-C6alkyl, and phenyl, wherein each of the substituents A) is independently substituted with 0, 1 or 2 RQ, and each of R1Q is a substituent on a carbon member that is at least one carbon member removed from the nitrogen member; B) a HetRa substituent; C) -alkyl of C? .7C (O) Rx, optionally substituted with CH2RAr or CH2RA ^; D) -alkyl of C2-5C (O) Rx, wherein two valence carbon members allowed in the C2-5 alkyl of said -C2-5C (0) RX alkyl are part of a C3-6 carbocycle saturated; E) -C2-5OH alkyl wherein two valence carbon members allowed in the C2-5 alkyl of said -C2-sOH alkyl are part of a saturated C3-6 carbocycle; F) -C0-4 alkylphenyl, wherein the phenyl is said to be -C0-4 alkylphenyl is fused to two adjacent carbon members in said phenyl to Rf, or is benzofused; G) -alkyl of Co ^ Ar6, where Ar6 is a 6-membered heteroaryl having a carbon member attachment point and having one or two heteroatom members -N =, and benzofused; H) -alkyl of C0-4Ar5, wherein Ar5 is a 5-membered heteroaryl, which has a member of heteroatom selected from the group consisting of O, S, and > NRY, and having 0 or 1 additional heteroatom member -N =, optionally containing two carbonyl groups, and optionally benzofused; I) -alkyl of C? -4Ar5 ', wherein Ar5' is a 5-membered heteroaryl containing 3 or 4 nitrogen members, optionally substituted with R ?, and having a valence site allowed as a point of attachment; J) -alkyl of Co-4Ar6"6, wherein Ar6" 6 is a phenyl bonded to C0-4 alkyl fused at sites of valence allowed to a 6-membered heteroaryl, wherein said 6-membered heteroaryl has one or two heteroatom members -N =; K) -alkyl of Co-4Ar6"5, wherein Ar6" 5 is a phenyl bonded to Co-4 alkyl fused at sites of valence allowed to a 5-membered heteroaryl, said 5-membered heteroaryl having a heteroatom member selected of the group consisting of O, S, and > NRY, and said 5-membered heteroaryl having 0 or 1 additional heteroatom member which is -N =; and L) one of 2- (4-ethyl-phenoxy) -benzothiazole, 2- (4-ethyl-phenoxy) -benzoxazole, and 2- (4-ethyl-phenoxy) -1 H-benzimidazole; M) SO2-C-4 alkyl; alternatively R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is the linking nitrogen, said heterocyclic ring being selected from the group consisting of i) a heterocyclic ring of 4-7 HetRb members, said 4-7 membered heterocyclic ring HetRb having a heteroatom member which is the linking nitrogen, and being substituted with 0, 1, or 2 substituents on the same or on different substitution members, said substituent being selected of the group consisting of -R ?, -CN, -C (0) R ?, -alkyl of C0-4CO2R ?, -alkyl of Co-4C (O) CO2RY, -alkyl of C0- ORY, -alkyl of Co - C (O) NR y R z, alkyl of C0-4NRYC (O) RZ, -C (O) -C ?, NRzOR of C0-4NRYC (O) CH2ORY, - alkyl of C0-4NRYC (O) CH2C (O ) RY, -C of C0-4NRYCO2RY, alkyl of C0 4NR C (O) NR Rz, alkyl of C0 NRYC (S) NR y R z, -? -NR C (O) CO2R ?, -NRYRZ,? Co-4NRWSO2RY -alkyl, 1, 3-dihydro-indol-2-one-1-yl, 1, tetrazol-5-yl-3-dihydro-benzimidazol-2-one-1-yl-, 1-R? - 1H-tetrazol-5-yl, R? -triazolyl, 2-R? -2H-tetrazol-5-yl, pyrrolidin-2-thion-1-yl, piperidin-2-thion-1-yl, -alkyl of C0 - 4C (0) N (R?) (S02R?), - C0-4N alkyl (R?) (SO2) NR? R ?, - C0-4N alkyl (R?) (SO2) NR? CO2R? halogen ii) a 5-7 membered heterocyclic ring HetRc, said heterocyclic ring of 5-7 HetRc having an additional heteroatom member separated from the binding nitrogen by at least one carbon members, said additional heteroatom member being selected from the group consists of O, S (= O) 0-2, and > NRM, said 5-7 membered heterocyclic ring HetRc having 0 or 1 carbonyl member, and being substituted with 0, 1, or 2 substituents on the same or on different carbon substitution means, said substituents being selected from the group consisting of -C (0) R ?, -C02R? -C3-4CO2R alkyl? and Rz; iii) one of imidazolidin-1-yl, 2-imidazolin-1-yl, pyrazol-1-yl, imidazol-1-yl, 2H-tetrazol-2-yl, 1H-tetrazol-1-yl, pyrrol-1- ilo, 2-pyrrolin-1-yl, and 3-pyrrolin-1-yl, wherein each of said 2H-tetrazol-2-yl and 1H-tetrazol-1-yl is substituted on the carbon member with 0 or 1 of -C0-4RZ alkyl, -alkyl of Co-4SR ?, -alkyl of Co-4CO2RY, and substituent HetRa; and iv) one of 1, 2,3,4-tetrahydro-quinolin-1-yl, 1, 2,3,4-tetrahydro-isoquinolin-2-yl, indole-1-yl, isoindole -2-yl, indolin-1-yl, benzimidazol-1-yl, 2,8-diaza-spiro [4.5] decan-1-one-8-yl, 4-. { [(2-tert-butoxycarbonylamino-cyclobutylenecarbonyl) -amino] -methyl} -piperidin-1 -yl, 4-. { [(2-amino-cyclobutanecarbonyl) -amino] -methyl} -piperidin-1-yl, 3,9-diaza-spiro [5.5] undecan-3-carboxylic acid 9-yl-tert-butyl ester, 4-oxo-1-phenyl-1,3,8-triaza-spiro [4.5] dec-8-yl, and 4-oxo-1, 3,8-triaza-spiro [4.5] dec-8-yl; wherein the HetRa substituent is a 4-7 membered heterocyclic ring having a carbon member attachment point and which confers a member > NRM as a heteroatom member, and said heteroatom member being separated from the carbon member attachment point by at least one additional carbon member; R? is selected from the group consisting of H, -C 4 alkyl, -Co-4RAr alkyl, each optionally substituted with 1, 2, or 3 RN substituent; RL is selected from the group consisting of -CO2Rs and -C (O) NRsRs; RM is selected from the group consisting of Rz, indole-7-yIo, -SO2R ?, -alkyl of C3-4CO2R ?, -CO2R ?, -C (0) NRzOR ?, -C (O) R ?, -C (O) C? -4OR? Alkyl, -C0-4C (O) NRsRs' alkyl, C0-4C (O) CO2R ?, 1,3-dihydro-indol-2-one-1-yl alkyl, 1, 3-dihydro-benzimidazol-2-yl-one-1-yl tetrazol-5-yl -1H-tetrazol-5-, 1-R?, R? -triazolyl, 2-R? -2H-tetrazol-5 -yl and -alkyl of C0-4C (O) N (R?) (SO2R?), each optionally substituted with 1, 2 or 3 RN substituents; RN is selected from group consisting of OCH3, Cl, F, Br, I, OH, NH2, CN, CF3, CH3, OC (O) CH3, and N02; Rp is selected from the group consisting of R ?, -alkyl of C2-4? R ?, RAr, -alkyl of C1-2CO2R ?, -alkyl of C? -2CONRsRs', indol-7-yl, and -SO2alkyl of C? -; RQ is selected from the group consisting of fluoro, chloro, bromo, iodo, trifluoromethyl, trichloromethyl, -CN, -alkyl of C4-4, -alkyl of C0-4RAr, -alkyl of C0-4RAr ', -alkyl of Co - ORY, - C0-4CO2RY alkyl, -C0-4NRYRZ alkyl, -C0-4NRYCORY alkyl, -C0-4NRYCONRYRZ alkyl, -C0-alkyl 4 NR? SO2R ?, and -C0-4SRY alkyl; Rs and Rs' are independently selected from the group consisting of H, -alkyl of Q1-4, and -alkylphenyl of C0-4; alternatively, Rs and Rs are taken together with the nitrogen member to which said Rs and Rs are bonded to form a 4- to 7-membered heterocyclic ring having 0 or 1 additional heteroatom member selected from the group consisting of O, S, and >NRY, provided that said additional heteroatom member is separated by at least two carbon members of said nitrogen member to which Rs and Rs are attached, and provided that where R? is C0-4RAr alkyl, then RAr is not substituted with RL; Rw is selected from the group consisting of R ?, and -C3-7 cycloalkyl; Rx is selected from the group consisting of -OR ?, -NRYRZ, -alkyl of C? -4, and -alkyl of C0-4RAr; RY is selected from the group consisting of H, -C4alkyl, -C0-4RAr alkyl and -C0-4RAr alkyl> and optionally substituted with 1, 2, or 3 RN substituents; Rz is selected from the group consisting of R ?, -alkyl of C2-4? R ?, -alkyl of C? -2C02RY, -alkyl of C? -2C (O) NRsRs ', and -alkyl of C2-4NRSRS'; when R? and Rz join a nitrogen member, R? and Rz are selected as defined above or R? and Rz are taken together with the nitrogen member attached to R? - and Rz- to form a 4-7 membered heterocyclic ring HetRd having 0 or 1 additional heteroatom member selected from the group consisting of O, S, and > NRM, said 4-7 membered heterocyclic ring HetRd having 0 or 1 carbonyl member, and said 4-7 membered heterocyclic ring HetRd having 0 or 1 allowed valence carbon member substituted with at least one of RM, -CO2H , and -coal of Co-? OR ?; RAr is a portion with a carbon member attachment point and said portion is selected from the group consisting of phenyl, pyridyl, pyrimidyl, and pyrazinyl, wherein each valence carbon member allowed in each of said portions is independently substituted with at least one of 0, 1, 2 or 3 RN, and 0 or 1 RL; RAr 'is a ring of 3 to 8 members, having 0, 1 or 2 heteroatom members selected from the group consisting of O, S, N, and > NRY, which has 0, 1, or 2 unsaturated bonds, having 0 or 1 carbonyl member, wherein each valence member allowed in each of the rings is independently substituted with 0, 1, or 2 R ?; and Rf is a linear 3 to 5 membered hydrocarbon portion having 0 or 1 unsaturated carbon-carbon bond having 0 or 1 carbonyl member; provided that (a) at least one of said R2 'and R3' is not ethyl when a selection in the group consisting of selections (s1), (s2), (s3), and (s4), is satisfied, and each of said selections is specified as (s1): R4 is H, Z is O, W is CH2, Y is CH2, and X is S; (s2): R4 is H, Z is O, W is CH2, Y is CH2 and X is NH; (s3): R4 is H, Z is O, W is CH2, Y is O, and X is S; (s4): R4 is 5-chloro, Z is O, W is CH2, Y is CH2, and X is S; (b) also provided that when Z is a link, Y is CH2, W is CHR1-CH2, R1 is H, and one of R2 'and R3' is 1H-imidazol-2-yl, then the other of R2 'and R3 is selected from A1), B) -L), where B) -L) are as defined above for the compound of the formula (I), and A1) consists of H, C3.7 alkenyl, wherein the carbon in said C3.7 alkenyl which is attached to the nitrogen member has only single bonds, C3-7 alkynyl, wherein the carbon in said alkynyl which is attached to the nitrogen has only individual bonds, 03.7 optionally benzofused cycloalkyl, C5.7 cycloalkenyl, C3.7 cycloalkyl- C1-7alkyl, -C3-7alkyl-C3-7cycloalkyl; and (c) also provided that when X is S, Y is O, Z is a bond and W is CH2, then one of R2 and R3 is not XCG when the other is C- | 6 alkyl, then XCG is the group HC16 wherein HC16 is one of H, C? -6 alkyl, halo? C6 alkyl, allyl, and C1-6 alkoxymethyl, and GO is a group attached to a carbon member that it has a substituent = 0 which forms an amido group with the nitrogen member to which said GO group is attached. 168. - The compound according to claim 167, further characterized in that said R4 is H. 160. - The compound according to claim 167, further characterized in that said R2 and R3 are each independently selected from the group consisting of A), B), C), D), E) and I), as defined in claim 167. The compound according to claim 167, further characterized in that said R2 and R3 are each independently selected from group A), as defined in claim 167. 171. The compound according to claim 167, further characterized in that said R2 and R3 are each independently selected from group B), as defined in claim 167. 172. The compound according to claim 167, further characterized in that said R2 and R3 are each selected independently of group C), as defined in claim 167. 173. The compound according to claim 167, further characterized in that said R2 and R3 are each independently selected from group D), as defined in claim 167. 174. The compound according to claim 167, further characterized in that said R2 and R3 are each independently selected. of group E), as defined in claim 167. 175. The compound according to claim 167, further characterized in that said R2 and R3 are each independently selected from group I), as defined in claim 167. 176.- The compound according to claim 167, further characterized in that said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is the binding nitrogen, said heterocyclic ring being selected from the group consisting of i) and ii), as defined in claim 167. 177. The compound according to claim 167, further characterized in that said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing minus one heteroatom member which is the binding nitrogen, said heterocyclic ring is selected from group i), as defined in claim 167. 178. The compound according to claim 167, further characterized in that said R2 and R3 are they take together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is the nitrogen of a nion, said heterocyclic ring is selected from group ii), as defined in claim 167. 179. The compound according to claim 167, further characterized in that said compound of the formula (II) is one of: 2- [ 4- (2-piperidin-1-yl-ethoxy) -phenoxy] -benzoxazole; (1 - { 2- [4- (benzooxanzol-2-yloxy) -phenoxy] ethyl} -piperidin-4-yl) -methanol; 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-ol; . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -etl} -dibutyl-amine; (1- { 2- [4- (benzoxazol-2-yloxy) -phenoxy] -etyl] -piperidin-2-yl) -methanol; 1-. { 3- [4- (benzoxazol-2- iloxy) -phenoxy] -propyl} -4-phenyl-piperidin-4-ol; 1-. { 3- [4- (benzoxazol-2-yloxy) -phenoxy] -propyl} -4-benzyl-piperidin-4-ol; 2- [4- (2-piperidin-1-ethyl-ethyl) -phenoxy] -benzoxazole; . { 3- [4- (benzoxazoI-2-yloxy) -phenyl] -propyl} -cyclohexyl-ethyl-amine; 1-3- [4- (benzoxazol-2-yloxy) -phenyl] -propyl} -piperidin-4-ol; 1-. { 3- [4- (benzoxazol-2-yloxy) -phenoxy] -2-hydroxy-propyl} -4-phenyl-piperidin-4-ol; 1 - [2- (4-Benzoxazol-2-ylmethyl-phenoxy) -ethyl] -piperidine-4-carboxylic acid ethyl ester; 2- [4- (2-pyrrolidin-1-yl-ethoxy) -phenoxy] -benzoxazole; . { 3- [4- (benzoxazol-2-yloxy) -phenoxy] -propyl} dimethyl amine; . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} dimethyl amine; and 2- [4- (2-azepan-1-yl-ethoxy) -phenoxy-benzoxazole. 180.- The compound according to claim 167, further characterized in that 1-. { 2- [4- (benzoxazol-2-yloxy) -phenoxyl-ethyl} -4-phenyl-piperidin-4-ol; . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -cyclohexyl-ethyl-amine; . { 2- [4- [2-ethyl-piperidin-1-yl] -ethoxy] -phenoxy} -benzoxazole; 1 -. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4-phenyl-piperidin-4-carbonitrile; 1- (1-. {2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4-pheni) -piperidin-4-yl) -ethanone; 2-. { 4- [2- (4-Methyl-piperidin-1-yl) -ethoxy] -phenoxy} -benzoxazole; 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4- (4-chloro-phenyl) -piperidin-4-ol; 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4- (4-bromo-phenyl) -piperidin-4-ol; 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4- (4-chloro-3-trifluoromethyl-phenyl) -piperidin-4-ol; 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -4-benzyl-piperidin-4-ol; . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -cyclohexyl-methyl-amine; Y . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -cyclopropylmethyl-propyl-amine. 181. The compound according to claim 167, further characterized in that. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -butil-ethyl- amine; 2- (. {2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -benzyl-amino) -ethanol; 2-. { 4- [2- (4-Benzyl-piperidin-1-yl) -ethoxy] -phenoxy} -benzoxazole; (1 - { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -piperidin-3-yl) -methanol; 2- (. {2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -propyl-amino) -ethanol; 2- [4- (2-Azetidin-1-yl-ethoxy) -phenoxy] -benzoxazole; ? / - (1 -. {2- 2- (4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -2-phenyl-acetamide; 1- ethyl ester. { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -peridine-3-carboxylic acid; 2-. { 4- [3- (4-Phenyl-piperidin-1-yl) -propoxy] -phenoxy} -benzoxazole; 1 -. { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -4-phenyl-piperidin-4-ol; . { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -cyclohexyl-ethyl-amine; 2- [4- (2-Pyrrolidin-1-yl-ethyl) -phenoxy] -benzoxazole; and 2- [4- (2-Azepan-1-ethyl-ethyl) -phenoxy] -benzoxazole. 182. The compound according to claim 167, further characterized in that. { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl-propyl-amine; . { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -dibutyl-amine; 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-ol; methyl ester of acid 1-. { 2- [4- (Benzoxazol-2-yloxy) -phenyl] -ethyl} -peridyl-4-carboxylic acid; 1-. { 3- [4- (Benzoxazol-2-yloxy) -phenyl] -propyl} -4-phenyl-piperidin-4-ol; 2- [4- (3-Piperidin-1-yl-propyl) -phenoxy] -benzoxazole; . { 3- [4- (Benzoxazol-2-yloxy) -phenyl] -propyl} -dibutyl-amine; . { 3- [4- (Benzoxazol-2-yloxy) -phenyl] -propyl} -cyclopropylmethyl-propyl-amine; 1 - [4- (Benzoxazol-2-yloxy) -phenoxy] -3-pyrrolidin-1-yl-propan-2-ol; 1 - [2- (4-Benzoxazol-2-ylmethyl-phenoxy) -ethyl] -4-phenyl-piperidin-4-ol; 1- [2- (4-Benzoxazol-2-ylmethyl-phenoxy) -ethyl] -piperidine-4-carboxylic acid amide; 2- [4- (2-Morpholin-4-yl-ethoxy) -phenoxy] -benzoxazole; Y . { 2- [4- (Benzoxazol-2-yloxy) -phenoxy] -ethyl} -diethyl-amine. 183. The compound according to claim 167, further characterized in that said compound of the formula (II) is one of:. { 2- [4- (6-chloro-benzothiazol-2-yloxy) -phenoxy] -phenoxy] -ethyl} -diethyl-amine; 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-ol; 1- ethyl ester. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carboxylic acid; acid 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carboxylic acid; (1 -. {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} - piperidin-4-yl) -pyrrolidin-1-yl-methanone; 3 - [(1- {2- [4- (Benzot-azazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carbonyl) -amino] -propionic acid ethyl ester; acid amide 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carboxylic acid; 1 - (1 -. {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} - piperidin-4-yl) -pyrrolidin-2-one; 1'-. { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethylH 1, 4 '] bipiperidinyl-2-one; 8-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -2,8-diaza-spiro [4.5] decan-1 -one; 2- [4- (3-pyrrolidin-1-yl-propoxy) -phenoxy] -benzothiazole; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclohexyl-ethyl-amine; acid amide 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-3-carboxylic acid; 1 - (1 -. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -3-methylene-1,3-dihydric acid benzimidazol-2-one; methyl ester of 1 - acid. { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} .pyridin-4-yl) - (4-methyl-piperazin-1) -yl) -metanone; 1- [2- (4-Benzothiazol-2-methylmethyl-phenoxy) -ethyl] -piperidine-4-carboxylic acid methyl ester; 3- ( { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -cyclopropyl-amino} -propionic acid; . { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} dimethyl amine; 2- [4- (2-pyrrolidin-1-yl-ethoxy) -phenoxy] -benzothiazole; . { 3- [4- (benzothiazol-2-yloxy) -phenoxy] -propyl} dimethyl amine; 2- [4- (2-azepan-1-yl-ethoxy) -phenoxy] -benzothiazole; 2- [4- (2-azepan-1-yl-ethoxy) -phenoxy] -6-methoxy-benzothiazole; 1-. { 2- [4- (benzothiazol-2-yloxy) - phenoxy] -ethyl} -4-phenyl-piperidin-4-ol; . { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -cyclohexyl-etii-amine; 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -4- (4-chloro-phenyl) -piperidin-4-ol; . { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -dibutyl-amine; 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -4- (4-bromo-phenyl) -piperdin-4-ol; 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -4- (4-chloro-3-trifluoromethyl-phenyl) -piperidin-4-ol; 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -4-benzyl-piperidin-4-ol; 1 '-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - [1, 4 '] bipiperidine; (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -methanol; ? / - (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -2-phenyl-acetamide; 2- (4- { 2- [4- (2-morpholin-4-yl-ethyl) -piperazin-1-yl] -ethoxy.} - phenoxy) -benzothiazole; 2- (4- { 2- [4- (2-morpholin-4-yl-ethyl) -piperazin-1-yl] -ethyl} -phenoxy) -benzothiazole; 1-. { 3- [4- (benzothiazol-2-yloxy) -phenoxy] -propyl} -4-phenyl-piperdin-4-ol; 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -4-phenyl-piperidin-4-ol; 2- [4- (2-pyrrolidin-1-yl-ethyl) -phenoxy] -benzothiazole; 2- [4- (2-azepan-1-ethyl-ethyl) -phenoxy] -benzothiazole; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl-propyl-amine; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -butyl amine; 2- [4- (2-piperidin-1-ethyl-ethyl) -phenoxy-benzothiazole; 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperdin-4-ol; acid amide 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; 1- ethyl ester. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-3-carboxylic acid; 1- ethyl ester. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etl} -4-phenylpiperidine-4-carboxylic acid; (1 -. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -acetic acid ethyl ester; 1- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -1,3-dihydro-indol-2-one; 1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -etiI.}. -piperdin-4-yl) -pyrrolidin-2-one; ? / - (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.}. -piper-dine-4-yl) -2-phenyl- acetamide; 8-. { 2- [4- (benzothiazol-2-yloxy) -pheni]] - eti)} -2,8-diaza-spiro [4.5] decan-1-one; 1-. { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl) -piperidin-3-ol; 1- ethyl ester. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-carboxylic acid; 1 '-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - [1, 4 '] bipiperidine; 2-. { 4- [2- (4-methyl-piperazin-1-yl) -ethyl] -phenoxy} -benzothiazole; 2- (4- { 2- [4- (1-benzyl-1H-tetrazol-5-yl) -piperidin-1-yl] -ethoxy}. Phenoxy) -benzothiazole; 4- (1. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -phenylperidin-4-carbonyl) -piperazyl-butyl ester. n-1 -carboxylic; 1- [2- (4-benzothiazol-2-ylmethyl-phenoxy) -ethyl] -pyridin-4-carboxylic acid amide; 1 -. { 1 - [2- (4-benzothiazol-2-ylmethyl-phenoxy) -ethyl] -piperidin-4-yl} -pyrrolidin-2-one; 1- [4- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-carbonyl) -piperazin-1-yl] -ethanone; acid 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; 1 - (1 -. {2- [4- (benzothiazol-2-yloxy) -phenoxy] -etyl] -piperidin-4-yl) -pyrrolidin-2-thone; 2- (4- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperazin-1-yl) -ethanol; 2- (4-. {2- 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl] -piperazin-1-yl) -1-pyrrolidin-1-yl-ethanone; 2- (4- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl.} - p-piperazin-1-yl) -1-morpholin-4-yl-ethanone; acid 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-3-carboxylic acid; acid 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-2-carboxylic acid; (1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-3-yl) -acetic acid; (1- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -acetic acid ethyl ester; (1- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -carbamic acid tert-butyl ester; (1 - { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -eti}.} - piperidin-4-yl) -acetic acid; (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-3-yl) -methanol; (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclohexyl-amino) -acetic acid methyl ester; acid (4- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperazin-1-yl) -acetic; 1- (1. {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -5-oxo-pyrrolidine-2-carboxylic acid ethyl ester; 1 - (1 -. {2- 2- [4- (Benzot-azazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -5-oxo-pyrrolidine-2-carboxylic acid; 4- (4- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperazin-1-yl) -phenol; ? / - (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -4-chloro-β-cyclopropyl-benzenesulfonamide; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - cyclopropylmethyl-amino) -propionic acid; 3- (. {2- 2- [4- (BenzothiazoI-2-yloxy) -phenoxy] -ethyl) -isopropyl-amino) -propionic acid; 1-. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-ilamine; 3- [acid. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - (1-methyl-piperidin-4-yl) -amino] -propionic; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -benzyl-amino) -propionic acid; 3 - ((1-Acetyl-piperidin-4-yl) -. {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -amino) -propionic acid; 4- (1 -. {2- 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -1-H-tetrazol-5-yl) -piperidine-1-carboxylic acid tert-butyl ester; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propionic acid; 3 - ((1-Acetyl-piperidin-4-yl) -. {- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -amino) -propionic acid; 3- [acid. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - (1-methyl-piperidin-4-yl) -amino] -propionic; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -propionic acid; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - isopropyl-amino) -propionic acid; 2- (4-. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl] -piperazin-1-yl) -1-pyrrolidin-1-yl-ethanone; acid (R) -1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-3-carboxylic acid; 1 - (1 -. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -1,3-dihydro-benzimidazol-2-one; 2- (4- { 2- [4- (6-Methyl-pyridin-2-yl) -piperazin-1-yl] -ethyl} -phenoxy) -benzothiazole; 2-4- [2- (4-ethanesulfonyl-piperazin-1-yl) - ethyl] -phenoxy} -benzothiazole; 2- (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -1-morpholin-4-yl-ethanone; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -methyl-amino) -propionic acid; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etyl] -cyclopentyl-amino) -propionic acid; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etii.} - cyclobutyl-amino) -propionic acid; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etyl] -benzyl-amino} -propionic acid; (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) - (4-hydroxymethyl-piperidn-1) -l) -metanone; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etl} -cyclopropyl-amine; (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) - [4- (2-hydroxy-ethyl) -piperazin-1-yl} ] -metanone; (1- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -etyl] -piperidin-4-yl) - [4- (2-hydroxy-ethyl) -piper Din-1-yl] -methanone; 2- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.} - cyclopropyl-amino) -ethanol; 3- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propan-1-ol; 4- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -butyric acid; 3 - [(1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carbonyl) -amino] -propionic acid; 4- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.} - c-chloropropyl-amino) -butyronitrile; 3- (1- { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -propionic acid; [(1 -. {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl] -piperidine-4-carbonyl) -methyl-amino] -acetic acid; 3- (4- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperazin-1-yl) -phenol; 2- (4- { 2- [4- (4-methoxy-phenyl) -piperazin-1-yl] -ethoxy.} - phenoxy) -benzothiazole; 2-. { 4- [2- (5-piperidin-4-yl-tetrazol-1-yl) -ethoxy] -phenoxy} -benzothiazole; (S) -1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -4-hydroxy-pyrrolidin-2-one; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethylamine; 2 - [(. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -.-cyclopropyl-amino) -methyl] -cyclopropanecarboxylic acid ethyl ester; ethyl ester of 4- (4-. {2- 2- 4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperazin-1 -carbonyl) -benzoic acid; 2 - [( { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -methyl] -cyclopropanecarboxylic acid; 1 - ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.} - cyclopropyl-amino) -propan-2-ol; 3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.} - cyclopropyl-amino) -1,1,1-trifluoro-propan-2-ol; 3- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propionamide; 3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propane-1,2-diol; 2-. { 4- [2- (5-phenyl-tetrazol-2-yl) -ethoxy] -phenoxy} -benzothiazole; 2-. { 4- [2- (5-phenyl-tetrazol-1-yl) -ethoxy] -phenoxy} -benzothiazole; ? -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -N-cyclopropyl-2- (2H-tetrazol-5-yl) -acetamide; (S) -3- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.} - cyclopropyl-amino) -2-methyl-propan-1-yl; (R) -3- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -2-methyl-propan-1-ol; 2-. { 4- [2- (5-methylsulfanyl-tetrazol-2-yl) -ethoxy] -phenoxy} -benzotiazoI; 2-. { 4- [2- (5-Methylsulfanyl-tetrazol-1-yl) -ethoxy] -phenoxy} -benzothiazole; 2- [4- (2-tetrazol-2-yl-ethoxy) -phenoxy] -benzothiazole; 2- [4- (2-tetrazol-1-yl-ethoxy) -phenoxy] -benzothiazole; acid (1 R, 2R) -2-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino} -cyclohexanecarboxylic; acid (1S, 2R) -2-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino} -cyclohexanecarboxylic; (1 R, 2R) -2-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino} -cyclohexanol; (1 S, 2R) -2-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino} -cyclohexanol; 4- (1- { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - p -peridin-4-yl) -butyric acid; (R) 1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl] -piperidin-4-yl) -4-hydroxy-pyrrolidin-2-one; 2- (4- { 2- [4- (1 H-Tetrazol-5-yl) -piperidin-1-yl] -ethyl} -phenoxy) -benzothiazole; (1- {2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidin-2-yl) -methanol; (1- {2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} -1H-tetrazol-5-yl) -acetic acid ethyl ester; (1- {2- {4- (benzothiazol-2-yloxy) -phenoxy] - ethyl ester - ethyl} -1 H-tetrazol-5-yl) -acetic; 2- hydrochloride. { 4- [2- (5-piperidin-4-yl-tetrazol-2-yl) -ethoxy] -phenoxy} -benzothiazole; 7- { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -etl} -4-esp.ro- [3-phthalide] -p.peridine; 1- ethyl ester. { 3- [4- (benzothiazol-2-yloxy) -phenyl] -propyl} -piperidine-4-carboxylic acid; 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamine hydrochloride; 2- (4- { 2- [4- (1 H-tetrazol-5-yl) -piperidin-1-yl] -ethoxy.} - phenoxy) -benzothiazole; cis-4- trifluoromethanesulfonate salt. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino-cyclohexanecarboxylic acid; (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1 -ii) - (tetrahydro-furan-2-yl) -methanone; (1 -. {-2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carbonyl) -amide of propan-2-sulfonic acid; (4- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) -oxo-acetic acid methyl ester; N- (1- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -ethyl} -piperidine-4-carbonyl) -benzenesulfonamide trifluoromethanesulfonate salt; N- (1 -. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carbonyl) -methanesulfonamide trifluoromethanesulfonate salt; (4- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) -oxo-acetic acid trifluoromethanesulfonate salt; (4- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -morpholin-4-yl-methanone; 1 - (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.} - p-piperazin-1-yl) -2-thiophen-2-yl-ethanone; (4-. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -pyridin-3-yl-methanone; (4-. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -cyclopropyl-methanone; 1 - (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -2-methoxy-ethanone; 1 - (4-. {2- 2- (4- (benzothiazol-2-yloxy) -fenii] -ethyl.} - piperazin-1-yl) -2,2,2-trifluoro-ethanone; 4- (4- { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etiI.} - piperazine-1-carbonyl) -benzoic acid; (4-. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -etyl] -piperazin-1-yl) -pyridin-4-yl-methanone; (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -etl} -piperazin-1-yl) - (5-methyl-pyrazin-2-yl) -methanone; (R) - (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.} - piperazin-1-yl) - (tetrahydro-furan-2-yl) -metanone; (S) - (4- { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) - (tertrahydro-furan-2-yl) -methanone; (4- { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) - (tetrahydro-furan-3-yl) -methanone; 1- (4- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -2-hydroxy-ethanone; 2- [2- (4- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperazin-1-yl) -2-oxo-ethyl] -cyclopentanone; 3- (4. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperazin-1-yl) -propionic acid trifluoromethanesulfonate salt; 3- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperidin-4-yl) -oxazolidin-2-one; 4- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - pyridin-4-yl) -morpholin-3-one; 4- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperdin-4-yl) -morpholin-3-one; 3- (1- { 2- [4- (benzothiazol-2-yloxy) -phenoxy] -ethyl] -piperidin-4-yl) -oxazolidin-2-one; benzyloxy-1-acid amide. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; (1 - { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -acetic acid; (R) -1- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -4-hydroxy-pyrrolidin-2- ona; hydroxyamide of acid 1-. { 2- [4- (Benzofiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; (S) -1- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - piperidin-4-yl) -4-hydroxy-pyrrolidin-2-one; (1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -carbamic acid tert-butyl ester; 2-. { 4- [2- (4-fluoro-piperidin-1-yl) -ethyl] -phenoxy} -benzothiazole; 2-. { 4- [2- (4,4-difluoro-piperidin-1-yl) -ethyl] -phenoxy} -benzothiazole; (R) -1 -. { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -pyrrolidin-3-ol; N-1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -formamide; (1- {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -urea; 1 - (1 - { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) - 3-cyano-2-phenyl-isourea; 1- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -3-cyano-2-methyl-isothiourea; N- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.}. -piperidn-4-yl) -methanesulfonamide; 1- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -3-cyano-2-methy-guanidine; 8-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -1-phenyl-1, 3,8-triaza-spiro [4.5] decan-4-one; 8-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -1, 3,8-triaza-spiro [4.5] decane-2,4-dione; (1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -methyl-carbamic acid tert-butyl ester; N- (1-. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -N-methyl-acetamide; N- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -N-methylene-methanesulfonamide; [(1- {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -methyl-carbamoyl] -methyl acetic acid ester; N- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -N-acetamide; (1- {2- [4- (Benzothiazol-2-yloxy) -phenyl-ethyl-ethyl} -piperidin-4-ylcarbamoyl) -methalic acid ester; 2- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -methyl-amino) -3- (1 H -imidazol-2-yl) -propionic acid; 2- (4- { 2- [4- (3-nitro-pyridin-2-yl) - [1,4] diazepan-1-yl] -ethyl} -phenoxy) -benzothiazole; [(1- {2- [4- (Benzothiazol-2-yloxy) -phenox] -etyl] -piperidine-4-carbonyl) -methyl-amino] -acetic acid ethyl ester; ethyl ester of 1 '- acid. { 2- [4- (Benzothiazol-2-yloxy) -phenoxy] -ethyl} - [1, 4 '] bipiperidinyl-4-carboxylic acid; 1 '- ^ - ^ - (Benzothiazole ^ -yloxyH-phenoxy-ethylH, 4'] bipiperidinyl-4-carboxylic acid; {. 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.} - cyclopropyl-ethyl-amine: trifluoromethanesulfonic acid salt of 3- (. {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino acid) -2- methyl-propionic; 2- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.} - cyclopropylmethyl-amino) -ethanol; 2- [2- (. {2- [2- 4- (benzothiazol-2-yloxy) -phenyl] -ethyl.} - cyclopropylmethyl-amino) -ethoxy] -ethanol; 3- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] - etl.}. - cyclopropylmethylamino) -propan-1-ol; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl- (3-tetrazol-2-yl-propyl) -amine; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etl} -cyclopropyl- (3-pyrrol-1-yl-propyl) -amine; 4- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.} - c-chloropropylmethyl-amino) -butyronitrile; (2-cyano-eti) -amide of 1- acid. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; . { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl- [3- (2H-tetrazol-5-yl) -propyl] -amine; 3- [5- (1- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidin-4-yl) -tetrazol-1-yl] -propionitrile; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl- [3- (2H-tetrazol-5-yl) -propyl] -amine; 1- (hydroxy-1, 1-dimethyl-ethyl) -amide. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -piperidine-4-carboxylic acid; . { 2- [4- (benzothiazoi-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl- [3- (1 H- [1, 2,4] triazol-3-yl) -propyl] -amine; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl- [3- (5-methyl-1 H- [1, 2,4] triazol-3-yl) -propyl] -amine; . { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl- [3- (5-phenyl] -1 H- [1, 2,4] triazol-3-yl) -propyl] -amine; 2- (4- { 2- [4- (1-methyl-1 H-tetrazol-5-yl) -piperidin-1-yl] -ethyl} -phenoxy) -benzothiazole; 2- (4- { 2- [4- (2-methyl-2H-tertrazol-5-yl) -piperidin-1-yl] -ethyl} -phenoxy) -benzothiazole; 1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etl} -piperdin-4-carbonitrile; 2- (4- { 2- [4- (1 H- [1, 2,3] triazol-4-yl) -piperidin-1-yl] -ethyl} - phenoxy) -benzothiazole; 4-ethyl ester. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethylamino} -butyric; 4- (. {2- 2- [4- (Benzot-azazol-2-yloxy) -phenyl] -ethyl} -cyclopropylmethyl-amino) -butyric acid ethyl ester; 2- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -propl] -isoindole-1,3-dione; 4- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -butyric acid; 1- (3- { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethylamino} -propyl) -pyrrolidin-2-one; N-1-. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -N1-cyclopropylmethyl-propane-1, 3- diamine; 5- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -.-cyclopropyl-amino) -pentanoic acid methyl ester; N- [3- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -propyl] -acetamide; [3- ( { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -propyl] -amido of morpholine-4-carboxylic acid; N- [3- ( { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -propyl] -methanesulfonamide; 5- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino) -pentanoic acid; 1- [3- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - isopropyl-amino) -propyl] -pyrrolidin-2-one; 1- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylmethyl-amino) -propyl] -pyrrolidin-2-one; 1- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl.} - cyclopropyl-amino) -propyl] -pyrrolidin-2-one; 1 - [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - propyl-amino) -propiI] -pyrrolidin-2-one; 4 - ((1-Acetyl-piperidin-4-yl) -. {2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -amino) -butyric acid ethyl ester; ethyl acyl ester 4 - ((1-acetyl-piperidin-4-yl) -. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -amino) -butyric acid; 4- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etyl} -metanesulfonic-amino) -butyric acid; 2- [4- (Benzothiazol-2-yloxy) -fenii] -etill-cyclopropyl-amino) -acetic acid; 6- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino) -hexanoic acid ethyl ester; 7- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino) -heptanoic acid ethyl ester; 6- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -hexanoic acid; 7- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropylamino) -heptanoic acid; N-1 -. { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -etiI} -N1-cyclopropyl-propane-1,3-diamine; N- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl] -acetamide; N- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino) -propyl] -isobutyramide; N- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino) -propyl] -benzamide; N- [3- ( { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl] -4-chloro-benzamide; N- [3- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl.} - cyclopropyl-amino) -propyl] -methanesulfonamide; [3- (. {2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl] -3-cyclopropyl-amino) -propyl] -amide trifluoromethanesulfonic acid of propan-2-sulfonic acid; 8- (. {2- 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -octanoic acid ethyl ester; 1- [3- ( { 2- [4- (benzothiazol-2-yloxy) -phenyl] -ethyl} - cyclopropyl-amino) -propyl] -3-phenyl-urea; 8- ( { 2- [4- (Benzothiazol-2-yloxy) -phenyl] -ethyl} -cyclopropyl-amino-octanoic acid; [3- ( { 2- [4- (benzothiazole-2 tetrahydro-furan-2-carboxylic acid amide; N- [3- (. {2- [4- (benzothiazole-) -hydroxy-2-carboxylic acid] -3-cyclopropyl-amino) -propyl] -amide; 2-yloxy) -phenyl] -ethyl.} - cyclopropylamino) -propyl] -2-hydroxy-acetamide, 4- (. {2- 2- [4- (benzothiazol-2-yloxy) -phenyl] - ethyl.} - cyclopropyl-amino) -butyric acid 2- [4- (2-morpholin-4-yl-ethoxy) -phenoxy] -benzothiazole; and. {2- [4- (2-piperidine -1-yl-ethoxy) -phenoxy] -benzothiazole 184. The compound according to claim 167, further characterized in that the compound of the formula (II) is one of: 1- { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl.} -4-phenyl-piperidin-4-ol;. {2- [4- (1 H-benzimidazol-2-yloxy) - phenyl] -ethyl.} - cyclopropylmethyl-propyl-amine; cyclohexyl-ethyl- {2- [4- (1-methyl-1 H-benzimidazol-2-yloxy) -phenyl} -ethyl}. -amine; 1 - { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl.} -4- (4-bromo-phenyl) -piperidin-4- ol; 1- { 2- [4- (1H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -4- (4-chloro-phenyl) -piperidin-4-ol; 1 -. { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -4-benzyl-piperidin-4-ol; . { 2- [4- (1 H -benzyldazol-2-yloxy) -phenyl] -ethyl} -cyclohexyl-ethyl-amine; 2- [4- (2-pyrrolidin-1-yl-ethyl) - phenoxy] -1H-benzimidazole; 2- [4- (2-azepan-1-ethyl-ethyl) -phenoxy] -1 H -benzimidazole; . { 2- [4- (1H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -dibutyl-amine; 1-. { 2- [4- (1H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-ol; methyl ester of acid 1-. { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carboxylic acid; . { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -cyclohexyl-ethyl-amine; 2-. { 4- [2- (4-methyl-piperidin-1-yl) -ethoxy] -phenoxy} -1 H-benzimidazole; 2-. { 4- [2- (2-ethyl-piperidn-1-yl) -ethoxy] -phenoxy} -1 H-benzimidazole; 2- [4- (2-piperidin-1-yl-ethoxy) -phenoxy] -1 H -benzimidazole; 1 -. { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-ol; 2- [4- (2-azepan-1-yl-ethoxy) -phenoxy] -1H-benzimidazole-amide; . { 3- [4- (1H-benzimidazol-2-yloxy) -phenoxy] -propyl} dimethyl amine; 2- [4- (2-pyrrolidin-1-yl-ethoxy) -phenoxy] -1 H -benzimidazole; . { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -diethyl-amine; 2- [4- (2-morpholin-4-yl-ethoxy) -phenoxy] -1 H -benzimidazoi; 2- [4- (2-piperidin-1-ethyl-ethyl) -phenoxy] -1H-benzimidazole; 1- (1- { 2- [4- (1 H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -pyrrolidin-2-one; (1- {2- [4- (1H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidin-4-yl) -methanol; and ethyl ester of acid 1-. { 2- [4- (1H-benzimidazol-2-yloxy) -phenoxy] -ethyl} -piperidine-4-carboxylic acid. 185.- A compound of the formula (III): (lll) or an enantiomer, diastereomer, racemate, tautomer, hydrate, solvate or a pharmaceutically acceptable salt, ester or amide thereof, wherein X is selected from the group consisting of NR 5, O, and S, wherein R 5 is one of H and CH 3; And it is selected from the group consisting of CH2, and O; Z is selected from the group consisting of O and bond; W is selected from the group consisting of CH2 and CHR1-CH2, R1 being one of H and OH, wherein the carbon member attached to R1 in said CHR1-CH2 is not directly attached to the nitrogen member to which W is attached; R 4 is selected from the group consisting of H, OCH 3, Cl, F, Br, I, OH, NH 2, CN, CF 3 and CH 3; R6 is H or F; and R2 'is defined as R2 and R3 is defined as R3, as follows: R2 and R3 are each independently selected from the group consisting of A) H, C1-7 alkyl, C3-7 alkenyl, wherein the carbon in said alkenyl which is attached to the nitrogen member has only single bonds, C3-7 alkynyl, wherein the carbon in said alkynyl which is attached to the nitrogen member has only individual bonds, optionally benzofused C3-7 cycloalkyl, cycloalkenyl C5-7, -cycloalkyl of C3- -alkyl of C? -7, -alkyl of C? -7-cycloalkyl of C3-7 and phenyl, wherein each of substituents A) is independently substituted with 0, 1 or 2 RQ, and each of R1Q is a substituent on a carbon member that is at least one carbon member removed from the nitrogen member; B) a HetRa substituent; C) -alkyl of C? -7C (O) Rx, optionally substituted with CH2RAr or CH2RAr; D) -alkyl of C2-5C (O) Rx, wherein two valence carbon members allowed in the C2-5 alkyl of said -C2-5C (O) Rx alkyl are part of a saturated C3-6 carbocycle; E) -C2-5OH alkyl wherein two valence carbon members allowed in the C2-5 alkyl of said -C2-sOH alkyl are part of a saturated C -6 carbocycle; F) -C0-4 alkylphenyl, wherein the phenyl is said to be -C0-4 alkylphenyl is fused to two adjacent carbon members in said phenyl to Rf, or is benzofused; G) -C0-4Ard alkyl, wherein Ar6 is a 6-membered heteroaryl having a carbon member attachment point and having one or two heteroatom members -N =, and benzofused; H) -C0-4Ar5 alkyl, wherein Ar5 is a 5-membered heteroaryl, having a heteroatom member selected from the group consisting of O, S, and > NRY, and having 0 or 1 additional heteroatom member -N =, optionally containing two carbonyl groups, and optionally benzofused; I) -alkyl of C? -4Ar5 ', where Ar5' is a 5-membered heteroaryl containing 3 or 4 nitrogen members, optionally substituted with R ?, and having a valence site allowed as a point of attachment; J) -alkyl of Co-4Ar6"6, wherein Ar6" 6 is a phenyl bonded to C0-4 alkyl fused at sites of valence allowed to a 6-membered heteroaryl, wherein said 6-membered heteroaryl has one or two heteroatom members -N =; K) -C0-4Ar6 alkyl "5, wherein Ar6" 5 is a phenyl bonded to Co-4 alkyl fused at sites of valence allowed to a 5-membered heteroaryl, said 5-membered heteroaryl having a heteroatom member selected of the group consisting of O, S, and > NRY, and said 5-membered heteroaryl having 0 or 1 additional heteroatom member which is -N =; and L) one of 2- (4-ethyl-phenoxy) - benzothiazole, 2- (4-ethyl-phenoxy) -benzoxazole, and 2- (4-ethyl-phenoxy) -1 H-benzimidazole; M) SO 2 -C 1-4 alkyl; alternatively R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is the linking nitrogen, said heterocyclic ring being selected from the group consisting of i) a heterocyclic ring of 4-7 HetRb members, said 4-7 membered heterocyclic ring HetRb having a heteroatom member which is the linking nitrogen, and being substituted with 0, 1, or 2 substituents on the same or on different substitution members, said substituent being selected from the group consisting of -R ?, -CN, -C (O) R ?, -alkyl of C0-4CO2RY, -alkyl of C0-4C (O) CO2RY, -alkyl of C0-4? R? , -alkyl of C0-4C (O) NRYRZ, -alkyl of C0- NRYC (O) RZ, -C (O) NRzOR ?, -alkyl of Co-4NRYC (0) CH2ORY, - -alkyl of C0-4NRYC ( O) CH2C (O) RY - C0-4NRYCO2RY alkyl, - C0 alkyl. 4NR? C (0) NR? Rz, -alkyl of C0-4NRYC (S) NRYRZ, - -NR? C (0) CO2R ?, -NRYRZ, -alkyl of C0.4NRwSO2R ?, 1,3-dihydro-indole -2-one-1-yl, 1,3-dihydro-benzimidazol-2-one-1-yl, tetrazol-5-yl, 1-R? -1 H-tetrazol-5-yl, R? -triazolyl, 2 -R? -2H-tetrazol-5-yl, pyrrolidin-2-thion-1-yl, piperidin-2-thion-1-yl, -alkyl of C0. 4C (O) N (R?) (SO2R?), -alkyl of Co-4N (RY) (SO2) NRYRY, -alkyl of C0. 4N (R?) (SO2) NR? CO2R ?, halogen, "N H ii) a 5-7 membered heterocyclic ring HetRc, said heterocyclic ring 5-7 HetRc having an additional heteroatom member separated from the binding nitrogen by at least one carbon members, said additional heteroatom member being selected from the group consisting of O, S (= O) 0-2. and > NRM, said 5-7 membered heterocyclic ring HetRc having 0 or 1 carbonyl member, and being substituted with 0, 1, or 2 substituents on the same or on different carbon substitution means, said substituents being selected from the group consisting of -C (0) R ?, -C02R? -alkyl of C3-4C02RY and Rz; iii) one of imidazolidin-1-yl, 2-imidazolin-1-yl, pyrazol-1-yl, imidazol-1-yl, 2H-tetrazol-2-yl, 1H-tetrazol-1-yl, pyrrole-1- ilo, 2-pyrrolin-1-yl, and 3-pyrrolin-1-yl, wherein each of said 2H-tetrazol-2-yl and 1 H-tetrazol-1-yl is substituted on the carbon member with 0 or 1-C0-4RZ alkyl, -C0-4SRY alkyl, -Co-4CO RY alkyl, and HetRa substituent; and v) one of 1, 2,3,4-tetrahydro-quinolin-1-yl, 1, 2,3,4-tetrahydro-isoquinolin-2-yl, indole-1-yl, isoindol-2-yl, indolin-1-yl, benzimidazol-1-yl, 2,8-diaza-spiro [4.5] decan-1-one-8-yl, 4-. { [(2-tert-butoxycarbonylamino-cyclobutylenecarbonyl) -amino] -methyl} -piperidin-1 -yl, 4-. { [(2-amino-cyclobutanecarbonyl) -amino] -methyl} -period-1-yl, 3,9-diaza-spiro [5.5] undecan-3-carboxylic acid 9-yl-tert-butyl ester, 4-oxo-1-phenyl-1,3,8 -triaza-spiro [4.5] dec-8-yl, and 4-oxo-1, 3,8-triaza-spiro [4.5] dec-8-yl; wherein the HetRa substituent is a 4-7 membered heterocyclic ring having a carbon member attachment point and containing a > NRM as a heteroatom member, and said heteroatom member being separated from the carbon member attachment point by at least one additional carbon member; R? is selected from a group consisting of H, -alkyl of d-4, -alkyl of C0-4RAr, each optionally substituted with 1, 2, or 3 substituent RN; RL is selected from the group consisting of -CO2Rs and -C (O) NRsRs'; RM is selected from the group consisting of Rz, indol-7-yl, -SO2R ?, -alkyl of C3-4CO2R ?, -CO2R ?, -C (O) NRzOR ?, -C (O) R ?, -C (O) d-4OR alkyl ?, -C0-4C (O) NRSRS 'alkyl, C0-4C (O) CO2R ?, 1,3-dihydro-indol-2-one-1-yl alkyl, , 3-dihydro-benzimidazol-2-one-1-yl, tetrazol-5-yl, 1-R? -1H-tetrazol-5-yl, R? -triazolyl, 2-R? -2H-tetrazole-5- ilo and -alkyl of C0-4C (O) N (RY) (SO2RY), each optionally substituted with 1, 2 or 3 RN substituents; RN is selected from the group consisting of OCH3, Cl, F, Br, I, OH, NH2, CN, CF3, CH3, OC (O) CH3, and NO2; Rp is selected from the group consisting of R ?, -alkyl of C2-4? R ?, RAr, -alkyl of C? -2CO2R ?, -alkyl of C? -2CONRsRs', indole-7-yl, and -SO2alkyl of C1.4; RQ is selected from the group consisting of fluoro, chloro, bromo, iodo, trifluoromethyl, trichloromethyl, -CN, -alkyl of d-, -alkyl of C0-4RAr, -alkyl of C0-4RAr ', -alkyl of Co-4ORY , -C0-4CO2RY alkyl, -C0-4NRYRZ alkyl, -C0-4NRYCORY alkyl, -C0-4NRYCONRYRZ alkyl, -C0-4NR alkyl? SO2R ?, and -C0-4SRY alkyl; Rs and Rs' are independently selected from the group consisting of H, -alkyl of d-, and -C0-4 alkylphenyl; alternatively, Rs and Rs are taken together with the nitrogen member to which said Rs and Rs are bonded to form a 4- to 7-membered heterocyclic ring having 0 or 1 additional heteroatom member selected from the group consisting of O, S, and > NRY, provided that said additional member and heteroatom is separated by at least two carbon members of said nitrogen member to which Rs and Rs are attached, and provided that where R? it is C0-4RAr alkyl. then RAr is not substituted with RL; Rw is selected from the group consisting of R ?, and -C3.7 cycloalkyl; Rx is selected from the group consisting of -OR ?, -NRYRZ, -alkyl of C? -4, and -alkyl of Co-4 Ar; RY is selected from the group consisting of H, -C1_4alkyl, -C04RAralkyl and -Co-4RRA alkyl, and optionally substituted with 1, 2, or 3 RN substituents; Rz is selected from the group consisting of R ?, -alkyl of C2-4OR ?, -alkyl of C? -2C02R ?, -alkyl of C1-2C (O) NRsRs', and -alkyl of C2-4NRSRS; when R? and Rz join a nitrogen member, R? and Rz are selected as defined above or R? and Rz are taken together with the nitrogen member attached to R? - and Rz- to form a 4-7 membered heterocyclic ring HetRd having 0 or 1 additional heteroatom member selected from the group consisting of O, S, and > NRM, said 4-7 membered heterocyclic ring HetRd having 0 or 1 carbonyl member, and said 4-7 membered heterocyclic ring HetRd having 0 or 1 allowed valence carbon member subsituted with at least one RM, -CO2H , and -alkyl of C0-? OR ?; RAr is a portion with a carbon member attachment point and said portion is selected from the group consisting of phenyl, pyridyl, pyrimidyl, and pyrazinyl, wherein each valence carbon member allowed in each of said portions is independently substituted with at least one of 0, 1, 2 or 3 RN, and 0 or 1 RL; RAr 'is a ring of 3 to 8 members, having 0, 1 or 2 heteroatom members selected from the group consisting of O, S, N, and > NRY, who has 0, 1, or 2 unsaturated bonds, having 0 or 1 carbonyl member, wherein each valence member allowed in each of the rings is independently substituted with 0, 1, or 2 R ?; and Rf is a linear 3 to 5 membered hydrocarbon portion having 0 or 1 unsaturated carbon-carbon bond having 0 or 1 carbonyl member; provided that (a) said R2 and R3"further satisfies one of the following: (e1): at least one of R2 and R3 is not C? -5 alkyl, when Z is O and X is S; (e2) : none of R2 and R3 'is C?-C (0) Rx alkyl, with Rx being one of C? - alkyl, OH, - C? - O - alkyl, - Co - 4RArO - alkyl, or --NRYRY when Y is O, Z is a link, and R2 'is different from R3"; and (e3): none of R2"and R3" is -alkyl of d-6CN, when Y is O, Z is a bond and R2"is different from R3"; and (b) further provided that when X is S, Y is O, Z is a bond, and W is CH2, then one of R2"and R3" is not XCG when the other is C6 alkyl, where XCG it's the group HCl 6 wherein HC16 is one of H, alkyl of d-6, halogen-alkyl of C? -6, allyl and alkoxymethyl of d-6, and GO is a group linked by a carbon member having a substituent a = Or forming an amido group with the nitrogen member to which said GO group is attached. 186. The compound according to claim 185, further characterized in that said R4 is H. 187. - The compound according to claim 185, further characterized in that said R2 and R3 are each independently selected from the group consisting of A), B), C), D), E) and I), as defined in claim 185. The compound according to claim 185, further characterized in that said R2 and R3 are each independently selected from group A), as defined in claim 185. 189. The compound according to claim 185, further characterized in that said R2 and R3 are each independently selected from group B), as defined in claim 185. 190. The compound according to claim 185, further characterized in that said R2 and R3 are each selected independently of group C), as defined in claim 185. 191. The compound according to claim 185, further characterized in that said R2 and R3 are each independently selected group D), as defined in claim 185. 192. The compound according to claim 185, further characterized in that said R2 and R3 are each independently selected from the group E), as defined in claim 185. 193.- The compound according to claim 185, further characterized in that said R2 and R3 are each independently selected from group I), as defined in claim 185. 194. The compound according to claim 185, further characterized in that said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is the binding nitrogen, said heterocyclic ring being selected from the group consisting of i) and ii), as defined in claim 185. 195. The compound according to claim 185, further characterized in that said R2 and R3 are taken together with the nitrogen to which they are attached to form a heterocyclic ring containing at least minus one heteroatom member which is the binding nitrogen, said heterocyclic ring is selected from group i), as defined in claim 185. 196. The compound according to claim 185, further characterized in that said R2 and R3 are they take together with the nitrogen to which they are attached to form a heterocyclic ring containing at least one heteroatom member which is the nitrogen of a nion, said heterocyclic ring is selected from group ii), as defined in claim 185.